{"2e94b196a9f39cebdb44424b50ad4ce14098d61c": [["Their role is to directly provide or coordinate the communication of response for out-of-hospital or pre-hospital emergency medical care in the community.", [["pre-hospital emergency medical care", "TREATMENT", 101, 136]]], ["Their contribution to the health and wellbeing of the community and to healthcare is overshadowed by more dominant dialogues and debates about community services, acute care and hospital emergency department tensions and resource demands [1] [2] [3] [4] .BackgroundIn Australia, the nature of ambulance work, the uncontrolled and often unpredictable environments, the everyday experience of trauma, and the cumulative nature of that trauma all play a key role in the development and impact of mental distress and psychological injury [3] [4] [5] .", [["trauma", "DISEASE", 391, 397], ["trauma", "DISEASE", 433, 439], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 238, 253], ["trauma", "PROBLEM", 391, 397], ["trauma", "PROBLEM", 433, 439], ["mental distress", "PROBLEM", 493, 508], ["psychological injury", "PROBLEM", 513, 533]]], ["This paper examines the peer-reviewed qualitative research to outline the effect of emergency medical response work on the psychological, psychosocial, and physical health of paramedics, ambulance officers, ambulance volunteers, and call-takers.BackgroundA recent systematic review of 27 international studies [7] reported on 30,878 ambulance personnel and found estimated prevalence rates of 11% for post-traumatic stress (PTS), 15% for depression, 15% for anxiety, and 27% for general psychological distress among ambulance personnel.", [["PTS", "DISEASE", 424, 427], ["depression", "DISEASE", 438, 448], ["anxiety", "DISEASE", 458, 465], ["psychological distress", "DISEASE", 487, 509], ["international studies", "TEST", 288, 309], ["prevalence rates", "TEST", 373, 389], ["depression", "PROBLEM", 438, 448], ["anxiety", "PROBLEM", 458, 465], ["general psychological distress", "PROBLEM", 479, 509]]], ["A broader Canadian study [8] of emergency response and correctional workers (5813 correctional workers, dispatchers, firefighters, paramedics, and police officers) showed that 44.5% screened positive for clinically significant symptoms of one or more diagnosable mental disorders; approximately four times higher than diagnosed rates for the general population at 10.1%.", [["A broader Canadian study", "TEST", 0, 24], ["clinically significant symptoms", "PROBLEM", 204, 235], ["more diagnosable mental disorders", "PROBLEM", 246, 279]]], ["Of concern, these rates were noted to be higher than earlier studies and suggested the rate of anxiety among paramedics to be as high as 22%, with depression and suicidal ideation both at 10% [8] .", [["anxiety", "DISEASE", 95, 102], ["depression", "DISEASE", 147, 157], ["suicidal ideation", "DISEASE", 162, 179], ["these rates", "TEST", 12, 23], ["earlier studies", "TEST", 53, 68], ["anxiety", "PROBLEM", 95, 102], ["depression", "PROBLEM", 147, 157], ["suicidal ideation", "PROBLEM", 162, 179]]], ["Apart from psychological impacts, a range of physical impacts resulting from the nature of ambulance work and exposure to occupational stress have also been reported.", [["psychological impacts", "PROBLEM", 11, 32], ["occupational stress", "PROBLEM", 122, 141]]], ["These include headaches, sleep disruption, muscular skeletal injuries, fatigue, dietary problems, weight gain and, in some cases, exposure to dangerous pathogens [9] [10] [11] .", [["muscular skeletal", "ANATOMY", 43, 60], ["headaches", "DISEASE", 14, 23], ["sleep disruption", "DISEASE", 25, 41], ["muscular skeletal injuries", "DISEASE", 43, 69], ["fatigue", "DISEASE", 71, 78], ["dietary problems", "DISEASE", 80, 96], ["weight gain", "DISEASE", 98, 109], ["muscular skeletal", "TISSUE", 43, 60], ["headaches", "PROBLEM", 14, 23], ["sleep disruption", "PROBLEM", 25, 41], ["muscular skeletal injuries", "PROBLEM", 43, 69], ["fatigue", "PROBLEM", 71, 78], ["dietary problems", "PROBLEM", 80, 96], ["weight gain", "PROBLEM", 98, 109], ["dangerous pathogens", "PROBLEM", 142, 161], ["muscular", "ANATOMY_MODIFIER", 43, 51], ["skeletal", "ANATOMY", 52, 60], ["injuries", "OBSERVATION", 61, 69]]], ["The research therefore suggests that rates of mental distress, mental illness, and the associated physical effects of psychological injury experienced by ambulance personnel demonstrate the large toll that emergency medical response takes on the individual.", [["illness", "DISEASE", 70, 77], ["psychological injury", "DISEASE", 118, 138], ["mental distress", "PROBLEM", 46, 61], ["mental illness", "PROBLEM", 63, 77], ["psychological injury", "PROBLEM", 118, 138], ["large", "OBSERVATION_MODIFIER", 190, 195]]], ["Safe Work Australia [12] , the Australian government statutory body established to develop national policy for work health and safety and workers' compensation, reports that, although serious mental disorder claims from first responders account for only around 10% of all claims, they have significantly more impact on the individual than other claims.", [["body", "ORGANISM_SUBDIVISION", 63, 67], ["serious mental disorder", "PROBLEM", 184, 207]]], ["These impacts included extended time off work and significant compensation for ongoing care and support.", [["ongoing care", "TREATMENT", 79, 91], ["support", "TREATMENT", 96, 103]]], ["Claims were almost five times longer than for other serious claims for all types of injuries and illnesses, and monetary payouts for serious mental disorder for first responders was almost double that of all payments [12] .", [["injuries", "DISEASE", 84, 92], ["mental disorder", "DISEASE", 141, 156], ["injuries", "PROBLEM", 84, 92], ["illnesses", "PROBLEM", 97, 106], ["serious mental disorder", "PROBLEM", 133, 156], ["injuries", "OBSERVATION", 84, 92]]], ["These statistics demonstrate the high cost in monetary value, lost productivity, and lost personnel which is experienced by Ambulance Services personnel and other first responders due to the effect of mental distress and psychological injury [12] .BackgroundThe predominant use of measures of stress and psychological injury which focus on current symptoms make the longitudinal screening of personal mental health and wellbeing difficult and potentially miss important information about late and cumulative development of work-related distress.", [["psychological injury", "DISEASE", 221, 241], ["psychological injury", "DISEASE", 304, 324], ["mental distress", "PROBLEM", 201, 216], ["psychological injury", "PROBLEM", 221, 241], ["stress and psychological injury", "PROBLEM", 293, 324], ["current symptoms", "PROBLEM", 340, 356], ["related distress", "PROBLEM", 528, 544], ["high", "OBSERVATION_MODIFIER", 33, 37], ["cost", "OBSERVATION_MODIFIER", 38, 42], ["productivity", "OBSERVATION_MODIFIER", 67, 79], ["predominant", "OBSERVATION_MODIFIER", 262, 273]]], ["This mismatch may result in failure to recognise and address adverse longer-term impacts of the work itself.", [["This mismatch", "PROBLEM", 0, 13], ["failure to recognise", "PROBLEM", 28, 48], ["failure", "OBSERVATION", 28, 35]]], ["It may also result in failure to identify effective evidence-based prevention measures or to intervene early to prevent potentially higher rates and prevalence of psychological distress in this group [6] .BackgroundGranter et al's [13] recent study with ambulance services in England explored how emergency workers respond to the varied and multidimensional nature of their work and how this influences resilience and vulnerability to distress.", [["psychological distress", "DISEASE", 163, 185], ["failure", "PROBLEM", 22, 29], ["psychological distress", "PROBLEM", 163, 185], ["BackgroundGranter et al's", "PROBLEM", 205, 230], ["recent study", "TEST", 236, 248], ["distress", "PROBLEM", 435, 443]]], ["Their study highlighted a cross-section of intense, high energy, and time-critical aspects of the work intermixed with a mundane, operational, and bureaucratic work life [13] .", [["Their study", "TEST", 0, 11], ["high energy", "OBSERVATION_MODIFIER", 52, 63]]], ["This mixture of high intensity and mundane work often created a difficult shift for paramedics' mindset, with little respite or time for debriefing and dealing with administrative requirements during periods of intense emotions [13] .BackgroundIn Australia, and internationally, there has been extensive measurement of prevalence of this problem and increasing focus on policy development, service-based strategies, and programs for promoting mental health and wellbeing among ambulance personnel and other first responder groups.", [["high intensity", "PROBLEM", 16, 30], ["paramedics' mindset", "TREATMENT", 84, 103], ["administrative requirements", "TREATMENT", 165, 192], ["this problem", "PROBLEM", 333, 345], ["high intensity", "OBSERVATION_MODIFIER", 16, 30], ["increasing", "OBSERVATION_MODIFIER", 350, 360]]], ["To date, quantitative study designs have provided the basis for these developments but with limited focus on the lived experience and qualitative evidence.", [["quantitative study", "TEST", 9, 27]]], ["Despite these initiatives and the existence of a broad range of organisational support services and programs, concern for the mental health of ambulance personnel continues to grow.", [["organisational support services", "TREATMENT", 64, 95]]], ["This review aims to provide a stronger spotlight on the lived experience of ambulance personnel to identify the gaps in provision of support and care, and the challenges faced by those who experience psychological distress as a consequence of their everyday work.Aim and research questionsThe aim of this study is to provide a comprehensive review of relevant international peer-reviewed qualitative literature on the effects of emergency medical service work on the psychological, physical, and social wellbeing of ambulance personnel (paramedics, ambulance officers, ambulance volunteers, and call-takers).", [["psychological distress", "PROBLEM", 200, 222], ["this study", "TEST", 300, 310]]], ["What causes the problem?", [["the problem", "PROBLEM", 12, 23]]], ["What is needed to address the problem?Aim and research questionsThe following questions guided this systematic review: Further questions about perceived stigma, help-seeking behaviours and how ambulance personnel identify and report signs of psychological distress related to their work were also explored for this systematic review.", [["psychological distress", "PROBLEM", 242, 264]]], ["However, dedicated examination of these specific issues will be reported elsewhere.Search methods and screeningA systematic literature search was conducted to identify the relevant peer-reviewed literature using the PICO tool for qualitative research to identify key concepts pertinent to 'participant problem (or population)', 'intervention', 'comparison or control' and 'outcome' [14] .", [["dedicated examination", "TEST", 9, 30], ["these specific issues", "PROBLEM", 34, 55], ["Search methods", "TEST", 83, 97], ["screening", "TEST", 102, 111], ["the PICO tool", "TEST", 212, 225]]], ["Research on the topic of this review is relatively young and has proliferated predominantly in the last two decades, with widespread professionalisation of the paramedic workforce via transfer of paramedic education to the university section in Australia, New Zealand and the UK around 2000, resulting in an increase in paramedic academics and subsequent research being conducted by them; therefore, only studies published since 2000 were included [15] .", [["paramedic education", "TREATMENT", 196, 215], ["New", "OBSERVATION_MODIFIER", 256, 259], ["increase", "OBSERVATION_MODIFIER", 308, 316]]], ["The main search was conducted in the Ovid Medline database, and incorporated both Subject headings (MeSH: Medical subject headings) and text words, and then translated into the PsycInfo, Ovid EMcare, CINAHL, and Scopus databases (executed in October 2018; see Appendix 1).", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Retrieved results of the database searches were then exported into Endnote for collation.Search methods and screeningA PRISMA diagram was used to report the search results and screening process.", [["the database searches", "TEST", 21, 42], ["Search methods", "TEST", 89, 103], ["screeningA PRISMA diagram", "TEST", 108, 133]]], ["Full texts deemed eligible for inclusion based on their title and abstract were obtained for further screening.Search methods and screeningThe review was registered with PROSPERO (Registration No.CRD42019117397).Data extraction and synthesisThe following data was extracted from each study: aim and methodology; sample characteristics; data collection methods; data analysis methods; and study limitations (see Appendix 2) .", [["further screening", "TEST", 93, 110], ["Search methods", "TEST", 111, 125], ["screening", "TEST", 130, 139], ["Data extraction", "TREATMENT", 212, 227], ["synthesis", "TREATMENT", 232, 241], ["sample characteristics", "TEST", 312, 334], ["data collection methods", "TEST", 336, 359], ["data analysis methods", "TEST", 361, 382], ["study limitations", "TEST", 388, 405]]], ["The findings of each study were extracted and collated according to the focus questions (see Appendix 3 and 4) .", [["each study", "TEST", 16, 26]]], ["This enabled a thematic narrative synthesis to be undertaken in which commonalities and discrepancies between the findings of the studies were identified [16] .", [["a thematic narrative synthesis", "PROBLEM", 13, 43], ["the studies", "TEST", 126, 137]]], ["To perform this step, two reviewers read and re-read the data extracted for each study, noting patterns within and across the data.", [["the data", "TEST", 53, 61], ["each study", "TEST", 76, 86]]], ["Tentative themes were then discussed within the broader research team over a series of formative meetings to reach consensus on the most pertinent themes arising from the data.Data extraction and synthesisIn the case of the literature reviews, only the data from relevant studies were included, and each qualitative study included within the systematic reviews was screened for inclusion as a primary study.", [["Data extraction", "TREATMENT", 176, 191], ["synthesis", "TREATMENT", 196, 205], ["relevant studies", "TEST", 263, 279], ["each qualitative study", "TEST", 299, 321], ["a primary study", "TEST", 391, 406]]], ["The quality of each included study was evaluated using the Critical Appraisal Skills Program (CASP) checklist for qualitative research, with quality of systematic literature reviews determined using the CASP tool of systematic reviews [17, 18] .", [["study", "TEST", 29, 34], ["systematic reviews", "TEST", 216, 234]]], ["The CASP checklists entail 10 questions related to various aspects of quality including whether aims were clearly stated, methodology, design, recruitment and sampling, ethical clearance, and rigor of data analysis.", [["sampling", "TEST", 159, 167], ["ethical clearance", "TEST", 169, 186], ["rigor of data analysis", "TEST", 192, 214]]], ["We determined high quality study were those that met eight or more of the 10 criteria, reasonable quality studies met 6-7 of the 10 criteria, and poorer quality studies met five or less of the 10 criteria.", [["poorer quality studies", "TEST", 146, 168]]], ["Where the reviewer assessing a study was unsure if the criteria had been met, input was sought from a second reviewer.ResultsA total of 6154 documents were retrieved from all searches, from which 1086 duplicates were removed.", [["a study", "TEST", 29, 36]]], ["The studies were conducted in a range of countries including the United States of America (n = 9) [9, [19] [20] [21] [22] [23] [24] [25] [26] , Australia (n = 8) [10, [27] [28] [29] [30] [31] [32] [33] , Canada (n = 6) [34] [35] [36] [37] [38] [39] , Sweden (n = 5) [40] [41] [42] [43] [44] , the England (n = 4) [44] [45] [46] [47] [48] , Ireland (n = 2) [49, 50] , Norway (n = 2) [11, 51] , Saudi Arabia (n = 1) [52] , and Israel (n = 1) [53] .", [["9, [19] [20] [21] [22] [23] [24] [25] [26]", "CHEMICAL", 99, 141], ["[19] [20] [21] [22] [23] [24] [25", "SIMPLE_CHEMICAL", 102, 135], ["[27] [28] [29] [30] [31] [32] [33]", "SIMPLE_CHEMICAL", 167, 201], ["Canada (n = 6) [34] [35] [36] [37] [38] [39]", "SIMPLE_CHEMICAL", 204, 248], ["n = 5) [40] [41] [42", "SIMPLE_CHEMICAL", 259, 279], ["The studies", "TEST", 0, 11], ["Australia (n", "TEST", 144, 156], ["Canada (n", "TEST", 204, 213], ["Sweden (n", "TEST", 251, 260]]], ["Another study was conducted in both Australia and the United Kingdom [54] .", [["Another study", "TEST", 0, 13]]], ["Of the 39 articles, the majority were deemed to be primary research articles (n = 26) [20, 21, 25-30, 34, 35, 37-42, 44-46, 48-50, 52-54] with the remainder being either non-systematic literature reviews (n = 9) [9, 19, 20, 22-24, 31, 32, 36, 43] or systematic literature reviews (n = 4) [11, 43, 47, 51] .", [["systematic literature reviews", "TEST", 250, 279]]], ["Of the primary research studies, the most common data collection method was semi-structured interviews (n = 11) [26, 27, 40-42, 44-46, 49, 51, 53] .", [["the primary research studies", "TEST", 3, 31]]], ["Four studies used a combination of semistructured interviews and focus groups [21, 34, 35, 54] , while another four utilised questionnaires with at least one open-ended question [10, 20, 29, 37] .", [["Four studies", "TEST", 0, 12]]], ["Six studies used a mixed methods approach, combining qualitative and quantitative approaches.", [["Six studies", "TEST", 0, 11], ["a mixed methods approach", "TREATMENT", 17, 41]]], ["These methods included a questionnaire and interviews (n = 4) [28, 30, 38, 39] , conducting both interviews and focus groups, attending organisational management meetings and examining information available on the public record (n = 1) [48] , and brainstorming, flow chart analysis, and examination of health service usage records (n = 1) [52] .", [["flow chart analysis", "TEST", 262, 281], ["examination", "TEST", 287, 298]]], ["Additionally, one study reported on the outcome of a court case pertaining to a paramedic who developed PTS as a result of his employment [25] .ResultsOf the 39 included studies, no studies focused explicitly on unpaid volunteers within ambulance services.", [["PTS", "DISEASE", 104, 107], ["volunteers", "ORGANISM", 219, 229], ["one study", "TEST", 14, 23], ["studies", "TEST", 170, 177], ["studies", "TEST", 182, 189]]], ["Their views may have been captures within individual study samples; however, their status as volunteers was not distinguished from other participants.", [["volunteers", "ORGANISM", 93, 103], ["participants", "SPECIES", 137, 149], ["individual study samples", "TEST", 42, 66]]], ["Only one study focused explicitly on retirement.", [["one study", "TEST", 5, 14]]], ["This study from Ireland explored policies and procedures for retirement within ambulance and fire services, with a primary focus on managers aged 42-73 years [49] .", [["This study", "TEST", 0, 10]]], ["One US study explored how EMS work impacts upon family life, with a convenience sample of 11 spouses and one parent of EMS providers [26] .", [["One US study", "TEST", 0, 12]]], ["The remaining 37 included studies related to ambulance personnel on active duty.Summary of quality evaluationThe majority of articles were generally of high quality, with all but one clearly stating the research aim and all using an appropriate research design.", [["quality evaluation", "TEST", 91, 109], ["majority", "OBSERVATION_MODIFIER", 113, 121], ["articles", "OBSERVATION", 125, 133]]], ["However, a qualitative methodology was not considered appropriate for one of the studies, and the appropriateness could not be determined for a further two studies.", [["the studies", "TEST", 77, 88], ["a further two studies", "TEST", 142, 163]]], ["Recruitment strategies were deemed appropriate, except for three studies where insufficient details were reported.", [["Recruitment strategies", "TREATMENT", 0, 22], ["three studies", "TEST", 59, 72]]], ["We were unable to determine if one study collected data in a way that addressed the research question; however, the remainder of the studies were deemed to have achieved this.", [["one study", "TEST", 31, 40], ["the studies", "TEST", 129, 140]]], ["Rigour of data analysis was considered acceptable in most cases except for one study, and five for which this could not be determined.", [["Rigour of data analysis", "TEST", 0, 23], ["one study", "TEST", 75, 84]]], ["Eight studies did not report on ethical issues and one did not provide sufficient information to determine this.", [["Eight studies", "TEST", 0, 13]]], ["The relationship between the researcher and the participants was adequately described in 12 studies; however, there was not enough detail to determine this in three studies.", [["participants", "SPECIES", 48, 60]]], ["All studies concluded with a clear statement of findings (see Appendix 5) .", [["All studies", "TEST", 0, 11]]], ["The four systematic literature reviews were deemed to be of high quality, with all stating a clearly focused question, and all considered to have adequately assessed the quality of included studies (see Appendix 6) .Summary of quality evaluationThe results are summarised in two main sections, with each section addressing the specific research questions identified for this review:Summary of quality evaluation1.", [["studies", "TEST", 190, 197], ["quality evaluation", "TEST", 227, 245]]], ["It addresses factors recognised by individuals and organisational management as being significant and contributing to mental health and well-being, or increasing the risk for developing conditions such as PTSD, depression, and anxiety.", [["PTSD", "DISEASE", 205, 209], ["depression", "DISEASE", 211, 221], ["anxiety", "DISEASE", 227, 234], ["organisational management", "TREATMENT", 51, 76], ["developing conditions", "PROBLEM", 175, 196], ["PTSD", "PROBLEM", 205, 209], ["depression", "PROBLEM", 211, 221], ["anxiety", "PROBLEM", 227, 234]]], ["Findings of the studies discussed in Section 1 are summarised in Appendix 3.Q1: impacts on psychological well-beingPsychological effects were framed within five themes: 1) Recognised reactions and associated signs and symptoms; 2) Effects on relationships with others; 3) Observations from \"above\" (e.g., the influence of organisational structures, policy, and support); 4) Perceived control versus real control and the nature of the event; and, 5) Protective and coping mechanisms employed.1) Recognised reactions, associated signs and symptoms, and causesA number of key commonly-recognised responses to trauma and the associated signs and symptoms of adverse impacts of that trauma on ambulance personnels' psychological well-being were identified.", [["trauma", "DISEASE", 606, 612], ["trauma", "DISEASE", 678, 684], ["the studies", "TEST", 12, 23], ["Psychological effects", "PROBLEM", 115, 136], ["Recognised reactions", "PROBLEM", 172, 192], ["associated signs and symptoms", "PROBLEM", 197, 226], ["Recognised reactions", "PROBLEM", 494, 514], ["associated signs and symptoms", "PROBLEM", 516, 545], ["trauma", "PROBLEM", 606, 612], ["the associated signs and symptoms", "PROBLEM", 617, 650], ["trauma", "PROBLEM", 678, 684], ["Appendix", "ANATOMY", 65, 73]]], ["These responses included angry outbursts and changes in tolerance to everyday interactions, sleep disturbances and deficits, irritability, decreased social life, and an increased sense of isolation.", [["angry outbursts", "DISEASE", 25, 40], ["sleep disturbances", "DISEASE", 92, 110], ["irritability", "DISEASE", 125, 137], ["angry outbursts", "PROBLEM", 25, 40], ["changes in tolerance", "PROBLEM", 45, 65], ["sleep disturbances", "PROBLEM", 92, 110], ["deficits", "PROBLEM", 115, 123], ["irritability", "PROBLEM", 125, 137], ["an increased sense of isolation", "PROBLEM", 166, 197]]], ["An increase in vigilance and fear of doing the required role, and recognition of associated triggers, unwanted and unpredictable flashbacks or intrusive thoughts, fatigue, stress, high rates of sickness and days absent, and difficulty switching off were significant [9, 11, 24, 25, 27, 31, 34, 36, 39, 46, 50] .", [["flashbacks", "DISEASE", 129, 139], ["fatigue", "DISEASE", 163, 170], ["sickness", "DISEASE", 194, 202], ["An increase in vigilance", "PROBLEM", 0, 24], ["associated triggers", "PROBLEM", 81, 100], ["unpredictable flashbacks", "PROBLEM", 115, 139], ["intrusive thoughts", "PROBLEM", 143, 161], ["fatigue", "PROBLEM", 163, 170], ["stress", "PROBLEM", 172, 178], ["high rates of sickness", "PROBLEM", 180, 202], ["increase", "OBSERVATION_MODIFIER", 3, 11]]], ["The high and increasing rates of depression and anxiety, and associated development of PTS and suicidal ideation [9, 11, 19, 20, 22, 23, 25, 34, 40, 41, 47, 52] were clearly outlined as current and systemic issues faced by paramedics and calltakers, with rates estimated as being twice as high as other health professionals [24, 25, 28, 30, 36, 39, 46, 47] .", [["depression", "DISEASE", 33, 43], ["anxiety", "DISEASE", 48, 55], ["PTS", "DISEASE", 87, 90], ["suicidal ideation", "DISEASE", 95, 112], ["depression", "PROBLEM", 33, 43], ["anxiety", "PROBLEM", 48, 55], ["PTS and suicidal ideation", "PROBLEM", 87, 112], ["high", "OBSERVATION_MODIFIER", 4, 8], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["rates", "OBSERVATION_MODIFIER", 24, 29], ["depression", "OBSERVATION", 33, 43]]], ["The nature of the work, including routine 'everyday' call-outs, and those that generated associated secondary or vicarious trauma, had a cumulative effect on ambulance personnel.", [["trauma", "DISEASE", 123, 129], ["vicarious trauma", "PROBLEM", 113, 129]]], ["This left them with feelings of frustration, helplessness, trepidation, and emotions of being overwhelmed during and after the event.", [["helplessness", "DISEASE", 45, 57], ["trepidation", "DISEASE", 59, 70], ["frustration", "PROBLEM", 32, 43], ["helplessness", "PROBLEM", 45, 57], ["trepidation", "PROBLEM", 59, 70]]], ["The cumulative build-up of emotions and continued exposure to stress led to compassion fatigue and self-blame [39, 41, 45, 53] .", [["fatigue", "DISEASE", 87, 94], ["compassion fatigue", "PROBLEM", 76, 94]]], ["The literature notes rates of substance use (e.g., alcohol and other drugs) by ambulance personnel accelerated following exposure to critical incidents as a means to mitigate and manage these lived experiences [9, 24, 34, 39] .1) Recognised reactions, associated signs and symptoms, and causesOne paper specifically outlined how attending critical incidents or traumatic events has six distinct stages related to the experience [42] .", [["alcohol", "CHEMICAL", 51, 58], ["alcohol", "CHEMICAL", 51, 58], ["alcohol", "SIMPLE_CHEMICAL", 51, 58], ["Recognised reactions", "PROBLEM", 230, 250], ["associated signs and symptoms", "PROBLEM", 252, 281], ["traumatic events", "PROBLEM", 361, 377]]], ["The initial stage involves anticipation of the event characterised as the (1) pretrauma and preparation for the unknown.", [["pretrauma", "DISEASE", 78, 87], ["pretrauma and preparation", "TREATMENT", 78, 103]]], ["Early in the management of the event, there is a keen sense of (2) feelings of responsibility and the associated anxiety and fear of mistakes.", [["anxiety", "DISEASE", 113, 120], ["the associated anxiety", "PROBLEM", 98, 120]]], ["After the event, feelings of (5) confusion, exhaustion, and of being in chaos were dominant.", [["confusion", "DISEASE", 33, 42], ["confusion", "PROBLEM", 33, 42], ["exhaustion", "PROBLEM", 44, 54], ["dominant", "OBSERVATION", 83, 91]]], ["Other more subtle feelings included being (6) rejected by relatives or fellow workers, feelings of anger, frustration, resentment, and bitterness, betrayal and rejection, self-loathing, guilt and humiliation, being out of control, trapped, and feelings of helplessness [42] .2) Effects of relationships with othersThe effects of workplace stress on the psychosocial well-being of ambulance personnel profoundly influenced how they interacted with others.", [["helplessness", "DISEASE", 256, 268], ["rejection", "PROBLEM", 160, 169], ["helplessness", "PROBLEM", 256, 268], ["rejection", "OBSERVATION", 160, 169]]], ["Social withdrawal and the above-mentioned signs and symptoms created an environment which negatively affected personal relationships, exacerbated the sense of isolation and withdrawal, and what they described as a debilitating loss of compassion.", [["loss of compassion", "DISEASE", 227, 245], ["Social withdrawal", "PROBLEM", 0, 17], ["signs and symptoms", "PROBLEM", 42, 60], ["withdrawal", "PROBLEM", 173, 183], ["a debilitating loss of compassion", "PROBLEM", 212, 245], ["debilitating", "OBSERVATION_MODIFIER", 214, 226]]], ["This enabled them to distance themselves from their negative emotions and alleviate their emotional distress.", [["emotional distress", "DISEASE", 90, 108], ["their emotional distress", "PROBLEM", 84, 108]]], ["Paramedics also found themselves being hyper-alert and over-protective of family and friends because they knew and saw worst-case scenarios as part of their everyday work [26, 34, 50, 53] .2) Effects of relationships with othersThe effects of shift work added to the psychological stress due to the continuous negotiation between their role and identity at work and their personal life.", [["the psychological stress", "PROBLEM", 263, 287]]], ["Prolonged and high exposure to excessive occupational demands and lack of crisis support led to poor physical and mental health, increased sick leave, and lower productivity [19, 26, 41, 50, 51] , and was associated with increased overall morbidity, and physical and mental illnesses [19, 30] .", [["physical and mental illnesses", "DISEASE", 254, 283], ["Prolonged and high exposure", "PROBLEM", 0, 27], ["excessive occupational demands", "PROBLEM", 31, 61], ["crisis support", "TREATMENT", 74, 88], ["poor physical and mental health", "PROBLEM", 96, 127], ["increased overall morbidity", "PROBLEM", 221, 248], ["physical and mental illnesses", "PROBLEM", 254, 283], ["high exposure", "OBSERVATION_MODIFIER", 14, 27], ["increased", "OBSERVATION_MODIFIER", 221, 230], ["overall", "OBSERVATION_MODIFIER", 231, 238], ["morbidity", "OBSERVATION", 239, 248]]], ["Along with a challenging occupational environment, operational factors (such as key performance indicators, quotas, operational standards, response times, and expectations) also contributed to psychological stress [32, 45] .", [["psychological stress", "PROBLEM", 193, 213]]], ["Another significant aspect was the feeling of a 'big brother' environment in which everything is observed and taped leading to call-takers being 'on-edge' [27] .", [["significant", "OBSERVATION_MODIFIER", 8, 19]]], ["The increased risk of potential aggression and violence that paramedics faced, particularly verbal abuse, added to the sense of work-related uncertainty and vulnerability.", [["aggression", "DISEASE", 32, 42], ["violence", "DISEASE", 47, 55], ["verbal abuse", "DISEASE", 92, 104], ["increased", "OBSERVATION_MODIFIER", 4, 13]]], ["This was compounded if reports were not taken seriously or were under-reported, as culturally, potential agression and violence was seen as a 'normal part of the job' [28] .4) Perceived control, real control, and nature of event/ traumaThe nature of the critical incident, and the perceived or real sense of control were identified as factors that either mediated or increased the incidence of psychological injury.", [["violence", "DISEASE", 119, 127], ["trauma", "DISEASE", 230, 236], ["psychological injury", "DISEASE", 394, 414], ["trauma", "PROBLEM", 230, 236], ["psychological injury", "PROBLEM", 394, 414]]], ["Key events and case types that contributed to signficant distress for ambulance personnel included the death of a baby or child, neglect, abuse or harm, burns, assault, family violence, drownings, harm to colleagues [20] , suicide, grotesque mutilation, and those cases that had a personal significance ascribed to them (e.g., personally knowing the patient, working with children or the critically ill, and the death of patients) [29, 38, 39, 43, 44, 50, 51] .", [["death", "DISEASE", 103, 108], ["neglect", "DISEASE", 129, 136], ["abuse or harm", "DISEASE", 138, 151], ["burns", "DISEASE", 153, 158], ["family violence", "DISEASE", 169, 184], ["drownings", "DISEASE", 186, 195], ["grotesque mutilation", "DISEASE", 232, 252], ["critically ill", "DISEASE", 388, 402], ["death", "DISEASE", 412, 417], ["patient", "ORGANISM", 350, 357], ["children", "ORGANISM", 372, 380], ["patients", "ORGANISM", 421, 429], ["patient", "SPECIES", 350, 357], ["children", "SPECIES", 372, 380], ["patients", "SPECIES", 421, 429], ["signficant distress", "PROBLEM", 46, 65], ["neglect", "PROBLEM", 129, 136]]], ["Adding to the burden was the need to complete administrative and documentation requirements and to remain professional in further interactions with others following a critical incident.4) Perceived control, real control, and nature of event/ traumaLack of control, whether perceived or real, particularly a lack of control over work, their environment, and work demands [28, 40, 47] , increased the incidence and severity of psychological distress, and were triggers for the development, or exacerbation, of existing mental illness.", [["psychological distress", "DISEASE", 425, 447], ["traumaLack of control", "TREATMENT", 242, 263], ["psychological distress", "PROBLEM", 425, 447], ["exacerbation", "PROBLEM", 491, 503], ["existing mental illness", "PROBLEM", 508, 531]]], ["Other prominent issues in relation to feelings of loss of control and safety were workplace bullying, actual assaults by others (patients, colleagues), loss of control through verbal and physical threats, remoteness and isolation felt if subjected to these behaviours, lack of back-up support and reports of incidents not being taken seriously or not being followed-up by supervisors or the service.5) Protective and coping mechanismsAmbulance personnel used a number of strategies to cope with the nature of the work they face; some that contributed to the delayed nature of mental illness presentations.", [["loss of control through verbal and physical threats", "DISEASE", 152, 203], ["illness", "DISEASE", 583, 590], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["Other prominent issues", "PROBLEM", 0, 22], ["loss of control", "PROBLEM", 50, 65], ["loss of control through verbal and physical threats", "PROBLEM", 152, 203], ["mental illness presentations", "PROBLEM", 576, 604], ["prominent", "OBSERVATION_MODIFIER", 6, 15], ["issues", "OBSERVATION", 16, 22]]], ["One strategy used was compartmentalising the event and associated emotions to manage the immediate demands and to be able to provide care which was protective in the short-term, but which may be detrimental in the longer-term, or they distanced themselves emotionally from the patient to protect themselves.", [["patient", "ORGANISM", 277, 284], ["patient", "SPECIES", 277, 284]]], ["Avoidant strategies and information searching were often used to try to regain a sense of control and manage the demands they faced [39, 45, 48] .5) Protective and coping mechanismsThe nature of the work, although complex and challenging for mental health, also offered individuals a sense of identity and status, affiliation and camaraderie, structure and routine, direction and meaning, and intellectual stimulation and challenge which together enhanced personal satisfaction and resilience.", [["Avoidant strategies", "TREATMENT", 0, 19], ["intellectual stimulation", "TREATMENT", 393, 417]]], ["Social support, mainly emotional support, was also crucial and protective against the development of PTSD [51] .", [["PTSD", "DISEASE", 101, 105], ["emotional support", "TREATMENT", 23, 40], ["PTSD", "PROBLEM", 101, 105]]], ["These protective aspects of the work are significant, but were often minimised or disrupted if a critical incident challenged their sense of role and connection to the service, especially if re-tasked or forced to medically retire due to mental health concerns or illness.Q2: impacts on physical well-beingPhysical side-effects of continued exposure to occupational stress manifested in predominantly somatic symptoms such as headaches, gastrointestinal distress, sleep disruption, fatigue, and their associated effects on work performance [9, 11, 24, 34] .", [["gastrointestinal", "ANATOMY", 437, 453], ["illness", "DISEASE", 264, 271], ["headaches", "DISEASE", 426, 435], ["gastrointestinal distress", "DISEASE", 437, 462], ["sleep disruption", "DISEASE", 464, 480], ["fatigue", "DISEASE", 482, 489], ["gastrointestinal", "ORGANISM_SUBDIVISION", 437, 453], ["mental health concerns", "PROBLEM", 238, 260], ["illness", "PROBLEM", 264, 271], ["occupational stress", "PROBLEM", 353, 372], ["predominantly somatic symptoms", "PROBLEM", 387, 417], ["headaches", "PROBLEM", 426, 435], ["gastrointestinal distress", "PROBLEM", 437, 462], ["sleep disruption", "PROBLEM", 464, 480], ["fatigue", "PROBLEM", 482, 489], ["gastrointestinal", "ANATOMY", 437, 453], ["distress", "OBSERVATION", 454, 462]]], ["The fast-paced nature of the work and the psychological demands of the job did not allow for physical rest and processing of incidents [38, 44] , which created a vicious cycle for ambulance personnel, and contributed to a difficult work-life balance and poor post-shift recovery [27, 30, 36, 46] .Q2: impacts on physical well-beingDue to the nature of the work, the major physical concerns experienced by paramedics were reported as musculoskeletal injuries, specifically back problems, associated with the weight of patients and manual handling requirements in challenging environments.", [["musculoskeletal", "ANATOMY", 433, 448], ["musculoskeletal injuries", "DISEASE", 433, 457], ["patients", "ORGANISM", 517, 525], ["patients", "SPECIES", 517, 525], ["musculoskeletal injuries", "PROBLEM", 433, 457], ["back problems", "PROBLEM", 472, 485], ["manual handling requirements", "TREATMENT", 530, 558]]], ["Other risks to physical health were blood-borne pathogens and needle-stick injuries which occurred mostly with inexperienced clinicians [22, 30, 44] .", [["blood", "ANATOMY", 36, 41], ["injuries", "DISEASE", 75, 83], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["blood-borne pathogens", "PROBLEM", 36, 57], ["needle-stick injuries", "PROBLEM", 62, 83]]], ["Critical incident stress particularly affected physical health due to associated weight gain, back problems, and changes in appetite and diet.", [["weight gain", "DISEASE", 81, 92], ["weight gain", "PROBLEM", 81, 92], ["back problems", "PROBLEM", 94, 107], ["changes in appetite", "PROBLEM", 113, 132]]], ["It was difficult for paramedics to maintain or improve their general levels of fitness and maintain diet because of shift work and the lack of on-site exercise facilities [30, 50] .Q2: impacts on physical well-beingSleep and disrupted sleep patterns are of interest as a key to understanding physical fatigue and psychological effects of work in this area.", [["fatigue", "DISEASE", 301, 308], ["physical fatigue", "PROBLEM", 292, 308]]], ["Inadequate or disrupted sleep has been associated with cardiovascular disease (CVD), metabolic disease, depression, impairment in immune function, and hormone secretion fluctuations which can instigate adverse psychological changes [33] .Q2: impacts on physical well-beingBoth increases and decreases in cortisol levels have been found following stress exposure and indicate strain on the endocrine system [33] .", [["cardiovascular", "ANATOMY", 55, 69], ["endocrine system", "ANATOMY", 389, 405], ["cardiovascular disease", "DISEASE", 55, 77], ["CVD", "DISEASE", 79, 82], ["metabolic disease", "DISEASE", 85, 102], ["depression", "DISEASE", 104, 114], ["impairment in immune function", "DISEASE", 116, 145], ["cortisol", "CHEMICAL", 304, 312], ["cortisol", "CHEMICAL", 304, 312], ["cardiovascular", "ANATOMICAL_SYSTEM", 55, 69], ["cortisol", "GENE_OR_GENE_PRODUCT", 304, 312], ["Inadequate or disrupted sleep", "PROBLEM", 0, 29], ["cardiovascular disease (CVD)", "PROBLEM", 55, 83], ["metabolic disease", "PROBLEM", 85, 102], ["depression", "PROBLEM", 104, 114], ["impairment in immune function", "PROBLEM", 116, 145], ["hormone secretion fluctuations", "PROBLEM", 151, 181], ["adverse psychological changes", "PROBLEM", 202, 231], ["cortisol levels", "TEST", 304, 319], ["stress exposure", "PROBLEM", 346, 361], ["strain on the endocrine system", "PROBLEM", 375, 405], ["metabolic disease", "OBSERVATION", 85, 102]]], ["The literature indicates that pro-inflammatory cytokines significantly increased or decreased from baseline following single as well as multiple nights of complete and partial sleep restriction [33] .", [["pro-inflammatory cytokines", "PROTEIN", 30, 56], ["pro-inflammatory cytokines", "PROBLEM", 30, 56], ["complete and partial sleep restriction", "TREATMENT", 155, 193], ["pro-inflammatory cytokines", "OBSERVATION", 30, 56], ["significantly", "OBSERVATION_MODIFIER", 57, 70], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["decreased", "OBSERVATION_MODIFIER", 84, 93]]], ["Elevated levels of sleep regulating cytokines have been associated CVD, metabolic syndrome and depression; higher, flatter diurnal cortisol patterns are related to depression and elevated morning cortisol levels are positively associated with CVD and metabolic syndrome [33] .Q3: articulation of well-being needsAmbulance personnel articulated their well-being needs in terms of occupational safety and in relation to their lived experience, across four key areas: organisational support; informal support; use of humour; and individual mechanisms to cope such as detachment and external supports [26, 43, 44, 47] .1) Organisational and informal support:Ambulance personnel reported a need for broader recognition of incidents that may be viewed as routine and yet have personal significance, or were cumulative in nature and caused significant distress, thus becoming a critical incident [20] .", [["CVD", "DISEASE", 67, 70], ["metabolic syndrome", "DISEASE", 72, 90], ["depression", "DISEASE", 95, 105], ["cortisol", "CHEMICAL", 131, 139], ["depression", "DISEASE", 164, 174], ["cortisol", "CHEMICAL", 196, 204], ["CVD", "DISEASE", 243, 246], ["metabolic syndrome", "DISEASE", 251, 269], ["cortisol", "CHEMICAL", 131, 139], ["cortisol", "CHEMICAL", 196, 204], ["cortisol", "GENE_OR_GENE_PRODUCT", 196, 204], ["cytokines", "PROTEIN", 36, 45], ["Elevated levels of sleep regulating cytokines", "PROBLEM", 0, 45], ["CVD", "PROBLEM", 67, 70], ["metabolic syndrome", "PROBLEM", 72, 90], ["depression", "PROBLEM", 95, 105], ["flatter diurnal cortisol patterns", "PROBLEM", 115, 148], ["depression", "PROBLEM", 164, 174], ["elevated morning cortisol levels", "PROBLEM", 179, 211], ["CVD", "PROBLEM", 243, 246], ["metabolic syndrome", "PROBLEM", 251, 269], ["organisational support", "TREATMENT", 465, 487], ["humour", "TREATMENT", 514, 520], ["significant distress", "PROBLEM", 833, 853], ["metabolic syndrome", "OBSERVATION", 72, 90], ["depression", "OBSERVATION", 95, 105], ["metabolic syndrome", "OBSERVATION", 251, 269]]], ["On occasion, they felt that paramedics did not value them and that they were seen as 'punching bags' in an 'us and them culture' [27, 46] .1) Organisational and informal support:Paramedics particularly identified that workplace violence and threats were a significant and common issue and played a major role in their feelings of vulnerability and poor mental well-being.", [["workplace violence", "DISEASE", 218, 236], ["them culture", "TEST", 115, 127]]], ["These issues need to be taken seriously by the organisation, with continued prevention and occupational safety measures implemented (e.g. duress alarms, recognition of dangerous addresses, increasing training and knowledge of staff of minimisation strategies and how to deal with violent patients) [20, 28] .2) Individual mechanisms to copeAmbulance personnel described experiencing emotional pain arising from the work they do, with associated feelings of helplessness during and after extreme events.", [["emotional pain", "DISEASE", 383, 397], ["helplessness", "DISEASE", 457, 469], ["patients", "ORGANISM", 288, 296], ["patients", "SPECIES", 288, 296], ["occupational safety measures", "TREATMENT", 91, 119], ["increasing training", "TREATMENT", 189, 208], ["minimisation strategies", "TREATMENT", 235, 258], ["emotional pain", "PROBLEM", 383, 397], ["helplessness", "PROBLEM", 457, 469], ["extreme events", "PROBLEM", 487, 501]]], ["They described feelings of emotional and cognitive detachment from patients and their families during more routine events.", [["feelings of emotional and cognitive detachment", "DISEASE", 15, 61], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["emotional and cognitive detachment", "PROBLEM", 27, 61]]], ["These skills were considered essential to protecting oneself, as feeling useful and managing people and incidents was a positive and protective aspect of the role and contributed to their sense of identity.", [["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99]]], ["They also used advocacy skills as a means of addressing workplace stress and in attempts to get better resourcing (e.g. more personnel, equipment, and recognition) from management and the organisation to be able to perform their role effectively [43] .2) Individual mechanisms to copeAmbulance personnel and their significant others employed cognitive strategies to manage not only the effects of their work environment, but also their relationships and life outside of work.", [["management", "TREATMENT", 169, 179], ["cognitive strategies", "TREATMENT", 342, 362]]], ["During and after the event, it was essential to recognise early signs of distress and to know when to seek social support and how to cultivate those friendships and networks of support as essential preventative and positive means to reduce isolation.", [["distress", "PROBLEM", 73, 81], ["support", "TREATMENT", 177, 184]]], ["As part of the balance of work and life outside of work, establishing and developing one's own interests created a sense of meaning and assisted in delineating work and home life [26] .2) Individual mechanisms to copeIf illness, either psychological or physical or both, became evident, it forced a change in personal views of the self and highlighted the concept of striking a balance with the experience of wellness and illness.", [["illness", "DISEASE", 220, 227], ["illness", "DISEASE", 422, 429], ["illness", "PROBLEM", 422, 429]]], ["The subthemes to this experience focused on the idea of attaining and maintaining wellness through personal nurturing, encountering illness as an experience and a threat, and accepting and managing illness.", [["illness", "DISEASE", 132, 139], ["illness", "DISEASE", 198, 205]]], ["If injury was severe, the positive and protective nature of being a contributing member was challenged and often created a sense of frustration, anger, and worthlessness.", [["worthlessness", "DISEASE", 156, 169], ["injury", "PROBLEM", 3, 9], ["severe", "PROBLEM", 14, 20], ["severe", "OBSERVATION_MODIFIER", 14, 20]]], ["As part of framing wellness and illness, there was a distinct narrative of encountering illness as an experience and a threat.", [["illness", "DISEASE", 32, 39], ["illness", "DISEASE", 88, 95], ["illness", "PROBLEM", 32, 39]]], ["The illness experience had a psychological, physical and social dimension which was encapsulated by the concepts that \"the body makes itself heard; one can get worn out; and one can become too vulnerable or hardened\" [44] .Section 2 impacts of organisational and systems parametersThe findings of the studies discussed in Section 2 are summarised in Appendix 4.Q4: effects of workflow and nature of the work on mental health and well-beingThe nature of the work performed by all first responders is distinguished from other occupations by exposure to human distress and tragedy, referred to in the literature as critical incidents [11, 20, 31, 35] .", [["body", "ANATOMY", 123, 127], ["illness", "DISEASE", 4, 11], ["human distress", "DISEASE", 551, 565], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["human", "ORGANISM", 551, 556], ["human", "SPECIES", 551, 556], ["human", "SPECIES", 551, 556], ["organisational and systems parameters", "TEST", 244, 281], ["the studies", "TEST", 297, 308], ["human distress", "PROBLEM", 551, 565], ["Appendix", "ANATOMY", 350, 358]]], ["However, ambulance personnel share with all other professions and occupations issues to do with how work is organised, the industrial relations and human resources factors that have an impact on the job, the skills and qualities of managers who organise the work, and the personalities and experience of their immediate supervisors.", [["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153]]], ["Several studies note problems under this category of workflow [9-11, 19-21, 23, 27, 31-34, 37, 38, 40, 44-48, 50, 54] .1) The type of work performed by ambulance personnelAmbulance personnel made a distinction between specific traumatic events that produce an emotional toll, such as attending the death of a child or a suicide of a young person [9, 20, 27, 41] , and a patient who may present a range of problematic or difficult responses such as someone with a mental health issue [9] , or domestic violence, a drug and alcohol incident, or road rage [37] .", [["death", "DISEASE", 298, 303], ["domestic violence", "DISEASE", 492, 509], ["alcohol", "CHEMICAL", 522, 529], ["alcohol", "CHEMICAL", 522, 529], ["patient", "ORGANISM", 370, 377], ["alcohol", "SIMPLE_CHEMICAL", 522, 529], ["person", "SPECIES", 339, 345], ["patient", "SPECIES", 370, 377], ["Several studies", "TEST", 0, 15], ["specific traumatic events", "PROBLEM", 218, 243]]], ["A further distinction was made under the broad heading of uncertainty or lack of control [38, 40, 47, 48, 55] , for situations in which they must proceed to a job without adequate knowledge, unsure of what they will find or how to prepare themselves [37] , or where they may be exposed to pathogens and it is difficult to ensure universal precautions [20, 27, 40, 47] .", [["pathogens", "PROBLEM", 289, 298]]], ["The event does not need to be traumatic; it merely needs to evoke a strong emotional response in the individual [11, 41] .", [["traumatic", "DISEASE", 30, 39], ["traumatic", "PROBLEM", 30, 39]]], ["Small or major events had a cumulative effect on stress levels [11, 27, 31, 34] , particularly if there was little time between jobs and shifts to switch off from the trauma of a previous incident [48, 54] .2) The way the work is organisedThe organisation of work can be examined from the perspective of the strength of the industrial protections in place, and the expertise of the human relations and managerial systems within the organisation [38] .", [["trauma", "DISEASE", 167, 173], ["human", "ORGANISM", 382, 387], ["human", "SPECIES", 382, 387], ["human", "SPECIES", 382, 387], ["Small or major events", "PROBLEM", 0, 21], ["stress levels", "TEST", 49, 62]]], ["In dealing with industrial relationships arrangements, they report that given the workload pressures and performance metrics governing their jobs, they had no time to deal with, or digest, the effects of critical events [23, 27, 29, 33, 34, [45] [46] [47] .", [["the workload pressures", "TEST", 78, 100]]], ["Other factors noted were lack of resources including a lack of available ambulances to send to a job [37, 38, 45] , too few staff [10] , and in the case of the USA, low salary requiring a second job [9] , long shifts, lack of sleep linked to shift work, fatigue as a result of long drives in rural areas, and failure to have the required breaks or meals as a result of work intensification resulting in poor eating habits and weight gain [10, 20, 29, 31-34, 48, 54] .", [["fatigue", "DISEASE", 254, 261], ["weight gain", "DISEASE", 426, 437], ["fatigue", "PROBLEM", 254, 261], ["work intensification", "TREATMENT", 369, 389], ["weight gain", "PROBLEM", 426, 437]]], ["Managers were seen to lack empathy or consideration towards paramedic work, to downplay the impact of critical incidents, or the pace of the work [33, 46, 53] , to stigmatise those seeking help [34, 35, 39] , and to lack the skills and training to deal with workplace bullying [34, 35, 54] .", [["bullying", "DISEASE", 268, 276]]], ["Ambulance personnel reported not being supported in legal and audit cases and to consistently have their skill-base ignored through either a failure to be promoted, to access higher level roles, or unable to make their own clinical decisions [38, 48, 55] .", [["a failure", "PROBLEM", 139, 148]]], ["A further frustration was the constant restructuring of the organisation [44] .Q5: effects of organisational structures on psychological and physical well-beingThe organisational response to ambulance personnel's psychological and physical well-being was influenced by the structure and culture of the organisation [38, 43] along with the personal attributes of the paramedic such as their age, gender, years of experience, and psychological factors such as internal locus of control and the capacity to ensure a work-life balance [9, 20] .", [["A further frustration", "PROBLEM", 0, 21], ["psychological factors", "PROBLEM", 428, 449], ["internal locus of control", "TREATMENT", 458, 483], ["the capacity", "PROBLEM", 488, 500]]], ["In Australia, historically, these services had their origins in paramilitary culture, with a strong hierarchical chain of command, which in-turn prizes stoicism in the face of adversity, and compliance, with little sense of worker control or clinical autonomy [48, 54] , but also a high level of teamwork, camaraderie, and public service [20, 38] .", [["stoicism", "DISEASE", 152, 160], ["paramilitary culture", "TEST", 64, 84]]], ["Paramedicine has moved from being a vocationallytrained, male-dominated, blue-collar occupation to a university-trained and registered profession with an increasing number of women and younger recruits who appear to be more comfortable with contemporary methods of stress management [34, 35] .", [["Paramedicine", "CHEMICAL", 0, 12], ["women", "ORGANISM", 175, 180], ["women", "SPECIES", 175, 180], ["stress management", "TREATMENT", 265, 282], ["increasing", "OBSERVATION_MODIFIER", 154, 164]]], ["Providing a comprehensive duty-of-care service to ambulance personnel along with meeting performance metrics during a time of cultural transition can prove difficult for any organisation [27, 46, 49] .1) Managerial response to paramedic well-being and workplace stressorsManagerial responses can be examined through the way managers respond to on-road or call-taker distress and to the type of welfare services provided [27, 34, 35, 45, 46, 48, 50, 54] .", [["cultural transition", "TREATMENT", 126, 145], ["distress", "PROBLEM", 366, 374]]], ["Importantly, management's lack of capacity to deal with organisational stressors such as bullying, workplace conflict, management of rosters and sleep deprivation, and promotion was also seen as a stressor that, in turn, exacerbated ambulance personnel's reactions to traumatic incidents [9, 20, 29, 30, 38, 50] .1) Managerial response to paramedic well-being and workplace stressorsManagers could assist through more thoughtful organisation of rosters to reduce fatigue and lack of sleep, along with ensuring adequate staffing to fill rosters and reduce overtime, and ensuring that rosters followed a clock-wise rotation [29, 31] .", [["bullying", "DISEASE", 89, 97], ["traumatic incidents", "DISEASE", 268, 287], ["fatigue", "DISEASE", 463, 470], ["organisational stressors", "PROBLEM", 56, 80], ["management of rosters", "TREATMENT", 119, 140], ["sleep deprivation", "PROBLEM", 145, 162], ["traumatic incidents", "PROBLEM", 268, 287], ["fatigue", "PROBLEM", 463, 470], ["lack of sleep", "PROBLEM", 475, 488]]], ["Including call-takers in debriefing sessions along with paramedics was also seen as a positive strategy for managers to employ [27] .2) Types of welfare services providedThe type of welfare services provided to ambulance personnel, including those who have retired, and the evidence-base, is also complex, with reported ambiguity around the usefulness or otherwise of critical incident debriefing or mandatory crisis meetings [20, 23, 35, 41, 49] , as well as cognitive behavioural therapy [22, 34, 47] .", [["cognitive behavioural therapy", "TREATMENT", 460, 489], ["base", "ANATOMY_MODIFIER", 283, 287]]], ["Prevailing strategies promoted were pre-employment testing, peer support programs, and psychological first aid along with adequate training of front-line staff as well as managers and team leaders in order to recognise symptoms in individuals at risk [19, 34, 35, 46, 51] .", [["pre-employment testing", "TEST", 36, 58], ["peer support programs", "TREATMENT", 60, 81], ["symptoms", "PROBLEM", 219, 227]]], ["In severe cases of PTSD, there was a recognition that pharmaceutical responses may be required until the individual gained emotional control [51] .", [["PTSD", "DISEASE", 19, 23], ["PTSD", "PROBLEM", 19, 23], ["severe", "OBSERVATION_MODIFIER", 3, 9]]], ["There is limited research on pre-employment testing [32, 51] .", [["pre-employment testing", "TEST", 29, 51]]], ["Peer support can be as simple as time out between jobs, but time scarcity is a factor [34, 35, 44] , and for younger personnel, time to learn to trust colleagues [34, 50] .", [["Peer support", "TREATMENT", 0, 12]]], ["Stress surrounding access to workers compensation was explored in the US context [25] .2) Types of welfare services providedTraining in stress management for managers was seen as essential, and for on-road staff was part of their personal armoury strengthening internal locus of control [9, 20] .", [["welfare services", "TREATMENT", 99, 115], ["stress management", "TREATMENT", 136, 153]]], ["What causes the problem?", [["the problem", "PROBLEM", 12, 23]]], ["What is needed to address the problem?DiscussionTheme 1 -mental health issues result from exposure to traumatic events, but also to the way personnel in the workplace respond (managers, peers) to worker distressDiscussionThe peer-reviewed literature reported on the negative impact of continuous and cumulative exposure to critical incidents.", [["traumatic events", "PROBLEM", 102, 118]]], ["There was also evidence to suggest that, on occasion, mundane jobs that may appear routine for one paramedic can trigger anxiety or distress for another, making exposure to stress an individual response.", [["anxiety", "DISEASE", 121, 128], ["anxiety", "PROBLEM", 121, 128], ["distress", "PROBLEM", 132, 140]]], ["Recovery is made difficult by the nature of shift-work, overtime, the physical demands of the job, and fatigue.", [["fatigue", "DISEASE", 103, 110], ["fatigue", "PROBLEM", 103, 110]]], ["The way the work is organised matters and needs to be addressed with physical and emotional well-being in mind.DiscussionBoth the Australian and international literature confirms that the incidence of psychological distress in ambulance personnel is not just a matter of exposure to traumatic incidents, but also arises from the way the organisation responds, at the managerial and organisational level.", [["psychological distress", "DISEASE", 201, 223], ["psychological distress", "PROBLEM", 201, 223], ["traumatic incidents", "PROBLEM", 283, 302]]], ["For example, at the managerial level, when paramedics experience work-related stress and require access to formal avenues of care, many managers are unsympathetic and lack personal empathy.", [["related stress", "PROBLEM", 70, 84], ["unsympathetic", "PROBLEM", 149, 162]]], ["This is often assumed to have its origins in the military-like or macho culture that discourages emotional displays of distress [48, 54] .DiscussionFurther to the above contributing factors, in several studies ambulance personnel reported that their access to appropriate care is made difficult through failure to acknowledge the stress, lack of confidentiality, use of inappropriate therapies, poor return-to-work mechanisms, isolation, and stigmatisation, concerted efforts to obstruct access to Worker's Compensation provisions, and the lack of support post-retirement.DiscussionThe interactional impact between exposure to traumatic events and workplace culture goes beyond the lack of support or open hostility shown by some managers within paramedic organisations, to the negative outcomes associated with New Public Management principles.", [["macho culture", "TEST", 66, 79], ["distress", "PROBLEM", 119, 127], ["difficult through failure", "PROBLEM", 285, 310], ["the stress", "PROBLEM", 326, 336], ["inappropriate therapies", "TREATMENT", 370, 393], ["isolation", "TREATMENT", 427, 436], ["support post-retirement", "TREATMENT", 548, 571], ["traumatic events", "PROBLEM", 627, 643], ["workplace culture", "TEST", 648, 665], ["New Public Management principles", "TREATMENT", 812, 844]]], ["This is best summed up by Hamling, in relation to the New Zealand experience [55, 56] , who argued that the productivity and efficiency targets set by governments and, of necessity, implemented by management, prevent on-road paramedics from achieving their vocation to care.", [["New", "OBSERVATION_MODIFIER", 54, 57]]], ["She suggested that the culture of metrics (key performance indicators used by managers) means that on-road staff become more concerned about the speed in which a job is performed, than caring for the patient.", [["patient", "ORGANISM", 200, 207], ["patient", "SPECIES", 200, 207], ["the culture", "TEST", 19, 30]]], ["This creates tension and stress in on-road paramedics and underpins their response to critical incidents and much of the workplace stress they experience.", [["tension", "OBSERVATION_MODIFIER", 13, 20], ["stress", "OBSERVATION_MODIFIER", 25, 31]]], ["Regehr and Millar encapsulate these issues within a framework of Demand and Control as factors affecting the individual's sense of support.", [["Demand and Control", "TREATMENT", 65, 83]]], ["Where these factors are perceived to be or are absent, it leads to work stress and depression [38] (see Fig. 2 ).DiscussionTheme 2ambulance personnel suffering from workrelated stress feel abandoned by peers, management, and service, during illness, in return-to-work, and postretirementDiscussionThe research reported overwhelmingly that ambulance personnel perceive that they receive little support from the organisation when they are suffering from workplace stress, burnout, anxiety, and/or PTSD.", [["depression", "DISEASE", 83, 93], ["illness", "DISEASE", 241, 248], ["burnout", "DISEASE", 470, 477], ["anxiety", "DISEASE", 479, 486], ["PTSD", "DISEASE", 495, 499], ["depression", "PROBLEM", 83, 93], ["burnout", "PROBLEM", 470, 477], ["anxiety", "PROBLEM", 479, 486], ["PTSD", "PROBLEM", 495, 499]]], ["They view mental illness as highly stigmatised within ambulance organisations, making them loathe to seek professional help.", [["illness", "DISEASE", 17, 24], ["mental illness", "PROBLEM", 10, 24]]], ["They report that informal helpful debriefing occurs largely outside of the service, with family or friends, despite most organisations providing peer support programs.", [["peer support programs", "TREATMENT", 145, 166]]], ["Relying on outside support is not always satisfactory given the possibility that family and friends may experience vicarious trauma [58] .", [["trauma", "DISEASE", 125, 131], ["vicarious trauma", "PROBLEM", 115, 131]]], ["Strategies such as black humour are used, but this is increasingly seen as politically inappropriate, with paramedics on edge as to where and how it can be exercised [59] .DiscussionGiven the recognition that stress is cumulative, it is surprising that support for well-being does not extend to those personnel who are forced to retire due to illness or at the end of their career.", [["illness", "DISEASE", 343, 350], ["Strategies", "TREATMENT", 0, 10], ["illness", "PROBLEM", 343, 350]]], ["There was little research reporting on support programs for retired personnel, or recognition that they may be able to assist those currently in the service in need of care.", [["support programs", "TREATMENT", 39, 55]]], ["As noted, despite many services providing support mechanisms, at all points in their career, the individual is seen as responsible, with management and the organisation being unable or unwilling to assist.", [["support mechanisms", "TREATMENT", 42, 60], ["management", "TREATMENT", 137, 147]]], ["Some research suggests that the failure of management to respond to paramedic stress does not arise from a lack of empathy, but a failure in appropriate skills in managing bullying, conflict, and confidentiality which 'boils over' into workplace management [9, 20, 29, 30, 38, 50] .", [["bullying", "DISEASE", 172, 180], ["the failure of management", "PROBLEM", 28, 53], ["paramedic stress", "PROBLEM", 68, 84], ["empathy", "PROBLEM", 115, 122], ["a failure", "PROBLEM", 128, 137]]], ["The overwhelming alienation between management and front-line ambulance personnel is a key finding emerging from a significant number of papers across the peerreviewed literature.DiscussionTheme 3 -policy, programmes and interventions, and education need to occur at an individual, peer, organisational, and government level (Programmes and resources)DiscussionResearch exploring how the issues highlighted above can be addressed takes a holistic approach moving from the individual through to the organisation.", [["management", "TREATMENT", 36, 46], ["interventions", "TREATMENT", 221, 234], ["a holistic approach", "TREATMENT", 436, 455], ["overwhelming", "OBSERVATION_MODIFIER", 4, 16], ["alienation", "OBSERVATION", 17, 27]]], ["Cultural action is required to remove the stigma associated with seeking help for work-related stress.", [["the stigma", "PROBLEM", 38, 48]]], ["This is a difficult task and is probably only achieved when actions speak louder than any rhetoric on the topic.", [["probably only", "UNCERTAINTY", 32, 45]]], ["This may mean that the service needs to organise staffing and rosters to allow paramedics with structured recovery time between jobs so that fatigue and emotional processes can be addressed.", [["fatigue", "DISEASE", 141, 148], ["fatigue and emotional processes", "PROBLEM", 141, 172]]], ["This will invariably have an impact on budgets along with the need for a more concerted focus on the training and education of leaders and managers in all aspects of their role, from designing rosters that safeguard well-being, to recognising colleagues in distress, to the management of workplace tensions.DiscussionA number of studies reported mixed results from the support programs currently used within Ambulance Services.", [["the training", "TREATMENT", 97, 109], ["distress", "PROBLEM", 257, 265], ["the support programs", "TREATMENT", 365, 385]]], ["For example, there was considerable discussion on the use of Critical Incident De-briefing with claims that it lacked an evidence base.", [["base", "ANATOMY_MODIFIER", 130, 134]]], ["Although the current recommendation is for psychological firstaid support programs, there is currently only limited evidence establishing efficacy of both peer support programs and psychological first aid in the emergency service context.DiscussionA number of studies suggested pre-employment testing, although there was insufficient evidence to support the recommendation [21, 51] .", [["psychological firstaid support programs", "TREATMENT", 43, 82], ["peer support programs", "TREATMENT", 155, 176], ["pre-employment testing", "TEST", 278, 300]]], ["The standard specifically aims to assist ambulance organisations to: raise awareness of stigma, self-stigma and harassment; systematically identify potential sources of stress and hazards to psychological wellbeing; and identify measures that can be implemented to address those hazards.", [["stigma", "PROBLEM", 88, 94], ["stress", "PROBLEM", 169, 175]]], ["For example, this could include policies that provide members and their families (employed and retired) with financial support to seek their own confidential psychological well-being counselling outside of the organisation, with no financial cap put on resource use.", [["financial support", "TREATMENT", 109, 126]]], ["Also, given the cumulative nature of psychological and physical impacts on this population, Workers Compensation claims systems and processes should be streamlined and accepted for conditions that are often chronic in nature and which require long-term support.LimitationsThis systematic review had several limitations.", [["long-term support", "TREATMENT", 243, 260], ["long-term", "OBSERVATION_MODIFIER", 243, 252]]], ["There were few studies about retirement issues, none devoted to volunteers, and none that examined potential gender differences.", [["volunteers", "ORGANISM", 64, 74]]], ["Most studies involved mixed samples; however, experiences and needs may vary across gender, role, education level, urban and rural location, availability of supports, experience and seniority level.", [["Most studies", "TEST", 0, 12], ["mixed samples", "PROBLEM", 22, 35]]], ["There are also limits associated with qualitative research which relies on self-report, often involving sample sizes and single organisations for recruitment, which may have led to recruitment bias and problems with generalising the findings to other contexts and other countries.", [["recruitment", "PROBLEM", 146, 157], ["recruitment bias", "PROBLEM", 181, 197]]], ["Further limitations included the inclusion of all available studies regardless of their quality which may have affected the trustworthiness of conclusions drawn and validity of themes.ConclusionThe research literature suggests that strategies to address psychological wellbeing of ambulance personnel are of two kinds: specific programs to assist them to manage the distress that comes with attending to critical incidents; and secondly, programs that deal with organisational issues.", [["all available studies", "TEST", 46, 67], ["the distress", "PROBLEM", 362, 374]]], ["Despite the limitations noted, the research literature reported in this review points overwhelmingly to an interactional effect between critical incidents and workplace culture and demands.", [["workplace culture", "TEST", 159, 176]]], ["This culture includes day-to-day managerial actions and responses, but also the impact of shift work, poorly managed rosters, and long hours of work with little time between for recovery.", [["This culture", "TEST", 0, 12]]], ["Coupled with work-flow issues are the negative consequences of New Public Management productivity and efficiency targets, now part of many ambulance services that require the job to be done within particular time limits.", [["work-flow issues", "PROBLEM", 13, 29], ["New", "OBSERVATION_MODIFIER", 63, 66]]]], "52ce19fe79de46d9bb0fa7e75a0631fed2d3efd2": [["BackgroundSevere Acute Respiratory Syndrome (SARS) is a new infectious disease reported first in the autumn of 2002 and diagnosed for the first time in March 2003 [1] .", [["Acute Respiratory Syndrome", "DISEASE", 17, 43], ["SARS", "DISEASE", 45, 49], ["infectious disease", "DISEASE", 60, 78], ["BackgroundSevere Acute Respiratory Syndrome (SARS)", "SPECIES", 0, 50], ["Acute Respiratory Syndrome", "PROBLEM", 17, 43], ["a new infectious disease", "PROBLEM", 54, 78], ["Acute", "OBSERVATION_MODIFIER", 17, 22], ["Respiratory Syndrome", "OBSERVATION", 23, 43], ["new", "OBSERVATION_MODIFIER", 56, 59], ["infectious", "OBSERVATION", 60, 70]]], ["It is still a serious threat to human health and SARS coronavirus (CoV) has been associated with the pathogenesis of SARS according to Koch's postulate [2] .BackgroundSignificant research efforts have been made into investigation of the SARS-CoV genome sequence, aimed at establishing its origin and evolution to help eventually in preventing or curing the disease it causes.", [["SARS coronavirus", "DISEASE", 49, 65], ["SARS", "DISEASE", 117, 121], ["human", "ORGANISM", 32, 37], ["SARS coronavirus", "ORGANISM", 49, 65], ["CoV", "ORGANISM", 67, 70], ["SARS-CoV genome sequence", "DNA", 237, 261], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["SARS coronavirus", "SPECIES", 49, 65], ["CoV", "SPECIES", 67, 70], ["SARS-CoV", "SPECIES", 237, 245], ["SARS coronavirus", "PROBLEM", 49, 65], ["SARS", "PROBLEM", 117, 121], ["the SARS", "TEST", 233, 241], ["CoV genome sequence", "TEST", 242, 261], ["the disease", "PROBLEM", 353, 364], ["Significant", "OBSERVATION_MODIFIER", 167, 178], ["disease", "OBSERVATION", 357, 364]]], ["Although the task is a hard one, it opens up the opportunity, amongst others, for comparative investigation of different SARS-CoV isolates aimed at identification of genome regions properties expressing different levels of sequence polymorphism [3] [4] [5] [6] [7] [8] .BackgroundThe genome of SARS-CoV consists of a single positive RNA strand approximately 30 Kb in length, consisting of about 10 open reading frames (ORF), and about 10 intergenic regions (IGRs).", [["SARS", "DISEASE", 121, 125], ["SARS-CoV", "ORGANISM", 121, 129], ["[3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 245, 268], ["SARS-CoV", "ORGANISM", 294, 302], ["genome regions", "DNA", 166, 180], ["SARS-CoV", "DNA", 294, 302], ["single positive RNA strand", "RNA", 317, 343], ["open reading frames", "DNA", 398, 417], ["ORF", "DNA", 419, 422], ["10 intergenic regions", "DNA", 435, 456], ["IGRs", "DNA", 458, 462], ["SARS-CoV", "SPECIES", 121, 129], ["SARS-CoV", "SPECIES", 294, 302], ["comparative investigation", "TEST", 82, 107], ["different SARS", "PROBLEM", 111, 125], ["CoV isolates", "TREATMENT", 126, 138], ["genome regions properties", "PROBLEM", 166, 191], ["sequence polymorphism", "TEST", 223, 244], ["SARS", "PROBLEM", 294, 298], ["a single positive RNA strand", "PROBLEM", 315, 343], ["SARS", "OBSERVATION", 294, 298], ["strand", "OBSERVATION_MODIFIER", 337, 343], ["approximately", "OBSERVATION_MODIFIER", 344, 357], ["30 Kb", "OBSERVATION_MODIFIER", 358, 363]]], ["The first two overlapping ORFs at the 5' end encompass two-thirds of the genome, while the rest of the ORFs at the 3' end account for the remaining third.", [["ORFs", "DNA", 26, 30], ["5' end", "DNA", 38, 44], ["ORFs", "DNA", 103, 107], ["3' end", "DNA", 115, 121], ["overlapping ORFs", "TREATMENT", 14, 30], ["the ORFs", "TREATMENT", 99, 107], ["genome", "OBSERVATION", 73, 79]]], ["[9] in gbk and fasta formats ( Table 1 ).", [["gbk", "CELL", 7, 10]]], ["The main goal was twofold: first, to analyze and compare nucleotide sequences, to identify SNPs positions, insertions and deletions, and second, to group them according to sequence similarity, eventually pointing to phylogeny of SARS-CoV isolates.BackgroundAccording to the length of isolates (insertions and deletions) and the presence of SNPs, we classified them into three main groups with subgroups: \"regular\" isolates with no insertions or deletions (with different numbers of SNPs), isolates with \"long insertions\" and isolates with \"many individual\" insertions and deletions (with different positions of SNPs), which is close to phylogenetic analysis results.Genome polymorphismAll the sequences are between 29573 and 29757 in length (Table 1) , with a high degree of similarity (>99% pairwise).", [["SARS", "DISEASE", 229, 233], ["nucleotide", "CHEMICAL", 57, 67], ["SARS-CoV", "ORGANISM", 229, 237], ["SNPs positions", "DNA", 91, 105], ["SNPs", "DNA", 611, 615], ["SARS-CoV", "SPECIES", 229, 237], ["nucleotide sequences", "TEST", 57, 77], ["insertions and deletions", "TREATMENT", 107, 131], ["CoV isolates", "TREATMENT", 234, 246], ["isolates (insertions and deletions", "TREATMENT", 284, 318], ["regular\" isolates", "TREATMENT", 405, 422], ["insertions or deletions", "PROBLEM", 431, 454], ["different numbers of SNPs", "TREATMENT", 461, 486], ["\"long insertions\"", "TREATMENT", 503, 520], ["individual\" insertions and deletions", "TREATMENT", 545, 581], ["different positions of SNPs", "TREATMENT", 588, 615], ["phylogenetic analysis", "TEST", 636, 657], ["Genome polymorphism", "PROBLEM", 666, 685], ["All the sequences", "TEST", 685, 702], ["a high degree of similarity", "PROBLEM", 758, 785], ["main", "OBSERVATION_MODIFIER", 4, 8], ["polymorphism", "OBSERVATION", 673, 685], ["high degree", "OBSERVATION_MODIFIER", 760, 771]]], ["Still, they can be differentiated on the basis of sequence polymorphism (insertions and deletions), number and sites of SNPs [8] .", [["sequence polymorphism (insertions and deletions)", "TREATMENT", 50, 98]]], ["TWH position 1---------------------------------27168 -----27782 ------27808 27814 ---------27883 ------------------29727 Isolate number | | || | | 1-6,11:TWH (TWC2) atattaggtt up to the poly-\"a\" of length 13 present at the 3' end of FRA ( Figure 1 ).Analysis of genomic polymorphism of the isolates resulted in the following factsII) Similarity analysis showed that a significant number of isolates have the same length (29727 bases), the same beginning and ending subsequences (that seem to be exact starts and ends of the complete SARS-CoV genome up to the poly-\"a\" at the 3' end), thus forming a kind of referent group; these are the isolates TWH, TWC3, TWK, TWS, TWY, Urbani, Frankfurt 1 ( Figure 1 ).", [["-----27782", "CHEMICAL", 53, 63], ["------27808 27814 ---------27883 ------------------29727", "CHEMICAL", 64, 120], ["------27808 27814 ---------27883 ------------------29727", "CHEMICAL", 64, 120], ["TWC2", "DNA", 159, 163], ["poly-\"a\" of length 13", "DNA", 186, 207], ["FRA", "PROTEIN", 233, 236], ["SARS-CoV genome", "DNA", 533, 548], ["poly-\"a\" at the 3' end", "DNA", 559, 581], ["SARS-CoV", "SPECIES", 533, 541], ["TWH", "TEST", 154, 157], ["TWC2", "TEST", 159, 163], ["atattaggtt", "TEST", 165, 175], ["genomic polymorphism of the isolates", "PROBLEM", 262, 298], ["Similarity analysis", "TEST", 334, 353], ["a significant number of isolates", "PROBLEM", 366, 398], ["the complete SARS", "PROBLEM", 520, 537], ["the isolates TWH", "TEST", 633, 649], ["TWC3", "TEST", 651, 655], ["TWK", "TEST", 657, 660], ["TWS", "TEST", 662, 665], ["genomic polymorphism", "OBSERVATION", 262, 282], ["significant", "OBSERVATION_MODIFIER", 368, 379], ["number", "OBSERVATION_MODIFIER", 380, 386], ["isolates", "OBSERVATION", 390, 398], ["length", "OBSERVATION_MODIFIER", 413, 419]]], ["The fully sequenced isolate TWH then has been chosen as the referent isolate for sequence comparisons since its average number of SNPs compared to other isolates is the smallest.", [["TWH", "DNA", 28, 31], ["sequence comparisons", "TEST", 81, 101], ["SNPs", "PROBLEM", 130, 134], ["smallest", "OBSERVATION_MODIFIER", 169, 177]]], ["For example, TWH and Urbani have an average number of SNPs 15.7 and 17.6 respectively for all the isolates, and 5.7 and 10.5 respectively for the referent group.Analysis of genomic polymorphism of the isolates resulted in the following factsFor SNPs see the tables in the additional files 1 and 2.Analysis of genomic polymorphism of the isolates resulted in the following factsIII) Most isolates, compared to TWH, are shorter at the 5'end (e.g., Sin2500, Sin2679, Sin2774, Sin2677, Sin2748, AS), have various length poly-\"a\" strings at the 3' end (e.g., Tor2, HSR1, FRA, BJ02, TW1, HKU-39489, WHU), or both (BJ01, BJ03, BJ04, CUHK-W1, CUHK-Su10).", [["HKU-39489", "CHEMICAL", 582, 591], ["Sin2679", "CHEMICAL", 455, 462], ["FRA", "GENE_OR_GENE_PRODUCT", 566, 569], ["HKU-39489", "GENE_OR_GENE_PRODUCT", 582, 591], ["CUHK-W1", "GENE_OR_GENE_PRODUCT", 626, 633], ["CUHK-Su10", "GENE_OR_GENE_PRODUCT", 635, 644], ["SNPs", "DNA", 245, 249], ["TWH", "DNA", 409, 412], ["5'end", "DNA", 433, 438], ["3' end", "DNA", 540, 546], ["Tor2", "DNA", 554, 558], ["HSR1", "DNA", 560, 564], ["FRA", "DNA", 566, 569], ["BJ02", "DNA", 571, 575], ["TW1", "DNA", 577, 580], ["HKU", "DNA", 582, 585], ["WHU", "DNA", 593, 596], ["BJ01", "DNA", 608, 612], ["BJ03", "DNA", 614, 618], ["BJ04", "DNA", 620, 624], ["CUHK", "DNA", 626, 630], ["W1", "DNA", 631, 633], ["CUHK", "DNA", 635, 639], ["Su10", "DNA", 640, 644], ["TWH", "TEST", 13, 16], ["Urbani", "TEST", 21, 27], ["SNPs", "TEST", 54, 58], ["all the isolates", "TEST", 90, 106], ["genomic polymorphism of the isolates", "PROBLEM", 173, 209], ["SNPs", "PROBLEM", 245, 249], ["genomic polymorphism of the isolates", "PROBLEM", 309, 345], ["various length poly", "TEST", 501, 520], ["Tor2", "TEST", 554, 558], ["HSR1", "TEST", 560, 564], ["FRA", "TEST", 566, 569], ["BJ02", "TEST", 571, 575], ["TW1", "TEST", 577, 580], ["HKU", "TEST", 582, 585], ["BJ01", "TEST", 608, 612], ["BJ03", "TEST", 614, 618], ["BJ04", "TEST", 620, 624], ["CUHK", "TEST", 626, 630], ["CUHK", "TEST", 635, 639], ["average", "OBSERVATION_MODIFIER", 36, 43], ["number", "OBSERVATION_MODIFIER", 44, 50], ["genomic polymorphism", "OBSERVATION", 173, 193], ["genomic polymorphism", "OBSERVATION", 309, 329]]], ["Three of the isolates, Taiwan TC1, Taiwan TC2, Taiwan TC3, have both starting and ending deletions (at the 5' end 69, at the 3' end 85 nucleotides).", [["5' end 69", "DNA", 107, 116], ["3' end 85 nucleotides", "DNA", 125, 146], ["Taiwan TC1", "SPECIES", 23, 33], ["Taiwan TC2", "SPECIES", 35, 45], ["Taiwan TC3", "TREATMENT", 47, 57]]], ["Several isolates (e.g. TWJ, TWC, Sin2677, Sin2748) have some short deletions inside the sequence ( Figure 1 ).Analysis of genomic polymorphism of the isolates resulted in the following factsIV) There is a group of isolates that have significant length insertions (29 nucleotides) inside the sequence.", [["Several isolates", "TEST", 0, 16], ["TWJ", "TEST", 23, 26], ["TWC", "TEST", 28, 31], ["some short deletions inside the sequence", "PROBLEM", 56, 96], ["genomic polymorphism of the isolates", "PROBLEM", 122, 158], ["a group of isolates", "PROBLEM", 203, 222], ["significant length insertions", "PROBLEM", 233, 262], ["genomic polymorphism", "OBSERVATION", 122, 142], ["significant", "OBSERVATION_MODIFIER", 233, 244], ["length", "OBSERVATION_MODIFIER", 245, 251]]], ["A significant number of individual insertions have been identified in ZJ01 and ZMY 1 isolates ( Figure 1 , additional files 3,4,5).Analysis of genomic polymorphism of the isolates resulted in the following factsAmong the SNP contents of isolates, there is a significant difference in the number of SNPs for different pairs of isolates.", [["SNP", "CHEMICAL", 221, 224], ["individual insertions", "PROBLEM", 24, 45], ["ZJ01", "TEST", 70, 74], ["genomic polymorphism of the isolates", "PROBLEM", 143, 179], ["different pairs of isolates", "PROBLEM", 307, 334], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["individual insertions", "OBSERVATION", 24, 45], ["genomic polymorphism", "OBSERVATION", 143, 163], ["isolates", "OBSERVATION_MODIFIER", 237, 245], ["significant", "OBSERVATION_MODIFIER", 258, 269], ["difference", "OBSERVATION_MODIFIER", 270, 280]]], ["For TWH as the referent isolate, this number varies from 1 to 80 SNPs.", [["TWH", "PROBLEM", 4, 7]]], ["Isolates may be classified into three groups based on the number of SNPs with TWH ( Figure 2 ):Analysis of genomic polymorphism of the isolates resulted in the following facts1. with less than 15 (TWC3, TWK, TWS, TWY, Urbani, TWJ, TWC, TW1 Finally, besides the number, there are differences in positions of SNPs (potential mutation sites).", [["Isolates", "TREATMENT", 0, 8], ["genomic polymorphism of the isolates", "PROBLEM", 107, 143], ["TWC3", "TEST", 197, 201], ["TWK", "TEST", 203, 206], ["TWS", "TEST", 208, 211], ["TWY", "TEST", 213, 216], ["Urbani", "TEST", 218, 224], ["TWJ", "TEST", 226, 229], ["TWC", "TEST", 231, 234], ["SNPs (potential mutation sites", "TREATMENT", 307, 337], ["genomic polymorphism", "OBSERVATION", 107, 127]]], ["In order to avoid nucleotide changes that probably arose during propagation of the virus in cell culture and sequencing, Figure 3 represents positions (on the relative scale of all isolates and on TWH scale) where two or more SNPs occurred, not taking into consideration isolates with long insertions (GD01, SZ3 and SZ16).", [["cell", "ANATOMY", 92, 96], ["nucleotide", "CHEMICAL", 18, 28], ["nucleotide", "CHEMICAL", 18, 28], ["cell", "CELL", 92, 96], ["long insertions", "DNA", 285, 300], ["GD01", "DNA", 302, 306], ["SZ3", "DNA", 308, 311], ["SZ16", "DNA", 316, 320], ["nucleotide changes", "PROBLEM", 18, 36], ["the virus", "PROBLEM", 79, 88], ["cell culture", "TEST", 92, 104], ["all isolates", "TREATMENT", 177, 189], ["TWH scale", "TREATMENT", 197, 206], ["long insertions (GD01, SZ3 and SZ16", "TREATMENT", 285, 320]]], ["The positions of multiple SNPs of these three isolates, similar as far as these three are concerned, are highly different from all the others and are represented in Figure 4 .", [["these three isolates", "TREATMENT", 34, 54], ["multiple", "OBSERVATION_MODIFIER", 17, 25], ["highly", "OBSERVATION_MODIFIER", 105, 111], ["different", "OBSERVATION_MODIFIER", 112, 121]]], ["These results coincide with those published in Marra et al's paper [4] for Urbani and Tor2 isolates, but differ from those published in Ruan's paper [8] for the 14 isolates therein analyzed (Sin-group, BJgroup, Tor2, Urbani, CUHK-W1, HKU-39849, GD01), which were obviously based on different revisions of the PubMed NCBI Entrez database [9] ;Grouping of isolatesThe isolates from the dataset considered may be classified according to their sequence polymorphism and SNP contents properties just described.", [["HKU-39849", "CHEMICAL", 234, 243], ["SNP", "CHEMICAL", 466, 469], ["Urbani", "SIMPLE_CHEMICAL", 75, 81], ["Tor2", "GENE_OR_GENE_PRODUCT", 86, 90], ["HKU-39849", "CELL", 234, 243], ["Urbani and Tor2 isolates", "TREATMENT", 75, 99], ["BJgroup", "TEST", 202, 209], ["Tor2", "TEST", 211, 215], ["Urbani", "TEST", 217, 223], ["CUHK", "TEST", 225, 229], ["HKU", "TEST", 234, 237], ["their sequence polymorphism and SNP contents properties", "PROBLEM", 434, 489]]], ["At first, properties (III, IV) may result in three different groups ( Figure 2 ):Grouping of isolatesA. \"regular isolates\" whose nucleotide structure is close to the referent group ( Structural tree for SARS-CoV isolates Figure 2 Structural tree for SARS-CoV isolates.", [["nucleotide", "CHEMICAL", 129, 139], ["nucleotide", "CHEMICAL", 129, 139], ["SARS-CoV", "ORGANISM", 250, 258], ["SARS-CoV", "SPECIES", 203, 211], ["SARS-CoV", "SPECIES", 250, 258], ["isolatesA", "PROBLEM", 93, 102], ["SARS", "PROBLEM", 203, 207], ["CoV isolates", "TEST", 208, 220], ["SARS", "PROBLEM", 250, 254], ["CoV isolates", "TREATMENT", 255, 267]]], ["The tree is based on qualitative analysis of sequence variation of 36 isolates. protein 1ab 1ab 1ab 1ab 1ab 1ab 1ab 1ab 1ab 1ab 1ab 1ab 1ab S S S hyp hyp E M M hyp hyp hyp N Relative scale 2562 3858 7930 8585 9417 9867 11461 11506 17590 18991 19090 19111 19865 21749 22250 24962 25329 26080 26233 26507 26630 27273 27843 27858 28328 TWH scale 2557 3852 7919 8572 9404 9854 11448 11493 17564 18965 19064 19084 19838 21721 22222 24933 25299 26050 26203 26477 26600 27243 27812 27827 28268 Positions with two or more SNPs in B group with amino acid changes Figure 4 Positions with two or more SNPs in B group with amino acid changes.", [["2562 3858 7930 8585 9417 9867 11461 11506 17590 18991 19090 19111 19865 21749 22250 24962 25329 26080 26233 26507 26630 27273 27843 27858 28328", "ANATOMY", 189, 332], ["scale 2562 3858 7930 8585 9417 9867 11461 11506 17590 18991 19090 19111 19865 21749 22250 24962 25329 26080 26233 26507 26630 27273 27843 27858 28328 TWH scale 2557 3852 7919 8572 9404 9854 11448 11493 17564 18965 19064 19084 19838 21721 22222 24933 25299 26050 26203 26477 26600 27243 27812 27827 28268", "CHEMICAL", 183, 486], ["amino acid", "CHEMICAL", 535, 545], ["amino acid", "CHEMICAL", 611, 621], ["amino acid", "CHEMICAL", 535, 545], ["amino acid", "CHEMICAL", 611, 621], ["amino acid", "AMINO_ACID", 535, 545], ["B", "CANCER", 598, 599], ["amino acid", "AMINO_ACID", 611, 621], ["qualitative analysis", "TEST", 21, 41], ["sequence variation", "TEST", 45, 63], ["protein", "TEST", 80, 87], ["ab", "TEST", 101, 103], ["ab", "TEST", 105, 107], ["ab", "TEST", 109, 111], ["ab", "TEST", 113, 115], ["ab", "TEST", 117, 119], ["ab", "TEST", 121, 123], ["ab", "TEST", 125, 127], ["ab", "TEST", 129, 131], ["ab", "TEST", 133, 135], ["ab S", "TEST", 137, 141], ["S S", "TEST", 142, 145], ["hyp hyp E M M hyp hyp hyp N", "TEST", 146, 173], ["scale", "TEST", 183, 188], ["scale", "TEST", 337, 342], ["more SNPs in B group", "TREATMENT", 509, 529], ["amino acid changes", "TREATMENT", 535, 553], ["more SNPs in B group", "TREATMENT", 585, 605], ["amino acid changes", "TREATMENT", 611, 629], ["tree", "ANATOMY_MODIFIER", 4, 8], ["amino acid", "OBSERVATION", 611, 621]]], ["Only SNPs in B group isolates, regarding TWH, have been counted.", [["B", "GENE_OR_GENE_PRODUCT", 13, 14], ["SNPs in B group isolates", "TREATMENT", 5, 29]]], ["(Figure 7b) Finally, the positions of SNPs will move CUHK-W1 from A1 into A2 group (more than 50% of common SNP positions) while WHU will move from A2 into A1 (less than 30% of common SNP positions), giving the final grouping of isolates presented as a structural tree (Figure 2 Although qualitative in nature, the structural tree turns out to be close to the quantitative grouping which is a basis for (computational) phylogenetic classification.", [["SNP", "CHEMICAL", 108, 111], ["SNP", "CHEMICAL", 184, 187], ["CUHK-W1", "GENE_OR_GENE_PRODUCT", 53, 60], ["A2", "GENE_OR_GENE_PRODUCT", 74, 76], ["A1", "GENE_OR_GENE_PRODUCT", 156, 158], ["SNPs", "DNA", 38, 42], ["CUHK", "DNA", 53, 57], ["W1", "DNA", 58, 60], ["A1", "DNA", 66, 68], ["A2", "PROTEIN", 148, 150], ["A1", "DNA", 156, 158], ["SNPs", "TREATMENT", 38, 42], ["CUHK", "TEST", 53, 57]]], ["Tables in additional files 1 additional files 2 for isolates of A2 group and TWH, on the TWH scale, additional files 3 for isolates of group B with TWH, and additional files 4,5 for isolates of C1, C2 groups, respectively).", [["TWH", "DISEASE", 148, 151], ["the TWH scale", "TEST", 85, 98], ["TWH", "TEST", 148, 151]]], ["Figures 5,6 ,7 represent density distribution of SNPs, insertions and deletions on the TWH scale, for the same groups of isolates.", [["SNPs", "DNA", 49, 53], ["Figures", "TEST", 0, 7], ["density distribution of SNPs", "PROBLEM", 25, 53], ["insertions and deletions", "PROBLEM", 55, 79], ["the TWH scale", "TEST", 83, 96], ["density", "OBSERVATION_MODIFIER", 25, 32], ["distribution", "OBSERVATION_MODIFIER", 33, 45], ["insertions", "OBSERVATION_MODIFIER", 55, 65]]], ["Figure 8 represents the overall density distribution of SNPs, insertions and deletions for all the 36 isolates, along with the gene map for TWH (which is quite similar to gene maps of other isolates).", [["SNPs", "DNA", 56, 60], ["TWH", "DNA", 140, 143], ["insertions and deletions", "TREATMENT", 62, 86], ["the gene map", "TEST", 123, 135], ["TWH", "PROBLEM", 140, 143], ["overall", "OBSERVATION_MODIFIER", 24, 31], ["density", "OBSERVATION_MODIFIER", 32, 39], ["distribution", "OBSERVATION_MODIFIER", 40, 52]]], ["Density distributions do not show regularities yet (with respect to the number of available sequences) that could provide for precise statistical characterization.", [["Density distributions", "PROBLEM", 0, 21], ["precise statistical characterization", "TEST", 126, 162]]], ["Still, they exhibit crowding regions close to the 3' end which is also characterized by the presence of a number of proteins of unknown function.SARS-CoV isolatesIt can also be noted that the proposed grouping of 36 isolates, based on different criteria, still conserves the previous classification T-T-T-T / C-G-C-C [8] .", [["SARS", "DISEASE", 145, 149], ["3' end", "CELLULAR_COMPONENT", 50, 56], ["SARS-CoV", "ORGANISM", 145, 153], ["3' end", "DNA", 50, 56], ["SARS-CoV", "SPECIES", 145, 153], ["crowding regions", "PROBLEM", 20, 36], ["SARS", "PROBLEM", 145, 149], ["crowding", "OBSERVATION", 20, 28], ["unknown function", "OBSERVATION", 128, 144]]], ["All the isolates from groups A1 and C have T-T-T-T configuration, while all the isolates from groups A2 and B have C-G-C-C configuration, except for GZ50, BJ04 being TGCC (Figure 2 , The fact that the enlarged number of isolates exhibits the same properties relating to the four loci supports the assumption that the mutations could not have arisen by chance base substitution during propagation in cell culture and the sequencing procedure [8] .Changes in amino acidsWe analyzed amino acid changes in proteins for the annotated isolates (19 out of 36), and presumed proteins in non-annotated ones for multiple SNPs in all the isolates.Changes in amino acidsResults of the analysis are represented in Figures 3 and 4 .", [["cell culture", "ANATOMY", 399, 411], ["amino acids", "CHEMICAL", 457, 468], ["amino acid", "CHEMICAL", 480, 490], ["amino acidsResults", "CHEMICAL", 647, 665], ["amino acids", "CHEMICAL", 457, 468], ["amino acid", "CHEMICAL", 480, 490], ["amino", "CHEMICAL", 647, 652], ["C", "CELL", 36, 37], ["B", "GENE_OR_GENE_PRODUCT", 108, 109], ["C-G-C-C", "GENE_OR_GENE_PRODUCT", 115, 122], ["cell culture", "CELL", 399, 411], ["amino acids", "AMINO_ACID", 457, 468], ["amino acid", "AMINO_ACID", 480, 490], ["amino acidsResults", "AMINO_ACID", 647, 665], ["T", "TEST", 43, 44], ["A2", "TEST", 101, 103], ["C", "TEST", 115, 116], ["G", "TEST", 117, 118], ["GZ50", "TEST", 149, 153], ["BJ04", "TEST", 155, 159], ["the enlarged number of isolates", "PROBLEM", 197, 228], ["the mutations", "PROBLEM", 313, 326], ["cell culture", "TEST", 399, 411], ["the sequencing procedure", "TREATMENT", 416, 440], ["Changes in amino acids", "PROBLEM", 446, 468], ["amino acid changes in proteins", "PROBLEM", 480, 510], ["the annotated isolates", "TEST", 515, 537], ["proteins in non-annotated ones", "PROBLEM", 567, 597], ["multiple SNPs", "PROBLEM", 602, 615], ["amino acidsResults", "TEST", 647, 665], ["the analysis", "TEST", 669, 681], ["enlarged", "OBSERVATION", 201, 209], ["amino acids", "OBSERVATION", 457, 468], ["amino acid", "OBSERVATION", 480, 490]]], ["Figure 3 shows that silent mutations occurred in envelope BJ04 TWH BJ03 GZ50 TWH BJ02 BJ03 BJ03 BJ03 BJ03 BJ02 BJ04 CUHK-W1 BJ01,BJ02 GZ50 TWH,BJ04,GZ50 CUHK-W1 TWH,GZ50,CUHK-W1 BJ02 BJ01 BJ04 TWH BJ04 BJ03 BJ02 GZ50 TWH BJ02 CUHK-W1 CUHK-W1 TWH,HZ50,CUHK-W1 BJ03 BJ02 BJ04 BJ02 BJ03 BJ04 BJ04 BJ02 GZ50 BJ02 BJ04 TWH,BJ04 BJ03 TWH BJ02 BJ02 GZ50 BJ03 BJ03 BJ04 BJ02,BJ03 GZ50 BJ01 BJ02 BJ01,BJ03 TWH BJ01,BJ02, protein E, while nucleotide changes resulted in amino acid changes in spike (S), membrane (M) and nucleocapside (N) proteins.", [["membrane", "ANATOMY", 493, 501], ["nucleotide", "CHEMICAL", 429, 439], ["amino acid", "CHEMICAL", 460, 470], ["nucleotide", "CHEMICAL", 429, 439], ["amino acid", "CHEMICAL", 460, 470], ["protein E", "GENE_OR_GENE_PRODUCT", 412, 421], ["amino acid", "AMINO_ACID", 460, 470], ["membrane", "CELLULAR_COMPONENT", 493, 501], ["nucleocapside (N) proteins", "GENE_OR_GENE_PRODUCT", 510, 536], ["W1 BJ01", "CELL_LINE", 121, 128], ["BJ04", "CELL_LINE", 143, 147], ["GZ50", "CELL_LINE", 165, 169], ["TWH BJ02", "CELL_LINE", 217, 225], ["CUHK", "CELL_LINE", 226, 230], ["W1 CUHK", "CELL_LINE", 231, 238], ["W1 TWH", "CELL_LINE", 239, 245], ["HZ50", "CELL_LINE", 246, 250], ["CUHK", "CELL_LINE", 251, 255], ["BJ03 BJ04", "CELL_LINE", 279, 288], ["BJ04 BJ02", "CELL_LINE", 289, 298], ["GZ50 BJ02", "CELL_LINE", 299, 308], ["BJ04 TWH", "CELL_LINE", 309, 317], ["BJ04 BJ03", "CELL_LINE", 318, 327], ["TWH BJ02", "CELL_LINE", 328, 336], ["BJ02 GZ50", "CELL_LINE", 337, 346], ["BJ03 BJ03", "CELL_LINE", 347, 356], ["BJ04 BJ02", "CELL_LINE", 357, 366], ["BJ03 GZ50", "CELL_LINE", 367, 376], ["BJ02 BJ01", "CELL_LINE", 382, 391], ["BJ03 TWH BJ01", "CELL_LINE", 392, 405], ["BJ02", "CELL_LINE", 406, 410], ["protein E", "PROTEIN", 412, 421], ["spike (S), membrane (M) and nucleocapside (N) proteins", "PROTEIN", 482, 536], ["BJ04 BJ03 TWH BJ02 BJ02 GZ50 BJ03 BJ03 BJ04 BJ02", "SPECIES", 318, 366], ["Figure", "TEST", 0, 6], ["silent mutations", "PROBLEM", 20, 36], ["envelope", "TEST", 49, 57], ["TWH", "TEST", 63, 66], ["GZ50", "TEST", 72, 76], ["TWH", "TEST", 77, 80], ["BJ02", "TEST", 81, 85], ["BJ03", "TEST", 86, 90], ["BJ03", "TEST", 91, 95], ["BJ03", "TEST", 96, 100], ["BJ03", "TEST", 101, 105], ["BJ02", "TEST", 106, 110], ["BJ04", "TEST", 111, 115], ["CUHK", "TEST", 116, 120], ["BJ01", "TEST", 124, 128], ["BJ02", "TEST", 129, 133], ["GZ50", "TEST", 134, 138], ["TWH", "TEST", 139, 142], ["BJ04", "TEST", 143, 147], ["GZ50", "TEST", 148, 152], ["CUHK", "TEST", 153, 157], ["TWH", "TEST", 161, 164], ["GZ50", "TEST", 165, 169], ["CUHK", "TEST", 170, 174], ["BJ01", "TEST", 183, 187], ["BJ04", "TEST", 188, 192], ["TWH", "TEST", 193, 196], ["BJ04", "TEST", 197, 201], ["BJ03", "TEST", 202, 206], ["BJ02", "TEST", 207, 211], ["GZ50", "TEST", 212, 216], ["TWH", "TEST", 217, 220], ["BJ02", "TEST", 221, 225], ["CUHK", "TEST", 226, 230], ["CUHK", "TEST", 234, 238], ["TWH", "TEST", 242, 245], ["HZ50", "TEST", 246, 250], ["CUHK", "TEST", 251, 255], ["BJ04", "TEST", 269, 273], ["BJ02", "TEST", 274, 278], ["BJ03", "TEST", 279, 283], ["BJ04", "TEST", 284, 288], ["BJ04", "TEST", 289, 293], ["BJ02", "TEST", 294, 298], ["GZ50", "TEST", 299, 303], ["BJ02", "TEST", 304, 308], ["BJ04", "TEST", 309, 313], ["TWH", "TEST", 314, 317], ["BJ04", "TEST", 318, 322], ["BJ03", "TEST", 323, 327], ["TWH", "TEST", 328, 331], ["BJ02", "TEST", 332, 336], ["BJ02", "TEST", 337, 341], ["GZ50", "TEST", 342, 346], ["BJ03", "TEST", 347, 351], ["BJ03", "TEST", 352, 356], ["BJ04", "TEST", 357, 361], ["BJ02", "TEST", 362, 366], ["BJ03", "TEST", 367, 371], ["GZ50", "TEST", 372, 376], ["BJ01", "TEST", 377, 381], ["BJ02", "TEST", 382, 386], ["BJ01", "TEST", 387, 391], ["BJ03", "TEST", 392, 396], ["TWH", "TEST", 397, 400], ["BJ01", "TEST", 401, 405], ["BJ02", "TEST", 406, 410], ["protein E", "TEST", 412, 421], ["nucleotide changes", "TEST", 429, 447], ["amino acid changes", "PROBLEM", 460, 478], ["spike (S", "TEST", 482, 490], ["membrane (M)", "TEST", 493, 505], ["nucleocapside (N) proteins", "PROBLEM", 510, 536], ["amino acid", "OBSERVATION", 460, 470]]], ["All three SNPs in the spike protein are situated in the outer membrane region and not within the potential epitope region (amino acid position 469-882) as proposed by Ren Y. et al. [13] .", [["outer membrane region", "ANATOMY", 56, 77], ["amino acid position 469-882", "CHEMICAL", 123, 150], ["amino acid", "CHEMICAL", 123, 133], ["outer membrane region", "CELLULAR_COMPONENT", 56, 77], ["amino acid", "AMINO_ACID", 123, 133], ["spike protein", "PROTEIN", 22, 35], ["outer membrane region", "PROTEIN", 56, 77], ["epitope region", "PROTEIN", 107, 121], ["All three SNPs in the spike protein", "PROBLEM", 0, 35], ["amino acid position", "TEST", 123, 142], ["outer", "ANATOMY_MODIFIER", 56, 61], ["membrane", "ANATOMY_MODIFIER", 62, 70]]], ["Amino acid changes occurred in two multiple SNPs in M protein, one multiple SNPs in N protein and 7 (out of 13) multiple SNPs of the polyprotein 1ab, as well as in one multiple SNP of a hypothetical protein, while the silent mutations occurred in three hypothetical proteins.", [["Amino acid", "CHEMICAL", 0, 10], ["SNP", "CHEMICAL", 177, 180], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["M protein", "PROTEIN", 52, 61], ["N protein", "PROTEIN", 84, 93], ["polyprotein 1ab", "DNA", 133, 148], ["hypothetical protein", "PROTEIN", 186, 206], ["hypothetical proteins", "PROTEIN", 253, 274], ["Amino acid changes", "PROBLEM", 0, 18], ["SNPs in N protein", "TEST", 76, 93], ["the polyprotein 1ab", "TREATMENT", 129, 148], ["a hypothetical protein", "PROBLEM", 184, 206], ["the silent mutations", "PROBLEM", 214, 234], ["acid", "OBSERVATION_MODIFIER", 6, 10]]], ["Figure 3 also represents properties of the corresponding amino acidsChanges in amino acidsPhylogenetic tree of 36 SARS-CoV complete genome isolates Figure 9 Phylogenetic tree of 36 SARS-CoV complete genome isolates.", [["amino acids", "CHEMICAL", 57, 68], ["amino acids", "CHEMICAL", 79, 90], ["amino acids", "CHEMICAL", 57, 68], ["amino acids", "CHEMICAL", 79, 90], ["amino acids", "AMINO_ACID", 57, 68], ["amino acids", "AMINO_ACID", 79, 90], ["SARS-CoV complete genome isolates", "DNA", 181, 214], ["SARS-CoV", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 181, 189], ["the corresponding amino acids", "TREATMENT", 39, 68], ["Changes in amino acids", "PROBLEM", 68, 90], ["Phylogenetic tree", "TEST", 90, 107], ["SARS", "TEST", 114, 118], ["Figure", "TEST", 148, 154], ["Phylogenetic tree", "TEST", 157, 174], ["amino acids", "OBSERVATION", 57, 68], ["amino acids", "OBSERVATION", 79, 90], ["tree", "OBSERVATION_MODIFIER", 103, 107]]], ["Distances represent degree of sequence variation.", [["degree", "OBSERVATION_MODIFIER", 20, 26]]], ["The largest distance is associated with ZMY 1, followed by ZJ01 isolate (groups C1, C2).", [["ZMY 1", "GENE_OR_GENE_PRODUCT", 40, 45], ["ZMY 1", "DNA", 40, 45], ["ZMY", "TEST", 40, 43], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["distance", "OBSERVATION_MODIFIER", 12, 20], ["C2", "ANATOMY", 84, 86]]], ["Groups A1, A2 and B are clearly distinguished.", [["A2", "GENE_OR_GENE_PRODUCT", 11, 13], ["B", "GENE_OR_GENE_PRODUCT", 18, 19], ["A1", "PROTEIN", 7, 9], ["A2", "PROTEIN", 11, 13]]], ["The tree has been obtained using CLUSTALW and PhyloDraw programs.Changes in amino acidsresulted by SNPs.", [["amino acidsresulted", "CHEMICAL", 76, 95], ["amino", "CHEMICAL", 76, 81], ["amino acidsresulted", "AMINO_ACID", 76, 95], ["CLUSTALW and PhyloDraw programs", "TREATMENT", 33, 64], ["amino acidsresulted", "TREATMENT", 76, 95], ["tree", "ANATOMY_MODIFIER", 4, 8], ["amino acidsresulted", "OBSERVATION", 76, 95]]], ["The only significant change in amino acid properties is in S protein Gly\u2192Asp (A2, B groups, i.e., in CUHK-W1, GZ50, BJ01-BJ03, GD01, SZ3 and SZ16 isolates) and hypothetical protein Cys\u2192Arg (the same isolates, BJ04 in addition).", [["amino acid", "CHEMICAL", 31, 41], ["amino acid", "CHEMICAL", 31, 41], ["Gly", "CHEMICAL", 69, 72], ["Asp", "CHEMICAL", 73, 76], ["Cys", "CHEMICAL", 181, 184], ["Arg", "CHEMICAL", 185, 188], ["amino acid", "AMINO_ACID", 31, 41], ["Arg", "AMINO_ACID", 185, 188], ["A2", "PROTEIN", 78, 80], ["CUHK", "PROTEIN", 101, 105], ["BJ01", "PROTEIN", 116, 120], ["SZ3", "PROTEIN", 133, 136], ["BJ04", "PROTEIN", 209, 213], ["significant change in amino acid properties", "PROBLEM", 9, 52], ["Asp", "TEST", 73, 76], ["A2", "TEST", 78, 80], ["CUHK", "TEST", 101, 105], ["GZ50", "TEST", 110, 114], ["BJ01", "TEST", 116, 120], ["BJ03", "TEST", 121, 125], ["GD01", "TEST", 127, 131], ["SZ3", "TEST", 133, 136], ["SZ16 isolates", "TEST", 141, 154], ["hypothetical protein Cys", "TEST", 160, 184], ["Arg", "TEST", 185, 188], ["the same isolates", "TEST", 190, 207], ["BJ04", "TEST", 209, 213], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["change", "OBSERVATION", 21, 27], ["amino acid", "OBSERVATION", 31, 41]]], ["The only addition in nonannotated sequences is in hypothetical protein following S protein in TWH, exhibiting silent change, and in nonannotated BJ02 and BJ03, corresponding to the hypothetical protein, Gly\u2192Glu.", [["Glu", "CHEMICAL", 207, 210], ["Gly", "CHEMICAL", 203, 206], ["Glu", "CHEMICAL", 207, 210], ["TWH", "GENE_OR_GENE_PRODUCT", 94, 97], ["Glu", "AMINO_ACID", 207, 210], ["nonannotated sequences", "DNA", 21, 43], ["S protein", "PROTEIN", 81, 90], ["TWH", "PROTEIN", 94, 97], ["BJ02", "PROTEIN", 145, 149], ["BJ03", "PROTEIN", 154, 158], ["nonannotated sequences", "TEST", 21, 43], ["S protein", "TEST", 81, 90], ["silent change", "PROBLEM", 110, 123], ["BJ03", "TEST", 154, 158], ["the hypothetical protein", "TEST", 177, 201], ["silent", "OBSERVATION_MODIFIER", 110, 116], ["change", "OBSERVATION", 117, 123]]], ["Similar analysis can be done for amino acid changes corresponding to SNPs at positions specific for B group isolates (Figure 4 ).", [["amino acid", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 33, 43], ["amino acid", "AMINO_ACID", 33, 43], ["Similar analysis", "TEST", 0, 16], ["amino acid changes", "PROBLEM", 33, 51], ["SNPs", "PROBLEM", 69, 73]]], ["Taking into account the only annotated isolate GD01, there are five amino acid changes in polyprotein 1ab, two amino acid properties changes in S protein (Ser\u2192Leu and Tyr\u2192Asp, the second being within the epitope region), one amino acid change in M protein and one amino acid property change (Cis\u2192Arg) in BGI-PUP.Phylogenetic analysisThe SARS-CoV isolates have been multialigned using the CLUSTALW program [10] as the very first step in obtaining a phylogenetic tree.", [["amino acid", "CHEMICAL", 68, 78], ["amino acid", "CHEMICAL", 111, 121], ["amino acid", "CHEMICAL", 225, 235], ["amino acid", "CHEMICAL", 264, 274], ["amino acid", "CHEMICAL", 68, 78], ["amino acid", "CHEMICAL", 111, 121], ["amino acid", "CHEMICAL", 225, 235], ["amino acid", "CHEMICAL", 264, 274], ["Cis\u2192Arg", "CHEMICAL", 292, 299], ["GD01", "GENE_OR_GENE_PRODUCT", 47, 51], ["amino acid", "AMINO_ACID", 68, 78], ["amino acid", "AMINO_ACID", 111, 121], ["S protein", "GENE_OR_GENE_PRODUCT", 144, 153], ["Ser\u2192Leu", "GENE_OR_GENE_PRODUCT", 155, 162], ["Tyr\u2192Asp", "GENE_OR_GENE_PRODUCT", 167, 174], ["amino acid", "AMINO_ACID", 225, 235], ["amino acid", "AMINO_ACID", 264, 274], ["Cis\u2192Arg", "SIMPLE_CHEMICAL", 292, 299], ["BGI-PUP", "GENE_OR_GENE_PRODUCT", 304, 311], ["SARS-CoV", "ORGANISM", 337, 345], ["GD01", "PROTEIN", 47, 51], ["S protein", "PROTEIN", 144, 153], ["Ser\u2192Leu", "PROTEIN", 155, 162], ["Tyr\u2192Asp", "PROTEIN", 167, 174], ["epitope region", "PROTEIN", 204, 218], ["M protein", "PROTEIN", 246, 255], ["BGI", "PROTEIN", 304, 307], ["PUP", "PROTEIN", 308, 311], ["SARS-CoV", "SPECIES", 337, 345], ["five amino acid changes", "PROBLEM", 63, 86], ["polyprotein 1ab", "TREATMENT", 90, 105], ["two amino acid properties", "TEST", 107, 132], ["S protein", "TEST", 144, 153], ["Ser\u2192Leu", "TEST", 155, 162], ["Tyr\u2192Asp", "TREATMENT", 167, 174], ["one amino acid change", "PROBLEM", 221, 242], ["M protein", "TREATMENT", 246, 255], ["one amino acid property change", "TREATMENT", 260, 290], ["Phylogenetic analysis", "TEST", 312, 333], ["the CLUSTALW program", "TREATMENT", 384, 404], ["amino acid", "OBSERVATION", 68, 78]]], ["The aligned sequences have been submitted then to CLUSTALW for bootstrapping and phylogenetic tree production.", [["bootstrapping", "TREATMENT", 63, 76], ["phylogenetic tree production", "PROBLEM", 81, 109], ["tree production", "OBSERVATION", 94, 109]]], ["Enlargement of the sequence set resulted in the refinement of the phylogenetic tree produced, as compared to previous results such as Ruan [8] and Zhang&Zheng [14] , obtained for 14 and 16 isolates, respectively.", [["Enlargement of the sequence set", "PROBLEM", 0, 31], ["phylogenetic tree", "OBSERVATION", 66, 83]]], ["The phylogenetic tree obtained, drawn using the PhyloDraw program [15] , is represented in Figure 9 .", [["The phylogenetic tree", "TEST", 0, 21], ["the PhyloDraw program", "TREATMENT", 44, 65]]], ["It is similar to our structural tree based on qualitative analysis of the isolates (Figure 2 ).Phylogenetic analysisThe results of the analysis of dissimilarities, described in previous paragraphs, are in accordance with the alignment obtained by CLUSTALW, but regrouped and formatted in a way that facilitates further interpretation and application.ConclusionComparative analysis of genome sequence variations of 38 SARS-CoV isolates resulted in some conclusions that might be of interest in further investigation of the SARS-CoV genome:Conclusion1.", [["SARS", "DISEASE", 417, 421], ["SARS", "DISEASE", 522, 526], ["SARS-CoV", "ORGANISM", 417, 425], ["SARS-CoV", "ORGANISM", 522, 530], ["SARS-CoV genome", "DNA", 522, 537], ["SARS-CoV", "SPECIES", 417, 425], ["SARS-CoV", "SPECIES", 522, 530], ["qualitative analysis", "TEST", 46, 66], ["Phylogenetic analysis", "TEST", 95, 116], ["the analysis", "TEST", 131, 143], ["ConclusionComparative analysis", "TEST", 350, 380], ["genome sequence variations", "TEST", 384, 410], ["38 SARS", "PROBLEM", 414, 421], ["CoV isolates", "TEST", 422, 434], ["tree", "OBSERVATION_MODIFIER", 32, 36]]], ["All of the SARS-CoV isolates are highly homologous (more than 99% pairwise).", [["SARS", "DISEASE", 11, 15], ["SARS-CoV", "ORGANISM", 11, 19], ["SARS-CoV", "SPECIES", 11, 19], ["CoV isolates", "TEST", 16, 28]]], ["Most of them have similar nucleotide structure, with the same 5' and 3' ends and poly-\"a\" at the 3' end of different length (0-24), some of them with a single short deletion close to the 3' end of the sequence; out of 312 SNPs in total, only two are in IGRs.Conclusion2.", [["nucleotide", "CHEMICAL", 26, 36], ["nucleotide", "CHEMICAL", 26, 36], ["3' ends", "CELLULAR_COMPONENT", 69, 76], ["3' end", "CELLULAR_COMPONENT", 97, 103], ["3' end", "CELLULAR_COMPONENT", 187, 193], ["IGRs", "GENE_OR_GENE_PRODUCT", 253, 257], ["5' and 3' ends", "DNA", 62, 76], ["3' end", "DNA", 97, 103], ["3' end", "DNA", 187, 193], ["IGRs", "DNA", 253, 257], ["similar nucleotide structure", "PROBLEM", 18, 46], ["poly", "TEST", 81, 85], ["a single short deletion", "PROBLEM", 150, 173], ["similar", "OBSERVATION_MODIFIER", 18, 25], ["nucleotide structure", "OBSERVATION", 26, 46], ["different", "OBSERVATION_MODIFIER", 107, 116], ["length", "OBSERVATION_MODIFIER", 117, 123]]], ["Two of the isolates have a large number of individual insertions / deletions, exhibiting different SNP positions;Conclusion4.", [["SNP", "CHEMICAL", 99, 102], ["SNP positions", "DNA", 99, 112], ["individual insertions / deletions", "TREATMENT", 43, 76], ["different SNP positions", "TREATMENT", 89, 112], ["large", "OBSERVATION_MODIFIER", 27, 32], ["number", "OBSERVATION_MODIFIER", 33, 39], ["individual insertions", "OBSERVATION", 43, 64], ["different", "OBSERVATION_MODIFIER", 89, 98], ["SNP positions", "OBSERVATION", 99, 112]]], ["Since the isolate sequences have a high degree of homology, different properties of groups are represented in a more transparent way in the classification tree obtained by such a qualitative analysis, than in a bootstrapped phylogenetic tree obtained from multialigned sequences using the CLUSTALW program [10].Conclusion5.", [["multialigned sequences", "DNA", 256, 278], ["the isolate sequences", "TEST", 6, 27], ["a qualitative analysis", "TEST", 177, 199], ["the CLUSTALW program", "TREATMENT", 285, 305], ["high degree", "OBSERVATION_MODIFIER", 35, 46]]], ["The total number of amino acid changes caused by multiple SNPs is 15 (in isolates of A, C groups) and 34 in isolates of B group.", [["amino acid", "CHEMICAL", 20, 30], ["amino acid", "CHEMICAL", 20, 30], ["amino acid", "AMINO_ACID", 20, 30], ["B", "CELL", 120, 121], ["amino acid changes", "PROBLEM", 20, 38], ["multiple SNPs", "PROBLEM", 49, 62], ["total", "OBSERVATION_MODIFIER", 4, 9], ["amino acid", "OBSERVATION", 20, 30]]], ["The total number of silent mutations is 10 (for A, C groups) and 7 (for B group).Conclusion6.", [["silent mutations", "PROBLEM", 20, 36], ["total", "OBSERVATION_MODIFIER", 4, 9], ["silent mutations", "OBSERVATION", 20, 36]]], ["Since S protein is of special interest regarding its receptor affinity and antigenecity, it is interesting to notice that all amino acid properties' changes are located in its outer membrane region, one for A, C groups and two for B group.Conclusion7.", [["outer membrane region", "ANATOMY", 176, 197], ["amino acid", "CHEMICAL", 126, 136], ["amino acid", "CHEMICAL", 126, 136], ["S protein", "GENE_OR_GENE_PRODUCT", 6, 15], ["amino acid", "AMINO_ACID", 126, 136], ["outer membrane region", "CELLULAR_COMPONENT", 176, 197], ["B", "GENE_OR_GENE_PRODUCT", 231, 232], ["S protein", "PROTEIN", 6, 15], ["outer membrane region", "PROTEIN", 176, 197], ["all amino acid properties' changes", "PROBLEM", 122, 156], ["A, C groups", "TREATMENT", 207, 218], ["outer membrane", "ANATOMY", 176, 190]]], ["The results obtained may be useful in further investigation aiming at identification of SARS-CoV genome regions responsible for its infectious nature.DatasetWe investigated the complete genomes of 38 SARS-CoV isolates.", [["SARS", "DISEASE", 88, 92], ["SARS", "DISEASE", 200, 204], ["SARS-CoV", "ORGANISM", 200, 208], ["SARS-CoV genome regions", "DNA", 88, 111], ["SARS-CoV", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 200, 208], ["further investigation", "TEST", 38, 59], ["SARS", "PROBLEM", 88, 92], ["CoV genome regions", "PROBLEM", 93, 111], ["infectious", "OBSERVATION_MODIFIER", 132, 142]]], ["Nucleotide sequences are taken from the PubMed NCBI Entrez database [9] in gbk and fasta formats ( Table 1) .DatasetThe coverage included all the isolates published by October 31 st 2003 (with updated revisions).", [["Nucleotide sequences", "TEST", 0, 20], ["Entrez database", "TEST", 52, 67], ["gbk", "TEST", 75, 78], ["fasta formats", "TEST", 83, 96]]], ["The identifiers, accession numbers, genomic size (in nucleotides), revision dates and country or source of the isolates considered are included in the table, together with labels as referred in this paper.", [["revision", "TREATMENT", 67, 75], ["the isolates", "PROBLEM", 107, 119], ["size", "OBSERVATION_MODIFIER", 44, 48]]], ["The fully sequenced isolate TWH has been chosen as the referent isolate, since its average number of SNPs was the lowest as compared to all other isolates.Methods for similarity analysisFor similarity analysis of isolates, the following procedure has been applied consisting of two steps:Methods for similarity analysis1. identification of structurally identical parts of isolates, i.e., insertion and deletion sites 2. identification of SNPs in structurally identical parts.Methods for similarity analysisStep 1 has been carried out by a function performing similarity analysis of subsequences of a given length (e.g., 100 bps), and identifying significantly non-matching strings as being inserted in the corresponding sequence (i.e. deleted from the other).", [["TWH", "CHEMICAL", 28, 31], ["TWH", "CANCER", 28, 31], ["TWH", "DNA", 28, 31], ["insertion and deletion sites 2", "DNA", 388, 418], ["SNPs", "DNA", 438, 442], ["SNPs", "TEST", 101, 105], ["similarity analysis", "TEST", 167, 186], ["similarity analysis", "TEST", 190, 209], ["isolates", "PROBLEM", 213, 221], ["the following procedure", "TREATMENT", 223, 246], ["similarity analysis1", "TEST", 300, 320], ["structurally identical parts of isolates", "PROBLEM", 340, 380], ["insertion and deletion sites", "TREATMENT", 388, 416], ["SNPs in structurally identical parts", "PROBLEM", 438, 474], ["similarity analysis", "TEST", 559, 578], ["significantly non-matching strings", "PROBLEM", 646, 680], ["isolates", "OBSERVATION_MODIFIER", 372, 380], ["SNPs", "OBSERVATION", 438, 442], ["structurally", "OBSERVATION_MODIFIER", 446, 458], ["identical", "OBSERVATION_MODIFIER", 459, 468], ["parts", "OBSERVATION_MODIFIER", 469, 474], ["non-matching strings", "OBSERVATION", 660, 680]]], ["Since significant number of isolates have the same length (29727 bases) and starting and ending subsequences (that seem to be the exact starts and ends of the complete SARS-CoV genome up to the poly-\"a\" at the 3' end), they may be considered as forming a representative group.", [["SARS-CoV genome", "DNA", 168, 183], ["poly-\"a\" at the 3' end", "DNA", 194, 216], ["SARS-CoV", "SPECIES", 168, 176], ["significant", "OBSERVATION_MODIFIER", 6, 17], ["number", "OBSERVATION_MODIFIER", 18, 24], ["isolates", "OBSERVATION", 28, 36], ["length", "OBSERVATION_MODIFIER", 51, 57]]], ["The nucleotide structure of all other isolates was analyzed with respect to this representative group.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["all other isolates", "PROBLEM", 28, 46]]], ["For each pair of isolates (x,y) (x from the representative group), a file InsDelx-y has been produced containing positions and lengths of each of the insertions or deletions in the isolate y.Methods for similarity analysisStep 2 has been carried out by comparing structurally identical parts (of the same length) of pairs of isolates.", [["InsDelx", "PROTEIN", 74, 81], ["isolates", "PROBLEM", 17, 25], ["the insertions or deletions", "TREATMENT", 146, 173], ["similarity analysisStep", "TEST", 203, 226]]], ["The procedure returns results in a file with SNPs in the two sequences (files Mismx-y).Methods for similarity analysisWe also used the CLUSTALW program [10] for multialignment as a control process, as well as for phylogenetic investigations.Methods for phylogenetic investigationIn order to use similarity analysis results for drawing any phylogenetic conclusions about the SARS-CoV genome dataset, a CLUSTALW [10] multialigned output has been generated and a bootstrapped phylogenetic tree has been produced and drawn using the PhyloDraw program [15] .", [["SARS-CoV genome dataset", "DNA", 374, 397], ["SARS-CoV", "SPECIES", 374, 382], ["The procedure", "TREATMENT", 0, 13], ["SNPs", "TREATMENT", 45, 49], ["multialignment", "TREATMENT", 161, 175], ["phylogenetic investigations", "TEST", 213, 240], ["phylogenetic investigation", "TEST", 253, 279], ["similarity analysis", "TEST", 295, 314], ["the SARS", "TEST", 370, 378], ["multialigned output", "TEST", 415, 434], ["a bootstrapped phylogenetic tree", "PROBLEM", 458, 490]]]], "PMC7194672": [], "3b5290a5bd5c9ac633320eed77f1a7929d72b749": [["IntroductionThe genus Coronavirus belongs to the family Coronaviridae in the order Nidovirales.", [["genus Coronavirus", "OBSERVATION", 16, 33]]], ["Coronaviruses (CoVs) infect a variety of livestock, poultry, and companion animals, in which they can cause serious and often fatal respiratory, enteric, cardiovascular, and neurological diseases.", [["respiratory", "ANATOMY", 132, 143], ["cardiovascular", "ANATOMY", 154, 168], ["neurological", "ANATOMY", 174, 186], ["respiratory, enteric, cardiovascular, and neurological diseases", "DISEASE", 132, 195], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["CoVs", "GENE_OR_GENE_PRODUCT", 15, 19], ["Coronaviruses (CoVs", "PROBLEM", 0, 19], ["fatal respiratory, enteric, cardiovascular, and neurological diseases", "PROBLEM", 126, 195], ["cardiovascular", "ANATOMY", 154, 168]]], ["1 The first reports on human coronaviruses (HCoVs) appeared in the mid-1960s.", [["human", "ORGANISM", 23, 28], ["coronaviruses", "ORGANISM", 29, 42], ["HCoVs", "CANCER", 44, 49], ["human", "SPECIES", 23, 28], ["human coronaviruses", "SPECIES", 23, 42]]], ["The human viruses were isolated from persons with the common cold, and two species were detected: HCoV-229E and HCoV-OC43.", [["human", "ORGANISM", 4, 9], ["persons", "ORGANISM", 37, 44], ["HCoV-229E", "CELL", 98, 107], ["HCoV-OC43", "CELL", 112, 121], ["human", "SPECIES", 4, 9], ["persons", "SPECIES", 37, 44], ["human viruses", "SPECIES", 4, 17], ["HCoV-229E", "SPECIES", 98, 107], ["The human viruses", "PROBLEM", 0, 17], ["two species", "TEST", 71, 82], ["HCoV", "TEST", 98, 102], ["HCoV", "TEST", 112, 116], ["viruses", "OBSERVATION", 10, 17]]], ["2 Almost 40 years later, an emergent HCoV was identified as the causative agent of severe acute respiratory syndrome (SARS).", [["acute respiratory syndrome", "DISEASE", 90, 116], ["SARS", "DISEASE", 118, 122], ["HCoV", "CANCER", 37, 41], ["HCoV", "SPECIES", 37, 41], ["severe acute respiratory syndrome", "PROBLEM", 83, 116], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116]]], ["3 While SARS-CoV was eradicated from the human population after a highly effective global public health response, 4 its emergence necessitated a rethinking of the role that CoVs play as a potential cause of more than just the common cold.", [["SARS", "DISEASE", 8, 12], ["SARS-CoV", "ORGANISM", 8, 16], ["human", "ORGANISM", 41, 46], ["CoVs", "GENE_OR_GENE_PRODUCT", 173, 177], ["human", "SPECIES", 41, 46], ["SARS-CoV", "SPECIES", 8, 16], ["human", "SPECIES", 41, 46], ["SARS", "PROBLEM", 8, 12]]], ["Thereafter, there was an increase in research on HCoVs worldwide, which has led to the discovery of two other HCoVs, HCoV-NL63 in the Netherlands and HCoV-HKU1 in China.", [["HCoVs", "CANCER", 49, 54], ["HCoVs", "GENE_OR_GENE_PRODUCT", 110, 115], ["HCoV-NL63", "ORGANISM", 117, 126], ["HCoV-HKU1", "ORGANISM", 150, 159], ["HCoV", "PROTEIN", 117, 121], ["HKU1", "DNA", 155, 159], ["HCoV", "TEST", 117, 121], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["5, 6 Reports have documented that HCoVs are involved in a wide spectrum of clinical presentation in upper and lower respiratory tract illnesses, [7] [8] [9] [10] [11] [12] [13] [14] [15] as well as being a contributor to exacerbations of chronic obstructive pulmonary disease 16 and among patients presenting cystic fibrosis.", [["lower respiratory tract", "ANATOMY", 110, 133], ["pulmonary", "ANATOMY", 258, 267], ["cystic", "ANATOMY", 309, 315], ["upper and lower respiratory tract illnesses", "DISEASE", 100, 143], ["[7] [8] [9] [10] [11] [12] [13] [14]", "CHEMICAL", 145, 181], ["chronic obstructive pulmonary disease", "DISEASE", 238, 275], ["fibrosis", "DISEASE", 316, 324], ["[7] [8] [9] [10] [11] [12] [13] [14]", "CHEMICAL", 145, 181], ["HCoVs", "GENE_OR_GENE_PRODUCT", 34, 39], ["upper", "ORGANISM_SUBDIVISION", 100, 105], ["tract", "ORGANISM_SUBDIVISION", 128, 133], ["[7] [8] [9] [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 145, 186], ["pulmonary", "ORGAN", 258, 267], ["patients", "ORGANISM", 289, 297], ["cystic", "PATHOLOGICAL_FORMATION", 309, 315], ["HCoVs", "PROTEIN", 34, 39], ["patients", "SPECIES", 289, 297], ["upper and lower respiratory tract illnesses", "PROBLEM", 100, 143], ["chronic obstructive pulmonary disease", "PROBLEM", 238, 275], ["cystic fibrosis", "PROBLEM", 309, 324], ["upper", "ANATOMY_MODIFIER", 100, 105], ["lower", "ANATOMY_MODIFIER", 110, 115], ["respiratory tract", "ANATOMY", 116, 133], ["chronic", "OBSERVATION_MODIFIER", 238, 245], ["obstructive", "OBSERVATION_MODIFIER", 246, 257], ["pulmonary", "ANATOMY", 258, 267], ["disease", "OBSERVATION", 268, 275], ["cystic", "OBSERVATION_MODIFIER", 309, 315], ["fibrosis", "OBSERVATION", 316, 324]]], ["17 The involvement of other non-respiratory organ systems is still controversial but can occur, for example the enteric and nervous systems.", [["organ", "ANATOMY", 44, 49], ["enteric", "ANATOMY", 112, 119], ["nervous systems", "ANATOMY", 124, 139], ["organ", "ORGAN", 44, 49], ["nervous", "ANATOMICAL_SYSTEM", 124, 131], ["systems", "ANATOMICAL_SYSTEM", 132, 139], ["The involvement of other non-respiratory organ systems", "PROBLEM", 3, 57], ["the enteric and nervous systems", "PROBLEM", 108, 139], ["non-respiratory organ", "ANATOMY", 28, 49], ["enteric", "ANATOMY", 112, 119], ["nervous", "ANATOMY", 124, 131]]], ["18, 19 Additionally, the role of HCoV infections among susceptible groups, outbreaks, and fatal cases has been documented.", [["HCoV infections", "DISEASE", 33, 48], ["HCoV", "GENE_OR_GENE_PRODUCT", 33, 37], ["HCoV", "SPECIES", 33, 37], ["HCoV infections", "PROBLEM", 33, 48], ["infections", "OBSERVATION", 38, 48]]], ["[20] [21] [22] [23] [24] [25] However, the majority of reports describe HCoV infections only among children.", [["infections", "DISEASE", 77, 87], ["[20] [21] [22] [23] [24] [25]", "SIMPLE_CHEMICAL", 0, 29], ["HCoV", "GENE_OR_GENE_PRODUCT", 72, 76], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["HCoV", "SPECIES", 72, 76], ["HCoV infections", "PROBLEM", 72, 87], ["infections", "OBSERVATION", 77, 87]]], ["Moreover, longitudinal studies of CoV epidemiology in the literature are lacking and are restricted to descriptions spanning 1-3 years at most.", [["CoV", "ORGANISM", 34, 37], ["longitudinal studies", "TEST", 10, 30]]], ["[26] [27] [28] In this study, we conducted a comprehensive 9-year study of the epidemiological and clinical features of all four circulating HCoVs (OC43, 229E, HKU1, and NL63) among four different subsets (asymptomatic, general community, with comorbidities, and hospitalized) of adult and child patients.Study design and populationDuring the 9-year study, respiratory samples were collected from patients presenting acute respiratory illnesses and those who were asymptomatic.", [["respiratory samples", "ANATOMY", 357, 376], ["respiratory", "ANATOMY", 423, 434], ["acute respiratory illnesses", "DISEASE", 417, 444], ["HCoVs", "GENE_OR_GENE_PRODUCT", 141, 146], ["HKU1", "GENE_OR_GENE_PRODUCT", 160, 164], ["patients", "ORGANISM", 296, 304], ["respiratory samples", "CANCER", 357, 376], ["patients", "ORGANISM", 397, 405], ["circulating HCoVs", "PROTEIN", 129, 146], ["NL63", "PROTEIN", 170, 174], ["patients", "SPECIES", 296, 304], ["patients", "SPECIES", 397, 405], ["this study", "TEST", 18, 28], ["OC43", "TEST", 148, 152], ["HKU1", "TEST", 160, 164], ["Study design", "TEST", 305, 317], ["year study", "TEST", 345, 355], ["respiratory samples", "TEST", 357, 376], ["acute respiratory illnesses", "PROBLEM", 417, 444], ["asymptomatic", "PROBLEM", 464, 476], ["acute", "OBSERVATION_MODIFIER", 417, 422], ["respiratory illnesses", "OBSERVATION", 423, 444]]], ["We collected 1137 samples and stored them at \u00c080\u00b0C. The clinical specimens from the studied patients were collected from specific units by trained professionals (nurses or doctors).", [["samples", "ANATOMY", 18, 25], ["specimens", "ANATOMY", 65, 74], ["specimens", "CANCER", 65, 74], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["The clinical specimens", "TEST", 52, 74]]], ["The specimens comprised 464 nasopharyngeal swabs, 208 nasal aspirations, and 465 nasal lavages.", [["specimens", "ANATOMY", 4, 13], ["nasopharyngeal swabs", "ANATOMY", 28, 48], ["nasal", "ANATOMY", 54, 59], ["nasal lavages", "ANATOMY", 81, 94], ["nasopharyngeal swabs", "CANCER", 28, 48], ["nasal lavages", "MULTI-TISSUE_STRUCTURE", 81, 94], ["The specimens", "TEST", 0, 13], ["nasopharyngeal swabs", "TEST", 28, 48], ["nasal aspirations", "TEST", 54, 71], ["nasal lavages", "TEST", 81, 94], ["nasopharyngeal", "ANATOMY", 28, 42], ["nasal", "ANATOMY", 54, 59], ["aspirations", "OBSERVATION", 60, 71], ["nasal", "ANATOMY", 81, 86], ["lavages", "OBSERVATION", 87, 94]]], ["The subjects were 50 asymptomatic adults and 1087 patients presenting acute respiratory infections (ARIs): 465 from the general community (adults, children, and healthcare workers), 410 with comorbidities (children with heart diseases, patients with stem cell and renal transplants), and 212 hospitalized patients (adults and children) originally suspected of H1N1 2009 influenza infection.", [["respiratory", "ANATOMY", 76, 87], ["heart", "ANATOMY", 220, 225], ["stem cell", "ANATOMY", 250, 259], ["renal", "ANATOMY", 264, 269], ["acute respiratory infections", "DISEASE", 70, 98], ["ARIs", "DISEASE", 100, 104], ["heart diseases", "DISEASE", 220, 234], ["influenza infection", "DISEASE", 370, 389], ["patients", "ORGANISM", 50, 58], ["children", "ORGANISM", 147, 155], ["children", "ORGANISM", 206, 214], ["heart", "ORGAN", 220, 225], ["patients", "ORGANISM", 236, 244], ["stem cell", "CELL", 250, 259], ["renal", "ORGAN", 264, 269], ["patients", "ORGANISM", 305, 313], ["children", "ORGANISM", 326, 334], ["patients", "SPECIES", 50, 58], ["children", "SPECIES", 147, 155], ["children", "SPECIES", 206, 214], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 305, 313], ["children", "SPECIES", 326, 334], ["acute respiratory infections", "PROBLEM", 70, 98], ["heart diseases", "PROBLEM", 220, 234], ["stem cell and renal transplants", "TREATMENT", 250, 281], ["H1N1", "PROBLEM", 360, 364], ["influenza infection", "PROBLEM", 370, 389], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["respiratory", "ANATOMY", 76, 87], ["infections", "OBSERVATION", 88, 98], ["heart", "ANATOMY", 220, 225], ["diseases", "OBSERVATION", 226, 234], ["stem cell", "OBSERVATION", 250, 259], ["renal", "ANATOMY", 264, 269], ["transplants", "OBSERVATION", 270, 281]]], ["Of the 1137 studied patients, 591 (51.9%) were adults, while the rest were children.", [["patients", "ORGANISM", 20, 28], ["children", "ORGANISM", 75, 83], ["patients", "SPECIES", 20, 28], ["children", "SPECIES", 75, 83]]], ["The patients were treated at the primary care health service section of S\u00e3o Paulo Federal University/S\u00e3o Paulo University Hospital in ambulatory or specific units and the emergency room.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Each of these specific health services had a variable flow of sampling to respiratory viruses diagnoses, which resulted in collections of different patient groups in this study.", [["respiratory viruses", "DISEASE", 74, 93], ["patient", "ORGANISM", 148, 155], ["patient", "SPECIES", 148, 155], ["respiratory viruses diagnoses", "PROBLEM", 74, 103], ["collections", "PROBLEM", 123, 134], ["this study", "TEST", 166, 176], ["respiratory viruses", "OBSERVATION", 74, 93], ["collections", "OBSERVATION_MODIFIER", 123, 134], ["different", "OBSERVATION_MODIFIER", 138, 147]]], ["Hence, the subjects groups were unevenly distributed throughout the study.", [["the study", "TEST", 64, 73]]], ["The distribution of the studied years and clinical specimens by studied patients is shown in Table 1 .Inclusion criteriaThe inclusion criteria were as follows: clinical diagnosis of influenza-like illness (ILI) defined by the presence of fever plus at least one respiratory symptom (cough and/or sore throat) and one constitutional symptom (headache, myalgia, sweat, or chills); clinical diagnosis of ARI, defined by the presence of respiratory symptoms that did not fulfill the definition of ILI; hospitalized patients suspected of 2009 H1N1 influenza A infection presenting fever >38\u00b0C, cough, and dyspnea.", [["specimens", "ANATOMY", 51, 60], ["respiratory", "ANATOMY", 262, 273], ["sweat", "ANATOMY", 360, 365], ["respiratory", "ANATOMY", 433, 444], ["influenza-like illness", "DISEASE", 182, 204], ["ILI", "DISEASE", 206, 209], ["fever", "DISEASE", 238, 243], ["cough", "DISEASE", 283, 288], ["sore throat", "DISEASE", 296, 307], ["headache", "DISEASE", 341, 349], ["myalgia", "DISEASE", 351, 358], ["chills", "DISEASE", 370, 376], ["ARI", "DISEASE", 401, 404], ["respiratory symptoms", "DISEASE", 433, 453], ["ILI", "DISEASE", 493, 496], ["influenza A infection", "DISEASE", 543, 564], ["fever", "DISEASE", 576, 581], ["38\u00b0C", "DISEASE", 583, 587], ["cough", "DISEASE", 589, 594], ["dyspnea", "DISEASE", 600, 607], ["specimens", "CANCER", 51, 60], ["patients", "ORGANISM", 72, 80], ["sweat", "ORGANISM_SUBDIVISION", 360, 365], ["patients", "ORGANISM", 511, 519], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 511, 519], ["H1N1 influenza", "SPECIES", 538, 552], ["clinical specimens", "TEST", 42, 60], ["The inclusion criteria", "TEST", 120, 142], ["influenza", "PROBLEM", 182, 191], ["fever", "PROBLEM", 238, 243], ["one respiratory symptom", "PROBLEM", 258, 281], ["cough", "PROBLEM", 283, 288], ["sore throat", "PROBLEM", 296, 307], ["one constitutional symptom", "PROBLEM", 313, 339], ["headache", "PROBLEM", 341, 349], ["myalgia", "PROBLEM", 351, 358], ["sweat", "PROBLEM", 360, 365], ["chills", "PROBLEM", 370, 376], ["ARI", "PROBLEM", 401, 404], ["respiratory symptoms", "PROBLEM", 433, 453], ["ILI", "PROBLEM", 493, 496], ["H1N1 influenza A infection", "PROBLEM", 538, 564], ["fever", "PROBLEM", 576, 581], ["cough", "PROBLEM", 589, 594], ["dyspnea", "PROBLEM", 600, 607], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["influenza", "OBSERVATION", 182, 191], ["fever", "OBSERVATION", 238, 243], ["sweat", "ANATOMY", 360, 365]]], ["Lower respiratory tract illness was defined as having suggestive clinical findings and one of the following: chest radiograph revealing possible or definite infiltrates, mechanical ventilation requirement, or supplemental oxygen requirement.Demographic and clinical dataEpidemiological and clinical data from outpatients were obtained using a standardized questionnaire, while data from hospitalized patients were extracted from medical charts using a standardized form.", [["Lower respiratory tract", "ANATOMY", 0, 23], ["chest", "ANATOMY", 109, 114], ["Lower respiratory tract illness", "DISEASE", 0, 31], ["oxygen", "CHEMICAL", 222, 228], ["oxygen", "CHEMICAL", 222, 228], ["respiratory tract", "ORGANISM_SUBDIVISION", 6, 23], ["oxygen", "SIMPLE_CHEMICAL", 222, 228], ["outpatients", "ORGANISM", 309, 320], ["patients", "ORGANISM", 400, 408], ["outpatients", "SPECIES", 309, 320], ["patients", "SPECIES", 400, 408], ["Lower respiratory tract illness", "PROBLEM", 0, 31], ["chest radiograph", "TEST", 109, 125], ["definite infiltrates", "PROBLEM", 148, 168], ["mechanical ventilation requirement", "PROBLEM", 170, 204], ["supplemental oxygen requirement", "PROBLEM", 209, 240], ["respiratory tract", "ANATOMY", 6, 23], ["chest", "ANATOMY", 109, 114], ["definite", "OBSERVATION_MODIFIER", 148, 156], ["infiltrates", "OBSERVATION", 157, 168], ["mechanical", "OBSERVATION_MODIFIER", 170, 180], ["ventilation requirement", "OBSERVATION", 181, 204], ["oxygen requirement", "OBSERVATION", 222, 240]]], ["Age, gender, occupation, presence of underlying conditions or diseases, and clinical findings at first attendance (for outpatients) or during the first 24 hours (for hospitalized patients) were recorded for analysis.", [["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["underlying conditions", "PROBLEM", 37, 58], ["diseases", "PROBLEM", 62, 70], ["analysis", "TEST", 207, 215]]], ["The number of days between admission and a positive CoV sampling, as well as the total length of respiratory illness, was evaluated for evidence of nosocomial acquisition.", [["respiratory", "ANATOMY", 97, 108], ["respiratory illness", "DISEASE", 97, 116], ["a positive CoV sampling", "PROBLEM", 41, 64], ["respiratory illness", "PROBLEM", 97, 116], ["nosocomial acquisition", "TEST", 148, 170], ["respiratory illness", "OBSERVATION", 97, 116], ["nosocomial", "OBSERVATION", 148, 158]]], ["The Ethics Committee of S\u00e3o Paulo Federal University (CEP 1968/09) approved this study, and written Pan-CoV RT-PCR one-step assay Viral genomic RNA was extracted from the collected specimens with a QIAamp Viral RNA extraction kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions.", [["specimens", "ANATOMY", 181, 190], ["Viral", "ORGANISM", 130, 135], ["Viral genomic RNA", "RNA", 130, 147], ["this study", "TEST", 76, 86], ["PCR", "TEST", 111, 114], ["Viral genomic RNA", "PROBLEM", 130, 147], ["a QIAamp Viral RNA extraction", "TREATMENT", 196, 225], ["genomic RNA", "OBSERVATION", 136, 147]]], ["A previously described pan-CoV RT-PCR assay 29 with minor modifications (from 50 amplification cycles to 40 and melting temperature from 48 to 50\u00b0C) was performed as a screening step to detect human and animal CoVs in the samples.", [["samples", "ANATOMY", 222, 229], ["human", "ORGANISM", 193, 198], ["CoVs", "GENE_OR_GENE_PRODUCT", 210, 214], ["pan-CoV RT-PCR assay 29", "DNA", 23, 46], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 193, 198], ["CoV RT-PCR assay", "TEST", 27, 43], ["minor modifications", "PROBLEM", 52, 71], ["melting temperature", "TEST", 112, 131], ["a screening step", "TEST", 166, 182], ["animal CoVs in the samples", "PROBLEM", 203, 229]]], ["The amplification of a 251-bp fragment of the polymerase gene was carried out using the following primer set: Cor-FW (5\u2032-ACWCARHTVAAYYTNAARTAYGC-3\u2032) and Cor-RV (5\u2032-TCRCAYTTDGGRTARTCCCA-3\u2032).", [["251-bp fragment", "DNA", 23, 38], ["polymerase gene", "DNA", 46, 61], ["Cor-RV", "DNA", 153, 159], ["a 251-bp fragment of the polymerase gene", "TREATMENT", 21, 61], ["Cor-FW", "TEST", 110, 116], ["ACWCARHTVAAYYTNAARTAYGC", "TEST", 121, 144], ["Cor-RV", "TEST", 153, 159], ["TCRCAYTTDGGRTARTCCCA", "TEST", 164, 184]]], ["These one-step RT-PCR assays (OneStep RT-PCR kit; Qiagen) were undertaken in a 50-ll reaction volume containing 10 ll RNA extract, 10 ll 5 9 Qiagen OneStep RT-PCR Buffer, 2 lL dNTP mix (final concentration of 400 lM of each dNTP), 1.8 ll Qiagen OneStep RT-PCR Enzyme Mix (a combination of Omniscript and Sensiscript reverse transcriptase and HotStarTaq DNA polymerase), 4 lM of each primer, and RNase-free water.", [["NTP", "CHEMICAL", 177, 180], ["dNTP", "CHEMICAL", 224, 228], ["dNTP", "CHEMICAL", 224, 228], ["DNA", "CELLULAR_COMPONENT", 353, 356], ["RNase", "GENE_OR_GENE_PRODUCT", 395, 400], ["Omniscript", "PROTEIN", 289, 299], ["Sensiscript reverse transcriptase", "PROTEIN", 304, 337], ["HotStarTaq DNA polymerase", "PROTEIN", 342, 367], ["RNase", "PROTEIN", 395, 400], ["PCR assays", "TEST", 18, 28], ["OneStep", "TEST", 30, 37], ["PCR kit", "TEST", 41, 48], ["volume", "TEST", 94, 100], ["ll", "TEST", 134, 136], ["Qiagen OneStep RT-PCR Buffer", "TREATMENT", 141, 169], ["2 lL dNTP mix", "TREATMENT", 171, 184], ["dNTP", "TEST", 224, 228], ["ll Qiagen OneStep RT", "TREATMENT", 235, 255], ["PCR Enzyme Mix", "TREATMENT", 256, 270], ["Omniscript", "TREATMENT", 289, 299], ["Sensiscript reverse transcriptase", "TREATMENT", 304, 337], ["HotStarTaq DNA polymerase", "TREATMENT", 342, 367], ["RNase", "TREATMENT", 395, 400]]], ["Positive and negative controls were included in each PCR experiment.", [["negative controls", "OBSERVATION_MODIFIER", 13, 30]]], ["The reaction was carried out with an initial reverse transcription step at 50\u00b0C for 30 minutes, followed by PCR activation at 95\u00b0C for 15 minutes, 40 cycles of amplification (30 seconds at 94\u00b0C; 30 seconds at 50\u00b0C; 1 minutes at 72\u00b0C), and a final extension step at 72\u00b0C for 10 minutes in a Veriti thermal cycler (Applied Biosystems, Foster City, CA, USA).", [["PCR activation", "TEST", 108, 122], ["amplification", "TREATMENT", 160, 173], ["a Veriti thermal cycler", "TREATMENT", 288, 311]]], ["PCR products were verified on an agarose gel, stained with ethidium bromide, and visualized under UV light.", [["ethidium bromide", "CHEMICAL", 59, 75], ["ethidium bromide", "CHEMICAL", 59, 75], ["agarose", "SIMPLE_CHEMICAL", 33, 40], ["ethidium bromide", "SIMPLE_CHEMICAL", 59, 75], ["PCR products", "TREATMENT", 0, 12], ["an agarose gel", "TREATMENT", 30, 44], ["ethidium bromide", "TREATMENT", 59, 75], ["UV light", "OBSERVATION", 98, 106]]], ["The sensitivity of the assay was assessed by testing 10-fold dilutions of HCoV-NL63 RNA standard curve, which showed sensitivity of 5 9 10 5 RNA copies/ll.", [["HCoV", "GENE_OR_GENE_PRODUCT", 74, 78], ["HCoV", "PROTEIN", 74, 78], ["HCoV", "SPECIES", 74, 78], ["the assay", "TEST", 19, 28], ["testing", "TEST", 45, 52], ["HCoV", "TEST", 74, 78], ["RNA standard curve", "TEST", 84, 102], ["sensitivity", "TEST", 117, 128], ["RNA copies", "TEST", 141, 151]]], ["The specificity was assessed by testing controls of other respiratory viruses (rhinovirus, bocavirus, human parainfluenza 1, 2, and 3, influenza A and B, metapneumovirus, adenovirus, and respiratory syncytial virus) through the methods for HCoVs detection.", [["respiratory viruses", "DISEASE", 58, 77], ["respiratory syncytial virus", "DISEASE", 187, 214], ["rhinovirus", "ORGANISM", 79, 89], ["human", "ORGANISM", 102, 107], ["parainfluenza 1", "ORGANISM", 108, 123], ["2", "GENE_OR_GENE_PRODUCT", 125, 126], ["3", "GENE_OR_GENE_PRODUCT", 132, 133], ["influenza A and B", "ORGANISM", 135, 152], ["metapneumovirus", "ORGANISM", 154, 169], ["adenovirus", "ORGANISM", 171, 181], ["respiratory syncytial virus", "ORGANISM", 187, 214], ["human", "SPECIES", 102, 107], ["parainfluenza 1", "SPECIES", 108, 123], ["B, metapneumovirus", "SPECIES", 151, 169], ["respiratory syncytial virus", "SPECIES", 187, 214], ["human parainfluenza 1", "SPECIES", 102, 123], ["adenovirus", "SPECIES", 171, 181], ["respiratory syncytial virus", "SPECIES", 187, 214], ["The specificity", "TEST", 0, 15], ["other respiratory viruses", "PROBLEM", 52, 77], ["rhinovirus", "PROBLEM", 79, 89], ["bocavirus", "TEST", 91, 100], ["human parainfluenza", "TEST", 102, 121], ["influenza A", "TEST", 135, 146], ["metapneumovirus", "PROBLEM", 154, 169], ["adenovirus", "PROBLEM", 171, 181], ["respiratory syncytial virus", "PROBLEM", 187, 214], ["HCoVs detection", "TEST", 240, 255], ["respiratory viruses", "ANATOMY", 58, 77], ["respiratory syncytial", "ANATOMY", 187, 208]]], ["There was no amplification of the non-HCoV controls through the method used for CoVs detection.Real-time RT-PCR for HCoV detectionPositive samples on the pan-CoV RT-PCR assay were tested to identify the HCoV species OC43, 229E, NL63, and HKU1 using a previously described real-time RT-PCR panel consisting of four different HCoV monoplex assays run under identical amplification conditions.", [["samples", "ANATOMY", 139, 146], ["CoVs", "SIMPLE_CHEMICAL", 80, 84], ["229E", "GENE_OR_GENE_PRODUCT", 222, 226], ["NL63", "GENE_OR_GENE_PRODUCT", 228, 232], ["HKU1", "GENE_OR_GENE_PRODUCT", 238, 242], ["CoVs", "PROTEIN", 80, 84], ["HCoV species OC43, 229E, NL63, and HKU1", "DNA", 203, 242], ["HCoV", "SPECIES", 116, 120], ["HCoV", "SPECIES", 324, 328], ["the non-HCoV controls", "TREATMENT", 30, 51], ["CoVs detection", "TEST", 80, 94], ["PCR", "TEST", 108, 111], ["HCoV", "TEST", 116, 120], ["the pan", "TEST", 150, 157], ["CoV RT-PCR assay", "TEST", 158, 174], ["NL63", "TEST", 228, 232], ["PCR panel", "TEST", 285, 294], ["no", "UNCERTAINTY", 10, 12]]], ["Reaction mixtures were prepared using the AgPath-ID TM One-Step RT-PCR Kit (Applied Biosystems).", [["Reaction mixtures", "PROBLEM", 0, 17], ["the AgPath", "TREATMENT", 38, 48], ["ID TM", "TREATMENT", 49, 54]]], ["Reactions (25 ll) contained 2 9 RT-PCR buffer, 25 9 RT-PCR enzyme mix, primers, probe, nuclease-free water, and nucleic acid.", [["nucleic acid", "CHEMICAL", 112, 124], ["nucleic acid", "SIMPLE_CHEMICAL", 112, 124], ["nuclease", "PROTEIN", 87, 95], ["PCR buffer", "TEST", 35, 45], ["RT", "TEST", 52, 54], ["PCR enzyme mix", "TEST", 55, 69], ["primers", "TEST", 71, 78], ["nuclease", "TEST", 87, 95], ["nucleic acid", "TREATMENT", 112, 124]]], ["Each specimen was also tested for the human ribonuclease P gene to measure nucleic acid integrity.", [["specimen", "ANATOMY", 5, 13], ["nucleic acid", "CHEMICAL", 75, 87], ["human", "ORGANISM", 38, 43], ["ribonuclease P", "GENE_OR_GENE_PRODUCT", 44, 58], ["human ribonuclease P gene", "DNA", 38, 63], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["the human ribonuclease P gene", "TREATMENT", 34, 63], ["nucleic acid integrity", "TEST", 75, 97]]], ["30 The sensitivity of the assay was assessed by testing 10-fold dilutions of each HCoVs RNA standard curve, which showed sensitivity of 5 9 10 2 copies/ll for HCoV-OC43, 5 9 10 4 copies/ll for HCoV-229E, 5 9 10 3 copies/ll for HCoV-NL63, and 5 9 10 3 copies/ll for HCoV-HKU1.", [["HCoV-NL63", "ANATOMY", 227, 236], ["HCoV-OC43", "CELL", 159, 168], ["HCoV-229E", "CELL", 193, 202], ["HCoV-NL63", "CELL", 227, 236], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 265, 274], ["HCoVs RNA", "RNA", 82, 91], ["HCoV-NL63", "DNA", 227, 236], ["HCoV", "DNA", 265, 269], ["HKU1", "DNA", 270, 274], ["HCoV-OC43", "SPECIES", 159, 168], ["HCoV-229E", "SPECIES", 193, 202], ["HCoV", "SPECIES", 227, 231], ["HCoV", "SPECIES", 265, 269], ["the assay", "TEST", 22, 31], ["testing", "TEST", 48, 55], ["each HCoVs RNA standard curve", "TEST", 77, 106], ["sensitivity", "TEST", 121, 132], ["HCoV", "TEST", 159, 163], ["OC43", "TEST", 164, 168], ["copies/ll", "TEST", 179, 188], ["HCoV", "TEST", 193, 197], ["copies/ll", "TEST", 213, 222], ["HCoV", "TEST", 227, 231], ["NL63", "TEST", 232, 236], ["copies/ll", "TEST", 251, 260], ["HCoV", "TEST", 265, 269], ["HKU1", "PROBLEM", 270, 274]]], ["The specificity was assessed as described in the Pan-CoV assay.Statistical analysisStatistical analysis consisted of Pearson's v 2 test for the comparison of categorical values, with a significance level of P < 0.05.", [["the Pan-CoV assay", "TEST", 45, 62], ["Statistical analysisStatistical analysis", "TEST", 63, 103], ["Pearson's v 2 test", "TEST", 117, 135], ["categorical values", "TEST", 158, 176]]], ["Non-conditional logistic regression was used to identify associations between CoV positivity and the studied populations.", [["CoV", "ORGANISM", 78, 81], ["Non-conditional logistic regression", "PROBLEM", 0, 35], ["CoV positivity", "TEST", 78, 92]]], ["Results are presented as odds ratios (OR) and the respective 95% confidence intervals (CI), and P values.", [["CI", "TEST", 87, 89], ["P values", "TEST", 96, 104]]], ["All data were analyzed using the Statistical Analysis Software, version 9.0 (SAS Institute Inc., Cary, NC, USA).Coronavirus detectionThe pan-CoV assay detected 128/1137 (11.2%) CoV-positive samples, and the real-time RT-PCR panel identified 88 HCoV of the 128 (68.7%) screened samples.", [["samples", "ANATOMY", 190, 197], ["samples", "ANATOMY", 277, 284], ["CoV", "ORGANISM", 177, 180], ["HCoV", "CANCER", 244, 248], ["samples", "CANCER", 277, 284], ["HCoV", "SPECIES", 244, 248], ["All data", "TEST", 0, 8], ["version", "TEST", 64, 71], ["Coronavirus detection", "TEST", 112, 133], ["The pan-CoV assay", "TEST", 133, 150], ["CoV", "TEST", 177, 180], ["PCR panel", "TEST", 220, 229], ["HCoV", "TEST", 244, 248], ["screened samples", "TEST", 268, 284]]], ["The most frequently detected HCoV species were NL63 (50.0%) and OC43 (27.3%).", [["HCoV", "GENE_OR_GENE_PRODUCT", 29, 33], ["HCoV species", "PROTEIN", 29, 41], ["HCoV", "SPECIES", 29, 33], ["HCoV species", "TEST", 29, 41], ["NL63", "TEST", 47, 51], ["OC43", "TEST", 64, 68]]], ["The 229E and HKU1 species were detected in 17.0 and 5.7% of the samples, respectively.", [["samples", "ANATOMY", 64, 71], ["229E", "GENE_OR_GENE_PRODUCT", 4, 8], ["HKU1", "GENE_OR_GENE_PRODUCT", 13, 17], ["229E and HKU1 species", "PROTEIN", 4, 25], ["The 229E and HKU1 species", "TEST", 0, 25], ["the samples", "TEST", 60, 71]]], ["The CoV infection among the studied settings was evaluated by logistic regression analysis.", [["CoV infection", "DISEASE", 4, 17], ["CoV", "ORGANISM", 4, 7], ["The CoV infection", "PROBLEM", 0, 17], ["logistic regression analysis", "TEST", 62, 90], ["CoV", "OBSERVATION_MODIFIER", 4, 7], ["infection", "OBSERVATION", 8, 17]]], ["When compared with the hospitalized, significant difference (P < 0.05) was observed among all subsets, except in children from the community (P = 0.3076) and asymptomatics (P = 0.9879; Table 2 ).", [["children", "ORGANISM", 113, 121], ["children", "SPECIES", 113, 121], ["P", "TEST", 173, 174], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["difference", "OBSERVATION_MODIFIER", 49, 59]]], ["Patients with comorbidities presented the highest risk of acquiring CoV infection (OR = 4.17; 95% CI 1.9-9.3; P = <0.05) when compared with the other subsets.", [["CoV infection", "DISEASE", 68, 81], ["Patients", "ORGANISM", 0, 8], ["CoV", "ORGANISM", 68, 71], ["Patients", "SPECIES", 0, 8], ["CoV", "SPECIES", 68, 71], ["comorbidities", "PROBLEM", 14, 27], ["acquiring CoV infection", "PROBLEM", 58, 81], ["CI", "TEST", 98, 100], ["P", "TEST", 110, 111], ["CoV", "OBSERVATION_MODIFIER", 68, 71], ["infection", "OBSERVATION", 72, 81]]], ["Children with heart diseases and renal transplant patients had the next highest rates of CoV infections after the comorbidities group, tallying 17.3 and 12.2%, respectively.", [["heart", "ANATOMY", 14, 19], ["renal", "ANATOMY", 33, 38], ["heart diseases", "DISEASE", 14, 28], ["CoV infections", "DISEASE", 89, 103], ["Children", "ORGANISM", 0, 8], ["heart", "ORGAN", 14, 19], ["renal", "ORGAN", 33, 38], ["patients", "ORGANISM", 50, 58], ["CoV", "ORGANISM", 89, 92], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 50, 58], ["CoV", "SPECIES", 89, 92], ["heart diseases", "PROBLEM", 14, 28], ["renal transplant", "TREATMENT", 33, 49], ["CoV infections", "PROBLEM", 89, 103], ["heart", "ANATOMY", 14, 19], ["diseases", "OBSERVATION", 20, 28], ["renal", "ANATOMY", 33, 38], ["transplant", "OBSERVATION", 39, 49], ["CoV", "OBSERVATION_MODIFIER", 89, 92], ["infections", "OBSERVATION", 93, 103]]], ["An important rate of detection was also found among healthcare workers (10.5%) and patients in stem cell transplantation programs (10.5%).", [["stem cell", "ANATOMY", 95, 104], ["patients", "ORGANISM", 83, 91], ["stem cell", "CELL", 95, 104], ["patients", "SPECIES", 83, 91], ["stem cell transplantation programs", "TREATMENT", 95, 129], ["stem cell transplantation", "OBSERVATION", 95, 120]]], ["No HCoV infection was found among asymptomatic patients.", [["infection", "DISEASE", 8, 17], ["HCoV", "GENE_OR_GENE_PRODUCT", 3, 7], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["HCoV", "SPECIES", 3, 7], ["HCoV infection", "PROBLEM", 3, 17], ["HCoV", "ANATOMY", 3, 7], ["infection", "OBSERVATION", 8, 17]]], ["Figure 1 illustrates the distribution of HCoV species among the positive cases based on the studied patient subsets.", [["HCoV", "GENE_OR_GENE_PRODUCT", 41, 45], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["HCoV", "SPECIES", 41, 45], ["HCoV species", "PROBLEM", 41, 53], ["the positive cases", "PROBLEM", 60, 78]]], ["HCoV-NL63 was the species most frequently associated with children, both from the community (100%) and presenting heart diseases (50%), while there was a high rate of HCoV-229E detection among renal transplant patients (44%).", [["heart", "ANATOMY", 114, 119], ["renal transplant", "ANATOMY", 193, 209], ["heart diseases", "DISEASE", 114, 128], ["HCoV-229E", "CHEMICAL", 167, 176], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["NL63", "GENE_OR_GENE_PRODUCT", 5, 9], ["children", "ORGANISM", 58, 66], ["heart", "ORGAN", 114, 119], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 167, 176], ["renal", "ORGAN", 193, 198], ["patients", "ORGANISM", 210, 218], ["HCoV", "PROTEIN", 0, 4], ["NL63", "DNA", 5, 9], ["children", "SPECIES", 58, 66], ["patients", "SPECIES", 210, 218], ["HCoV", "SPECIES", 0, 4], ["HCoV-229E", "SPECIES", 167, 176], ["HCoV", "TEST", 0, 4], ["presenting heart diseases", "PROBLEM", 103, 128], ["a high rate of HCoV", "PROBLEM", 152, 171], ["renal transplant", "TREATMENT", 193, 209], ["heart", "ANATOMY", 114, 119], ["diseases", "OBSERVATION", 120, 128], ["renal", "ANATOMY", 193, 198], ["transplant", "OBSERVATION", 199, 209]]], ["Patients in stem cell transplantation programs were more frequently infected with HCoV species OC43 (47%) and NL63 (42%) when compared with the other HCoV species.", [["stem cell", "ANATOMY", 12, 21], ["Patients", "ORGANISM", 0, 8], ["stem cell", "CELL", 12, 21], ["Patients", "SPECIES", 0, 8], ["HCoV", "SPECIES", 82, 86], ["HCoV", "SPECIES", 150, 154], ["stem cell transplantation programs", "TREATMENT", 12, 46], ["HCoV species OC43", "TEST", 82, 99], ["NL63", "TEST", 110, 114], ["the other HCoV species", "PROBLEM", 140, 162], ["stem cell transplantation", "OBSERVATION", 12, 37]]], ["HCoV-NL63 was not detected among adults from the community, and HCoV-HKU1 was detected only among adults, healthcare workers, and children with heart diseases.Circulation trendCoronaviruses were most frequently detected during winter and autumn (75%) (Figure 2 HCoV-OC43 was detected in all studied years (except in 2006, when no CoV cases were detected) from March to November (autumn to spring), with detection frequencies peaking in August (winter).", [["heart", "ANATOMY", 144, 149], ["heart diseases", "DISEASE", 144, 158], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 64, 73], ["children", "ORGANISM", 130, 138], ["heart", "ORGAN", 144, 149], ["HCoV", "PROTEIN", 0, 4], ["NL63", "DNA", 5, 9], ["HCoV", "DNA", 64, 68], ["HKU1", "DNA", 69, 73], ["children", "SPECIES", 130, 138], ["HCoV", "SPECIES", 0, 4], ["HCoV", "SPECIES", 64, 68], ["HCoV", "TEST", 0, 4], ["heart diseases", "PROBLEM", 144, 158], ["Circulation trendCoronaviruses", "PROBLEM", 159, 189], ["Figure", "TEST", 252, 258], ["CoV cases", "PROBLEM", 330, 339], ["heart", "ANATOMY", 144, 149], ["diseases", "OBSERVATION", 150, 158]]], ["Interseason HCoV-OC43 detection frequencies were more consistent than that for the other CoVs.Circulation trendHCoV HCoV-NL63 was the most frequently detected species in the study, circulating in all seasons.", [["CoVs", "GENE_OR_GENE_PRODUCT", 89, 93], ["OC43", "DNA", 17, 21], ["CoVs", "DNA", 89, 93], ["NL63", "DNA", 121, 125], ["Interseason HCoV", "TEST", 0, 16], ["OC43 detection frequencies", "TEST", 17, 43], ["the other CoVs", "PROBLEM", 79, 93], ["Circulation trendHCoV HCoV", "TEST", 94, 120], ["the study", "TEST", 170, 179]]], ["Although the NL63 species presented a high frequency of detection in July (winter), it was a unique HCoV species with cases also being detected in the summer.Patient parametersThe median age of HCoV-infected patients was 28 years (range, 1 month to 68 years).", [["HCoV-infected", "DISEASE", 194, 207], ["HCoV", "CANCER", 100, 104], ["HCoV", "CANCER", 194, 198], ["patients", "ORGANISM", 208, 216], ["Patient", "SPECIES", 158, 165], ["patients", "SPECIES", 208, 216], ["HCoV", "SPECIES", 194, 198], ["the NL63 species", "PROBLEM", 9, 25], ["Patient parameters", "TEST", 158, 176], ["infected", "OBSERVATION_MODIFIER", 199, 207]]], ["The frequency was higher in patients aged 50-59 years (15.9%).", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["higher", "OBSERVATION_MODIFIER", 18, 24]]], ["Figure 3 depicts the distribution of CoV-infected cases by age.", [["CoV-infected", "DISEASE", 37, 49], ["CoV", "ORGANISM", 37, 40], ["CoV", "OBSERVATION_MODIFIER", 37, 40], ["infected", "OBSERVATION", 41, 49]]], ["Predominantly, infected patients were female (60 9 28, P < 0.001).", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["infected", "OBSERVATION_MODIFIER", 15, 23]]], ["Sixteen percent (16/88) of the infected patients reported underlying conditions such as human immunodeficiency virus (HIV) and human T-cell leukemia virus (HTLV)-type infection, diabetes mellitus, liver transplant, megacolon syndrome, hypertension, Wiskott-Aldrich syndrome, and congenital kidney and lung diseases.", [["liver", "ANATOMY", 197, 202], ["kidney", "ANATOMY", 290, 296], ["lung", "ANATOMY", 301, 305], ["infected", "DISEASE", 31, 39], ["human immunodeficiency virus (HIV)", "DISEASE", 88, 122], ["human T-cell leukemia virus (HTLV)-type infection", "DISEASE", 127, 176], ["diabetes mellitus", "DISEASE", 178, 195], ["liver transplant, megacolon syndrome", "DISEASE", 197, 233], ["hypertension", "DISEASE", 235, 247], ["Wiskott-Aldrich syndrome", "DISEASE", 249, 273], ["congenital kidney and lung diseases", "DISEASE", 279, 314], ["patients", "ORGANISM", 40, 48], ["human immunodeficiency virus", "ORGANISM", 88, 116], ["HIV", "ORGANISM", 118, 121], ["human T-cell leukemia virus (HTLV)-type", "ORGANISM", 127, 166], ["liver", "ORGAN", 197, 202], ["kidney", "ORGAN", 290, 296], ["lung", "ORGAN", 301, 305], ["patients", "SPECIES", 40, 48], ["human immunodeficiency virus", "SPECIES", 88, 116], ["HIV", "SPECIES", 118, 121], ["human", "SPECIES", 127, 132], ["T-cell leukemia virus", "SPECIES", 133, 154], ["human immunodeficiency virus", "SPECIES", 88, 116], ["HIV", "SPECIES", 118, 121], ["human T-cell leukemia virus", "SPECIES", 127, 154], ["HTLV", "SPECIES", 156, 160], ["underlying conditions", "PROBLEM", 58, 79], ["human immunodeficiency virus (HIV)", "PROBLEM", 88, 122], ["human T-cell leukemia virus (HTLV)", "PROBLEM", 127, 161], ["type infection", "PROBLEM", 162, 176], ["diabetes mellitus", "PROBLEM", 178, 195], ["liver transplant", "TREATMENT", 197, 213], ["megacolon syndrome", "PROBLEM", 215, 233], ["hypertension", "PROBLEM", 235, 247], ["Wiskott", "PROBLEM", 249, 256], ["Aldrich syndrome", "PROBLEM", 257, 273], ["congenital kidney", "PROBLEM", 279, 296], ["lung diseases", "PROBLEM", 301, 314], ["cell leukemia virus", "OBSERVATION", 135, 154], ["diabetes mellitus", "OBSERVATION", 178, 195], ["liver", "ANATOMY", 197, 202], ["transplant", "OBSERVATION", 203, 213], ["megacolon syndrome", "OBSERVATION", 215, 233], ["hypertension", "OBSERVATION", 235, 247], ["Aldrich syndrome", "OBSERVATION", 257, 273], ["congenital", "ANATOMY_MODIFIER", 279, 289], ["kidney", "ANATOMY", 290, 296], ["lung", "ANATOMY", 301, 305], ["diseases", "OBSERVATION", 306, 314]]], ["In addition, four patients were born prematurely and seven were smokers.Clinical associations of CoV infectionsClinical data were available for all 88 HCoV-infected patients (Table 3) .", [["CoV infections", "DISEASE", 97, 111], ["HCoV-infected", "DISEASE", 151, 164], ["patients", "ORGANISM", 18, 26], ["CoV", "ORGANISM", 97, 100], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 165, 173], ["HCoV", "SPECIES", 151, 155], ["CoV infections", "PROBLEM", 97, 111], ["Clinical data", "TEST", 111, 124], ["CoV infections", "OBSERVATION", 97, 111]]], ["Coryza, cough, and fever were the most common symptoms at presentation, being reported in 86%, 77%, and 51% of positive cases, respectively.", [["cough", "DISEASE", 8, 13], ["fever", "DISEASE", 19, 24], ["Coryza", "PROBLEM", 0, 6], ["cough", "PROBLEM", 8, 13], ["fever", "PROBLEM", 19, 24], ["the most common symptoms", "PROBLEM", 30, 54], ["cough", "OBSERVATION", 8, 13], ["fever", "OBSERVATION", 19, 24]]], ["Fever was found less frequently among renal transplant patients and patients in stem cell transplantation programs when compared with the other patient subsets.", [["renal", "ANATOMY", 38, 43], ["stem cell", "ANATOMY", 80, 89], ["Fever", "DISEASE", 0, 5], ["renal", "ORGAN", 38, 43], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 68, 76], ["stem cell", "CELL", 80, 89], ["patient", "ORGANISM", 144, 151], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 68, 76], ["patient", "SPECIES", 144, 151], ["Fever", "PROBLEM", 0, 5], ["stem cell transplantation programs", "TREATMENT", 80, 114], ["less frequently", "OBSERVATION_MODIFIER", 16, 31], ["renal", "ANATOMY", 38, 43], ["transplant", "OBSERVATION", 44, 54], ["stem cell transplantation", "OBSERVATION", 80, 105]]], ["Cyanosis was observed among children with heart disease, and wheezing was reported among hospitalized patients, children from the community, and children with heart diseases.", [["heart", "ANATOMY", 42, 47], ["heart", "ANATOMY", 159, 164], ["Cyanosis", "DISEASE", 0, 8], ["heart disease", "DISEASE", 42, 55], ["wheezing", "DISEASE", 61, 69], ["heart diseases", "DISEASE", 159, 173], ["children", "ORGANISM", 28, 36], ["heart", "ORGAN", 42, 47], ["patients", "ORGANISM", 102, 110], ["children", "ORGANISM", 112, 120], ["children", "ORGANISM", 145, 153], ["heart", "ORGAN", 159, 164], ["children", "SPECIES", 28, 36], ["patients", "SPECIES", 102, 110], ["children", "SPECIES", 112, 120], ["children", "SPECIES", 145, 153], ["Cyanosis", "PROBLEM", 0, 8], ["heart disease", "PROBLEM", 42, 55], ["wheezing", "PROBLEM", 61, 69], ["heart diseases", "PROBLEM", 159, 173], ["heart", "ANATOMY", 42, 47], ["disease", "OBSERVATION", 48, 55], ["heart", "ANATOMY", 159, 164], ["diseases", "OBSERVATION", 165, 173]]], ["Dyspnea, another lower respiratory tract infection symptom other than wheezing, was documented among patients in stem cell transplantation programs, children with heart diseases, children from the community, and hospitalized patients.", [["lower respiratory tract", "ANATOMY", 17, 40], ["stem cell", "ANATOMY", 113, 122], ["heart", "ANATOMY", 163, 168], ["Dyspnea", "DISEASE", 0, 7], ["respiratory tract infection", "DISEASE", 23, 50], ["wheezing", "DISEASE", 70, 78], ["heart diseases", "DISEASE", 163, 177], ["lower", "ORGANISM_SUBDIVISION", 17, 22], ["respiratory tract", "ORGANISM_SUBDIVISION", 23, 40], ["patients", "ORGANISM", 101, 109], ["stem cell", "CELL", 113, 122], ["children", "ORGANISM", 149, 157], ["heart", "ORGAN", 163, 168], ["children", "ORGANISM", 179, 187], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 101, 109], ["children", "SPECIES", 149, 157], ["children", "SPECIES", 179, 187], ["patients", "SPECIES", 225, 233], ["Dyspnea", "PROBLEM", 0, 7], ["another lower respiratory tract infection symptom", "PROBLEM", 9, 58], ["wheezing", "PROBLEM", 70, 78], ["stem cell transplantation programs", "TREATMENT", 113, 147], ["heart diseases", "PROBLEM", 163, 177], ["lower", "ANATOMY_MODIFIER", 17, 22], ["respiratory tract", "ANATOMY", 23, 40], ["infection", "OBSERVATION", 41, 50], ["stem cell transplantation", "OBSERVATION", 113, 138], ["heart", "ANATOMY", 163, 168], ["diseases", "OBSERVATION", 169, 177]]], ["Healthcare workers presented more cases of sore throat and myalgia than did adults from the community group, patients under transplantation program, and hospitalized patients.", [["sore throat", "DISEASE", 43, 54], ["myalgia", "DISEASE", 59, 66], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 166, 174], ["sore throat", "PROBLEM", 43, 54], ["myalgia", "PROBLEM", 59, 66]]], ["Differences in clinical presentation were observed among each HCoV species infection ( Figure 4 ).", [["infection", "DISEASE", 75, 84], ["HCoV", "SPECIES", 62, 66], ["each HCoV species infection", "PROBLEM", 57, 84], ["infection", "OBSERVATION", 75, 84]]], ["Patients infected with HCoV-HKU1 presented more fever, coryza, and myalgia when compared with the other HCoV-infected cases (P < 0.05).", [["fever", "DISEASE", 48, 53], ["coryza", "DISEASE", 55, 61], ["myalgia", "DISEASE", 67, 74], ["HCoV-infected", "DISEASE", 104, 117], ["Patients", "ORGANISM", 0, 8], ["HCoV-HKU1", "ORGANISM", 23, 32], ["Patients", "SPECIES", 0, 8], ["HCoV", "SPECIES", 23, 27], ["HCoV", "SPECIES", 104, 108], ["HCoV", "TEST", 23, 27], ["HKU1", "PROBLEM", 28, 32], ["fever", "PROBLEM", 48, 53], ["coryza", "PROBLEM", 55, 61], ["myalgia", "PROBLEM", 67, 74], ["myalgia", "OBSERVATION", 67, 74], ["infected", "OBSERVATION", 109, 117]]], ["Dyspnea was more frequently associated with patients infected with HCoV-229E (66.6%).", [["Dyspnea", "DISEASE", 0, 7], ["HCoV-229E", "CHEMICAL", 67, 76], ["HCoV-229E", "CHEMICAL", 67, 76], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["HCoV-229E", "SPECIES", 67, 76], ["Dyspnea", "PROBLEM", 0, 7], ["HCoV", "TEST", 67, 71]]], ["Cyanosis was reported only among patients infected with HCoV-OC43, and diarrhea was reported only in HCoV-NL63 cases.", [["Cyanosis", "DISEASE", 0, 8], ["HCoV-OC43", "CHEMICAL", 56, 65], ["diarrhea", "DISEASE", 71, 79], ["patients", "ORGANISM", 33, 41], ["HCoV-OC43", "ORGANISM", 56, 65], ["HCoV-NL63", "CANCER", 101, 110], ["patients", "SPECIES", 33, 41], ["HCoV", "SPECIES", 56, 60], ["HCoV", "SPECIES", 101, 105], ["Cyanosis", "PROBLEM", 0, 8], ["HCoV", "TEST", 56, 60], ["OC43", "PROBLEM", 61, 65], ["diarrhea", "PROBLEM", 71, 79], ["HCoV", "TEST", 101, 105]]], ["The median time for hospitalized CoV-infected patients to be discharged was 12 days (range, 5-30 days); of the seven hospitalized CoV-infected patients, three were infected with HCoV-NL63, two with HCoV-229E, and the other two with HCoV-OC43.", [["CoV-infected", "DISEASE", 33, 45], ["CoV-infected", "DISEASE", 130, 142], ["HCoV-229E", "CHEMICAL", 198, 207], ["CoV", "ORGANISM", 33, 36], ["patients", "ORGANISM", 46, 54], ["CoV", "ORGANISM", 130, 133], ["patients", "ORGANISM", 143, 151], ["OC43", "DNA", 237, 241], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 143, 151], ["HCoV", "SPECIES", 178, 182], ["HCoV-229E", "SPECIES", 198, 207], ["HCoV", "TEST", 178, 182], ["HCoV", "TEST", 198, 202], ["HCoV", "TEST", 232, 236], ["infected", "OBSERVATION", 134, 142], ["OC43", "OBSERVATION", 237, 241]]], ["Patients infected with HCoV-OC43 stayed longer in hospital (average, 19 days) than did patients infected with HCoV-NL63 or HCoV-229E.", [["HCoV-229E", "CHEMICAL", 123, 132], ["Patients", "ORGANISM", 0, 8], ["HCoV-OC43", "ORGANISM", 23, 32], ["patients", "ORGANISM", 87, 95], ["HCoV-NL63", "ORGANISM", 110, 119], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 123, 132], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 87, 95], ["HCoV", "SPECIES", 23, 27], ["HCoV", "SPECIES", 110, 114], ["HCoV-229E", "SPECIES", 123, 132], ["HCoV", "TREATMENT", 23, 27], ["OC43", "PROBLEM", 28, 32], ["HCoV", "TEST", 110, 114], ["HCoV", "TEST", 123, 127], ["infected", "OBSERVATION", 9, 17], ["infected", "OBSERVATION", 96, 104]]], ["Four hospitalized patients of seven (57.1%) were admitted to the intensive care unit.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Lower respiratory tract infections were found in 6/7 (85.7%) hospitalized CoV-infected patients.", [["respiratory tract", "ANATOMY", 6, 23], ["Lower respiratory tract infections", "DISEASE", 0, 34], ["CoV-infected", "DISEASE", 74, 86], ["respiratory tract", "ORGANISM_SUBDIVISION", 6, 23], ["CoV", "ORGANISM", 74, 77], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Lower respiratory tract infections", "PROBLEM", 0, 34], ["respiratory tract", "ANATOMY", 6, 23], ["infections", "OBSERVATION", 24, 34], ["infected", "OBSERVATION", 78, 86]]], ["The remaining patient was infected by HCoV-OC43 and presented upper respiratory tract infection.", [["upper respiratory tract", "ANATOMY", 62, 85], ["HCoV-OC43", "CHEMICAL", 38, 47], ["respiratory tract infection", "DISEASE", 68, 95], ["patient", "ORGANISM", 14, 21], ["HCoV-OC43", "CELL", 38, 47], ["upper", "ORGANISM_SUBDIVISION", 62, 67], ["respiratory tract", "ORGANISM_SUBDIVISION", 68, 85], ["patient", "SPECIES", 14, 21], ["HCoV", "SPECIES", 38, 42], ["OC43", "PROBLEM", 43, 47], ["upper respiratory tract infection", "PROBLEM", 62, 95], ["infected", "OBSERVATION", 26, 34], ["upper", "ANATOMY_MODIFIER", 62, 67], ["respiratory tract", "ANATOMY", 68, 85], ["infection", "OBSERVATION", 86, 95]]], ["This patient was a nosocomial case documented in a child who had been admitted for an intestinal surgery due to megacolon.", [["intestinal", "ANATOMY", 86, 96], ["megacolon", "DISEASE", 112, 121], ["patient", "ORGANISM", 5, 12], ["child", "ORGANISM", 51, 56], ["intestinal", "ORGAN", 86, 96], ["megacolon", "PATHOLOGICAL_FORMATION", 112, 121], ["patient", "SPECIES", 5, 12], ["an intestinal surgery", "TREATMENT", 83, 104], ["megacolon", "PROBLEM", 112, 121], ["intestinal", "ANATOMY", 86, 96], ["surgery", "OBSERVATION", 97, 104], ["megacolon", "OBSERVATION", 112, 121]]], ["Six of the patients had a good outcome, but 1 diabetic adult died of HCoV-NL63associated pneumonia 9 days after admission.CoinfectionsInvestigations into other respiratory viruses (rhinovirus, bocavirus, human metapneumovirus, adenovirus, influenza A or B, and respiratory syncytial virus) were available in 87 of 88 CoV-infected cases, in which at least 1 respiratory virus other than CoV was detected in 26 samples (29.8%).", [["samples", "ANATOMY", 409, 416], ["diabetic", "DISEASE", 46, 54], ["pneumonia", "DISEASE", 89, 98], ["respiratory viruses", "DISEASE", 160, 179], ["human metapneumovirus", "DISEASE", 204, 225], ["influenza A or B", "DISEASE", 239, 255], ["respiratory syncytial virus", "DISEASE", 261, 288], ["CoV-infected", "DISEASE", 317, 329], ["patients", "ORGANISM", 11, 19], ["rhinovirus", "ORGANISM", 181, 191], ["bocavirus", "ORGANISM", 193, 202], ["human metapneumovirus", "ORGANISM", 204, 225], ["adenovirus", "ORGANISM", 227, 237], ["influenza A", "ORGANISM", 239, 250], ["B", "GENE_OR_GENE_PRODUCT", 254, 255], ["respiratory syncytial virus", "ORGANISM", 261, 288], ["CoV", "ORGANISM", 317, 320], ["CoV", "ORGANISM", 386, 389], ["patients", "SPECIES", 11, 19], ["human", "SPECIES", 204, 209], ["metapneumovirus", "SPECIES", 210, 225], ["respiratory syncytial virus", "SPECIES", 261, 288], ["HCoV", "SPECIES", 69, 73], ["human metapneumovirus", "SPECIES", 204, 225], ["respiratory syncytial virus", "SPECIES", 261, 288], ["CoV", "SPECIES", 386, 389], ["HCoV", "PROBLEM", 69, 73], ["NL63associated pneumonia", "PROBLEM", 74, 98], ["CoinfectionsInvestigations", "TEST", 122, 148], ["other respiratory viruses", "PROBLEM", 154, 179], ["rhinovirus", "PROBLEM", 181, 191], ["bocavirus", "PROBLEM", 193, 202], ["human metapneumovirus", "PROBLEM", 204, 225], ["adenovirus", "PROBLEM", 227, 237], ["influenza", "PROBLEM", 239, 248], ["respiratory syncytial virus", "PROBLEM", 261, 288], ["infected cases", "PROBLEM", 321, 335], ["1 respiratory virus", "PROBLEM", 355, 374], ["CoV", "TEST", 386, 389], ["pneumonia", "OBSERVATION", 89, 98], ["respiratory viruses", "ANATOMY", 160, 179], ["respiratory syncytial", "ANATOMY", 261, 282]]], ["Rhinovirus (46.1%) and adenovirus (26.9%) were the most frequently codetected viruses in CoV-positive cases.", [["adenovirus", "ORGANISM", 23, 33], ["CoV", "ORGANISM", 89, 92], ["adenovirus", "SPECIES", 23, 33], ["Rhinovirus", "TEST", 0, 10], ["adenovirus", "TEST", 23, 33], ["positive cases", "OBSERVATION", 93, 107]]], ["HCoV-NL63 was associated most frequently with coinfection (57.7%), followed by HCoV-229E (23.1%) and HCoV-OC43 (19.2%).", [["coinfection", "DISEASE", 46, 57], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["HCoV-229E", "ORGANISM", 79, 88], ["HCoV-OC43", "CANCER", 101, 110], ["HCoV", "PROTEIN", 0, 4], ["NL63", "DNA", 5, 9], ["HCoV", "SPECIES", 0, 4], ["HCoV-229E", "SPECIES", 79, 88], ["HCoV-OC43", "SPECIES", 101, 110], ["HCoV", "TEST", 0, 4], ["coinfection", "PROBLEM", 46, 57], ["HCoV", "TEST", 79, 83], ["HCoV", "TEST", 101, 105], ["OC43", "TEST", 106, 110], ["coinfection", "OBSERVATION", 46, 57]]], ["There was no codetection of HCoV-HKU1 with other respiratory viruses.", [["respiratory viruses", "DISEASE", 49, 68], ["HCoV", "GENE_OR_GENE_PRODUCT", 28, 32], ["HKU1", "GENE_OR_GENE_PRODUCT", 33, 37], ["HCoV", "PROTEIN", 28, 32], ["HKU1", "PROTEIN", 33, 37], ["HCoV", "SPECIES", 28, 32], ["codetection of HCoV", "PROBLEM", 13, 32], ["HKU1", "PROBLEM", 33, 37], ["other respiratory viruses", "PROBLEM", 43, 68], ["no", "UNCERTAINTY", 10, 12], ["respiratory", "ANATOMY", 49, 60], ["viruses", "OBSERVATION", 61, 68]]], ["The most common associations were HCoV-NL63 plus adenovirus (46.1%) and HCoV-NL63 plus rhinovirus (38.5%).", [["HCoV", "GENE_OR_GENE_PRODUCT", 34, 38], ["adenovirus", "ORGANISM", 49, 59], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 72, 81], ["rhinovirus", "ORGANISM", 87, 97], ["HCoV", "SPECIES", 34, 38], ["HCoV-NL63 plus rhinovirus", "SPECIES", 72, 97], ["HCoV", "TEST", 34, 38], ["adenovirus", "TEST", 49, 59], ["HCoV", "TEST", 72, 76], ["rhinovirus", "TEST", 87, 97]]], ["The methods used for detecting the coinfections were conventional RT-PCR (for rhinovirus, bocavirus, and human metapneumovirus detection) and direct immunofluorescence (adenovirus, influenza A or B, and respiratory syncytial virus detection).DiscussionSince the emergence of SARS-CoV, numerous studies have been carried out on the clinical impact of different HCoV species.", [["coinfections", "DISEASE", 35, 47], ["respiratory syncytial virus", "DISEASE", 203, 230], ["SARS-CoV", "DISEASE", 275, 283], ["rhinovirus", "ORGANISM", 78, 88], ["human", "ORGANISM", 105, 110], ["metapneumovirus", "ORGANISM", 111, 126], ["adenovirus", "ORGANISM", 169, 179], ["influenza A", "ORGANISM", 181, 192], ["B", "GENE_OR_GENE_PRODUCT", 196, 197], ["respiratory syncytial virus", "ORGANISM", 203, 230], ["SARS-CoV", "ORGANISM", 275, 283], ["HCoV", "ORGANISM", 360, 364], ["human", "SPECIES", 105, 110], ["metapneumovirus", "SPECIES", 111, 126], ["human metapneumovirus", "SPECIES", 105, 126], ["adenovirus", "SPECIES", 169, 179], ["respiratory syncytial virus", "SPECIES", 203, 230], ["SARS-CoV", "SPECIES", 275, 283], ["HCoV", "SPECIES", 360, 364], ["the coinfections", "PROBLEM", 31, 47], ["conventional RT-PCR", "TEST", 53, 72], ["rhinovirus", "PROBLEM", 78, 88], ["bocavirus", "PROBLEM", 90, 99], ["human metapneumovirus detection", "TEST", 105, 136], ["direct immunofluorescence", "TEST", 142, 167], ["adenovirus", "PROBLEM", 169, 179], ["influenza", "PROBLEM", 181, 190], ["respiratory syncytial virus detection", "TEST", 203, 240], ["numerous studies", "TEST", 285, 301], ["different HCoV species", "PROBLEM", 350, 372]]], ["8, 9, 13, 14, 16, [26] [27] [28] [30] [31] [32] However, the majority of these studies were only performed in children, with small sample sizes and short sample collection periods.", [["[26] [27] [28] [30] [31] [32", "SIMPLE_CHEMICAL", 18, 46], ["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["these studies", "TEST", 73, 86], ["small sample sizes", "PROBLEM", 125, 143], ["short sample collection periods", "PROBLEM", 148, 179]]], ["This is the first study reporting on the epidemiological and clinical features of non-SARS HCoV infections among different clinical patient subsets, both adult and child, over a 9-year period.DiscussionHuman coronaviruses were detected among all studied subjects presenting respiratory tract illnesses, but not among those who were asymptomatic.", [["respiratory tract", "ANATOMY", 274, 291], ["HCoV infections", "DISEASE", 91, 106], ["respiratory tract illnesses", "DISEASE", 274, 301], ["HCoV", "CANCER", 91, 95], ["patient", "ORGANISM", 132, 139], ["DiscussionHuman coronaviruses", "ORGANISM", 192, 221], ["tract", "ORGANISM_SUBDIVISION", 286, 291], ["patient", "SPECIES", 132, 139], ["HCoV", "SPECIES", 91, 95], ["DiscussionHuman coronaviruses", "SPECIES", 192, 221], ["the first study", "TEST", 8, 23], ["non-SARS HCoV infections", "PROBLEM", 82, 106], ["DiscussionHuman coronaviruses", "PROBLEM", 192, 221], ["respiratory tract illnesses", "PROBLEM", 274, 301], ["respiratory tract", "ANATOMY", 274, 291]]], ["Recently, studies have demonstrated HCoV detection among asymptomatic patients, with a positive rate of approximately 4-7%.", [["HCoV", "CANCER", 36, 40], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["HCoV", "SPECIES", 36, 40], ["a positive rate", "TEST", 85, 100]]], ["33, 34 In contrast to our study, the evaluated asymptomatic patients from those reports were children, and we hypothesize that asymptomatic respiratory infection may be more frequent among children than in adults.", [["respiratory", "ANATOMY", 140, 151], ["respiratory infection", "DISEASE", 140, 161], ["patients", "ORGANISM", 60, 68], ["children", "ORGANISM", 93, 101], ["children", "ORGANISM", 189, 197], ["patients", "SPECIES", 60, 68], ["children", "SPECIES", 93, 101], ["children", "SPECIES", 189, 197], ["our study", "TEST", 22, 31], ["asymptomatic respiratory infection", "PROBLEM", 127, 161], ["respiratory", "ANATOMY", 140, 151], ["infection", "OBSERVATION", 152, 161]]], ["An important CoV detection rate was found among the subset of patients with comorbidities, being most frequent in children with heart diseases and in renal transplant patients.", [["heart", "ANATOMY", 128, 133], ["renal transplant", "ANATOMY", 150, 166], ["heart diseases", "DISEASE", 128, 142], ["CoV", "ORGANISM", 13, 16], ["patients", "ORGANISM", 62, 70], ["children", "ORGANISM", 114, 122], ["heart", "ORGAN", 128, 133], ["renal", "ORGAN", 150, 155], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 62, 70], ["children", "SPECIES", 114, 122], ["patients", "SPECIES", 167, 175], ["An important CoV detection rate", "TEST", 0, 31], ["comorbidities", "PROBLEM", 76, 89], ["heart diseases", "PROBLEM", 128, 142], ["renal transplant patients", "TREATMENT", 150, 175], ["heart", "ANATOMY", 128, 133], ["diseases", "OBSERVATION", 134, 142], ["renal", "ANATOMY", 150, 155], ["transplant", "OBSERVATION", 156, 166]]], ["Additionally, underlying conditions other than cardiac disease/transplantation were observed in 18% of CoVinfected patients.", [["cardiac", "ANATOMY", 47, 54], ["cardiac disease", "DISEASE", 47, 62], ["cardiac", "ORGAN", 47, 54], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["underlying conditions", "PROBLEM", 14, 35], ["cardiac disease", "PROBLEM", 47, 62], ["transplantation", "TREATMENT", 63, 78], ["cardiac", "ANATOMY", 47, 54], ["disease", "OBSERVATION", 55, 62], ["transplantation", "OBSERVATION", 63, 78]]], ["These data point to the relevance of CoVs causing respiratory tract illness in patients with comorbidities.", [["respiratory tract", "ANATOMY", 50, 67], ["respiratory tract illness", "DISEASE", 50, 75], ["CoVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["respiratory tract", "ORGANISM_SUBDIVISION", 50, 67], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["CoVs", "PROBLEM", 37, 41], ["respiratory tract illness", "PROBLEM", 50, 75], ["comorbidities", "PROBLEM", 93, 106], ["respiratory tract", "ANATOMY", 50, 67]]], ["Some reports have demonstrated a correlation between CoV-induced respiratory tract illness and populations with comorbidities.", [["respiratory tract", "ANATOMY", 65, 82], ["respiratory tract illness", "DISEASE", 65, 90], ["CoV", "GENE_OR_GENE_PRODUCT", 53, 56], ["tract", "ORGANISM_SUBDIVISION", 77, 82], ["CoV-induced respiratory tract illness", "PROBLEM", 53, 90], ["comorbidities", "PROBLEM", 112, 125], ["respiratory tract", "ANATOMY", 65, 82]]], ["22, [35] [36] [37] In spite of there being a lower HCoV detection rate in the hospitalized subset, the majority of positive cases presented with lower respiratory tract infections, and one fatal case was documented.", [["lower respiratory tract", "ANATOMY", 145, 168], ["respiratory tract infections", "DISEASE", 151, 179], ["HCoV", "CANCER", 51, 55], ["tract", "ORGANISM_SUBDIVISION", 163, 168], ["a lower HCoV detection rate", "PROBLEM", 43, 70], ["lower respiratory tract infections", "PROBLEM", 145, 179], ["lower", "ANATOMY_MODIFIER", 145, 150], ["respiratory tract", "ANATOMY", 151, 168], ["infections", "OBSERVATION", 169, 179]]], ["This result supports the premise that HCoV infection may cause more than mild respiratory tract disease.DiscussionA significant frequency of HCoVs among healthcare workers was also documented.", [["respiratory tract", "ANATOMY", 78, 95], ["HCoV infection", "DISEASE", 38, 52], ["respiratory tract disease", "DISEASE", 78, 103], ["HCoVs", "CHEMICAL", 141, 146], ["HCoV", "GENE_OR_GENE_PRODUCT", 38, 42], ["tract", "ORGANISM_SUBDIVISION", 90, 95], ["HCoVs", "CANCER", 141, 146], ["HCoV", "SPECIES", 38, 42], ["HCoV infection", "PROBLEM", 38, 52], ["mild respiratory tract disease", "PROBLEM", 73, 103], ["infection", "OBSERVATION", 43, 52], ["respiratory tract disease", "OBSERVATION", 78, 103]]], ["Previous studies have demonstrated the important burden of healthcare workers associated with respiratory tract infections, as well as their being strongly implicated in HCoV outbreaks.", [["respiratory tract", "ANATOMY", 94, 111], ["respiratory tract infections", "DISEASE", 94, 122], ["tract", "ORGANISM_SUBDIVISION", 106, 111], ["HCoV", "CANCER", 170, 174], ["HCoV", "SPECIES", 170, 174], ["Previous studies", "TEST", 0, 16], ["respiratory tract infections", "PROBLEM", 94, 122], ["respiratory tract", "ANATOMY", 94, 111], ["infections", "OBSERVATION", 112, 122]]], ["20, 25, [38] [39] [40] Although HCoV is considered one of the most common respiratory viruses associated with respiratory tract infections in children, the present study revealed a higher rate of detection among adults in the 50-to 59-year range.", [["respiratory tract", "ANATOMY", 110, 127], ["respiratory viruses", "DISEASE", 74, 93], ["respiratory tract infections", "DISEASE", 110, 138], ["[38] [39] [40", "SIMPLE_CHEMICAL", 8, 21], ["HCoV", "GENE_OR_GENE_PRODUCT", 32, 36], ["respiratory tract", "ORGANISM_SUBDIVISION", 110, 127], ["children", "ORGANISM", 142, 150], ["children", "SPECIES", 142, 150], ["respiratory tract infections", "PROBLEM", 110, 138], ["the present study", "TEST", 152, 169], ["viruses", "OBSERVATION", 86, 93], ["respiratory tract", "ANATOMY", 110, 127]]], ["As our study cohort contained a significant number of adult patients with comorbidities, this result can represent a bias.DiscussionAs different age groups were tested for HCoV infections in different years in our study, this represents a flaw in the study design which prevents us from comparing the frequency of infection in one age group to another, and it is considered as the major limitation of this work.", [["infections", "DISEASE", 177, 187], ["infection", "DISEASE", 314, 323], ["patients", "ORGANISM", 60, 68], ["HCoV", "ORGANISM", 172, 176], ["patients", "SPECIES", 60, 68], ["HCoV", "SPECIES", 172, 176], ["our study", "TEST", 3, 12], ["comorbidities", "PROBLEM", 74, 87], ["HCoV infections", "PROBLEM", 172, 187], ["our study", "TEST", 210, 219], ["the study", "TEST", 247, 256], ["infection", "PROBLEM", 314, 323], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["flaw", "OBSERVATION", 239, 243], ["infection", "OBSERVATION", 314, 323]]], ["Nevertheless, the results of our study showed interesting findings on HCoVs infection, which means that HCoVs may be the causal agents of respiratory diseases among patients under different clinical conditions, either adults or children.DiscussionOur data revealed that NL63 and OC43 were the most commonly detected HCoV species in our study.", [["respiratory", "ANATOMY", 138, 149], ["infection", "DISEASE", 76, 85], ["respiratory diseases", "DISEASE", 138, 158], ["HCoVs", "GENE_OR_GENE_PRODUCT", 70, 75], ["HCoVs", "GENE_OR_GENE_PRODUCT", 104, 109], ["patients", "ORGANISM", 165, 173], ["children", "ORGANISM", 228, 236], ["NL63", "GENE_OR_GENE_PRODUCT", 270, 274], ["OC43", "GENE_OR_GENE_PRODUCT", 279, 283], ["HCoV", "CANCER", 316, 320], ["NL63", "DNA", 270, 274], ["OC43", "DNA", 279, 283], ["patients", "SPECIES", 165, 173], ["children", "SPECIES", 228, 236], ["our study", "TEST", 29, 38], ["HCoVs infection", "PROBLEM", 70, 85], ["respiratory diseases", "PROBLEM", 138, 158], ["DiscussionOur data", "TEST", 237, 255], ["NL63", "TEST", 270, 274], ["OC43", "PROBLEM", 279, 283], ["HCoV species", "PROBLEM", 316, 328], ["our study", "TEST", 332, 341], ["infection", "OBSERVATION", 76, 85]]], ["Recently, Dijkman et al. 41 demonstrated that HCoV-OC43 and HCoV-NL63 may elicit immunity that protects from subsequent HCoV-HKU1 and HCoV-229E infection, respectively, which would explain why HCoV-OC43 and HCoV-NL63 are the most frequently infecting HCoVs.", [["HCoVs", "ANATOMY", 251, 256], ["NL63", "CHEMICAL", 65, 69], ["infection", "DISEASE", 144, 153], ["HCoV-OC43", "CELL", 46, 55], ["HCoV-NL63", "ORGANISM", 60, 69], ["HCoV", "GENE_OR_GENE_PRODUCT", 120, 124], ["HKU1", "GENE_OR_GENE_PRODUCT", 125, 129], ["HCoV-229E", "ORGANISM", 134, 143], ["HCoV-OC43", "ORGANISM", 193, 202], ["HCoV-NL63", "ORGANISM", 207, 216], ["HCoVs", "CANCER", 251, 256], ["HCoV-OC43 and HCoV-NL63", "DNA", 46, 69], ["HCoV", "SPECIES", 60, 64], ["HCoV", "SPECIES", 120, 124], ["HCoV-229E", "SPECIES", 134, 143], ["HCoV", "SPECIES", 193, 197], ["HCoV", "SPECIES", 207, 211], ["Dijkman et al.", "TEST", 10, 24], ["HCoV", "TEST", 46, 50], ["OC43", "TEST", 51, 55], ["HCoV", "TEST", 60, 64], ["HCoV", "TEST", 120, 124], ["HKU1", "PROBLEM", 125, 129], ["HCoV", "PROBLEM", 134, 138], ["229E infection", "PROBLEM", 139, 153], ["HCoV", "TEST", 193, 197], ["OC43", "TEST", 198, 202], ["HCoV", "TEST", 207, 211]]], ["Other studies have demonstrated a higher frequency of HCoV-NL63 among children 12, 32, 42 and HCoV-OC43 among adults.", [["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 54, 63], ["children", "ORGANISM", 70, 78], ["HCoV-OC43", "ORGANISM", 94, 103], ["adults", "ORGANISM", 110, 116], ["HCoV", "PROTEIN", 54, 58], ["children", "SPECIES", 70, 78], ["Other studies", "TEST", 0, 13], ["HCoV", "TEST", 54, 58], ["HCoV", "TEST", 94, 98], ["higher", "OBSERVATION_MODIFIER", 34, 40]]], ["43 Although it is possible to verify the periodicity of HCoVs infection in the presented data of this study, that is, HCoV-HKU1 (Figure 2 ), our study focuses on HCoV-type specificity frequency in particular patient groups.", [["infection", "DISEASE", 62, 71], ["HCoVs", "GENE_OR_GENE_PRODUCT", 56, 61], ["HCoV", "ORGANISM", 162, 166], ["patient", "ORGANISM", 208, 215], ["patient", "SPECIES", 208, 215], ["HCoVs infection", "PROBLEM", 56, 71], ["this study", "TEST", 97, 107], ["HCoV", "TEST", 118, 122], ["our study", "TEST", 141, 150], ["HCoV", "TEST", 162, 166], ["HCoVs", "OBSERVATION_MODIFIER", 56, 61], ["infection", "OBSERVATION", 62, 71]]], ["In this regard, HCoV-229E was mainly associated with renal transplant patients and HCoV-NL63 was involved in a death.", [["renal transplant", "ANATOMY", 53, 69], ["HCoV-229E", "CHEMICAL", 16, 25], ["death", "DISEASE", 111, 116], ["HCoV-229E", "CHEMICAL", 16, 25], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 16, 25], ["renal", "ORGAN", 53, 58], ["patients", "ORGANISM", 70, 78], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 83, 92], ["patients", "SPECIES", 70, 78], ["HCoV-229E", "SPECIES", 16, 25], ["HCoV", "SPECIES", 83, 87], ["HCoV", "TEST", 16, 20], ["renal transplant", "TREATMENT", 53, 69], ["HCoV", "TEST", 83, 87], ["a death", "PROBLEM", 109, 116], ["renal", "ANATOMY", 53, 58], ["transplant", "OBSERVATION", 59, 69]]], ["HCoV-229E has previously been associated with infections in immunocompromised individuals, 37, 44 and some reports have demonstrated the further association of HCoV-NL63 with fatal cases.", [["HCoV-229E", "CHEMICAL", 0, 9], ["infections", "DISEASE", 46, 56], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 0, 9], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 160, 169], ["HCoV", "PROTEIN", 160, 164], ["HCoV-229E", "SPECIES", 0, 9], ["HCoV", "TEST", 0, 4], ["infections in immunocompromised individuals", "PROBLEM", 46, 89], ["HCoV", "TEST", 160, 164], ["fatal cases", "PROBLEM", 175, 186], ["associated with", "UNCERTAINTY", 30, 45], ["infections", "OBSERVATION", 46, 56], ["immunocompromised", "OBSERVATION", 60, 77]]], ["[22] [23] [24] However, there are no consistent indications that infection by one HCoV is more pathogenic than that with another.", [["infection", "DISEASE", 65, 74], ["HCoV", "GENE_OR_GENE_PRODUCT", 82, 86], ["HCoV", "SPECIES", 82, 86], ["infection", "PROBLEM", 65, 74], ["no consistent", "UNCERTAINTY", 34, 47], ["infection", "OBSERVATION", 65, 74]]], ["Thus, our data provide evidence that the detection and diagnosis of HCoV infections should be considered for immunocompromised individuals with respiratory tract symptoms.DiscussionCoronaviruses display the marked seasonality typical of other respiratory viruses, with high detection frequencies in the winter months but few or no detections in the summer.", [["respiratory tract", "ANATOMY", 144, 161], ["HCoV infections", "DISEASE", 68, 83], ["respiratory tract symptoms", "DISEASE", 144, 170], ["respiratory viruses", "DISEASE", 243, 262], ["HCoV", "ORGANISM", 68, 72], ["respiratory tract", "ORGANISM_SUBDIVISION", 144, 161], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 181, 194], ["HCoV", "SPECIES", 68, 72], ["the detection", "TEST", 37, 50], ["HCoV infections", "PROBLEM", 68, 83], ["immunocompromised individuals", "PROBLEM", 109, 138], ["respiratory tract symptoms", "PROBLEM", 144, 170], ["Coronaviruses", "PROBLEM", 181, 194], ["other respiratory viruses", "PROBLEM", 237, 262], ["marked", "OBSERVATION_MODIFIER", 207, 213], ["respiratory viruses", "OBSERVATION", 243, 262]]], ["The climate of the city of Sao Paulo (Southeast of Brazil) is under constant influence of both the southern coast and the northern part of the state, which presents a subtropical climate.", [["climate", "OBSERVATION_MODIFIER", 4, 11]]], ["Thus, this city has an uncharacterized climate marked by a wide thermal and meteorological variety.", [["a wide thermal and meteorological variety", "PROBLEM", 57, 98], ["uncharacterized", "OBSERVATION_MODIFIER", 23, 38], ["climate", "OBSERVATION_MODIFIER", 39, 46], ["marked", "OBSERVATION_MODIFIER", 47, 53], ["wide", "OBSERVATION_MODIFIER", 59, 63], ["thermal", "OBSERVATION_MODIFIER", 64, 71], ["meteorological variety", "OBSERVATION", 76, 98]]], ["In this regard, it is not possible for us to trace any interaction between climatic and meteorological factors and HCoVs detection.", [["HCoVs", "GENE_OR_GENE_PRODUCT", 115, 120], ["HCoVs detection", "TEST", 115, 130], ["not possible", "UNCERTAINTY", 22, 34]]], ["However, due to the long-term HCoV surveillance performed in the present study, it was possible to demonstrate particular trends concerning CoV species seasonality, where different marked peaks of detection were observed for each HCoV species during the 9-year study.", [["CoV", "ORGANISM", 140, 143], ["HCoV", "SPECIES", 230, 234], ["the present study", "TEST", 61, 78], ["CoV species seasonality", "PROBLEM", 140, 163], ["different marked peaks of detection", "PROBLEM", 171, 206], ["each HCoV species", "PROBLEM", 225, 242], ["CoV species", "OBSERVATION", 140, 151], ["marked", "OBSERVATION_MODIFIER", 181, 187], ["peaks", "OBSERVATION_MODIFIER", 188, 193]]], ["Other studies have demonstrated differences between CoV species seasonalities and a winter preference. van der Hoek et al. 45 performed a study on HCoV-NL63 revealing that this species infection follows a 2-year interepidemic period with peaks of infection in the winters.", [["infection", "DISEASE", 185, 194], ["infection", "DISEASE", 247, 256], ["CoV", "ORGANISM", 52, 55], ["HCoV-NL63", "CELL", 147, 156], ["NL63", "DNA", 152, 156], ["HCoV", "SPECIES", 147, 151], ["Other studies", "TEST", 0, 13], ["CoV species seasonalities", "PROBLEM", 52, 77], ["a study", "TEST", 136, 143], ["HCoV", "TEST", 147, 151], ["this species infection", "PROBLEM", 172, 194], ["infection", "PROBLEM", 247, 256], ["infection", "OBSERVATION", 185, 194], ["peaks", "OBSERVATION_MODIFIER", 238, 243], ["infection", "OBSERVATION", 247, 256]]], ["Gaunt et al. 28 in a study carried out over a period of 3 years in the UK demonstrated a high detection of HCoVs species during winter months.DiscussionOur study showed a very low HCoVs detection rate in 2007 and none in 2006.", [["HCoVs", "CANCER", 180, 185], ["a study", "TEST", 19, 26], ["HCoVs species", "PROBLEM", 107, 120], ["DiscussionOur study", "TEST", 142, 161], ["a very low HCoVs detection rate", "PROBLEM", 169, 200]]], ["These were the years that presented the lowest number of samples included in the study, and we believe this might have influenced the HCoVs detection during these 2 years.DiscussionDifferent clinical specimens were used in search of HCoVs.", [["specimens", "ANATOMY", 200, 209], ["HCoVs", "GENE_OR_GENE_PRODUCT", 233, 238], ["HCoVs", "PROTEIN", 233, 238], ["the study", "TEST", 77, 86], ["clinical specimens", "TEST", 191, 209]]], ["Although some studies have shown the sensitivity of different kinds of specimens for respiratory viruses diagnosis through many different detection methods, we did not evaluate data on HCoVs detection from the different specimens collected using the molecular methods applied in our study.DiscussionIn conclusion, our data provide a novel insight into the epidemiology and clinical knowledge of HCoV among different subsets of patients, supporting the notion that HCoVs play an important role among patients with comorbidities.", [["specimens", "ANATOMY", 71, 80], ["specimens", "ANATOMY", 220, 229], ["respiratory viruses", "DISEASE", 85, 104], ["HCoVs", "SIMPLE_CHEMICAL", 185, 190], ["HCoV", "CANCER", 395, 399], ["patients", "ORGANISM", 427, 435], ["HCoVs", "GENE_OR_GENE_PRODUCT", 464, 469], ["patients", "ORGANISM", 499, 507], ["patients", "SPECIES", 427, 435], ["patients", "SPECIES", 499, 507], ["HCoV", "SPECIES", 395, 399], ["some studies", "TEST", 9, 21], ["respiratory viruses", "PROBLEM", 85, 104], ["HCoVs detection", "TEST", 185, 200], ["the different specimens", "TEST", 206, 229], ["the molecular methods", "TEST", 246, 267], ["our study", "TEST", 279, 288]]], ["HCoV infections were found not only in children, but also among adults, mainly in healthcare workers.", [["HCoV infections", "DISEASE", 0, 15], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["HCoV", "SPECIES", 0, 4], ["HCoV infections", "PROBLEM", 0, 15], ["infections", "OBSERVATION", 5, 15]]], ["Therefore, HCoVs are important pathogens involved in unexplained respiratory illness among patients with different clinical patterns.", [["respiratory", "ANATOMY", 65, 76], ["respiratory illness", "DISEASE", 65, 84], ["HCoVs", "GENE_OR_GENE_PRODUCT", 11, 16], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["HCoVs", "SPECIES", 11, 16], ["unexplained respiratory illness", "PROBLEM", 53, 84]]]], "bc564d081e2ae9760838bb34534f126ae3479a79": [["IntroductionMajor histocompatibility complex (MHC) molecules are polymorphic membrane glycoproteins [Zinkernagel 1986 ].", [["membrane", "ANATOMY", 77, 85], ["IntroductionMajor histocompatibility complex", "GENE_OR_GENE_PRODUCT", 0, 44], ["IntroductionMajor histocompatibility complex (MHC) molecules", "PROTEIN", 0, 60], ["polymorphic membrane glycoproteins", "PROTEIN", 65, 99], ["polymorphic membrane glycoproteins", "PROBLEM", 65, 99]]], ["Human MHCs are also called human leukocyte antigen, often abbreviated to HLA [Clark & Forman 1984] .", [["MHCs", "ANATOMY", 6, 10], ["Human", "ORGANISM", 0, 5], ["MHCs", "GENE_OR_GENE_PRODUCT", 6, 10], ["human", "ORGANISM", 27, 32], ["leukocyte antigen", "GENE_OR_GENE_PRODUCT", 33, 50], ["Human MHCs", "PROTEIN", 0, 10], ["human leukocyte antigen", "PROTEIN", 27, 50], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 27, 32], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 27, 32], ["human leukocyte antigen", "TEST", 27, 50]]], ["There are two classes of HLA, class I and class II.", [["class I and class II", "PROTEIN", 30, 50], ["two", "OBSERVATION_MODIFIER", 10, 13], ["classes", "OBSERVATION_MODIFIER", 14, 21]]], ["Class I HLA is present on most nucleated cells, including the surfaces of lymphocytes, which have 1000 to 10000 HLA molecules per cell [Goust 1993] .", [["nucleated cells", "ANATOMY", 31, 46], ["surfaces", "ANATOMY", 62, 70], ["lymphocytes", "ANATOMY", 74, 85], ["cell", "ANATOMY", 130, 134], ["Class I HLA", "GENE_OR_GENE_PRODUCT", 0, 11], ["nucleated cells", "CELL", 31, 46], ["lymphocytes", "CELL", 74, 85], ["cell", "CELL", 130, 134], ["Class I HLA", "PROTEIN", 0, 11], ["nucleated cells", "CELL_TYPE", 31, 46], ["lymphocytes", "CELL_TYPE", 74, 85], ["HLA molecules", "PROTEIN", 112, 125], ["most nucleated cells", "OBSERVATION_MODIFIER", 26, 46], ["surfaces", "ANATOMY_MODIFIER", 62, 70], ["lymphocytes", "ANATOMY", 74, 85]]], ["Class II HLA is mostly expressed on antigen presenting cells (APC) such as macrophages, B cells and dendritic cells.", [["antigen presenting cells", "ANATOMY", 36, 60], ["APC", "ANATOMY", 62, 65], ["macrophages", "ANATOMY", 75, 86], ["B cells", "ANATOMY", 88, 95], ["dendritic cells", "ANATOMY", 100, 115], ["Class II HLA", "GENE_OR_GENE_PRODUCT", 0, 12], ["antigen presenting cells", "CELL", 36, 60], ["APC", "CELL", 62, 65], ["macrophages", "CELL", 75, 86], ["B cells", "CELL", 88, 95], ["dendritic cells", "CELL", 100, 115], ["Class II HLA", "PROTEIN", 0, 12], ["antigen presenting cells", "CELL_TYPE", 36, 60], ["APC", "CELL_TYPE", 62, 65], ["macrophages", "CELL_TYPE", 75, 86], ["B cells", "CELL_TYPE", 88, 95], ["dendritic cells", "CELL_TYPE", 100, 115], ["APC", "TEST", 62, 65], ["macrophages", "PROBLEM", 75, 86], ["dendritic cells", "PROBLEM", 100, 115], ["macrophages", "ANATOMY", 75, 86], ["B cells", "OBSERVATION", 88, 95], ["dendritic cells", "OBSERVATION", 100, 115]]], ["Partly as a result of their importance in mediating tissue rejection, sequencing has identified MHC proteins as amongst the most polymorphic of all human gene products.", [["tissue", "ANATOMY", 52, 58], ["tissue", "TISSUE", 52, 58], ["human", "ORGANISM", 148, 153], ["MHC proteins", "PROTEIN", 96, 108], ["human gene products", "PROTEIN", 148, 167], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["mediating tissue rejection", "PROBLEM", 42, 68], ["MHC proteins", "PROBLEM", 96, 108], ["all human gene products", "TREATMENT", 144, 167], ["tissue", "ANATOMY", 52, 58], ["rejection", "OBSERVATION", 59, 68]]], ["According to the international ImMunoGeneTics information system (IMGT), there are over 2000 different HLA class I and II alleles and a significant number of new alleles are discovered every year [Robinson et aL 2003] .", [["HLA class I", "GENE_OR_GENE_PRODUCT", 103, 114], ["HLA class I and II alleles", "DNA", 103, 129], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["number", "OBSERVATION_MODIFIER", 148, 154], ["new", "OBSERVATION_MODIFIER", 158, 161]]], ["In Chapter 9, Borghans et aL explore the nature and origin of MHC diversity in more detail.IntroductionMHCs exhibit much polymorphic amino acid variation, and seemingly trivial alterations in the identity of binding site amino acid residues give rise to differences in peptide selectivity exhibited during peptide binding.", [["amino acid", "CHEMICAL", 133, 143], ["amino acid", "CHEMICAL", 221, 231], ["amino acid", "CHEMICAL", 133, 143], ["amino acid", "CHEMICAL", 221, 231], ["amino acid", "AMINO_ACID", 133, 143], ["amino acid", "AMINO_ACID", 221, 231], ["MHC", "PROTEIN", 62, 65], ["IntroductionMHCs", "TEST", 91, 107], ["much polymorphic amino acid variation", "PROBLEM", 116, 153], ["seemingly trivial alterations", "PROBLEM", 159, 188], ["binding site amino acid residues", "PROBLEM", 208, 240], ["differences in peptide selectivity", "PROBLEM", 254, 288], ["peptide binding", "PROBLEM", 306, 321], ["amino acid variation", "OBSERVATION", 133, 153], ["trivial", "OBSERVATION_MODIFIER", 169, 176], ["alterations", "OBSERVATION", 177, 188]]], ["Peptide binding assays are the most widely-used way of identifying T cell epitopes and measuring the affinities of peptides binding to MHC.", [["T cell", "ANATOMY", 67, 73], ["T cell", "CELL", 67, 73], ["T cell epitopes", "PROTEIN", 67, 82], ["MHC", "PROTEIN", 135, 138], ["Peptide binding assays", "TEST", 0, 22], ["T cell epitopes", "TREATMENT", 67, 82], ["cell epitopes", "OBSERVATION", 69, 82]]], ["Such assays include direct binding and the quantitative measurement of radio-or fiuorescence-labeled peptides bound to the MHC molecules [Chen & Parham 1989 , Schumacher & Heemels 1990 , Cerottini & Luescher 1991 Luscher 1991 , Kast &: Melief 1991 , Mendez-Samperio Sz Jimenez-Zamudio 1991 , Stuber & Dillner 1995 , Wauben & van der Kraan 1997 Liu 2000] .", [["MHC molecules", "PROTEIN", 123, 136], ["Chen & Parham 1989 , Schumacher & Heemels 1990 , Cerottini & Luescher 1991 Luscher 1991 , Kast &: Melief 1991 , Mendez-Samperio Sz Jimenez-Zamudio 1991 , Stuber & Dillner 1995 , Wauben & van der Kraan 1997 Liu 2000", "SPECIES", 138, 352], ["direct binding", "PROBLEM", 20, 34], ["Mendez", "TEST", 250, 256]]], ["Several databases have been set up to store peptide binding affinity data, such as MHCPEP [Brusic et aL 1998] , MHCBN [Bhasin & Singh 2003] , and AntiJen [Blythe et aL 2002 , McSparron et aL 2003 , Toseland et aL 2005 .IntroductionMany HLA alleles have been demonstrated to bind peptides with similar anchor residues [Southwood et aL 1998 ].", [["HLA", "GENE_OR_GENE_PRODUCT", 236, 239], ["HLA alleles", "DNA", 236, 247], ["AntiJen [Blythe et aL", "TREATMENT", 146, 167], ["McSparron et aL", "TREATMENT", 175, 190], ["IntroductionMany HLA alleles", "TREATMENT", 219, 247], ["similar anchor residues", "PROBLEM", 293, 316]]], ["This has led to the concept of MHC supertypes: the idea that MHCs with distinct sequences can be classified into separate groups, each of which displays equivalent, if not necessarily identical, specificities when binding peptides.", [["MHCs", "GENE_OR_GENE_PRODUCT", 61, 65], ["MHC supertypes", "PROTEIN", 31, 45], ["MHCs", "PROTEIN", 61, 65]]], ["The celerity of experimental research will be greatly accelerated if one could identify a procedure able to cluster HLA alleles with similar specificities.", [["HLA", "GENE_OR_GENE_PRODUCT", 116, 119], ["HLA alleles", "DNA", 116, 127], ["a procedure", "TREATMENT", 88, 99]]], ["Several research groups have sought to classify HLA alleles in this way, using a wide variety of different methods.", [["HLA alleles", "DNA", 48, 59], ["a wide variety of different methods", "TREATMENT", 79, 114]]], ["Examples of such disparate methodologies include sequence analysis [Lawlor & Warren 1991] , structural analysis [Chelvanayagam 1997 ], use of geometrical similarity matrix methods [Cano & Fan 1998 ], and motif search [Sette & Sidney 1998 , Lund et aL 2004 .IntroductionWe have recently developed and applied chemometric GRID/CPCA and hierarchical clustering methods to the identification of MHC supertypes [Doytchinova et aL 2004b] .", [["MHC", "PROTEIN", 391, 394], ["sequence analysis", "TEST", 49, 66], ["structural analysis", "TEST", 92, 111], ["chemometric GRID/CPCA", "TREATMENT", 308, 329], ["hierarchical clustering methods", "PROBLEM", 334, 365]]], ["Within vaccinology, HLA classification, using bioinformatics methods, can potentially reduce the overall experimental burden by rending unnecessary the individual study of every allele.", [["allele", "DNA", 178, 184], ["bioinformatics methods", "TEST", 46, 68], ["the individual study", "TEST", 148, 168]]], ["It can thus accelerate the discovery of both epitope-based vaccines, and other immunotherapies, that are targeted at multiple alleles.", [["both epitope-based vaccines", "TREATMENT", 40, 67], ["other immunotherapies", "TREATMENT", 73, 94]]], ["In the remainder of this chapter, we will explore attempts, both ours and those of others, to address the problem of finding and populating MHC supertypes.Evolutionary AnalysisAn early attempt to classify MHC molecules is from protein sequence studies [Lawlor & Warren 1991] .", [["MHC supertypes", "PROTEIN", 140, 154], ["MHC molecules", "PROTEIN", 205, 218], ["protein sequence studies", "TEST", 227, 251]]], ["Lawlor compared the sequences of 14 gorilla class I MHC alleles with HLA-A, B and C alleles in human and MHC in chimpanzees.", [["HLA-A", "GENE_OR_GENE_PRODUCT", 69, 74], ["B", "GENE_OR_GENE_PRODUCT", 76, 77], ["C", "GENE_OR_GENE_PRODUCT", 82, 83], ["human", "ORGANISM", 95, 100], ["chimpanzees", "ORGANISM", 112, 123], ["gorilla class I MHC alleles", "DNA", 36, 63], ["HLA-A, B and C alleles", "DNA", 69, 91], ["MHC", "PROTEIN", 105, 108], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["the sequences", "TEST", 16, 29], ["HLA", "TEST", 69, 72]]], ["Sequences of human, gorilla and chimpanzee MHC alleles are similar but not identical, as most of the polymorphic residues appear in the same region.", [["human", "ORGANISM", 13, 18], ["gorilla", "ORGANISM", 20, 27], ["chimpanzee", "ORGANISM", 32, 42], ["MHC", "GENE_OR_GENE_PRODUCT", 43, 46], ["human, gorilla and chimpanzee MHC alleles", "DNA", 13, 54], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["Sequences of human, gorilla and chimpanzee MHC alleles", "TEST", 0, 54], ["the polymorphic residues", "PROBLEM", 97, 121]]], ["Also genes at A, B and C locus of gorilla and chimpanzee MHCs are similar to HLA-A, HLA-B and HLA-C, respectively.", [["MHCs", "ANATOMY", 57, 61], ["A", "GENE_OR_GENE_PRODUCT", 14, 15], ["B", "GENE_OR_GENE_PRODUCT", 17, 18], ["C", "GENE_OR_GENE_PRODUCT", 23, 24], ["gorilla", "ORGANISM", 34, 41], ["chimpanzee", "ORGANISM", 46, 56], ["MHCs", "GENE_OR_GENE_PRODUCT", 57, 61], ["HLA-A", "GENE_OR_GENE_PRODUCT", 77, 82], ["HLA-B", "GENE_OR_GENE_PRODUCT", 84, 89], ["HLA-C", "GENE_OR_GENE_PRODUCT", 94, 99], ["A, B and C locus", "DNA", 14, 30], ["gorilla and chimpanzee MHCs", "DNA", 34, 61], ["HLA", "DNA", 77, 80], ["HLA", "DNA", 84, 87], ["HLA-C", "DNA", 94, 99], ["HLA", "TEST", 77, 80], ["HLA", "TEST", 84, 87], ["HLA", "TEST", 94, 97]]], ["Phylogenetic trees are generated for A, B and C genes and it is found that HLA-A alleles are divided into five families: A2, A3, A9, AlO and A19.", [["B", "GENE_OR_GENE_PRODUCT", 40, 41], ["C", "GENE_OR_GENE_PRODUCT", 46, 47], ["HLA-A", "GENE_OR_GENE_PRODUCT", 75, 80], ["A9", "GENE_OR_GENE_PRODUCT", 129, 131], ["AlO", "GENE_OR_GENE_PRODUCT", 133, 136], ["A19", "GENE_OR_GENE_PRODUCT", 141, 144], ["A, B and C genes", "DNA", 37, 53], ["HLA-A alleles", "DNA", 75, 88], ["A2", "DNA", 121, 123], ["A3", "DNA", 125, 127], ["A9", "DNA", 129, 131], ["AlO", "DNA", 133, 136], ["A19", "DNA", 141, 144], ["Phylogenetic trees", "PROBLEM", 0, 18], ["A, B and C genes", "PROBLEM", 37, 53], ["HLA", "TEST", 75, 78]]], ["Two divergent groups of HLA-C alleles are found, one containing Cw0702, the other with Cw0601 and Cw8001 and some of the A19 and the other with A2, AlO, A28, A0207 was added to the A2 supertype and B5602 were added to the B7 supertype [Sette & Sidney 1998 , Sette et al. 1989 .", [["B5602", "CHEMICAL", 198, 203], ["HLA-C", "GENE_OR_GENE_PRODUCT", 24, 29], ["A2", "GENE_OR_GENE_PRODUCT", 144, 146], ["AlO", "GENE_OR_GENE_PRODUCT", 148, 151], ["B5602", "CANCER", 198, 203], ["HLA-C alleles", "DNA", 24, 37], ["A19", "DNA", 121, 124], ["A2", "DNA", 144, 146], ["A28", "DNA", 153, 156], ["A0207", "DNA", 158, 163], ["A2 supertype", "DNA", 181, 193], ["B5602", "DNA", 198, 203], ["HLA", "TEST", 24, 27], ["C alleles", "PROBLEM", 28, 37], ["divergent", "OBSERVATION_MODIFIER", 4, 13]]], ["Recently A3002 are added to the Al supertype [Sidney et al. 2005] .", [["A3002", "CHEMICAL", 9, 14], ["Al", "CHEMICAL", 32, 34], ["A3002", "SIMPLE_CHEMICAL", 9, 14]]], ["Sette and Sidney carried out further analysis in 1999 and defined a total of nine supertypes including the previously defined supertypes [Sette et al. 1989 ].", [["further analysis", "TEST", 29, 45], ["nine supertypes", "TREATMENT", 77, 92]]], ["The nine supertypes were estimated to cover 99% of the world population ( Based on Sette's study, [Lund et al. 2004 ] classified HLA-A and B molecules using specificity matrices.", [["HLA-A", "GENE_OR_GENE_PRODUCT", 129, 134], ["B molecules", "GENE_OR_GENE_PRODUCT", 139, 150], ["HLA-A and B molecules", "PROTEIN", 129, 150], ["Sette's study", "TEST", 83, 96], ["HLA", "TEST", 129, 132]]], ["The nonamer ligands of all HLA-A and B molecules were collected from SYFPEITHI and MHCPEP and were aligned.", [["HLA-A", "GENE_OR_GENE_PRODUCT", 27, 32], ["B molecules", "GENE_OR_GENE_PRODUCT", 37, 48], ["HLA-A and B molecules", "PROTEIN", 27, 48], ["all HLA", "TEST", 23, 30]]], ["The frequencies of each amino acid at each position were summarised as a matrix, and this was used for a cluster analysis.", [["amino acid", "CHEMICAL", 24, 34], ["amino acid", "CHEMICAL", 24, 34], ["amino acid", "AMINO_ACID", 24, 34], ["matrix", "CELLULAR_COMPONENT", 73, 79], ["each amino acid", "TREATMENT", 19, 34], ["a cluster analysis", "TEST", 103, 121]]], ["In their results, the A26 alleles were separated from the Al cluster described by Sette, and a new B8 superfamily was defined.", [["Al", "CHEMICAL", 58, 60], ["A26", "GENE_OR_GENE_PRODUCT", 22, 25], ["A26 alleles", "DNA", 22, 33], ["Al cluster", "DNA", 58, 68], ["B8 superfamily", "PROTEIN", 99, 113], ["the A26 alleles", "PROBLEM", 18, 33]]], ["The other superfamilies were the It should be noted that class II HLA molecules have also been classified using a sequence approach.", [["class II HLA", "GENE_OR_GENE_PRODUCT", 57, 69], ["class II HLA molecules", "PROTEIN", 57, 79], ["a sequence approach", "TREATMENT", 112, 131]]], ["Chelvanayagam defined the HLA-DR roadmap by allele binding specificities and the polymorphic residues inside the binding site.", [["Chelvanayagam", "CHEMICAL", 0, 13], ["Chelvanayagam", "SIMPLE_CHEMICAL", 0, 13], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 26, 32], ["HLA-DR roadmap", "DNA", 26, 40], ["binding site", "DNA", 113, 125], ["allele binding specificities", "PROBLEM", 44, 72], ["the polymorphic residues inside the binding site", "PROBLEM", 77, 125], ["binding site", "OBSERVATION", 113, 125]]], ["The important residues were identified by studying the crystal structures of known HLA-DRpeptide complexes [Chelvanayagam 1997 ].", [["HLA-DRpeptide complexes", "PROTEIN", 83, 106], ["The important residues", "PROBLEM", 0, 22]]], ["HLA-DP [Castelli k, Buhot 202] and DQ [Baas & Gao 1999] supertypes have also been defined based on a combination of binding studies to define motifs together with structural modelling of the peptide-MHC complexes.", [["MHC complexes", "PROTEIN", 199, 212], ["HLA", "TEST", 0, 3], ["DP", "TEST", 4, 6], ["Castelli k", "TEST", 8, 18], ["Buhot", "TEST", 20, 25], ["binding studies", "TEST", 116, 131], ["DP", "ANATOMY_MODIFIER", 4, 6]]], ["Reche and Reinherz used multiple sequence alignment to find important residues in 774 class I and 485 II HLA molecules.", [["774 class I and 485 II HLA molecules", "PROTEIN", 82, 118], ["multiple sequence alignment", "TEST", 24, 51]]], ["Consensus sequence patterns were obtained for the binding sites of HLA-A, B, C, DP, DR and DQ groups [Reche & Reinherz 2003 ].GRID/CPCA AND Hierarchical ClusteringClass I HLA supertypes have been defined by Doytchinova et al. using GRID/CPCA combined with hierarchical clustering based on comparative molecular similarity indices (CoMSIA) fields.", [["DQ", "GENE_OR_GENE_PRODUCT", 91, 93], ["GRID", "DNA", 126, 130], ["GRID", "DNA", 232, 236], ["CPCA", "DNA", 237, 241], ["Consensus sequence patterns", "TEST", 0, 27], ["HLA", "TEST", 67, 70], ["GRID/CPCA", "TREATMENT", 232, 241], ["hierarchical clustering", "PROBLEM", 256, 279]]], ["The GRID program identifies the energetically favoured or disfavoured regions on molecules with known three-dimensional structures.", [["energetically", "OBSERVATION_MODIFIER", 32, 45], ["favoured", "OBSERVATION_MODIFIER", 46, 54]]], ["A selection of chemical probes is included in the program; each probe represents atoms or functional groups with different properties.", [["chemical probes", "TREATMENT", 15, 30], ["chemical probes", "OBSERVATION", 15, 30]]], ["GRID calculates the interaction energy between selected chemical probes and each of the molecules.", [["GRID", "PROTEIN", 0, 4], ["the interaction energy", "PROBLEM", 16, 38], ["selected chemical probes", "TREATMENT", 47, 71], ["interaction energy", "OBSERVATION", 20, 38]]], ["Molecular interaction fields (MIFs) between diff'erent chemical probes and a set of diff'erent HLA proteins were calculated in GRID, and these were used to build PGA and CPCA models in GOLPE.GRID/CPCA AND Hierarchical ClusteringThe program Generating Optimal Linear Partial least square Estimations (GOLPE) [Cruciani & Watson 1994 ] has one module for PGA calculation.", [["HLA", "GENE_OR_GENE_PRODUCT", 95, 98], ["PGA", "SIMPLE_CHEMICAL", 162, 165], ["HLA proteins", "PROTEIN", 95, 107], ["GRID", "CELL_LINE", 127, 131], ["Molecular interaction fields", "PROBLEM", 0, 28], ["diff'erent chemical probes", "PROBLEM", 44, 70], ["diff'erent HLA proteins", "PROBLEM", 84, 107], ["PGA calculation", "TEST", 352, 367]]], ["PC A decomposes a matrix X into two smaller matrices: the scores matrix T and the loading matrix P', which explain the overall variance of the X matrix.", [["matrix", "CELLULAR_COMPONENT", 145, 151], ["PC A decomposes a matrix X into two smaller matrices", "TREATMENT", 0, 52], ["the loading matrix P'", "TREATMENT", 78, 99]]], ["The scores matrix contains a few variables M, that is, the principal components (PC), which can be used to describe the observations.", [["few", "OBSERVATION_MODIFIER", 29, 32]]], ["The loading matrix reveals the relationship between the variables in the original matrix and the principal components.", [["matrix", "CELLULAR_COMPONENT", 82, 88], ["The loading matrix", "TREATMENT", 0, 18], ["loading matrix", "OBSERVATION", 4, 18], ["matrix", "ANATOMY_MODIFIER", 82, 88], ["principal", "OBSERVATION_MODIFIER", 97, 106], ["components", "OBSERVATION_MODIFIER", 107, 117]]], ["Plots of the observations in the multidimensional space are called the scores plot, which identifies similarities and differences within the observations and groups them accordingly, while the loading plot relates the original variables to the PCs and identifies variables that are important in distinguishing groups of observations.", [["the scores plot", "TEST", 67, 82], ["the loading plot", "TEST", 189, 205]]], ["When more than one probe is used in the GRID calculation, the data generated by different probes are grouped into blocks, and they are often analysed by hierarchical PC A methods such as consensus PC A (CPCA).", [["GRID", "DNA", 40, 44], ["the GRID calculation", "TEST", 36, 56]]], ["The advantage of CPCA compared to PCA is that it compares the relative importance of each block in the calculation and makes a 'consensus' clustering of the objects.", [["CPCA", "TREATMENT", 17, 21]]], ["CPCA uses the same underlying principle as PCA: a CPCA model tries to explain the overall variance of the original data matrix.", [["matrix", "CELLULAR_COMPONENT", 120, 126], ["a CPCA model", "TREATMENT", 48, 60]]], ["The algorithm used in CPCA is an adaptation of the NIPALS algorithm used in PCA [Wold & Hellberg 1987] .", [["the NIPALS algorithm", "TREATMENT", 47, 67]]], ["Like PCA, CPCA calculates the principal components and gives the scores and loading matrix.", [["matrix", "CELLULAR_COMPONENT", 84, 90], ["CPCA", "PROTEIN", 10, 14], ["loading matrix", "TREATMENT", 76, 90], ["PCA", "OBSERVATION", 5, 8]]], ["In addition, CPCA also calculates the importance of each data block.", [["CPCA", "PROTEIN", 13, 17]]], ["It calculates the scores and the loading matrix for each probe used, and also returns the weight matrix that can illustrate the contribution of each probe to the overall scores.GRID/CPCA AND Hierarchical ClusteringCluster analysis is a process of grouping of observations into subsets or clusters, the grouping is dependent on the similarities between each observation.", [["matrix", "CELLULAR_COMPONENT", 41, 47], ["GRID", "DNA", 177, 181], ["the loading matrix", "TREATMENT", 29, 47]]], ["Commonly used clustering methods are hierarchical clustering and k-means clustering, etc. Hierarchical clustering based on the agglomerative method is used in HLA classification, in which observations are separated into n clusters at the beginning of the clustering, each cluster contains one observation.", [["Hierarchical clustering", "PROBLEM", 90, 113], ["the agglomerative method", "TREATMENT", 123, 147]]], ["The distance between two clusters is proportional to the similarities of the observations.", [["distance", "OBSERVATION_MODIFIER", 4, 12], ["clusters", "OBSERVATION_MODIFIER", 25, 33], ["proportional", "OBSERVATION_MODIFIER", 37, 49]]], ["Clusters with the shortest distance are merged and the distance between the new cluster and others is computed.", [["new", "OBSERVATION_MODIFIER", 76, 79], ["cluster", "OBSERVATION_MODIFIER", 80, 87]]], ["These steps are repeated until there is only one cluster left.", [["left", "ANATOMY_MODIFIER", 57, 61]]], ["The cluster analysis used is as implemented in Sybyl6.9, complete Hnkage clustering is used in distance computation, in which the maximum distance between data points in two clusters is used.", [["Sybyl6.9", "DNA", 47, 55], ["The cluster analysis", "TEST", 0, 20]]], ["The clustering process makes use of the five molecular interaction fields calculated by CoMSIA.GRID/CPCA AND Hierarchical ClusteringA total of 783 class I HLA sequences were found in the IMGT/HLA database and were included in the classification.", [["GRID", "DNA", 95, 99], ["783 class I HLA sequences", "DNA", 143, 168], ["GRID/CPCA", "TEST", 95, 104], ["HLA sequences", "TEST", 155, 168], ["the IMGT/HLA database", "TEST", 183, 204]]], ["The sequences were selected on the basis of the differences at protein sequence level.", [["The sequences", "TEST", 0, 13], ["protein sequence level", "TEST", 63, 85]]], ["The classification is defined according to the scores plots of the CPCA model and the dedrograms obtained from hierarchical clustering.", [["the CPCA model", "TEST", 63, 77], ["the dedrograms", "TEST", 82, 96]]], ["The scores plot showed the clustering of the HLA alleles, whereas the loading maps highlighted regions in the peptide binding site that contributed significantly in clustering different super families.", [["HLA", "GENE_OR_GENE_PRODUCT", 45, 48], ["HLA alleles", "DNA", 45, 56], ["peptide binding site", "DNA", 110, 130], ["The scores plot", "TEST", 0, 15], ["the HLA alleles", "PROBLEM", 41, 56], ["the loading maps", "TREATMENT", 66, 82], ["the peptide binding site", "PROBLEM", 106, 130], ["peptide binding", "OBSERVATION", 110, 125], ["significantly", "OBSERVATION_MODIFIER", 148, 161]]], ["Amino acid fingerprints are identified from the loading plots of the CPCA models, the fingerprints are the basis of the classification and can be used for future classification.GRID/CPCA AND Hierarchical ClusteringThree HLA-A clusters are defined from the scores plot of the CPCA model and hierarchical clustering, A2, A3 and A24 (Fig 1, Fig 2) .", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["GRID", "DNA", 177, 181], ["A2", "PROTEIN", 315, 317], ["Amino acid fingerprints", "TEST", 0, 23], ["GRID/CPCA", "TEST", 177, 186], ["the CPCA model", "TEST", 271, 285], ["A2", "TEST", 315, 317], ["A24", "TEST", 326, 329], ["Fig", "TEST", 331, 334], ["acid fingerprints", "OBSERVATION", 6, 23], ["loading plots", "OBSERVATION", 48, 61], ["CPCA", "ANATOMY", 182, 186], ["Hierarchical", "OBSERVATION_MODIFIER", 191, 203], ["hierarchical", "OBSERVATION_MODIFIER", 290, 302], ["clustering", "OBSERVATION_MODIFIER", 303, 313]]], ["In the scores plot, the first component of the CPCA model separated A23 and most of the A24 molecules on the left, with negative PCI scores, from the rest of the HLA-A molecules.", [["left", "ANATOMY", 109, 113], ["A23", "CANCER", 68, 71], ["HLA-A molecules", "GENE_OR_GENE_PRODUCT", 162, 177], ["A24 molecules", "PROTEIN", 88, 101], ["HLA-A molecules", "PROTEIN", 162, 177], ["left", "ANATOMY_MODIFIER", 109, 113], ["negative", "OBSERVATION_MODIFIER", 120, 128], ["PCI", "OBSERVATION", 129, 132], ["HLA", "ANATOMY", 162, 165]]], ["The second principal component separated the HLA-All, A26, A03, A32, A34, A66, A74 families with positive PC2 scores from the others.", [["HLA", "GENE_OR_GENE_PRODUCT", 45, 48], ["PC2", "GENE_OR_GENE_PRODUCT", 106, 109], ["PC2", "PROTEIN", 106, 109], ["the HLA", "TEST", 41, 48], ["A03", "TEST", 59, 62], ["A32", "TEST", 64, 67], ["A34", "TEST", 69, 72], ["positive PC2 scores", "PROBLEM", 97, 116], ["second", "OBSERVATION_MODIFIER", 4, 10], ["principal", "OBSERVATION_MODIFIER", 11, 20], ["component", "OBSERVATION_MODIFIER", 21, 30], ["separated", "OBSERVATION_MODIFIER", 31, 40], ["HLA", "ANATOMY", 45, 48], ["All", "ANATOMY_MODIFIER", 49, 52]]], ["Therefore, the CPCA analysis revealed three clusters as demonstrated in the 3D scores plot: the A3 cluster on the top right of figure 10 .4, including the alleles A03, A25, A29, A31, A33, A36, A66, A8001.", [["CPCA", "DNA", 15, 19], ["A3 cluster", "DNA", 96, 106], ["A25", "DNA", 168, 171], ["A29", "DNA", 173, 176], ["A36", "DNA", 188, 191], ["A66", "DNA", 193, 196], ["A8001", "DNA", 198, 203], ["the CPCA analysis", "TEST", 11, 28], ["the alleles A03", "TEST", 151, 166], ["A31", "TEST", 178, 181], ["A33", "TEST", 183, 186], ["A36", "TEST", 188, 191], ["A66", "TEST", 193, 196], ["top", "OBSERVATION_MODIFIER", 114, 117], ["right", "ANATOMY_MODIFIER", 118, 123]]], ["Most of the A6802 and A23 and A02 alleles.", [["A6802", "CANCER", 12, 17], ["A23", "GENE_OR_GENE_PRODUCT", 22, 25], ["A02", "GENE_OR_GENE_PRODUCT", 30, 33], ["A6802 and A23 and A02 alleles", "DNA", 12, 41], ["the A6802", "TEST", 8, 17]]], ["Other alleles in the A2 cluster were A6802, A6823 and A02, A26, A3405, A66, A6815, A6901.", [["A2", "GENE_OR_GENE_PRODUCT", 21, 23], ["A2 cluster", "DNA", 21, 31], ["A02", "TEST", 54, 57], ["A2", "ANATOMY", 21, 23]]], ["This cluster was the A2 cluster.", [["A2", "GENE_OR_GENE_PRODUCT", 21, 23], ["A2 cluster", "DNA", 21, 31], ["A2 cluster", "OBSERVATION", 21, 31]]], ["The A24 cluster was well distinguished and included A24 alleles.", [["A24", "GENE_OR_GENE_PRODUCT", 4, 7], ["A24 cluster", "DNA", 4, 15], ["A24 alleles", "DNA", 52, 63]]], ["Finally, the A3 cluster included A03, A29, A31, A33, A34 and A74 and A01, Cw07, Cw12 and Cw02, Cw04, Cw06, Cw17 and Cw03, Cw12 are also grouped into the second cluster.", [["A03, A29, A31, A33, A34 and A74", "CHEMICAL", 33, 64], ["A01", "CHEMICAL", 69, 72], ["Cw07", "CHEMICAL", 74, 78], ["Cw12", "CHEMICAL", 80, 84], ["Cw02", "CHEMICAL", 89, 93], ["Cw04", "CHEMICAL", 95, 99], ["Cw06", "CHEMICAL", 101, 105], ["Cw17", "CHEMICAL", 107, 111], ["Cw03", "CHEMICAL", 116, 120], ["Cw12", "CHEMICAL", 122, 126], ["A03", "GENE_OR_GENE_PRODUCT", 33, 36], ["A29", "GENE_OR_GENE_PRODUCT", 38, 41], ["A31", "GENE_OR_GENE_PRODUCT", 43, 46], ["A33", "GENE_OR_GENE_PRODUCT", 48, 51], ["A34", "GENE_OR_GENE_PRODUCT", 53, 56], ["A74", "GENE_OR_GENE_PRODUCT", 61, 64], ["A01", "GENE_OR_GENE_PRODUCT", 69, 72], ["Cw07", "GENE_OR_GENE_PRODUCT", 74, 78], ["Cw12", "GENE_OR_GENE_PRODUCT", 80, 84], ["Cw02", "GENE_OR_GENE_PRODUCT", 89, 93], ["Cw04", "GENE_OR_GENE_PRODUCT", 95, 99], ["Cw03", "GENE_OR_GENE_PRODUCT", 116, 120], ["Cw12", "GENE_OR_GENE_PRODUCT", 122, 126], ["A3 cluster", "DNA", 13, 23], ["Cw17", "DNA", 107, 111], ["Cw03", "DNA", 116, 120], ["Cw12", "DNA", 122, 126], ["A03", "TEST", 33, 36], ["A29", "TEST", 38, 41], ["A31", "TEST", 43, 46], ["A33", "TEST", 48, 51], ["A34", "TEST", 53, 56], ["A74", "TEST", 61, 64], ["A01", "TEST", 69, 72], ["Cw07", "TEST", 74, 78], ["Cw12", "TEST", 80, 84], ["Cw02", "TEST", 89, 93], ["Cw04", "TEST", 95, 99], ["Cw06", "TEST", 101, 105], ["Cw17", "TEST", 107, 111], ["Cw03", "TEST", 116, 120], ["Cw12", "TEST", 122, 126]]], ["The first cluster is named CI and the second cluster is named C4.", [["CI", "DNA", 27, 29], ["C4", "DNA", 62, 64]]], ["The result from hierarchical clustering gave nearly identical groups, with only eight amino acids mis-placed Cw0310, Cw0706, Cw0718, Cw1404 (Table 10 .4).GRID/CPCA AND Hierarchical ClusteringThe PC2 loading plots showed that positions 70, 74, 77 and 81 of the HLA-C molecules are involved in the classification (Fig 9) .", [["amino acids", "CHEMICAL", 86, 97], ["amino acids", "CHEMICAL", 86, 97], ["Cw", "CHEMICAL", 109, 111], ["amino acids", "AMINO_ACID", 86, 97], ["HLA-C", "GENE_OR_GENE_PRODUCT", 260, 265], ["GRID", "DNA", 154, 158], ["PC2", "PROTEIN", 195, 198], ["HLA-C molecules", "PROTEIN", 260, 275], ["GRID/CPCA", "TEST", 154, 163], ["The PC2 loading plots", "TEST", 191, 212], ["positions", "TEST", 225, 234], ["the HLA", "TEST", 256, 263]]], ["Among the HLA-C molecules, only position 77 was polymorphic.", [["HLA-C", "GENE_OR_GENE_PRODUCT", 10, 15], ["HLA-C molecules", "PROTEIN", 10, 25]]], ["The amino acids presented at this position were Ser and Asn.", [["amino acids", "CHEMICAL", 4, 15], ["amino acids", "CHEMICAL", 4, 15], ["Ser", "CHEMICAL", 48, 51], ["Asn", "CHEMICAL", 56, 59], ["amino acids", "AMINO_ACID", 4, 15], ["Ser", "AMINO_ACID", 48, 51], ["Asn", "AMINO_ACID", 56, 59], ["The amino acids", "TREATMENT", 0, 15], ["amino acids", "OBSERVATION", 4, 15]]], ["The molecules in the C4 class all have Asn at position 77.", [["Asn", "CHEMICAL", 39, 42], ["Asn", "CHEMICAL", 39, 42], ["Asn", "AMINO_ACID", 39, 42], ["C4 class", "PROTEIN", 21, 29], ["position 77", "PROTEIN", 46, 57], ["molecules", "OBSERVATION", 4, 13], ["C4", "ANATOMY_MODIFIER", 21, 23]]], ["The ones in the CI cluster, on the other hand, all have serine at this position.", [["serine", "CHEMICAL", 56, 62], ["serine", "AMINO_ACID", 56, 62], ["CI cluster", "DNA", 16, 26]]], ["As Asn is more polar than serine, they are more favoured for interaction with polar probes and hydrogen-bond formation.GRID/CPCA AND Hierarchical ClusteringClass I HLA classification using GRID/CPCA and hierarchical clustering based on CoMSIA fields exhibit, on average, a 77% consensus.", [["Asn", "CHEMICAL", 3, 6], ["Asn", "CHEMICAL", 3, 6], ["serine", "CHEMICAL", 26, 32], ["hydrogen", "CHEMICAL", 95, 103], ["Asn", "AMINO_ACID", 3, 6], ["serine", "AMINO_ACID", 26, 32], ["GRID", "DNA", 119, 123], ["GRID", "DNA", 189, 193], ["CPCA", "DNA", 194, 198], ["polar probes", "TREATMENT", 78, 90], ["hydrogen-bond formation", "TREATMENT", 95, 118], ["GRID/CPCA", "TREATMENT", 189, 198], ["CoMSIA fields", "TEST", 236, 249], ["more polar", "OBSERVATION_MODIFIER", 10, 20], ["bond formation", "OBSERVATION", 104, 118]]], ["HLA-B classification by the two methods gave a slightly lower consensus (68%), which may be because the group had the largest number of molecules among the three (447 HLA-B alleles) and the binding site consisted of more amino acids.", [["amino acids", "CHEMICAL", 221, 232], ["amino acids", "CHEMICAL", 221, 232], ["HLA-B", "GENE_OR_GENE_PRODUCT", 0, 5], ["HLA-B", "GENE_OR_GENE_PRODUCT", 167, 172], ["amino acids", "AMINO_ACID", 221, 232], ["binding site", "DNA", 190, 202], ["the two methods", "TEST", 24, 39], ["a slightly lower consensus", "PROBLEM", 45, 71], ["HLA", "TEST", 167, 170], ["the binding site", "PROBLEM", 186, 202], ["amino acids", "TREATMENT", 221, 232], ["largest", "OBSERVATION_MODIFIER", 118, 125], ["amino acids", "OBSERVATION", 221, 232]]], ["The classification of the cluster B27 was debatable, as most of the molecules in the B27 cluster, as defined by hierarchical clustering, were in the B7 cluster in the CPCA model.", [["B27", "GENE_OR_GENE_PRODUCT", 85, 88], ["B7", "GENE_OR_GENE_PRODUCT", 149, 151], ["B27 cluster", "DNA", 85, 96], ["B7 cluster", "PROTEIN", 149, 159], ["the cluster B27", "PROBLEM", 22, 37], ["B27 cluster", "OBSERVATION", 85, 96], ["hierarchical clustering", "OBSERVATION", 112, 135]]], ["The HLA-C classification gave the best agreement using the two methods (93% consensus).", [["HLA-C", "GENE_OR_GENE_PRODUCT", 4, 9]]], ["Only 8 molecules were classified into different subtypes by the two methods.", [["8 molecules", "OBSERVATION_MODIFIER", 5, 16], ["different subtypes", "OBSERVATION_MODIFIER", 38, 56]]], ["Molecules that have been classified into different clusters by the two methods were considered as outliers as it was not possible to classify them properly into clusters.", [["different", "OBSERVATION_MODIFIER", 41, 50], ["clusters", "OBSERVATION_MODIFIER", 51, 59]]], ["They require future re-classification using other, more sensitive techniques.", [["future re-classification", "TREATMENT", 13, 37]]], ["A closer look at the protein sequence level showed that these outliers do not significantly resemble the classified alleles.", [["the protein sequence level", "TEST", 17, 43]]], ["For example, A2503 alleles had Tyr at 9 and Asp at 116, which were identical as A* 11 alleles, but they also had Glu at position 114 fike the A32 alleles.GRID/CPCA AND Hierarchical ClusteringThe GRID/CPCA procedure grouped all class I HLA-A, B and C alleles into several supertypes.", [["Glu", "CHEMICAL", 113, 116], ["Tyr", "CHEMICAL", 31, 34], ["Asp", "CHEMICAL", 44, 47], ["Glu", "CHEMICAL", 113, 116], ["A2503", "GENE_OR_GENE_PRODUCT", 13, 18], ["Tyr", "AMINO_ACID", 31, 34], ["Asp", "AMINO_ACID", 44, 47], ["Glu", "AMINO_ACID", 113, 116], ["A32", "GENE_OR_GENE_PRODUCT", 142, 145], ["HLA-A", "GENE_OR_GENE_PRODUCT", 235, 240], ["B", "GENE_OR_GENE_PRODUCT", 242, 243], ["C", "GENE_OR_GENE_PRODUCT", 248, 249], ["A2503 alleles", "DNA", 13, 26], ["A32 alleles", "DNA", 142, 153], ["GRID", "DNA", 154, 158], ["GRID", "DNA", 195, 199], ["CPCA", "DNA", 200, 204], ["class I HLA-A, B and C alleles", "DNA", 227, 257], ["Tyr", "TEST", 31, 34], ["Asp", "TEST", 44, 47], ["Glu", "TEST", 113, 116], ["GRID/CPCA", "PROBLEM", 154, 163], ["The GRID/CPCA procedure", "TREATMENT", 191, 214], ["several", "OBSERVATION_MODIFIER", 263, 270], ["supertypes", "OBSERVATION", 271, 281]]], ["Of these alleles, A0202, A0206 and A0204, which, like the A3 alleles, possessed Met at position 97 and was classified as belonging to the A3 family.", [["Met", "CHEMICAL", 80, 83], ["Met", "CHEMICAL", 80, 83], ["Met", "GENE_OR_GENE_PRODUCT", 80, 83], ["alleles", "DNA", 9, 16], ["A0202", "DNA", 18, 23], ["A0206", "DNA", 25, 30], ["A3 alleles", "DNA", 58, 68], ["A3 family", "DNA", 138, 147], ["alleles", "OBSERVATION", 9, 16]]], ["A0201 by having one amino acid mutation Arg -> Met at position 97.", [["A0201", "CHEMICAL", 0, 5], ["amino acid", "CHEMICAL", 20, 30], ["Met", "CHEMICAL", 47, 50], ["amino acid", "CHEMICAL", 20, 30], ["Arg ->", "CHEMICAL", 40, 46], ["Met", "CHEMICAL", 47, 50], ["amino acid", "AMINO_ACID", 20, 30], ["Arg", "AMINO_ACID", 40, 43], ["Met", "GENE_OR_GENE_PRODUCT", 47, 50]]], ["Met97 is inside pocket F. The side chain of Met97 is smaller compared with Arg, therefore increasing the volume of pocket F. However, the A0201, therefore it was possible that A6801 and A0101, A2601, A3201), the A3 superfamily (A1101, A3101 and A2301, A2403, A3001, A3003).", [["Met97", "CHEMICAL", 0, 5], ["Arg", "CHEMICAL", 75, 78], ["A6801", "CHEMICAL", 176, 181], ["A0101", "CHEMICAL", 186, 191], ["Met97", "GENE_OR_GENE_PRODUCT", 0, 5], ["Met97", "GENE_OR_GENE_PRODUCT", 44, 49], ["Arg", "AMINO_ACID", 75, 78], ["Met97", "PROTEIN", 0, 5], ["Met97", "PROTEIN", 44, 49], ["A3 superfamily", "PROTEIN", 212, 226], ["A3101", "TEST", 235, 240], ["A2301", "TEST", 245, 250], ["smaller", "OBSERVATION_MODIFIER", 53, 60]]], ["The Al and A3 families were grouped into the A3 superfamily in the GRID/CPCA analysis.", [["Al and A3 families", "PROTEIN", 4, 22], ["A3 superfamily", "PROTEIN", 45, 59], ["GRID", "DNA", 67, 71], ["CPCA", "DNA", 72, 76], ["the GRID/CPCA analysis", "TEST", 63, 85]]], ["The A24 alleles were in the A24 superfamily, but A3002 and A*3003 were placed in the A3 superfamily.", [["A24", "GENE_OR_GENE_PRODUCT", 4, 7], ["A24", "GENE_OR_GENE_PRODUCT", 28, 31], ["A24 alleles", "DNA", 4, 15], ["A24 superfamily", "PROTEIN", 28, 43], ["A3 superfamily", "PROTEIN", 85, 99]]], ["Our work was also compared with the classification by Lund et al..GRID/CPCA AND Hierarchical Clusteringwhich produced a set of five distinct HLA-A clusters (Al, A2, A3, A24, A26) using both motif information and binding site structure analysis [Lund et al. 2004 ].", [["HLA-A", "GENE_OR_GENE_PRODUCT", 141, 146], ["GRID", "DNA", 66, 70], ["HLA-A clusters", "DNA", 141, 155], ["Al", "DNA", 157, 159], ["A2", "DNA", 161, 163], ["A3", "DNA", 165, 167], ["A24", "DNA", 169, 172], ["GRID/CPCA", "TEST", 66, 75]]], ["The Al, A3 and A26 cluster in Lund's classification were grouped into the A3 superfamily in the present classification, although the A2 and A24 families in the two analyses were in good agreement. et al. 1998 , Sidney et al. 1996a , Doolan & Hoffman 1997 , Lamas et al. 1998 , Sidney et al. 2003 ].", [["Al, A3 and A26", "CHEMICAL", 4, 18], ["A2", "GENE_OR_GENE_PRODUCT", 133, 135], ["Al, A3 and A26 cluster", "DNA", 4, 26], ["A3 superfamily", "PROTEIN", 74, 88], ["A2", "PROTEIN", 133, 135], ["A24 families", "PROTEIN", 140, 152]]], ["Most of the B7 alleles in Sette's classification were in the B7 cluster defined by GRID/CPCA, apart from B53, which were in the B44 cluster.", [["B7", "GENE_OR_GENE_PRODUCT", 12, 14], ["B7", "GENE_OR_GENE_PRODUCT", 61, 63], ["GRID", "GENE_OR_GENE_PRODUCT", 83, 87], ["B53", "GENE_OR_GENE_PRODUCT", 105, 108], ["B44", "GENE_OR_GENE_PRODUCT", 128, 131], ["B7 alleles", "DNA", 12, 22], ["B7 cluster", "DNA", 61, 71], ["GRID", "DNA", 83, 87], ["CPCA", "DNA", 88, 92], ["B53", "DNA", 105, 108], ["B44 cluster", "DNA", 128, 139], ["GRID/CPCA", "TEST", 83, 92]]], ["Alleles in the B7 and B44 family of Sette's classification were found scattered within the B7, B27 and B44 superfamilies in the present analysis.", [["B7", "GENE_OR_GENE_PRODUCT", 15, 17], ["Sette", "GENE_OR_GENE_PRODUCT", 36, 41], ["B7", "GENE_OR_GENE_PRODUCT", 91, 93], ["B7", "PROTEIN", 15, 17], ["B44 family", "PROTEIN", 22, 32], ["B7", "PROTEIN", 91, 93], ["B27", "PROTEIN", 95, 98], ["B44 superfamilies", "PROTEIN", 103, 120], ["Sette's classification", "TEST", 36, 58], ["B27", "TEST", 95, 98], ["B7", "ANATOMY", 15, 17], ["scattered", "OBSERVATION_MODIFIER", 70, 79]]], ["In Sette's classification two more clusters B58 (B5701-02, B5708) and B62 (B1302, B1502, B1512-14, B1521, B4652) were defined.", [["B1502", "CHEMICAL", 82, 87], ["B1512-14, B1521, B4652", "CHEMICAL", 89, 111], ["B62", "TEST", 70, 73], ["B1302", "TEST", 75, 80], ["B1502", "TEST", 82, 87], ["B1512-", "TEST", 89, 95]]], ["Molecules in the B62 cluster of Sette's classification were located in either the B7 or the B44 superfamilies in the GRID/CPCA analysis.", [["Sette", "GENE_OR_GENE_PRODUCT", 32, 37], ["B7", "GENE_OR_GENE_PRODUCT", 82, 84], ["B7 or the B44 superfamilies", "DNA", 82, 109], ["GRID", "DNA", 117, 121], ["CPCA", "DNA", 122, 126], ["the GRID/CPCA analysis", "TEST", 113, 135]]], ["The B58 cluster in Sette's classification can be found in the B44 cluster in the present study.", [["B58", "GENE_OR_GENE_PRODUCT", 4, 7], ["B58 cluster", "DNA", 4, 15], ["B44 cluster", "DNA", 62, 73]]], ["Compared with Lund's classification (B7, B8, B27, B44, B58, B62), the B8 cluster was included in the B7 supertype and alleles in the B58 and B62 cluster were in the B7 or B27 cluster in the current analysis.HLAAlthough there is no previous HLA-C classification available for comparison, we can nonetheless make the interesting observation that the NK cell inhibitor receptor KIR2DL can be divided into two groups based on their HLA-C specificity.", [["NK cell", "ANATOMY", 348, 355], ["B7", "GENE_OR_GENE_PRODUCT", 37, 39], ["B62", "GENE_OR_GENE_PRODUCT", 60, 63], ["B8", "GENE_OR_GENE_PRODUCT", 70, 72], ["B7", "GENE_OR_GENE_PRODUCT", 101, 103], ["B58", "GENE_OR_GENE_PRODUCT", 133, 136], ["B62", "GENE_OR_GENE_PRODUCT", 141, 144], ["B7", "GENE_OR_GENE_PRODUCT", 165, 167], ["HLA-C", "GENE_OR_GENE_PRODUCT", 240, 245], ["NK cell", "CELL", 348, 355], ["KIR2DL", "GENE_OR_GENE_PRODUCT", 375, 381], ["HLA-C", "GENE_OR_GENE_PRODUCT", 428, 433], ["B7", "PROTEIN", 37, 39], ["B8", "PROTEIN", 41, 43], ["B27", "PROTEIN", 45, 48], ["B44", "PROTEIN", 50, 53], ["B58", "PROTEIN", 55, 58], ["B62", "PROTEIN", 60, 63], ["B8 cluster", "DNA", 70, 80], ["B7 supertype", "DNA", 101, 113], ["B58 and B62 cluster", "DNA", 133, 152], ["B7 or B27 cluster", "DNA", 165, 182], ["NK cell inhibitor receptor", "PROTEIN", 348, 374], ["KIR2DL", "PROTEIN", 375, 381], ["Lund's classification", "TEST", 14, 35], ["B7", "TEST", 37, 39], ["B8", "TEST", 41, 43], ["B27", "TEST", 45, 48], ["B44", "TEST", 50, 53], ["B58", "TEST", 55, 58], ["B62", "TEST", 60, 63], ["the current analysis", "TEST", 186, 206], ["the NK cell inhibitor receptor KIR2DL", "TREATMENT", 344, 381], ["their HLA", "TEST", 422, 431], ["B7", "ANATOMY", 165, 167], ["no", "UNCERTAINTY", 228, 230]]], ["KIR2DL1 recognised HLA-Cw4, Cw6, all of which possessed Asn77, whereas KIR2DL2 recognised HLA-Cw3, Cw8, which had Ser at position 77 [Fan & Long 2001] .", [["Ser", "CHEMICAL", 114, 117], ["KIR2DL1", "GENE_OR_GENE_PRODUCT", 0, 7], ["HLA-Cw4", "GENE_OR_GENE_PRODUCT", 19, 26], ["Cw6", "GENE_OR_GENE_PRODUCT", 28, 31], ["Asn77", "GENE_OR_GENE_PRODUCT", 56, 61], ["KIR2DL2", "GENE_OR_GENE_PRODUCT", 71, 78], ["HLA-Cw3", "GENE_OR_GENE_PRODUCT", 90, 97], ["Cw8", "GENE_OR_GENE_PRODUCT", 99, 102], ["Ser", "AMINO_ACID", 114, 117], ["KIR2DL1", "PROTEIN", 0, 7], ["HLA", "PROTEIN", 19, 22], ["Cw4", "DNA", 23, 26], ["Cw6", "DNA", 28, 31], ["Asn77", "PROTEIN", 56, 61], ["KIR2DL2", "PROTEIN", 71, 78], ["HLA", "PROTEIN", 90, 93], ["Cw3", "DNA", 94, 97], ["Cw8", "DNA", 99, 102], ["HLA", "TEST", 19, 22], ["HLA", "TEST", 90, 93]]], ["The specificity of KIR2DL was in agreement with our HLA-C classification, which suggested that position 77 was important in substrate binding: HLA-C molecules with the same residue at position 77 tend to share the same specificity.HLAA hierarchical clustering study based on HLA binding pockets has also been carried out, in which HLA-A molecules are classified according to molecular specificities of each of the six binding pockets.", [["KIR2DL", "GENE_OR_GENE_PRODUCT", 19, 25], ["HLA-C", "GENE_OR_GENE_PRODUCT", 52, 57], ["HLA-C", "GENE_OR_GENE_PRODUCT", 143, 148], ["KIR2DL", "PROTEIN", 19, 25], ["HLA-C molecules", "PROTEIN", 143, 158], ["HLA binding pockets", "PROTEIN", 275, 294], ["HLA-A molecules", "PROTEIN", 331, 346], ["C molecules", "PROBLEM", 147, 158], ["HLAA hierarchical clustering study", "TEST", 231, 265], ["HLA binding pockets", "PROBLEM", 275, 294], ["the six binding pockets", "PROBLEM", 410, 433], ["binding pockets", "OBSERVATION", 418, 433]]], ["Compared with classifications on the whole binding site, the pocket classification considers one pocket at a time, therefore one allele may be classified into different groups in different classifications.", [["whole binding site", "DNA", 37, 55], ["pocket", "OBSERVATION_MODIFIER", 61, 67], ["pocket", "OBSERVATION_MODIFIER", 97, 103]]], ["For example, pocket B of some A03 alleles favour aliphatic amino acids therefore they are in the same group.", [["aliphatic amino acids", "CHEMICAL", 49, 70], ["amino acids", "CHEMICAL", 59, 70], ["A03", "GENE_OR_GENE_PRODUCT", 30, 33], ["aliphatic", "SIMPLE_CHEMICAL", 49, 58], ["amino acids", "AMINO_ACID", 59, 70], ["pocket B", "PROTEIN", 13, 21], ["A03 alleles", "DNA", 30, 41], ["some A03 alleles", "PROBLEM", 25, 41], ["aliphatic amino acids", "TREATMENT", 49, 70], ["pocket", "OBSERVATION_MODIFIER", 13, 19], ["aliphatic amino acids", "OBSERVATION", 49, 70]]], ["However, pocket F of the A02 alleles accept small aliphatic amino acids and they are in different clusters.", [["amino acids", "CHEMICAL", 60, 71], ["amino acids", "CHEMICAL", 60, 71], ["A02", "GENE_OR_GENE_PRODUCT", 25, 28], ["amino acids", "AMINO_ACID", 60, 71], ["A02 alleles", "DNA", 25, 36], ["the A02 alleles", "TREATMENT", 21, 36], ["small aliphatic amino acids", "TREATMENT", 44, 71], ["pocket", "OBSERVATION_MODIFIER", 9, 15], ["small", "OBSERVATION_MODIFIER", 44, 49], ["aliphatic amino acids", "OBSERVATION", 50, 71]]], ["In contrast to the three amino acids fingerprint from whole binding site classification, eight amino acids (position 63, 66, 70, 74, 114, 116, 152, 156) are identified in the pocket classification, indicating that more amino acids of the binding site are important in peptide specificity.", [["amino acids", "CHEMICAL", 25, 36], ["amino acids", "CHEMICAL", 95, 106], ["amino acids", "CHEMICAL", 219, 230], ["amino acids", "CHEMICAL", 25, 36], ["amino acids", "CHEMICAL", 95, 106], ["amino acids", "CHEMICAL", 219, 230], ["amino acids", "AMINO_ACID", 25, 36], ["amino acids", "AMINO_ACID", 95, 106], ["amino acids", "AMINO_ACID", 219, 230], ["the three amino acids fingerprint", "TEST", 15, 48], ["eight amino acids", "TEST", 89, 106], ["more amino acids of the binding site", "PROBLEM", 214, 250], ["pocket classification", "OBSERVATION", 175, 196]]], ["However, as peptide binding motifs are only available for a small group of alleles, therefore the current classifications can not be validated.Class II HLA ClassificationClass II HLA alleles have also been classified by clustering.", [["Class II HLA", "GENE_OR_GENE_PRODUCT", 170, 182], ["Class II HLA alleles", "DNA", 170, 190], ["a small group of alleles", "PROBLEM", 58, 82]]], ["Doytchinova et al. applied hierarchical clustering using CoMSIA fields and non-hierarchical clustering based on z-scores.", [["CoMSIA fields", "TREATMENT", 57, 70], ["non-hierarchical clustering", "PROBLEM", 75, 102], ["z-scores", "TEST", 112, 120]]], ["The hierarchical clustering follows the same procedure as class I classification described above.", [["the same procedure", "TREATMENT", 36, 54], ["hierarchical", "OBSERVATION_MODIFIER", 4, 16], ["clustering", "OBSERVATION", 17, 27]]], ["Nonhierarchical clustering uses five z descriptors to describe hydrophobicity, steric bulk, polarity and electronic effects of the HLA molecules.", [["HLA molecules", "PROTEIN", 131, 144], ["the HLA molecules", "PROBLEM", 127, 144], ["steric bulk", "OBSERVATION", 79, 90]]], ["K-means clustering is applied to the set and the initial number of k seeds is equal to the number of clusters obtained from the hierarchical clustering.", [["K", "CHEMICAL", 0, 1], ["K", "TEST", 0, 1], ["hierarchical clustering", "OBSERVATION", 128, 151]]], ["The known crystal structures of class II HLA are used as templates in homology modelling.", [["class II HLA", "GENE_OR_GENE_PRODUCT", 32, 44], ["class II HLA", "PROTEIN", 32, 44], ["crystal", "OBSERVATION_MODIFIER", 10, 17]]], ["Like the class I HLA classification, the class II alleles are grouped into twelve families.", [["class II alleles", "DNA", 41, 57]]], ["HLA-DR alleles are classified into DRl, DR3, DR4, DR5 and DR9 supertypes (Table 10 .4).", [["HLA-DR", "GENE_OR_GENE_PRODUCT", 0, 6], ["DRl", "GENE_OR_GENE_PRODUCT", 35, 38], ["DR3", "GENE_OR_GENE_PRODUCT", 40, 43], ["DR4", "GENE_OR_GENE_PRODUCT", 45, 48], ["DR5", "GENE_OR_GENE_PRODUCT", 50, 53], ["DR9", "GENE_OR_GENE_PRODUCT", 58, 61], ["HLA-DR alleles", "DNA", 0, 14], ["DRl", "DNA", 35, 38], ["DR3", "DNA", 40, 43], ["DR4", "PROTEIN", 45, 48], ["DR5", "PROTEIN", 50, 53], ["DR5", "ANATOMY", 50, 53]]], ["Hierarchical clustering groups DRB11501-11 and DRBl0701-07, DRBl0101-10, DRB30422 and DRB10401, 03-48, DRB11309 , DRBl1001 , DRB40402,12,15, 25, 36, 37, 47, DRB11201 -09, DRBl1403 , DRB10901-02, DRB50202-05 in DR9.", [["DRB50202-05", "DNA", 195, 206], ["DR9", "DNA", 210, 213], ["DRB11501", "TEST", 31, 39], ["DRBl0701", "TEST", 47, 55], ["DRBl0101", "TEST", 60, 68], ["DRB", "TEST", 103, 106], ["DRB", "TEST", 114, 117], ["DRB40402,", "TEST", 125, 134], ["DRB11201", "TEST", 157, 165], ["DRB", "TEST", 171, 174], ["DRB10901", "TEST", 182, 190]]], ["Nonhierarchical clustering classifies DRB11501-11 and DRBl0101-10, DRB30301-03, DRB11447 in DR3, DRB11107, 13, 17, DRBl0215, DRB10101-06, DRBl0402, 15, 25, 36, 47, DRBl1201 -09DRBl1403 , DRBl0101-12, DRB50901-02, DRBl0501-03, DQB10301-13, DQB10402 and DQAl0201, DPB132, 33, 41, 46, 47, 48, 71, 81, 86, 95) , DPw4 (DPB115, 18, 23, 24, 28, 34, 39, 40, 49, 51, 53, 59, 60, 62, 66, 72, 73, 74, 75, 77, 80, 83, 94, 96, 99) and DPw6 (Table 10 .4).", [["DRBl0101-10", "GENE_OR_GENE_PRODUCT", 54, 65], ["DR3", "GENE_OR_GENE_PRODUCT", 92, 95], ["DRB11107", "GENE_OR_GENE_PRODUCT", 97, 105], ["DPw4", "GENE_OR_GENE_PRODUCT", 308, 312], ["DRB11501", "DNA", 38, 46], ["DRBl0101", "DNA", 54, 62], ["DRB30301", "DNA", 67, 75], ["DRB11447", "DNA", 80, 88], ["DR3", "DNA", 92, 95], ["DRB11107", "DNA", 97, 105], ["DRB10101", "DNA", 125, 133], ["DRBl0402", "DNA", 138, 146], ["DRBl0101", "DNA", 187, 195], ["DRB50901", "DNA", 200, 208], ["DRBl0501", "DNA", 213, 221], ["DQB10301", "DNA", 226, 234], ["DQB10402", "DNA", 239, 247], ["DQAl0201", "DNA", 252, 260], ["DPw6", "DNA", 422, 426], ["DRB11501", "TEST", 38, 46], ["DRBl0101", "TEST", 54, 62], ["DRB30301", "TEST", 67, 75], ["DRB", "TEST", 80, 83], ["DR3", "TEST", 92, 95], ["DRB", "TEST", 97, 100], ["DRBl", "TEST", 115, 119], ["DRB10101", "TEST", 125, 133], ["DRBl", "TEST", 138, 142], ["DRB", "TEST", 164, 167], ["DRBl0101", "TEST", 187, 195], ["DRB50901", "TEST", 200, 208], ["DRBl0501", "TEST", 213, 221], ["DQB10301", "TEST", 226, 234], ["DQAl0201", "TEST", 252, 260], ["DPB132", "TEST", 262, 268], ["DPw4", "TEST", 308, 312], ["DPB115", "TEST", 314, 320], ["DPw6", "TEST", 422, 426]]], ["In hierarchical clustering, DPwl cluster includes DPB114, 20, 25, 26, 27, 31, 35, 36, 38, 45, 50, 52, 56, 57, 63, 65, 67, 68, 70, 76, 78, 79, 84, 85, 87, 89, 90, 91, 92, 97 and 98.", [["DPwl cluster", "DNA", 28, 40], ["DPB114", "TEST", 50, 56]]], ["DPw6 cluster has DPB108, 09, 10, 11, 13, 16, 17, 19, 21, 22, 29, 30, 37, 44, 54, 55, 58, 69, 88, 93 .", [["DPw6", "GENE_OR_GENE_PRODUCT", 0, 4], ["DPw6 cluster", "DNA", 0, 12]]], ["Epitopes have been shown to crossreact with the A24 family [Burrows Sz Elkington 2003] .", [["A24 family", "PROTEIN", 48, 58]]], ["Many viral and tumour antigen derived vaccine candidates have also been shown to be able to bind multiple alleles.", [["tumour", "ANATOMY", 15, 21], ["tumour", "CANCER", 15, 21], ["alleles", "DNA", 106, 113], ["Many viral and tumour antigen derived vaccine", "TREATMENT", 0, 45]]], ["Sette et al. predicted 223 potential cancer peptides of CEA, Her-2/neu, P53 and MAGE antigens using a T cell epitope prediction algorithm, among which 115 were cross-reactive with peptides of the A2 supertype.", [["cancer", "ANATOMY", 37, 43], ["T cell", "ANATOMY", 102, 108], ["cancer", "DISEASE", 37, 43], ["cancer", "CANCER", 37, 43], ["CEA", "GENE_OR_GENE_PRODUCT", 56, 59], ["Her-2", "GENE_OR_GENE_PRODUCT", 61, 66], ["neu", "GENE_OR_GENE_PRODUCT", 67, 70], ["P53", "GENE_OR_GENE_PRODUCT", 72, 75], ["MAGE antigens", "GENE_OR_GENE_PRODUCT", 80, 93], ["T cell", "CELL", 102, 108], ["A2", "GENE_OR_GENE_PRODUCT", 196, 198], ["CEA, Her-2/neu, P53 and MAGE antigens", "PROTEIN", 56, 93], ["A2 supertype", "PROTEIN", 196, 208], ["CEA", "TEST", 56, 59], ["MAGE antigens", "TEST", 80, 93], ["a T cell epitope prediction algorithm", "TEST", 100, 137], ["cancer", "OBSERVATION", 37, 43], ["CEA", "ANATOMY", 56, 59], ["A2 supertype", "OBSERVATION", 196, 208]]], ["43 peptides were tested for immunogenecity and 73% were positive [Sette & Livingston 2001] .", [["peptides", "TEST", 3, 11], ["immunogenecity", "TEST", 28, 42]]], ["Recently a protein sequence scan has been carried out to search for T cell epitopes within the sequence of the SARS virus, based on the nine HLA supertypes in Sette's analysis [Sylvester-Hvid et al. 2004] .", [["T cell", "ANATOMY", 68, 74], ["SARS", "DISEASE", 111, 115], ["T cell", "CELL", 68, 74], ["SARS virus", "ORGANISM", 111, 121], ["T cell epitopes", "PROTEIN", 68, 83], ["SARS virus", "SPECIES", 111, 121], ["a protein sequence scan", "TEST", 9, 32], ["T cell epitopes", "PROBLEM", 68, 83], ["the SARS virus", "PROBLEM", 107, 121]]], ["Fifteen predicted epitopes for each supertype were identified and tested experimentally: 75% of the predicted epitopes were found to be high affinity peptides (IC50 < 500nM) and about 112 candidate epitopes were obtained.DiscussionAll supertypes are theoretically derived, even the experimental supertypes promulgated by Sette.", [["supertype", "PROTEIN", 36, 45], ["epitopes", "PROTEIN", 110, 118], ["high affinity peptides", "PROBLEM", 136, 158], ["IC50", "TEST", 160, 164]]], ["His supertypes were derived from the comparison of binding motifs.", [["His", "CHEMICAL", 0, 3], ["binding motifs", "PROTEIN", 51, 65]]], ["Possessing a certain verisimilitude, they can only give rise to a partial and largely incomplete definition of supertypes, limited by the lack of data for most MHC molecules.", [["MHC molecules", "PROTEIN", 160, 173], ["partial", "OBSERVATION_MODIFIER", 66, 73]]], ["Modern methods in particular, such as the GRID/CPCA method we outline here, allow us to propose supertype definitions solely based on sequence and structural data.", [["Modern methods", "TREATMENT", 0, 14], ["the GRID/CPCA method", "TREATMENT", 38, 58], ["sequence and structural data", "TEST", 134, 162]]], ["In one seamless movement we can preogress from HLA sequencing to structure to supertype classification to binding specificity to epitope prediction.", [["epitope prediction", "TEST", 129, 147]]], ["Moreover, the same fundamental methodology can be used to address the issue of identifying benign HLA mismatches in tissue rejection, such as kidney transplants, bone marrow donation, and the like.", [["tissue", "ANATOMY", 116, 122], ["kidney", "ANATOMY", 142, 148], ["bone marrow", "ANATOMY", 162, 173], ["HLA", "GENE_OR_GENE_PRODUCT", 98, 101], ["tissue", "TISSUE", 116, 122], ["kidney", "ORGAN", 142, 148], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 162, 173], ["benign HLA mismatches in tissue rejection", "PROBLEM", 91, 132], ["kidney transplants", "TREATMENT", 142, 160], ["bone marrow donation", "TREATMENT", 162, 182], ["benign", "OBSERVATION_MODIFIER", 91, 97], ["HLA mismatches", "OBSERVATION", 98, 112], ["tissue", "ANATOMY", 116, 122], ["rejection", "OBSERVATION", 123, 132], ["kidney", "ANATOMY", 142, 148], ["transplants", "OBSERVATION", 149, 160], ["bone", "ANATOMY", 162, 166], ["marrow donation", "OBSERVATION", 167, 182]]], ["Such problems require a robust, reliable and, preferably, transparent measure of structural similarity between HLA molecules in order to suggest which pairs of alleles will present the same peptides or be equally invisible to antibody surveillance.", [["HLA molecules", "GENE_OR_GENE_PRODUCT", 111, 124], ["HLA molecules", "PROTEIN", 111, 124], ["Such problems", "PROBLEM", 0, 13], ["antibody surveillance", "TEST", 226, 247]]], ["The GRID/CPCA method offers the possibility of effectively addressing all these problems and many more.", [["The GRID/CPCA method", "TREATMENT", 0, 20], ["all these problems", "PROBLEM", 70, 88]]], ["The 3D scores plot of the HLA-C CPCA analysis.", [["HLA-C", "GENE_OR_GENE_PRODUCT", 26, 31], ["The 3D scores plot", "TEST", 0, 18], ["the HLA", "TEST", 22, 29], ["C CPCA analysis", "TEST", 30, 45]]], ["Two clusters were displayed in the plot.", [["clusters", "OBSERVATION_MODIFIER", 4, 12]]], ["The main cluster above the X axis had many CI molecules and was named the CI cluster.", [["CI molecules", "PROTEIN", 43, 55], ["CI cluster", "PROTEIN", 74, 84], ["many CI molecules", "PROBLEM", 38, 55], ["main", "OBSERVATION_MODIFIER", 4, 8], ["cluster", "OBSERVATION_MODIFIER", 9, 16], ["X axis", "OBSERVATION_MODIFIER", 27, 33]]], ["The cluster below the X axis had lots of C4 molecules and was named the C4 cluster.", [["C4 molecules", "PROTEIN", 41, 53], ["C4 cluster", "PROTEIN", 72, 82], ["lots of C4 molecules", "PROBLEM", 33, 53], ["X axis", "OBSERVATION_MODIFIER", 22, 28], ["C4 molecules", "OBSERVATION", 41, 53], ["C4", "ANATOMY_MODIFIER", 72, 74]]]], "PMC7516626": [["IntroductionOne decade after passage of the Patient Protection and Affordable Care Act (ACA), despite substantial gains in insurance coverage, health care affordability remains a major concern among US residents.1 Premiums are increasingly unaffordable, and underinsurance\u2014incomplete financial protection despite coverage\u2014is increasingly common.2 Although previous research has shown that the ACA\u2019s Medicaid expansions decreased out-of-pocket spending among low-income adults,3 broader trends in out-of-pocket spending have not been well characterized.", [["the Patient Protection", "TREATMENT", 40, 62], ["Medicaid expansions", "PROBLEM", 399, 418], ["expansions", "OBSERVATION_MODIFIER", 408, 418], ["decreased", "OBSERVATION_MODIFIER", 419, 428], ["well characterized", "OBSERVATION_MODIFIER", 533, 551]]], ["We thus sought to analyze changes in financial risk protection associated with ACA implementation across all income strata and insurance types.MethodsWe obtained income, insurance coverage, and spending data from a nationally representative sample of adults aged 20 to 64 years in the Medical Expenditure Panel Survey, collected from 2010 to 2017.", [["financial risk protection", "TREATMENT", 37, 62], ["ACA implementation", "TREATMENT", 79, 97]]], ["Our primary outcome was catastrophic health expenditures, defined with the World Health Organization threshold of calendar-year out-of-pocket plus premium spending exceeding 40% of postsubsistence income4 (calendar-year income minus typical food and housing expenditures from the Bureau of Labor Statistics5).", [["catastrophic", "OBSERVATION_MODIFIER", 24, 36]]], ["Interrupted time series analysis was used to evaluate changes in the rate of catastrophic expenditures, with an inflection point in January 2014, the start of full ACA implementation.2 Individuals were stratified for analysis by quartile of household income as a percentage of the federal poverty level and by insurance type (eFigure in the Supplement).", [["Interrupted time series analysis", "TEST", 0, 32], ["catastrophic expenditures", "PROBLEM", 77, 102], ["full ACA implementation", "TREATMENT", 159, 182], ["catastrophic expenditures", "OBSERVATION", 77, 102]]], ["We also analyzed individuals across insurance types within the lowest income quartile.MethodsAnalyses were performed with multivariable linear regression models adjusted for sociodemographic characteristics, self-reported health, and Census region (eTable in the Supplement).", [["MethodsAnalyses", "TEST", 86, 101], ["multivariable linear regression models", "TREATMENT", 122, 160]]], ["We adjusted for inflation using the Consumer Price Index.6 Cluster-robust standard errors and survey weights for national estimates were used, with a 2-tailed P value threshold of .05.", [["inflation", "TREATMENT", 16, 25], ["the Consumer Price Index", "TREATMENT", 32, 56], ["survey weights", "TEST", 94, 108], ["national estimates", "TEST", 113, 131]]], ["Analysis was conducted with Stata/SE version 16.1.MethodsThis study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.ResultsWe identified 159 941 survey respondents (49.1% men; mean age, 41.8 years [SD, 12.6 years]), representing 186 million individuals annually after survey weighting.", [["men", "ORGANISM", 253, 256], ["men", "SPECIES", 253, 256], ["Analysis", "TEST", 0, 8], ["Stata/SE version", "TEST", 28, 44], ["This study", "TEST", 57, 67], ["Observational Studies", "TEST", 112, 133], ["cohort studies", "TEST", 183, 197], ["survey weighting", "TEST", 350, 366]]], ["The number of uninsured nonelderly adults declined from 42.9 million (23.5%) in 2010 to 27.9 million (14.8%) in 2017, whereas those with Medicaid coverage increased from 11.0 million (6.0%) to 18.3 million (9.7%) (P < .001).", [["adults", "ORGANISM", 35, 41], ["Medicaid coverage", "TREATMENT", 137, 154]]], ["Coverage gains were concentrated in the 2 lower income quartiles, in which the uninsured rate decreased from 44.1% to 28.6% (lowest quartile) and 27.0% to 18.7% (P < .001).ResultsThe number of adults experiencing catastrophic expenditures yearly declined from 13.6 million (7.4%) in 2010 to 11.2 million (5.9%) in 2017 (P < .001) (Figure 1).", [["adults", "ORGANISM", 193, 199], ["the uninsured rate", "TEST", 75, 93], ["catastrophic expenditures", "PROBLEM", 213, 238]]], ["Privately insured adults composed 46.4% of catastrophic expenditure cases in 2010 and 53.6% in 2017 (P < .001).ResultsIn our interrupted time series analysis, individuals in the lowest income quartile experienced a 2.3 percentage point decrease in likelihood of catastrophic expenditures (95% CI, \u22124.6 to \u22120.1) (Figure 2A), whereas no change was observed in other income quartiles.", [["adults", "ORGANISM", 18, 24], ["catastrophic expenditure cases", "TEST", 43, 73], ["series analysis", "TEST", 142, 157], ["individuals", "TEST", 159, 170], ["catastrophic expenditures", "PROBLEM", 262, 287], ["CI", "TEST", 293, 295], ["\u2212", "TEST", 297, 298], ["decrease", "OBSERVATION_MODIFIER", 236, 244], ["catastrophic", "OBSERVATION_MODIFIER", 262, 274], ["no", "UNCERTAINTY", 332, 334], ["change", "OBSERVATION", 335, 341]]], ["Stratified by insurance type, privately insured individuals experienced no change in catastrophic expenditures (adjusted change, \u22120.2 percentage point; 95% CI, \u22121.4 to 1.0) (Figure 2B).", [["individuals", "ORGANISM", 48, 59], ["change in catastrophic expenditures", "PROBLEM", 75, 110], ["CI", "TEST", 156, 158], ["\u2212", "TEST", 160, 161], ["catastrophic", "OBSERVATION_MODIFIER", 85, 97]]], ["Finally, in our subanalysis of the lowest income quartile, privately insured individuals again experienced no change (adjusted change, \u22122.8 percentage points; 95% CI, \u22129.5 to 3.8) (Figure 2C), and in fact had the highest rate of catastrophic spending in 2017 (34.6% vs 8.3% among Medicaid enrollees and 13.9% among the uninsured).DiscussionACA implementation was associated with 2 million fewer US adults with catastrophic expenditures each year.", [["individuals", "ORGANISM", 77, 88], ["CI", "TEST", 163, 165], ["\u2212", "TEST", 167, 168], ["Medicaid enrollees", "TREATMENT", 280, 298], ["catastrophic", "OBSERVATION_MODIFIER", 229, 241], ["catastrophic", "OBSERVATION_MODIFIER", 410, 422]]], ["However, improvements were not observed in higher income quartiles or among the privately insured, who represent an increasing share of those experiencing catastrophic expenditures.", [["catastrophic expenditures", "PROBLEM", 155, 180], ["catastrophic", "OBSERVATION_MODIFIER", 155, 167], ["expenditures", "OBSERVATION", 168, 180]]], ["These findings help to explain why so many US residents, including those with insurance, continue to worry about their ability to afford needed care.DiscussionLimitations include changing patient composition within insurance groups, meaning our analysis evaluates financial protection currently conferred by each insurance type, rather than the effect of gaining coverage.", [["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195], ["meaning our analysis", "TEST", 233, 253], ["financial protection", "TREATMENT", 264, 284], ["gaining coverage", "TREATMENT", 355, 371]]], ["Also, because the Medical Expenditure Panel Survey does not quantify unpaid bills or medical debt, our analysis likely underestimates patients\u2019 true financial hardship.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["our analysis", "TEST", 99, 111]]], ["Last, changes in catastrophic spending could have gone undetected in subgroups with small sample size, such as low-income privately insured individuals.DiscussionDespite large coverage gains, 11 million US adults, including 6 million with private insurance, continue to experience catastrophic health expenditures annually.", [["small sample size", "PROBLEM", 84, 101], ["catastrophic", "OBSERVATION_MODIFIER", 17, 29], ["small", "OBSERVATION_MODIFIER", 84, 89], ["size", "OBSERVATION_MODIFIER", 97, 101]]], ["These figures are likely to increase as millions lose employment or require unexpected medical care because of coronavirus disease 2019.", [["coronavirus disease", "DISEASE", 111, 130], ["unexpected medical care", "TREATMENT", 76, 99], ["coronavirus disease", "PROBLEM", 111, 130], ["likely to", "UNCERTAINTY", 18, 27], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["coronavirus disease", "OBSERVATION", 111, 130]]], ["Health reform should move beyond expanding insurance coverage alone to address persistently high out-of-pocket spending among the insured.", [["expanding insurance coverage", "TREATMENT", 33, 61], ["persistently high out-of-pocket", "PROBLEM", 79, 110]]]], "PMC7433774": [["IntroductionThe public health sector\u2019s increasing demand for mapping, analytics and visualization had started a date back in the last 20 years, which has resulted in a growing information-age technology for communicable disease surveillance and epidemiology (Baker et al. 1995; Bos and Blobel 2007; Friede et al. 1993; Friede 1995; Khan et al. 2010; Reeder et al. 2012; Yu and Edberg 2005).", [["visualization", "TEST", 84, 97], ["communicable disease surveillance", "PROBLEM", 207, 240]]], ["This continuous public health burden with advances in information technology combined with spatial data led to the development of various tools and systems that provides visualization of disease data in space and time (Dredger et al. 2007; Kothari et al. 2008; Robertson and Nelson 2010; Schriml et al. 2009).IntroductionThe first integral definition of public health was given by Winslow (1920) as \u201cscience and art of preventing disease, prolonging life, and promoting health through the organized efforts and informed choices of society, organizations, public and private communities, and individuals\u201d.", [["disease", "PROBLEM", 430, 437], ["disease", "OBSERVATION", 430, 437]]], ["The American Public Health Association (APHA) mentioned public health as a practice of preventing the spread of disease and an aim of promoting good health from small communities to across the world (Turnock 2012).", [["disease", "PROBLEM", 112, 119]]], ["Advances in information technology and spatial features resulted in geospatial technology which is acute for mapping, surveillance, predicting outbreaks, detecting clustering and analysing spread patterns of infectious diseases with epidemic or pandemic potential in communities and across territories (AvRuskin et al. 2004; Carpenter 2011; Castronovo et al. 2009; Dominkovics et al. 2011; Gao et al. 2008; Heymann and Brilliant 2011; Hills et al. 2008; Klompas et al. 2011; Reis et al. 2007).", [["infectious diseases", "DISEASE", 208, 227], ["pandemic", "DISEASE", 245, 253], ["surveillance", "TEST", 118, 130], ["infectious diseases", "PROBLEM", 208, 227], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["infectious", "OBSERVATION_MODIFIER", 208, 218], ["Heymann", "ANATOMY", 407, 414]]], ["Geospatial technology has provided visualization and analytical tools to public health professionals and decision makers to execute diseases control programs in affected and/or suspected regions and make analysis and predictions possible that was once technologically out of reach.IntroductionGeospatial technology includes geographical information systems (GIS), global positioning systems (GPS) and satellite-based technologies such as remote sensing (RS).", [["diseases control programs", "TREATMENT", 132, 157], ["satellite-based technologies", "PROBLEM", 401, 429]]], ["GPS provides positioning, navigation and timing (PNT) services by capturing data from satellites and providing it to users (Eldredge et al. 2010), and RS is an earth observation instrument that delivers regional information on climatic factors and landscape features.", [["navigation and timing (PNT) services", "TREATMENT", 26, 62]]], ["Therefore, GPS and RS provide regional and spatial information, while GIS provides geospatial data integration as well as accurate geospatial analysis in real-time manner (Zhen et al. 2010).Geospatial Technology and Infectious Disease SurveillanceInfectious diseases mostly adapts anti-microbial and mobility features later formed in a shape of pandemic and/or epidemic (Chen et al. 2019; Cheng et al. 2019; Lee and Nishiura 2019), which forced public health authorities to understand not only the diseases virulence, but also its demographic and environmental factors that helps in making spread patterns though space and time domain (Croner 2004).", [["Infectious Disease SurveillanceInfectious diseases", "DISEASE", 216, 266], ["GPS", "TEST", 11, 14], ["accurate geospatial analysis", "TEST", 122, 150], ["Infectious Disease SurveillanceInfectious diseases", "PROBLEM", 216, 266], ["pandemic", "PROBLEM", 345, 353], ["epidemic", "PROBLEM", 361, 369], ["the diseases virulence", "PROBLEM", 494, 516], ["Infectious", "OBSERVATION_MODIFIER", 216, 226]]], ["For example, the global spread of highly pathogenic avian influenza (HPAI) H5N1 in 2005\u201306 with no effective vaccines led to concern among public health decision makers, in spite of many international programs (Rappole and Hub\u00e1lek 2006)32.", [["avian influenza", "DISEASE", 52, 67], ["HPAI", "DISEASE", 69, 73], ["H5N1", "DISEASE", 75, 79], ["highly pathogenic", "ORGANISM", 34, 51], ["avian influenza", "ORGANISM", 52, 67], ["HPAI) H5N1", "ORGANISM", 69, 79], ["avian influenza", "SPECIES", 52, 67], ["HPAI) H5N1", "SPECIES", 69, 79], ["HPAI", "SPECIES", 69, 73], ["highly pathogenic avian influenza (HPAI) H5N1", "PROBLEM", 34, 79], ["effective vaccines", "TREATMENT", 99, 117], ["global", "OBSERVATION_MODIFIER", 17, 23], ["spread", "OBSERVATION_MODIFIER", 24, 30], ["highly", "OBSERVATION_MODIFIER", 34, 40], ["pathogenic", "OBSERVATION_MODIFIER", 41, 51]]], ["The reason behind their concern was they were lacking of disease surveillance tool in its initial stage which caused inaccessibility to populations at risk, and faced difficulties in implementing immunization strategies at a global scale (Kitler et al. 2002; Stoto et al. 2004).", [["disease surveillance tool", "PROBLEM", 57, 82], ["faced difficulties", "PROBLEM", 161, 179], ["immunization strategies", "TREATMENT", 196, 219]]], ["However, the impact of environmental and demographic factors also plays a major role as this can inform about the interaction between hosts and pathogens, and patterns of spread in space and time.Geospatial Technology and Infectious Disease SurveillanceThe GIS provides dynamic maps to understand geographical distribution of diseases for analysis on frequency of cases, disease mapping, spatial cluster of diseases, disease association with environmental factors, network analysis, etc. With such a visualization and analytical capabilities, GIS technology is holding a widespread growth in public health (Ahmad et al. 2011a, b; Booman et al. 2000; Hanafi-Bojd et al. 2012; Kolivras 2006; Martin et al. 2002; Nykiforuk and Flaman 2011; Abdul Rasam et al. 2011; Zhang et al. 2008; Zhen et al. 2010).", [["Infectious Disease", "DISEASE", 222, 240], ["environmental factors", "PROTEIN", 442, 463], ["pathogens", "PROBLEM", 144, 153], ["diseases", "PROBLEM", 326, 334], ["disease mapping", "TEST", 371, 386], ["diseases", "PROBLEM", 407, 415], ["disease association", "PROBLEM", 417, 436], ["network analysis", "TEST", 465, 481], ["a visualization", "TEST", 498, 513], ["Infectious", "OBSERVATION", 222, 232], ["diseases", "OBSERVATION", 326, 334], ["diseases", "OBSERVATION", 407, 415], ["widespread", "OBSERVATION_MODIFIER", 571, 581], ["growth", "OBSERVATION_MODIFIER", 582, 588]]], ["The seamless integration of GIS with real-time infectious disease-related diverse datasets through web-based mapping leads to the development of geospatial dashboard, geospatial service framework, for infectious disease surveillance (Dent 2006; Gao et al. 2008; Yun 2007).", [["infectious disease", "DISEASE", 201, 219]]], ["The infectious disease-related data might include disease surveillance data (active/confirmed cases) and health system data (hospital visits, emergency services availability, nurse/doctor availability, ICU/bed availability).", [["disease surveillance data", "TEST", 50, 75], ["infectious", "OBSERVATION", 4, 14]]], ["Also, many other popular industrial geospatial standards are developed by ESRI, Google, Yahoo, and MapInfo (Granell et al. 2014) to fetch location-based data and provide infectious disease surveillance dashboard to monitor and control the geographically spread of disease (Zhang et al. 2007).", [["disease", "PROBLEM", 264, 271], ["geographically", "OBSERVATION_MODIFIER", 239, 253], ["spread", "OBSERVATION_MODIFIER", 254, 260]]], ["The Geocoded Really Simple Syndication (GeoRSS) tagged XML files from GeoRSS services can also be used to provide geocoded infectious disease news from social media platform (Tolentino et al. 2007; Kass-Hout and Alhinnawi 2013a, b; Kodong et al. 2020).Historical ContextThe mapping of infectious diseases using geospatial and information technology to benefit public health is not a new way of tracking the diseases (Ahmad et al. 2017; Cui et al. 2011; Hirsch 1883; Hornsby 2000; Matthew et al. 2004; May 1951; Mujica 2013; Nicholson and Mather 1996; Noble et al. 2012; Perl and Moalem 2006; Williams et al. 1986).", [["infectious disease", "DISEASE", 123, 141], ["infectious diseases", "DISEASE", 285, 304], ["infectious diseases", "PROBLEM", 285, 304], ["the diseases", "PROBLEM", 403, 415], ["infectious", "OBSERVATION", 285, 295]]], ["The historical disease mapping has faced many challenges\u2014(1) authors rarely documented the evidence that were used to create map, (2) after mapping had been implemented before the beginning of geographical information systems, many errors arouse which were expanded extremely at global scales, and (3) there were no fidelity assessment of maps which resulted in inaccurate precision.", [["The historical disease mapping", "PROBLEM", 0, 30], ["mapping", "TEST", 140, 147], ["fidelity assessment of maps", "TEST", 316, 343], ["historical disease", "OBSERVATION", 4, 22]]], ["But nowadays, wide range of geospatial applications are available in public health community with a possibilities of visualization, analysis, detection of clusters formed and calculate disease-related metrics such as incidence and prevalence rate (Beck et al. 2000; Clarke et al. 1996; Hay 2000; Jacquez 2000; Kleinschmidt et al. 2000; Lawson and Leimich 2000; Moore and Carpenter 1999; Robinson 2000; Wilkinson et al. 1998).Historical ContextThe earliest mapping for visualisation of the link between disease and place was done in 1694 on plague epidemic in Italy (Dent 2006).", [["visualization", "TEST", 117, 130], ["analysis", "TEST", 132, 140], ["clusters formed and calculate disease", "PROBLEM", 155, 192], ["prevalence rate", "TEST", 231, 246], ["disease", "OBSERVATION", 502, 509]]], ["During cholera outbreak in 1854, the study of physician John Snow had made a novel contribution in history of public health and epidemiology by using cartography applications and geographic visualization in fighting cholera.", [["cholera", "DISEASE", 7, 14], ["cholera", "DISEASE", 216, 223], ["cartography applications", "TEST", 150, 174], ["geographic visualization", "TEST", 179, 203]]], ["After 225 years, the maps were identified as a communication tool in understanding and tracking of infectious diseases, such as the 1918 influenza pandemic, yellow fever, and cholera.", [["infectious diseases", "DISEASE", 99, 118], ["influenza pandemic", "DISEASE", 137, 155], ["yellow fever", "DISEASE", 157, 169], ["cholera", "DISEASE", 175, 182], ["the maps", "TEST", 17, 25], ["infectious diseases", "PROBLEM", 99, 118], ["yellow fever", "PROBLEM", 157, 169], ["cholera", "PROBLEM", 175, 182], ["infectious", "OBSERVATION", 99, 109]]], ["The trend of infectious disease mapping could be seen from 2014 review of the Health GIS literature which demonstrated that 248 research papers out of 865 were focused on infectious disease mapping (Lyseen et al. 2014).Covid-19The ongoing pandemic outbreak targeting humans\u2019 respiratory system was recently discovered in December 2019 by the name of Coronavirus Disease 19 (Covid-19) (World Health Organization) from a cluster of patients with acute respiratory distress syndrome in Wuhan, Hubei Province, China (Huang et al. 2020; Lu et al. 2020a, b) and spread globally by March 2020.", [["infectious disease", "DISEASE", 171, 189], ["Covid-19", "CHEMICAL", 219, 227], ["Coronavirus Disease", "DISEASE", 350, 369], ["acute respiratory distress syndrome", "DISEASE", 444, 479], ["Covid-19", "CHEMICAL", 219, 227], ["humans", "ORGANISM", 267, 273], ["patients", "ORGANISM", 430, 438], ["humans", "SPECIES", 267, 273], ["patients", "SPECIES", 430, 438], ["humans", "SPECIES", 267, 273], ["Coronavirus Disease 19 (Covid-19", "SPECIES", 350, 382], ["infectious disease mapping", "TEST", 13, 39], ["infectious disease mapping", "TREATMENT", 171, 197], ["Covid", "TEST", 219, 224], ["Coronavirus Disease", "PROBLEM", 350, 369], ["Covid", "TEST", 374, 379], ["acute respiratory distress syndrome", "PROBLEM", 444, 479], ["trend", "OBSERVATION_MODIFIER", 4, 9], ["infectious", "OBSERVATION", 13, 23], ["pandemic", "OBSERVATION_MODIFIER", 239, 247], ["Coronavirus Disease", "OBSERVATION", 350, 369], ["acute", "OBSERVATION_MODIFIER", 444, 449], ["respiratory", "ANATOMY", 450, 461], ["distress syndrome", "OBSERVATION", 462, 479]]], ["This pathogenic disease is structurally related to the Coronavirus (CoV), which belongs to family Coronaviridae and the order Nidovirales.", [["Coronavirus", "GENE_OR_GENE_PRODUCT", 55, 66], ["CoV", "ORGANISM", 68, 71], ["CoV", "SPECIES", 68, 71], ["This pathogenic disease", "PROBLEM", 0, 23], ["the Coronavirus (CoV)", "PROBLEM", 51, 72], ["Coronaviridae", "TREATMENT", 98, 111], ["Nidovirales", "TREATMENT", 126, 137]]], ["This family is classified into four genera\u2014Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus, on the basis of their phylogenetic and genomic analysis.", [["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 43, 59], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 61, 76], ["Alphacoronavirus", "SPECIES", 43, 59], ["Alphacoronavirus", "TEST", 43, 59], ["Betacoronavirus", "TREATMENT", 61, 76], ["Gammacoronavirus", "TREATMENT", 78, 94], ["Deltacoronavirus", "TREATMENT", 100, 116], ["genomic analysis", "TEST", 157, 173]]], ["The species of Alphacoronavirus and Betacoronavirus infect mammals, causes respiratory illness in humans and gastroenteritis in animals, while species of Gammacoronaviruses and Deltacoronaviruses infect birds, but some of them can also infect mammals (Woo et al. 2012).", [["respiratory", "ANATOMY", 75, 86], ["Alphacoronavirus", "CHEMICAL", 15, 31], ["respiratory illness", "DISEASE", 75, 94], ["gastroenteritis", "DISEASE", 109, 124], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 15, 31], ["Betacoronavirus", "ORGANISM", 36, 51], ["humans", "ORGANISM", 98, 104], ["Gammacoronaviruses", "GENE_OR_GENE_PRODUCT", 154, 172], ["Deltacoronaviruses", "GENE_OR_GENE_PRODUCT", 177, 195], ["birds", "ORGANISM", 203, 208], ["humans", "SPECIES", 98, 104], ["humans", "SPECIES", 98, 104], ["Alphacoronavirus", "PROBLEM", 15, 31], ["Betacoronavirus infect mammals", "PROBLEM", 36, 66], ["respiratory illness in humans", "PROBLEM", 75, 104], ["gastroenteritis", "PROBLEM", 109, 124], ["Gammacoronaviruses", "TREATMENT", 154, 172], ["Deltacoronaviruses infect birds", "PROBLEM", 177, 208], ["respiratory illness", "OBSERVATION", 75, 94], ["gastroenteritis", "OBSERVATION", 109, 124]]], ["The two virus species from Betacoronavirus genus\u2014Severe Acute Respiratory Syndrome (SARS-CoV) or Middle East Respiratory Syndrome (MERS-CoV)\u2014had earlier demonstrated that coronaviruses can cause significant public threat (Ge et al. 2013).", [["Acute Respiratory Syndrome (SARS-CoV) or Middle East Respiratory Syndrome", "DISEASE", 56, 129], ["coronaviruses", "DISEASE", 171, 184], ["Betacoronavirus genus", "ORGANISM", 27, 48], ["coronaviruses", "ORGANISM", 171, 184], ["Severe Acute Respiratory Syndrome (SARS-CoV", "SPECIES", 49, 92], ["Middle East Respiratory Syndrome (MERS-CoV", "SPECIES", 97, 139], ["The two virus species", "PROBLEM", 0, 21], ["Severe Acute Respiratory Syndrome", "PROBLEM", 49, 82], ["SARS-CoV)", "PROBLEM", 84, 93], ["Middle East Respiratory Syndrome", "PROBLEM", 97, 129], ["coronaviruses", "PROBLEM", 171, 184], ["virus species", "OBSERVATION", 8, 21], ["Acute", "OBSERVATION_MODIFIER", 56, 61], ["Respiratory Syndrome", "OBSERVATION", 62, 82], ["Middle", "ANATOMY_MODIFIER", 97, 103], ["Respiratory Syndrome", "OBSERVATION", 109, 129]]], ["The COVID-19 is categorized into Betacoronavirus by World Health Organization (WHO) on the basis of genomic sequencing analysis of lower respiratory tract samples, which is obtained from total of nine patients (Huang et al. 2020; Lu et al. 2020a, b).", [["lower respiratory tract samples", "ANATOMY", 131, 162], ["lower respiratory tract samples", "CANCER", 131, 162], ["patients", "ORGANISM", 201, 209], ["COVID-19", "DNA", 4, 12], ["patients", "SPECIES", 201, 209], ["The COVID", "TEST", 0, 9], ["genomic sequencing analysis", "TEST", 100, 127], ["lower respiratory tract samples", "PROBLEM", 131, 162], ["lower", "ANATOMY_MODIFIER", 131, 136], ["respiratory tract", "ANATOMY", 137, 154]]], ["COVID-19 has started behaving like the once-in-a-century pandemic by affecting healthy adults as well as elderly people with some health issues and by infecting others at an exponential rate of increase than SARS or MERS.Geospatial TechnologyDuring occurrence of diseases, geospatial technologies and services could help in representing the spatio-temporal information and in analysing the dynamic spread of diseases.", [["COVID-19", "CHEMICAL", 0, 8], ["SARS", "DISEASE", 208, 212], ["people", "ORGANISM", 113, 119], ["people", "SPECIES", 113, 119], ["diseases", "PROBLEM", 263, 271], ["diseases", "PROBLEM", 408, 416], ["diseases", "OBSERVATION", 263, 271]]], ["In this section, a review on many geospatial technologies with enabled IT services is carried out to understand and analyse the spread and outbreak of disease with a case study on COVID-19 pandemic.Crowdsource/VGI Mobile Apps ::: Citizen ScienceDespite technological and computational developments in GeoWeb, many web technologies (such as jQuery and AJAX), mapping APIs (like Google), and GPS devices resulted in a new revolution of neogeography (Turner 2006), where mapping is done by crowd and can be reached by anyone from general public members group.", [["a case study", "TEST", 164, 176], ["COVID", "TEST", 180, 185], ["GPS devices", "TREATMENT", 390, 401], ["new", "OBSERVATION_MODIFIER", 416, 419]]], ["According to Goodchild (2007b), VGI highlighted the human capabilities in collecting geospatial information by using five senses and then integrating with external sensors of mobile devices like GPS, accelerometer, camera, digital compass and microphone gives valuable datasets which can neither be retrieved from satellite imagery nor collected with any GPS receivers.", [["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["external sensors of mobile devices", "TREATMENT", 155, 189]]], ["Another successful term in geospatial mapping using mobile technology is crowdsourcing (Heipke 2010; Hudson-Smith et al. 2009), which was coined by Howe (2006), that involves the collection of geospatial information or mapping of any particular activity by an undefined crowd or network of people.", [["people", "ORGANISM", 290, 296], ["people", "SPECIES", 290, 296], ["geospatial mapping", "TEST", 27, 45]]], ["Over the last decade, VGI-oriented open-source mobile apps are EpiCollect (Aanensen et al. 2009) for ecology and epidemiology; NoiseTube (Maisonneuve et al. 2010) (http://noisetube.net) and Noise Battle (Garcia-Mart\u00ed et al. 2013) for noise monitoring; Skywatch Windoo (http://windoo.ch) for weather monitoring; Mappiness (http://www.mappiness.org.uk) for behavioural analysis (MacKerron and Mourato 2010).Crowdsource/VGI Mobile Apps ::: Citizen ScienceThe open-source mechanism for data collection using Android devices can be performed by Open Data Kit (ODK) suite107 (https://opendatakit.org), which is composed of ODK Collect and ODK Aggregate.", [["ODK", "PROTEIN", 617, 620], ["ODK", "PROTEIN", 633, 636], ["noise monitoring", "TEST", 234, 250], ["weather monitoring", "TEST", 291, 309], ["behavioural analysis", "TEST", 355, 375], ["Android devices", "TREATMENT", 504, 519]]], ["ODK Collect (https://opendatakit.org/use/collect) provides a customizable framework for geospatial data collection, and ODK Aggregate is a web application that runs on Apache Tomcat server (http://tomcat.apache.org) to store collected data through a synchronization with a database, for example, PostgreSQL (Brunette et al. 2013).", [["geospatial data collection", "TEST", 88, 114]]], ["As such, suite\u2019s performance can be seen in various activities like agricultural monitoring (Krosing and Roybal 2013), monitoring of deforestation and school attendance, documentation of war crimes, and health programs (Anokwa et al. 2009).Digital Contact Tracing ::: Citizen ScienceNowadays, COVID-19 has become the greatest threat for public health in last 100 years, and due to such pandemic, various levels of lockdown are issued across the world to break its chain of infection transmission.", [["COVID-19", "CHEMICAL", 293, 301], ["infection", "DISEASE", 473, 482], ["agricultural monitoring", "TEST", 68, 91], ["infection transmission", "PROBLEM", 473, 495], ["infection", "OBSERVATION", 473, 482]]], ["Therefore, to combat with such a global pandemic threat, another approach is discovered by a group of researchers, known as digital contact tracing.Digital Contact Tracing ::: Citizen ScienceSmartphone-based contact tracing is known as a digital contact tracing which presents a sustainable solution to limit the transmission of infectious disease by tracing their potential transmission routes in a population; however, such an app presents significant concerns regarding privacy.", [["infectious disease", "DISEASE", 329, 347], ["digital contact tracing", "TEST", 124, 147], ["a digital contact tracing", "TEST", 236, 261], ["a sustainable solution", "TREATMENT", 277, 299], ["infectious disease", "PROBLEM", 329, 347], ["infectious", "OBSERVATION", 329, 339]]], ["The digital contact tracing works on the principle of \u2018crowdsource data\u2019 by measuring the proximity to an infectious person.", [["person", "SPECIES", 117, 123], ["The digital contact tracing", "TEST", 0, 27], ["infectious", "OBSERVATION", 106, 116]]], ["In previous diseases risk surveillance, the contact tracing apps were used to pool location timestamped data to determine the exposures to risk of infections (Sacks et al. 2015).", [["infections", "DISEASE", 147, 157], ["the contact tracing apps", "TEST", 40, 64], ["infections", "PROBLEM", 147, 157], ["infections", "OBSERVATION", 147, 157]]], ["Therefore, various smartphone apps are developed in COVID-19 pandemic in which some apps use location for proximity and some of them are not using location services of mobile device subject to the privacy-preserving nature.COVID-19 Contact Tracing ::: Citizen ScienceIn order to illuminate the epidemiology of COVID-19 and to characterize its severity (Lipsitch et al. 2020), there is an urgent need of digital platform that captures real-time accurate information on COVID-19 patients, diseases, diagnosis, treatment, and clinical reports, and whom they get interacted at which place to detect clusters and generate alerts.", [["COVID-19", "CELL", 310, 318], ["patients", "ORGANISM", 477, 485], ["patients", "SPECIES", 477, 485], ["mobile device", "TREATMENT", 168, 181], ["COVID", "TEST", 310, 315], ["digital platform", "TEST", 403, 419], ["diseases", "PROBLEM", 487, 495], ["treatment", "TREATMENT", 508, 517]]], ["Such information may help in understanding risk factors of infection and in predicting the next generation of infectious persons (FitzGerald 2020).", [["infection", "DISEASE", 59, 68], ["persons", "ORGANISM", 121, 128], ["persons", "SPECIES", 121, 128], ["infection", "PROBLEM", 59, 68], ["infection", "OBSERVATION", 59, 68]]], ["Addressing this unprecedented challenge, many mobile apps have been developed and are being used at large scale, and some of them are as follows:COVID Symptom Study (COVID Symptom Tracker)\u2014This mobile app is developed in collaboration of Zoe Global Ltd., a digital health care company, and a group of academic scientists from Massachusetts General Hospital and King\u2019s College London, which was launched in UK on March 24, 2020, and became available after 5 days in USA.", [["Symptom Study", "TEST", 151, 164]]], ["This app enquires about age, location, and other diseases risks, and also, a self-reporting function is enabled which is associated with COVID-19 infection and exposure (Drew et al. 2020).", [["infection", "DISEASE", 146, 155], ["COVID-19 infection", "PROBLEM", 137, 155], ["infection", "OBSERVATION", 146, 155]]], ["This app retrieve updates on healthcare worker\u2019s experiences who are on COVID-19 duty, their stress and anxiety, and use of personal protective equipment (PPE) kits are being surveyed through this app to observe intensity of health care workers (Drew et al. 2020).Aarogya Setu\u2014This mobile app is launched on April 2, 2020, by Government of India to aware general public on COVID-19 symptoms, government advisory measures, online consultation facility, and dynamics of disease.", [["anxiety", "DISEASE", 104, 111], ["anxiety", "PROBLEM", 104, 111], ["personal protective equipment (PPE) kits", "TREATMENT", 124, 164], ["COVID", "TEST", 373, 378], ["symptoms", "PROBLEM", 382, 390], ["disease", "PROBLEM", 468, 475], ["disease", "OBSERVATION", 468, 475]]], ["This app implemented crowdsourcing approach by which general public members enter their details for self-assessment, and this assessment is then used to trace the infectious contacts or agents as a digital contact tracing concept.", [["self-assessment", "TEST", 100, 115], ["this assessment", "TEST", 121, 136], ["infectious", "OBSERVATION", 163, 173]]], ["This app uses location services to geolocate the users and Bluetooth to maintain the log of contacts when one user/device comes in contact with another user/device, and as such, digital contact tracing activity helps in identifying the cluster of diseases and communities which are at risk of infection.", [["infection", "DISEASE", 293, 302], ["diseases", "PROBLEM", 247, 255], ["infection", "PROBLEM", 293, 302], ["infection", "OBSERVATION", 293, 302]]], ["13,000 positive cases, informed 130,000 probable users of being at risk, and identified 300 potential clusters (The Times of India).COVID-19 Contact Tracing ::: Citizen ScienceNumerous digital contact tracing apps are in use in different parts of world\u2014TrackCOVID (Yasaka et al. 2020), TraceTogether (Bay et al. 2020), WeTrace (De Carli et al. 2020), and Google and Apple\u2019s recently announced joint initiative (Li and Guo 2020).COVID-19 Data Visualization and Exploratory Data Analysis ::: Citizen ScienceWith early experiences of epidemics such as 2002\u20132003 SARS-CoV (Boulos 2004) and the 2012\u20132014 MERS-CoV (Gikonyo et al. 2018), and other seasonal flu\u2019s, online real-time or near-real-time mapping of diseases\u2019 occurrences using geospatial technologies and web applications have always been used as a pivotal web-based tools in tracking health threats and combating infectious diseases.", [["SARS", "DISEASE", 559, 563], ["infectious diseases", "DISEASE", 869, 888], ["SARS-CoV", "SPECIES", 559, 567], ["2012\u20132014 MERS-CoV", "SPECIES", 590, 608], ["COVID", "TEST", 428, 433], ["Exploratory Data Analysis", "TEST", 460, 485], ["epidemics", "PROBLEM", 531, 540], ["diseases", "PROBLEM", 704, 712], ["geospatial technologies", "TREATMENT", 732, 755], ["web applications", "TREATMENT", 760, 776], ["infectious diseases", "PROBLEM", 869, 888], ["joint", "ANATOMY", 393, 398]]], ["This section described a range of mapping dashboards based on geospatial technologies for tracking and unfolding the coronavirus disease around the world.", [["coronavirus disease", "DISEASE", 117, 136], ["coronavirus", "ORGANISM", 117, 128], ["geospatial technologies", "TEST", 62, 85], ["unfolding the coronavirus disease", "PROBLEM", 103, 136], ["coronavirus disease", "OBSERVATION", 117, 136]]], ["Some of the global and national geospatial initiatives with an aim to supply information faster than diseases are as summarized in Table 1.Clustering ::: Infectious Diseases ModellingClustering deals with the study of spatial-temporal patterns of the spread of communicable diseases and identification of other disease-related aspects allied with heterogeneous geographical distribution which might be helpful in elucidating the diseases\u2019 spread mechanism.", [["Infectious Diseases", "DISEASE", 154, 173], ["communicable diseases", "DISEASE", 261, 282], ["the study", "TEST", 205, 214], ["communicable diseases", "PROBLEM", 261, 282], ["other disease", "PROBLEM", 305, 318], ["the diseases", "PROBLEM", 425, 437], ["global", "OBSERVATION_MODIFIER", 12, 18], ["temporal", "OBSERVATION_MODIFIER", 226, 234], ["spread", "OBSERVATION_MODIFIER", 251, 257], ["communicable diseases", "OBSERVATION", 261, 282], ["heterogeneous", "OBSERVATION_MODIFIER", 347, 360], ["diseases", "OBSERVATION", 429, 437]]], ["Such study and analysis on space-time patterns is a kind of disease surveillance which involves detecting the outbreak clusters of active cases, monitoring of localisation and isolation of infectious agents, and relative risks assessment of affected sites at early stage (Clements et al. 2013; Cromley 2019; Kulldorff 2001).", [["sites", "ANATOMY", 250, 255], ["Such study", "TEST", 0, 10], ["analysis on space", "TEST", 15, 32], ["disease surveillance", "TEST", 60, 80], ["infectious agents", "TREATMENT", 189, 206], ["relative risks assessment", "TEST", 212, 237], ["affected sites", "PROBLEM", 241, 255], ["Cromley", "TEST", 294, 301], ["Kulldorff", "TEST", 308, 317], ["active", "OBSERVATION_MODIFIER", 131, 137], ["infectious", "OBSERVATION", 189, 199]]], ["This study on geographical clustering of infectious diseases with temporal features helps in making strategies that dynamically update on emergence source of disease outbreak to help epidemiologists and decision makers for identification of spread and risk zones.", [["infectious diseases", "DISEASE", 41, 60], ["This study", "TEST", 0, 10], ["infectious diseases", "PROBLEM", 41, 60], ["temporal features", "PROBLEM", 66, 83], ["disease outbreak", "PROBLEM", 158, 174], ["spread and risk zones", "PROBLEM", 241, 262], ["infectious", "OBSERVATION", 41, 51]]], ["Thus, clustering helps to enable timely prevention and containment measures and timely resource allocation to mitigate the diffusion of diseases.Clustering ::: Infectious Diseases ModellingBased on space-time surveillance of diseases, space-time scan statistic (Kulldorff 1997) is one of the cluster detection tools which is widely used in geographical surveillance of diseases during epidemic and/or pandemic.", [["Infectious Diseases", "DISEASE", 160, 179], ["containment measures", "TREATMENT", 55, 75], ["the diffusion of diseases", "PROBLEM", 119, 144], ["diseases", "PROBLEM", 225, 233], ["space-time scan statistic", "TEST", 235, 260], ["diseases", "PROBLEM", 369, 377], ["pandemic", "PROBLEM", 401, 409], ["diseases", "OBSERVATION", 136, 144], ["Infectious", "OBSERVATION", 160, 170], ["diseases", "OBSERVATION", 225, 233], ["diseases", "OBSERVATION", 369, 377]]], ["The space-time scan statistic comes with two versions\u2014prospective and retrospective (Desjardins et al. 2018; Owusu et al. 2019), and difference between both is that prospective neglects historical clusters which may have previously occurred before the most current time period of analysis with no health threat (Kulldorff 2001).", [["The space-time scan statistic", "TEST", 0, 29], ["prospective neglects historical clusters", "PROBLEM", 165, 205]]], ["Therefore, the prospective version of space-time scan statistic is commonly used to detect statistically significant active or evolving clusters of diseases for the present time period, and when more data become available, the tool can be re-run to detect new evolving clusters with update on relative risks for each affected sites.", [["space-time scan statistic", "TEST", 38, 63], ["diseases", "PROBLEM", 148, 156], ["each affected sites", "PROBLEM", 312, 331], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["active", "OBSERVATION_MODIFIER", 117, 123]]], ["Previously, the prospective space-time scan statistic was used in thyroid cancer (Kulldorff 2001), shigellosis (Jones et al. 2006), measles (Yin et al. 2007), syndromic surveillance (Yih et al. 2010), and many other diseases.", [["thyroid cancer", "ANATOMY", 66, 80], ["thyroid cancer", "DISEASE", 66, 80], ["shigellosis", "DISEASE", 99, 110], ["measles", "DISEASE", 132, 139], ["thyroid cancer", "CANCER", 66, 80], ["the prospective space-time scan statistic", "TEST", 12, 53], ["thyroid cancer", "PROBLEM", 66, 80], ["shigellosis", "PROBLEM", 99, 110], ["syndromic surveillance", "TEST", 159, 181], ["many other diseases", "PROBLEM", 205, 224], ["thyroid", "ANATOMY", 66, 73], ["cancer", "OBSERVATION", 74, 80], ["diseases", "OBSERVATION", 216, 224]]], ["However, cluster analysis of diseases can be performed through several packages and libraries in R (G\u00f3mez-Rubio et al. 2005) and Python software (Yeng et al. 2019).Clustering ::: Infectious Diseases ModellingThe contribution of cluster detections and analysis in COVID-19 pandemic is becoming useful nowadays as it detects active and emerging clusters of COVID-19 and notify epidemiologist, decision makers, and public health care officials, which can help in eradicating infections from affected sites, and improving interventions, quarantine, and isolation measures.", [["Infectious Diseases", "DISEASE", 179, 198], ["infections", "DISEASE", 472, 482], ["COVID-19", "SPECIES", 263, 271], ["diseases", "PROBLEM", 29, 37], ["cluster detections", "TEST", 228, 246], ["analysis", "TEST", 251, 259], ["COVID", "TEST", 263, 268], ["COVID", "TEST", 355, 360], ["eradicating infections from affected sites", "PROBLEM", 460, 502], ["quarantine", "TREATMENT", 533, 543], ["isolation measures", "TREATMENT", 549, 567], ["diseases", "OBSERVATION", 29, 37], ["Infectious", "OBSERVATION", 179, 189], ["active", "OBSERVATION_MODIFIER", 323, 329]]], ["The significant applications of clustering with respect to infectious diseases modelling are demonstrated across the world (Zarikas et al. 2020), for example, India (Bhosale and Shinde 2020), USA (Desjardins et al. 2020; Hohl et al. 2020), Brazil (Martines et al. 2020), Italy (Cereda et al. 2020), China (Ji et al. 2020; Liu et al. 2020a, b; Qiu et al. 2020; Zhang et al. 2020), Singapore (Bhosale and Shinde 2020; Pung et al. 2020), South Korea (Shim et al. 2020), French Alps (Danis et al. 2020), Germany (Pfefferle et al. 2020), Sergipe (Andrade et al. 2020), etc.Outlier Analysis ::: Infectious Diseases ModellingThe outlier is defined by Hawkins (1980) as \u201can observation which deviates so much from the other observations as to arouse suspicions that it was generated by a different mechanism.\u201d", [["infectious diseases", "DISEASE", 59, 78], ["Infectious Diseases", "DISEASE", 589, 608], ["infectious diseases modelling", "PROBLEM", 59, 88], ["USA (Desjardins et al.", "TREATMENT", 192, 214], ["Brazil (Martines et", "TREATMENT", 240, 259], ["an observation", "TEST", 663, 677], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["infectious", "OBSERVATION_MODIFIER", 59, 69]]], ["In other words, when data generation process starts behaving abnormal and reflects the abnormalities or errors in data, such abnormalities are known as outliers (Bansal et al. 2016).", [["behaving abnormal", "PROBLEM", 52, 69], ["the abnormalities", "PROBLEM", 83, 100], ["errors in data", "PROBLEM", 104, 118], ["such abnormalities", "PROBLEM", 120, 138]]], ["Some of the useful applications of outliers in diseases are (Cleynen et al. 2016; Dai and Bikdash 2016; Krishnan et al. 2017; Lo et al. 2015; Prensner et al. 2011; Washington 2007; Wu and Krishnan 2010).", [["outliers in diseases", "PROBLEM", 35, 55]]], ["Clustering algorithms are optimized to find clusters rather than outliers, and the accuracy of outlier detection depends on how good the clustering algorithm captures the structure of clusters.Maximum Entropy Modelling (Maxent) Approach ::: Infectious Diseases ModellingIn context of disease systems, disease transmission risks depend on distribution of pathogens (species) in space and time in some complex environmental conditions (Townsend 2015), and as such treatments are focused mainly on spatial dimensions; therefore, diseases transmission risks are purely handled through geographical phenomena.", [["Infectious Diseases", "DISEASE", 241, 260], ["Clustering algorithms", "TEST", 0, 21], ["outlier detection", "TEST", 95, 112], ["disease systems", "PROBLEM", 284, 299], ["disease transmission risks", "PROBLEM", 301, 327], ["pathogens", "PROBLEM", 354, 363], ["such treatments", "TREATMENT", 457, 472], ["diseases transmission risks", "PROBLEM", 526, 553], ["disease", "OBSERVATION", 284, 291], ["pathogens", "OBSERVATION", 354, 363]]], ["Such geographical link with diseases leads to the challenge of spatial mapping of disease transmission which overcame through the branches of biodiversity science\u2014ecology and biogeography.", [["diseases", "PROBLEM", 28, 36], ["disease transmission", "PROBLEM", 82, 102], ["diseases", "OBSERVATION", 28, 36], ["disease", "OBSERVATION", 82, 89], ["branches", "ANATOMY_MODIFIER", 130, 138], ["biodiversity", "OBSERVATION_MODIFIER", 142, 154]]], ["Such approach of ecological and biogeographical modelling can be seen from various studies on disease transmission risks mapping, for example, Arboleda et al. (2009), Deka and Morshed (2018), Ferreira et al. (2020), Holt et al. (2009), Mweya et al. (2013), Nakazawa et al. (2013), Reeves et al. (2015), Samy et al. (2014), Qian et al. (2014), Zhao et al. (2016), Zhu et al. (2017).Maximum Entropy Modelling (Maxent) Approach ::: Infectious Diseases ModellingFollowing recent studies on geographical mapping of pathogens causing disease transmission, machine learning-based maximum entropy method (Maxent) (Elith et al. 2011; Phillips 2010) is applied on spatial records of COVID-19 with a set of 19 bioclimatic environmental variables from WorldClim (Poggio et al. 2018; Ram\u00edrez Villegas and Bueno Cabrera 2009) to analyse their favourable environmental conditions (as shown in Fig. 1 and Table 2), required in maintaining its population.", [["Infectious Diseases", "DISEASE", 429, 448], ["risks mapping", "TEST", 115, 128], ["recent studies", "TEST", 468, 482], ["geographical mapping", "TEST", 486, 506], ["pathogens", "PROBLEM", 510, 519], ["disease transmission", "PROBLEM", 528, 548], ["based maximum entropy method", "TREATMENT", 567, 595], ["COVID", "TEST", 673, 678]]], ["The Maxent principle is to estimate the target probability distribution by applying the maximum entropy to distribution which is most spread or closest.", [["Maxent", "OBSERVATION", 4, 10], ["maximum", "OBSERVATION_MODIFIER", 88, 95], ["entropy", "OBSERVATION", 96, 103]]], ["This study is carried out in R software (Ihaka and Gentleman 1996), and a geographical dataset consists of latitude and longitude of those regions which were affected till March, 2020.Maximum Entropy Modelling (Maxent) Approach ::: Infectious Diseases ModellingFigure 1 depicts the habitat suitability map of virus with probability range in colour scale to visualize the high suitability (light and dark green colour), medium suitability (yellow and dark brown), low suitability (light brown colour) and unsuitable (grey colour).", [["Infectious Diseases", "DISEASE", 232, 251], ["This study", "TEST", 0, 10], ["a geographical dataset", "TEST", 72, 94], ["virus", "PROBLEM", 309, 314], ["colour scale", "TEST", 341, 353], ["the high suitability (light and dark green colour", "PROBLEM", 367, 416], ["medium suitability (yellow and dark brown", "PROBLEM", 419, 460], ["low suitability (light brown colour", "PROBLEM", 463, 498], ["grey colour", "TEST", 516, 527], ["latitude", "OBSERVATION_MODIFIER", 107, 115], ["longitude", "OBSERVATION_MODIFIER", 120, 129], ["high suitability", "OBSERVATION_MODIFIER", 371, 387], ["low suitability", "OBSERVATION_MODIFIER", 463, 478]]], ["Table 2 lists the favourable bioclimatic variables and their contribution in percent in maintaining the suitability of virus.Susceptible-Infectious-Recovered (SIR) Model ::: Infectious Diseases ModellingEpidemiology deals with the study of pattern and occurrence of diseases in space and time associated with other factors such as environment demography, and the translation of epidemiology into mathematical equations to describe the spread of infectious diseases is known as mathematical epidemiology (Allen et al. 2008; Rayner and Bender 1980).", [["Infectious Diseases", "DISEASE", 174, 193], ["infectious diseases", "DISEASE", 445, 464], ["virus", "PROBLEM", 119, 124], ["the study", "TEST", 227, 236], ["diseases in space", "PROBLEM", 266, 283], ["infectious diseases", "PROBLEM", 445, 464], ["Infectious", "OBSERVATION", 137, 147], ["diseases", "OBSERVATION", 266, 274], ["infectious", "OBSERVATION", 445, 455]]], ["The mathematical epidemiology model is implemented to understand the transmission dynamics of communicable diseases by categorizing population into susceptible, infectious, and recovered compartments.", [["communicable diseases", "DISEASE", 94, 115], ["communicable diseases", "PROBLEM", 94, 115], ["infectious", "OBSERVATION", 161, 171]]], ["The first basic model, known as Susceptible-Infectious-Recovered (SIR) model, was proposed by Kermack and McKendrick (1991) to describe the transmission of epidemic diseases from individual to individual.", [["epidemic diseases", "PROBLEM", 156, 173], ["Susceptible", "OBSERVATION_MODIFIER", 32, 43], ["Infectious", "OBSERVATION", 44, 54]]]], "2108a4d24bbdc526870d33ae20c9eed3f826c989": [["Non-enveloped viruses, such as coxsackieviruses, rotavirus, or poliovirus, can survive for extended periods on surfaces (9, 10) , while enveloped viruses, including H1N1 and human coronaviruses, remain infectious on surfaces after several days (6) .", [["H1N1 and human coronaviruses", "DISEASE", 165, 193], ["coxsackieviruses", "GENE_OR_GENE_PRODUCT", 31, 47], ["rotavirus", "ORGANISM", 49, 58], ["human", "ORGANISM", 174, 179], ["coronaviruses", "ORGANISM", 180, 193], ["H1N1 and", "SPECIES", 165, 173], ["human", "SPECIES", 174, 179], ["coronaviruses", "SPECIES", 180, 193], ["poliovirus", "SPECIES", 63, 73], ["human coronaviruses", "SPECIES", 174, 193], ["Non-enveloped viruses", "PROBLEM", 0, 21], ["coxsackieviruses", "PROBLEM", 31, 47], ["rotavirus", "PROBLEM", 49, 58], ["poliovirus", "PROBLEM", 63, 73], ["H1N1", "PROBLEM", 165, 169], ["human coronaviruses", "PROBLEM", 174, 193], ["viruses", "OBSERVATION", 14, 21], ["viruses", "OBSERVATION", 146, 153], ["infectious", "OBSERVATION", 202, 212]]], ["The persistence of dried viruses is affected by various environmental conditions and factors such as heat, moisture, pH, and the type of surface (12, 15) .", [["surface", "ANATOMY", 137, 144], ["surface", "CELLULAR_COMPONENT", 137, 144], ["dried viruses", "PROBLEM", 19, 32], ["persistence", "OBSERVATION_MODIFIER", 4, 15], ["dried viruses", "OBSERVATION", 19, 32], ["surface", "OBSERVATION_MODIFIER", 137, 144]]], ["Furthermore, the compositions of media may also influence the persistence of viruses.", [["the compositions of media", "TREATMENT", 13, 38], ["viruses", "PROBLEM", 77, 84], ["viruses", "OBSERVATION", 77, 84]]], ["The impact of drying on viral persistence has been evaluated in previous studies using viruses typically prepared in standardized media, including a cell culture medium supplemented or not with fetal calf serum (FCS) (4, 19) .", [["cell", "ANATOMY", 149, 153], ["fetal calf serum", "ANATOMY", 194, 210], ["cell", "CELL", 149, 153], ["fetal calf serum", "ORGANISM_SUBSTANCE", 194, 210], ["FCS", "ORGANISM_SUBSTANCE", 212, 215], ["calf", "SPECIES", 200, 204], ["viral persistence", "PROBLEM", 24, 41], ["previous studies", "TEST", 64, 80], ["viruses", "TREATMENT", 87, 94], ["a cell culture", "TEST", 147, 161], ["fetal calf serum (FCS", "TEST", 194, 215], ["drying", "OBSERVATION_MODIFIER", 14, 20], ["viral persistence", "OBSERVATION_MODIFIER", 24, 41], ["calf", "ANATOMY", 200, 204]]], ["However, these media are not representative of clinical situations because viruses have been detected in protein-rich media, such as serum, and protein-poor media, including water (11, 17) .", [["serum", "ANATOMY", 133, 138], ["serum", "ORGANISM_SUBSTANCE", 133, 138], ["clinical situations", "PROBLEM", 47, 66], ["viruses", "PROBLEM", 75, 82], ["serum", "TEST", 133, 138], ["protein", "TEST", 144, 151], ["poor media", "OBSERVATION_MODIFIER", 152, 162]]]], "452edb53e3bbabfb88490b02504b9f5e646d2dad": [["Abstract:Chloroquine (CQ) and hydroxychloroquine (HCQ) were among the first drugs repurposed for the treatment of SARS-CoV-2 infection.", [["Chloroquine", "CHEMICAL", 9, 20], ["CQ", "CHEMICAL", 22, 24], ["hydroxychloroquine", "CHEMICAL", 30, 48], ["HCQ", "CHEMICAL", 50, 53], ["SARS-CoV-2 infection", "DISEASE", 114, 134], ["Chloroquine", "CHEMICAL", 9, 20], ["CQ", "CHEMICAL", 22, 24], ["hydroxychloroquine", "CHEMICAL", 30, 48], ["HCQ", "CHEMICAL", 50, 53], ["Chloroquine", "SIMPLE_CHEMICAL", 9, 20], ["CQ", "SIMPLE_CHEMICAL", 22, 24], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 30, 48], ["HCQ", "SIMPLE_CHEMICAL", 50, 53], ["SARS-CoV-2", "ORGANISM", 114, 124], ["SARS-CoV-2", "SPECIES", 114, 124], ["Chloroquine (CQ)", "TREATMENT", 9, 25], ["hydroxychloroquine (HCQ)", "TREATMENT", 30, 54], ["the first drugs", "TREATMENT", 66, 81], ["SARS", "PROBLEM", 114, 118], ["CoV-2 infection", "PROBLEM", 119, 134], ["infection", "OBSERVATION", 125, 134]]], ["A few in vitro studies confirmed that both drugs exhibited dose dependent anti-SARS-CoV-2 activities.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 74, 89], ["vitro studies", "TEST", 9, 22], ["both drugs", "TREATMENT", 38, 48], ["dose dependent anti-SARS", "TREATMENT", 59, 83], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["These observations and the encouraging results from early poorly conducted observational studies created a major hype about the therapeutic potential of these drugs in the treatment of COVID-19 disease.", [["COVID-19", "CANCER", 185, 193], ["observational studies", "TEST", 75, 96], ["these drugs", "TREATMENT", 153, 164], ["COVID-19 disease", "PROBLEM", 185, 201]]], ["This was further catalyzed by media and political influences leading to a widespread use of these agents.", [["these agents", "TREATMENT", 92, 104]]], ["Subsequent randomized trials revealed lack of efficacy of these agents in improving the outcomes of COVID-19 or in preventing infection in post-exposure prophylaxis studies.", [["COVID-19", "CHEMICAL", 100, 108], ["infection", "DISEASE", 126, 135], ["Subsequent randomized trials", "TEST", 0, 28], ["these agents", "TREATMENT", 58, 70], ["COVID", "TEST", 100, 105], ["infection", "PROBLEM", 126, 135], ["post-exposure prophylaxis studies", "TEST", 139, 172], ["infection", "OBSERVATION", 126, 135]]], ["Nevertheless, many ongoing trials continue to actively recruit tens of thousands of patients to receive HCQ worldwide.", [["HCQ", "CHEMICAL", 104, 107], ["HCQ", "CHEMICAL", 104, 107], ["patients", "ORGANISM", 84, 92], ["HCQ", "SIMPLE_CHEMICAL", 104, 107], ["patients", "SPECIES", 84, 92], ["HCQ worldwide", "TREATMENT", 104, 117]]], ["In this perspective, we address the possible mechanisms behind the lack of efficacy and the increased risk of cardiac toxicity of HCQ in COVID-19 disease.", [["cardiac", "ANATOMY", 110, 117], ["cardiac toxicity", "DISEASE", 110, 126], ["HCQ", "CHEMICAL", 130, 133], ["HCQ", "CHEMICAL", 130, 133], ["cardiac", "ORGAN", 110, 117], ["HCQ", "SIMPLE_CHEMICAL", 130, 133], ["COVID-19 disease", "CANCER", 137, 153], ["cardiac toxicity", "PROBLEM", 110, 126], ["HCQ in COVID-19 disease", "PROBLEM", 130, 153], ["cardiac", "ANATOMY", 110, 117], ["toxicity", "OBSERVATION", 118, 126]]], ["For the lack of efficacy, we discuss the fundamental differences of treatment initiation between in vitro and in vivo studies, the pitfalls of the pharmacological calculations of effective blood drug concentrations and related dosing regimens and the possible negative effect of HCQ on the antiviral type-I interferon response.", [["blood", "ANATOMY", 189, 194], ["HCQ", "CHEMICAL", 279, 282], ["HCQ", "CHEMICAL", 279, 282], ["blood", "ORGANISM_SUBSTANCE", 189, 194], ["HCQ", "SIMPLE_CHEMICAL", 279, 282], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 300, 317], ["interferon", "PROTEIN", 307, 317], ["treatment initiation", "TREATMENT", 68, 88], ["the pharmacological calculations", "TREATMENT", 143, 175], ["effective blood drug concentrations", "TREATMENT", 179, 214], ["related dosing regimens", "TREATMENT", 219, 242], ["HCQ", "TREATMENT", 279, 282], ["the antiviral type-I interferon response", "TREATMENT", 286, 326]]], ["Although it has been repeatedly claimed that HCQ has a longstanding safety track record for many decades in use, we present counterarguments for this contention due to disease-drug and drug-drug interactions.", [["HCQ", "CHEMICAL", 45, 48], ["HCQ", "CHEMICAL", 45, 48], ["HCQ", "SIMPLE_CHEMICAL", 45, 48], ["disease", "PROBLEM", 168, 175]]], ["We discuss the molecular mechanisms and the cumulative epidemiological evidence of HCQ cardiac toxicity.Introduction:Because of their long-standing known in vitro antiviral activity, antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) were among the first medications that were repurposed for the treatment of COVID-19 disease.", [["cardiac", "ANATOMY", 87, 94], ["HCQ", "CHEMICAL", 83, 86], ["cardiac toxicity", "DISEASE", 87, 103], ["chloroquine", "CHEMICAL", 197, 208], ["CQ", "CHEMICAL", 210, 212], ["hydroxychloroquine", "CHEMICAL", 218, 236], ["HCQ", "CHEMICAL", 238, 241], ["HCQ", "CHEMICAL", 83, 86], ["chloroquine", "CHEMICAL", 197, 208], ["CQ", "CHEMICAL", 210, 212], ["hydroxychloroquine", "CHEMICAL", 218, 236], ["HCQ", "CHEMICAL", 238, 241], ["HCQ", "SIMPLE_CHEMICAL", 83, 86], ["cardiac", "ORGAN", 87, 94], ["chloroquine", "SIMPLE_CHEMICAL", 197, 208], ["CQ", "SIMPLE_CHEMICAL", 210, 212], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 218, 236], ["HCQ", "SIMPLE_CHEMICAL", 238, 241], ["COVID-19", "CANCER", 318, 326], ["HCQ cardiac toxicity", "PROBLEM", 83, 103], ["vitro antiviral activity", "TREATMENT", 157, 181], ["antimalarials chloroquine (CQ)", "TREATMENT", 183, 213], ["hydroxychloroquine (HCQ)", "TREATMENT", 218, 242], ["the first medications", "TREATMENT", 254, 275], ["COVID-19 disease", "PROBLEM", 318, 334], ["cardiac", "ANATOMY", 87, 94], ["toxicity", "OBSERVATION", 95, 103], ["antiviral activity", "OBSERVATION", 163, 181]]], ["Indeed, in vitro anti-SARS-CoV-2 effects of CQ/HCQ have been demonstrated in a few studies [1-3].", [["CQ", "CHEMICAL", 44, 46], ["HCQ", "CHEMICAL", 47, 50], ["CQ", "CHEMICAL", 44, 46], ["HCQ", "CHEMICAL", 47, 50], ["CQ", "SIMPLE_CHEMICAL", 44, 46], ["HCQ", "SIMPLE_CHEMICAL", 47, 50], ["CoV", "TEST", 27, 30], ["CQ/HCQ", "TREATMENT", 44, 50], ["a few studies", "TEST", 77, 90]]], ["Hashem et al [4] recently reviewed the possible molecular sites of action of CQ /HCQ as SARS-CoV-2 antiviral agents.", [["CQ", "CHEMICAL", 77, 79], ["HCQ", "CHEMICAL", 81, 84], ["CQ", "CHEMICAL", 77, 79], ["HCQ", "CHEMICAL", 81, 84], ["CQ", "SIMPLE_CHEMICAL", 77, 79], ["HCQ", "SIMPLE_CHEMICAL", 81, 84], ["SARS-CoV-2", "ORGANISM", 88, 98], ["CQ /HCQ", "TREATMENT", 77, 84], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["2 antiviral agents", "TREATMENT", 97, 115]]], ["HCQ can inhibit cellular entry of SARS-CoV-2 by interfering with the glycosylation of its cellular receptor angiotensin converting enzyme 2 (ACE2) receptor.", [["cellular", "ANATOMY", 16, 24], ["cellular", "ANATOMY", 90, 98], ["HCQ", "CHEMICAL", 0, 3], ["SARS", "DISEASE", 34, 38], ["angiotensin", "CHEMICAL", 108, 119], ["HCQ", "CHEMICAL", 0, 3], ["HCQ", "SIMPLE_CHEMICAL", 0, 3], ["cellular", "CELL", 16, 24], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 34, 44], ["cellular", "CELL", 90, 98], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 108, 139], ["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["cellular receptor angiotensin converting enzyme 2 (ACE2) receptor", "PROTEIN", 90, 155], ["SARS-CoV", "SPECIES", 34, 42], ["HCQ", "TREATMENT", 0, 3], ["SARS", "PROBLEM", 34, 38], ["CoV", "TEST", 39, 42], ["its cellular receptor angiotensin", "TREATMENT", 86, 119], ["enzyme 2 (ACE2) receptor", "TREATMENT", 131, 155], ["entry", "OBSERVATION_MODIFIER", 25, 30]]], ["HCQ can also affect the early stages of viral replication by inhibiting virus-endosome fusion, likely via increasing endosomal pH [4] .Introduction:Furthermore, early clinical studies in COVID-19 patients, although with methodological flaws, reported less severe pneumonia, shorter disease course and faster viral clearance in response to CQ therapy [5] and reduced nasopharyngeal viral carrier sate with HCQ and azithromycin treatment [6] .", [["endosome", "ANATOMY", 78, 86], ["endosomal", "ANATOMY", 117, 126], ["nasopharyngeal", "ANATOMY", 366, 380], ["HCQ", "CHEMICAL", 0, 3], ["pneumonia", "DISEASE", 263, 272], ["CQ", "CHEMICAL", 339, 341], ["HCQ", "CHEMICAL", 405, 408], ["azithromycin", "CHEMICAL", 413, 425], ["HCQ", "CHEMICAL", 0, 3], ["CQ", "CHEMICAL", 339, 341], ["HCQ", "CHEMICAL", 405, 408], ["azithromycin", "CHEMICAL", 413, 425], ["HCQ", "SIMPLE_CHEMICAL", 0, 3], ["endosome", "CELLULAR_COMPONENT", 78, 86], ["endosomal", "CELLULAR_COMPONENT", 117, 126], ["patients", "ORGANISM", 196, 204], ["CQ", "SIMPLE_CHEMICAL", 339, 341], ["nasopharyngeal", "ORGAN", 366, 380], ["HCQ", "SIMPLE_CHEMICAL", 405, 408], ["azithromycin", "SIMPLE_CHEMICAL", 413, 425], ["patients", "SPECIES", 196, 204], ["HCQ", "TREATMENT", 0, 3], ["viral replication", "PROBLEM", 40, 57], ["inhibiting virus", "PROBLEM", 61, 77], ["endosome fusion", "TREATMENT", 78, 93], ["increasing endosomal pH", "PROBLEM", 106, 129], ["early clinical studies", "TEST", 161, 183], ["methodological flaws", "PROBLEM", 220, 240], ["less severe pneumonia", "PROBLEM", 251, 272], ["shorter disease course", "PROBLEM", 274, 296], ["faster viral clearance", "PROBLEM", 301, 323], ["CQ therapy", "TREATMENT", 339, 349], ["reduced nasopharyngeal viral carrier sate", "TREATMENT", 358, 399], ["HCQ", "TREATMENT", 405, 408], ["azithromycin treatment", "TREATMENT", 413, 435], ["early stages", "OBSERVATION_MODIFIER", 24, 36], ["viral replication", "OBSERVATION", 40, 57], ["less", "OBSERVATION_MODIFIER", 251, 255], ["severe", "OBSERVATION_MODIFIER", 256, 262], ["pneumonia", "OBSERVATION", 263, 272], ["nasopharyngeal", "ANATOMY", 366, 380]]], ["These limited data along with media and political influences led to a wide adoption of CQ/HCQ as a therapeutic option for COVID-19.", [["CQ", "CHEMICAL", 87, 89], ["HCQ", "CHEMICAL", 90, 93], ["CQ", "CHEMICAL", 87, 89], ["HCQ", "CHEMICAL", 90, 93], ["CQ", "SIMPLE_CHEMICAL", 87, 89], ["HCQ", "SIMPLE_CHEMICAL", 90, 93], ["media", "TREATMENT", 30, 35], ["a wide adoption of CQ/HCQ", "TREATMENT", 68, 93], ["COVID", "TEST", 122, 127]]], ["Countries filled their national stockpiles with HCQ and included it in their treatment guidelines while the drug was being studied in clinical trials.", [["HCQ", "CHEMICAL", 48, 51], ["HCQ", "CHEMICAL", 48, 51], ["HCQ", "SIMPLE_CHEMICAL", 48, 51], ["HCQ", "TREATMENT", 48, 51], ["their treatment guidelines", "TREATMENT", 71, 97]]], ["In USA, for example, there was a major increase in CQ/HCQ prescriptions of approximately 2000% [7] .", [["CQ", "CHEMICAL", 51, 53], ["HCQ", "CHEMICAL", 54, 57], ["HCQ", "CHEMICAL", 54, 57], ["CQ", "SIMPLE_CHEMICAL", 51, 53], ["HCQ", "SIMPLE_CHEMICAL", 54, 57], ["CQ/HCQ prescriptions", "TREATMENT", 51, 71], ["major", "OBSERVATION_MODIFIER", 33, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["Nevertheless, early hopes started to dissipate in June when the US Food and Drug Administration revoked permission for the drug to be distributed to treat COVID-19 after preliminary negative findings from the RECOVERY trial, leaving the US federal government stuck with 63 million doses of hydroxychloroquine [8] .Introduction:Although large randomized controlled trials (RCTs) were started worldwide, a few were either stopped early for futility or showed no benefits [9] [10] [11] .", [["hydroxychloroquine", "CHEMICAL", 290, 308], ["COVID-19", "CHEMICAL", 155, 163], ["hydroxychloroquine", "CHEMICAL", 290, 308], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 290, 308], ["Drug Administration", "TREATMENT", 76, 95], ["COVID", "TEST", 155, 160], ["hydroxychloroquine", "TREATMENT", 290, 308], ["large randomized controlled trials (RCTs", "TREATMENT", 336, 376], ["large", "OBSERVATION_MODIFIER", 336, 341]]], ["Moreover, two recent RCTs for postexposure prophylaxis did not find any significant decrease in risk of COVID-19 [12, 13] .Introduction:Conflicting data from cohort studies and RCTs [9] [10] [11] about the efficacy and safety of CQ/HCQ in COVID-19 started to emerge.", [["CQ", "CHEMICAL", 229, 231], ["HCQ", "CHEMICAL", 232, 235], ["COVID-19", "CHEMICAL", 104, 112], ["HCQ", "CHEMICAL", 232, 235], ["COVID-19", "CHEMICAL", 239, 247], ["CQ", "SIMPLE_CHEMICAL", 229, 231], ["HCQ", "SIMPLE_CHEMICAL", 232, 235], ["postexposure prophylaxis", "TREATMENT", 30, 54], ["COVID", "TEST", 104, 109], ["cohort studies", "TEST", 158, 172], ["RCTs", "TEST", 177, 181], ["CQ/HCQ", "TREATMENT", 229, 235], ["COVID", "TEST", 239, 244], ["significant", "OBSERVATION_MODIFIER", 72, 83], ["decrease", "OBSERVATION_MODIFIER", 84, 92]]], ["Our group conducted a systematic review and meta-analysis of reported observational studies and RCTs that included 22 studies with 21,615 patients COVID-19 patients.", [["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 156, 164], ["observational studies", "TEST", 70, 91], ["RCTs", "TEST", 96, 100], ["22 studies", "TEST", 115, 125], ["patients COVID", "TEST", 138, 152]]], ["We observed, with moderate certainty evidence, that HCQ, with or without AZ, lacks efficacy in reducing short-term mortality in patients hospitalized with COVID-19 or risk of hospitalization in outpatients with COVID-19 [14] .", [["HCQ", "CHEMICAL", 52, 55], ["AZ", "CHEMICAL", 73, 75], ["HCQ", "CHEMICAL", 52, 55], ["COVID-19", "CHEMICAL", 211, 219], ["HCQ", "SIMPLE_CHEMICAL", 52, 55], ["AZ", "SIMPLE_CHEMICAL", 73, 75], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["COVID", "TREATMENT", 155, 160], ["COVID", "TEST", 211, 216], ["moderate", "OBSERVATION_MODIFIER", 18, 26], ["certainty", "OBSERVATION", 27, 36]]], ["Moreover, we reported in another recent meta-analysis that CQ/HCQ therapy in COVID-19 patients was associated with a significant increased risk of QT prolongation associated drug discontinuation and arrhythmias, and other cardiac toxicities [15] .Introduction:Nevertheless, despite the cumulative evidence against the benefit of HCQ in COVID-19 patients, there are at least 72 ongoing RCTs worldwide actively recruiting patients to receive HCQ vs.Introduction:other control groups as of July 28, 2020, with a total of 121,272 patients planned to be enrolled in these trials (https://clinicaltrials.gov/).", [["cardiac", "ANATOMY", 222, 229], ["CQ", "CHEMICAL", 59, 61], ["HCQ", "CHEMICAL", 62, 65], ["QT prolongation", "DISEASE", 147, 162], ["arrhythmias", "DISEASE", 199, 210], ["cardiac toxicities", "DISEASE", 222, 240], ["HCQ", "CHEMICAL", 329, 332], ["HCQ", "CHEMICAL", 440, 443], ["CQ", "CHEMICAL", 59, 61], ["HCQ", "CHEMICAL", 62, 65], ["HCQ", "CHEMICAL", 329, 332], ["HCQ", "CHEMICAL", 440, 443], ["CQ", "SIMPLE_CHEMICAL", 59, 61], ["HCQ", "SIMPLE_CHEMICAL", 62, 65], ["patients", "ORGANISM", 86, 94], ["HCQ", "SIMPLE_CHEMICAL", 329, 332], ["patients", "ORGANISM", 345, 353], ["patients", "ORGANISM", 420, 428], ["HCQ", "SIMPLE_CHEMICAL", 440, 443], ["patients", "ORGANISM", 526, 534], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 345, 353], ["patients", "SPECIES", 420, 428], ["patients", "SPECIES", 526, 534], ["CQ/HCQ therapy", "TREATMENT", 59, 73], ["QT prolongation", "PROBLEM", 147, 162], ["drug discontinuation", "TREATMENT", 174, 194], ["arrhythmias", "PROBLEM", 199, 210], ["other cardiac toxicities", "PROBLEM", 216, 240], ["HCQ", "TREATMENT", 329, 332], ["HCQ vs", "TREATMENT", 440, 446], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["QT prolongation", "OBSERVATION", 147, 162]]], ["For example, funded by the COVID-19 Bill & Melinda Gates Foundation, Wellcome and Mastercard Therapeutics Accelerator grant, the COPCOV study is ongoing and will enroll around 40,000 health care workers who have close contact with COVID-19 patients to determine whether CQ or HCQ are effective in preventing COVID-19.Introduction:In this perspective, we discuss the possible reasons and mechanisms for the lack of efficacy and increased cardiac toxicity of HCQ in the context of COVID-19 disease.Efficacy ShortcomingsThe discordant findings of the in vitro anti-SARS-CoV-2 effects of CQ/HCQ and their clinical inefficacy are concordant with previous observations from several other viral infections' studies.Efficacy ShortcomingsThree main reasons could explain this discrepancy.", [["cardiac", "ANATOMY", 437, 444], ["CQ", "CHEMICAL", 270, 272], ["HCQ", "CHEMICAL", 276, 279], ["cardiac toxicity", "DISEASE", 437, 453], ["HCQ", "CHEMICAL", 457, 460], ["CQ", "CHEMICAL", 584, 586], ["HCQ", "CHEMICAL", 587, 590], ["viral infections", "DISEASE", 682, 698], ["HCQ", "CHEMICAL", 276, 279], ["COVID-19", "CHEMICAL", 308, 316], ["HCQ", "CHEMICAL", 457, 460], ["CQ", "CHEMICAL", 584, 586], ["HCQ", "CHEMICAL", 587, 590], ["patients", "ORGANISM", 240, 248], ["CQ", "SIMPLE_CHEMICAL", 270, 272], ["HCQ", "SIMPLE_CHEMICAL", 276, 279], ["cardiac", "ORGAN", 437, 444], ["HCQ", "SIMPLE_CHEMICAL", 457, 460], ["CQ", "SIMPLE_CHEMICAL", 584, 586], ["HCQ", "SIMPLE_CHEMICAL", 587, 590], ["patients", "SPECIES", 240, 248], ["the COVID", "TEST", 23, 32], ["the COPCOV study", "TEST", 125, 141], ["HCQ", "TREATMENT", 276, 279], ["COVID", "TEST", 308, 313], ["increased cardiac toxicity of HCQ", "PROBLEM", 427, 460], ["COVID-19 disease", "PROBLEM", 479, 495], ["vitro anti-SARS", "TEST", 551, 566], ["CoV", "TEST", 567, 570], ["CQ/HCQ", "TREATMENT", 584, 590], ["several other viral infections' studies", "PROBLEM", 668, 707], ["this discrepancy", "PROBLEM", 762, 778], ["cardiac", "ANATOMY", 437, 444], ["toxicity", "OBSERVATION", 445, 453], ["disease", "OBSERVATION", 488, 495], ["infections", "OBSERVATION", 688, 698]]], ["CQ at 0.1, 1.0 and 10 \uf06dM, added 20-24 hours before the infection, decreased infectivity by 28%, 53% and 100%.", [["CQ", "CHEMICAL", 0, 2], ["infection", "DISEASE", 55, 64], ["CQ", "SIMPLE_CHEMICAL", 0, 2], ["CQ", "TEST", 0, 2], ["the infection", "PROBLEM", 51, 64], ["decreased infectivity", "PROBLEM", 66, 87], ["infection", "OBSERVATION", 55, 64], ["decreased", "OBSERVATION_MODIFIER", 66, 75], ["infectivity", "OBSERVATION_MODIFIER", 76, 87]]], ["However, when CQ was added 3-5 hours after infecting the cells, higher concentrations of CQ of up to 50 \uf06dM were needed to decrease infectivity [17] .", [["cells", "ANATOMY", 57, 62], ["CQ", "CHEMICAL", 14, 16], ["CQ", "CHEMICAL", 89, 91], ["CQ", "SIMPLE_CHEMICAL", 14, 16], ["cells", "CELL", 57, 62], ["CQ", "SIMPLE_CHEMICAL", 89, 91], ["infecting the cells", "PROBLEM", 43, 62]]], ["Similar observations were reported with MERS-CoV virus where CQ effectively inhibited virus production if added prior to infection of Vero E6 cells but failed to reduce virus production if added one-hour post-infection [18] .", [["Vero E6 cells", "ANATOMY", 134, 147], ["CQ", "CHEMICAL", 61, 63], ["infection", "DISEASE", 121, 130], ["infection", "DISEASE", 209, 218], ["MERS-CoV virus", "ORGANISM", 40, 54], ["CQ", "SIMPLE_CHEMICAL", 61, 63], ["Vero E6 cells", "CELL", 134, 147], ["Vero E6 cells", "CELL_LINE", 134, 147], ["CoV virus", "SPECIES", 45, 54], ["MERS-CoV virus", "SPECIES", 40, 54], ["Vero E6", "SPECIES", 134, 141], ["MERS-CoV virus", "PROBLEM", 40, 54], ["CQ", "PROBLEM", 61, 63], ["virus production", "PROBLEM", 86, 102], ["infection", "PROBLEM", 121, 130], ["Vero E6 cells", "PROBLEM", 134, 147], ["virus production", "PROBLEM", 169, 185], ["infection", "PROBLEM", 209, 218]]], ["These observations indicate that the main mechanism of action of CQ/HCQ is at the early stages of viral infection, namely, at the adherence and entry stages to the host cells.", [["cells", "ANATOMY", 169, 174], ["CQ", "CHEMICAL", 65, 67], ["HCQ", "CHEMICAL", 68, 71], ["viral infection", "DISEASE", 98, 113], ["CQ", "CHEMICAL", 65, 67], ["HCQ", "CHEMICAL", 68, 71], ["CQ", "SIMPLE_CHEMICAL", 65, 67], ["HCQ", "SIMPLE_CHEMICAL", 68, 71], ["host cells", "CELL", 164, 174], ["host cells", "CELL_TYPE", 164, 174], ["CQ/HCQ", "PROBLEM", 65, 71], ["viral infection", "PROBLEM", 98, 113], ["main", "OBSERVATION_MODIFIER", 37, 41], ["early stages", "OBSERVATION_MODIFIER", 82, 94], ["viral", "OBSERVATION_MODIFIER", 98, 103], ["infection", "OBSERVATION", 104, 113], ["host cells", "OBSERVATION", 164, 174]]], ["Therefore, achieving viral control with CQ/HCQ might not be feasible since SARS-CoV-2 viral load peaks early with symptom onset [19, 20] .Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic IndexThe translation of in vitro antiviral activity to appropriate clinical dosing regimens is very complex.", [["CQ", "CHEMICAL", 40, 42], ["HCQ", "CHEMICAL", 43, 46], ["CQ", "CHEMICAL", 40, 42], ["HCQ", "CHEMICAL", 43, 46], ["CQ", "SIMPLE_CHEMICAL", 40, 42], ["HCQ", "SIMPLE_CHEMICAL", 43, 46], ["SARS-CoV-2", "ORGANISM", 75, 85], ["CQ/HCQ", "TREATMENT", 40, 46], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["2 viral load peaks", "PROBLEM", 84, 102], ["symptom onset", "PROBLEM", 114, 127], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 138, 177], ["Narrow Therapeutic Index", "TREATMENT", 182, 206], ["vitro antiviral activity", "TREATMENT", 228, 252], ["appropriate clinical dosing regimens", "TREATMENT", 256, 292]]], ["The in vitro half-maximal effective antiviral concentrations (EC 50 very high tissue to plasma ratio, this high tissue concentration is due to sequestered drug inside acidic cellular organelles.", [["tissue", "ANATOMY", 78, 84], ["plasma", "ANATOMY", 88, 94], ["tissue", "ANATOMY", 112, 118], ["cellular organelles", "ANATOMY", 174, 193], ["EC", "CELL", 62, 64], ["tissue", "TISSUE", 78, 84], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["tissue", "TISSUE", 112, 118], ["cellular organelles", "CELLULAR_COMPONENT", 174, 193], ["maximal effective antiviral concentrations", "TREATMENT", 18, 60], ["plasma ratio", "TEST", 88, 100], ["this high tissue concentration", "PROBLEM", 102, 132], ["high tissue", "OBSERVATION_MODIFIER", 73, 84], ["acidic cellular organelles", "OBSERVATION", 167, 193]]], ["CQ/HCQ are known to accumulate in endosomes, Golgi apparatus and lysosomes (Reviewed by [21] ).", [["endosomes", "ANATOMY", 34, 43], ["Golgi apparatus", "ANATOMY", 45, 60], ["lysosomes", "ANATOMY", 65, 74], ["CQ", "CHEMICAL", 0, 2], ["HCQ", "CHEMICAL", 3, 6], ["HCQ", "CHEMICAL", 3, 6], ["CQ", "SIMPLE_CHEMICAL", 0, 2], ["HCQ", "SIMPLE_CHEMICAL", 3, 6], ["endosomes", "CELLULAR_COMPONENT", 34, 43], ["Golgi apparatus", "CELLULAR_COMPONENT", 45, 60], ["lysosomes", "CELLULAR_COMPONENT", 65, 74], ["CQ", "TEST", 0, 2], ["HCQ", "PROBLEM", 3, 6]]], ["In fact, it has been calculated that the lysosomal HCQ concentration can reach 80 \uf06dM while extracellular concentrations were around 0.5 \uf06dM [22] .Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic IndexThus, these EC 50 suggesting that current dosing regimens lack the antiviral effect against SARS-CoV-2 and making it unlikely to achieve antiviral activity with a safe oral dosing regimen [23] .", [["lysosomal", "ANATOMY", 41, 50], ["extracellular", "ANATOMY", 91, 104], ["oral", "ANATOMY", 381, 385], ["HCQ", "CHEMICAL", 51, 54], ["SARS", "DISEASE", 305, 309], ["HCQ", "CHEMICAL", 51, 54], ["lysosomal", "CELLULAR_COMPONENT", 41, 50], ["HCQ", "SIMPLE_CHEMICAL", 51, 54], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 104], ["EC", "CELL", 225, 227], ["SARS-CoV-2", "ORGANISM", 305, 315], ["oral", "ORGANISM_SUBDIVISION", 381, 385], ["SARS-CoV", "SPECIES", 305, 313], ["the lysosomal HCQ concentration", "TREATMENT", 37, 68], ["extracellular concentrations", "TEST", 91, 119], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 145, 184], ["Narrow Therapeutic IndexThus", "TREATMENT", 189, 217], ["these EC", "TREATMENT", 219, 227], ["current dosing regimens", "TREATMENT", 247, 270], ["the antiviral effect", "TREATMENT", 276, 296], ["SARS", "PROBLEM", 305, 309], ["antiviral activity", "TREATMENT", 350, 368], ["a safe oral dosing regimen", "TREATMENT", 374, 400]]], ["Garcia-Cremades et al. also made calculation for the predicted plasma antiviral EC 50 of HCQ and found it to be 4.7 \uf06dM (1.58 mg/ml), which is much higher than the original estimates of Yao et al. [24] .Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic IndexThey predicted that HCQ of > 400 mg twice a day for 5 days or more are necessary to achieve this plasma concentration.", [["plasma", "ANATOMY", 63, 69], ["plasma", "ANATOMY", 367, 373], ["HCQ", "CHEMICAL", 89, 92], ["HCQ", "CHEMICAL", 290, 293], ["HCQ", "CHEMICAL", 89, 92], ["HCQ", "CHEMICAL", 290, 293], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["EC", "CELL", 80, 82], ["HCQ", "SIMPLE_CHEMICAL", 89, 92], ["HCQ", "SIMPLE_CHEMICAL", 290, 293], ["plasma", "ORGANISM_SUBSTANCE", 367, 373], ["the predicted plasma antiviral EC", "TREATMENT", 49, 82], ["HCQ", "TREATMENT", 89, 92], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 202, 241], ["Narrow Therapeutic IndexThey", "TREATMENT", 246, 274], ["this plasma concentration", "TREATMENT", 362, 387]]], ["This higher dose regiment could significantly increase the risk of QT prolongation [24] .Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic IndexDespite the above dosing considerations, a review of all ongoing actively recruiting RCTs registered on clinicaltrials.gov as of July 28, 2020, revealed only a single RCT using HCQ 800 mg loading dose on day 1 and followed by 400 mg twice daily for 6 days.", [["QT prolongation", "DISEASE", 67, 82], ["HCQ", "CHEMICAL", 334, 337], ["HCQ", "CHEMICAL", 334, 337], ["HCQ", "SIMPLE_CHEMICAL", 334, 337], ["This higher dose regiment", "TREATMENT", 0, 25], ["QT prolongation", "PROBLEM", 67, 82], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 89, 128], ["Narrow Therapeutic IndexDespite the above dosing", "TREATMENT", 133, 181], ["a single RCT", "TREATMENT", 315, 327], ["HCQ", "TREATMENT", 334, 337]]], ["The majority of other treatment RCTs used the dose suggested by Yao et al [3] or even lower doses.", [["other treatment RCTs", "TREATMENT", 16, 36]]], ["The few prevention RCTs used lower does.Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic IndexIt has been observed in mice models that high dose of 90 mg/kg of CQ given twice a day was required to achieve a steady-state blood level of 2.5 mg/ml [25] .", [["blood", "ANATOMY", 234, 239], ["CQ", "CHEMICAL", 174, 176], ["mice", "ORGANISM", 132, 136], ["CQ", "SIMPLE_CHEMICAL", 174, 176], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 132, 136], ["The few prevention RCTs", "TREATMENT", 0, 23], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 40, 79], ["Narrow Therapeutic IndexIt", "TREATMENT", 84, 110], ["few", "OBSERVATION_MODIFIER", 4, 7]]], ["Adopting high dose CQ/HCQ regimens in humans would increase the risk of adverse events significantly, as was experienced in a recent RCT of high dose QC in COVID-19 patients, that was stopped early for harm [26] .Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic IndexAdditionally, the optimal CQ or HCQ blood levels for effective antiviral action is at large unknown, and the human studies correlating CQ/HCQ blood levels and clinical response in viral illnesses and other diseases are limited.", [["blood", "ANATOMY", 317, 322], ["blood", "ANATOMY", 423, 428], ["CQ", "CHEMICAL", 19, 21], ["HCQ", "CHEMICAL", 22, 25], ["CQ", "CHEMICAL", 307, 309], ["HCQ", "CHEMICAL", 313, 316], ["CQ", "CHEMICAL", 416, 418], ["HCQ", "CHEMICAL", 419, 422], ["viral illnesses", "DISEASE", 461, 476], ["CQ", "CHEMICAL", 19, 21], ["HCQ", "CHEMICAL", 22, 25], ["HCQ", "CHEMICAL", 313, 316], ["HCQ", "CHEMICAL", 419, 422], ["CQ", "SIMPLE_CHEMICAL", 19, 21], ["HCQ", "SIMPLE_CHEMICAL", 22, 25], ["humans", "ORGANISM", 38, 44], ["patients", "ORGANISM", 165, 173], ["CQ", "SIMPLE_CHEMICAL", 307, 309], ["HCQ", "SIMPLE_CHEMICAL", 313, 316], ["blood", "ORGANISM_SUBSTANCE", 317, 322], ["human", "ORGANISM", 390, 395], ["CQ", "SIMPLE_CHEMICAL", 416, 418], ["HCQ", "SIMPLE_CHEMICAL", 419, 422], ["blood", "ORGANISM_SUBSTANCE", 423, 428], ["humans", "SPECIES", 38, 44], ["patients", "SPECIES", 165, 173], ["human", "SPECIES", 390, 395], ["humans", "SPECIES", 38, 44], ["human", "SPECIES", 390, 395], ["Adopting high dose CQ/HCQ regimens", "TREATMENT", 0, 34], ["adverse events", "PROBLEM", 72, 86], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 213, 252], ["Narrow Therapeutic IndexAdditionally", "TREATMENT", 257, 293], ["the optimal CQ", "TREATMENT", 295, 309], ["HCQ blood levels", "TEST", 313, 329], ["effective antiviral action", "TREATMENT", 334, 360], ["the human studies", "TEST", 386, 403], ["CQ", "TEST", 416, 418], ["HCQ blood levels", "TEST", 419, 435], ["clinical response", "TEST", 440, 457], ["viral illnesses", "PROBLEM", 461, 476], ["other diseases", "PROBLEM", 481, 495], ["viral illnesses", "OBSERVATION", 461, 476]]], ["For example, Sperber et al reported a wide range of HCQ blood concentrations of 0.27-1.0 mg/ml in 40 HIV-1 patients treated with HCQ 800 mg/day for 8 weeks [27] .", [["blood", "ANATOMY", 56, 61], ["HCQ", "CHEMICAL", 52, 55], ["HCQ", "CHEMICAL", 129, 132], ["HCQ", "CHEMICAL", 52, 55], ["HCQ", "CHEMICAL", 129, 132], ["HCQ", "SIMPLE_CHEMICAL", 52, 55], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["patients", "ORGANISM", 107, 115], ["HCQ", "SIMPLE_CHEMICAL", 129, 132], ["HIV-1", "SPECIES", 101, 106], ["patients", "SPECIES", 107, 115], ["HIV-1", "SPECIES", 101, 106], ["a wide range of HCQ blood concentrations", "TREATMENT", 36, 76], ["HCQ", "TREATMENT", 129, 132]]], ["They noticed favourable outcomes only in those patients achieved the highest HCQ blood concentrations [27] .", [["blood", "ANATOMY", 81, 86], ["HCQ", "CHEMICAL", 77, 80], ["HCQ", "CHEMICAL", 77, 80], ["patients", "ORGANISM", 47, 55], ["HCQ", "SIMPLE_CHEMICAL", 77, 80], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["patients", "SPECIES", 47, 55], ["blood concentrations", "TEST", 81, 101], ["favourable", "OBSERVATION_MODIFIER", 13, 23]]], ["Similar trends between HCQ levels and clinical response were noted in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis [28, 29] .Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic IndexA recent study by Balevic et al. evaluated serum and plasma HCQ concentration from published studies and serum samples of pediatric SLE patients treated with HCQ, as well as simulated concentrations based on published pharmacokinetics [30] .", [["serum", "ANATOMY", 265, 270], ["plasma", "ANATOMY", 275, 281], ["serum samples", "ANATOMY", 327, 340], ["HCQ", "CHEMICAL", 23, 26], ["systemic lupus erythematosus", "DISEASE", 84, 112], ["SLE", "DISEASE", 114, 117], ["rheumatoid arthritis", "DISEASE", 123, 143], ["HCQ", "CHEMICAL", 282, 285], ["SLE", "DISEASE", 354, 357], ["HCQ", "CHEMICAL", 380, 383], ["HCQ", "CHEMICAL", 23, 26], ["HCQ", "CHEMICAL", 282, 285], ["HCQ", "CHEMICAL", 380, 383], ["HCQ", "SIMPLE_CHEMICAL", 23, 26], ["patients", "ORGANISM", 70, 78], ["serum", "ORGANISM_SUBSTANCE", 265, 270], ["plasma", "ORGANISM_SUBSTANCE", 275, 281], ["HCQ", "SIMPLE_CHEMICAL", 282, 285], ["serum samples", "ORGANISM_SUBSTANCE", 327, 340], ["patients", "ORGANISM", 358, 366], ["HCQ", "SIMPLE_CHEMICAL", 380, 383], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 358, 366], ["HCQ levels", "TEST", 23, 33], ["systemic lupus erythematosus", "PROBLEM", 84, 112], ["SLE)", "PROBLEM", 114, 118], ["rheumatoid arthritis", "PROBLEM", 123, 143], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 154, 193], ["Narrow Therapeutic IndexA", "TREATMENT", 198, 223], ["recent study", "TEST", 224, 236], ["serum", "TEST", 265, 270], ["plasma HCQ concentration", "TEST", 275, 299], ["published studies", "TEST", 305, 322], ["serum samples", "TEST", 327, 340], ["pediatric SLE patients", "TREATMENT", 344, 366], ["HCQ", "TREATMENT", 380, 383], ["systemic", "OBSERVATION_MODIFIER", 84, 92], ["lupus erythematosus", "OBSERVATION", 93, 112], ["rheumatoid arthritis", "OBSERVATION", 123, 143]]], ["They found that in all included studies, the average serum/plasma HCQ concentration were below the lowest antiviral target levels for SARS-CoV-2 of 0.48 mg/ml that were observed by Yao et al [30] .", [["serum", "ANATOMY", 53, 58], ["plasma", "ANATOMY", 59, 65], ["HCQ", "CHEMICAL", 66, 69], ["HCQ", "CHEMICAL", 66, 69], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["HCQ", "SIMPLE_CHEMICAL", 66, 69], ["SARS-CoV", "SPECIES", 134, 142], ["studies", "TEST", 32, 39], ["the average serum", "TEST", 41, 58], ["plasma HCQ concentration", "TEST", 59, 83], ["SARS", "TEST", 134, 138], ["CoV", "TEST", 139, 142]]], ["Two other small studies examined the pharmacokinetics of HCQ in COVID-19 patients [6, 31] .", [["HCQ", "CHEMICAL", 57, 60], ["HCQ", "CHEMICAL", 57, 60], ["HCQ", "SIMPLE_CHEMICAL", 57, 60], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["Two other small studies", "TEST", 0, 23], ["HCQ", "TEST", 57, 60], ["COVID", "TEST", 64, 69], ["small", "OBSERVATION_MODIFIER", 10, 15]]], ["Gautret et al.Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic Indexmeasured HCQ blood levels in 20 COVID-19 patients treated with HCQ 600 mg/day and found that the mean HCQ blood concentration was 0.46 mg/ml [6] .", [["blood", "ANATOMY", 95, 100], ["blood", "ANATOMY", 188, 193], ["HCQ", "CHEMICAL", 91, 94], ["HCQ", "CHEMICAL", 145, 148], ["HCQ", "CHEMICAL", 184, 187], ["HCQ", "CHEMICAL", 91, 94], ["HCQ", "CHEMICAL", 145, 148], ["HCQ", "CHEMICAL", 184, 187], ["HCQ", "SIMPLE_CHEMICAL", 91, 94], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["patients", "ORGANISM", 123, 131], ["HCQ", "SIMPLE_CHEMICAL", 145, 148], ["HCQ", "SIMPLE_CHEMICAL", 184, 187], ["blood", "ORGANISM_SUBSTANCE", 188, 193], ["patients", "SPECIES", 123, 131], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 14, 53], ["Narrow Therapeutic Indexmeasured HCQ", "TREATMENT", 58, 94], ["blood levels", "TEST", 95, 107], ["HCQ", "TREATMENT", 145, 148], ["the mean HCQ blood concentration", "TREATMENT", 175, 207]]], ["These levels were below the lowest estimated levels of 0.48 mg/ml based on the lowest effective in vitro concentration of 0.72 \uf06dM.Subtherapeutic Clinical Dosing Regimens and Narrow Therapeutic IndexIn another study, Perinel et al determined HCQ blood levels in 13 COVID-19 patients admitted to intensive care unit and treated with HCQ 600 mg/day.", [["blood", "ANATOMY", 245, 250], ["HCQ", "CHEMICAL", 241, 244], ["HCQ", "CHEMICAL", 331, 334], ["HCQ", "CHEMICAL", 241, 244], ["HCQ", "CHEMICAL", 331, 334], ["HCQ", "SIMPLE_CHEMICAL", 241, 244], ["blood", "ORGANISM_SUBSTANCE", 245, 250], ["patients", "ORGANISM", 273, 281], ["HCQ", "SIMPLE_CHEMICAL", 331, 334], ["patients", "SPECIES", 273, 281], ["These levels", "TEST", 0, 12], ["vitro concentration", "TEST", 99, 118], ["Subtherapeutic Clinical Dosing Regimens", "TREATMENT", 130, 169], ["Narrow Therapeutic IndexIn", "TREATMENT", 174, 200], ["another study", "TEST", 201, 214], ["HCQ blood levels", "TEST", 241, 257], ["HCQ", "TREATMENT", 331, 334]]], ["They observed that only 61% of them achieved what they considered the minimum therapeutic concentration of 1 mg/ml with the mean time to reach this concentration of 2.7 days [31] .", [["the minimum therapeutic concentration", "TREATMENT", 66, 103]]], ["These studies indicate that even using the lowest in vitro HCQ inhibitory concentration, achieving minimum clinical therapeutic concentration of HCQ seems not possible.HCQ Negative Effect on Type I Interferon ResponseType I interferon response plays a critical role in early suppression of viral replication.HCQ Negative Effect on Type I Interferon ResponseChannappanavar et al. [32] used a SARS-CoV-1 animal model to describe how rapid and robust virus replication with delayed IFN-I can lead to lung immunopathology, with fatal outcomes.Recently, investigators reported on an integrated immune analysis on a cohort of 50 COVID-19patients with various disease severity [33] .", [["lung", "ANATOMY", 497, 501], ["HCQ", "CHEMICAL", 59, 62], ["HCQ", "CHEMICAL", 145, 148], ["HCQ", "CHEMICAL", 168, 171], ["HCQ", "CHEMICAL", 308, 311], ["lung immunopathology", "DISEASE", 497, 517], ["HCQ", "CHEMICAL", 59, 62], ["HCQ", "CHEMICAL", 145, 148], ["HCQ", "CHEMICAL", 168, 171], ["HCQ", "CHEMICAL", 308, 311], ["HCQ", "SIMPLE_CHEMICAL", 59, 62], ["HCQ", "SIMPLE_CHEMICAL", 145, 148], ["HCQ", "SIMPLE_CHEMICAL", 168, 171], ["Type I Interferon ResponseType I interferon", "GENE_OR_GENE_PRODUCT", 191, 234], ["HCQ", "SIMPLE_CHEMICAL", 308, 311], ["IFN-I", "GENE_OR_GENE_PRODUCT", 479, 484], ["lung", "ORGAN", 497, 501], ["interferon", "PROTEIN", 224, 234], ["IFN-I", "PROTEIN", 479, 484], ["These studies", "TEST", 0, 13], ["the lowest in vitro HCQ inhibitory concentration", "TREATMENT", 39, 87], ["HCQ", "TREATMENT", 145, 148], ["HCQ", "TEST", 168, 171], ["Type I Interferon ResponseType I interferon response", "TREATMENT", 191, 243], ["viral replication", "TREATMENT", 290, 307], ["HCQ", "TEST", 308, 311], ["Type I Interferon ResponseChannappanavar", "TREATMENT", 331, 371], ["a SARS", "TEST", 389, 395], ["CoV", "TEST", 396, 399], ["robust virus replication", "PROBLEM", 441, 465], ["lung immunopathology", "PROBLEM", 497, 517], ["fatal outcomes", "PROBLEM", 524, 538], ["various disease severity", "PROBLEM", 645, 669], ["not possible", "UNCERTAINTY", 155, 167], ["viral replication", "OBSERVATION", 290, 307], ["lung", "ANATOMY", 497, 501], ["immunopathology", "OBSERVATION", 502, 517]]], ["They observed that a unique phenotype was observed in severe and critical patients, consisting of a highly impaired type I interferon response, associated with a persistent blood viral load and an exacerbated inflammatory response.", [["blood", "ANATOMY", 173, 178], ["impaired type I interferon", "DISEASE", 107, 133], ["patients", "ORGANISM", 74, 82], ["type I interferon", "GENE_OR_GENE_PRODUCT", 116, 133], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["interferon", "PROTEIN", 123, 133], ["patients", "SPECIES", 74, 82], ["a unique phenotype", "PROBLEM", 19, 37], ["a highly impaired type I interferon response", "PROBLEM", 98, 142], ["a persistent blood viral load", "PROBLEM", 160, 189], ["an exacerbated inflammatory response", "PROBLEM", 194, 230], ["viral load", "OBSERVATION", 179, 189], ["exacerbated", "OBSERVATION_MODIFIER", 197, 208], ["inflammatory response", "OBSERVATION", 209, 230]]], ["It is well established that antimalarials have solid anti-inflammatory and immunomodulatory effects.Recently, investigators reported on an integrated immune analysis on a cohort of 50 COVID-19Among these long-term effects are their ability to decrease the production of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-a), interleukin-1 beta (IL-1b) and interleukin-6 (IL-6), and improve endothelial function and reduce prothrombotic state [34, 35] .", [["endothelial", "ANATOMY", 404, 415], ["tumor necrosis", "DISEASE", 302, 316], ["COVID-19Among", "CELL", 184, 197], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 302, 329], ["TNF-a", "GENE_OR_GENE_PRODUCT", 331, 336], ["interleukin-1 beta", "GENE_OR_GENE_PRODUCT", 339, 357], ["IL-1b", "GENE_OR_GENE_PRODUCT", 359, 364], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 370, 383], ["IL-6", "GENE_OR_GENE_PRODUCT", 385, 389], ["endothelial", "CELL", 404, 415], ["pro-inflammatory cytokines", "PROTEIN", 270, 296], ["tumor necrosis factor-alpha", "PROTEIN", 302, 329], ["TNF", "PROTEIN", 331, 334], ["interleukin-6", "PROTEIN", 370, 383], ["antimalarials", "TREATMENT", 28, 41], ["solid anti-inflammatory", "TREATMENT", 47, 70], ["immunomodulatory effects", "TREATMENT", 75, 99], ["pro-inflammatory cytokines", "PROBLEM", 270, 296], ["tumor necrosis factor", "PROBLEM", 302, 323], ["alpha", "TEST", 324, 329], ["TNF", "TEST", 331, 334], ["interleukin", "TEST", 339, 350], ["IL", "TEST", 359, 361], ["interleukin", "TEST", 370, 381], ["prothrombotic state", "PROBLEM", 436, 455], ["immunomodulatory effects", "OBSERVATION", 75, 99], ["pro-inflammatory", "OBSERVATION_MODIFIER", 270, 286], ["tumor", "OBSERVATION", 302, 307]]], ["These effects could potentially be beneficial in patients with severe COVID-19 disease associated cytokine storm.", [["patients", "ORGANISM", 49, 57], ["cytokine", "PROTEIN", 98, 106], ["patients", "SPECIES", 49, 57], ["severe COVID-19 disease associated cytokine storm", "PROBLEM", 63, 112], ["could potentially be", "UNCERTAINTY", 14, 34], ["cytokine storm", "OBSERVATION", 98, 112]]], ["However, HCQ has been shown to reduce the affinity of toll-like receptor 7 and 9 (TLR7 and TLR9) to viral RNA and to inhibit cyclic GMP-AMP synthase (cGAS) pathway and thereby inhibit type I interferon response [34] .", [["HCQ", "CHEMICAL", 9, 12], ["GMP", "CHEMICAL", 132, 135], ["AMP", "CHEMICAL", 136, 139], ["HCQ", "CHEMICAL", 9, 12], ["cyclic GMP-AMP", "CHEMICAL", 125, 139], ["HCQ", "SIMPLE_CHEMICAL", 9, 12], ["toll-like receptor 7", "GENE_OR_GENE_PRODUCT", 54, 74], ["9", "GENE_OR_GENE_PRODUCT", 79, 80], ["TLR7", "GENE_OR_GENE_PRODUCT", 82, 86], ["TLR9", "GENE_OR_GENE_PRODUCT", 91, 95], ["GMP-AMP synthase", "GENE_OR_GENE_PRODUCT", 132, 148], ["cGAS", "GENE_OR_GENE_PRODUCT", 150, 154], ["type I interferon", "GENE_OR_GENE_PRODUCT", 184, 201], ["toll-like receptor 7 and 9", "PROTEIN", 54, 80], ["TLR7", "PROTEIN", 82, 86], ["TLR9", "PROTEIN", 91, 95], ["viral RNA", "RNA", 100, 109], ["AMP synthase", "PROTEIN", 136, 148], ["cGAS", "PROTEIN", 150, 154], ["type I interferon", "PROTEIN", 184, 201], ["HCQ", "TREATMENT", 9, 12], ["TLR7 and TLR9)", "TREATMENT", 82, 96], ["viral RNA", "PROBLEM", 100, 109], ["cyclic GMP", "TEST", 125, 135], ["AMP synthase (cGAS) pathway", "TREATMENT", 136, 163], ["type I interferon response", "PROBLEM", 184, 210]]], ["This blunting effect on type I interferon response might counteract the direct antiviral effects of HCQ, which provides another reason for the lack of efficacy of HCQ in controlling SARS-CoV-2 infection.Significant Cardiac Toxicity ConcernsAlthough it has been repeatedly claimed that HCQ has a longstanding safety track record for many decades in use, this contention is not applicable in COVID-19 patients due to disease-drug interactions and drug-drug interactions.", [["Cardiac", "ANATOMY", 215, 222], ["HCQ", "CHEMICAL", 100, 103], ["HCQ", "CHEMICAL", 163, 166], ["SARS-CoV-2 infection", "DISEASE", 182, 202], ["Cardiac Toxicity", "DISEASE", 215, 231], ["HCQ", "CHEMICAL", 285, 288], ["HCQ", "CHEMICAL", 100, 103], ["HCQ", "CHEMICAL", 163, 166], ["HCQ", "CHEMICAL", 285, 288], ["type I interferon", "GENE_OR_GENE_PRODUCT", 24, 41], ["HCQ", "SIMPLE_CHEMICAL", 100, 103], ["HCQ", "SIMPLE_CHEMICAL", 163, 166], ["SARS-CoV-2", "ORGANISM", 182, 192], ["HCQ", "SIMPLE_CHEMICAL", 285, 288], ["patients", "ORGANISM", 399, 407], ["type I interferon", "PROTEIN", 24, 41], ["patients", "SPECIES", 399, 407], ["SARS-CoV-2", "SPECIES", 182, 192], ["This blunting effect", "PROBLEM", 0, 20], ["type I interferon response", "TREATMENT", 24, 50], ["HCQ", "TREATMENT", 100, 103], ["HCQ", "TREATMENT", 163, 166], ["CoV-2 infection", "PROBLEM", 187, 202], ["Significant Cardiac Toxicity", "PROBLEM", 203, 231], ["disease", "PROBLEM", 415, 422], ["drug interactions", "PROBLEM", 423, 440], ["blunting", "OBSERVATION_MODIFIER", 5, 13], ["effect", "OBSERVATION_MODIFIER", 14, 20], ["infection", "OBSERVATION", 193, 202], ["Cardiac", "ANATOMY", 215, 222], ["Toxicity", "OBSERVATION", 223, 231]]], ["Moreover, several studies have reported an increased risk of cardiac toxicity among COVID-19 patients treated with CQ/HCQ.", [["cardiac", "ANATOMY", 61, 68], ["cardiac toxicity", "DISEASE", 61, 77], ["CQ", "CHEMICAL", 115, 117], ["HCQ", "CHEMICAL", 118, 121], ["CQ", "CHEMICAL", 115, 117], ["HCQ", "CHEMICAL", 118, 121], ["cardiac", "ORGAN", 61, 68], ["patients", "ORGANISM", 93, 101], ["CQ", "SIMPLE_CHEMICAL", 115, 117], ["HCQ", "SIMPLE_CHEMICAL", 118, 121], ["patients", "SPECIES", 93, 101], ["several studies", "TEST", 10, 25], ["cardiac toxicity", "PROBLEM", 61, 77], ["CQ/HCQ", "TREATMENT", 115, 121], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["cardiac", "ANATOMY", 61, 68], ["toxicity", "OBSERVATION", 69, 77]]], ["We have shown in a recent meta-analysis that CQ/HCQ treatment in COVID-19 increased the risk of QTc prolongation and discontinuation of drug due to QT prolongation.", [["CQ", "CHEMICAL", 45, 47], ["HCQ", "CHEMICAL", 48, 51], ["QTc prolongation", "DISEASE", 96, 112], ["QT prolongation", "DISEASE", 148, 163], ["CQ", "CHEMICAL", 45, 47], ["HCQ", "CHEMICAL", 48, 51], ["COVID-19", "CHEMICAL", 65, 73], ["CQ", "SIMPLE_CHEMICAL", 45, 47], ["HCQ", "SIMPLE_CHEMICAL", 48, 51], ["COVID-19", "CELL", 65, 73], ["CQ/HCQ treatment", "TREATMENT", 45, 61], ["COVID", "TEST", 65, 70], ["QTc prolongation", "PROBLEM", 96, 112], ["drug", "TREATMENT", 136, 140], ["QT prolongation", "PROBLEM", 148, 163]]], ["In addition, the risk of torsades de pointes ventricular tachycardia (TdP) or monomorphic VT or cardiac arrest was 3 per 1000 (95% CI 0\u00b70-21) [15] .", [["ventricular", "ANATOMY", 45, 56], ["cardiac", "ANATOMY", 96, 103], ["torsades de pointes", "DISEASE", 25, 44], ["ventricular tachycardia", "DISEASE", 45, 68], ["TdP", "DISEASE", 70, 73], ["VT", "DISEASE", 90, 92], ["cardiac arrest", "DISEASE", 96, 110], ["ventricular", "ORGAN", 45, 56], ["torsades", "PROBLEM", 25, 33], ["ventricular tachycardia", "PROBLEM", 45, 68], ["TdP", "PROBLEM", 70, 73], ["monomorphic VT", "PROBLEM", 78, 92], ["cardiac arrest", "PROBLEM", 96, 110], ["CI", "TEST", 131, 133], ["cardiac", "ANATOMY", 96, 103], ["arrest", "OBSERVATION", 104, 110]]], ["Although, in absolute terms, the incidence of TdP was low, it was higher than the reported incidence for some drugs that were withdrawn from the market such as cisapride.", [["TdP", "DISEASE", 46, 49], ["cisapride", "CHEMICAL", 160, 169], ["cisapride", "CHEMICAL", 160, 169], ["cisapride", "SIMPLE_CHEMICAL", 160, 169], ["TdP", "PROBLEM", 46, 49], ["some drugs", "TREATMENT", 105, 115], ["cisapride", "TREATMENT", 160, 169], ["TdP", "OBSERVATION", 46, 49]]], ["We have also found an increased risk of other arrhythmias and other cardiac complications [15] .Significant Cardiac Toxicity ConcernsThe principal mechanism responsible for QT prolongation produced by CQ and HCQ is due to blocking of the KCNH2-encoded hERG/Kv11.1 potassium channel, which is responsible for the rapidly-activating potassium current (I Kr ).", [["cardiac", "ANATOMY", 68, 75], ["Cardiac", "ANATOMY", 108, 115], ["arrhythmias", "DISEASE", 46, 57], ["cardiac complications", "DISEASE", 68, 89], ["Cardiac Toxicity", "DISEASE", 108, 124], ["QT prolongation", "DISEASE", 173, 188], ["CQ", "CHEMICAL", 201, 203], ["HCQ", "CHEMICAL", 208, 211], ["potassium", "CHEMICAL", 264, 273], ["potassium", "CHEMICAL", 331, 340], ["CQ", "CHEMICAL", 201, 203], ["HCQ", "CHEMICAL", 208, 211], ["potassium", "CHEMICAL", 264, 273], ["potassium", "CHEMICAL", 331, 340], ["cardiac", "ORGAN", 68, 75], ["CQ", "SIMPLE_CHEMICAL", 201, 203], ["HCQ", "SIMPLE_CHEMICAL", 208, 211], ["KCNH2", "GENE_OR_GENE_PRODUCT", 238, 243], ["hERG", "GENE_OR_GENE_PRODUCT", 252, 256], ["Kv11.1", "GENE_OR_GENE_PRODUCT", 257, 263], ["potassium", "SIMPLE_CHEMICAL", 331, 340], ["KCNH2", "PROTEIN", 238, 243], ["hERG", "PROTEIN", 252, 256], ["Kv11.1 potassium channel", "PROTEIN", 257, 281], ["I Kr", "PROTEIN", 350, 354], ["other arrhythmias", "PROBLEM", 40, 57], ["other cardiac complications", "PROBLEM", 62, 89], ["Significant Cardiac Toxicity", "PROBLEM", 96, 124], ["QT prolongation", "PROBLEM", 173, 188], ["HCQ", "TREATMENT", 208, 211], ["the KCNH2", "PROBLEM", 234, 243], ["potassium channel", "TREATMENT", 264, 281], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["arrhythmias", "OBSERVATION", 46, 57], ["cardiac", "ANATOMY", 68, 75], ["complications", "OBSERVATION", 76, 89], ["Cardiac", "ANATOMY", 108, 115], ["Toxicity", "OBSERVATION", 116, 124], ["mechanism responsible for", "UNCERTAINTY", 147, 172]]], ["This rapidly-activating current along with the slowlyactivating current (I Ks ) are responsible for pumping potassium ions outside cardiomyocytes.", [["cardiomyocytes", "ANATOMY", 131, 145], ["potassium", "CHEMICAL", 108, 117], ["potassium", "CHEMICAL", 108, 117], ["potassium ions", "SIMPLE_CHEMICAL", 108, 122], ["cardiomyocytes", "CELL", 131, 145], ["cardiomyocytes", "CELL_TYPE", 131, 145], ["pumping potassium ions outside cardiomyocytes", "PROBLEM", 100, 145]]], ["This outward potassium current after the plateau phase (phase 2) of the action potential results in rapid repolarization phase of the action potential (phase 3) [36] .", [["potassium", "CHEMICAL", 13, 22], ["potassium", "CHEMICAL", 13, 22], ["potassium", "SIMPLE_CHEMICAL", 13, 22], ["This outward potassium", "TEST", 0, 22], ["the plateau phase", "TEST", 37, 54]]], ["Genetic mutations in the genes encoding these potassium channels as well as drug-blockage of hERG/Kv11.1 potassium channels result in prolongation of the cardiac action potential that manifests as prolonged QT interval on the surface electrocardiogram [36] .", [["cardiac", "ANATOMY", 154, 161], ["surface", "ANATOMY", 226, 233], ["potassium", "CHEMICAL", 46, 55], ["potassium", "CHEMICAL", 105, 114], ["potassium", "CHEMICAL", 46, 55], ["potassium", "CHEMICAL", 105, 114], ["potassium", "GENE_OR_GENE_PRODUCT", 46, 55], ["hERG", "GENE_OR_GENE_PRODUCT", 93, 97], ["Kv11.1", "GENE_OR_GENE_PRODUCT", 98, 104], ["cardiac", "ORGAN", 154, 161], ["potassium channels", "PROTEIN", 46, 64], ["hERG", "PROTEIN", 93, 97], ["Kv11.1 potassium channels", "PROTEIN", 98, 123], ["Genetic mutations", "PROBLEM", 0, 17], ["these potassium channels", "TREATMENT", 40, 64], ["hERG/Kv11.1 potassium channels", "TREATMENT", 93, 123], ["prolonged QT interval", "PROBLEM", 197, 218], ["the surface electrocardiogram", "TEST", 222, 251], ["cardiac", "ANATOMY", 154, 161]]], ["The intracellular face of the hERG channel is large and is lined with a number of aromatic residues allowing drugs like CQ and HCQ and others to bind this part of the channel and block the outward potassium current [36, 37] .", [["intracellular", "ANATOMY", 4, 17], ["CQ", "CHEMICAL", 120, 122], ["HCQ", "CHEMICAL", 127, 130], ["potassium", "CHEMICAL", 197, 206], ["CQ", "CHEMICAL", 120, 122], ["HCQ", "CHEMICAL", 127, 130], ["potassium", "CHEMICAL", 197, 206], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["hERG", "GENE_OR_GENE_PRODUCT", 30, 34], ["CQ", "SIMPLE_CHEMICAL", 120, 122], ["HCQ", "SIMPLE_CHEMICAL", 127, 130], ["potassium", "SIMPLE_CHEMICAL", 197, 206], ["hERG channel", "PROTEIN", 30, 42], ["aromatic residues", "PROBLEM", 82, 99], ["drugs", "TREATMENT", 109, 114], ["HCQ", "TREATMENT", 127, 130], ["intracellular", "ANATOMY_MODIFIER", 4, 17], ["face", "ANATOMY_MODIFIER", 18, 22], ["hERG channel", "OBSERVATION", 30, 42], ["large", "OBSERVATION", 46, 51], ["aromatic residues", "OBSERVATION", 82, 99]]], ["In a recent study using ex-vivo guinea pig and rabbit heart models, it was shown that HCQ resulted in the generation of repolarization alternans and precipitated polymorphic ventricular tachycardia [38] .Significant Cardiac Toxicity ConcernsIt is also important to take in consideration that the prevalence of congenital long QT syndrome (LQTS) is approximately1 in 2000 people worldwide.", [["heart", "ANATOMY", 54, 59], ["ventricular", "ANATOMY", 174, 185], ["Cardiac", "ANATOMY", 216, 223], ["HCQ", "CHEMICAL", 86, 89], ["ventricular tachycardia", "DISEASE", 174, 197], ["Cardiac Toxicity", "DISEASE", 216, 232], ["congenital long QT syndrome", "DISEASE", 310, 337], ["LQTS", "DISEASE", 339, 343], ["HCQ", "CHEMICAL", 86, 89], ["guinea pig", "ORGANISM", 32, 42], ["rabbit", "ORGANISM", 47, 53], ["heart", "ORGAN", 54, 59], ["HCQ", "SIMPLE_CHEMICAL", 86, 89], ["ventricular", "ORGAN", 174, 185], ["people", "ORGANISM", 371, 377], ["guinea pig", "SPECIES", 32, 42], ["rabbit", "SPECIES", 47, 53], ["people", "SPECIES", 371, 377], ["pig", "SPECIES", 39, 42], ["rabbit", "SPECIES", 47, 53], ["a recent study", "TEST", 3, 17], ["ex-vivo guinea pig and rabbit heart models", "TREATMENT", 24, 66], ["HCQ", "TREATMENT", 86, 89], ["repolarization alternans", "PROBLEM", 120, 144], ["polymorphic ventricular tachycardia", "PROBLEM", 162, 197], ["Significant Cardiac Toxicity", "PROBLEM", 204, 232], ["congenital long QT syndrome", "PROBLEM", 310, 337], ["repolarization alternans", "OBSERVATION", 120, 144], ["Cardiac", "ANATOMY", 216, 223], ["Toxicity", "OBSERVATION", 224, 232]]], ["Importantly, many individuals with LQTS have normal baseline QTc values, but their risk of drug-induced QT prolongation and lethal arrhythmias is increased substantially.", [["LQTS", "DISEASE", 35, 39], ["QT prolongation", "DISEASE", 104, 119], ["arrhythmias", "DISEASE", 131, 142], ["LQTS", "PROBLEM", 35, 39], ["drug-induced QT prolongation", "PROBLEM", 91, 119], ["lethal arrhythmias", "PROBLEM", 124, 142], ["lethal", "OBSERVATION_MODIFIER", 124, 130], ["arrhythmias", "OBSERVATION", 131, 142], ["increased", "OBSERVATION_MODIFIER", 146, 155]]], ["Furthermore, 8% of individuals of African descent (p.Ser1103Tyr-SCN5A) and 2% of individuals of European descent (p.Asp85Asn-KCNE1) possess potentially pro-arrhythmic common variants associated with an increased risk of druginduced long QT and sudden cardiac death [39] .", [["cardiac", "ANATOMY", 251, 258], ["sudden cardiac death", "DISEASE", 244, 264], ["p.Asp85Asn-KCNE1", "GENE_OR_GENE_PRODUCT", 114, 130], ["cardiac", "ORGAN", 251, 258], ["KCNE1", "PROTEIN", 125, 130], ["African descent", "TEST", 34, 49], ["European descent", "PROBLEM", 96, 112], ["pro-arrhythmic common variants", "PROBLEM", 152, 182], ["druginduced long QT", "PROBLEM", 220, 239], ["sudden cardiac death", "PROBLEM", 244, 264], ["increased", "OBSERVATION_MODIFIER", 202, 211], ["cardiac", "ANATOMY", 251, 258], ["death", "OBSERVATION", 259, 264]]], ["Although the percentage of people with an inherent genetic risk is small (roughly 10%), the fact that SARS-CoV-2 infection has been spreading widely across the globe affecting millions of people, the total number of individuals at risk for drug-induced QT prolongation and TdP associated with indiscriminate use of CQ and HCQ may be unacceptably high [40] .Significant Cardiac Toxicity ConcernsIt is important to note that patients with underlying cardiac diseases and comorbidities as well as inflammatory states are at increased risk of drug induced QTc prolongation [41] .", [["Cardiac", "ANATOMY", 369, 376], ["cardiac", "ANATOMY", 448, 455], ["SARS", "DISEASE", 102, 106], ["infection", "DISEASE", 113, 122], ["QT prolongation", "DISEASE", 253, 268], ["TdP", "DISEASE", 273, 276], ["CQ", "CHEMICAL", 315, 317], ["HCQ", "CHEMICAL", 322, 325], ["Cardiac Toxicity", "DISEASE", 369, 385], ["cardiac diseases", "DISEASE", 448, 464], ["QTc prolongation", "DISEASE", 552, 568], ["HCQ", "CHEMICAL", 322, 325], ["people", "ORGANISM", 27, 33], ["SARS-CoV-2", "ORGANISM", 102, 112], ["people", "ORGANISM", 188, 194], ["CQ", "SIMPLE_CHEMICAL", 315, 317], ["HCQ", "SIMPLE_CHEMICAL", 322, 325], ["patients", "ORGANISM", 423, 431], ["cardiac", "ORGAN", 448, 455], ["people", "SPECIES", 27, 33], ["people", "SPECIES", 188, 194], ["patients", "SPECIES", 423, 431], ["SARS-CoV-2", "SPECIES", 102, 112], ["SARS", "PROBLEM", 102, 106], ["CoV-2 infection", "PROBLEM", 107, 122], ["drug-induced QT prolongation", "PROBLEM", 240, 268], ["TdP", "PROBLEM", 273, 276], ["HCQ", "TREATMENT", 322, 325], ["Significant Cardiac Toxicity", "PROBLEM", 357, 385], ["underlying cardiac diseases", "PROBLEM", 437, 464], ["comorbidities", "PROBLEM", 469, 482], ["inflammatory states", "PROBLEM", 494, 513], ["drug induced QTc prolongation", "PROBLEM", 539, 568], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["small", "OBSERVATION_MODIFIER", 67, 72], ["SARS", "OBSERVATION", 102, 106], ["infection", "OBSERVATION", 113, 122], ["globe", "ANATOMY", 160, 165], ["Cardiac", "ANATOMY", 369, 376], ["Toxicity", "OBSERVATION", 377, 385], ["cardiac", "ANATOMY", 448, 455], ["diseases", "OBSERVATION", 456, 464], ["inflammatory", "OBSERVATION", 494, 506]]], ["Patients with severe COVID-19 disease usually have hypoxemia and may manifest hypotension and electrolyte imbalance and may need ICU admission; all of which have been shown to increase the risk of QTc prolongation in response to QT prolonging drugs [41] [42] [43] [44] [45] .", [["COVID-19 disease", "DISEASE", 21, 37], ["hypoxemia", "DISEASE", 51, 60], ["hypotension", "DISEASE", 78, 89], ["QTc prolongation", "DISEASE", 197, 213], ["[41] [42] [43] [44]", "CHEMICAL", 249, 268], ["Patients", "ORGANISM", 0, 8], ["[41] [42] [43] [44] [45]", "SIMPLE_CHEMICAL", 249, 273], ["Patients", "SPECIES", 0, 8], ["severe COVID-19 disease", "PROBLEM", 14, 37], ["hypoxemia", "PROBLEM", 51, 60], ["hypotension", "PROBLEM", 78, 89], ["electrolyte imbalance", "PROBLEM", 94, 115], ["QTc prolongation", "PROBLEM", 197, 213], ["QT prolonging drugs", "TREATMENT", 229, 248], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["hypoxemia", "OBSERVATION", 51, 60]]], ["Moreover, COVID-19 patient manifest fever and raised interleukin-6 levels, which have been linked to increased risk of QT prolongation in response to drugs and inflammation [46, 47] .Significant Cardiac Toxicity ConcernsHCQ use has also been associated with bradycardia.", [["Cardiac", "ANATOMY", 195, 202], ["fever", "DISEASE", 36, 41], ["QT prolongation", "DISEASE", 119, 134], ["inflammation", "DISEASE", 160, 172], ["Cardiac Toxicity", "DISEASE", 195, 211], ["bradycardia", "DISEASE", 258, 269], ["patient", "ORGANISM", 19, 26], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 53, 66], ["interleukin-6", "PROTEIN", 53, 66], ["patient", "SPECIES", 19, 26], ["COVID", "TEST", 10, 15], ["fever", "PROBLEM", 36, 41], ["raised interleukin-6 levels", "PROBLEM", 46, 73], ["QT prolongation", "PROBLEM", 119, 134], ["drugs", "TREATMENT", 150, 155], ["inflammation", "PROBLEM", 160, 172], ["Significant Cardiac Toxicity", "PROBLEM", 183, 211], ["bradycardia", "PROBLEM", 258, 269], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["QT prolongation", "OBSERVATION", 119, 134], ["Cardiac", "ANATOMY", 195, 202], ["Toxicity", "OBSERVATION", 203, 211]]], ["In a study of mouse atria, spontaneous beating was significantly reduced by HCQ.", [["atria", "ANATOMY", 20, 25], ["HCQ", "CHEMICAL", 76, 79], ["HCQ", "CHEMICAL", 76, 79], ["mouse", "ORGANISM", 14, 19], ["atria", "MULTI-TISSUE_STRUCTURE", 20, 25], ["HCQ", "SIMPLE_CHEMICAL", 76, 79], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["a study", "TEST", 3, 10], ["spontaneous beating", "PROBLEM", 27, 46], ["mouse atria", "ANATOMY", 14, 25]]], ["Similarly, these findings were confirmed in sinoatrial node cells from pigs with a clear dose-dependent effect [48] .", [["sinoatrial node cells", "ANATOMY", 44, 65], ["sinoatrial node cells", "CELL", 44, 65], ["pigs", "ORGANISM", 71, 75], ["sinoatrial node cells", "CELL_TYPE", 44, 65], ["pigs", "SPECIES", 71, 75], ["pigs", "SPECIES", 71, 75], ["sinoatrial node cells", "PROBLEM", 44, 65], ["sinoatrial node cells", "OBSERVATION", 44, 65]]], ["This is important for patients who might be taking HCQ and concomitant beta-blockers or amiodarone.", [["HCQ", "CHEMICAL", 51, 54], ["amiodarone", "CHEMICAL", 88, 98], ["HCQ", "CHEMICAL", 51, 54], ["amiodarone", "CHEMICAL", 88, 98], ["patients", "ORGANISM", 22, 30], ["HCQ", "SIMPLE_CHEMICAL", 51, 54], ["beta-blockers", "SIMPLE_CHEMICAL", 71, 84], ["amiodarone", "SIMPLE_CHEMICAL", 88, 98], ["patients", "SPECIES", 22, 30], ["HCQ", "TREATMENT", 51, 54], ["concomitant beta-blockers", "TREATMENT", 59, 84], ["amiodarone", "TREATMENT", 88, 98]]], ["These combinations especially in the setting of electrolyte imbalances will result in significant reduction of the automaticity of the heart and may lead to significant bradycardia.", [["heart", "ANATOMY", 135, 140], ["bradycardia", "DISEASE", 169, 180], ["heart", "ORGAN", 135, 140], ["electrolyte imbalances", "PROBLEM", 48, 70], ["significant reduction of the automaticity of the heart", "PROBLEM", 86, 140], ["significant bradycardia", "PROBLEM", 157, 180], ["electrolyte imbalances", "OBSERVATION", 48, 70], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["reduction", "OBSERVATION", 98, 107], ["automaticity", "OBSERVATION", 115, 127], ["heart", "ANATOMY", 135, 140], ["may lead to", "UNCERTAINTY", 145, 156], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["bradycardia", "OBSERVATION", 169, 180]]], ["Finally, these drugs have active metabolites and relatively long elimination half-lives, especially in critically ill patients with multi-organ failure and this might increase their arrhythmogenic risk [49] .Significant Cardiac Toxicity ConcernsIt is also important to mention that it has been a common practice to use HCQ in combination with azithromycin for COVID-19 during the current pandemic.", [["multi-organ", "ANATOMY", 132, 143], ["Cardiac", "ANATOMY", 220, 227], ["critically ill", "DISEASE", 103, 117], ["multi-organ failure", "DISEASE", 132, 151], ["Cardiac Toxicity", "DISEASE", 220, 236], ["HCQ", "CHEMICAL", 319, 322], ["azithromycin", "CHEMICAL", 343, 355], ["COVID-19", "CHEMICAL", 360, 368], ["HCQ", "CHEMICAL", 319, 322], ["azithromycin", "CHEMICAL", 343, 355], ["patients", "ORGANISM", 118, 126], ["multi-organ", "ORGAN", 132, 143], ["HCQ", "SIMPLE_CHEMICAL", 319, 322], ["azithromycin", "SIMPLE_CHEMICAL", 343, 355], ["patients", "SPECIES", 118, 126], ["active metabolites", "PROBLEM", 26, 44], ["multi-organ failure", "PROBLEM", 132, 151], ["Significant Cardiac Toxicity", "PROBLEM", 208, 236], ["HCQ", "TREATMENT", 319, 322], ["azithromycin", "TREATMENT", 343, 355], ["COVID", "TREATMENT", 360, 365], ["multi-organ", "ANATOMY", 132, 143], ["failure", "OBSERVATION", 144, 151], ["Cardiac", "ANATOMY", 220, 227], ["Toxicity", "OBSERVATION", 228, 236]]], ["Azithromycin has been identified as a potential cause of significant serious cardiac arrhythmias through QT prolongation dependent and independent mechanisms and has been linked to increased risk of sudden cardiac death [50, 51] .", [["cardiac", "ANATOMY", 77, 84], ["cardiac", "ANATOMY", 206, 213], ["Azithromycin", "CHEMICAL", 0, 12], ["cardiac arrhythmias", "DISEASE", 77, 96], ["sudden cardiac death", "DISEASE", 199, 219], ["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["cardiac", "ORGAN", 77, 84], ["cardiac", "ORGAN", 206, 213], ["Azithromycin", "TREATMENT", 0, 12], ["significant serious cardiac arrhythmias", "PROBLEM", 57, 96], ["QT prolongation dependent", "PROBLEM", 105, 130], ["sudden cardiac death", "PROBLEM", 199, 219], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["serious", "OBSERVATION_MODIFIER", 69, 76], ["cardiac", "ANATOMY", 77, 84], ["arrhythmias", "OBSERVATION", 85, 96], ["cardiac", "ANATOMY", 206, 213], ["death", "OBSERVATION", 214, 219]]], ["Hence, the concomitant use of CQ/HCQ and azithromycin or other QT prolonging agents could potentially increase the risk of serious cardiac arrhythmias and death particularly in critically ill patients or those with risk factors for QT prolongation.Significant Cardiac Toxicity ConcernsIncreased risk of cardiac complications associated with the combination therapy of HCQ and azithromycin has also been reported in a recent preprint of a large population study of 956,374 users of HCQ.", [["cardiac", "ANATOMY", 131, 138], ["Cardiac", "ANATOMY", 260, 267], ["cardiac", "ANATOMY", 303, 310], ["CQ", "CHEMICAL", 30, 32], ["HCQ", "CHEMICAL", 33, 36], ["azithromycin", "CHEMICAL", 41, 53], ["cardiac arrhythmias", "DISEASE", 131, 150], ["death", "DISEASE", 155, 160], ["critically ill", "DISEASE", 177, 191], ["QT prolongation", "DISEASE", 232, 247], ["Cardiac Toxicity", "DISEASE", 260, 276], ["cardiac complications", "DISEASE", 303, 324], ["HCQ", "CHEMICAL", 368, 371], ["azithromycin", "CHEMICAL", 376, 388], ["HCQ", "CHEMICAL", 481, 484], ["CQ", "CHEMICAL", 30, 32], ["HCQ", "CHEMICAL", 33, 36], ["azithromycin", "CHEMICAL", 41, 53], ["HCQ", "CHEMICAL", 368, 371], ["azithromycin", "CHEMICAL", 376, 388], ["HCQ", "CHEMICAL", 481, 484], ["CQ", "SIMPLE_CHEMICAL", 30, 32], ["HCQ", "SIMPLE_CHEMICAL", 33, 36], ["azithromycin", "SIMPLE_CHEMICAL", 41, 53], ["cardiac", "ORGAN", 131, 138], ["patients", "ORGANISM", 192, 200], ["cardiac", "ORGAN", 303, 310], ["HCQ", "SIMPLE_CHEMICAL", 368, 371], ["azithromycin", "SIMPLE_CHEMICAL", 376, 388], ["HCQ", "SIMPLE_CHEMICAL", 481, 484], ["patients", "SPECIES", 192, 200], ["CQ/HCQ", "TREATMENT", 30, 36], ["azithromycin", "TREATMENT", 41, 53], ["other QT prolonging agents", "TREATMENT", 57, 83], ["serious cardiac arrhythmias", "PROBLEM", 123, 150], ["death", "PROBLEM", 155, 160], ["QT prolongation", "PROBLEM", 232, 247], ["Significant Cardiac Toxicity", "PROBLEM", 248, 276], ["cardiac complications", "PROBLEM", 303, 324], ["the combination therapy", "TREATMENT", 341, 364], ["HCQ", "TREATMENT", 368, 371], ["azithromycin", "TREATMENT", 376, 388], ["a large population study", "TEST", 436, 460], ["HCQ", "TREATMENT", 481, 484], ["serious", "OBSERVATION_MODIFIER", 123, 130], ["cardiac", "ANATOMY", 131, 138], ["arrhythmias", "OBSERVATION", 139, 150], ["Cardiac", "ANATOMY", 260, 267], ["Toxicity", "OBSERVATION", 268, 276], ["cardiac", "ANATOMY", 303, 310], ["complications", "OBSERVATION", 311, 324]]], ["Among these patients, 323,122 were also treated with azithromycin.", [["azithromycin", "CHEMICAL", 53, 65], ["azithromycin", "CHEMICAL", 53, 65], ["patients", "ORGANISM", 12, 20], ["azithromycin", "SIMPLE_CHEMICAL", 53, 65], ["patients", "SPECIES", 12, 20], ["azithromycin", "TREATMENT", 53, 65]]], ["This combination therapy was associated with increased risk of 30-day cardiac mortality (CalHR 2.19, 95% CI 1.22-3.94), chest pain/angina (CalHR 1.15, 95% CI 1.05-1.26), and heart failure (CalHR 1.22, 95% CI 1.02-1.45) [52] .Significant Cardiac Toxicity ConcernsA recent study examined the prescription pattern of several drugs in USA and observed an almost 2000% increase in prescriptions for CQ and HCQ for fewer than 28 tablet fills for the week of March 15-21, 2020 in comparison with the same week in 2019.", [["cardiac", "ANATOMY", 70, 77], ["chest", "ANATOMY", 120, 125], ["heart", "ANATOMY", 174, 179], ["Cardiac", "ANATOMY", 237, 244], ["chest pain", "DISEASE", 120, 130], ["angina", "DISEASE", 131, 137], ["heart failure", "DISEASE", 174, 187], ["Cardiac Toxicity", "DISEASE", 237, 253], ["CQ", "CHEMICAL", 394, 396], ["HCQ", "CHEMICAL", 401, 404], ["HCQ", "CHEMICAL", 401, 404], ["cardiac", "ORGAN", 70, 77], ["chest", "ORGANISM_SUBDIVISION", 120, 125], ["heart", "ORGAN", 174, 179], ["CQ", "SIMPLE_CHEMICAL", 394, 396], ["HCQ", "SIMPLE_CHEMICAL", 401, 404], ["This combination therapy", "TREATMENT", 0, 24], ["CalHR", "TEST", 89, 94], ["CI", "TEST", 105, 107], ["chest pain", "PROBLEM", 120, 130], ["angina", "PROBLEM", 131, 137], ["CalHR", "TEST", 139, 144], ["CI", "TEST", 155, 157], ["heart failure", "PROBLEM", 174, 187], ["CalHR", "TEST", 189, 194], ["CI", "TEST", 205, 207], ["Significant Cardiac Toxicity", "PROBLEM", 225, 253], ["recent study", "TEST", 264, 276], ["CQ", "TREATMENT", 394, 396], ["HCQ", "TREATMENT", 401, 404], ["chest", "ANATOMY", 120, 125], ["angina", "OBSERVATION", 131, 137], ["heart", "ANATOMY", 174, 179], ["failure", "OBSERVATION", 180, 187], ["Cardiac", "ANATOMY", 237, 244], ["Toxicity", "OBSERVATION", 245, 253]]], ["This remarkable surge in CQ/HCQ use could lead to a substantial increase in preventable serious cardiac adverse events and mortality.Conclusion:Treatment of SARS-CoV-2 infection with HCQ was not met with the expected success.", [["cardiac", "ANATOMY", 96, 103], ["CQ", "CHEMICAL", 25, 27], ["HCQ", "CHEMICAL", 28, 31], ["cardiac adverse events", "DISEASE", 96, 118], ["SARS-CoV-2 infection", "DISEASE", 157, 177], ["HCQ", "CHEMICAL", 183, 186], ["CQ", "CHEMICAL", 25, 27], ["HCQ", "CHEMICAL", 28, 31], ["HCQ", "CHEMICAL", 183, 186], ["CQ", "SIMPLE_CHEMICAL", 25, 27], ["HCQ", "SIMPLE_CHEMICAL", 28, 31], ["cardiac", "ORGAN", 96, 103], ["SARS-CoV-2", "ORGANISM", 157, 167], ["HCQ", "SIMPLE_CHEMICAL", 183, 186], ["SARS-CoV-2", "SPECIES", 157, 167], ["CQ/HCQ", "TREATMENT", 25, 31], ["preventable serious cardiac adverse events", "PROBLEM", 76, 118], ["SARS", "PROBLEM", 157, 161], ["CoV", "PROBLEM", 162, 165], ["2 infection", "PROBLEM", 166, 177], ["HCQ", "TREATMENT", 183, 186], ["substantial", "OBSERVATION_MODIFIER", 52, 63], ["increase", "OBSERVATION_MODIFIER", 64, 72], ["preventable", "OBSERVATION_MODIFIER", 76, 87], ["serious", "OBSERVATION_MODIFIER", 88, 95]]], ["This is probably related to its mechanism of action and the inability of the current dosing regimens to achieve the required blood concentration necessary for effective antiviral activity.", [["blood", "ANATOMY", 125, 130], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["the current dosing regimens", "TREATMENT", 73, 100], ["the required blood concentration", "TREATMENT", 112, 144], ["effective antiviral activity", "TREATMENT", 159, 187], ["probably related to", "UNCERTAINTY", 8, 27], ["antiviral activity", "OBSERVATION", 169, 187]]], ["Moreover, HCQ monotherapy or in combination with azithromycin increased the risk of cardiac adverse events including QT prolongation, arrhythmias and other cardiac complications.", [["cardiac", "ANATOMY", 84, 91], ["cardiac", "ANATOMY", 156, 163], ["HCQ", "CHEMICAL", 10, 13], ["azithromycin", "CHEMICAL", 49, 61], ["cardiac adverse events", "DISEASE", 84, 106], ["QT prolongation", "DISEASE", 117, 132], ["arrhythmias", "DISEASE", 134, 145], ["cardiac complications", "DISEASE", 156, 177], ["HCQ", "CHEMICAL", 10, 13], ["azithromycin", "CHEMICAL", 49, 61], ["HCQ", "SIMPLE_CHEMICAL", 10, 13], ["azithromycin", "SIMPLE_CHEMICAL", 49, 61], ["cardiac", "ORGAN", 84, 91], ["cardiac", "ORGAN", 156, 163], ["HCQ monotherapy", "TREATMENT", 10, 25], ["azithromycin", "TREATMENT", 49, 61], ["cardiac adverse events", "PROBLEM", 84, 106], ["QT prolongation", "PROBLEM", 117, 132], ["arrhythmias", "PROBLEM", 134, 145], ["other cardiac complications", "PROBLEM", 150, 177], ["cardiac", "ANATOMY", 84, 91], ["adverse", "OBSERVATION", 92, 99], ["cardiac", "ANATOMY", 156, 163], ["complications", "OBSERVATION", 164, 177]]], ["It is time to move on and examine other potential therapeutics in our battle against the COVID-19 pandemic.", [["COVID-19", "ORGANISM", 89, 97], ["the COVID", "TEST", 85, 94], ["pandemic", "PROBLEM", 98, 106]]]], "PMC7113789": [["IntroductionThe severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome during the 2002\u20132003 outbreak (Peiris et al., 2003).", [["acute respiratory syndrome coronavirus", "DISEASE", 23, 61], ["SARS-CoV)", "DISEASE", 63, 72], ["acute respiratory syndrome", "DISEASE", 123, 149], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 16, 61], ["SARS-CoV", "ORGANISM", 63, 71], ["severe acute respiratory syndrome coronavirus", "SPECIES", 16, 61], ["SARS-CoV", "SPECIES", 63, 71], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 12, 61], ["severe acute respiratory syndrome", "PROBLEM", 116, 149], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome coronavirus", "OBSERVATION", 29, 61], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory syndrome", "OBSERVATION", 129, 149]]], ["SARS-CoV belongs to the genus Betacoronavirus of the family Coronaviridae (King et al., 2011).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8]]], ["Coronaviruses are enveloped viruses with positive-sense, non-segmented, single-stranded RNA genomes, characterized by club-like projections on the virus particles (Masters, 2006).", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["non-segmented, single-stranded RNA genomes", "DNA", 57, 99], ["Coronaviruses", "PROBLEM", 0, 13], ["single-stranded RNA genomes", "PROBLEM", 72, 99], ["enveloped", "OBSERVATION_MODIFIER", 18, 27], ["viruses", "OBSERVATION", 28, 35], ["RNA genomes", "OBSERVATION", 88, 99], ["club", "OBSERVATION_MODIFIER", 118, 122]]], ["The first two thirds of the coronavirus genome encode the replicase genes, which are translated into two large polyproteins, pp1a and pp1ab, that are processed into 15 or 16 non-structural proteins (nsp) via proteolytic cleavage (Thiel et al., 2003).", [["coronavirus", "ORGANISM", 28, 39], ["pp1a", "GENE_OR_GENE_PRODUCT", 125, 129], ["pp1ab", "GENE_OR_GENE_PRODUCT", 134, 139], ["nsp", "GENE_OR_GENE_PRODUCT", 199, 202], ["coronavirus genome", "DNA", 28, 46], ["replicase genes", "DNA", 58, 73], ["polyproteins", "PROTEIN", 111, 123], ["pp1a", "PROTEIN", 125, 129], ["pp1ab", "PROTEIN", 134, 139], ["structural proteins", "PROTEIN", 178, 197], ["nsp", "PROTEIN", 199, 202], ["coronavirus", "SPECIES", 28, 39], ["16 non-structural proteins (nsp) via proteolytic cleavage", "PROBLEM", 171, 228], ["coronavirus genome", "OBSERVATION", 28, 46], ["replicase genes", "OBSERVATION", 58, 73], ["large", "OBSERVATION_MODIFIER", 105, 110], ["polyproteins", "OBSERVATION", 111, 123]]], ["The remaining one third of the genome contains ORFs for the structural proteins, namely the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins.IntroductionIn addition to these genomic elements shared by other coronaviruses, the SARS-CoV genome also contains eight ORFs coding for accessory proteins, namely ORFs 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b (Fig. 1).", [["membrane", "ANATOMY", 117, 125], ["SARS", "DISEASE", 246, 250], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 135, 160], ["SARS-CoV", "ORGANISM", 246, 254], ["7b", "GENE_OR_GENE_PRODUCT", 345, 347], ["8a", "GENE_OR_GENE_PRODUCT", 349, 351], ["b", "GENE_OR_GENE_PRODUCT", 354, 355], ["ORFs", "DNA", 47, 51], ["structural proteins", "PROTEIN", 60, 79], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 92, 129], ["nucleocapsid (N) proteins", "PROTEIN", 135, 160], ["genomic elements", "DNA", 194, 210], ["SARS-CoV genome", "DNA", 246, 261], ["ORFs", "DNA", 282, 286], ["accessory proteins", "PROTEIN", 298, 316], ["ORFs 3a, 3b, 6, 7a, 7b, 8a, 8b", "DNA", 325, 355], ["SARS-CoV", "SPECIES", 246, 254], ["the structural proteins", "PROBLEM", 56, 79], ["the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins", "PROBLEM", 88, 160], ["IntroductionIn", "TREATMENT", 161, 175], ["these genomic elements", "TREATMENT", 188, 210], ["the SARS-CoV genome", "PROBLEM", 242, 261], ["accessory proteins", "PROBLEM", 298, 316], ["ORFs", "TEST", 325, 329], ["genome", "OBSERVATION", 31, 37], ["ORFs", "OBSERVATION", 47, 51]]], ["These proteins are specific for SARS-CoV and do not show significant homology to accessory proteins of other coronaviruses, with the exception of the SARS-like coronavirus SL-CoV-WIV1 that was recently discovered in bats (Ge et al., 2013) and has the same set of accessory proteins as SARS-CoV.", [["SARS", "DISEASE", 150, 154], ["SARS-CoV", "ORGANISM", 32, 40], ["coronaviruses", "ORGANISM", 109, 122], ["SARS-like coronavirus SL-CoV", "ORGANISM", 150, 178], ["-WIV1", "ORGANISM", 178, 183], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 285, 293], ["accessory proteins", "PROTEIN", 81, 99], ["WIV1", "DNA", 179, 183], ["accessory proteins", "PROTEIN", 263, 281], ["SARS-CoV", "PROTEIN", 285, 293], ["coronavirus", "SPECIES", 160, 171], ["SARS-CoV", "SPECIES", 32, 40], ["SARS-CoV", "SPECIES", 285, 293], ["These proteins", "TEST", 0, 14], ["SARS", "PROBLEM", 32, 36], ["CoV", "PROBLEM", 37, 40], ["other coronaviruses", "PROBLEM", 103, 122], ["the SARS", "PROBLEM", 146, 154], ["coronavirus SL", "TEST", 160, 174]]], ["The potential connection between these accessory proteins and the high virulence of SARS-CoV has led to detailed structural and functional studies.IntroductionCoronavirus accessory proteins have been generally considered to be dispensable for viral replication in vitro (de Haan et al., 2002, Haijema et al., 2004, Yount et al., 2005, Ontiveros et al., 2001, Shen et al., 2003, Hodgson et al., 2006, Casais et al., 2005).", [["SARS", "DISEASE", 84, 88], ["SARS-CoV", "ORGANISM", 84, 92], ["Coronavirus accessory proteins", "GENE_OR_GENE_PRODUCT", 159, 189], ["accessory proteins", "PROTEIN", 39, 57], ["Coronavirus accessory proteins", "PROTEIN", 159, 189], ["SARS-CoV", "SPECIES", 84, 92], ["these accessory proteins", "PROBLEM", 33, 57], ["SARS", "PROBLEM", 84, 88], ["detailed structural and functional studies", "TEST", 104, 146], ["IntroductionCoronavirus accessory proteins", "PROBLEM", 147, 189]]], ["However, several accessory proteins have been shown to exhibit functions in virus-host interactions during coronavirus infection in vivo.", [["coronavirus infection", "DISEASE", 107, 128], ["coronavirus", "ORGANISM", 107, 118], ["accessory proteins", "PROTEIN", 17, 35], ["coronavirus", "SPECIES", 107, 118], ["several accessory proteins", "PROBLEM", 9, 35], ["functions in virus", "PROBLEM", 63, 81], ["coronavirus infection", "PROBLEM", 107, 128], ["virus", "OBSERVATION", 76, 81]]], ["For example, deletion of ORF2a (NS2), HE, ORF4, and ORF5a in the mouse hepatitis virus (MHV) led to a significant attenuation of the virus in its natural host (de Haan et al., 2002).", [["hepatitis virus", "DISEASE", 71, 86], ["ORF2a", "GENE_OR_GENE_PRODUCT", 25, 30], ["NS2", "GENE_OR_GENE_PRODUCT", 32, 35], ["HE", "GENE_OR_GENE_PRODUCT", 38, 40], ["ORF4", "GENE_OR_GENE_PRODUCT", 42, 46], ["ORF5a", "GENE_OR_GENE_PRODUCT", 52, 57], ["mouse hepatitis virus", "ORGANISM", 65, 86], ["MHV", "ORGANISM", 88, 91], ["ORF2a", "PROTEIN", 25, 30], ["NS2", "PROTEIN", 32, 35], ["HE", "PROTEIN", 38, 40], ["ORF4", "PROTEIN", 42, 46], ["ORF5a", "DNA", 52, 57], ["mouse", "SPECIES", 65, 70], ["hepatitis virus", "SPECIES", 71, 86], ["mouse hepatitis virus", "SPECIES", 65, 86], ["MHV", "SPECIES", 88, 91], ["deletion of ORF2a (NS2)", "PROBLEM", 13, 36], ["ORF4", "TEST", 42, 46], ["ORF5a", "TREATMENT", 52, 57], ["the mouse hepatitis virus", "PROBLEM", 61, 86], ["a significant attenuation of the virus", "PROBLEM", 100, 138], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["attenuation", "OBSERVATION_MODIFIER", 114, 125], ["virus", "OBSERVATION", 133, 138]]], ["On the other hand, continuous passage of infectious bronchitis virus (IBV) in cell culture results in a mutation in the 3b gene coding for a C-terminally truncated 3b protein.", [["cell culture", "ANATOMY", 78, 90], ["infectious bronchitis", "DISEASE", 41, 62], ["C", "CHEMICAL", 141, 142], ["infectious bronchitis virus", "ORGANISM", 41, 68], ["IBV", "ORGANISM", 70, 73], ["cell culture", "CELL", 78, 90], ["C-terminally truncated 3b", "GENE_OR_GENE_PRODUCT", 141, 166], ["3b gene", "DNA", 120, 127], ["C-terminally truncated 3b protein", "PROTEIN", 141, 174], ["infectious bronchitis virus", "SPECIES", 41, 68], ["infectious bronchitis virus", "SPECIES", 41, 68], ["IBV", "SPECIES", 70, 73], ["infectious bronchitis virus", "PROBLEM", 41, 68], ["cell culture", "TEST", 78, 90], ["a mutation", "PROBLEM", 102, 112], ["a C", "TEST", 139, 142], ["infectious", "OBSERVATION_MODIFIER", 41, 51], ["bronchitis", "OBSERVATION", 52, 62]]], ["Interestingly, compared with wild-type virus, the mutant virus has a growth advantage and increases virulence in the chicken embryo (Shen et al., 2003).", [["embryo", "ANATOMY", 125, 131], ["wild-type virus", "ORGANISM", 29, 44], ["mutant virus", "ORGANISM", 50, 62], ["chicken", "ORGANISM", 117, 124], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 125, 131], ["chicken", "SPECIES", 117, 124], ["chicken", "SPECIES", 117, 124], ["wild-type virus", "PROBLEM", 29, 44], ["the mutant virus", "PROBLEM", 46, 62]]], ["Similarly, recent studies have suggested that SARS-CoV accessory proteins may confer biological advantages to the virus in the natural host, and contribute to the pathogenesis of SARS (Narayanan et al., 2008).", [["SARS", "DISEASE", 46, 50], ["SARS", "DISEASE", 179, 183], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 46, 54], ["SARS-CoV accessory proteins", "PROTEIN", 46, 73], ["SARS-CoV", "SPECIES", 46, 54], ["recent studies", "TEST", 11, 25], ["SARS", "PROBLEM", 46, 50], ["CoV accessory proteins", "TREATMENT", 51, 73], ["the virus", "PROBLEM", 110, 119], ["SARS", "PROBLEM", 179, 183]]], ["Extensive functional studies in cell culture and animal models have shown that SARS-CoV accessory proteins are involved in a wide variety of cellular processes, such as cell proliferation, programmed cell death, activation of stress response pathways and cytokine production, to name just a few.", [["cell culture", "ANATOMY", 32, 44], ["cellular", "ANATOMY", 141, 149], ["cell", "ANATOMY", 169, 173], ["cell", "ANATOMY", 200, 204], ["cell culture", "CELL", 32, 44], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 79, 87], ["cellular", "CELL", 141, 149], ["cell", "CELL", 169, 173], ["cell", "CELL", 200, 204], ["SARS-CoV accessory proteins", "PROTEIN", 79, 106], ["cytokine", "PROTEIN", 255, 263], ["SARS-CoV", "SPECIES", 79, 87], ["Extensive functional studies", "TEST", 0, 28], ["cell culture", "TEST", 32, 44], ["animal models", "TEST", 49, 62], ["SARS", "PROBLEM", 79, 83], ["CoV accessory proteins", "PROBLEM", 84, 106], ["cellular processes", "PROBLEM", 141, 159], ["cell proliferation", "PROBLEM", 169, 187], ["programmed cell death", "PROBLEM", 189, 210], ["stress response pathways", "PROBLEM", 226, 250], ["cytokine production", "PROBLEM", 255, 274], ["cellular processes", "OBSERVATION", 141, 159], ["cell proliferation", "OBSERVATION", 169, 187], ["cell death", "OBSERVATION", 200, 210]]], ["Notably, some coronaviral accessory proteins have also been shown to modulate the interferon signaling, which is of paramount importance for host antiviral immunity (Frieman et al., 2007, Dedeurwaerder et al., 2014, Zhang et al., 2013, Cruz et al., 2013).IntroductionAs part of a series of invited articles in Antiviral Research on \u201cFrom SARS to MERS: 10 years of research on highly pathogenic human coronaviruses\u201d (Hilgenfeld and Peiris, 2013), this review summerizes our current knowledge on SARS-CoV accessory proteins, including an update on structural and functional studies, with a particular emphasis on the involvement of accessory proteins in virus-host interactions.", [["SARS", "DISEASE", 338, 342], ["human coronaviruses", "DISEASE", 394, 413], ["interferon", "GENE_OR_GENE_PRODUCT", 82, 92], ["human", "ORGANISM", 394, 399], ["coronaviruses", "ORGANISM", 400, 413], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 494, 502], ["coronaviral accessory proteins", "PROTEIN", 14, 44], ["interferon", "PROTEIN", 82, 92], ["SARS-CoV accessory proteins", "PROTEIN", 494, 521], ["accessory proteins", "PROTEIN", 630, 648], ["human", "SPECIES", 394, 399], ["human coronaviruses", "SPECIES", 394, 413], ["SARS-CoV", "SPECIES", 494, 502], ["some coronaviral accessory proteins", "PROBLEM", 9, 44], ["the interferon signaling", "PROBLEM", 78, 102], ["functional studies", "TEST", 561, 579], ["accessory proteins", "PROBLEM", 630, 648], ["interferon", "OBSERVATION", 82, 92]]], ["In addition, we will briefly summarize the current knowledge on accessory proteins of other coronaviruses.Orf3a ::: Accessory proteins of the SARS-CoVProteins 3a and 3b (p3a and p3b, previously also known as X1 and X2), comprise 274 and 154 amino-acid residues, respectively (Marra et al., 2003, Rota et al., 2003).", [["amino-acid", "CHEMICAL", 241, 251], ["amino-acid", "CHEMICAL", 241, 251], ["coronaviruses", "ORGANISM", 92, 105], ["SARS-CoVProteins 3a", "GENE_OR_GENE_PRODUCT", 142, 161], ["3b", "GENE_OR_GENE_PRODUCT", 166, 168], ["p3a", "GENE_OR_GENE_PRODUCT", 170, 173], ["p3b", "GENE_OR_GENE_PRODUCT", 178, 181], ["X1", "GENE_OR_GENE_PRODUCT", 208, 210], ["X2", "GENE_OR_GENE_PRODUCT", 215, 217], ["accessory proteins", "PROTEIN", 64, 82], ["Orf3", "PROTEIN", 106, 110], ["Accessory proteins", "PROTEIN", 116, 134], ["SARS-CoVProteins 3a and 3b", "PROTEIN", 142, 168], ["p3a", "PROTEIN", 170, 173], ["p3b", "PROTEIN", 178, 181], ["X1", "PROTEIN", 208, 210], ["X2", "PROTEIN", 215, 217], ["other coronaviruses", "PROBLEM", 86, 105], ["the SARS", "TEST", 138, 146], ["CoVProteins", "TEST", 147, 158], ["p3a", "TEST", 170, 173], ["p3b", "TEST", 178, 181], ["amino-acid residues", "TEST", 241, 260]]], ["They are encoded by ORF3a (commonly known as ORF3 or U274) and ORF3b and both make up the second largest sub-genomic RNA in the SARS-CoV genome (Tan et al., 2006).", [["ORF3a", "GENE_OR_GENE_PRODUCT", 20, 25], ["ORF3", "GENE_OR_GENE_PRODUCT", 45, 49], ["U274", "GENE_OR_GENE_PRODUCT", 53, 57], ["ORF3b", "GENE_OR_GENE_PRODUCT", 63, 68], ["ORF3a", "PROTEIN", 20, 25], ["ORF3", "DNA", 45, 49], ["U274", "DNA", 53, 57], ["ORF3b", "DNA", 63, 68], ["sub-genomic RNA", "RNA", 105, 120], ["SARS-CoV genome", "DNA", 128, 143], ["SARS-CoV", "SPECIES", 128, 136], ["ORF3b", "TREATMENT", 63, 68], ["genomic RNA", "OBSERVATION", 109, 120]]], ["So far, the structures of the p3a and p3b are still not known (Bartlam et al., 2005) (see Table 1).Orf3a ::: Accessory proteins of the SARS-CoVProtein 3a was detected in vivo or in vitro when anti-p3a antibodies were used in SARS-infected specimens or patients (Yu et al., 2004).", [["specimens", "ANATOMY", 239, 248], ["SARS", "DISEASE", 135, 139], ["SARS-infected", "DISEASE", 225, 238], ["p3a", "GENE_OR_GENE_PRODUCT", 30, 33], ["p3b", "GENE_OR_GENE_PRODUCT", 38, 41], ["SARS-CoVProtein 3a", "GENE_OR_GENE_PRODUCT", 135, 153], ["-p3a", "GENE_OR_GENE_PRODUCT", 196, 200], ["specimens", "CELL", 239, 248], ["patients", "ORGANISM", 252, 260], ["p3a", "PROTEIN", 30, 33], ["p3b", "PROTEIN", 38, 41], ["Orf3", "PROTEIN", 99, 103], ["Accessory proteins", "PROTEIN", 109, 127], ["SARS-CoVProtein 3a", "PROTEIN", 135, 153], ["anti-p3a antibodies", "PROTEIN", 192, 211], ["patients", "SPECIES", 252, 260], ["the SARS", "PROBLEM", 131, 139], ["CoVProtein 3a", "TREATMENT", 140, 153], ["anti-p3a antibodies", "TREATMENT", 192, 211], ["SARS", "PROBLEM", 225, 229], ["infected specimens", "PROBLEM", 230, 248]]], ["Hence, the protein can be used as a diagnostic marker for patients infected with SARS-CoV.", [["SARS-CoV", "DISEASE", 81, 89], ["patients", "ORGANISM", 58, 66], ["SARS-CoV", "ORGANISM", 81, 89], ["patients", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 81, 89], ["a diagnostic marker", "TEST", 34, 53]]], ["In vivo, the presence of p3a was found in autopsy sections from lung and intestinal tissues of SARS patients (Law et al., 2005).", [["sections", "ANATOMY", 50, 58], ["lung", "ANATOMY", 64, 68], ["intestinal tissues", "ANATOMY", 73, 91], ["SARS", "DISEASE", 95, 99], ["p3a", "GENE_OR_GENE_PRODUCT", 25, 28], ["autopsy sections", "MULTI-TISSUE_STRUCTURE", 42, 58], ["lung", "ORGAN", 64, 68], ["intestinal tissues", "TISSUE", 73, 91], ["patients", "ORGANISM", 100, 108], ["p3a", "PROTEIN", 25, 28], ["patients", "SPECIES", 100, 108], ["autopsy sections", "TEST", 42, 58], ["p3a", "OBSERVATION", 25, 28], ["lung", "ANATOMY", 64, 68], ["intestinal tissues", "ANATOMY", 73, 91]]], ["Uniquely, frameshift mutations do not necessarily cause protein 3a to be non-functional (Tan et al., 2005) and even the virus can deliberately make use of frameshift mutations to code for 3a variants by exploiting hepta- and octa-uridine sites (Wang et al., 2006).Orf3a ::: Accessory proteins of the SARS-CoVIt has been shown that SARS-CoV protein 3a is a structural component by using electron microscopy (Ito et al., 2005).", [["hepta- and octa-uridine", "CHEMICAL", 214, 237], ["SARS", "DISEASE", 300, 304], ["hepta- and octa-uridine", "CHEMICAL", 214, 237], ["octa-uridine", "SIMPLE_CHEMICAL", 225, 237], ["SARS-CoV protein 3a", "GENE_OR_GENE_PRODUCT", 331, 350], ["protein 3a", "PROTEIN", 56, 66], ["hepta- and octa-uridine sites", "DNA", 214, 243], ["Orf3", "PROTEIN", 264, 268], ["Accessory proteins", "PROTEIN", 274, 292], ["SARS-CoVIt", "PROTEIN", 300, 310], ["SARS-CoV protein 3a", "PROTEIN", 331, 350], ["SARS-CoV", "SPECIES", 331, 339], ["frameshift mutations", "PROBLEM", 10, 30], ["protein 3a", "PROBLEM", 56, 66], ["the virus", "PROBLEM", 116, 125], ["frameshift mutations", "PROBLEM", 155, 175], ["the SARS", "PROBLEM", 296, 304], ["SARS", "PROBLEM", 331, 335], ["CoV protein 3a", "PROBLEM", 336, 350], ["electron microscopy", "TEST", 386, 405], ["SARS", "OBSERVATION", 331, 335]]], ["Shen et al. supported this finding by demonstrating that the protein can be incorporated into virus-like particles (VLPs) using recombinant baculoviruses expressing E, M, and p3a (Shen et al., 2005).", [["VLPs", "ORGANISM", 116, 120], ["E", "GENE_OR_GENE_PRODUCT", 165, 166], ["p3a", "GENE_OR_GENE_PRODUCT", 175, 178], ["the protein", "PROBLEM", 57, 68], ["recombinant baculoviruses", "TREATMENT", 128, 153]]], ["However, for the formation of these VLPs, p3a of SARS-CoV is dispensible (Yount et al., 2005).", [["SARS", "DISEASE", 49, 53], ["VLPs", "ORGANISM", 36, 40], ["p3a", "GENE_OR_GENE_PRODUCT", 42, 45], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 49, 57], ["p3a", "PROTEIN", 42, 45], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "PROBLEM", 49, 53]]], ["Being efficiently expressed on the cell surface, the protein was easily detected in a majority of SARS patients due to the triggering of a humoral and cellular immune response in these patients (Lu et al., 2009).", [["cell surface", "ANATOMY", 35, 47], ["cellular", "ANATOMY", 151, 159], ["SARS", "DISEASE", 98, 102], ["cell surface", "CELLULAR_COMPONENT", 35, 47], ["patients", "ORGANISM", 103, 111], ["cellular", "CELL", 151, 159], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 185, 193], ["cellular immune response", "OBSERVATION", 151, 175]]], ["In light of immunity, p3a can cause the activation of NF-\u03baB and JNK leading to the upregulation of RANTES and IL-8 in A549 and HEK293T cells (Kanzawa et al., 2006).", [["A549", "ANATOMY", 118, 122], ["HEK293T cells", "ANATOMY", 127, 140], ["p3a", "GENE_OR_GENE_PRODUCT", 22, 25], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 54, 59], ["JNK", "GENE_OR_GENE_PRODUCT", 64, 67], ["RANTES", "GENE_OR_GENE_PRODUCT", 99, 105], ["IL-8", "GENE_OR_GENE_PRODUCT", 110, 114], ["A549", "CELL", 118, 122], ["HEK293T cells", "CELL", 127, 140], ["p3a", "PROTEIN", 22, 25], ["NF-\u03baB", "PROTEIN", 54, 59], ["JNK", "PROTEIN", 64, 67], ["RANTES", "PROTEIN", 99, 105], ["IL-8", "PROTEIN", 110, 114], ["A549", "CELL_LINE", 118, 122], ["HEK293T cells", "CELL_LINE", 127, 140], ["the activation of NF", "PROBLEM", 36, 56], ["JNK", "PROBLEM", 64, 67], ["RANTES", "TEST", 99, 105], ["IL", "TEST", 110, 112]]], ["It has also been demonstrated to up-regulate fibrinogen mRNA and protein levels in A549 cells (Tan et al., 2005).Orf3a ::: Accessory proteins of the SARS-CoVProtein 3a has been shown to be present in both the plasma membrane as well as intracellularly (Ito et al., 2005, Oostra et al., 2006, Tan et al., 2004, Yuan et al., 2005).", [["A549 cells", "ANATOMY", 83, 93], ["plasma membrane", "ANATOMY", 209, 224], ["SARS", "DISEASE", 149, 153], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 45, 55], ["A549 cells", "CELL", 83, 93], ["SARS-CoVProtein 3a", "GENE_OR_GENE_PRODUCT", 149, 167], ["plasma membrane", "CELLULAR_COMPONENT", 209, 224], ["fibrinogen mRNA", "RNA", 45, 60], ["A549 cells", "CELL_LINE", 83, 93], ["Orf3", "PROTEIN", 113, 117], ["Accessory proteins", "PROTEIN", 123, 141], ["SARS-CoVProtein 3a", "PROTEIN", 149, 167], ["fibrinogen mRNA", "TEST", 45, 60], ["protein levels", "TEST", 65, 79], ["A549 cells", "TEST", 83, 93], ["the SARS", "PROBLEM", 145, 153], ["CoVProtein 3a", "TREATMENT", 154, 167], ["A549 cells", "OBSERVATION", 83, 93], ["plasma membrane", "ANATOMY", 209, 224]]], ["It can also be detected by Western blot in SARS-CoV particles purified by sucrose gradient centrifugation.", [["sucrose", "CHEMICAL", 74, 81], ["sucrose", "CHEMICAL", 74, 81], ["CoV", "ORGANISM", 48, 51], ["sucrose", "SIMPLE_CHEMICAL", 74, 81], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV particles", "TREATMENT", 43, 61], ["sucrose gradient centrifugation", "TREATMENT", 74, 105], ["gradient centrifugation", "OBSERVATION", 82, 105]]], ["Yu et al. used confocal microscopy and fractionation to show that p3a is distributed in a \u201cpunctate pattern\u201d in the cytoplasm while the majority of its expression is concentrated at the Golgi apparatus (Yu et al., 2004).", [["cytoplasm", "ANATOMY", 116, 125], ["Golgi apparatus", "ANATOMY", 186, 201], ["p3a", "GENE_OR_GENE_PRODUCT", 66, 69], ["cytoplasm", "ORGANISM_SUBSTANCE", 116, 125], ["Golgi", "CELLULAR_COMPONENT", 186, 191], ["p3a", "PROTEIN", 66, 69], ["confocal microscopy", "TEST", 15, 34], ["fractionation", "TEST", 39, 52], ["p3a", "PROBLEM", 66, 69], ["a \u201cpunctate pattern\u201d in the cytoplasm", "PROBLEM", 88, 125], ["p3a", "OBSERVATION", 66, 69], ["punctate", "OBSERVATION_MODIFIER", 91, 99], ["pattern", "OBSERVATION_MODIFIER", 100, 107], ["cytoplasm", "OBSERVATION_MODIFIER", 116, 125], ["majority", "OBSERVATION_MODIFIER", 136, 144]]], ["On top of all these findings, Tan et al. have shown that this protein can also be transported to the cell surface and enter the cell through endocytosis (Tan et al., 2004).", [["cell surface", "ANATOMY", 101, 113], ["cell", "ANATOMY", 128, 132], ["cell surface", "CELLULAR_COMPONENT", 101, 113], ["cell", "CELL", 128, 132]]], ["Additionally, through immunoprecipitation, this protein was shown to interact with SARS-CoV M, S, E, and 7a proteins (Tan et al., 2004, von Brunn et al., 2007).Orf3a ::: Accessory proteins of the SARS-CoVBeing the largest accessory protein (Narayanan et al., 2008), p3a has an extracellular N-terminus and an intracellular C-terminus (Fig. 2) Tan et al., 2004, Lu et al., 2006.", [["extracellular", "ANATOMY", 277, 290], ["intracellular", "ANATOMY", 309, 322], ["N", "CHEMICAL", 291, 292], ["C", "CHEMICAL", 323, 324], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 83, 91], ["S, E", "GENE_OR_GENE_PRODUCT", 95, 99], ["p3a", "GENE_OR_GENE_PRODUCT", 266, 269], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 309, 322], ["C-terminus", "CELLULAR_COMPONENT", 323, 333], ["SARS-CoV M, S, E, and 7a proteins", "PROTEIN", 83, 116], ["Orf3", "PROTEIN", 160, 164], ["Accessory proteins", "PROTEIN", 170, 188], ["SARS-CoVBeing", "PROTEIN", 196, 209], ["accessory protein", "PROTEIN", 222, 239], ["p3a", "PROTEIN", 266, 269], ["extracellular N-terminus", "PROTEIN", 277, 301], ["intracellular C-terminus", "PROTEIN", 309, 333], ["SARS-CoV", "SPECIES", 83, 91], ["immunoprecipitation", "TEST", 22, 41], ["this protein", "TEST", 43, 55], ["SARS", "TEST", 83, 87], ["CoV M", "TEST", 88, 93], ["the SARS", "PROBLEM", 192, 200], ["p3a", "TEST", 266, 269], ["an intracellular C-terminus (Fig", "PROBLEM", 306, 338], ["largest", "OBSERVATION_MODIFIER", 214, 221]]], ["Another feature of the protein is the presence of a cysteine-rich domain (aa 81\u2013160) Lu et al., 2006.Orf3a ::: Accessory proteins of the SARS-CoVThe N-terminal region consists of three transmembrane domains (TMDs) (Tan et al., 2004) (Fig. 3).", [["cysteine", "CHEMICAL", 52, 60], ["SARS", "DISEASE", 137, 141], ["cysteine", "CHEMICAL", 52, 60], ["Co", "CHEMICAL", 142, 144], ["N", "CHEMICAL", 149, 150], ["cysteine", "AMINO_ACID", 52, 60], ["cysteine-rich domain", "PROTEIN", 52, 72], ["Orf3", "PROTEIN", 101, 105], ["Accessory proteins", "PROTEIN", 111, 129], ["SARS-CoVThe N-terminal region", "PROTEIN", 137, 166], ["transmembrane domains", "PROTEIN", 185, 206], ["TMDs", "PROTEIN", 208, 212], ["the SARS", "TEST", 133, 141], ["three transmembrane domains (TMDs", "PROBLEM", 179, 212], ["terminal", "ANATOMY_MODIFIER", 151, 159], ["region", "ANATOMY_MODIFIER", 160, 166]]], ["Recently, through computational modeling, Kruger and Fischer proposed a theoretical model of the protein being an ion channel through the use of its transmembrane domains (Kruger and Fischer, 2009).", [["transmembrane", "ANATOMY", 149, 162], ["transmembrane domains", "PROTEIN", 149, 170], ["an ion channel", "TREATMENT", 111, 125]]], ["Chien et al. expressed the full-length p3a and reconstituted it into lipid bilayers to characterize the ion-channel activity and suggested that either TMD 2 or 3 lines the pore of the channel (Chien et al., 2013).", [["pore", "ANATOMY", 172, 176], ["p3a", "GENE_OR_GENE_PRODUCT", 39, 42], ["TMD 2", "GENE_OR_GENE_PRODUCT", 151, 156], ["full-length p3a", "DNA", 27, 42], ["TMD 2", "PROBLEM", 151, 156]]], ["The central region comprising residues 125\u2013200 of p3a has been shown to be bound to the 5\u2019 UTR of the SARS-CoV genome (Sharma et al., 2007), characterized by Sharma et al. by using yeast-three-hybrid screen, electrophoretic mobility shift assay, and ultraviolet crosslinking (Sharma et al., 2007).", [["p3a", "GENE_OR_GENE_PRODUCT", 50, 53], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 102, 110], ["p3a", "PROTEIN", 50, 53], ["5\u2019 UTR", "DNA", 88, 94], ["SARS-CoV genome", "DNA", 102, 117], ["yeast", "SPECIES", 181, 186], ["SARS-CoV", "SPECIES", 102, 110], ["yeast", "SPECIES", 181, 186], ["the SARS", "PROBLEM", 98, 106], ["ultraviolet crosslinking", "TREATMENT", 250, 274], ["central", "ANATOMY_MODIFIER", 4, 11], ["CoV genome", "OBSERVATION", 107, 117]]], ["Intriguingly, just the N-terminal portion of p3a is able to evoke a strong humoral immune response (Zhong et al., 2006).Orf3a ::: Accessory proteins of the SARS-CoVThe cysteine-rich domain of p3a serves a multitude of functions and some have suggested its role in the p3a ion channel.", [["SARS", "DISEASE", 156, 160], ["N", "CHEMICAL", 23, 24], ["cysteine", "CHEMICAL", 168, 176], ["p3a", "GENE_OR_GENE_PRODUCT", 45, 48], ["p3a", "GENE_OR_GENE_PRODUCT", 192, 195], ["p3a", "GENE_OR_GENE_PRODUCT", 268, 271], ["N-terminal portion", "PROTEIN", 23, 41], ["p3a", "PROTEIN", 45, 48], ["Orf3", "PROTEIN", 120, 124], ["Accessory proteins", "PROTEIN", 130, 148], ["SARS-CoVThe cysteine-rich domain", "PROTEIN", 156, 188], ["p3a", "PROTEIN", 192, 195], ["p3a ion channel", "PROTEIN", 268, 283], ["the SARS", "PROBLEM", 152, 160], ["CoVThe cysteine", "TREATMENT", 161, 176]]], ["The p3a is able to interact with the SARS-CoV S protein by formation of disulfide linkages through its cysteine-rich regions, mainly the CWLCWKC region (aa 127\u2013133) (Zeng et al., 2004).", [["disulfide", "CHEMICAL", 72, 81], ["cysteine", "CHEMICAL", 103, 111], ["p3a", "GENE_OR_GENE_PRODUCT", 4, 7], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 37, 47], ["cysteine", "AMINO_ACID", 103, 111], ["p3a", "PROTEIN", 4, 7], ["SARS-CoV S protein", "PROTEIN", 37, 55], ["cysteine-rich regions", "PROTEIN", 103, 124], ["CWLCWKC region", "PROTEIN", 137, 151], ["SARS-CoV", "SPECIES", 37, 45], ["the SARS", "TEST", 33, 41], ["CWLCWKC", "ANATOMY_MODIFIER", 137, 144], ["region", "ANATOMY_MODIFIER", 145, 151]]], ["Another important feature is the oligomerization of p3a as it is able to form homodimers and homotetramers (Lu et al., 2006).", [["p3a", "GENE_OR_GENE_PRODUCT", 52, 55], ["p3a", "PROTEIN", 52, 55], ["homodimers", "PROTEIN", 78, 88]]], ["Through inducing point mutations, Lu et al. showed that Cys133 is important for oligomerization of the protein and confirmed the formation of dimers and tetramers through FRET (Lu et al., 2006).", [["Cys133", "CHEMICAL", 56, 62], ["Cys133", "GENE_OR_GENE_PRODUCT", 56, 62], ["Cys133", "PROTEIN", 56, 62], ["tetramers", "PROTEIN", 153, 162], ["the protein", "TEST", 99, 110]]], ["Utilizing Xenopus oocytes, their results were suggestive of the tetramers being able to form a potassium-permeable ion channel and modulating release of SARS-CoV particles (Lu et al., 2006, Shi et al., 2006).", [["oocytes", "ANATOMY", 18, 25], ["potassium", "CHEMICAL", 95, 104], ["potassium", "CHEMICAL", 95, 104], ["Xenopus", "ORGANISM", 10, 17], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 18, 25], ["potassium", "SIMPLE_CHEMICAL", 95, 104], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 153, 161], ["potassium-permeable ion channel", "PROTEIN", 95, 126], ["Xenopus oocytes", "TREATMENT", 10, 25], ["the tetramers", "PROBLEM", 60, 73], ["a potassium-permeable ion channel", "TREATMENT", 93, 126], ["SARS", "PROBLEM", 153, 157], ["Xenopus oocytes", "OBSERVATION", 10, 25]]], ["Chan et al. further validated that blocking these ion channels suppressed SARS-CoV-mediated apoptosis (Chan et al., 2009).Orf3a ::: Accessory proteins of the SARS-CoVThe C-terminal domain is hydrophilic in nature and contains both the Yxx\u03a6 (where x represents any aa and \u03a6 is an amino acid with a hydrophobic, bulky side-chain) and the diacidic motifs (ExD, Asp-x-Glu, where x represents any aa).", [["SARS", "DISEASE", 158, 162], ["amino acid", "CHEMICAL", 279, 289], ["Asp-x-Glu", "CHEMICAL", 358, 367], ["Co", "CHEMICAL", 163, 165], ["C", "CHEMICAL", 170, 171], ["amino acid", "CHEMICAL", 279, 289], ["Asp", "CHEMICAL", 358, 361], ["Glu", "CHEMICAL", 364, 367], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 74, 82], ["Yxx\u03a6", "GENE_OR_GENE_PRODUCT", 235, 239], ["amino acid", "AMINO_ACID", 279, 289], ["Orf3", "PROTEIN", 122, 126], ["Accessory proteins", "PROTEIN", 132, 150], ["SARS-CoVThe C-terminal domain", "PROTEIN", 158, 187], ["Yxx\u03a6", "PROTEIN", 235, 239], ["aa and \u03a6", "PROTEIN", 264, 272], ["hydrophobic, bulky side-chain", "PROTEIN", 297, 326], ["diacidic motifs", "PROTEIN", 336, 351], ["SARS", "PROBLEM", 74, 78], ["the SARS", "PROBLEM", 154, 162], ["an amino acid", "TREATMENT", 276, 289], ["a hydrophobic, bulky side-chain", "TREATMENT", 295, 326], ["the diacidic motifs", "TEST", 332, 351], ["ExD", "TEST", 353, 356], ["Asp", "TEST", 358, 361], ["hydrophilic", "OBSERVATION_MODIFIER", 191, 202]]], ["This domain can play a role in G1 cell-cycle arrest by depletion of cyclin D3 (Yuan et al., 2007).", [["cell", "ANATOMY", 34, 38], ["cell", "CELL", 34, 38], ["cyclin D3", "GENE_OR_GENE_PRODUCT", 68, 77], ["cyclin D3", "PROTEIN", 68, 77], ["G1 cell-cycle arrest", "TREATMENT", 31, 51], ["cyclin D3", "TREATMENT", 68, 77]]], ["Interestingly, p3a seems to share a similar topology with the M protein (Marra et al., 2003).", [["p3a", "GENE_OR_GENE_PRODUCT", 15, 18], ["p3a", "PROTEIN", 15, 18], ["M protein", "PROTEIN", 62, 71]]], ["The Yxx\u03a6 motif plays a role in internalization of proteins into various intracellular components, including proteins from the plasma membrane into the endosomes (Bonifacino and Traub, 2003, Trowbridge et al., 1993).", [["intracellular components", "ANATOMY", 72, 96], ["plasma membrane", "ANATOMY", 126, 141], ["endosomes", "ANATOMY", 151, 160], ["Yxx\u03a6", "GENE_OR_GENE_PRODUCT", 4, 8], ["intracellular components", "CELLULAR_COMPONENT", 72, 96], ["plasma membrane", "CELLULAR_COMPONENT", 126, 141], ["endosomes", "CELLULAR_COMPONENT", 151, 160], ["Yxx\u03a6 motif", "DNA", 4, 14]]], ["The diacidic motif is required for ER export (Nishimura and Balch, 1997).", [["ER", "GENE_OR_GENE_PRODUCT", 35, 37], ["diacidic motif", "PROTEIN", 4, 18], ["ER", "PROTEIN", 35, 37], ["The diacidic motif", "TREATMENT", 0, 18]]], ["Tan et al. demonstrated that deletion of the C-terminal domain would prevent the protein from being expressed on the cell surface (Tan et al., 2004).", [["cell surface", "ANATOMY", 117, 129], ["C", "CHEMICAL", 45, 46], ["cell surface", "CELLULAR_COMPONENT", 117, 129], ["C-terminal domain", "PROTEIN", 45, 62], ["deletion of the C-terminal domain", "PROBLEM", 29, 62], ["the protein", "PROBLEM", 77, 88], ["protein", "OBSERVATION", 81, 88]]], ["Furthermore, they also hypothesized that the Yxx\u03a6 motif presented in p3a would allow the internalization of the S protein and prevent its presentation on the cell surface (Tan, 2005).", [["cell surface", "ANATOMY", 158, 170], ["Yxx\u03a6", "GENE_OR_GENE_PRODUCT", 45, 49], ["p3a", "GENE_OR_GENE_PRODUCT", 69, 72], ["cell surface", "CELLULAR_COMPONENT", 158, 170], ["Yxx\u03a6 motif", "DNA", 45, 55], ["p3a", "PROTEIN", 69, 72], ["S protein", "PROTEIN", 112, 121], ["the S protein", "TREATMENT", 108, 121]]], ["This could be involved in evading host immunity systems or even facilitate the assembly of SARS-CoV.Orf3a ::: Accessory proteins of the SARS-CoVp3a can be detected in the supernatant in two different forms from infected Vero E6 cells or Caco2 cells (Lu et al., 2006, Huang et al., 2006).", [["supernatant", "ANATOMY", 171, 182], ["Vero E6 cells", "ANATOMY", 220, 233], ["Caco2 cells", "ANATOMY", 237, 248], ["SARS", "DISEASE", 91, 95], ["SARS-CoV.Orf3", "GENE_OR_GENE_PRODUCT", 91, 104], ["SARS-CoVp3a", "GENE_OR_GENE_PRODUCT", 136, 147], ["Vero E6 cells", "CELL", 220, 233], ["Caco2 cells", "CELL", 237, 248], ["Accessory proteins", "PROTEIN", 110, 128], ["SARS-CoVp3a", "PROTEIN", 136, 147], ["infected Vero E6 cells", "CELL_LINE", 211, 233], ["Caco2 cells", "CELL_LINE", 237, 248], ["Vero E6", "SPECIES", 220, 227], ["the SARS", "PROBLEM", 132, 140], ["CoVp3a", "TREATMENT", 141, 147], ["infected Vero E6 cells", "PROBLEM", 211, 233], ["Caco2 cells", "PROBLEM", 237, 248], ["SARS", "OBSERVATION", 136, 140], ["two different", "OBSERVATION_MODIFIER", 186, 199], ["infected", "OBSERVATION_MODIFIER", 211, 219], ["Vero E6 cells", "OBSERVATION", 220, 233], ["Caco2 cells", "OBSERVATION", 237, 248]]], ["Huang et al. demonstrated by sucrose-gradient centrifugation and densitometric scans the presence of a 37-kDa form (protein 3a-1) and a 31-kDa form (protein 3a-2).", [["sucrose", "CHEMICAL", 29, 36], ["sucrose", "CHEMICAL", 29, 36], ["sucrose", "SIMPLE_CHEMICAL", 29, 36], ["protein 3a-1", "GENE_OR_GENE_PRODUCT", 116, 128], ["protein 3a-1", "PROTEIN", 116, 128], ["31-kDa form", "PROTEIN", 136, 147], ["protein 3a-2", "PROTEIN", 149, 161], ["sucrose-gradient centrifugation", "TREATMENT", 29, 60], ["densitometric scans", "TEST", 65, 84], ["protein 3a", "TEST", 116, 126], ["protein 3a", "TEST", 149, 159]]], ["The 37-kDa form was detected in fractions with similar densities (1.18\u20131.20 g/ml) to the SARS-CoV particles, as opposed to fractions containing the 31-kDa form (1.13\u20131.15 g/ml) Tan et al., 2005, Yuan et al., 2007, suggesting that the 31-kDa form may be present as extracellular membrane structures while the 37-kDa form may be assembled into the mature virons.", [["extracellular membrane structures", "ANATOMY", 264, 297], ["SARS", "DISEASE", 89, 93], ["extracellular membrane structures", "CELLULAR_COMPONENT", 264, 297], ["virons", "GENE_OR_GENE_PRODUCT", 353, 359], ["SARS-CoV", "SPECIES", 89, 97], ["similar densities", "PROBLEM", 47, 64], ["the SARS", "TEST", 85, 93], ["extracellular membrane structures", "TEST", 264, 297], ["may be", "UNCERTAINTY", 320, 326]]], ["The presence of these two forms is due to the protein 3a being able to be modified post-translationally.", [["protein 3a", "GENE_OR_GENE_PRODUCT", 46, 56], ["protein 3a", "PROTEIN", 46, 56], ["the protein 3a", "PROBLEM", 42, 56]]], ["This protein can be O-glycosylated as demonstrated by Oostra et al. through electrophoretic mobility-shift assays, transforming the unmodified 31-kDa form into a 33-kDa form (Oostra et al., 2006). p3a resembles the M protein of other coronaviruses, such as MHV, in terms of (1) the subcellular localization pattern of M protein (Tan et al., 2004, Klumperman et al., 1994, Yuan et al., 2005), (2) having an extracellular N-terminus and a C-terminal endodomain, (3) spanning the membrane three times (Rottier et al., 1984, Rottier et al., 1986, Braakman and Van Anken, 2000), and (4) being considered a structural protein (Ito et al., 2005, Shen et al., 2005).", [["subcellular", "ANATOMY", 282, 293], ["extracellular", "ANATOMY", 406, 419], ["membrane", "ANATOMY", 477, 485], ["O", "CHEMICAL", 20, 21], ["N", "CHEMICAL", 420, 421], ["C", "CHEMICAL", 437, 438], ["p3a", "GENE_OR_GENE_PRODUCT", 197, 200], ["M protein", "GENE_OR_GENE_PRODUCT", 318, 327], ["membrane", "CELLULAR_COMPONENT", 477, 485], ["p3a", "PROTEIN", 197, 200], ["M protein", "PROTEIN", 215, 224], ["M protein", "PROTEIN", 318, 327], ["extracellular N-terminus", "PROTEIN", 406, 430], ["C-terminal endodomain", "PROTEIN", 437, 458], ["structural protein", "PROTEIN", 601, 619], ["MHV", "SPECIES", 257, 260], ["glycosylated", "TREATMENT", 22, 34], ["other coronaviruses", "PROBLEM", 228, 247], ["an extracellular N-terminus", "PROBLEM", 403, 430], ["terminal", "ANATOMY_MODIFIER", 439, 447], ["endodomain", "ANATOMY", 448, 458]]], ["Despite both M and 3a proteins being glycosylated, p3a in Ost-7 cells is neuraminidase-sensitive but not O-glycosidase sensitive, in contrast to the M protein where it is sensitive to both (Oostra et al., 2006).Orf3a ::: Accessory proteins of the SARS-CoVRecombinant viruses with ORF3a deleted (i.e., SARS-CoV \u03943a) showed significant reduction in virus titres after infecting Vero, MA104, and Caco2 cells (Yount et al., 2005).", [["Ost-7 cells", "ANATOMY", 58, 69], ["Vero", "ANATOMY", 376, 380], ["MA104", "ANATOMY", 382, 387], ["Caco2 cells", "ANATOMY", 393, 404], ["O", "CHEMICAL", 105, 106], ["p3a", "GENE_OR_GENE_PRODUCT", 51, 54], ["Ost-7 cells", "CELL", 58, 69], ["O-glycosidase", "GENE_OR_GENE_PRODUCT", 105, 118], ["SARS-CoVRecombinant viruses", "ORGANISM", 247, 274], ["ORF3a", "GENE_OR_GENE_PRODUCT", 280, 285], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 301, 309], ["Vero", "CELL", 376, 380], ["MA104", "CELL", 382, 387], ["Caco2 cells", "CELL", 393, 404], ["M and 3a proteins", "PROTEIN", 13, 30], ["p3a", "PROTEIN", 51, 54], ["Ost-7 cells", "CELL_LINE", 58, 69], ["O-glycosidase", "PROTEIN", 105, 118], ["M protein", "PROTEIN", 149, 158], ["Orf3", "PROTEIN", 211, 215], ["Accessory proteins", "PROTEIN", 221, 239], ["ORF3a deleted", "DNA", 280, 293], ["SARS-CoV \u03943a", "DNA", 301, 313], ["MA104", "CELL_LINE", 382, 387], ["Caco2 cells", "CELL_LINE", 393, 404], ["SARS-CoV", "SPECIES", 301, 309], ["glycosylated", "TEST", 37, 49], ["p3a in Ost", "TEST", 51, 61], ["neuraminidase", "TEST", 73, 86], ["glycosidase", "PROBLEM", 107, 118], ["the SARS", "PROBLEM", 243, 251], ["CoVRecombinant viruses", "PROBLEM", 252, 274], ["SARS-CoV \u03943a", "TEST", 301, 313], ["significant reduction in virus titres", "PROBLEM", 322, 359], ["infecting Vero, MA104", "PROBLEM", 366, 387], ["Caco2 cells", "PROBLEM", 393, 404], ["significant", "OBSERVATION_MODIFIER", 322, 333], ["reduction", "OBSERVATION_MODIFIER", 334, 343], ["virus titres", "OBSERVATION", 347, 359]]], ["Interestingly, Yount et al. demonstrated that deletion of ORF3 and ORF6 decreased the overall virus titres as compared to just deleting ORF 3a alone, suggesting that ORF3a is non-essential (Yount et al., 2005).", [["ORF3", "GENE_OR_GENE_PRODUCT", 58, 62], ["ORF6", "GENE_OR_GENE_PRODUCT", 67, 71], ["ORF3a", "GENE_OR_GENE_PRODUCT", 166, 171], ["ORF3", "DNA", 58, 62], ["ORF6", "DNA", 67, 71], ["ORF 3", "DNA", 136, 141], ["ORF3a", "DNA", 166, 171], ["deletion of ORF3", "PROBLEM", 46, 62], ["ORF6", "TREATMENT", 67, 71], ["the overall virus titres", "PROBLEM", 82, 106]]], ["In contrast, there is conflicting evidence that ORF3a may be essential, because of the reduction of viral titres in SARS-CoV-infected cells transfected with a siRNA targeting p3a (\u00c5kerstr\u00f6m et al., 2007).", [["cells", "ANATOMY", 134, 139], ["SARS-CoV-infected", "DISEASE", 116, 133], ["ORF3a", "GENE_OR_GENE_PRODUCT", 48, 53], ["SARS-CoV", "ORGANISM", 116, 124], ["cells", "CELL", 134, 139], ["p3a", "GENE_OR_GENE_PRODUCT", 175, 178], ["ORF3a", "PROTEIN", 48, 53], ["SARS-CoV-infected cells", "CELL_LINE", 116, 139], ["p3a", "PROTEIN", 175, 178], ["SARS-CoV", "SPECIES", 116, 124], ["viral titres", "PROBLEM", 100, 112], ["SARS", "PROBLEM", 116, 120], ["infected cells", "PROBLEM", 125, 139], ["a siRNA targeting p3a", "TREATMENT", 157, 178], ["viral titres", "OBSERVATION", 100, 112], ["infected cells", "OBSERVATION", 125, 139]]], ["We propose that this may be due to the subsequent knockdown of p3b as well, resulting in the lower virus production.Orf3a ::: Accessory proteins of the SARS-CoVUsing transmission electron microscopy (TEM), Freundt et al. observed in Vero cells that only in the presence of p3a, intracellular vesicles will be formed, as observed in the pathology in SARS patients (Freundt et al., 2010).", [["Vero cells", "ANATOMY", 233, 243], ["intracellular vesicles", "ANATOMY", 278, 300], ["SARS", "DISEASE", 349, 353], ["p3b", "GENE_OR_GENE_PRODUCT", 63, 66], ["Vero cells", "CELL", 233, 243], ["p3a", "GENE_OR_GENE_PRODUCT", 273, 276], ["intracellular vesicles", "CELLULAR_COMPONENT", 278, 300], ["patients", "ORGANISM", 354, 362], ["p3b", "PROTEIN", 63, 66], ["Orf3", "PROTEIN", 116, 120], ["Accessory proteins", "PROTEIN", 126, 144], ["Vero cells", "CELL_LINE", 233, 243], ["p3a", "PROTEIN", 273, 276], ["patients", "SPECIES", 354, 362], ["the subsequent knockdown of p3b", "PROBLEM", 35, 66], ["the lower virus production", "PROBLEM", 89, 115], ["the SARS", "PROBLEM", 148, 156], ["intracellular vesicles", "PROBLEM", 278, 300], ["lower virus production", "OBSERVATION", 93, 115], ["Vero cells", "OBSERVATION", 233, 243], ["intracellular vesicles", "OBSERVATION", 278, 300]]], ["The presence of Lamp-1 through immunofluorescence can also be detected in these vesicles (Freundt et al., 2010), indicating the formation of late endosomes.", [["vesicles", "ANATOMY", 80, 88], ["late endosomes", "ANATOMY", 141, 155], ["Lamp-1", "GENE_OR_GENE_PRODUCT", 16, 22], ["vesicles", "CELLULAR_COMPONENT", 80, 88], ["late endosomes", "CELLULAR_COMPONENT", 141, 155], ["Lamp", "PROTEIN", 16, 20], ["Lamp-1 through immunofluorescence", "TEST", 16, 49], ["late endosomes", "PROBLEM", 141, 155], ["vesicles", "ANATOMY", 80, 88], ["late endosomes", "OBSERVATION", 141, 155]]], ["Expression of p3a is also required for the Golgi fragmentation for its acquisition of a viral envelope.", [["Golgi", "ANATOMY", 43, 48], ["p3a", "GENE_OR_GENE_PRODUCT", 14, 17], ["Golgi", "CELLULAR_COMPONENT", 43, 48], ["p3a", "PROTEIN", 14, 17], ["Expression of p3a", "PROBLEM", 0, 17], ["the Golgi fragmentation", "PROBLEM", 39, 62], ["a viral envelope", "PROBLEM", 86, 102], ["p3a", "OBSERVATION", 14, 17]]], ["Through yeast-2-hybrid and FRET assays, Padhan et al. have demonstrated caveolin-1 binding to p3a, which may play a role in virus uptake and release (Padhan et al., 2007).p3a has also been associated with ER stress through the activation of the PERK pathway but not the IRE-1 and ATF6 pathway (Minakshi et al., 2009).", [["caveolin-1", "GENE_OR_GENE_PRODUCT", 72, 82], ["p3a", "GENE_OR_GENE_PRODUCT", 94, 97], ["p3a", "GENE_OR_GENE_PRODUCT", 171, 174], ["ER", "GENE_OR_GENE_PRODUCT", 205, 207], ["PERK", "GENE_OR_GENE_PRODUCT", 245, 249], ["IRE-1", "GENE_OR_GENE_PRODUCT", 270, 275], ["ATF6", "GENE_OR_GENE_PRODUCT", 280, 284], ["caveolin", "PROTEIN", 72, 80], ["p3a", "PROTEIN", 94, 97], ["p3a", "PROTEIN", 171, 174], ["ER", "PROTEIN", 205, 207], ["PERK", "PROTEIN", 245, 249], ["IRE", "PROTEIN", 270, 273], ["ATF6", "PROTEIN", 280, 284], ["yeast", "SPECIES", 8, 13], ["yeast", "TEST", 8, 13], ["ER stress", "PROBLEM", 205, 214]]], ["Minakshi et al. analyzed this by transfecting Huh7 cells with p3a and luciferase-tagged ER stress-related molecules, showing that it can enhance protein folding, but not activate Endoplasmic Reticulum Associated Degradation (ERAD) Minakshi et al., 2009.", [["Huh7 cells", "ANATOMY", 46, 56], ["Huh7 cells", "CELL", 46, 56], ["p3a", "GENE_OR_GENE_PRODUCT", 62, 65], ["luciferase", "GENE_OR_GENE_PRODUCT", 70, 80], ["ER", "GENE_OR_GENE_PRODUCT", 88, 90], ["Huh7 cells", "CELL_LINE", 46, 56], ["p3a", "PROTEIN", 62, 65], ["luciferase", "PROTEIN", 70, 80], ["ER", "PROTEIN", 88, 90], ["Huh7 cells", "TEST", 46, 56], ["p3a", "TEST", 62, 65], ["luciferase", "TEST", 70, 80], ["protein folding", "PROBLEM", 145, 160], ["Endoplasmic Reticulum Associated Degradation", "PROBLEM", 179, 223], ["protein folding", "OBSERVATION", 145, 160], ["Endoplasmic Reticulum", "OBSERVATION", 179, 200]]], ["The long-term triggering of the PERK pathway can also induce virus-related apoptosis through the expression of its downstream mediators of ATF4 and CHOP, similar to IBV infection (Liao et al., 2013).", [["IBV infection", "DISEASE", 165, 178], ["PERK", "GENE_OR_GENE_PRODUCT", 32, 36], ["ATF4", "GENE_OR_GENE_PRODUCT", 139, 143], ["CHOP", "GENE_OR_GENE_PRODUCT", 148, 152], ["IBV", "ORGANISM", 165, 168], ["PERK", "PROTEIN", 32, 36], ["downstream mediators", "PROTEIN", 115, 135], ["ATF4", "PROTEIN", 139, 143], ["CHOP", "PROTEIN", 148, 152], ["IBV", "SPECIES", 165, 168], ["the PERK pathway", "PROBLEM", 28, 44], ["virus", "PROBLEM", 61, 66], ["apoptosis", "PROBLEM", 75, 84], ["CHOP", "TREATMENT", 148, 152], ["IBV infection", "PROBLEM", 165, 178], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["IBV", "OBSERVATION_MODIFIER", 165, 168], ["infection", "OBSERVATION", 169, 178]]], ["Padhan et al. have shown that protein 3a can lead to increased activation of the p38 MAP kinase pathway and induce the mitochondria to leak cytochrome c to induce apoptosis (Padhan et al., 2008).Orf3b ::: Accessory proteins of the SARS-CoVProtein 3b (p3b) is translated from ORF3 using an IRES (Rota et al., 2003), overlapping the SARS-CoV E gene as well as the ORF3a.", [["mitochondria", "ANATOMY", 119, 131], ["protein 3a", "GENE_OR_GENE_PRODUCT", 30, 40], ["p38 MAP kinase", "GENE_OR_GENE_PRODUCT", 81, 95], ["mitochondria", "CELLULAR_COMPONENT", 119, 131], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 140, 152], ["SARS-CoVProtein 3b", "GENE_OR_GENE_PRODUCT", 231, 249], ["p3b", "GENE_OR_GENE_PRODUCT", 251, 254], ["ORF3", "GENE_OR_GENE_PRODUCT", 275, 279], ["SARS-CoV E", "GENE_OR_GENE_PRODUCT", 331, 341], ["ORF3a", "GENE_OR_GENE_PRODUCT", 362, 367], ["protein 3a", "PROTEIN", 30, 40], ["p38 MAP kinase", "PROTEIN", 81, 95], ["cytochrome c", "PROTEIN", 140, 152], ["Orf3b", "PROTEIN", 195, 200], ["Accessory proteins", "PROTEIN", 205, 223], ["SARS-CoVProtein 3b", "PROTEIN", 231, 249], ["p3b", "PROTEIN", 251, 254], ["ORF3", "DNA", 275, 279], ["IRES", "DNA", 289, 293], ["SARS-CoV E gene", "DNA", 331, 346], ["ORF3a", "DNA", 362, 367], ["SARS-CoV", "SPECIES", 331, 339], ["protein 3a", "PROBLEM", 30, 40], ["the p38 MAP kinase pathway", "TREATMENT", 77, 103], ["the mitochondria", "PROBLEM", 115, 131], ["leak cytochrome c", "PROBLEM", 135, 152], ["apoptosis", "PROBLEM", 163, 172], ["the SARS", "PROBLEM", 227, 235], ["CoVProtein 3b", "TREATMENT", 236, 249], ["CoV E gene", "TREATMENT", 336, 346], ["leak cytochrome", "OBSERVATION", 135, 150]]], ["Similarly to the SARS-CoV p3a, p3b does not share any homology with other known proteins (Marra et al., 2003).", [["SARS", "DISEASE", 17, 21], ["SARS-CoV p3a", "GENE_OR_GENE_PRODUCT", 17, 29], ["p3b", "GENE_OR_GENE_PRODUCT", 31, 34], ["SARS-CoV p3a", "DNA", 17, 29], ["p3b", "PROTEIN", 31, 34], ["SARS-CoV", "SPECIES", 17, 25], ["the SARS", "TEST", 13, 21]]], ["Moreover, p3b is not expressed in SARS-CoV isolates from bats due to the presence of a stop codon (Ren et al., 2006).", [["p3b", "GENE_OR_GENE_PRODUCT", 10, 13], ["SARS-CoV isolates", "ORGANISM", 34, 51], ["bats", "ORGANISM", 57, 61], ["p3b", "PROTEIN", 10, 13], ["SARS-CoV", "SPECIES", 34, 42]]], ["Anti-p3b antibodies can also be detected in the sera of infected SARS patients (Guo et al., 2004).", [["sera", "ANATOMY", 48, 52], ["SARS", "DISEASE", 65, 69], ["Anti-p3b", "GENE_OR_GENE_PRODUCT", 0, 8], ["sera", "ORGANISM_SUBSTANCE", 48, 52], ["patients", "ORGANISM", 70, 78], ["Anti-p3b antibodies", "PROTEIN", 0, 19], ["patients", "SPECIES", 70, 78], ["Anti-p3b antibodies", "TEST", 0, 19]]], ["Yuan et al. have shown using immunofluorescence that the SARS-CoV p3b is localized in the nucleolus of infected Vero E6 cells (Yuan et al., 2005) as well as in the mitochondria (Yuan et al., 2006, Freundt et al., 2009).", [["nucleolus", "ANATOMY", 90, 99], ["Vero E6 cells", "ANATOMY", 112, 125], ["mitochondria", "ANATOMY", 164, 176], ["SARS-CoV", "ORGANISM", 57, 65], ["p3b", "GENE_OR_GENE_PRODUCT", 66, 69], ["nucleolus", "CELLULAR_COMPONENT", 90, 99], ["Vero E6 cells", "CELL", 112, 125], ["mitochondria", "CELLULAR_COMPONENT", 164, 176], ["SARS-CoV p3b", "PROTEIN", 57, 69], ["infected Vero E6 cells", "CELL_LINE", 103, 125], ["SARS-CoV", "SPECIES", 57, 65], ["Vero E6", "SPECIES", 112, 119], ["immunofluorescence", "TEST", 29, 47], ["the SARS", "TEST", 53, 61], ["CoV p3b", "TEST", 62, 69], ["infected", "OBSERVATION_MODIFIER", 103, 111], ["Vero E6 cells", "OBSERVATION", 112, 125]]], ["The shuttling behavior may be due to the presence of a nuclear export sequence and determined by a leptomycin B-sensitive mechanism.", [["nuclear", "ANATOMY", 55, 62], ["leptomycin B", "CHEMICAL", 99, 111], ["leptomycin B", "CHEMICAL", 99, 111], ["nuclear", "CELLULAR_COMPONENT", 55, 62], ["leptomycin B", "SIMPLE_CHEMICAL", 99, 111], ["nuclear export sequence", "PROTEIN", 55, 78], ["leptomycin B", "PROTEIN", 99, 111], ["a nuclear export sequence", "TEST", 53, 78], ["a leptomycin B", "TREATMENT", 97, 111]]], ["Furthermore, involvement of p3b has also been demonstrated in the induction of necrosis and apoptosis independent of its subcellular localization (Khan et al., 2006, Yuan et al., 2005). p3b is also able to inhibit the antiviral response by down-regulating type-I interferon (IFN-\u03b2) as well as the mitochondrial antiviral response (Freundt et al., 2009, Spiegel et al., 2005).", [["subcellular", "ANATOMY", 121, 132], ["mitochondrial", "ANATOMY", 297, 310], ["necrosis", "DISEASE", 79, 87], ["p3b", "GENE_OR_GENE_PRODUCT", 28, 31], ["p3b", "GENE_OR_GENE_PRODUCT", 186, 189], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 256, 273], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 275, 280], ["mitochondrial", "CELLULAR_COMPONENT", 297, 310], ["p3b", "PROTEIN", 28, 31], ["p3b", "PROTEIN", 186, 189], ["type-I interferon", "PROTEIN", 256, 273], ["IFN", "PROTEIN", 275, 278], ["\u03b2", "PROTEIN", 279, 280], ["involvement of p3b", "PROBLEM", 13, 31], ["necrosis", "PROBLEM", 79, 87], ["apoptosis", "PROBLEM", 92, 101], ["type-I interferon (IFN", "TREATMENT", 256, 278], ["p3b", "OBSERVATION", 28, 31], ["necrosis", "OBSERVATION", 79, 87], ["apoptosis", "OBSERVATION_MODIFIER", 92, 101], ["independent", "OBSERVATION_MODIFIER", 102, 113], ["antiviral response", "OBSERVATION", 311, 329]]], ["Using flow cytometry, Yuan et al., showed that COS-7 cells transfected with p3b are arrested at the G0/G1 phase (Yuan et al., 2005).", [["COS-7 cells", "ANATOMY", 47, 58], ["COS-7 cells", "CELL", 47, 58], ["p3b", "GENE_OR_GENE_PRODUCT", 76, 79], ["COS-7 cells", "CELL_LINE", 47, 58], ["p3b", "PROTEIN", 76, 79], ["flow cytometry", "TEST", 6, 20], ["Yuan et al.", "TEST", 22, 33], ["COS", "TEST", 47, 50]]], ["The protein may play a role in immunomodulation through binding to RUNX1b, as seen from yeast-two-hybrid and co-immunoprecipitation by Varshney et al. Varshney et al. (2012).", [["RUNX1b", "GENE_OR_GENE_PRODUCT", 67, 73], ["RUNX1b", "PROTEIN", 67, 73], ["yeast", "SPECIES", 88, 93], ["yeast", "TEST", 88, 93]]], ["Additionally, p3b can act as an interferon antagonist through inhibition of IRF3 (Kopecky-Bromberg et al., 2007) and activation of AP-1 through upregulating the expression levels of JNK and ERK (Varshney and Lal, 2011) (see Table 2).Orf6 ::: Accessory proteins of the SARS-CoVProtein 6 (p6) is detected in lung and ileum tissues of patients and in SARS-CoV-infected Vero E6 cells (Geng et al., 2005).", [["lung", "ANATOMY", 306, 310], ["ileum tissues", "ANATOMY", 315, 328], ["cells", "ANATOMY", 374, 379], ["SARS-CoV-infected", "DISEASE", 348, 365], ["p3b", "GENE_OR_GENE_PRODUCT", 14, 17], ["IRF3", "GENE_OR_GENE_PRODUCT", 76, 80], ["AP-1", "GENE_OR_GENE_PRODUCT", 131, 135], ["JNK", "GENE_OR_GENE_PRODUCT", 182, 185], ["ERK", "GENE_OR_GENE_PRODUCT", 190, 193], ["Orf6", "GENE_OR_GENE_PRODUCT", 233, 237], ["SARS-CoVProtein 6", "GENE_OR_GENE_PRODUCT", 268, 285], ["p6", "GENE_OR_GENE_PRODUCT", 287, 289], ["lung", "ORGAN", 306, 310], ["ileum tissues", "TISSUE", 315, 328], ["patients", "ORGANISM", 332, 340], ["SARS-CoV", "ORGANISM", 348, 356], ["Vero E6 cells", "CELL", 366, 379], ["p3b", "PROTEIN", 14, 17], ["IRF3", "PROTEIN", 76, 80], ["AP-1", "PROTEIN", 131, 135], ["JNK", "PROTEIN", 182, 185], ["ERK", "PROTEIN", 190, 193], ["Orf6", "PROTEIN", 233, 237], ["Accessory proteins", "PROTEIN", 242, 260], ["SARS-CoVProtein 6", "PROTEIN", 268, 285], ["p6", "PROTEIN", 287, 289], ["Vero E6 cells", "CELL_LINE", 366, 379], ["patients", "SPECIES", 332, 340], ["SARS-CoV", "SPECIES", 348, 356], ["Vero E6", "SPECIES", 366, 373], ["an interferon antagonist", "TREATMENT", 29, 53], ["IRF3", "TEST", 76, 80], ["Kopecky", "TEST", 82, 89], ["AP", "TEST", 131, 133], ["JNK", "TEST", 182, 185], ["ERK", "TEST", 190, 193], ["the SARS", "PROBLEM", 264, 272], ["CoVProtein", "TREATMENT", 273, 283], ["SARS", "PROBLEM", 348, 352], ["CoV", "TEST", 353, 356], ["infected Vero E6 cells", "PROBLEM", 357, 379], ["JNK", "ANATOMY", 182, 185], ["lung", "ANATOMY", 306, 310], ["ileum tissues", "ANATOMY", 315, 328], ["E6 cells", "OBSERVATION", 371, 379]]], ["The protein is found to associate with cellular membranes and is mainly localized in the ER and Golgi apparatus, either when expressed via a recombinant murine coronavirus or when it is transfected as an EGFP-fusion protein (Geng et al., 2005, Pewe et al., 2005).", [["cellular membranes", "ANATOMY", 39, 57], ["ER", "ANATOMY", 89, 91], ["Golgi apparatus", "ANATOMY", 96, 111], ["cellular membranes", "CELLULAR_COMPONENT", 39, 57], ["ER", "GENE_OR_GENE_PRODUCT", 89, 91], ["Golgi apparatus", "CELLULAR_COMPONENT", 96, 111], ["murine coronavirus", "ORGANISM", 153, 171], ["EGFP", "GENE_OR_GENE_PRODUCT", 204, 208], ["ER", "PROTEIN", 89, 91], ["EGFP", "PROTEIN", 204, 208], ["fusion protein", "PROTEIN", 209, 223], ["murine", "SPECIES", 153, 159], ["murine coronavirus", "SPECIES", 153, 171], ["cellular membranes", "PROBLEM", 39, 57], ["a recombinant murine coronavirus", "PROBLEM", 139, 171], ["cellular membranes", "OBSERVATION", 39, 57]]], ["By sucrose gradient centrifugation and a virus-capture assay, Huang et al. have demonstrated that p6 is incorporated into mature virions (Huang et al., 2007).", [["virions", "ANATOMY", 129, 136], ["sucrose", "CHEMICAL", 3, 10], ["sucrose", "CHEMICAL", 3, 10], ["sucrose", "SIMPLE_CHEMICAL", 3, 10], ["p6", "GENE_OR_GENE_PRODUCT", 98, 100], ["p6", "PROTEIN", 98, 100], ["sucrose gradient centrifugation", "TREATMENT", 3, 34]]], ["Moreover, when co-expressed with SARS-CoV S, M, and E proteins, p6 is incorporated into VLPs.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["M", "GENE_OR_GENE_PRODUCT", 45, 46], ["E proteins", "GENE_OR_GENE_PRODUCT", 52, 62], ["p6", "GENE_OR_GENE_PRODUCT", 64, 66], ["VLPs", "GENE_OR_GENE_PRODUCT", 88, 92], ["SARS-CoV S, M, and E proteins", "PROTEIN", 33, 62], ["p6", "PROTEIN", 64, 66], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV S", "TEST", 38, 43]]], ["However, p6 is not detected in the virions when expressed via a recombinant murine coronavirus (MHV) (Pewe et al., 2005).", [["virions", "ANATOMY", 35, 42], ["p6", "GENE_OR_GENE_PRODUCT", 9, 11], ["murine coronavirus", "ORGANISM", 76, 94], ["MHV", "ORGANISM", 96, 99], ["p6", "PROTEIN", 9, 11], ["murine", "SPECIES", 76, 82], ["coronavirus", "SPECIES", 83, 94], ["murine coronavirus", "SPECIES", 76, 94], ["MHV", "SPECIES", 96, 99], ["not detected", "UNCERTAINTY", 15, 27]]], ["These results indicate that specific physical interactions between p6 and other SARS-CoV structural proteins may be required for recruiting p6 into the virus particles (see Table 3).Orf6 ::: Accessory proteins of the SARS-CoVInitial reverse genetic studies by Yount et al. have shown that recombinant SARS-CoV with ORF6 deleted (rSARS-CoV-\u03946) replicates similarly to wild-type virus in cell cultures as well as in infected BALB/c mice (Yount et al., 2005).", [["cell cultures", "ANATOMY", 386, 399], ["SARS", "DISEASE", 217, 221], ["p6", "GENE_OR_GENE_PRODUCT", 67, 69], ["p6", "GENE_OR_GENE_PRODUCT", 140, 142], ["Orf6", "GENE_OR_GENE_PRODUCT", 182, 186], ["SARS-CoV", "ORGANISM", 301, 309], ["ORF6", "GENE_OR_GENE_PRODUCT", 315, 319], ["rSARS-CoV-\u03946", "GENE_OR_GENE_PRODUCT", 329, 341], ["wild-type virus", "ORGANISM", 367, 382], ["cell cultures", "CELL", 386, 399], ["BALB/c mice", "ORGANISM", 423, 434], ["p6", "PROTEIN", 67, 69], ["SARS-CoV structural proteins", "PROTEIN", 80, 108], ["p6", "PROTEIN", 140, 142], ["Orf6", "PROTEIN", 182, 186], ["Accessory proteins", "PROTEIN", 191, 209], ["ORF6 deleted", "DNA", 315, 327], ["rSARS", "DNA", 329, 334], ["CoV", "DNA", 335, 338], ["\u03946", "DNA", 339, 341], ["cell cultures", "CELL_LINE", 386, 399], ["mice", "SPECIES", 430, 434], ["SARS-CoV", "SPECIES", 301, 309], ["mice", "SPECIES", 430, 434], ["other SARS", "PROBLEM", 74, 84], ["CoV structural proteins", "PROBLEM", 85, 108], ["the SARS", "PROBLEM", 213, 221], ["recombinant SARS", "PROBLEM", 289, 305], ["ORF6", "TEST", 315, 319], ["rSARS", "TEST", 329, 334], ["CoV", "TEST", 335, 338], ["type virus in cell cultures", "PROBLEM", 372, 399]]], ["However, a later study by Zhao et al. has demonstrated that, at a low MOI (0.01), rSARS-CoV-\u03946 replicates slower and to lower titres in cell cultures (Zhao et al., 2009).", [["cell cultures", "ANATOMY", 136, 149], ["rSARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 91], ["cell cultures", "CELL", 136, 149], ["rSARS", "PROTEIN", 82, 87], ["CoV", "PROTEIN", 88, 91], ["\u03946", "PROTEIN", 92, 94], ["cell cultures", "CELL_LINE", 136, 149], ["a later study", "TEST", 9, 22], ["rSARS", "TEST", 82, 87], ["CoV", "TEST", 88, 91], ["cell cultures", "TEST", 136, 149]]], ["Compared with wild-type virus, lower viral titres as well as lower levels of viral RNA and protein were observed for rSARS-CoV-\u03946 at the early stage of infection, but the differences gradually diminished as the infection progressed.", [["infection", "DISEASE", 152, 161], ["infection", "DISEASE", 211, 220], ["wild-type virus", "ORGANISM", 14, 29], ["rSARS-CoV-\u03946", "GENE_OR_GENE_PRODUCT", 117, 129], ["viral RNA", "RNA", 77, 86], ["rSARS", "PROTEIN", 117, 122], ["CoV", "PROTEIN", 123, 126], ["wild-type virus", "PROBLEM", 14, 29], ["lower viral titres", "TEST", 31, 49], ["viral RNA and protein", "PROBLEM", 77, 98], ["rSARS", "TEST", 117, 122], ["CoV", "TEST", 123, 126], ["infection", "PROBLEM", 152, 161], ["the infection", "PROBLEM", 207, 220], ["viral titres", "OBSERVATION", 37, 49], ["viral RNA", "OBSERVATION", 77, 86], ["early stage", "OBSERVATION_MODIFIER", 137, 148], ["infection", "OBSERVATION", 152, 161], ["diminished", "OBSERVATION_MODIFIER", 193, 203], ["infection", "OBSERVATION", 211, 220]]], ["Importantly, when transgenic mice expressing the SARS-CoV receptor hACE2 were used, rSARS-CoV-\u03946-infected mice demonstrated a lower morbidity and mortality, with slightly lower virus titres in lung and brain tissue compared with wild-type virus (Zhao et al., 2009).", [["lung", "ANATOMY", 193, 197], ["brain tissue", "ANATOMY", 202, 214], ["mice", "ORGANISM", 29, 33], ["SARS-CoV", "ORGANISM", 49, 57], ["hACE2", "GENE_OR_GENE_PRODUCT", 67, 72], ["rSARS-CoV", "ORGANISM", 84, 93], ["\u03946", "GENE_OR_GENE_PRODUCT", 94, 96], ["mice", "ORGANISM", 106, 110], ["lung", "ORGAN", 193, 197], ["brain tissue", "TISSUE", 202, 214], ["wild-type virus", "ORGANISM", 229, 244], ["SARS-CoV receptor", "PROTEIN", 49, 66], ["hACE2", "PROTEIN", 67, 72], ["rSARS", "PROTEIN", 84, 89], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 29, 33], ["SARS-CoV", "SPECIES", 49, 57], ["mice", "SPECIES", 106, 110], ["the SARS", "PROBLEM", 45, 53], ["CoV receptor hACE2", "TEST", 54, 72], ["rSARS", "TEST", 84, 89], ["CoV", "TEST", 90, 93], ["a lower morbidity", "PROBLEM", 124, 141], ["slightly lower virus titres in lung and brain tissue", "PROBLEM", 162, 214], ["lower", "OBSERVATION_MODIFIER", 126, 131], ["morbidity", "OBSERVATION", 132, 141], ["virus titres", "OBSERVATION", 177, 189], ["lung", "ANATOMY", 193, 197], ["brain tissue", "ANATOMY", 202, 214]]], ["Moreover, when ORF6 was introduced into an otherwise sub-lethal strain of MHV, the recombinant virus displayed enhanced growth in cell cultures and resulted in lethal encephalitis in infected mice (Pewe et al., 2005, Tangudu et al., 2007).", [["cell cultures", "ANATOMY", 130, 143], ["encephalitis", "DISEASE", 167, 179], ["ORF6", "GENE_OR_GENE_PRODUCT", 15, 19], ["MHV", "ORGANISM", 74, 77], ["cell cultures", "CELL", 130, 143], ["mice", "ORGANISM", 192, 196], ["ORF6", "PROTEIN", 15, 19], ["cell cultures", "CELL_LINE", 130, 143], ["mice", "SPECIES", 192, 196], ["MHV", "SPECIES", 74, 77], ["mice", "SPECIES", 192, 196], ["an otherwise sub-lethal strain of MHV", "PROBLEM", 40, 77], ["the recombinant virus", "PROBLEM", 79, 100], ["enhanced growth in cell cultures", "PROBLEM", 111, 143], ["lethal encephalitis", "PROBLEM", 160, 179], ["enhanced", "OBSERVATION_MODIFIER", 111, 119], ["growth", "OBSERVATION_MODIFIER", 120, 126], ["cell cultures", "OBSERVATION", 130, 143], ["lethal", "OBSERVATION_MODIFIER", 160, 166], ["encephalitis", "OBSERVATION", 167, 179]]], ["Taken together, these results indicate that SARS-CoV p6 enhances viral replication in vitro and in vivo, and it may serve an important role in the pathogenesis during SARS-CoV infection.Orf6 ::: Accessory proteins of the SARS-CoVSARS-CoV protein 6 is a 63-aa polypeptide with an amphipathic N-terminal portion (aa 1\u201340) and a highly polar C-terminal portion.", [["SARS-CoV infection", "DISEASE", 167, 185], ["N", "CHEMICAL", 291, 292], ["C", "CHEMICAL", 339, 340], ["SARS-CoV p6", "ORGANISM", 44, 55], ["SARS-CoV", "ORGANISM", 167, 175], ["Orf6", "GENE_OR_GENE_PRODUCT", 186, 190], ["SARS-CoVSARS-CoV protein 6", "GENE_OR_GENE_PRODUCT", 221, 247], ["SARS-CoV p6", "PROTEIN", 44, 55], ["Orf6", "PROTEIN", 186, 190], ["Accessory proteins", "PROTEIN", 195, 213], ["SARS-CoVSARS-CoV protein 6", "PROTEIN", 221, 247], ["amphipathic N-terminal portion", "PROTEIN", 279, 309], ["aa 1\u201340", "PROTEIN", 311, 318], ["highly polar C-terminal portion", "PROTEIN", 326, 357], ["SARS-CoV", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 167, 175], ["SARS-CoVSARS-CoV", "SPECIES", 221, 237], ["SARS", "PROBLEM", 44, 48], ["viral replication", "TREATMENT", 65, 82], ["SARS", "PROBLEM", 167, 171], ["CoV infection", "PROBLEM", 172, 185], ["the SARS", "TEST", 217, 225], ["CoVSARS", "TEST", 226, 233], ["CoV protein", "TEST", 234, 245], ["aa polypeptide", "TEST", 256, 270], ["viral replication", "OBSERVATION", 65, 82], ["infection", "OBSERVATION", 176, 185], ["terminal", "ANATOMY_MODIFIER", 293, 301], ["polar", "ANATOMY_MODIFIER", 333, 338], ["terminal", "ANATOMY_MODIFIER", 341, 349], ["portion", "ANATOMY_MODIFIER", 350, 357]]], ["An initial study using GFP-fusion protein and digitonin permeabilization supported an N-endo, C-endo membrane topology (Netland et al., 2007) (Fig. 3).", [["digitonin", "CHEMICAL", 46, 55], ["GFP", "GENE_OR_GENE_PRODUCT", 23, 26], ["digitonin", "SIMPLE_CHEMICAL", 46, 55], ["GFP", "PROTEIN", 23, 26], ["fusion protein", "PROTEIN", 27, 41], ["An initial study", "TEST", 0, 16], ["GFP", "TEST", 23, 26], ["fusion protein", "TEST", 27, 41], ["digitonin permeabilization", "TREATMENT", 46, 72], ["endo", "TEST", 88, 92], ["endo membrane topology", "TREATMENT", 96, 118]]], ["Later, it was confirmed that residues 2\u201337 in the N-terminal region form an \u03b1-helix and are embedded in the cellular membrane (Zhao et al., 2009).", [["cellular membrane", "ANATOMY", 108, 125], ["N", "CHEMICAL", 50, 51], ["cellular membrane", "CELLULAR_COMPONENT", 108, 125], ["N-terminal region", "PROTEIN", 50, 67], ["\u03b1-helix", "PROTEIN", 76, 83], ["terminal", "ANATOMY_MODIFIER", 52, 60], ["region", "ANATOMY_MODIFIER", 61, 67], ["cellular membrane", "ANATOMY", 108, 125]]], ["On the other hand, the C-terminal part contains two signal sequences.", [["C", "CHEMICAL", 23, 24], ["C-terminal part", "DNA", 23, 38], ["terminal", "ANATOMY_MODIFIER", 25, 33]]], ["The sequence YSEL (aa 49\u201352) is known to target proteins for internalization into endosomes, while the acidic tail signals ER export (Fig. 2) (Netland et al., 2007).Orf6 ::: Accessory proteins of the SARS-CoVUtilizing the recombinant MHV expressing SARS-CoV p6 as mentioned above, Netland et al. demonstrated that the enhancement effect of p6 is dependent on the N-terminal amphipathic region but not the C-terminal polar region (Netland et al., 2007).", [["endosomes", "ANATOMY", 82, 91], ["tail", "ANATOMY", 110, 114], ["N", "CHEMICAL", 363, 364], ["C", "CHEMICAL", 405, 406], ["endosomes", "CELLULAR_COMPONENT", 82, 91], ["ER", "GENE_OR_GENE_PRODUCT", 123, 125], ["Orf6", "GENE_OR_GENE_PRODUCT", 165, 169], ["recombinant MHV", "ORGANISM", 222, 237], ["SARS-CoV p6", "ORGANISM", 249, 260], ["p6", "GENE_OR_GENE_PRODUCT", 340, 342], ["YSEL", "DNA", 13, 17], ["aa 49\u201352", "PROTEIN", 19, 27], ["acidic tail", "PROTEIN", 103, 114], ["ER", "PROTEIN", 123, 125], ["Orf6", "PROTEIN", 165, 169], ["Accessory proteins", "PROTEIN", 174, 192], ["SARS-CoVUtilizing the recombinant MHV", "PROTEIN", 200, 237], ["SARS-CoV p6", "PROTEIN", 249, 260], ["p6", "PROTEIN", 340, 342], ["N-terminal amphipathic region", "PROTEIN", 363, 392], ["C-terminal polar region", "PROTEIN", 405, 428], ["MHV", "SPECIES", 234, 237], ["SARS-CoV", "SPECIES", 249, 257], ["The sequence YSEL", "TEST", 0, 17], ["internalization into endosomes", "PROBLEM", 61, 91], ["the SARS", "PROBLEM", 196, 204], ["CoV p6", "TREATMENT", 254, 260], ["the enhancement effect of p6", "PROBLEM", 314, 342], ["enhancement", "OBSERVATION_MODIFIER", 318, 329], ["effect", "OBSERVATION_MODIFIER", 330, 336], ["dependent", "OBSERVATION_MODIFIER", 346, 355], ["terminal", "ANATOMY_MODIFIER", 365, 373], ["amphipathic", "ANATOMY_MODIFIER", 374, 385], ["region", "ANATOMY_MODIFIER", 386, 392], ["terminal", "ANATOMY_MODIFIER", 407, 415], ["polar", "ANATOMY_MODIFIER", 416, 421], ["region", "ANATOMY_MODIFIER", 422, 428]]], ["Using transmission electron microscopy, Zhou et al. showed that full-length p6 or the N-terminal domain modified the cellular membrane, producing perinuclear vesicles that resemble the double-membrane vesicles (DMVs) known to be associated with coronavirus replication (Zhou et al., 2010).", [["cellular membrane", "ANATOMY", 117, 134], ["perinuclear vesicles", "ANATOMY", 146, 166], ["double-membrane vesicles", "ANATOMY", 185, 209], ["DMVs", "ANATOMY", 211, 215], ["N", "CHEMICAL", 86, 87], ["p6", "GENE_OR_GENE_PRODUCT", 76, 78], ["cellular membrane", "CELLULAR_COMPONENT", 117, 134], ["perinuclear vesicles", "CELLULAR_COMPONENT", 146, 166], ["membrane vesicles", "CELLULAR_COMPONENT", 192, 209], ["coronavirus", "ORGANISM", 245, 256], ["full-length p6", "PROTEIN", 64, 78], ["N-terminal domain", "PROTEIN", 86, 103], ["transmission electron microscopy", "TEST", 6, 38], ["full-length p6", "TREATMENT", 64, 78], ["perinuclear vesicles", "PROBLEM", 146, 166], ["coronavirus replication", "PROBLEM", 245, 268], ["cellular membrane", "OBSERVATION", 117, 134], ["perinuclear vesicles", "OBSERVATION", 146, 166], ["double", "OBSERVATION_MODIFIER", 185, 191], ["membrane vesicles", "OBSERVATION", 192, 209]]], ["The ability to modify intracellular membranes may also explain the observation that SARS-CoV p6 induces ER stress in transfected cells (Ye et al., 2008).", [["intracellular membranes", "ANATOMY", 22, 45], ["cells", "ANATOMY", 129, 134], ["intracellular membranes", "CELLULAR_COMPONENT", 22, 45], ["SARS-CoV p6", "GENE_OR_GENE_PRODUCT", 84, 95], ["ER", "GENE_OR_GENE_PRODUCT", 104, 106], ["cells", "CELL", 129, 134], ["SARS-CoV p6", "PROTEIN", 84, 95], ["ER", "PROTEIN", 104, 106], ["transfected cells", "CELL_LINE", 117, 134], ["intracellular membranes", "TREATMENT", 22, 45], ["SARS", "PROBLEM", 84, 88], ["CoV p6", "PROBLEM", 89, 95], ["ER stress in transfected cells", "PROBLEM", 104, 134]]], ["The p6-induced perinuclear vesicles, similar to the virus-induced DMVs, may derive and reorganize the membrane from the ER, thus leading to perturbation of ER function and induction of ER stress (Ye et al., 2008, Knoops et al., 2008).", [["perinuclear vesicles", "ANATOMY", 15, 35], ["membrane", "ANATOMY", 102, 110], ["ER", "ANATOMY", 120, 122], ["ER", "ANATOMY", 156, 158], ["p6", "GENE_OR_GENE_PRODUCT", 4, 6], ["perinuclear vesicles", "CELLULAR_COMPONENT", 15, 35], ["DMVs", "GENE_OR_GENE_PRODUCT", 66, 70], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["ER", "GENE_OR_GENE_PRODUCT", 120, 122], ["ER", "GENE_OR_GENE_PRODUCT", 156, 158], ["ER", "GENE_OR_GENE_PRODUCT", 185, 187], ["p6", "PROTEIN", 4, 6], ["DMVs", "PROTEIN", 66, 70], ["ER", "PROTEIN", 120, 122], ["ER", "PROTEIN", 156, 158], ["ER", "PROTEIN", 185, 187], ["The p6-induced perinuclear vesicles", "PROBLEM", 0, 35], ["the virus-induced DMVs", "PROBLEM", 48, 70], ["ER stress", "PROBLEM", 185, 194], ["perinuclear vesicles", "OBSERVATION", 15, 35]]], ["Notably, p6 is found to partially co-localize with nonstructural protein 3 (nsp3), which contains the papain-like viral protease and is a marker of the replication complex, as well as nonstructural protein 8 (nsp8), the primer-independent, non-canonical RNA polymerase (Tangudu et al., 2007, Zhou et al., 2010, Kumar et al., 2007).", [["p6", "GENE_OR_GENE_PRODUCT", 9, 11], ["nonstructural protein 3", "GENE_OR_GENE_PRODUCT", 51, 74], ["nsp3", "GENE_OR_GENE_PRODUCT", 76, 80], ["papain", "GENE_OR_GENE_PRODUCT", 102, 108], ["nonstructural protein 8", "GENE_OR_GENE_PRODUCT", 184, 207], ["nsp8", "GENE_OR_GENE_PRODUCT", 209, 213], ["p6", "PROTEIN", 9, 11], ["nonstructural protein 3", "PROTEIN", 51, 74], ["nsp3", "PROTEIN", 76, 80], ["papain", "PROTEIN", 102, 108], ["viral protease", "PROTEIN", 114, 128], ["replication complex", "PROTEIN", 152, 171], ["nonstructural protein 8", "PROTEIN", 184, 207], ["nsp8", "PROTEIN", 209, 213], ["non-canonical RNA polymerase", "PROTEIN", 240, 268], ["nonstructural protein", "TEST", 51, 72], ["the papain", "TREATMENT", 98, 108], ["viral protease", "PROBLEM", 114, 128], ["nonstructural protein", "TEST", 184, 205], ["nonstructural protein", "OBSERVATION", 51, 72], ["viral protease", "OBSERVATION", 114, 128]]], ["Moreover, physical interaction between p6 and nsp8 in SARS-CoV-infected Vero E6 cells has been confirmed by Kumar et al. using yeast two-hybrid and co-immunoprecipitation (Kumar et al., 2007).", [["Vero E6 cells", "ANATOMY", 72, 85], ["SARS", "DISEASE", 54, 58], ["p6", "GENE_OR_GENE_PRODUCT", 39, 41], ["nsp8", "GENE_OR_GENE_PRODUCT", 46, 50], ["SARS-CoV", "ORGANISM", 54, 62], ["Vero E6 cells", "CELL", 72, 85], ["p6", "PROTEIN", 39, 41], ["nsp8", "PROTEIN", 46, 50], ["SARS-CoV-infected Vero E6 cells", "CELL_LINE", 54, 85], ["yeast", "SPECIES", 127, 132], ["SARS-CoV", "SPECIES", 54, 62], ["Vero E6", "SPECIES", 72, 79], ["yeast", "SPECIES", 127, 132], ["SARS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["infected Vero E6 cells", "PROBLEM", 63, 85], ["E6 cells", "OBSERVATION", 77, 85]]], ["These results indicate that the N-terminal domain of p6 may play a role in the formation of the replication complex in SARS-CoV-infected cells and serve auxiliary or modulatory functions during SARS-CoV genome replication.Orf6 ::: Accessory proteins of the SARS-CoVProtein 6 was identified as a \u03b2-interferon antagonist by Kopecky-Bromberg et al. with the intriguing finding that overexpression of p6 inhibits nuclear import of STAT1 in cells treated with IFN-\u03b2 (Kopecky-Bromberg et al., 2007).", [["cells", "ANATOMY", 137, 142], ["nuclear", "ANATOMY", 409, 416], ["cells", "ANATOMY", 436, 441], ["SARS", "DISEASE", 119, 123], ["N", "CHEMICAL", 32, 33], ["p6", "GENE_OR_GENE_PRODUCT", 53, 55], ["SARS-CoV", "ORGANISM", 119, 127], ["cells", "CELL", 137, 142], ["SARS-CoV", "ORGANISM", 194, 202], ["Orf6", "GENE_OR_GENE_PRODUCT", 222, 226], ["SARS-CoVProtein 6", "GENE_OR_GENE_PRODUCT", 257, 274], ["\u03b2-interferon", "GENE_OR_GENE_PRODUCT", 295, 307], ["p6", "GENE_OR_GENE_PRODUCT", 397, 399], ["nuclear", "CELLULAR_COMPONENT", 409, 416], ["STAT1", "GENE_OR_GENE_PRODUCT", 427, 432], ["cells", "CELL", 436, 441], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 455, 460], ["N-terminal domain", "PROTEIN", 32, 49], ["p6", "PROTEIN", 53, 55], ["replication complex", "PROTEIN", 96, 115], ["SARS-CoV-infected cells", "CELL_TYPE", 119, 142], ["Orf6", "PROTEIN", 222, 226], ["Accessory proteins", "PROTEIN", 231, 249], ["SARS-CoVProtein 6", "PROTEIN", 257, 274], ["p6", "PROTEIN", 397, 399], ["STAT1", "PROTEIN", 427, 432], ["IFN", "PROTEIN", 455, 458], ["SARS-CoV", "SPECIES", 119, 127], ["SARS-CoV", "SPECIES", 194, 202], ["the N-terminal domain of p6", "TREATMENT", 28, 55], ["the replication complex", "PROBLEM", 92, 115], ["SARS", "PROBLEM", 119, 123], ["infected cells", "PROBLEM", 128, 142], ["modulatory functions", "PROBLEM", 166, 186], ["CoV genome replication", "TREATMENT", 199, 221], ["the SARS", "PROBLEM", 253, 261], ["CoVProtein", "TREATMENT", 262, 272], ["a \u03b2-interferon antagonist", "TREATMENT", 293, 318], ["overexpression of p6", "PROBLEM", 379, 399], ["STAT1 in cells", "TREATMENT", 427, 441], ["IFN", "TREATMENT", 455, 458], ["infected cells", "OBSERVATION", 128, 142]]], ["Further studies by the same group revealed that p6 can physically interact with karyopherin alpha 2 (KPNA2) and tether it to the rough ER (Frieman et al., 2007).", [["p6", "GENE_OR_GENE_PRODUCT", 48, 50], ["karyopherin alpha 2", "GENE_OR_GENE_PRODUCT", 80, 99], ["KPNA2", "GENE_OR_GENE_PRODUCT", 101, 106], ["ER", "GENE_OR_GENE_PRODUCT", 135, 137], ["p6", "PROTEIN", 48, 50], ["karyopherin alpha 2", "PROTEIN", 80, 99], ["KPNA2", "PROTEIN", 101, 106], ["ER", "PROTEIN", 135, 137], ["Further studies", "TEST", 0, 15]]], ["The immobilized KPNA2 interacts with karyopherin beta 1 (KPNB1) and prevents it from forming a complex with STAT1 to facilitate nuclear import (Zhao et al., 2009).", [["nuclear", "ANATOMY", 128, 135], ["KPNA2", "GENE_OR_GENE_PRODUCT", 16, 21], ["karyopherin beta 1", "GENE_OR_GENE_PRODUCT", 37, 55], ["KPNB1", "GENE_OR_GENE_PRODUCT", 57, 62], ["STAT1", "GENE_OR_GENE_PRODUCT", 108, 113], ["nuclear", "CELLULAR_COMPONENT", 128, 135], ["KPNA2", "PROTEIN", 16, 21], ["karyopherin beta 1", "PROTEIN", 37, 55], ["KPNB1", "PROTEIN", 57, 62], ["STAT1", "PROTEIN", 108, 113], ["The immobilized KPNA2", "TREATMENT", 0, 21], ["karyopherin beta", "TREATMENT", 37, 53]]], ["The KPNA2-interacting region in p6 is mapped to 10 aa in the C-terminal region (Frieman et al., 2007).", [["C", "CHEMICAL", 61, 62], ["KPNA2", "GENE_OR_GENE_PRODUCT", 4, 9], ["p6", "GENE_OR_GENE_PRODUCT", 32, 34], ["KPNA2", "PROTEIN", 4, 9], ["p6", "DNA", 32, 34], ["C-terminal region", "DNA", 61, 78], ["The KPNA2", "TREATMENT", 0, 9], ["region", "OBSERVATION_MODIFIER", 22, 28], ["p6", "ANATOMY_MODIFIER", 32, 34], ["10 aa", "OBSERVATION_MODIFIER", 48, 53], ["terminal", "ANATOMY_MODIFIER", 63, 71], ["region", "ANATOMY_MODIFIER", 72, 78]]], ["Later, Hussain et al. confirmed that p6 but not its C-terminally truncated mutant (p6\u0394C) impeded the nuclear import of proteins harboring a classical nuclear localization signal (NLS) (Hussain et al., 2008).", [["nuclear", "ANATOMY", 101, 108], ["nuclear", "ANATOMY", 150, 157], ["C", "CHEMICAL", 52, 53], ["p6", "GENE_OR_GENE_PRODUCT", 37, 39], ["nuclear", "CELLULAR_COMPONENT", 101, 108], ["p6", "PROTEIN", 37, 39], ["C-terminally truncated mutant", "PROTEIN", 52, 81], ["p6\u0394C", "PROTEIN", 83, 87], ["classical nuclear localization signal", "PROTEIN", 140, 177], ["NLS", "PROTEIN", 179, 182], ["p6", "PROBLEM", 37, 39]]], ["Further studies also demonstrated that the C-terminal tail is necessary but not sufficient to impede nuclear import, and a lipophilic N-terminus context is required (Hussain and Gallagher, 2010).", [["nuclear", "ANATOMY", 101, 108], ["C", "CHEMICAL", 43, 44], ["N", "CHEMICAL", 134, 135], ["nuclear", "CELLULAR_COMPONENT", 101, 108], ["C-terminal tail", "PROTEIN", 43, 58], ["N-terminus", "PROTEIN", 134, 144], ["Further studies", "TEST", 0, 15], ["the C-terminal tail", "PROBLEM", 39, 58], ["terminal", "ANATOMY_MODIFIER", 45, 53], ["tail", "ANATOMY", 54, 58]]], ["Taken together, these results point to a role of the C-terminal domain of p6 in modulating host protein nuclear transport and type-I interferon signaling, which may be important for immune evasion during SARS-CoV infection.Orf6 ::: Accessory proteins of the SARS-CoVOne recent study has demonstrated a physical interaction and co-localization between SARS-CoV p6 and another accessory protein, 9b (Calvo et al., 2012).", [["nuclear", "ANATOMY", 104, 111], ["SARS-CoV infection", "DISEASE", 204, 222], ["C", "CHEMICAL", 53, 54], ["p6", "GENE_OR_GENE_PRODUCT", 74, 76], ["nuclear", "CELLULAR_COMPONENT", 104, 111], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 126, 143], ["SARS-CoV", "ORGANISM", 204, 212], ["Orf6", "GENE_OR_GENE_PRODUCT", 223, 227], ["SARS-CoV p6", "GENE_OR_GENE_PRODUCT", 351, 362], ["C-terminal domain", "PROTEIN", 53, 70], ["p6", "PROTEIN", 74, 76], ["interferon", "PROTEIN", 133, 143], ["Orf6", "PROTEIN", 223, 227], ["Accessory proteins", "PROTEIN", 232, 250], ["SARS-CoV p6", "PROTEIN", 351, 362], ["accessory protein", "PROTEIN", 375, 392], ["SARS-CoV", "SPECIES", 204, 212], ["SARS-CoV", "SPECIES", 351, 359], ["the C-terminal domain of p6", "TREATMENT", 49, 76], ["type-I interferon signaling", "PROBLEM", 126, 153], ["immune evasion", "PROBLEM", 182, 196], ["SARS", "PROBLEM", 204, 208], ["CoV infection", "PROBLEM", 209, 222], ["the SARS", "PROBLEM", 254, 262], ["CoVOne recent study", "TEST", 263, 282], ["a physical interaction", "PROBLEM", 300, 322], ["SARS", "TEST", 351, 355], ["another accessory protein", "TEST", 367, 392], ["infection", "OBSERVATION", 213, 222]]], ["Other studies have also shown that when overexpressed, SARS-CoV p6 can stimulate DNA synthesis in cell culture and suppress the expression of co-transfected constructs (Geng et al., 2005, Hussain et al., 2008, Gunalan et al., 2011).", [["cell culture", "ANATOMY", 98, 110], ["SARS-CoV p6", "GENE_OR_GENE_PRODUCT", 55, 66], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["cell culture", "CELL", 98, 110], ["SARS-CoV p6", "PROTEIN", 55, 66], ["co-transfected constructs", "DNA", 142, 167], ["SARS-CoV", "SPECIES", 55, 63], ["Other studies", "TEST", 0, 13], ["SARS", "PROBLEM", 55, 59], ["CoV p6", "TREATMENT", 60, 66], ["DNA synthesis", "PROBLEM", 81, 94], ["cell culture", "TEST", 98, 110]]], ["The physiological significances of these findings in SARS-CoV replication and pathogenesis are currently unknown.Orf7a ::: Accessory proteins of the SARS-CoVSARS-CoV accessory protein 7a (p7a, also known as ORF8, U122, or X4) is detected in SARS-CoV-infected Vero E6 cells and in lung specimens from SARS patients (Chen et al., 2005, Fielding et al., 2004, Nelson et al., 2005).", [["Vero E6 cells", "ANATOMY", 259, 272], ["lung specimens", "ANATOMY", 280, 294], ["SARS", "DISEASE", 53, 57], ["SARS", "DISEASE", 300, 304], ["SARS-CoV", "ORGANISM", 53, 61], ["Orf7a", "GENE_OR_GENE_PRODUCT", 113, 118], ["SARS-CoVSARS-CoV accessory protein 7a", "GENE_OR_GENE_PRODUCT", 149, 186], ["p7a", "GENE_OR_GENE_PRODUCT", 188, 191], ["ORF8", "GENE_OR_GENE_PRODUCT", 207, 211], ["U122", "GENE_OR_GENE_PRODUCT", 213, 217], ["X4", "GENE_OR_GENE_PRODUCT", 222, 224], ["SARS-CoV", "ORGANISM", 241, 249], ["Vero E6 cells", "CELL", 259, 272], ["lung specimens", "CANCER", 280, 294], ["patients", "ORGANISM", 305, 313], ["Orf7a", "PROTEIN", 113, 118], ["Accessory proteins", "PROTEIN", 123, 141], ["SARS-CoVSARS-CoV accessory protein 7a", "PROTEIN", 149, 186], ["p7a", "PROTEIN", 188, 191], ["ORF8", "PROTEIN", 207, 211], ["U122", "PROTEIN", 213, 217], ["X4", "PROTEIN", 222, 224], ["SARS-CoV-infected Vero E6 cells", "CELL_LINE", 241, 272], ["patients", "SPECIES", 305, 313], ["SARS-CoV", "SPECIES", 53, 61], ["SARS-CoV", "SPECIES", 241, 249], ["Vero E6", "SPECIES", 259, 266], ["SARS", "PROBLEM", 53, 57], ["CoV replication", "TREATMENT", 58, 73], ["pathogenesis", "PROBLEM", 78, 90], ["the SARS", "TEST", 145, 153], ["CoVSARS", "TEST", 154, 161], ["CoV accessory protein", "TEST", 162, 183], ["ORF8", "TEST", 207, 211], ["SARS", "PROBLEM", 241, 245], ["CoV", "TEST", 246, 249], ["infected Vero E6 cells", "PROBLEM", 250, 272], ["Vero E6 cells", "OBSERVATION", 259, 272], ["lung", "ANATOMY", 280, 284]]], ["The protein is localized in the ER and ER-Golgi intermediate compartment (ERGIC) in SARS-CoV-infected cells and in transfected cells (Fielding et al., 2004, Nelson et al., 2005).", [["ER", "ANATOMY", 32, 34], ["ER-Golgi intermediate compartment", "ANATOMY", 39, 72], ["cells", "ANATOMY", 102, 107], ["cells", "ANATOMY", 127, 132], ["ER", "GENE_OR_GENE_PRODUCT", 32, 34], ["ER", "GENE_OR_GENE_PRODUCT", 39, 41], ["Golgi", "CELLULAR_COMPONENT", 42, 47], ["intermediate compartment", "CELLULAR_COMPONENT", 48, 72], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 84, 92], ["cells", "CELL", 102, 107], ["cells", "CELL", 127, 132], ["ER", "PROTEIN", 32, 34], ["ER", "PROTEIN", 39, 41], ["ERGIC", "PROTEIN", 74, 79], ["SARS-CoV-infected cells", "CELL_LINE", 84, 107], ["transfected cells", "CELL_LINE", 115, 132], ["SARS-CoV", "SPECIES", 84, 92], ["The protein", "TEST", 0, 11], ["SARS", "PROBLEM", 84, 88], ["infected cells", "PROBLEM", 93, 107], ["intermediate compartment", "OBSERVATION", 48, 72], ["infected cells", "OBSERVATION", 93, 107], ["transfected cells", "OBSERVATION", 115, 132]]], ["Using sucrose gradient centrifugation and a virus capture assay, Huang et al. have shown that SARS-CoV p7a is a structural protein incorporated into mature virions (Huang et al., 2006).", [["virions", "ANATOMY", 156, 163], ["sucrose", "CHEMICAL", 6, 13], ["SARS", "DISEASE", 94, 98], ["sucrose", "CHEMICAL", 6, 13], ["sucrose", "SIMPLE_CHEMICAL", 6, 13], ["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 94, 106], ["SARS-CoV p7a", "PROTEIN", 94, 106], ["structural protein", "PROTEIN", 112, 130], ["SARS-CoV", "SPECIES", 94, 102], ["sucrose gradient centrifugation", "TREATMENT", 6, 37], ["a virus capture assay", "TREATMENT", 42, 63], ["SARS", "PROBLEM", 94, 98], ["a structural protein", "PROBLEM", 110, 130], ["SARS", "OBSERVATION", 94, 98]]], ["Although p7a physically interacts with the SARS-CoV S protein and accessory protein 3a, neither S nor p3a is required for recruiting p7a into the virus particle; since p7a-containing VLPs can be produced in cells expressing only SARS-CoV M, E, and 7a (Tan et al., 2004, Huang et al., 2006) (see Table 4).Orf7a ::: Accessory proteins of the SARS-CoVAn early study based on reverse genetics has shown that deletion of ORF7a from the SARS-CoV genome does not significantly affect viral RNA synthesis and replication efficiency in cell culture (Yount et al., 2005).", [["cells", "ANATOMY", 207, 212], ["cell culture", "ANATOMY", 527, 539], ["SARS", "DISEASE", 431, 435], ["p7a", "GENE_OR_GENE_PRODUCT", 9, 12], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 43, 53], ["accessory protein 3a", "GENE_OR_GENE_PRODUCT", 66, 86], ["p3a", "GENE_OR_GENE_PRODUCT", 102, 105], ["p7a", "GENE_OR_GENE_PRODUCT", 133, 136], ["p7a-", "GENE_OR_GENE_PRODUCT", 168, 172], ["VLPs", "GENE_OR_GENE_PRODUCT", 183, 187], ["cells", "CELL", 207, 212], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 229, 237], ["E", "GENE_OR_GENE_PRODUCT", 241, 242], ["Orf7a", "GENE_OR_GENE_PRODUCT", 304, 309], ["ORF7a", "GENE_OR_GENE_PRODUCT", 416, 421], ["SARS-CoV", "ORGANISM", 431, 439], ["cell culture", "CELL", 527, 539], ["p7a", "PROTEIN", 9, 12], ["SARS-CoV S protein", "PROTEIN", 43, 61], ["accessory protein 3a", "PROTEIN", 66, 86], ["S", "PROTEIN", 96, 97], ["p3a", "PROTEIN", 102, 105], ["p7a", "PROTEIN", 133, 136], ["p7a-containing VLPs", "PROTEIN", 168, 187], ["Orf7a", "PROTEIN", 304, 309], ["Accessory proteins", "PROTEIN", 314, 332], ["ORF7a", "DNA", 416, 421], ["SARS-CoV genome", "DNA", 431, 446], ["viral RNA", "RNA", 477, 486], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 229, 237], ["SARS-CoV", "SPECIES", 431, 439], ["the SARS", "TEST", 39, 47], ["CoV S protein", "TEST", 48, 61], ["accessory protein 3a", "TEST", 66, 86], ["the virus particle", "PROBLEM", 142, 160], ["p7a-containing VLPs", "TREATMENT", 168, 187], ["the SARS", "PROBLEM", 336, 344], ["deletion of ORF7a", "PROBLEM", 404, 421], ["the SARS", "PROBLEM", 427, 435], ["CoV genome", "PROBLEM", 436, 446], ["viral RNA synthesis", "PROBLEM", 477, 496], ["replication efficiency", "PROBLEM", 501, 523], ["cell culture", "TEST", 527, 539]]], ["Schaecher et al. have also found that deletion of both ORF7a and 7b does not significantly affect SARS-CoV replication in transformed cells and in infected golden Syrian hamsters (Schaecher et al., 2007, Pekosz et al., 2006).", [["cells", "ANATOMY", 134, 139], ["ORF7a", "GENE_OR_GENE_PRODUCT", 55, 60], ["7b", "GENE_OR_GENE_PRODUCT", 65, 67], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 98, 106], ["cells", "CELL", 134, 139], ["golden Syrian hamsters", "ORGANISM", 156, 178], ["ORF7a and 7b", "PROTEIN", 55, 67], ["transformed cells", "CELL_LINE", 122, 139], ["golden Syrian hamsters", "SPECIES", 156, 178], ["SARS-CoV", "SPECIES", 98, 106], ["golden Syrian hamsters", "SPECIES", 156, 178], ["deletion of both ORF7a and 7b", "PROBLEM", 38, 67], ["SARS", "PROBLEM", 98, 102], ["transformed cells", "OBSERVATION", 122, 139]]], ["Later, Dediego et al. confirmed that recombinant SARS-CoV with ORF6, 7a, 7b, 8a, 8b, and 9b deleted produced viral particles with similar morphology as wild-type SARS-CoV and replicated similarly in transgenic mice expressing the SARS-CoV receptor (DeDiego et al., 2008).", [["SARS-CoV", "ORGANISM", 49, 57], ["ORF6", "GENE_OR_GENE_PRODUCT", 63, 67], ["7a", "GENE_OR_GENE_PRODUCT", 69, 71], ["7b", "GENE_OR_GENE_PRODUCT", 73, 75], ["8a", "GENE_OR_GENE_PRODUCT", 77, 79], ["8", "GENE_OR_GENE_PRODUCT", 81, 82], ["b", "GENE_OR_GENE_PRODUCT", 82, 83], ["9b", "GENE_OR_GENE_PRODUCT", 89, 91], ["SARS-CoV", "ORGANISM", 162, 170], ["mice", "ORGANISM", 210, 214], ["SARS-CoV receptor", "GENE_OR_GENE_PRODUCT", 230, 247], ["ORF6, 7a, 7b, 8a, 8b, and 9b", "DNA", 63, 91], ["SARS-CoV receptor", "PROTEIN", 230, 247], ["mice", "SPECIES", 210, 214], ["SARS-CoV", "SPECIES", 49, 57], ["SARS-CoV", "SPECIES", 162, 170], ["mice", "SPECIES", 210, 214], ["SARS-CoV", "SPECIES", 230, 238], ["ORF6", "TEST", 63, 67], ["viral particles", "PROBLEM", 109, 124], ["type SARS", "PROBLEM", 157, 166], ["viral particles", "OBSERVATION", 109, 124]]], ["These results indicate that p7a is not essential for SARS-CoV replication in vitro and in vivo.Orf7a ::: Accessory proteins of the SARS-CoVSARS-CoV p7a is a type-I transmembrane protein with 122 amino-acid residues in length (Fig.3).", [["SARS", "DISEASE", 131, 135], ["amino-acid", "CHEMICAL", 195, 205], ["amino-acid", "CHEMICAL", 195, 205], ["p7a", "GENE_OR_GENE_PRODUCT", 28, 31], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["Orf7a", "GENE_OR_GENE_PRODUCT", 95, 100], ["CoVSARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 136, 151], ["p7a", "PROTEIN", 28, 31], ["Orf7a", "PROTEIN", 95, 100], ["Accessory proteins", "PROTEIN", 105, 123], ["SARS-CoVSARS-CoV p7a", "PROTEIN", 131, 151], ["type-I transmembrane protein", "PROTEIN", 157, 185], ["SARS-CoV", "SPECIES", 53, 61], ["SARS-CoVSARS-CoV", "SPECIES", 131, 147], ["SARS", "PROBLEM", 53, 57], ["CoV replication", "TREATMENT", 58, 73], ["the SARS", "TEST", 127, 135], ["CoVSARS", "TEST", 136, 143], ["transmembrane protein", "TEST", 164, 185], ["amino-acid residues in", "TREATMENT", 195, 217], ["length", "TEST", 218, 224]]], ["The 15 N-terminal residues constitute a signal peptide, which is cleaved by signal peptidase in both SARS-CoV-infected cells and in transfected cells (Fielding et al., 2004, Nelson et al., 2005).", [["cells", "ANATOMY", 119, 124], ["cells", "ANATOMY", 144, 149], ["N", "CHEMICAL", 7, 8], ["SARS-CoV", "ORGANISM", 101, 109], ["cells", "CELL", 119, 124], ["cells", "CELL", 144, 149], ["15 N-terminal residues", "PROTEIN", 4, 26], ["signal peptidase", "PROTEIN", 76, 92], ["SARS-CoV-infected cells", "CELL_LINE", 101, 124], ["transfected cells", "CELL_LINE", 132, 149], ["SARS-CoV", "SPECIES", 101, 109], ["terminal residues", "PROBLEM", 9, 26], ["a signal peptide", "PROBLEM", 38, 54], ["signal peptidase", "TEST", 76, 92], ["both SARS", "PROBLEM", 96, 105], ["infected cells", "PROBLEM", 110, 124], ["infected cells", "OBSERVATION", 110, 124], ["transfected cells", "OBSERVATION", 132, 149]]], ["The aa residues 16\u201396 comprise the luminal domain, which folds into a compact seven-stranded \u03b2 sandwich that resembles members of the Ig superfamily (Nelson et al., 2005).", [["luminal domain", "ANATOMY", 35, 49], ["luminal", "CHEMICAL", 35, 42], ["Ig", "GENE_OR_GENE_PRODUCT", 134, 136], ["aa residues 16\u201396", "PROTEIN", 4, 21], ["luminal domain", "PROTEIN", 35, 49], ["compact seven-stranded \u03b2 sandwich", "PROTEIN", 70, 103], ["Ig superfamily", "PROTEIN", 134, 148], ["The aa residues", "TEST", 0, 15], ["luminal", "ANATOMY_MODIFIER", 35, 42]]], ["The sequence and structural homology between SARS-CoV p7a and ICAM-1 suggested that p7a may interact with the lymphocyte function-associated antigen 1 (LFA-1), which was later confirmed by direct in vitro binding experiments in Jurkat cells (H\u00e4nel et al., 2006, H\u00e4nel and Willbold, 2007).", [["lymphocyte", "ANATOMY", 110, 120], ["Jurkat cells", "ANATOMY", 228, 240], ["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 45, 57], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 62, 68], ["p7a", "GENE_OR_GENE_PRODUCT", 84, 87], ["lymphocyte function-associated antigen 1", "GENE_OR_GENE_PRODUCT", 110, 150], ["LFA-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["Jurkat cells", "CELL", 228, 240], ["SARS-CoV p7a", "PROTEIN", 45, 57], ["ICAM", "PROTEIN", 62, 66], ["p7a", "PROTEIN", 84, 87], ["lymphocyte function-associated antigen 1", "PROTEIN", 110, 150], ["LFA-1", "PROTEIN", 152, 157], ["Jurkat cells", "CELL_LINE", 228, 240], ["SARS-CoV", "SPECIES", 45, 53], ["The sequence", "TEST", 0, 12], ["SARS", "TEST", 45, 49], ["ICAM", "TEST", 62, 66], ["the lymphocyte function", "TEST", 106, 129], ["LFA", "TEST", 152, 155], ["Jurkat cells", "OBSERVATION", 228, 240]]], ["These data suggest LFA-1 to be an attachment factor or even receptor for SARS-CoV on human leukocytes, although a majority of p7a is found to remain intracellular in SARS-CoV-infected cells (Nelson et al., 2005, H\u00e4nel and Willbold, 2007).", [["leukocytes", "ANATOMY", 91, 101], ["intracellular", "ANATOMY", 149, 162], ["cells", "ANATOMY", 184, 189], ["SARS-CoV-infected", "DISEASE", 166, 183], ["LFA-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 73, 81], ["human", "ORGANISM", 85, 90], ["leukocytes", "CELL", 91, 101], ["p7a", "GENE_OR_GENE_PRODUCT", 126, 129], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 149, 162], ["SARS-CoV", "ORGANISM", 166, 174], ["cells", "CELL", 184, 189], ["LFA", "PROTEIN", 19, 22], ["attachment factor", "PROTEIN", 34, 51], ["human leukocytes", "CELL_TYPE", 85, 101], ["p7a", "PROTEIN", 126, 129], ["SARS-CoV-infected cells", "CELL_TYPE", 166, 189], ["human", "SPECIES", 85, 90], ["SARS-CoV", "SPECIES", 73, 81], ["human", "SPECIES", 85, 90], ["SARS-CoV", "SPECIES", 166, 174], ["These data", "TEST", 0, 10], ["LFA", "TEST", 19, 22], ["an attachment factor", "PROBLEM", 31, 51], ["SARS", "PROBLEM", 73, 77], ["CoV", "PROBLEM", 78, 81], ["human leukocytes", "TEST", 85, 101], ["intracellular in SARS", "PROBLEM", 149, 170], ["infected cells", "PROBLEM", 175, 189], ["infected cells", "OBSERVATION", 175, 189]]], ["Residues 97\u2013117 of SARS-CoV p7a are highly hydrophobic and transverse the cellular membrane.", [["cellular membrane", "ANATOMY", 74, 91], ["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 19, 31], ["cellular membrane", "CELLULAR_COMPONENT", 74, 91], ["SARS-CoV p7a", "DNA", 19, 31], ["SARS-CoV", "SPECIES", 19, 27], ["Residues", "TEST", 0, 8], ["SARS-CoV p7a", "TEST", 19, 31], ["hydrophobic", "OBSERVATION_MODIFIER", 43, 54], ["cellular membrane", "OBSERVATION", 74, 91]]], ["The last 5 residues of the C-terminal tail (KRKTE) form a typical ER retention motif (KKXX or KXKXX, where X is any amino acid).", [["ER", "ANATOMY", 66, 68], ["amino acid", "CHEMICAL", 116, 126], ["C", "CHEMICAL", 27, 28], ["amino acid", "CHEMICAL", 116, 126], ["ER", "GENE_OR_GENE_PRODUCT", 66, 68], ["amino acid", "AMINO_ACID", 116, 126], ["C-terminal tail", "PROTEIN", 27, 42], ["KRKTE", "PROTEIN", 44, 49], ["ER retention motif", "PROTEIN", 66, 84], ["KKXX", "PROTEIN", 86, 90], ["KXKXX", "PROTEIN", 94, 99], ["X", "PROTEIN", 107, 108], ["a typical ER retention motif", "TREATMENT", 56, 84], ["KXKXX", "TEST", 94, 99], ["any amino acid", "TREATMENT", 112, 126], ["terminal", "ANATOMY_MODIFIER", 29, 37], ["tail", "ANATOMY", 38, 42], ["retention motif", "OBSERVATION", 69, 84]]], ["When this motif is mutated from KRKTE to ERETE, p7a fails to be retro-transported to the ER and accumulates in the Golgi, where it undergoes rapid proteolytic processing (Fielding et al., 2004).", [["ER", "ANATOMY", 89, 91], ["Golgi", "ANATOMY", 115, 120], ["KRKTE", "GENE_OR_GENE_PRODUCT", 32, 37], ["ERETE", "GENE_OR_GENE_PRODUCT", 41, 46], ["p7a", "GENE_OR_GENE_PRODUCT", 48, 51], ["ER", "GENE_OR_GENE_PRODUCT", 89, 91], ["Golgi", "CELLULAR_COMPONENT", 115, 120], ["KRKTE", "PROTEIN", 32, 37], ["ERETE", "PROTEIN", 41, 46], ["p7a", "PROTEIN", 48, 51], ["ER", "PROTEIN", 89, 91], ["rapid proteolytic processing", "PROBLEM", 141, 169], ["rapid", "OBSERVATION_MODIFIER", 141, 146]]], ["Moreover, when the transmembrane domain and the short C-terminal tail of SARS-CoV p7a are fused with the cell-surface protein CD4, the chimera protein (CD4/orf7a-TM-tail) is found to be partially retained in the Golgi (Nelson et al., 2005).", [["transmembrane", "ANATOMY", 19, 32], ["cell", "ANATOMY", 105, 109], ["Golgi", "ANATOMY", 212, 217], ["C", "CHEMICAL", 54, 55], ["transmembrane", "CELLULAR_COMPONENT", 19, 32], ["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 73, 85], ["cell", "CELL", 105, 109], ["CD4", "GENE_OR_GENE_PRODUCT", 126, 129], ["CD4", "GENE_OR_GENE_PRODUCT", 152, 155], ["orf7a", "GENE_OR_GENE_PRODUCT", 156, 161], ["Golgi", "CELLULAR_COMPONENT", 212, 217], ["transmembrane domain", "PROTEIN", 19, 39], ["C-terminal tail", "PROTEIN", 54, 69], ["SARS-CoV p7a", "PROTEIN", 73, 85], ["cell-surface protein", "PROTEIN", 105, 125], ["CD4", "PROTEIN", 126, 129], ["chimera protein", "PROTEIN", 135, 150], ["CD4", "PROTEIN", 152, 155], ["orf7a", "PROTEIN", 156, 161], ["TM", "PROTEIN", 162, 164], ["tail", "PROTEIN", 165, 169], ["SARS-CoV", "SPECIES", 73, 81], ["the transmembrane domain", "TEST", 15, 39], ["the short C-terminal tail of SARS", "PROBLEM", 44, 77], ["the cell", "TEST", 101, 109], ["CD4", "TEST", 126, 129], ["the chimera protein", "TEST", 131, 150], ["CD4", "TEST", 152, 155], ["orf7a", "TEST", 156, 161], ["tail", "ANATOMY", 165, 169]]], ["Fielding et al. have demonstrated physical interaction between SARS-CoV p7a and the host protein small glutamine-rich tetratricopeptide repeat-containing protein (SGT) (Fielding et al., 2006).", [["glutamine", "CHEMICAL", 103, 112], ["glutamine", "CHEMICAL", 103, 112], ["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 63, 75], ["glutamine", "AMINO_ACID", 103, 112], ["-rich tetratricopeptide repeat-containing protein", "GENE_OR_GENE_PRODUCT", 112, 161], ["SARS-CoV p7a", "PROTEIN", 63, 75], ["host protein small glutamine-rich tetratricopeptide repeat-containing protein", "PROTEIN", 84, 161], ["SGT", "PROTEIN", 163, 166], ["SARS-CoV", "SPECIES", 63, 71], ["the host protein small glutamine", "TREATMENT", 80, 112]]], ["Previous studies have shown that SGT interacts with the HIV-1 accessory protein vpu, which is essential in modulating viral particle release (Bour and Strebel, 2003).", [["SGT", "CHEMICAL", 33, 36], ["SGT", "GENE_OR_GENE_PRODUCT", 33, 36], ["HIV-1", "ORGANISM", 56, 61], ["vpu", "GENE_OR_GENE_PRODUCT", 80, 83], ["SGT", "PROTEIN", 33, 36], ["HIV-1 accessory protein", "PROTEIN", 56, 79], ["vpu", "PROTEIN", 80, 83], ["HIV-1", "SPECIES", 56, 61], ["HIV-1", "SPECIES", 56, 61], ["Previous studies", "TEST", 0, 16], ["the HIV", "TEST", 52, 59], ["viral particle", "OBSERVATION", 118, 132]]], ["These results, together with the fact that SARS-CoV p7a is localized in the ER and ERGIC where coronaviruses generally assemble, and that p7a physically interacts with SARS-CoV M and E proteins, indicate that p7a may serve a function in the assembly stage during SARS-CoV replication (Fielding et al., 2006).Orf7a ::: Accessory proteins of the SARS-CoVWhen transfected in mammalian cells, SARS-CoV p7a has been shown to induce caspase-dependent apoptosis as evidenced by the cleavage of poly(ADP-ribose) polymerase (PARP), a well-characterized apoptotic marker (Tan et al., 2004).", [["ER", "ANATOMY", 76, 78], ["mammalian cells", "ANATOMY", 372, 387], ["SARS", "DISEASE", 43, 47], ["poly(ADP-ribose", "CHEMICAL", 487, 502], ["poly(ADP-ribose)", "CHEMICAL", 487, 503], ["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 43, 55], ["ER", "GENE_OR_GENE_PRODUCT", 76, 78], ["ERGIC", "GENE_OR_GENE_PRODUCT", 83, 88], ["p7a", "GENE_OR_GENE_PRODUCT", 138, 141], ["SARS-CoV M", "GENE_OR_GENE_PRODUCT", 168, 178], ["E proteins", "GENE_OR_GENE_PRODUCT", 183, 193], ["p7a", "GENE_OR_GENE_PRODUCT", 209, 212], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 263, 271], ["Orf7a", "GENE_OR_GENE_PRODUCT", 308, 313], ["CoVWhen", "GENE_OR_GENE_PRODUCT", 349, 356], ["mammalian cells", "CELL", 372, 387], ["SARS-CoV p7a", "ORGANISM", 389, 401], ["caspase", "GENE_OR_GENE_PRODUCT", 427, 434], ["poly(ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 487, 514], ["PARP", "GENE_OR_GENE_PRODUCT", 516, 520], ["SARS-CoV p7a", "PROTEIN", 43, 55], ["ER", "PROTEIN", 76, 78], ["ERGIC", "PROTEIN", 83, 88], ["p7a", "PROTEIN", 138, 141], ["SARS-CoV M and E proteins", "PROTEIN", 168, 193], ["p7a", "PROTEIN", 209, 212], ["Orf7a", "PROTEIN", 308, 313], ["Accessory proteins", "PROTEIN", 318, 336], ["SARS-CoVWhen", "PROTEIN", 344, 356], ["mammalian cells", "CELL_TYPE", 372, 387], ["SARS-CoV p7a", "PROTEIN", 389, 401], ["caspase", "PROTEIN", 427, 434], ["poly(ADP-ribose) polymerase", "PROTEIN", 487, 514], ["PARP", "PROTEIN", 516, 520], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 263, 271], ["SARS-CoV", "SPECIES", 389, 397], ["SARS", "PROBLEM", 43, 47], ["coronaviruses", "PROBLEM", 95, 108], ["SARS-CoV M and E proteins", "TEST", 168, 193], ["the SARS", "PROBLEM", 340, 348], ["SARS", "PROBLEM", 389, 393], ["caspase", "PROBLEM", 427, 434], ["dependent apoptosis", "PROBLEM", 435, 454], ["the cleavage of poly(ADP-ribose) polymerase", "TREATMENT", 471, 514], ["mammalian cells", "OBSERVATION", 372, 387], ["dependent", "OBSERVATION_MODIFIER", 435, 444], ["apoptosis", "OBSERVATION", 445, 454]]], ["This is consolidated by the finding that recombinant SARS-CoV with 7a and 7b deleted is not as efficient as wild-type virus in inducing DNA fragmentation, although the induction of early apoptotic markers such as annexin-V binding and caspase-3 activation are similar (Schaecher et al., 2007).", [["SARS", "DISEASE", 53, 57], ["SARS-CoV", "ORGANISM", 53, 61], ["7a", "GENE_OR_GENE_PRODUCT", 67, 69], ["7b", "GENE_OR_GENE_PRODUCT", 74, 76], ["wild-type virus", "ORGANISM", 108, 123], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["annexin-V", "GENE_OR_GENE_PRODUCT", 213, 222], ["caspase-3", "GENE_OR_GENE_PRODUCT", 235, 244], ["recombinant SARS-CoV with 7a and 7b", "PROTEIN", 41, 76], ["early apoptotic markers", "PROTEIN", 181, 204], ["caspase-3", "PROTEIN", 235, 244], ["SARS-CoV", "SPECIES", 53, 61], ["type virus", "PROBLEM", 113, 123], ["DNA fragmentation", "PROBLEM", 136, 153], ["early apoptotic markers", "PROBLEM", 181, 204], ["annexin", "TEST", 213, 220], ["not as", "UNCERTAINTY", 88, 94], ["DNA fragmentation", "OBSERVATION", 136, 153]]], ["These results indicate that SARS-CoV-induced apoptosis is only partially contributed by p7a, and other viral factors may be involved in the process.", [["SARS", "DISEASE", 28, 32], ["SARS-CoV", "ORGANISM", 28, 36], ["p7a", "GENE_OR_GENE_PRODUCT", 88, 91], ["p7a", "PROTEIN", 88, 91], ["viral factors", "PROTEIN", 103, 116], ["SARS-CoV", "SPECIES", 28, 36], ["SARS", "PROBLEM", 28, 32], ["apoptosis", "PROBLEM", 45, 54], ["other viral factors", "PROBLEM", 97, 116]]], ["Later, Tan et al. demonstrated that the pro-apoptotic property of SARS-CoV p7a depends on its transmembrane domain, which is also required for its interaction with Bcl-XL, an anti-apoptotic protein belonging to the Bcl-2 family (Tan et al., 2007).", [["transmembrane", "ANATOMY", 94, 107], ["SARS", "DISEASE", 66, 70], ["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 66, 78], ["transmembrane", "CELLULAR_COMPONENT", 94, 107], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 164, 170], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 215, 220], ["SARS-CoV p7a", "PROTEIN", 66, 78], ["transmembrane domain", "PROTEIN", 94, 114], ["Bcl-XL", "PROTEIN", 164, 170], ["anti-apoptotic protein", "PROTEIN", 175, 197], ["Bcl-2 family", "PROTEIN", 215, 227], ["SARS-CoV", "SPECIES", 66, 74], ["SARS", "PROBLEM", 66, 70], ["Bcl-XL", "TREATMENT", 164, 170], ["an anti-apoptotic protein", "TREATMENT", 172, 197]]], ["Interestingly, SARS-CoV p7a interacts strongly with the pro-survival members of the Bcl-2 family (such as Bcl-XL, Bcl-w, Mcl-1, and A1), but not the pro-apoptotic Bcl-2 family proteins (such as BAD, BID, BAX and BAK) (Tan et al., 2007).", [["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 15, 27], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 84, 89], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 106, 112], ["Bcl-w", "GENE_OR_GENE_PRODUCT", 114, 119], ["Mcl-1", "GENE_OR_GENE_PRODUCT", 121, 126], ["A1", "GENE_OR_GENE_PRODUCT", 132, 134], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 163, 168], ["BAD", "GENE_OR_GENE_PRODUCT", 194, 197], ["BID", "GENE_OR_GENE_PRODUCT", 199, 202], ["BAX", "GENE_OR_GENE_PRODUCT", 204, 207], ["BAK", "GENE_OR_GENE_PRODUCT", 212, 215], ["SARS-CoV p7a", "PROTEIN", 15, 27], ["Bcl-2 family", "PROTEIN", 84, 96], ["Bcl", "PROTEIN", 106, 109], ["XL", "PROTEIN", 110, 112], ["Bcl", "PROTEIN", 114, 117], ["Mcl", "PROTEIN", 121, 124], ["A1", "PROTEIN", 132, 134], ["pro-apoptotic Bcl-2 family proteins", "PROTEIN", 149, 184], ["BAD", "PROTEIN", 194, 197], ["BID", "PROTEIN", 199, 202], ["BAX", "PROTEIN", 204, 207], ["BAK", "PROTEIN", 212, 215], ["SARS-CoV", "SPECIES", 15, 23], ["Bcl", "TEST", 106, 109], ["Bcl", "TEST", 114, 117], ["Mcl", "TEST", 121, 124]]], ["The selective interactions may hinder the pro-survival functions of these proteins and result in apoptosis induction in SARS-CoV-infected cells.Orf7a ::: Accessory proteins of the SARS-CoVWhen overexpressed, protein 7a can inhibit the growth of Balb/c 3T3 cells in a dose-dependent and time-dependent manner (Chen et al., 2005).", [["cells", "ANATOMY", 138, 143], ["Balb/c 3T3 cells", "ANATOMY", 245, 261], ["SARS-CoV-infected", "DISEASE", 120, 137], ["SARS-CoV", "ORGANISM", 120, 128], ["cells", "CELL", 138, 143], ["SARS-CoVWhen", "GENE_OR_GENE_PRODUCT", 180, 192], ["protein 7a", "GENE_OR_GENE_PRODUCT", 208, 218], ["Balb/c 3T3 cells", "CELL", 245, 261], ["SARS-CoV-infected cells", "CELL_LINE", 120, 143], ["Orf7", "PROTEIN", 144, 148], ["Accessory proteins", "PROTEIN", 154, 172], ["CoVWhen", "PROTEIN", 185, 192], ["protein 7a", "PROTEIN", 208, 218], ["Balb/c 3T3 cells", "CELL_LINE", 245, 261], ["SARS-CoV", "SPECIES", 120, 128], ["these proteins", "TEST", 68, 82], ["apoptosis induction", "TREATMENT", 97, 116], ["SARS", "PROBLEM", 120, 124], ["infected cells", "PROBLEM", 129, 143], ["the SARS", "PROBLEM", 176, 184], ["Balb/c 3T3 cells", "TREATMENT", 245, 261], ["infected cells", "OBSERVATION", 129, 143]]], ["A later study by Yuan et al. confirmed that overexpression of 7a led to cell cycle arrest at the G0/G1 phase, possibly by inhibiting the phosphorylation of retinoblastoma (Rb) protein (Yuan et al., 2006).", [["cell", "ANATOMY", 72, 76], ["cell", "CELL", 72, 76], ["retinoblastoma", "GENE_OR_GENE_PRODUCT", 156, 170], ["Rb", "GENE_OR_GENE_PRODUCT", 172, 174], ["retinoblastoma (Rb) protein", "PROTEIN", 156, 183], ["A later study", "TEST", 0, 13], ["cell cycle arrest", "PROBLEM", 72, 89], ["retinoblastoma", "PROBLEM", 156, 170], ["retinoblastoma", "OBSERVATION", 156, 170]]], ["Deletion-mutant experiments narrowed down the domain spanning aa 44\u201382 to be essential for cytoplasmic localization and cell-cycle arrest (Yuan et al., 2006).", [["cytoplasmic", "ANATOMY", 91, 102], ["cell", "ANATOMY", 120, 124], ["cytoplasmic", "ORGANISM_SUBSTANCE", 91, 102], ["cell", "CELL", 120, 124], ["aa 44\u201382", "PROTEIN", 62, 70], ["Deletion", "TEST", 0, 8], ["mutant experiments", "PROBLEM", 9, 27], ["cytoplasmic localization", "TEST", 91, 115], ["cell-cycle arrest", "TREATMENT", 120, 137], ["narrowed", "OBSERVATION_MODIFIER", 28, 36]]], ["Overexpression of 7a has also been shown to activate nuclear factor kappa B (NF-\u03baB) and c-Jun N-terminal kinase (JNK), which in turn induce the production of pro-inflammatory cytokines such as interleukin 8 (IL-8) and RANTES (Kanzawa et al., 2006).", [["N", "CHEMICAL", 94, 95], ["7a", "GENE_OR_GENE_PRODUCT", 18, 20], ["nuclear factor kappa B", "GENE_OR_GENE_PRODUCT", 53, 75], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 77, 82], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 88, 111], ["JNK", "GENE_OR_GENE_PRODUCT", 113, 116], ["interleukin 8", "GENE_OR_GENE_PRODUCT", 193, 206], ["IL-8", "GENE_OR_GENE_PRODUCT", 208, 212], ["RANTES", "GENE_OR_GENE_PRODUCT", 218, 224], ["nuclear factor kappa B", "PROTEIN", 53, 75], ["NF-\u03baB", "PROTEIN", 77, 82], ["Jun N-terminal kinase", "PROTEIN", 90, 111], ["JNK", "PROTEIN", 113, 116], ["pro-inflammatory cytokines", "PROTEIN", 158, 184], ["interleukin 8", "PROTEIN", 193, 206], ["IL-8", "PROTEIN", 208, 212], ["RANTES", "PROTEIN", 218, 224], ["nuclear factor kappa", "TEST", 53, 73], ["NF", "TEST", 77, 79], ["c", "TEST", 88, 89], ["pro-inflammatory cytokines", "PROBLEM", 158, 184], ["interleukin 8 (IL", "TREATMENT", 193, 210], ["terminal kinase", "ANATOMY", 96, 111], ["pro-inflammatory cytokines", "OBSERVATION", 158, 184]]], ["Moreover, using EGFP fusion protein, Kopecky-Bromberg et al. showed that overexpression of 7a activates the p38 mitogen-activated protein kinase (MAPK) and inhibits cellular protein synthesis at the translation level (Kopecky-Bromberg et al., 2006).", [["cellular", "ANATOMY", 165, 173], ["EGFP", "GENE_OR_GENE_PRODUCT", 16, 20], ["p38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 108, 144], ["MAPK", "GENE_OR_GENE_PRODUCT", 146, 150], ["cellular", "CELL", 165, 173], ["EGFP fusion protein", "PROTEIN", 16, 35], ["p38 mitogen-activated protein kinase", "PROTEIN", 108, 144], ["MAPK", "PROTEIN", 146, 150], ["EGFP fusion protein", "TEST", 16, 35], ["Kopecky", "TEST", 37, 44], ["the p38 mitogen", "TEST", 104, 119], ["activated protein kinase", "TEST", 120, 144], ["MAPK", "TEST", 146, 150], ["cellular protein synthesis", "TEST", 165, 191], ["the translation level", "TEST", 195, 216], ["Kopecky", "TEST", 218, 225], ["protein synthesis", "OBSERVATION", 174, 191]]], ["However, p7a-induced apoptosis is not inhibited in the presence of a p38 inhibitor, indicating that p7a induces apoptosis via mechanisms independent of the MAPK pathways (Kopecky-Bromberg et al., 2006).Orf7a ::: Accessory proteins of the SARS-CoVTaken together, although SARS-CoV p7a is not essential for viral replication, it is a minor structural protein and may serve certain functions during viral assembly.", [["p7a-", "CHEMICAL", 9, 13], ["SARS", "DISEASE", 271, 275], ["p7a-", "GENE_OR_GENE_PRODUCT", 9, 13], ["p38", "GENE_OR_GENE_PRODUCT", 69, 72], ["p7a", "GENE_OR_GENE_PRODUCT", 100, 103], ["MAPK", "GENE_OR_GENE_PRODUCT", 156, 160], ["Orf7a", "GENE_OR_GENE_PRODUCT", 202, 207], ["SARS-CoV p7a", "GENE_OR_GENE_PRODUCT", 271, 283], ["p7a", "PROTEIN", 100, 103], ["MAPK", "PROTEIN", 156, 160], ["Orf7a", "PROTEIN", 202, 207], ["Accessory proteins", "PROTEIN", 212, 230], ["SARS-CoV p7a", "PROTEIN", 271, 283], ["SARS-CoV", "SPECIES", 271, 279], ["p7a-induced apoptosis", "PROBLEM", 9, 30], ["a p38 inhibitor", "TREATMENT", 67, 82], ["apoptosis", "PROBLEM", 112, 121], ["the MAPK pathways", "TEST", 152, 169], ["Kopecky", "TEST", 171, 178], ["the SARS", "PROBLEM", 234, 242], ["SARS-CoV p7a", "TEST", 271, 283], ["viral replication", "PROBLEM", 305, 322], ["a minor structural protein", "PROBLEM", 330, 356], ["apoptosis", "OBSERVATION", 21, 30]]], ["Notably, p7a is actively involved in virus\u2013host interaction.", [["p7a", "GENE_OR_GENE_PRODUCT", 9, 12], ["p7a", "PROTEIN", 9, 12]]], ["By inhibiting cellular translation, activating stress-induced MAP kinases, suppressing cell-cycle progression and inducing caspase-dependent apoptosis, p7a may be an important player in SARS-CoV pathogenesis.Orf7b ::: Accessory proteins of the SARS-CoVAccessory protein 7b was predicted to be translated from a second ORF of SARS-CoV sgRNA7 (Snijder et al., 2003).", [["cellular", "ANATOMY", 14, 22], ["cell", "ANATOMY", 87, 91], ["SARS", "DISEASE", 325, 329], ["cellular", "CELL", 14, 22], ["MAP kinases", "GENE_OR_GENE_PRODUCT", 62, 73], ["cell", "CELL", 87, 91], ["caspase", "GENE_OR_GENE_PRODUCT", 123, 130], ["p7a", "GENE_OR_GENE_PRODUCT", 152, 155], ["SARS-CoV", "ORGANISM", 186, 194], ["SARS-CoVAccessory protein 7b", "GENE_OR_GENE_PRODUCT", 244, 272], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 325, 333], ["MAP kinases", "PROTEIN", 62, 73], ["caspase", "PROTEIN", 123, 130], ["p7a", "PROTEIN", 152, 155], ["Accessory proteins", "PROTEIN", 218, 236], ["SARS-CoVAccessory protein 7b", "PROTEIN", 244, 272], ["ORF", "DNA", 318, 321], ["SARS-CoV", "SPECIES", 186, 194], ["SARS-CoV", "SPECIES", 325, 333], ["activating stress-induced MAP kinases", "PROBLEM", 36, 73], ["suppressing cell-cycle progression", "PROBLEM", 75, 109], ["inducing caspase-dependent apoptosis", "PROBLEM", 114, 150], ["SARS", "PROBLEM", 186, 190], ["CoV pathogenesis", "PROBLEM", 191, 207], ["the SARS", "PROBLEM", 240, 248], ["CoVAccessory protein 7b", "PROBLEM", 249, 272], ["SARS", "PROBLEM", 325, 329], ["dependent", "OBSERVATION_MODIFIER", 131, 140], ["apoptosis", "OBSERVATION", 141, 150]]], ["The expression of 7b was later confirmed in Vero cells infected with SARS-CoV (Schaecher et al., 2007).", [["Vero cells", "ANATOMY", 44, 54], ["7b", "GENE_OR_GENE_PRODUCT", 18, 20], ["Vero cells", "CELL", 44, 54], ["SARS-CoV", "ORGANISM", 69, 77], ["Vero cells", "CELL_LINE", 44, 54], ["SARS-CoV", "SPECIES", 69, 77], ["SARS", "PROBLEM", 69, 73]]], ["No experiments have been performed to detect the expression of 7b in tissue samples from SARS-CoV patients, although the presence of anti-p7b antibodies in SARS-convalescent patient sera indicates that the 7b protein is likely expressed in vivo (Guo et al., 2004).", [["tissue samples", "ANATOMY", 69, 83], ["sera", "ANATOMY", 182, 186], ["SARS-CoV", "DISEASE", 89, 97], ["SARS", "DISEASE", 156, 160], ["7b", "GENE_OR_GENE_PRODUCT", 63, 65], ["tissue samples", "TISSUE", 69, 83], ["SARS-CoV", "ORGANISM", 89, 97], ["patients", "ORGANISM", 98, 106], ["anti-p7b antibodies", "GENE_OR_GENE_PRODUCT", 133, 152], ["patient", "ORGANISM", 174, 181], ["sera", "ORGANISM_SUBSTANCE", 182, 186], ["7b", "GENE_OR_GENE_PRODUCT", 206, 208], ["anti-p7b antibodies", "PROTEIN", 133, 152], ["7b protein", "PROTEIN", 206, 216], ["patients", "SPECIES", 98, 106], ["patient", "SPECIES", 174, 181], ["SARS-CoV", "SPECIES", 89, 97], ["tissue samples", "TEST", 69, 83], ["anti-p7b antibodies in SARS", "PROBLEM", 133, 160], ["the 7b protein", "TEST", 202, 216]]], ["Using sucrose gradient fractionation and immune-gold labeling, Schaecher et al. demonstrated that p7b is associated with intracellular viruses and incorporated into purified virions, although more stringent virus-capture assays have not been performed (Schaecher et al., 2007) (see Table 5).Orf7b ::: Accessory proteins of the SARS-CoVSARS-CoV 7b is proposed to be translated via a ribosome leaky scanning mechanism, because the expression of 7b is significantly reduced when the upstream 7a start codon is mutated to a strong Kozak sequence or when an additional AUG is introduced upstream of the 7b start codon (Schaecher et al., 2007).", [["intracellular", "ANATOMY", 121, 134], ["virions", "ANATOMY", 174, 181], ["sucrose", "CHEMICAL", 6, 13], ["SARS", "DISEASE", 327, 331], ["sucrose", "CHEMICAL", 6, 13], ["sucrose", "SIMPLE_CHEMICAL", 6, 13], ["p7b", "GENE_OR_GENE_PRODUCT", 98, 101], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 121, 134], ["SARS-CoVSARS-CoV 7b", "GENE_OR_GENE_PRODUCT", 327, 346], ["7b", "GENE_OR_GENE_PRODUCT", 443, 445], ["p7b", "PROTEIN", 98, 101], ["Accessory proteins", "PROTEIN", 301, 319], ["SARS-CoVSARS-CoV 7b", "DNA", 327, 346], ["upstream 7a start codon", "DNA", 480, 503], ["Kozak sequence", "DNA", 527, 541], ["AUG", "DNA", 564, 567], ["7b start codon", "DNA", 598, 612], ["SARS-CoVSARS-CoV", "SPECIES", 327, 343], ["sucrose gradient fractionation", "TREATMENT", 6, 36], ["intracellular viruses", "PROBLEM", 121, 142], ["purified virions", "PROBLEM", 165, 181], ["capture assays", "TEST", 213, 227], ["the SARS", "PROBLEM", 323, 331], ["CoV 7b", "TREATMENT", 340, 346], ["a ribosome leaky scanning mechanism", "TREATMENT", 380, 415], ["associated with", "UNCERTAINTY", 105, 120], ["intracellular viruses", "OBSERVATION", 121, 142]]], ["Protein 7b is a 44-aa, highly hydrophobic polypeptide (Schaecher et al., 2007).", [["Protein 7b", "GENE_OR_GENE_PRODUCT", 0, 10], ["Protein 7b", "TEST", 0, 10]]], ["It is an integral transmembrane protein with a luminal N-terminus and a cytoplasmic C-terminus (Fig. 3).", [["transmembrane", "ANATOMY", 18, 31], ["luminal", "ANATOMY", 47, 54], ["cytoplasmic", "ANATOMY", 72, 83], ["luminal", "CHEMICAL", 47, 54], ["N", "CHEMICAL", 55, 56], ["C", "CHEMICAL", 84, 85], ["transmembrane", "CELLULAR_COMPONENT", 18, 31], ["cytoplasmic", "ORGANISM_SUBSTANCE", 72, 83], ["integral transmembrane protein", "PROTEIN", 9, 39], ["luminal N-terminus", "PROTEIN", 47, 65], ["cytoplasmic C-terminus", "PROTEIN", 72, 94], ["Fig. 3", "PROTEIN", 96, 102], ["an integral transmembrane protein", "TEST", 6, 39], ["transmembrane protein", "OBSERVATION", 18, 39], ["luminal", "ANATOMY_MODIFIER", 47, 54], ["terminus", "ANATOMY_MODIFIER", 57, 65], ["cytoplasmic", "OBSERVATION_MODIFIER", 72, 83]]], ["Similar to p7a, the 7b protein is localized throughout the Golgi compartment in both SARS-CoV-infected cells and in cells transfected with 7b cDNA (Schaecher et al., 2007).", [["Golgi compartment", "ANATOMY", 59, 76], ["cells", "ANATOMY", 103, 108], ["cells", "ANATOMY", 116, 121], ["p7a", "GENE_OR_GENE_PRODUCT", 11, 14], ["7b", "GENE_OR_GENE_PRODUCT", 20, 22], ["Golgi compartment", "CELLULAR_COMPONENT", 59, 76], ["SARS-CoV", "ORGANISM", 85, 93], ["cells", "CELL", 103, 108], ["cells", "CELL", 116, 121], ["p7a", "PROTEIN", 11, 14], ["7b protein", "PROTEIN", 20, 30], ["SARS-CoV-infected cells", "CELL_LINE", 85, 108], ["7b cDNA", "DNA", 139, 146], ["SARS-CoV", "SPECIES", 85, 93], ["the 7b protein", "TEST", 16, 30], ["infected cells", "PROBLEM", 94, 108], ["Golgi compartment", "OBSERVATION", 59, 76], ["both", "OBSERVATION_MODIFIER", 80, 84], ["SARS", "OBSERVATION", 85, 89], ["infected cells", "OBSERVATION", 94, 108]]], ["The Golgi-restricted localization of p7b was attributed to the transmembrane domain, specifically aa 21\u201323 and 27\u201330 of p7b (Schaecher et al., 2008).", [["transmembrane", "ANATOMY", 63, 76], ["p7b", "GENE_OR_GENE_PRODUCT", 37, 40], ["transmembrane", "CELLULAR_COMPONENT", 63, 76], ["p7b", "GENE_OR_GENE_PRODUCT", 120, 123], ["p7b", "PROTEIN", 37, 40], ["transmembrane domain", "PROTEIN", 63, 83], ["p7b", "PROTEIN", 120, 123], ["the transmembrane domain", "PROBLEM", 59, 83], ["aa", "TEST", 98, 100]]], ["Notably, when the Golgi-targeting sequence of SARS-CoV p7b is used to replace the transmembrane domain of the cell-surface protein CD4, the chimeric protein is retained in the Golgi complex (Schaecher et al., 2008).", [["Golgi", "ANATOMY", 18, 23], ["transmembrane", "ANATOMY", 82, 95], ["cell", "ANATOMY", 110, 114], ["surface", "ANATOMY", 115, 122], ["Golgi complex", "ANATOMY", 176, 189], ["SARS", "DISEASE", 46, 50], ["Golgi", "CELLULAR_COMPONENT", 18, 23], ["SARS-CoV p7b", "GENE_OR_GENE_PRODUCT", 46, 58], ["cell", "CELL", 110, 114], ["CD4", "GENE_OR_GENE_PRODUCT", 131, 134], ["Golgi", "CELLULAR_COMPONENT", 176, 181], ["Golgi-targeting sequence", "DNA", 18, 42], ["SARS-CoV p7b", "PROTEIN", 46, 58], ["transmembrane domain", "PROTEIN", 82, 102], ["cell-surface protein", "PROTEIN", 110, 130], ["CD4", "PROTEIN", 131, 134], ["chimeric protein", "PROTEIN", 140, 156], ["Golgi complex", "PROTEIN", 176, 189], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "PROBLEM", 46, 50], ["the chimeric protein", "TEST", 136, 156]]], ["Thus, the transmembrane domain of p7b is both necessary and sufficient for its Golgi localization.Orf7b ::: Accessory proteins of the SARS-CoVVarious reverse genetic experiments have shown that the SARS-CoV ORF7b is not essential for viral replication in vitro and in vivo (Yount et al., 2005, Schaecher et al., 2007, DeDiego et al., 2008).", [["transmembrane", "ANATOMY", 10, 23], ["Golgi", "ANATOMY", 79, 84], ["SARS", "DISEASE", 198, 202], ["transmembrane", "CELLULAR_COMPONENT", 10, 23], ["p7b", "GENE_OR_GENE_PRODUCT", 34, 37], ["Golgi", "CELLULAR_COMPONENT", 79, 84], ["SARS-CoV", "ORGANISM", 198, 206], ["ORF7b", "GENE_OR_GENE_PRODUCT", 207, 212], ["transmembrane domain", "PROTEIN", 10, 30], ["p7b", "PROTEIN", 34, 37], ["Accessory proteins", "PROTEIN", 108, 126], ["SARS-CoV ORF7b", "DNA", 198, 212], ["SARS-CoV", "SPECIES", 198, 206], ["the transmembrane domain", "TEST", 6, 30], ["the SARS", "PROBLEM", 130, 138], ["the SARS", "TEST", 194, 202]]], ["Interestingly, a prototype virus (strain Frankfurt-I) isolated during the 2003 SARS outbreak has a 45-nt deletion in the transmembrane domain of ORF7b upon propagation in cell culture for 3 passages (Thiel et al., 2003).", [["transmembrane", "ANATOMY", 121, 134], ["cell culture", "ANATOMY", 171, 183], ["SARS", "DISEASE", 79, 83], ["strain Frankfurt-I", "ORGANISM", 34, 52], ["ORF7b", "GENE_OR_GENE_PRODUCT", 145, 150], ["cell culture", "CELL", 171, 183], ["45-nt deletion", "DNA", 99, 113], ["transmembrane domain", "PROTEIN", 121, 141], ["ORF7b", "PROTEIN", 145, 150], ["Frankfurt-I", "SPECIES", 41, 52], ["a prototype virus", "PROBLEM", 15, 32], ["a 45-nt deletion", "PROBLEM", 97, 113], ["cell culture", "TEST", 171, 183]]], ["Pfefferle et al. have performed extensive investigations on the consequence of this deletion using reverse genetics (Pfefferle et al., 2009).", [["extensive investigations", "TEST", 32, 56], ["this deletion", "PROBLEM", 79, 92]]], ["It was found that compared with the parental virus, the recombinant SARS-CoV with ORF7b deleted had a replicative advantage in Caco-2 and Huh7 cells, but not in Vero cells (Pfefferle et al., 2009).", [["Caco-2", "ANATOMY", 127, 133], ["Huh7 cells", "ANATOMY", 138, 148], ["Vero cells", "ANATOMY", 161, 171], ["SARS", "DISEASE", 68, 72], ["SARS-CoV", "ORGANISM", 68, 76], ["ORF7b", "GENE_OR_GENE_PRODUCT", 82, 87], ["Caco-2", "CELL", 127, 133], ["Huh7 cells", "CELL", 138, 148], ["Vero cells", "CELL", 161, 171], ["ORF7b", "PROTEIN", 82, 87], ["Caco-2", "CELL_LINE", 127, 133], ["Huh7 cells", "CELL_LINE", 138, 148], ["Vero cells", "CELL_LINE", 161, 171], ["SARS-CoV", "SPECIES", 68, 76], ["the parental virus", "PROBLEM", 32, 50], ["Caco", "TEST", 127, 131], ["Huh7 cells", "PROBLEM", 138, 148], ["Huh7 cells", "ANATOMY", 138, 148]]], ["Moreover, the virus titre and viral RNA levels were significantly higher in Syrian Golden Hamsters infected with the 7b-deleted virus, indicating that SARS-CoV p7b may be an attenuating factor in vivo (Pfefferle et al., 2009).", [["SARS", "DISEASE", 151, 155], ["Syrian Golden Hamsters", "ORGANISM", 76, 98], ["7b-deleted virus", "ORGANISM", 117, 133], ["SARS-CoV p7b", "ORGANISM", 151, 163], ["SARS-CoV p7b", "PROTEIN", 151, 163], ["Syrian Golden Hamsters", "SPECIES", 76, 98], ["Syrian Golden Hamsters", "SPECIES", 76, 98], ["SARS-CoV", "SPECIES", 151, 159], ["the virus titre", "TEST", 10, 25], ["viral RNA levels", "TEST", 30, 46], ["the 7b-deleted virus", "PROBLEM", 113, 133], ["SARS", "PROBLEM", 151, 155], ["virus titre", "OBSERVATION", 14, 25]]], ["In a different approach, \u00c5kerstr\u00f6m et al. showed that siRNA specific for SARS-CoV sgRNA7 can inhibit sgRNA7 and sgRNA8 (thus silencing the expression of 7a, 7b, 8a, 8b) without affecting the full-length genomic mRNA and other sgRNAs (\u00c5kerstr\u00f6m et al., 2007).", [["SARS-CoV sgRNA7", "ORGANISM", 73, 88], ["sgRNA7", "GENE_OR_GENE_PRODUCT", 101, 107], ["sgRNA8", "GENE_OR_GENE_PRODUCT", 112, 118], ["7b", "GENE_OR_GENE_PRODUCT", 157, 159], ["8a", "GENE_OR_GENE_PRODUCT", 161, 163], ["b", "GENE_OR_GENE_PRODUCT", 166, 167], ["SARS-CoV sgRNA7", "PROTEIN", 73, 88], ["sgRNA7", "PROTEIN", 101, 107], ["sgRNA8", "PROTEIN", 112, 118], ["7a, 7b, 8a, 8b", "PROTEIN", 153, 167], ["genomic mRNA", "RNA", 203, 215], ["SARS-CoV", "SPECIES", 73, 81], ["a different approach", "TREATMENT", 3, 23], ["SARS", "PROBLEM", 73, 77], ["CoV sgRNA7", "PROBLEM", 78, 88], ["sgRNA7", "PROBLEM", 101, 107], ["sgRNA8", "PROBLEM", 112, 118], ["7b", "TEST", 157, 159], ["siRNA", "OBSERVATION", 54, 59]]], ["In Vero E6 cells expressing this siRNA, the production of progeny viruses was significantly reduced, indicating that p7a/p7b (and p8a/p8b) may play certain roles during the replication cycle of SARS-CoV.", [["Vero E6 cells", "ANATOMY", 3, 16], ["SARS", "DISEASE", 194, 198], ["Vero E6 cells", "CELL", 3, 16], ["p7a", "GENE_OR_GENE_PRODUCT", 117, 120], ["p7b", "GENE_OR_GENE_PRODUCT", 121, 124], ["p8a", "GENE_OR_GENE_PRODUCT", 130, 133], ["p8b", "GENE_OR_GENE_PRODUCT", 134, 137], ["SARS-CoV", "ORGANISM", 194, 202], ["Vero E6 cells", "CELL_LINE", 3, 16], ["p7a", "PROTEIN", 117, 120], ["p7b", "PROTEIN", 121, 124], ["p8a", "PROTEIN", 130, 133], ["p8b", "PROTEIN", 134, 137], ["Vero E6", "SPECIES", 3, 10], ["SARS-CoV", "SPECIES", 194, 202], ["Vero E6 cells", "TREATMENT", 3, 16], ["this siRNA", "PROBLEM", 28, 38], ["progeny viruses", "PROBLEM", 58, 73], ["E6 cells", "OBSERVATION", 8, 16]]], ["The discrepancies regarding the functions of p7b during SARS-CoV replication may be due to the different systems and animal models used.", [["SARS", "DISEASE", 56, 60], ["p7b", "GENE_OR_GENE_PRODUCT", 45, 48], ["SARS-CoV", "ORGANISM", 56, 64], ["p7b", "PROTEIN", 45, 48], ["SARS-CoV", "SPECIES", 56, 64], ["SARS", "PROBLEM", 56, 60], ["CoV replication", "TREATMENT", 61, 76]]], ["Further studies are required to validate these results and characterize the detailed mechanisms.ORF8a and ORF8b ::: Accessory proteins of the SARS-CoVIn SARS-CoV isolated from animals and early human isolates, sgRNA8 encodes a single protein 8ab.", [["ORF8a", "GENE_OR_GENE_PRODUCT", 96, 101], ["ORF8b", "GENE_OR_GENE_PRODUCT", 106, 111], ["SARS-CoVIn SARS-CoV", "ORGANISM", 142, 161], ["human", "ORGANISM", 194, 199], ["sgRNA8", "GENE_OR_GENE_PRODUCT", 210, 216], ["ORF8a", "DNA", 96, 101], ["ORF8b", "PROTEIN", 106, 111], ["Accessory proteins", "PROTEIN", 116, 134], ["sgRNA8", "PROTEIN", 210, 216], ["single protein 8ab", "PROTEIN", 227, 245], ["human", "SPECIES", 194, 199], ["SARS-CoV", "SPECIES", 153, 161], ["human", "SPECIES", 194, 199], ["Further studies", "TEST", 0, 15], ["the SARS", "PROBLEM", 138, 146], ["CoVIn SARS", "PROBLEM", 147, 157], ["CoV", "PROBLEM", 158, 161], ["early human isolates", "PROBLEM", 188, 208]]], ["Interestingly, in SARS-CoV isolated from humans during the peak of the epidemic, there is a 29-nt deletion in the middle of ORF8, resulting in the splitting of ORF8 into two smaller ORFs, namely ORF8a and ORF8b (He et al., 2004, Guan et al., 2003).", [["SARS", "DISEASE", 18, 22], ["SARS-CoV", "ORGANISM", 18, 26], ["humans", "ORGANISM", 41, 47], ["ORF8", "GENE_OR_GENE_PRODUCT", 124, 128], ["ORF8", "GENE_OR_GENE_PRODUCT", 160, 164], ["ORF8a", "GENE_OR_GENE_PRODUCT", 195, 200], ["ORF8b", "GENE_OR_GENE_PRODUCT", 205, 210], ["29-nt deletion", "DNA", 92, 106], ["ORF8", "DNA", 124, 128], ["ORF8", "DNA", 160, 164], ["ORFs", "DNA", 182, 186], ["ORF8a", "DNA", 195, 200], ["ORF8b", "DNA", 205, 210], ["humans", "SPECIES", 41, 47], ["SARS-CoV", "SPECIES", 18, 26], ["humans", "SPECIES", 41, 47], ["SARS", "PROBLEM", 18, 22], ["a 29-nt deletion", "PROBLEM", 90, 106], ["CoV isolated", "OBSERVATION_MODIFIER", 23, 35], ["middle", "ANATOMY_MODIFIER", 114, 120], ["smaller", "OBSERVATION_MODIFIER", 174, 181], ["ORFs", "OBSERVATION", 182, 186]]], ["During the late stage of the SARS epidemic, larger deletions (82-nt and 415-nt deletion) were also identified in clusters of viruses from human isolates (He et al., 2004, Chiu et al., 2005).", [["SARS", "DISEASE", 29, 33], ["human", "ORGANISM", 138, 143], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["the SARS epidemic", "PROBLEM", 25, 42], ["larger deletions (82-nt and 415-nt deletion", "PROBLEM", 44, 87], ["larger", "OBSERVATION_MODIFIER", 44, 50], ["viruses", "OBSERVATION", 125, 132]]], ["Initially, this dramatic genomic change in ORF8 has been proposed to contribute to the zoonotic transition of SARS-CoV from palm civets to humans and thus has attracted particular attention.", [["ORF8", "CHEMICAL", 43, 47], ["SARS", "DISEASE", 110, 114], ["ORF8", "GENE_OR_GENE_PRODUCT", 43, 47], ["SARS-CoV", "ORGANISM", 110, 118], ["palm", "ORGANISM_SUBDIVISION", 124, 128], ["humans", "ORGANISM", 139, 145], ["ORF8", "PROTEIN", 43, 47], ["humans", "SPECIES", 139, 145], ["SARS-CoV", "SPECIES", 110, 118], ["humans", "SPECIES", 139, 145], ["this dramatic genomic change", "PROBLEM", 11, 39], ["dramatic", "OBSERVATION_MODIFIER", 16, 24], ["genomic", "OBSERVATION_MODIFIER", 25, 32], ["change", "OBSERVATION_MODIFIER", 33, 39]]], ["However, it has been shown that palm civets are equally susceptible to human SARS-CoV isolates with or without the 29-nt deletion (Wu et al., 2005).", [["SARS", "DISEASE", 77, 81], ["human", "ORGANISM", 71, 76], ["SARS-CoV isolates", "ORGANISM", 77, 94], ["29-nt deletion", "DNA", 115, 129], ["human", "SPECIES", 71, 76], ["human SARS-CoV", "SPECIES", 71, 85]]], ["Moreover, further studies using reverse genetics showed that the ORF8 of SARS-CoV is not essential for virus replication in vitro and in vivo (Yount et al., 2005, DeDiego et al., 2008).", [["SARS", "DISEASE", 73, 77], ["ORF8", "GENE_OR_GENE_PRODUCT", 65, 69], ["SARS-CoV", "ORGANISM", 73, 81], ["ORF8", "PROTEIN", 65, 69], ["SARS-CoV", "SPECIES", 73, 81], ["further studies", "TEST", 10, 25], ["reverse genetics", "TEST", 32, 48], ["SARS", "PROBLEM", 73, 77], ["virus replication", "TREATMENT", 103, 120]]], ["Thus, whether the mutations in ORF8 are due to genomic instability or adaptive evolution remains to be investigated (see Table 6).ORF8a and ORF8b ::: Accessory proteins of the SARS-CoVThe undeleted ORF8 (or ORF8ab) encodes a 122-amino-acid protein with an N-terminal hydrophobic signal sequence.", [["122-amino-acid", "CHEMICAL", 225, 239], ["amino-acid", "CHEMICAL", 229, 239], ["N", "CHEMICAL", 256, 257], ["ORF8", "GENE_OR_GENE_PRODUCT", 31, 35], ["ORF8a", "GENE_OR_GENE_PRODUCT", 130, 135], ["ORF8b", "GENE_OR_GENE_PRODUCT", 140, 145], ["SARS-CoVThe", "GENE_OR_GENE_PRODUCT", 176, 187], ["ORF8", "GENE_OR_GENE_PRODUCT", 198, 202], ["ORF8ab", "GENE_OR_GENE_PRODUCT", 207, 213], ["ORF8", "DNA", 31, 35], ["ORF8a", "DNA", 130, 135], ["ORF8b", "PROTEIN", 140, 145], ["Accessory proteins", "PROTEIN", 150, 168], ["SARS-CoVThe", "PROTEIN", 176, 187], ["ORF8", "PROTEIN", 198, 202], ["ORF8ab", "PROTEIN", 207, 213], ["122-amino-acid protein", "PROTEIN", 225, 247], ["N-terminal hydrophobic signal sequence", "PROTEIN", 256, 294], ["the mutations in ORF8", "PROBLEM", 14, 35], ["genomic instability", "PROBLEM", 47, 66], ["the SARS", "TEST", 172, 180], ["amino-acid protein", "TEST", 229, 247], ["an N", "TEST", 253, 257]]], ["ORF8a encodes a 39-amino-acid polypeptide, and residues 1\u201335 are identical to the N-terminal of 8ab.", [["39-amino-acid", "CHEMICAL", 16, 29], ["39-amino-acid", "CHEMICAL", 16, 29], ["N", "CHEMICAL", 82, 83], ["ORF8a", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF8a", "PROTEIN", 0, 5], ["39-amino-acid polypeptide", "PROTEIN", 16, 41], ["N-terminal of 8ab", "PROTEIN", 82, 99], ["amino-acid polypeptide", "TREATMENT", 19, 41]]], ["ORF8b encodes an 84-aa polypeptide and residues 9\u201384 are identical to the C-terminal of 8ab (Oostra et al., 2007).", [["C", "CHEMICAL", 74, 75], ["ORF8b", "GENE_OR_GENE_PRODUCT", 0, 5], ["9\u201384", "AMINO_ACID", 48, 52], ["ORF8b", "DNA", 0, 5]]], ["Whereas Keng et al. have demonstrated by indirect immunofluorescence that 8a and 8b are expressed in SARS-CoV-infected Vero E6 cells, Oostra et al. were unable to detect 8b in SARS-CoV-infected Vero E6 cells (Oostra et al., 2007, Keng et al., 2006).", [["cells", "ANATOMY", 127, 132], ["Vero E6 cells", "ANATOMY", 194, 207], ["SARS", "DISEASE", 176, 180], ["8b", "GENE_OR_GENE_PRODUCT", 81, 83], ["SARS-CoV", "ORGANISM", 101, 109], ["Vero E6 cells", "CELL", 119, 132], ["SARS-CoV", "ORGANISM", 176, 184], ["Vero E6 cells", "CELL", 194, 207], ["8a and 8b", "PROTEIN", 74, 83], ["SARS-CoV-infected Vero E6 cells", "CELL_LINE", 101, 132], ["SARS-CoV-infected Vero E6 cells", "CELL_LINE", 176, 207], ["SARS-CoV", "SPECIES", 101, 109], ["Vero E6", "SPECIES", 119, 126], ["SARS-CoV", "SPECIES", 176, 184], ["Vero E6", "SPECIES", 194, 201], ["indirect immunofluorescence", "TEST", 41, 68], ["SARS", "PROBLEM", 101, 105], ["CoV", "TEST", 106, 109], ["infected Vero E6 cells", "PROBLEM", 110, 132], ["SARS", "PROBLEM", 176, 180], ["CoV", "TEST", 181, 184], ["infected Vero E6 cells", "PROBLEM", 185, 207], ["Vero E6 cells", "OBSERVATION", 119, 132], ["E6 cells", "OBSERVATION", 199, 207]]], ["Although there is no data regarding the expression of 8a or 8b in vivo, Chen et al. have identified anti-p8a antibodies in two out of 37 patients with SARS (Chen et al., 2007).", [["SARS", "DISEASE", 151, 155], ["8b", "GENE_OR_GENE_PRODUCT", 60, 62], ["anti-p8a antibodies", "GENE_OR_GENE_PRODUCT", 100, 119], ["patients", "ORGANISM", 137, 145], ["anti-p8a antibodies", "PROTEIN", 100, 119], ["patients", "SPECIES", 137, 145], ["anti-p8a antibodies", "TEST", 100, 119], ["SARS", "PROBLEM", 151, 155], ["no", "UNCERTAINTY", 18, 20]]], ["Also, different subcellular localizations have been reported for p8a, p8b, and p8ab.", [["subcellular", "ANATOMY", 16, 27], ["p8a", "GENE_OR_GENE_PRODUCT", 65, 68], ["p8b", "GENE_OR_GENE_PRODUCT", 70, 73], ["p8ab", "GENE_OR_GENE_PRODUCT", 79, 83], ["p8a", "PROTEIN", 65, 68], ["p8b", "PROTEIN", 70, 73], ["p8ab", "PROTEIN", 79, 83]]], ["Using an EGFP fusion protein, Keng et al. have shown that p8a and p8b are found in cytoplasmic punctuated vesicle-like structures, whereas p8ab localizes diffusely to the cytoplasm (Keng et al., 2006).", [["cytoplasmic", "ANATOMY", 83, 94], ["vesicle-like structures", "ANATOMY", 106, 129], ["cytoplasm", "ANATOMY", 171, 180], ["EGFP", "GENE_OR_GENE_PRODUCT", 9, 13], ["p8a", "GENE_OR_GENE_PRODUCT", 58, 61], ["p8b", "GENE_OR_GENE_PRODUCT", 66, 69], ["cytoplasmic", "ORGANISM_SUBSTANCE", 83, 94], ["vesicle-like structures", "CELLULAR_COMPONENT", 106, 129], ["p8ab", "GENE_OR_GENE_PRODUCT", 139, 143], ["cytoplasm", "ORGANISM_SUBSTANCE", 171, 180], ["EGFP fusion protein", "PROTEIN", 9, 28], ["p8a", "PROTEIN", 58, 61], ["p8b", "PROTEIN", 66, 69], ["p8ab", "PROTEIN", 139, 143], ["an EGFP fusion protein", "TREATMENT", 6, 28], ["cytoplasmic punctuated vesicle", "PROBLEM", 83, 113], ["cytoplasmic", "OBSERVATION", 83, 94], ["punctuated vesicle", "OBSERVATION", 95, 113], ["diffusely", "OBSERVATION_MODIFIER", 154, 163]]], ["On the other hand, Law et al. have observed EGFP-fused p8b to localize diffusely in both the cytosol and the nucleus (Law et al., 2006).", [["cytosol", "ANATOMY", 93, 100], ["nucleus", "ANATOMY", 109, 116], ["EGFP", "GENE_OR_GENE_PRODUCT", 44, 48], ["p8b", "GENE_OR_GENE_PRODUCT", 55, 58], ["cytosol", "CELLULAR_COMPONENT", 93, 100], ["nucleus", "CELLULAR_COMPONENT", 109, 116], ["EGFP", "PROTEIN", 44, 48], ["p8b", "PROTEIN", 55, 58], ["EGFP", "TEST", 44, 48], ["diffusely", "OBSERVATION_MODIFIER", 71, 80], ["both", "ANATOMY_MODIFIER", 84, 88], ["cytosol", "ANATOMY", 93, 100], ["nucleus", "ANATOMY", 109, 116]]], ["Finally, using a T7 promoter-driven expression system, Oostra et al. have demonstrated a reticular pattern and ER localization for p8a and p8ab, but a diffuse cytoplasmic localization for p8b (Oostra et al., 2007).", [["reticular", "ANATOMY", 89, 98], ["ER", "ANATOMY", 111, 113], ["cytoplasmic", "ANATOMY", 159, 170], ["ER", "GENE_OR_GENE_PRODUCT", 111, 113], ["p8a", "GENE_OR_GENE_PRODUCT", 131, 134], ["p8ab", "GENE_OR_GENE_PRODUCT", 139, 143], ["cytoplasmic", "ORGANISM_SUBSTANCE", 159, 170], ["p8b", "GENE_OR_GENE_PRODUCT", 188, 191], ["T7 promoter", "DNA", 17, 28], ["ER", "PROTEIN", 111, 113], ["p8a", "PROTEIN", 131, 134], ["p8ab", "PROTEIN", 139, 143], ["p8b", "PROTEIN", 188, 191], ["a T7 promoter", "TREATMENT", 15, 28], ["a reticular pattern", "PROBLEM", 87, 106], ["ER localization", "TEST", 111, 126], ["p8a", "TEST", 131, 134], ["a diffuse cytoplasmic localization", "PROBLEM", 149, 183], ["reticular", "ANATOMY_MODIFIER", 89, 98], ["diffuse", "OBSERVATION_MODIFIER", 151, 158]]], ["These discrepancies should be addressed, possibly by using more specific monoclonal antibodies, or expressing 8a and 8b fusion proteins under a more physiologically relevant background, such as using recombinant coronaviruses.ORF8a and ORF8b ::: Accessory proteins of the SARS-CoVOostra et al. have characterized the biochemical properties of p8a, p8b, and p8ab (Oostra et al., 2007).", [["recombinant coronaviruses", "ORGANISM", 200, 225], ["ORF8a", "GENE_OR_GENE_PRODUCT", 226, 231], ["ORF8b", "GENE_OR_GENE_PRODUCT", 236, 241], ["p8a", "GENE_OR_GENE_PRODUCT", 343, 346], ["p8b", "GENE_OR_GENE_PRODUCT", 348, 351], ["p8ab", "GENE_OR_GENE_PRODUCT", 357, 361], ["monoclonal antibodies", "PROTEIN", 73, 94], ["8a and 8b fusion proteins", "PROTEIN", 110, 135], ["ORF8a", "DNA", 226, 231], ["ORF8b", "PROTEIN", 236, 241], ["Accessory proteins", "PROTEIN", 246, 264], ["p8a", "PROTEIN", 343, 346], ["p8b", "PROTEIN", 348, 351], ["p8ab", "PROTEIN", 357, 361], ["specific monoclonal antibodies", "TEST", 64, 94], ["8b fusion proteins", "TREATMENT", 117, 135], ["the SARS", "PROBLEM", 268, 276], ["biochemical properties", "OBSERVATION_MODIFIER", 317, 339]]], ["Owing to its N-terminal signal sequence, SARS-CoV p8ab enters the ER, where it is N-glycosylated at asparagine residue 81.", [["ER", "ANATOMY", 66, 68], ["asparagine", "CHEMICAL", 100, 110], ["N", "CHEMICAL", 13, 14], ["N", "CHEMICAL", 82, 83], ["asparagine", "CHEMICAL", 100, 110], ["SARS-CoV p8ab", "GENE_OR_GENE_PRODUCT", 41, 54], ["ER", "GENE_OR_GENE_PRODUCT", 66, 68], ["asparagine residue 81", "AMINO_ACID", 100, 121], ["N-terminal signal sequence", "PROTEIN", 13, 39], ["SARS-CoV p8ab", "PROTEIN", 41, 54], ["ER", "PROTEIN", 66, 68], ["SARS-CoV", "SPECIES", 41, 49], ["its N-terminal signal sequence", "TEST", 9, 39], ["SARS", "PROBLEM", 41, 45], ["glycosylated at asparagine residue", "PROBLEM", 84, 118]]], ["The mature p8ab remains associated with the ER and possibly undergoes multimerization, but it is not transported to the Golgi for secretion (Oostra et al., 2007).", [["ER", "ANATOMY", 44, 46], ["Golgi", "ANATOMY", 120, 125], ["p8ab", "GENE_OR_GENE_PRODUCT", 11, 15], ["ER", "GENE_OR_GENE_PRODUCT", 44, 46], ["Golgi", "CELLULAR_COMPONENT", 120, 125], ["p8ab", "PROTEIN", 11, 15], ["ER", "PROTEIN", 44, 46], ["mature", "OBSERVATION_MODIFIER", 4, 10], ["p8ab", "OBSERVATION", 11, 15], ["multimerization", "OBSERVATION", 70, 85]]], ["Inside the ER, the protein up-regulates the synthesis of ER chaperons and activates the ATF6 branch of unfolded-protein response (UPR), but shows no effect on the PERK and IRE1 branches of the UPR (Sung et al., 2009).", [["ER", "ANATOMY", 11, 13], ["ER", "GENE_OR_GENE_PRODUCT", 11, 13], ["ER", "GENE_OR_GENE_PRODUCT", 57, 59], ["ATF6", "GENE_OR_GENE_PRODUCT", 88, 92], ["unfolded-protein response", "GENE_OR_GENE_PRODUCT", 103, 128], ["UPR", "GENE_OR_GENE_PRODUCT", 130, 133], ["PERK", "GENE_OR_GENE_PRODUCT", 163, 167], ["IRE1", "GENE_OR_GENE_PRODUCT", 172, 176], ["ER", "PROTEIN", 11, 13], ["ER chaperons", "PROTEIN", 57, 69], ["ATF6 branch", "PROTEIN", 88, 99], ["UPR", "PROTEIN", 130, 133], ["PERK", "PROTEIN", 163, 167], ["IRE1", "PROTEIN", 172, 176], ["UPR", "PROTEIN", 193, 196], ["the protein", "TEST", 15, 26], ["ER chaperons", "TREATMENT", 57, 69], ["unfolded", "OBSERVATION_MODIFIER", 103, 111], ["protein response", "OBSERVATION", 112, 128], ["no", "UNCERTAINTY", 146, 148], ["branches", "ANATOMY_MODIFIER", 177, 185]]], ["The 29-nt deletion disrupts the functional expression of ORF8.", [["ORF8", "GENE_OR_GENE_PRODUCT", 57, 61], ["29-nt deletion", "DNA", 4, 18], ["ORF8", "PROTEIN", 57, 61], ["The 29-nt deletion", "TREATMENT", 0, 18]]], ["Although ORF8a contains the signal sequence, the protein is too short to be transported into the ER.", [["ER", "ANATOMY", 97, 99], ["ORF8a", "GENE_OR_GENE_PRODUCT", 9, 14], ["ER", "GENE_OR_GENE_PRODUCT", 97, 99], ["ORF8a", "PROTEIN", 9, 14], ["ER", "PROTEIN", 97, 99], ["the signal sequence", "TEST", 24, 43]]], ["For ORF8b, due to the lack of a signal sequence, it cannot enter the ER and thus is not glycosylated at the same asparagine residue as in 8ab (Oostra et al., 2007).ORF8a and ORF8b ::: Accessory proteins of the SARS-CoVProteins 8b and 8ab have been shown to undergo ubiquitination when expressed in both in vitro expression systems and in cell culture (Le et al., 2007).", [["ER", "ANATOMY", 69, 71], ["cell culture", "ANATOMY", 338, 350], ["asparagine", "CHEMICAL", 113, 123], ["asparagine", "CHEMICAL", 113, 123], ["ORF8b", "GENE_OR_GENE_PRODUCT", 4, 9], ["ER", "GENE_OR_GENE_PRODUCT", 69, 71], ["ORF8a", "GENE_OR_GENE_PRODUCT", 164, 169], ["ORF8b", "GENE_OR_GENE_PRODUCT", 174, 179], ["SARS-CoVProteins 8b", "GENE_OR_GENE_PRODUCT", 210, 229], ["8", "GENE_OR_GENE_PRODUCT", 234, 235], ["cell culture", "CELL", 338, 350], ["ORF8b", "PROTEIN", 4, 9], ["ER", "PROTEIN", 69, 71], ["ORF8a", "DNA", 164, 169], ["ORF8b", "PROTEIN", 174, 179], ["Accessory proteins", "PROTEIN", 184, 202], ["SARS-CoVProteins 8b and 8ab", "PROTEIN", 210, 237], ["a signal sequence", "TEST", 30, 47], ["the SARS", "TEST", 206, 214], ["CoVProteins", "TREATMENT", 215, 226], ["cell culture", "TEST", 338, 350]]], ["Moreover, p8b and p8ab physically interact with monoubiquitin as well as polyubiquitin, suggesting potential involvement of these proteins in the host ubiquitin\u2013proteasome system.", [["p8b", "GENE_OR_GENE_PRODUCT", 10, 13], ["p8ab", "GENE_OR_GENE_PRODUCT", 18, 22], ["monoubiquitin", "GENE_OR_GENE_PRODUCT", 48, 61], ["polyubiquitin", "GENE_OR_GENE_PRODUCT", 73, 86], ["p8b", "PROTEIN", 10, 13], ["p8ab", "PROTEIN", 18, 22], ["monoubiquitin", "PROTEIN", 48, 61], ["polyubiquitin", "PROTEIN", 73, 86], ["monoubiquitin", "TREATMENT", 48, 61], ["polyubiquitin", "TREATMENT", 73, 86], ["these proteins", "PROBLEM", 124, 138]]], ["Interestingly, the N-linked glycosylation on residue Asn81 in p8ab stabilizes it and protects it from degradation by the proteasome.", [["Asn81", "CHEMICAL", 53, 58], ["N", "CHEMICAL", 19, 20], ["Asn81", "AMINO_ACID", 53, 58], ["p8ab", "AMINO_ACID", 62, 66], ["p8ab", "PROTEIN", 62, 66], ["proteasome", "PROTEIN", 121, 131], ["the N-linked glycosylation", "TREATMENT", 15, 41], ["residue Asn81", "TREATMENT", 45, 58]]], ["In sharp contrast, in the absence of the p8a region, p8b, which is not N-glycosylated at the same asparagine residue, undergoes rapid proteasomal degradation (Le et al., 2007).ORF8a and ORF8b ::: Accessory proteins of the SARS-CoVChen et al. have shown that SARS-CoV replication is enhanced in cells stably expressing 8a and reduced in cells transfected with siRNA targeting 8a (Chen et al., 2007).", [["proteasomal", "ANATOMY", 134, 145], ["cells", "ANATOMY", 294, 299], ["cells", "ANATOMY", 336, 341], ["asparagine", "CHEMICAL", 98, 108], ["SARS", "DISEASE", 258, 262], ["N", "CHEMICAL", 71, 72], ["asparagine", "CHEMICAL", 98, 108], ["p8a", "GENE_OR_GENE_PRODUCT", 41, 44], ["p8b", "GENE_OR_GENE_PRODUCT", 53, 56], ["asparagine", "AMINO_ACID", 98, 108], ["ORF8a", "GENE_OR_GENE_PRODUCT", 176, 181], ["ORF8b", "GENE_OR_GENE_PRODUCT", 186, 191], ["SARS-CoV", "ORGANISM", 258, 266], ["cells", "CELL", 294, 299], ["8a", "CELL", 318, 320], ["cells", "CELL", 336, 341], ["p8a region", "PROTEIN", 41, 51], ["p8b", "PROTEIN", 53, 56], ["ORF8a", "DNA", 176, 181], ["ORF8b", "PROTEIN", 186, 191], ["Accessory proteins", "PROTEIN", 196, 214], ["SARS-CoV", "SPECIES", 258, 266], ["the same asparagine residue", "PROBLEM", 89, 116], ["rapid proteasomal degradation", "PROBLEM", 128, 157], ["the SARS", "PROBLEM", 218, 226], ["SARS", "PROBLEM", 258, 262], ["CoV replication", "PROBLEM", 263, 278], ["sharp", "OBSERVATION_MODIFIER", 3, 8], ["contrast", "OBSERVATION", 9, 17], ["asparagine residue", "OBSERVATION", 98, 116], ["rapid", "OBSERVATION_MODIFIER", 128, 133], ["proteasomal degradation", "OBSERVATION", 134, 157], ["SARS", "OBSERVATION", 258, 262]]], ["However, the results were based on detection of virus RNA and assessment of virus-induced CPE only, and a direct measure of infective virus titre should have been performed.", [["virus RNA", "RNA", 48, 57], ["virus RNA", "PROBLEM", 48, 57], ["assessment", "TEST", 62, 72], ["virus", "PROBLEM", 76, 81], ["induced CPE", "PROBLEM", 82, 93], ["infective virus titre", "PROBLEM", 124, 145]]], ["Moreover, overexpression of 8a also induces caspase-dependent apoptosis (Chen et al., 2007).", [["8a", "GENE_OR_GENE_PRODUCT", 28, 30], ["caspase", "GENE_OR_GENE_PRODUCT", 44, 51], ["caspase", "PROTEIN", 44, 51], ["caspase", "PROBLEM", 44, 51], ["dependent apoptosis", "PROBLEM", 52, 71], ["dependent", "OBSERVATION_MODIFIER", 52, 61], ["apoptosis", "OBSERVATION_MODIFIER", 62, 71]]], ["Ectopic expression of 8b reduces the level of co-transfected SARS-CoV E protein, but not that of other structural proteins.", [["8b", "GENE_OR_GENE_PRODUCT", 22, 24], ["SARS-CoV E", "GENE_OR_GENE_PRODUCT", 61, 71], ["8b", "PROTEIN", 22, 24], ["co-transfected SARS-CoV E protein", "PROTEIN", 46, 79], ["structural proteins", "PROTEIN", 103, 122], ["SARS-CoV", "SPECIES", 61, 69], ["Ectopic expression of 8b", "PROBLEM", 0, 24], ["co-transfected SARS", "PROBLEM", 46, 65], ["CoV E protein", "TEST", 66, 79], ["other structural proteins", "PROBLEM", 97, 122], ["co-transfected SARS", "OBSERVATION", 46, 65], ["proteins", "OBSERVATION", 114, 122]]], ["Strikingly, in SARS-CoV-infected cells, the expression of 8b and E are found to be mutually exclusive, indicating a functional antagonism between the two proteins (Keng et al., 2006).", [["cells", "ANATOMY", 33, 38], ["SARS-CoV-infected", "DISEASE", 15, 32], ["SARS-CoV", "ORGANISM", 15, 23], ["cells", "CELL", 33, 38], ["b", "GENE_OR_GENE_PRODUCT", 59, 60], ["E", "GENE_OR_GENE_PRODUCT", 65, 66], ["SARS-CoV-infected cells", "CELL_LINE", 15, 38], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["infected cells", "PROBLEM", 24, 38], ["the expression", "TEST", 40, 54], ["a functional antagonism", "PROBLEM", 114, 137], ["infected cells", "OBSERVATION", 24, 38]]], ["Similar to SARS-CoV p6, overexpression of 8b has been shown to stimulate DNA synthesis, although co-expression of p6 and 8b does not produce a synergistic effect (Law et al., 2006).", [["SARS", "DISEASE", 11, 15], ["SARS-CoV p6", "GENE_OR_GENE_PRODUCT", 11, 22], ["8b", "GENE_OR_GENE_PRODUCT", 42, 44], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["p6", "GENE_OR_GENE_PRODUCT", 114, 116], ["8b", "GENE_OR_GENE_PRODUCT", 121, 123], ["8b", "PROTEIN", 42, 44], ["p6 and 8b", "PROTEIN", 114, 123], ["SARS-CoV", "SPECIES", 11, 19], ["DNA synthesis", "PROBLEM", 73, 86], ["SARS", "OBSERVATION", 11, 15], ["CoV p6", "OBSERVATION_MODIFIER", 16, 22]]], ["The significance of these findings in SARS-CoV pathogenesis remains to be determined.Orf9b ::: Accessory proteins of the SARS-CoVAccessory protein 9b is translated from a second ORF of SARS-CoV sgRNA9 via a ribosomal leaky scanning mechanism (Xu et al., 2009).", [["ribosomal", "ANATOMY", 207, 216], ["SARS", "DISEASE", 38, 42], ["SARS", "DISEASE", 185, 189], ["SARS-CoV", "ORGANISM", 38, 46], ["SARS-CoVAccessory protein 9b", "GENE_OR_GENE_PRODUCT", 121, 149], ["SARS-CoV sgRNA9", "GENE_OR_GENE_PRODUCT", 185, 200], ["ribosomal", "CELLULAR_COMPONENT", 207, 216], ["Accessory proteins", "PROTEIN", 95, 113], ["SARS-CoVAccessory protein 9b", "PROTEIN", 121, 149], ["ORF", "DNA", 178, 181], ["SARS-CoV sgRNA9", "DNA", 185, 200], ["SARS-CoV", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 185, 193], ["SARS", "PROBLEM", 38, 42], ["CoV pathogenesis", "PROBLEM", 43, 59], ["the SARS", "PROBLEM", 117, 125], ["CoVAccessory protein 9b", "TEST", 126, 149], ["SARS", "PROBLEM", 185, 189], ["a ribosomal leaky scanning", "TEST", 205, 231], ["ribosomal leaky", "OBSERVATION", 207, 222]]], ["The sgRNA9 also encodes the SARS-CoV N protein, and in fact ORF9b is a complete internal ORF within the N gene in an alternate reading frame (Xu et al., 2009).", [["sgRNA9", "GENE_OR_GENE_PRODUCT", 4, 10], ["SARS-CoV N", "GENE_OR_GENE_PRODUCT", 28, 38], ["ORF9b", "GENE_OR_GENE_PRODUCT", 60, 65], ["sgRNA9", "PROTEIN", 4, 10], ["SARS-CoV N protein", "PROTEIN", 28, 46], ["ORF9b", "PROTEIN", 60, 65], ["ORF", "DNA", 89, 92], ["N gene", "DNA", 104, 110], ["alternate reading frame", "DNA", 117, 140], ["SARS-CoV", "SPECIES", 28, 36], ["the SARS", "TEST", 24, 32], ["a complete internal ORF", "PROBLEM", 69, 92]]], ["The 9b protein is detected in SARS-CoV-infected cells and the lung and ileum tissues from SARS patients (Nal et al., 2005).", [["cells", "ANATOMY", 48, 53], ["lung", "ANATOMY", 62, 66], ["ileum tissues", "ANATOMY", 71, 84], ["SARS", "DISEASE", 90, 94], ["9b", "GENE_OR_GENE_PRODUCT", 4, 6], ["SARS-CoV", "ORGANISM", 30, 38], ["cells", "CELL", 48, 53], ["lung", "ORGAN", 62, 66], ["ileum tissues", "TISSUE", 71, 84], ["patients", "ORGANISM", 95, 103], ["9b protein", "PROTEIN", 4, 14], ["SARS-CoV-infected cells", "CELL_TYPE", 30, 53], ["patients", "SPECIES", 95, 103], ["SARS-CoV", "SPECIES", 30, 38], ["The 9b protein", "TEST", 0, 14], ["SARS", "PROBLEM", 30, 34], ["infected cells and the lung and ileum tissues", "PROBLEM", 39, 84], ["infected cells", "OBSERVATION", 39, 53], ["lung", "ANATOMY", 62, 66], ["ileum tissues", "ANATOMY", 71, 84]]], ["Moreover, anti-p9b antibodies are also detected in the serum of SARS patients (Qiu et al., 2005).", [["serum", "ANATOMY", 55, 60], ["SARS", "DISEASE", 64, 68], ["anti-p9b antibodies", "GENE_OR_GENE_PRODUCT", 10, 29], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["patients", "ORGANISM", 69, 77], ["anti-p9b antibodies", "PROTEIN", 10, 29], ["patients", "SPECIES", 69, 77], ["anti-p9b antibodies", "TEST", 10, 29]]], ["These results indicate that SARS-CoV 9b is expressed in vitro and in vivo.", [["SARS", "DISEASE", 28, 32], ["SARS-CoV 9b", "GENE_OR_GENE_PRODUCT", 28, 39], ["SARS-CoV", "SPECIES", 28, 36], ["SARS-CoV 9b", "PROBLEM", 28, 39], ["SARS", "OBSERVATION", 28, 32]]], ["Using sucrose gradient fractionation, Xu et al. have shown that p9b is incorporated into mature virions and packaged into VLPs when co-expressed with E and M proteins (Xu et al., 2009).", [["virions", "ANATOMY", 96, 103], ["sucrose", "CHEMICAL", 6, 13], ["sucrose", "CHEMICAL", 6, 13], ["sucrose", "SIMPLE_CHEMICAL", 6, 13], ["p9b", "GENE_OR_GENE_PRODUCT", 64, 67], ["VLPs", "GENE_OR_GENE_PRODUCT", 122, 126], ["E", "GENE_OR_GENE_PRODUCT", 150, 151], ["p9b", "PROTEIN", 64, 67], ["E and M proteins", "PROTEIN", 150, 166], ["sucrose gradient fractionation", "TREATMENT", 6, 36]]], ["These data indicate that p9b may be a structural component of SARS-CoV virions, but it is also possible that p9b is included during virus assembly due to interaction with E protein, as demonstrated by von Brunn et al. von Brunn et al. (2007).", [["p9b", "GENE_OR_GENE_PRODUCT", 25, 28], ["SARS-CoV virions", "ORGANISM", 62, 78], ["p9b", "GENE_OR_GENE_PRODUCT", 109, 112], ["E protein", "GENE_OR_GENE_PRODUCT", 171, 180], ["p9b", "PROTEIN", 25, 28], ["p9b", "PROTEIN", 109, 112], ["E protein", "PROTEIN", 171, 180], ["SARS-CoV", "SPECIES", 62, 70], ["SARS", "PROBLEM", 62, 66], ["CoV virions", "PROBLEM", 67, 78]]], ["The SARS-CoV 9b protein is also shown to self-interact and interact with nsp5, nsp14, and the accessory protein p6, although the functional significances are not fully understood (von Brunn et al., 2007, Calvo et al., 2012).", [["SARS-CoV 9b", "GENE_OR_GENE_PRODUCT", 4, 15], ["nsp5", "GENE_OR_GENE_PRODUCT", 73, 77], ["nsp14", "GENE_OR_GENE_PRODUCT", 79, 84], ["p6", "GENE_OR_GENE_PRODUCT", 112, 114], ["SARS-CoV 9b protein", "PROTEIN", 4, 23], ["nsp5", "PROTEIN", 73, 77], ["nsp14", "PROTEIN", 79, 84], ["accessory protein p6", "PROTEIN", 94, 114], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV 9b protein", "TEST", 9, 23], ["the accessory protein p6", "PROBLEM", 90, 114]]], ["Several reverse genetic studies have demonstrated that p9b is not essential for SARS-CoV replication in vitro and in vivo (von Brunn et al., 2007, DeDiego et al., 2008) (see Table 7).Orf9b ::: Accessory proteins of the SARS-CoVProtein 9b is a 98-amino-acid polypeptide with no sequence homology to any known proteins.", [["SARS", "DISEASE", 219, 223], ["98-amino-acid", "CHEMICAL", 243, 256], ["amino-acid", "CHEMICAL", 246, 256], ["p9b", "GENE_OR_GENE_PRODUCT", 55, 58], ["SARS-CoV", "ORGANISM", 80, 88], ["SARS-CoVProtein 9b", "GENE_OR_GENE_PRODUCT", 219, 237], ["p9b", "PROTEIN", 55, 58], ["Accessory proteins", "PROTEIN", 193, 211], ["SARS-CoVProtein 9b", "PROTEIN", 219, 237], ["SARS-CoV", "SPECIES", 80, 88], ["Several reverse genetic studies", "TEST", 0, 31], ["SARS", "PROBLEM", 80, 84], ["the SARS", "TEST", 215, 223], ["CoVProtein 9b", "TEST", 224, 237], ["amino-acid polypeptide", "TREATMENT", 246, 268], ["any known proteins", "PROBLEM", 298, 316]]], ["Meier et al. have determined the crystal structure of p9b and shown that the protein has a novel fold with seven \u03b2-strands (Meier et al., 2006).", [["p9b", "GENE_OR_GENE_PRODUCT", 54, 57], ["p9b", "PROTEIN", 54, 57]]], ["The \u03b2-strands from two molecules form two adjacent twisted \u03b2-sheets, resulting in a highly interlocked handshake structure (Meier et al., 2006) (Fig. 3).", [["a highly interlocked handshake structure", "PROBLEM", 82, 122], ["highly", "OBSERVATION_MODIFIER", 84, 90], ["interlocked", "OBSERVATION_MODIFIER", 91, 102], ["handshake", "OBSERVATION", 103, 112]]], ["Interestingly, the structure contains a hydrophobic central cavity, which binds lipid and stabilizes the molecule.", [["lipid", "SIMPLE_CHEMICAL", 80, 85], ["a hydrophobic central cavity", "PROBLEM", 38, 66], ["hydrophobic", "OBSERVATION_MODIFIER", 40, 51], ["central cavity", "OBSERVATION", 52, 66], ["lipid", "OBSERVATION_MODIFIER", 80, 85], ["molecule", "OBSERVATION_MODIFIER", 105, 113]]], ["Together with its membrane-association nature, this suggested that p9b may have a function during virus assembly (Meier et al., 2006).Orf9b ::: Accessory proteins of the SARS-CoVProtein 9b contains no known NLS and enters the nucleus by passive diffusion (Sharma et al., 2011).", [["membrane", "ANATOMY", 18, 26], ["nucleus", "ANATOMY", 226, 233], ["SARS", "DISEASE", 170, 174], ["membrane", "CELLULAR_COMPONENT", 18, 26], ["p9b", "GENE_OR_GENE_PRODUCT", 67, 70], ["SARS-CoVProtein 9b", "GENE_OR_GENE_PRODUCT", 170, 188], ["NLS", "GENE_OR_GENE_PRODUCT", 207, 210], ["nucleus", "CELLULAR_COMPONENT", 226, 233], ["p9b", "PROTEIN", 67, 70], ["Accessory proteins", "PROTEIN", 144, 162], ["SARS-CoVProtein 9b", "PROTEIN", 170, 188], ["NLS", "PROTEIN", 207, 210], ["the SARS", "TEST", 166, 174], ["CoVProtein 9b", "TEST", 175, 188], ["known NLS", "PROBLEM", 201, 210], ["no known", "UNCERTAINTY", 198, 206], ["NLS", "OBSERVATION", 207, 210], ["nucleus", "ANATOMY", 226, 233]]], ["However, amino-acid residues 46 to 54 (LRLGSQLSL) of p9b belong to a nuclear export signal (NES) motif LX1-3LX2-4LXL known to be transported by exportin 1 via an energy-dependent mechanism (Moshynskyy et al., 2007).", [["nuclear", "ANATOMY", 69, 76], ["amino-acid", "CHEMICAL", 9, 19], ["amino-acid", "CHEMICAL", 9, 19], ["amino", "AMINO_ACID", 9, 14], ["p9b", "GENE_OR_GENE_PRODUCT", 53, 56], ["LX1-3LX2-4LXL", "GENE_OR_GENE_PRODUCT", 103, 116], ["exportin 1", "GENE_OR_GENE_PRODUCT", 144, 154], ["amino-acid residues 46 to 54", "PROTEIN", 9, 37], ["LRLGSQLSL", "PROTEIN", 39, 48], ["p9b", "PROTEIN", 53, 56], ["nuclear export signal (NES) motif", "PROTEIN", 69, 102], ["LX1", "PROTEIN", 103, 106], ["3LX2", "PROTEIN", 107, 111], ["4LXL", "PROTEIN", 112, 116], ["exportin 1", "PROTEIN", 144, 154], ["amino-acid residues", "TEST", 9, 28], ["motif LX1", "TEST", 97, 106]]], ["Indeed, SARS-CoV p9b has been shown to physically interact with exportin 1 and moreover, mutation of the leucine-rich NES or inhibition of exportin 1 by leptomycin B have been shown to inhibit nuclear export of the 9b protein (Sharma et al., 2011, Moshynskyy et al., 2007).", [["nuclear", "ANATOMY", 193, 200], ["SARS", "DISEASE", 8, 12], ["leucine", "CHEMICAL", 105, 112], ["leptomycin B", "CHEMICAL", 153, 165], ["leucine", "CHEMICAL", 105, 112], ["leptomycin B", "CHEMICAL", 153, 165], ["SARS-CoV p9b", "GENE_OR_GENE_PRODUCT", 8, 20], ["exportin 1", "GENE_OR_GENE_PRODUCT", 64, 74], ["leucine", "AMINO_ACID", 105, 112], ["-rich NES", "GENE_OR_GENE_PRODUCT", 112, 121], ["exportin 1", "GENE_OR_GENE_PRODUCT", 139, 149], ["leptomycin B", "SIMPLE_CHEMICAL", 153, 165], ["nuclear", "CELLULAR_COMPONENT", 193, 200], ["SARS-CoV p9b", "PROTEIN", 8, 20], ["exportin 1", "PROTEIN", 64, 74], ["leucine-rich NES", "PROTEIN", 105, 121], ["exportin 1", "PROTEIN", 139, 149], ["leptomycin B", "PROTEIN", 153, 165], ["9b protein", "PROTEIN", 215, 225], ["SARS-CoV", "SPECIES", 8, 16]]], ["The nuclear export of p9b facilitates its degradation in the cytoplasm, whereas accumulation of p9b in the nucleus can induce caspase-dependent apoptosis (Sharma et al., 2011).Accessory proteins of other betacoronavirusesSARS coronavirus and its likely precursor, bat coronavirus SL-CoV WIV1 (Ge et al., 2013), as well as bat coronavirus HKU3 belong to lineage b of the genus Betacoronavirus (Lau et al., 2005).", [["nuclear", "ANATOMY", 4, 11], ["cytoplasm", "ANATOMY", 61, 70], ["nucleus", "ANATOMY", 107, 114], ["SARS coronavirus", "DISEASE", 221, 237], ["nuclear", "CELLULAR_COMPONENT", 4, 11], ["p9b", "GENE_OR_GENE_PRODUCT", 22, 25], ["cytoplasm", "ORGANISM_SUBSTANCE", 61, 70], ["p9b", "GENE_OR_GENE_PRODUCT", 96, 99], ["nucleus", "CELLULAR_COMPONENT", 107, 114], ["caspase", "GENE_OR_GENE_PRODUCT", 126, 133], ["betacoronavirusesSARS coronavirus", "ORGANISM", 204, 237], ["bat coronavirus SL-CoV WIV1", "ORGANISM", 264, 291], ["bat coronavirus HKU3", "ORGANISM", 322, 342], ["p9b", "PROTEIN", 22, 25], ["p9b", "PROTEIN", 96, 99], ["caspase", "PROTEIN", 126, 133], ["Accessory proteins", "PROTEIN", 176, 194], ["bat coronavirus HKU3", "PROTEIN", 322, 342], ["betacoronavirusesSARS coronavirus", "SPECIES", 204, 237], ["bat coronavirus SL-CoV", "SPECIES", 264, 286], ["bat coronavirus HKU3", "SPECIES", 322, 342], ["SARS coronavirus", "SPECIES", 221, 237], ["bat coronavirus SL-CoV", "SPECIES", 264, 286], ["bat coronavirus", "SPECIES", 322, 337], ["its degradation in the cytoplasm", "PROBLEM", 38, 70], ["accumulation of p9b in the nucleus", "PROBLEM", 80, 114], ["caspase", "PROBLEM", 126, 133], ["dependent apoptosis", "PROBLEM", 134, 153], ["Accessory proteins", "PROBLEM", 176, 194], ["other betacoronavirusesSARS coronavirus", "PROBLEM", 198, 237], ["bat coronavirus SL", "TEST", 264, 282], ["bat coronavirus HKU3", "PROBLEM", 322, 342], ["nucleus", "ANATOMY", 107, 114], ["dependent", "OBSERVATION_MODIFIER", 134, 143], ["apoptosis", "OBSERVATION_MODIFIER", 144, 153], ["likely", "UNCERTAINTY", 246, 252], ["genus Betacoronavirus", "ANATOMY", 370, 391]]], ["Lineage a (see Fig. 4for a phylogenetic tree) comprises a number of viruses that probably did not originate from bat coronavirus precursors, such as Bovine Coronavirus (BCoV), Murine Coronavirus (Mouse Hepatitis Virus, MHV), Human Coronavirus HKU1, and Human Coronavirus OC43.", [["Mouse Hepatitis Virus", "DISEASE", 196, 217], ["bat coronavirus", "ORGANISM", 113, 128], ["Bovine Coronavirus", "ORGANISM", 149, 167], ["BCoV", "ORGANISM", 169, 173], ["Murine Coronavirus", "ORGANISM", 176, 194], ["Mouse Hepatitis Virus", "ORGANISM", 196, 217], ["MHV", "ORGANISM", 219, 222], ["Human", "ORGANISM", 225, 230], ["Coronavirus HKU1", "ORGANISM", 231, 247], ["Human", "ORGANISM", 253, 258], ["Coronavirus OC43", "ORGANISM", 259, 275], ["bat coronavirus", "SPECIES", 113, 128], ["Bovine", "SPECIES", 149, 155], ["Murine", "SPECIES", 176, 182], ["Mouse Hepatitis Virus", "SPECIES", 196, 217], ["Human", "SPECIES", 225, 230], ["Human", "SPECIES", 253, 258], ["bat coronavirus", "SPECIES", 113, 128], ["Bovine Coronavirus", "SPECIES", 149, 167], ["BCoV", "SPECIES", 169, 173], ["Murine Coronavirus", "SPECIES", 176, 194], ["Mouse Hepatitis Virus", "SPECIES", 196, 217], ["MHV", "SPECIES", 219, 222], ["Human Coronavirus HKU1", "SPECIES", 225, 247], ["Human Coronavirus OC43", "SPECIES", 253, 275], ["viruses", "PROBLEM", 68, 75], ["bat coronavirus precursors", "PROBLEM", 113, 139], ["Bovine Coronavirus (BCoV", "TREATMENT", 149, 173], ["Murine Coronavirus (Mouse Hepatitis Virus", "PROBLEM", 176, 217], ["Human Coronavirus HKU1", "TEST", 225, 247], ["Human Coronavirus OC43", "PROBLEM", 253, 275], ["viruses", "OBSERVATION", 68, 75], ["probably did not originate", "UNCERTAINTY", 81, 107], ["coronavirus", "OBSERVATION", 117, 128]]], ["The genomes of BCoV, MHV, and Human Coronavirus OC43 encode the accessory protein NS2 (See Fig. 5), which, at least in case of MHV, has been shown to have phosphodiesterase activity specific for 2\u2032,5\u2032-oligoadenylate (2-5A) (Zhao et al., 2011, Zhao et al., 2012).", [["2\u2032,5\u2032-oligoadenylate", "CHEMICAL", 195, 215], ["2-5A", "CHEMICAL", 217, 221], ["2\u2032,5\u2032-oligoadenylate", "CHEMICAL", 195, 215], ["BCoV", "GENE_OR_GENE_PRODUCT", 15, 19], ["MHV", "ORGANISM", 21, 24], ["Human Coronavirus OC43", "ORGANISM", 30, 52], ["MHV", "ORGANISM", 127, 130], ["2\u2032,5\u2032-oligoadenylate", "SIMPLE_CHEMICAL", 195, 215], ["2-5A", "SIMPLE_CHEMICAL", 217, 221], ["BCoV", "DNA", 15, 19], ["Human Coronavirus OC43", "DNA", 30, 52], ["accessory protein NS2", "PROTEIN", 64, 85], ["See Fig. 5", "PROTEIN", 87, 97], ["MHV", "PROTEIN", 127, 130], ["Human", "SPECIES", 30, 35], ["BCoV", "SPECIES", 15, 19], ["MHV", "SPECIES", 21, 24], ["Human Coronavirus OC43", "SPECIES", 30, 52], ["MHV", "SPECIES", 127, 130], ["MHV", "TREATMENT", 21, 24], ["Human Coronavirus OC43", "PROBLEM", 30, 52], ["the accessory protein NS2", "TREATMENT", 60, 85], ["MHV", "PROBLEM", 127, 130], ["phosphodiesterase activity", "TEST", 155, 181], ["MHV", "ANATOMY", 21, 24]]], ["Synthesis of the latter by the host enzyme oligo-2\u2032,5\u2032-A synthetase (OAS) is induced by double-stranded RNA intermediates occurring during viral replication, and leads to activation of the host\u2019s RNase L, which in turn degrades viral and cellular mRNA (Silverman, 2007).", [["cellular", "ANATOMY", 238, 246], ["oligo-2\u2032,5\u2032-A", "CHEMICAL", 43, 56], ["oligo-2\u2032,5\u2032-A synthetase", "GENE_OR_GENE_PRODUCT", 43, 67], ["RNase L", "GENE_OR_GENE_PRODUCT", 196, 203], ["cellular", "CELL", 238, 246], ["host enzyme oligo-2\u2032,5\u2032-A synthetase", "PROTEIN", 31, 67], ["OAS", "PROTEIN", 69, 72], ["RNase L", "PROTEIN", 196, 203], ["viral and cellular mRNA", "RNA", 228, 251], ["the host enzyme oligo", "TEST", 27, 48], ["A synthetase (OAS)", "PROBLEM", 55, 73], ["double-stranded RNA intermediates", "PROBLEM", 88, 121], ["viral replication", "TREATMENT", 139, 156], ["stranded RNA", "OBSERVATION", 95, 107], ["viral replication", "OBSERVATION", 139, 156], ["viral", "OBSERVATION", 228, 233], ["cellular mRNA", "OBSERVATION", 238, 251]]], ["As a result, viral replication and protein synthesis are interrupted.", [["viral replication and protein synthesis", "TREATMENT", 13, 52], ["viral replication", "OBSERVATION", 13, 30]]], ["Thus, reduction of 2-5A levels by NS2 constitutes a mechanism of subversion of the interferon-inducible OAS \u2013 RNase L pathway.", [["2-5A", "SIMPLE_CHEMICAL", 19, 23], ["NS2", "GENE_OR_GENE_PRODUCT", 34, 37], ["RNase L", "GENE_OR_GENE_PRODUCT", 110, 117], ["NS2", "PROTEIN", 34, 37], ["interferon", "PROTEIN", 83, 93], ["OAS", "PROTEIN", 104, 107], ["RNase L", "PROTEIN", 110, 117], ["the interferon", "TREATMENT", 79, 93], ["RNase L pathway", "TREATMENT", 110, 125], ["reduction", "OBSERVATION_MODIFIER", 6, 15]]], ["Interestingly, this process is organ- and cell-type specific; NS2 is essential for replication of MHV A59 only in the liver, but not in the brain (Zhao et al., 2013).", [["organ", "ANATOMY", 31, 36], ["cell", "ANATOMY", 42, 46], ["liver", "ANATOMY", 118, 123], ["brain", "ANATOMY", 140, 145], ["organ", "ORGAN", 31, 36], ["cell", "CELL", 42, 46], ["NS2", "GENE_OR_GENE_PRODUCT", 62, 65], ["MHV A59", "ORGANISM", 98, 105], ["liver", "ORGAN", 118, 123], ["brain", "ORGAN", 140, 145], ["NS2", "PROTEIN", 62, 65], ["MHV A59", "PROTEIN", 98, 105], ["MHV", "SPECIES", 98, 101], ["MHV", "OBSERVATION_MODIFIER", 98, 101], ["liver", "ANATOMY", 118, 123], ["brain", "ANATOMY", 140, 145]]], ["This seems to depend on the level of the IFN-induced expression of the OAS gene, which differs between cell types.", [["cell", "ANATOMY", 103, 107], ["IFN", "GENE_OR_GENE_PRODUCT", 41, 44], ["OAS", "GENE_OR_GENE_PRODUCT", 71, 74], ["cell", "CELL", 103, 107], ["IFN", "PROTEIN", 41, 44], ["OAS gene", "DNA", 71, 79], ["the IFN", "TREATMENT", 37, 44], ["cell types", "OBSERVATION", 103, 113]]], ["The NS2 protein belongs to the superfamily of 2H phosphodiesterases that is characterized by the presence of a pair of conserved His-X-Thr/Ser motifs (Mazumder et al., 2002).Accessory proteins of other betacoronavirusesBetacoronaviruses of lineage a also include a haemagglutinin esterase (HE) gene between orf1ab and the S gene (Fig. 5).", [["2H", "CHEMICAL", 46, 48], ["His", "CHEMICAL", 129, 132], ["Thr", "CHEMICAL", 135, 138], ["Ser", "CHEMICAL", 139, 142], ["Ser", "AMINO_ACID", 139, 142], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 202, 219], ["haemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 265, 288], ["HE", "GENE_OR_GENE_PRODUCT", 290, 292], ["orf1ab", "GENE_OR_GENE_PRODUCT", 307, 313], ["NS2 protein", "PROTEIN", 4, 15], ["2H phosphodiesterases", "PROTEIN", 46, 67], ["-X", "PROTEIN", 132, 134], ["Accessory proteins", "PROTEIN", 174, 192], ["haemagglutinin esterase (HE) gene", "DNA", 265, 298], ["orf1ab", "DNA", 307, 313], ["S gene", "DNA", 322, 328], ["2H phosphodiesterases", "TREATMENT", 46, 67], ["Thr/Ser motifs", "TREATMENT", 135, 149], ["Accessory proteins", "PROBLEM", 174, 192], ["a haemagglutinin esterase", "TREATMENT", 263, 288]]], ["The hemagglutinin-esterases (HEs) are a family of viral envelope glycoproteins that mediate reversible attachment to O-acetylated sialic acids by acting both as receptor-binding (\u201clectins\u201d) and as receptor-destroying enzymes (RDEs) with esterase activity (Woo et al., 2010, Zhang et al., 1992, Vlasak et al., 1988, Schultze et al., 1991).", [["sialic acids", "CHEMICAL", 130, 142], ["O-acetylated sialic acids", "CHEMICAL", 117, 142], ["hemagglutinin-esterases", "GENE_OR_GENE_PRODUCT", 4, 27], ["HEs", "GENE_OR_GENE_PRODUCT", 29, 32], ["O-acetylated sialic acids", "SIMPLE_CHEMICAL", 117, 142], ["lectins", "GENE_OR_GENE_PRODUCT", 180, 187], ["RDEs", "GENE_OR_GENE_PRODUCT", 226, 230], ["esterase", "GENE_OR_GENE_PRODUCT", 237, 245], ["hemagglutinin-esterases", "PROTEIN", 4, 27], ["HEs", "PROTEIN", 29, 32], ["viral envelope glycoproteins", "PROTEIN", 50, 78], ["receptor-destroying enzymes", "PROTEIN", 197, 224], ["RDEs", "PROTEIN", 226, 230], ["esterase", "PROTEIN", 237, 245], ["viral envelope glycoproteins", "TREATMENT", 50, 78], ["reversible attachment", "PROBLEM", 92, 113], ["O-acetylated sialic acids", "TREATMENT", 117, 142]]], ["In coronaviruses, this gene is exclusively present in betacoronaviruses of clade a and has probably been acquired after diverging from the ancestors of other betacoronavirus lineages (Zeng et al., 2008), possibly via horizontal gene transfer from Influenza C virus (Langereis et al., 2012).", [["coronaviruses", "ORGANISM", 3, 16], ["Influenza C virus", "ORGANISM", 247, 264], ["betacoronavirus lineages", "CELL_TYPE", 158, 182], ["Influenza C virus", "SPECIES", 247, 264], ["Influenza C virus", "SPECIES", 247, 264], ["coronaviruses", "PROBLEM", 3, 16], ["Influenza C virus", "PROBLEM", 247, 264], ["coronaviruses", "OBSERVATION", 3, 16]]], ["Crystal structures have been determined for the hemagglutinin esterases of BCoV and MHV (Vlasak et al., 1988, Schultze et al., 1991).", [["hemagglutinin esterases", "GENE_OR_GENE_PRODUCT", 48, 71], ["BCoV", "GENE_OR_GENE_PRODUCT", 75, 79], ["MHV", "ORGANISM", 84, 87], ["hemagglutinin esterases", "PROTEIN", 48, 71], ["MHV", "SPECIES", 84, 87], ["the hemagglutinin esterases", "TEST", 44, 71]]], ["The E domain (with esterase activity) is found to be highly conserved but the RBD (receptor binding domain) is found to be flexible (Vlasak et al., 1988).", [["esterase", "GENE_OR_GENE_PRODUCT", 19, 27], ["E domain", "DNA", 4, 12], ["esterase", "PROTEIN", 19, 27], ["RBD", "PROTEIN", 78, 81], ["receptor binding domain", "PROTEIN", 83, 106], ["esterase activity", "TEST", 19, 36]]], ["HCoV OC43 and BCoV use 9-O-acetylated sialic acids as receptor to initiate infection, and correspondingly possess sialate-9-O-acetylesterases as RDE.", [["9-O", "CHEMICAL", 23, 26], ["sialic acids", "CHEMICAL", 38, 50], ["infection", "DISEASE", 75, 84], ["sialate-9-O-acetylesterases", "CHEMICAL", 114, 141], ["9-O-acetylated sialic acids", "CHEMICAL", 23, 50], ["sialate", "CHEMICAL", 114, 121], ["O", "CHEMICAL", 124, 125], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["9-O-acetylated sialic acids", "SIMPLE_CHEMICAL", 23, 50], ["sialate-9-O-acetylesterases", "SIMPLE_CHEMICAL", 114, 141], ["RDE", "SIMPLE_CHEMICAL", 145, 148], ["sialate-9-O-acetylesterases", "PROTEIN", 114, 141], ["RDE", "PROTEIN", 145, 148], ["HCoV", "SPECIES", 0, 4], ["HCoV", "TEST", 0, 4], ["acetylated sialic acids", "TREATMENT", 27, 50], ["infection", "PROBLEM", 75, 84], ["sialate", "TEST", 114, 121], ["infection", "OBSERVATION", 75, 84]]], ["Most betacoronaviruses of lineage a attach to 9-O-acetylated sialic acid, but one group of murine coronaviruses has switched to using 4-O-acetylated sialic acid (Schultze et al., 1991).", [["9-O-acetylated sialic acid", "CHEMICAL", 46, 72], ["4-O-acetylated sialic acid", "CHEMICAL", 134, 160], ["9-O-acetylated sialic acid", "CHEMICAL", 46, 72], ["4-O-acetylated sialic acid", "CHEMICAL", 134, 160], ["9-O-acetylated sialic acid", "SIMPLE_CHEMICAL", 46, 72], ["murine", "ORGANISM", 91, 97], ["coronaviruses", "ORGANISM", 98, 111], ["4-O-acetylated sialic acid", "SIMPLE_CHEMICAL", 134, 160], ["murine", "SPECIES", 91, 97], ["acetylated sialic acid", "TREATMENT", 50, 72], ["murine coronaviruses", "PROBLEM", 91, 111], ["acetylated sialic acid", "TREATMENT", 138, 160]]], ["The available crystal structures reveal the adaptations of the RBD to differences in receptor usage (Vlasak et al., 1988, Schultze et al., 1991).Accessory proteins of other betacoronavirusesBetacoronaviruses of lineage a also encode an internal ORF within the nucleocapsid gene (Fig. 5).", [["RBD", "DISEASE", 63, 66], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 173, 190], ["RBD", "PROTEIN", 63, 66], ["Accessory proteins", "PROTEIN", 145, 163], ["ORF", "DNA", 245, 248], ["nucleocapsid gene", "DNA", 260, 277], ["the RBD", "PROBLEM", 59, 66], ["an internal ORF", "PROBLEM", 233, 248]]], ["This ORF shares with SARS-CoV ORF9b the property of being completely overlapping with the nucleocapsid gene, but the encoded protein appears to have little in common with protein 9b of the SARS virus.", [["SARS", "DISEASE", 189, 193], ["SARS-CoV ORF9b", "GENE_OR_GENE_PRODUCT", 21, 35], ["protein 9b", "GENE_OR_GENE_PRODUCT", 171, 181], ["SARS virus", "ORGANISM", 189, 199], ["ORF", "DNA", 5, 8], ["SARS-CoV ORF9b", "DNA", 21, 35], ["nucleocapsid gene", "DNA", 90, 107], ["protein 9b", "PROTEIN", 171, 181], ["SARS-CoV", "SPECIES", 21, 29], ["SARS virus", "SPECIES", 189, 199], ["SARS", "PROBLEM", 21, 25], ["the nucleocapsid gene", "PROBLEM", 86, 107], ["the SARS virus", "PROBLEM", 185, 199], ["SARS virus", "OBSERVATION", 189, 199]]], ["A study performed on the internal ORF within the nucleocapsid gene of MHV suggests that this gene encodes a structural protein that is, however, found to be non-essential for virion formation and viral replication (Fischer et al., 1997).Accessory proteins of other betacoronavirusesIn the genomes of betacoronaviruses of lineage c, for example in the bat viruses (BtCoV) HKU4, HKU5, and the recently characterized Middle-East Respiratory Syndrome (MERS) coronavirus, there are four ORFs between the S and E genes, which encode proteins p3 (also known as p3a), p4a (also known as p3b), p4b (also known as p3c), and p5 (also known as p3d) (Fig. 5). p3 and p4b have been predicted to each contain one transmembrane helix, whereas p5 has been proposed to comprise three such helices (Siu et al., 2014). p3 and p5 have been found in the ERGIC, whereas p4a and p4b display a diffuse cytoplasmic distribution and are also partly localized to the nucleus (Siu et al., 2014), although in another study, p4b was found to localize exclusively to the nucleus (Matthews et al., 2014).", [["virion", "ANATOMY", 175, 181], ["transmembrane", "ANATOMY", 698, 711], ["cytoplasmic", "ANATOMY", 877, 888], ["nucleus", "ANATOMY", 939, 946], ["nucleus", "ANATOMY", 1039, 1046], ["Middle-East Respiratory Syndrome (MERS) coronavirus", "DISEASE", 414, 465], ["nucleocapsid", "CELLULAR_COMPONENT", 49, 61], ["MHV", "ORGANISM", 70, 73], ["virion", "CELLULAR_COMPONENT", 175, 181], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 265, 282], ["lineage c", "CELL", 321, 330], ["bat viruses", "ORGANISM", 351, 362], ["BtCoV", "GENE_OR_GENE_PRODUCT", 364, 369], ["HKU4", "GENE_OR_GENE_PRODUCT", 371, 375], ["HKU5", "GENE_OR_GENE_PRODUCT", 377, 381], ["Middle-East Respiratory Syndrome (MERS) coronavirus", "ORGANISM", 414, 465], ["E", "GENE_OR_GENE_PRODUCT", 505, 506], ["p3", "GENE_OR_GENE_PRODUCT", 536, 538], ["p3a", "GENE_OR_GENE_PRODUCT", 554, 557], ["p4a", "GENE_OR_GENE_PRODUCT", 560, 563], ["p3b", "GENE_OR_GENE_PRODUCT", 579, 582], ["p4b", "GENE_OR_GENE_PRODUCT", 585, 588], ["p3c", "GENE_OR_GENE_PRODUCT", 604, 607], ["p5", "GENE_OR_GENE_PRODUCT", 614, 616], ["p3", "GENE_OR_GENE_PRODUCT", 647, 649], ["p4b", "GENE_OR_GENE_PRODUCT", 654, 657], ["p5", "GENE_OR_GENE_PRODUCT", 727, 729], ["p3", "GENE_OR_GENE_PRODUCT", 799, 801], ["p5", "GENE_OR_GENE_PRODUCT", 806, 808], ["ERGIC", "GENE_OR_GENE_PRODUCT", 832, 837], ["p4a", "GENE_OR_GENE_PRODUCT", 847, 850], ["p4b", "GENE_OR_GENE_PRODUCT", 855, 858], ["cytoplasmic", "ORGANISM_SUBSTANCE", 877, 888], ["nucleus", "CELLULAR_COMPONENT", 939, 946], ["p4b", "GENE_OR_GENE_PRODUCT", 994, 997], ["nucleus", "CELLULAR_COMPONENT", 1039, 1046], ["internal ORF", "DNA", 25, 37], ["nucleocapsid gene", "DNA", 49, 66], ["structural protein", "PROTEIN", 108, 126], ["Accessory proteins", "PROTEIN", 237, 255], ["betacoronaviruses", "PROTEIN", 265, 282], ["HKU5", "PROTEIN", 377, 381], ["ORFs", "DNA", 482, 486], ["S and E genes", "DNA", 499, 512], ["p3", "PROTEIN", 536, 538], ["p3a", "PROTEIN", 554, 557], ["p4a", "PROTEIN", 560, 563], ["p3b", "PROTEIN", 579, 582], ["p4b", "PROTEIN", 585, 588], ["p3c", "PROTEIN", 604, 607], ["p5", "PROTEIN", 614, 616], ["p3d", "PROTEIN", 632, 635], ["Fig. 5", "PROTEIN", 638, 644], ["p3", "PROTEIN", 647, 649], ["p4b", "PROTEIN", 654, 657], ["transmembrane helix", "PROTEIN", 698, 717], ["p5", "PROTEIN", 727, 729], ["p3", "PROTEIN", 799, 801], ["p5", "PROTEIN", 806, 808], ["ERGIC", "PROTEIN", 832, 837], ["p4a", "PROTEIN", 847, 850], ["p4b", "PROTEIN", 855, 858], ["p4b", "PROTEIN", 994, 997], ["MHV", "SPECIES", 70, 73], ["bat viruses", "SPECIES", 351, 362], ["BtCoV", "SPECIES", 364, 369], ["Middle-East Respiratory Syndrome (MERS) coronavirus", "SPECIES", 414, 465], ["A study", "TEST", 0, 7], ["the internal ORF", "TEST", 21, 37], ["a structural protein", "PROBLEM", 106, 126], ["virion formation", "PROBLEM", 175, 191], ["Accessory proteins of other betacoronaviruses", "PROBLEM", 237, 282], ["the bat viruses", "PROBLEM", 347, 362], ["Middle-East Respiratory Syndrome", "PROBLEM", 414, 446], ["coronavirus", "PROBLEM", 454, 465], ["a diffuse cytoplasmic distribution", "PROBLEM", 867, 901], ["another study", "TEST", 979, 992], ["lineage c", "OBSERVATION", 321, 330], ["bat", "ANATOMY", 351, 354], ["viruses", "OBSERVATION", 355, 362], ["Middle", "ANATOMY_MODIFIER", 414, 420], ["Respiratory Syndrome", "OBSERVATION", 426, 446], ["ERGIC", "ANATOMY_MODIFIER", 832, 837], ["diffuse", "OBSERVATION_MODIFIER", 869, 876], ["cytoplasmic distribution", "OBSERVATION", 877, 901], ["nucleus", "ANATOMY_MODIFIER", 939, 946], ["nucleus", "ANATOMY", 1039, 1046]]], ["Both the p4a and the p4b protein of MERS coronavirus have been shown to be a type-I interferon antagonists (Siu et al., 2014, Matthews et al., 2014, Niemeyer et al., 2013).", [["p4a", "GENE_OR_GENE_PRODUCT", 9, 12], ["p4b", "GENE_OR_GENE_PRODUCT", 21, 24], ["MERS coronavirus", "ORGANISM", 36, 52], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 77, 94], ["p4a", "PROTEIN", 9, 12], ["p4b protein", "PROTEIN", 21, 32], ["MERS coronavirus", "SPECIES", 36, 52], ["the p4b protein", "TEST", 17, 32], ["MERS coronavirus", "PROBLEM", 36, 52]]], ["The p4a is particularly interesting in this context, as it is a double-stranded (ds) RNA-binding protein that prevents dsRNA (which occurs as an intermediate of viral RNA replication) from binding to the cellular dsRNA-binding protein PACT, which, as a consequence, cannot activate the cellular dsRNA sensors RIG-I and MDA5 (Siu et al., 2014, Niemeyer et al., 2013).", [["cellular", "ANATOMY", 204, 212], ["cellular", "ANATOMY", 286, 294], ["p4a", "GENE_OR_GENE_PRODUCT", 4, 7], ["cellular", "CELL", 204, 212], ["PACT", "GENE_OR_GENE_PRODUCT", 235, 239], ["cellular", "CELL", 286, 294], ["RIG-I", "GENE_OR_GENE_PRODUCT", 309, 314], ["MDA5", "GENE_OR_GENE_PRODUCT", 319, 323], ["p4a", "DNA", 4, 7], ["double-stranded (ds) RNA-binding protein", "PROTEIN", 64, 104], ["cellular dsRNA-binding protein", "PROTEIN", 204, 234], ["PACT", "PROTEIN", 235, 239], ["RIG-I", "PROTEIN", 309, 314], ["MDA5", "PROTEIN", 319, 323], ["a double-stranded (ds) RNA-binding protein", "PROBLEM", 62, 104], ["dsRNA", "PROBLEM", 119, 124], ["viral RNA replication", "TREATMENT", 161, 182], ["binding protein PACT", "PROBLEM", 219, 239]]], ["In another study, it has been shown that p4a, p4b and p5 are all potent interferon antagonists with p4a being the most powerful in counteracting the antiviral effects of IFN via the inhibition of both interferon production and ISRE (Interferon-Stimulated Response Element) promoter element signaling pathways (Yang et al., 2013).", [["IFN", "CHEMICAL", 170, 173], ["p4a", "GENE_OR_GENE_PRODUCT", 41, 44], ["p4b", "GENE_OR_GENE_PRODUCT", 46, 49], ["p5", "GENE_OR_GENE_PRODUCT", 54, 56], ["p4a", "GENE_OR_GENE_PRODUCT", 100, 103], ["IFN", "GENE_OR_GENE_PRODUCT", 170, 173], ["Interferon-Stimulated Response Element", "GENE_OR_GENE_PRODUCT", 233, 271], ["p4a", "PROTEIN", 41, 44], ["p4b", "PROTEIN", 46, 49], ["p5", "PROTEIN", 54, 56], ["IFN", "PROTEIN", 170, 173], ["interferon", "PROTEIN", 201, 211], ["ISRE (Interferon-Stimulated Response Element) promoter element", "DNA", 227, 289], ["another study", "TEST", 3, 16], ["all potent interferon antagonists", "TREATMENT", 61, 94], ["p4a", "TREATMENT", 100, 103], ["the antiviral effects", "TREATMENT", 145, 166], ["IFN", "TREATMENT", 170, 173], ["both interferon production", "TREATMENT", 196, 222], ["ISRE (Interferon", "TREATMENT", 227, 243], ["antiviral", "OBSERVATION", 149, 158]]], ["MERS coronavirus also contains an internal ORF within the nucleocapsid gene, which has not yet been characterized (van Boheemen et al., 2012).", [["MERS coronavirus", "ORGANISM", 0, 16], ["nucleocapsid", "CELLULAR_COMPONENT", 58, 70], ["ORF", "DNA", 43, 46], ["nucleocapsid gene", "DNA", 58, 75], ["MERS coronavirus", "SPECIES", 0, 16], ["MERS coronavirus", "PROBLEM", 0, 16], ["an internal ORF", "PROBLEM", 31, 46], ["internal ORF", "OBSERVATION", 34, 46], ["nucleocapsid gene", "OBSERVATION", 58, 75]]], ["This ORF was not previously described for BtCoV-HKU4 and BtCoV-HKU5 but is conserved in the genome sequences of both viruses.Accessory proteins of other betacoronavirusesIn betacoronavirus lineage d, for example in bat coronavirus HKU9, two ORFs, both of which are connected with a transcription regulatory sequence (TRS), are found downstream of the N gene (Fig. 5).", [["BtCoV-HKU4", "GENE_OR_GENE_PRODUCT", 42, 52], ["BtCoV-HKU5", "GENE_OR_GENE_PRODUCT", 57, 67], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 153, 170], ["betacoronavirus lineage", "CELL", 173, 196], ["bat coronavirus", "ORGANISM", 215, 230], ["HKU9", "GENE_OR_GENE_PRODUCT", 231, 235], ["ORF", "DNA", 5, 8], ["BtCoV", "DNA", 42, 47], ["HKU4", "DNA", 48, 52], ["BtCoV", "DNA", 57, 62], ["HKU5", "DNA", 63, 67], ["genome sequences", "DNA", 92, 108], ["Accessory proteins", "PROTEIN", 125, 143], ["betacoronaviruses", "PROTEIN", 153, 170], ["bat coronavirus HKU9", "DNA", 215, 235], ["ORFs", "DNA", 241, 245], ["transcription regulatory sequence", "DNA", 282, 315], ["TRS", "DNA", 317, 320], ["N gene", "DNA", 351, 357], ["bat coronavirus", "SPECIES", 215, 230], ["bat coronavirus", "SPECIES", 215, 230], ["This ORF", "TEST", 0, 8], ["BtCoV", "TEST", 42, 47], ["BtCoV", "TEST", 57, 62], ["HKU5", "PROBLEM", 63, 67], ["Accessory proteins of other betacoronaviruses", "PROBLEM", 125, 170], ["two ORFs", "PROBLEM", 237, 245], ["both", "ANATOMY_MODIFIER", 112, 116], ["viruses", "OBSERVATION", 117, 124], ["lineage d", "OBSERVATION", 189, 198]]], ["The TRSs are located at the 5\u2032 end of coronavirus genes and include a highly conserved AU-rich core sequence that is essential for mediating a 100- to 1000-fold increase in mRNA synthesis when it is located in the appropriate context (Sawicki et al., 2007).", [["TRSs", "GENE_OR_GENE_PRODUCT", 4, 8], ["coronavirus", "ORGANISM", 38, 49], ["TRSs", "DNA", 4, 8], ["5\u2032 end", "DNA", 28, 34], ["coronavirus genes", "DNA", 38, 55], ["AU-rich core sequence", "DNA", 87, 108], ["mRNA", "RNA", 173, 177], ["mRNA synthesis", "TREATMENT", 173, 187], ["coronavirus genes", "OBSERVATION", 38, 55], ["increase", "OBSERVATION_MODIFIER", 161, 169], ["mRNA synthesis", "OBSERVATION", 173, 187]]], ["Thus, the identification of TRSs before a predicted ORF helps identify new genes.", [["TRSs", "GENE_OR_GENE_PRODUCT", 28, 32], ["TRSs", "DNA", 28, 32], ["ORF", "DNA", 52, 55], ["TRSs", "TREATMENT", 28, 32], ["a predicted ORF", "PROBLEM", 40, 55]]], ["The two accessory ORFs in bat-coronavirus HKU9 encode two putative non-structural proteins, NS7a and NS7b (Woo et al., 2007, Lau et al., 2010).", [["bat-coronavirus", "ORGANISM", 26, 41], ["HKU9", "GENE_OR_GENE_PRODUCT", 42, 46], ["NS7a", "GENE_OR_GENE_PRODUCT", 92, 96], ["NS7b", "GENE_OR_GENE_PRODUCT", 101, 105], ["accessory ORFs", "DNA", 8, 22], ["bat-coronavirus HKU9", "DNA", 26, 46], ["non-structural proteins", "PROTEIN", 67, 90], ["NS7a", "PROTEIN", 92, 96], ["NS7b", "PROTEIN", 101, 105], ["bat-coronavirus", "SPECIES", 26, 41], ["bat-coronavirus", "SPECIES", 26, 41], ["The two accessory ORFs", "PROBLEM", 0, 22], ["accessory ORFs", "OBSERVATION", 8, 22], ["bat", "ANATOMY", 26, 29], ["non-structural proteins", "OBSERVATION", 67, 90]]], ["This is in fact the first time that ORFs downstream of the N gene have been observed in a betacoronavirus.Accessory proteins in AlphacoronavirusIn the genome of Feline Infectious Peritonitis Virus (FIPV), there are five ORFs coding for five accessory proteins (Fig. 5).", [["Feline", "DISEASE", 161, 167], ["Infectious Peritonitis", "DISEASE", 168, 190], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 128, 144], ["Feline Infectious Peritonitis Virus", "ORGANISM", 161, 196], ["FIPV", "CANCER", 198, 202], ["ORFs", "DNA", 36, 40], ["N gene", "DNA", 59, 65], ["Accessory proteins", "PROTEIN", 106, 124], ["ORFs", "DNA", 220, 224], ["accessory proteins", "PROTEIN", 241, 259], ["Fig. 5", "PROTEIN", 261, 267], ["Feline Infectious Peritonitis Virus", "SPECIES", 161, 196], ["FIPV", "SPECIES", 198, 202], ["Accessory proteins", "PROBLEM", 106, 124], ["Alphacoronavirus", "TREATMENT", 128, 144], ["Feline Infectious Peritonitis Virus", "PROBLEM", 161, 196], ["proteins", "OBSERVATION", 116, 124], ["Feline", "OBSERVATION_MODIFIER", 161, 167], ["Infectious", "OBSERVATION_MODIFIER", 168, 178], ["Peritonitis", "OBSERVATION", 179, 190]]], ["These are the ORF3 proteins (comprising p3a, p3b, and p3c) and the ORF7 proteins, interestingly encoded by two ORFs (7a and 7b) downstream of the N gene.", [["ORF3", "GENE_OR_GENE_PRODUCT", 14, 18], ["p3a", "GENE_OR_GENE_PRODUCT", 40, 43], ["p3b", "GENE_OR_GENE_PRODUCT", 45, 48], ["p3c", "GENE_OR_GENE_PRODUCT", 54, 57], ["ORF7", "GENE_OR_GENE_PRODUCT", 67, 71], ["7b", "GENE_OR_GENE_PRODUCT", 124, 126], ["ORF3 proteins", "PROTEIN", 14, 27], ["p3a", "PROTEIN", 40, 43], ["p3b", "PROTEIN", 45, 48], ["p3c", "PROTEIN", 54, 57], ["ORF7 proteins", "PROTEIN", 67, 80], ["ORFs", "DNA", 111, 115], ["N gene", "DNA", 146, 152], ["the ORF3 proteins", "TEST", 10, 27], ["p3a", "TEST", 40, 43], ["the ORF7 proteins", "TEST", 63, 80]]], ["It has been demonstrated that the ORF7 proteins are essential for efficient replication in vitro and for virulence in vivo (Haijema et al., 2004).", [["ORF7", "GENE_OR_GENE_PRODUCT", 34, 38], ["ORF7 proteins", "PROTEIN", 34, 47], ["the ORF7 proteins", "TEST", 30, 47], ["virulence", "PROBLEM", 105, 114]]], ["The ORF3 proteins were found to have only supportive roles during infection of the target cell by FIPV (Dedeurwaerder et al., 2013).", [["cell", "ANATOMY", 90, 94], ["infection", "DISEASE", 66, 75], ["ORF3", "GENE_OR_GENE_PRODUCT", 4, 8], ["cell", "CELL", 90, 94], ["ORF3 proteins", "PROTEIN", 4, 17], ["target cell", "CELL_TYPE", 83, 94], ["The ORF3 proteins", "TEST", 0, 17], ["infection", "OBSERVATION", 66, 75]]], ["It has also been shown that the FIPV p7a protein is a type-I IFN antagonist but needs the presence of ORF3 proteins to fully exert its antagonistic function (Dedeurwaerder et al., 2014).Accessory proteins in AlphacoronavirusThe ORF3 and ORF7 proteins of Porcine Respiratory coronavirus (PRCoV) and Transmissible Gastroenteritis Virus (TGEV) are known to play potential roles in determining virulence (Paul et al., 1997, McGoldrick et al., 1999, Tung et al., 1992).Accessory proteins in AlphacoronavirusAnother notable accessory protein of an alphacoronavirus is the protein encoded by ORF4 in Human Coronavirus 229E (HCoV 229E; Fig. 5).", [["Respiratory coronavirus", "DISEASE", 262, 285], ["FIPV p7a", "GENE_OR_GENE_PRODUCT", 32, 40], ["type-I IFN", "GENE_OR_GENE_PRODUCT", 54, 64], ["ORF3", "GENE_OR_GENE_PRODUCT", 102, 106], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 208, 224], ["ORF3", "GENE_OR_GENE_PRODUCT", 228, 232], ["ORF7", "GENE_OR_GENE_PRODUCT", 237, 241], ["Porcine Respiratory coronavirus", "ORGANISM", 254, 285], ["PRCoV", "GENE_OR_GENE_PRODUCT", 287, 292], ["Transmissible Gastroenteritis Virus", "ORGANISM", 298, 333], ["TGEV", "ORGANISM", 335, 339], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 486, 502], ["alphacoronavirus", "GENE_OR_GENE_PRODUCT", 542, 558], ["ORF4", "GENE_OR_GENE_PRODUCT", 585, 589], ["Human Coronavirus 229E", "ORGANISM", 593, 615], ["FIPV p7a protein", "PROTEIN", 32, 48], ["ORF3 proteins", "PROTEIN", 102, 115], ["Accessory proteins", "PROTEIN", 186, 204], ["Alphacoronavirus", "PROTEIN", 208, 224], ["ORF3 and ORF7 proteins", "PROTEIN", 228, 250], ["Accessory proteins", "PROTEIN", 464, 482], ["Alphacoronavirus", "PROTEIN", 486, 502], ["accessory protein", "PROTEIN", 518, 535], ["alphacoronavirus", "PROTEIN", 542, 558], ["ORF4", "PROTEIN", 585, 589], ["Porcine Respiratory coronavirus", "SPECIES", 254, 285], ["Transmissible Gastroenteritis Virus", "SPECIES", 298, 333], ["TGEV", "SPECIES", 335, 339], ["Human", "SPECIES", 593, 598], ["Porcine Respiratory coronavirus", "SPECIES", 254, 285], ["PRCoV", "SPECIES", 287, 292], ["Transmissible Gastroenteritis Virus", "SPECIES", 298, 333], ["TGEV", "SPECIES", 335, 339], ["Human Coronavirus 229E (HCoV 229E", "SPECIES", 593, 626], ["the FIPV p7a protein", "TEST", 28, 48], ["a type-I IFN antagonist", "TREATMENT", 52, 75], ["ORF3 proteins", "PROBLEM", 102, 115], ["Accessory proteins", "PROBLEM", 186, 204], ["Alphacoronavirus", "TEST", 208, 224], ["The ORF3", "TEST", 224, 232], ["Porcine Respiratory coronavirus", "PROBLEM", 254, 285], ["Transmissible Gastroenteritis Virus", "PROBLEM", 298, 333], ["Accessory proteins in Alphacoronavirus", "PROBLEM", 464, 502], ["the protein", "TEST", 562, 573], ["Human Coronavirus", "TEST", 593, 610], ["HCoV", "TEST", 617, 621], ["FIPV", "OBSERVATION", 32, 36], ["proteins", "OBSERVATION", 196, 204], ["Porcine", "OBSERVATION", 254, 261], ["Respiratory coronavirus", "OBSERVATION", 262, 285], ["proteins", "OBSERVATION", 474, 482], ["notable", "OBSERVATION_MODIFIER", 510, 517], ["accessory protein", "OBSERVATION", 518, 535]]], ["It has been previously shown that the HCoV-229E genome codes for two accessory proteins, p4a and p4b.", [["HCoV-229E", "GENE_OR_GENE_PRODUCT", 38, 47], ["p4a", "GENE_OR_GENE_PRODUCT", 89, 92], ["p4b", "GENE_OR_GENE_PRODUCT", 97, 100], ["HCoV-229E genome", "DNA", 38, 54], ["accessory proteins", "PROTEIN", 69, 87], ["p4a", "PROTEIN", 89, 92], ["p4b", "PROTEIN", 97, 100], ["HCoV-229E", "SPECIES", 38, 47], ["the HCoV", "TEST", 34, 42], ["two accessory proteins", "TEST", 65, 87]]], ["However, recent sequencing of clinical isolates revealed the presence of a full-length p4, whereas laboratory strains show the presence of a truncated p4 (Farsani et al., 2012).", [["p4", "GENE_OR_GENE_PRODUCT", 87, 89], ["full-length p4", "DNA", 75, 89], ["truncated p4", "PROTEIN", 141, 153], ["clinical isolates", "TEST", 30, 47], ["laboratory strains", "TEST", 99, 117], ["a truncated p4", "PROBLEM", 139, 153]]], ["It has been suggested that extensive culturing of HCoV 229E might have resulted in this truncation (Dijkman et al., 2006).", [["HCoV 229E", "CHEMICAL", 50, 59], ["HCoV 229E", "GENE_OR_GENE_PRODUCT", 50, 59], ["HCoV 229E", "PROTEIN", 50, 59], ["HCoV", "SPECIES", 50, 54], ["extensive culturing of HCoV 229E", "PROBLEM", 27, 59], ["this truncation", "PROBLEM", 83, 98], ["extensive", "OBSERVATION_MODIFIER", 27, 36]]], ["The high degree of conservation of the amino-acid sequence of p4 among clinical isolates suggests that the protein plays an important role in vivo.Accessory proteins in GammacoronavirusThe most studied gammacoronavirus to date is IBV.", [["amino-acid", "CHEMICAL", 39, 49], ["amino-acid", "CHEMICAL", 39, 49], ["amino-acid", "AMINO_ACID", 39, 49], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 169, 185], ["gammacoronavirus", "CANCER", 202, 218], ["IBV", "ORGANISM", 230, 233], ["amino-acid sequence", "PROTEIN", 39, 58], ["p4", "PROTEIN", 62, 64], ["Accessory proteins", "PROTEIN", 147, 165], ["IBV", "SPECIES", 230, 233], ["the amino-acid sequence", "TREATMENT", 35, 58], ["Accessory proteins in Gammacoronavirus", "PROBLEM", 147, 185], ["IBV", "PROBLEM", 230, 233], ["high degree", "OBSERVATION_MODIFIER", 4, 15], ["proteins", "OBSERVATION", 157, 165]]], ["The genomic organization of a classic gammacoronavirus is 5\u2032-UTR-Pol-S-3a-3b-E-M-5a-5b-N-UTR-3\u2032 (UTR = untranslated region).", [["5\u2032-UTR", "DNA", 58, 64], ["Pol", "DNA", 65, 68], ["E", "DNA", 77, 78], ["5a-5b", "DNA", 81, 86], ["N-UTR-3\u2032", "DNA", 87, 95], ["UTR", "DNA", 97, 100], ["a classic gammacoronavirus", "TEST", 28, 54], ["UTR", "TEST", 61, 64], ["3b", "TEST", 74, 76], ["E", "TEST", 77, 78], ["UTR", "TEST", 89, 92], ["UTR = untranslated region", "PROBLEM", 97, 122]]], ["Hence, it contains four accessory genes.", [["accessory genes", "DNA", 24, 39], ["four", "OBSERVATION_MODIFIER", 19, 23], ["accessory genes", "OBSERVATION", 24, 39]]], ["The IBV sub-genomic mRNA 3 (sgRNA3) and sgRNA5 are known to be polycistronic (Liu et al., 1991, Liu and Inglis, 1992a, Liu and Inglis, 1992b).", [["IBV sub-genomic mRNA 3", "GENE_OR_GENE_PRODUCT", 4, 26], ["sgRNA3", "GENE_OR_GENE_PRODUCT", 28, 34], ["sgRNA5", "GENE_OR_GENE_PRODUCT", 40, 46], ["IBV sub-genomic mRNA 3", "DNA", 4, 26], ["sgRNA3", "DNA", 28, 34], ["sgRNA5", "DNA", 40, 46], ["The IBV sub-genomic mRNA", "TEST", 0, 24], ["sgRNA3", "TEST", 28, 34], ["sgRNA5", "TEST", 40, 46], ["Liu", "TEST", 96, 99], ["Inglis", "TEST", 104, 110], ["Liu", "TEST", 119, 122], ["Inglis", "TEST", 127, 133], ["genomic mRNA", "OBSERVATION", 12, 24]]], ["The sgRNA3 has been shown to be tricistronic and encodes 3a, 3b and E protein (previously known as 3c protein) (Liu et al., 1991, Liu and Inglis, 1991, Liu and Inglis, 1992a, Liu and Inglis, 1992b), whereas sgRNA5 is bi-cistronic and encodes 5a and 5b (Liu and Inglis, 1992a, Liu and Inglis, 1992b).", [["sgRNA3", "CHEMICAL", 4, 10], ["sgRNA3", "GENE_OR_GENE_PRODUCT", 4, 10], ["3a", "GENE_OR_GENE_PRODUCT", 57, 59], ["3b", "GENE_OR_GENE_PRODUCT", 61, 63], ["E", "GENE_OR_GENE_PRODUCT", 68, 69], ["sgRNA5", "GENE_OR_GENE_PRODUCT", 207, 213], ["sgRNA3", "PROTEIN", 4, 10], ["3a, 3b and E protein", "PROTEIN", 57, 77], ["3c protein", "PROTEIN", 99, 109], ["sgRNA5", "PROTEIN", 207, 213], ["b and E protein", "TEST", 62, 77], ["Liu", "TEST", 130, 133], ["Inglis", "TEST", 138, 144], ["Liu", "TEST", 152, 155], ["Inglis", "TEST", 160, 166], ["Liu", "TEST", 175, 178], ["Inglis", "TEST", 183, 189], ["sgRNA5", "TEST", 207, 213], ["Inglis", "TEST", 261, 267], ["Inglis", "TEST", 284, 290]]], ["Serial passages of IBV in Vero cells led to the emergence of a mutant IBV with a truncated 3b gene (Shen et al., 2003).", [["Vero cells", "ANATOMY", 26, 36], ["IBV", "ORGANISM", 19, 22], ["Vero cells", "CELL", 26, 36], ["IBV", "ORGANISM", 70, 73], ["3b", "GENE_OR_GENE_PRODUCT", 91, 93], ["Vero cells", "CELL_LINE", 26, 36], ["truncated 3b gene", "DNA", 81, 98], ["IBV", "SPECIES", 19, 22], ["IBV", "SPECIES", 70, 73], ["IBV in Vero cells", "TREATMENT", 19, 36], ["a mutant IBV", "TREATMENT", 61, 73]]], ["The mutant virus is more virulent in chicken embryos, suggesting that the 3b protein may play a certain function in viral pathogenesis (Shen et al., 2003).", [["embryos", "ANATOMY", 45, 52], ["mutant virus", "ORGANISM", 4, 16], ["chicken", "ORGANISM", 37, 44], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 45, 52], ["3b", "GENE_OR_GENE_PRODUCT", 74, 76], ["3b protein", "PROTEIN", 74, 84], ["chicken", "SPECIES", 37, 44], ["chicken", "SPECIES", 37, 44], ["The mutant virus", "PROBLEM", 0, 16], ["the 3b protein", "PROBLEM", 70, 84], ["viral pathogenesis", "PROBLEM", 116, 134], ["virus", "OBSERVATION", 11, 16], ["more", "OBSERVATION_MODIFIER", 20, 24], ["virulent", "OBSERVATION_MODIFIER", 25, 33]]], ["Reverse genetics studies have shown that proteins 3a, 3b.", [["proteins 3a, 3b", "PROTEIN", 41, 56], ["Reverse genetics studies", "TEST", 0, 24], ["proteins", "TEST", 41, 49]]], ["5a, and 5b are dispensable for viral replication (Hodgson et al., 2006, Casais et al., 2005).", [["5a", "GENE_OR_GENE_PRODUCT", 0, 2], ["5b", "GENE_OR_GENE_PRODUCT", 8, 10], ["5a, and 5b", "PROTEIN", 0, 10], ["dispensable for", "UNCERTAINTY", 15, 30], ["viral replication", "OBSERVATION", 31, 48]]], ["In non-classical Australian strains of IBV, accessory genes 3a and 3b were found to be replaced by the unrelated X1 gene, and 5a was lacking (Mardani et al., 2008).", [["IBV", "ORGANISM", 39, 42], ["3b", "GENE_OR_GENE_PRODUCT", 67, 69], ["X1", "GENE_OR_GENE_PRODUCT", 113, 115], ["accessory genes 3a and 3b", "DNA", 44, 69], ["X1 gene", "DNA", 113, 120], ["IBV", "SPECIES", 39, 42], ["IBV", "TREATMENT", 39, 42]]], ["More recently, it has been demonstrated that a potential ORF situated between the M gene and gene 5a/b of IBV is transcribed through template-switching involving a non-canonical TRS, resulting in a 11-kD-protein of unknown function (Bentley et al., 2013).ConclusionsSARS-CoV encodes eight accessory proteins, namely p3a, p3b, p6, p7a, p7b, p8a, p8b, and p9b.", [["b", "GENE_OR_GENE_PRODUCT", 101, 102], ["IBV", "ORGANISM", 106, 109], ["ConclusionsSARS-CoV", "GENE_OR_GENE_PRODUCT", 255, 274], ["p3a", "GENE_OR_GENE_PRODUCT", 316, 319], ["p3b", "GENE_OR_GENE_PRODUCT", 321, 324], ["p6", "GENE_OR_GENE_PRODUCT", 326, 328], ["p7a", "GENE_OR_GENE_PRODUCT", 330, 333], ["p7b", "GENE_OR_GENE_PRODUCT", 335, 338], ["p8a", "GENE_OR_GENE_PRODUCT", 340, 343], ["p8b", "GENE_OR_GENE_PRODUCT", 345, 348], ["p9b", "GENE_OR_GENE_PRODUCT", 354, 357], ["ORF", "DNA", 57, 60], ["M gene", "DNA", 82, 88], ["gene 5a/b", "DNA", 93, 102], ["non-canonical TRS", "DNA", 164, 181], ["CoV", "DNA", 271, 274], ["accessory proteins", "PROTEIN", 289, 307], ["p3a", "PROTEIN", 316, 319], ["p3b", "PROTEIN", 321, 324], ["p6", "PROTEIN", 326, 328], ["p7a", "PROTEIN", 330, 333], ["p7b", "PROTEIN", 335, 338], ["p8a", "PROTEIN", 340, 343], ["p8b", "PROTEIN", 345, 348], ["p9b", "PROTEIN", 354, 357], ["IBV", "SPECIES", 106, 109], ["ConclusionsSARS-CoV", "SPECIES", 255, 274], ["a potential ORF", "PROBLEM", 45, 60], ["gene 5a/b of IBV", "TREATMENT", 93, 109], ["a non-canonical TRS", "PROBLEM", 162, 181], ["ConclusionsSARS", "TEST", 255, 270], ["accessory proteins", "TEST", 289, 307], ["p3a", "TEST", 316, 319], ["p3b", "TEST", 321, 324], ["p7a", "TEST", 330, 333], ["p7b", "TEST", 335, 338], ["p8a", "TEST", 340, 343]]], ["Reverse genetic studies have demonstrated that, whereas none of these proteins is essential for SARS-CoV replication, some of them, in particular p6 and p7b, may contribute to the virulence of SARS-CoV (Pewe et al., 2005, Pfefferle et al., 2009).", [["SARS", "DISEASE", 193, 197], ["SARS-CoV", "ORGANISM", 96, 104], ["p6", "GENE_OR_GENE_PRODUCT", 146, 148], ["p7b", "GENE_OR_GENE_PRODUCT", 153, 156], ["SARS-CoV", "ORGANISM", 193, 201], ["p6", "PROTEIN", 146, 148], ["p7b", "PROTEIN", 153, 156], ["SARS-CoV", "SPECIES", 96, 104], ["SARS-CoV", "SPECIES", 193, 201], ["Reverse genetic studies", "TEST", 0, 23], ["these proteins", "TEST", 64, 78], ["SARS", "PROBLEM", 96, 100], ["CoV replication", "TREATMENT", 101, 116], ["SARS", "PROBLEM", 193, 197]]], ["Five of the SARS-CoV accessory proteins (p3a, p6, p7a, p7b, and p9b) have been shown to be incorporated into mature virions and are thus minor structural proteins.", [["virions", "ANATOMY", 116, 123], ["SARS-CoV", "ORGANISM", 12, 20], ["p3a", "GENE_OR_GENE_PRODUCT", 41, 44], ["p6", "GENE_OR_GENE_PRODUCT", 46, 48], ["p7a", "GENE_OR_GENE_PRODUCT", 50, 53], ["p7b", "GENE_OR_GENE_PRODUCT", 55, 58], ["p9b", "GENE_OR_GENE_PRODUCT", 64, 67], ["SARS-CoV accessory proteins", "PROTEIN", 12, 39], ["p3a", "PROTEIN", 41, 44], ["p6", "PROTEIN", 46, 48], ["p7a", "PROTEIN", 50, 53], ["p7b", "PROTEIN", 55, 58], ["p9b", "PROTEIN", 64, 67], ["structural proteins", "PROTEIN", 143, 162], ["SARS-CoV", "SPECIES", 12, 20], ["the SARS", "TEST", 8, 16], ["CoV accessory proteins", "TEST", 17, 39], ["p3a", "TEST", 41, 44], ["p6", "TEST", 46, 48], ["p7a", "TEST", 50, 53], ["p7b", "TEST", 55, 58], ["minor structural proteins", "PROBLEM", 137, 162], ["mature virions", "OBSERVATION", 109, 123]]], ["Most SARS-CoV accessory proteins are involved in more than one cellular process, such as interfering with the MAP-kinase pathway, DNA synthesis, induction of pro-inflammatory cytokines, or induction of caspase-dependent apoptosis, to name just a few.", [["cellular", "ANATOMY", 63, 71], ["SARS", "DISEASE", 5, 9], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 5, 13], ["cellular", "CELL", 63, 71], ["MAP-kinase", "GENE_OR_GENE_PRODUCT", 110, 120], ["DNA", "CELLULAR_COMPONENT", 130, 133], ["caspase", "GENE_OR_GENE_PRODUCT", 202, 209], ["SARS-CoV accessory proteins", "PROTEIN", 5, 32], ["MAP-kinase", "PROTEIN", 110, 120], ["pro-inflammatory cytokines", "PROTEIN", 158, 184], ["caspase", "PROTEIN", 202, 209], ["SARS-CoV", "SPECIES", 5, 13], ["Most SARS", "PROBLEM", 0, 9], ["CoV accessory proteins", "PROBLEM", 10, 32], ["the MAP-kinase pathway", "TREATMENT", 106, 128], ["DNA synthesis", "PROBLEM", 130, 143], ["pro-inflammatory cytokines", "TREATMENT", 158, 184], ["caspase", "TREATMENT", 202, 209], ["dependent apoptosis", "PROBLEM", 210, 229], ["process", "OBSERVATION", 72, 79], ["dependent", "OBSERVATION_MODIFIER", 210, 219], ["apoptosis", "OBSERVATION", 220, 229]]], ["The crystal structures of SARS-CoV accessory proteins 7a and 9b have been determined, providing a structural basis for their biological functions (Nelson et al., 2005, Meier et al., 2006).", [["SARS-CoV accessory proteins 7a", "GENE_OR_GENE_PRODUCT", 26, 56], ["9b", "GENE_OR_GENE_PRODUCT", 61, 63], ["SARS-CoV accessory proteins 7a and 9b", "PROTEIN", 26, 63], ["SARS-CoV", "SPECIES", 26, 34], ["SARS", "PROBLEM", 26, 30], ["SARS", "OBSERVATION", 26, 30]]], ["However, the pathophysiological significances of these accessory proteins in the context of SARS-CoV infection are not completely understood, and further structural and functional studies are required.ConclusionsKnowledge on the accessory proteins of other coronaviruses is even more limited than for SARS-CoV.", [["SARS-CoV infection", "DISEASE", 92, 110], ["SARS-CoV", "ORGANISM", 92, 100], ["coronaviruses", "ORGANISM", 257, 270], ["SARS-CoV", "ORGANISM", 301, 309], ["accessory proteins", "PROTEIN", 55, 73], ["accessory proteins", "PROTEIN", 229, 247], ["SARS-CoV", "SPECIES", 92, 100], ["SARS-CoV", "SPECIES", 301, 309], ["these accessory proteins", "PROBLEM", 49, 73], ["SARS", "PROBLEM", 92, 96], ["CoV infection", "PROBLEM", 97, 110], ["further structural and functional studies", "TEST", 146, 187], ["other coronaviruses", "PROBLEM", 251, 270], ["SARS", "PROBLEM", 301, 305], ["SARS", "OBSERVATION", 92, 96], ["CoV", "OBSERVATION_MODIFIER", 97, 100], ["infection", "OBSERVATION", 101, 110], ["coronaviruses", "OBSERVATION", 257, 270]]], ["The best characterized member of betacoronaviruses of lineage a, murine coronavirus (MHV), as well as some related viruses encode a hemagglutinin esterase and a 2\u2019,5\u2019-oligoadenylate phosphodiesterase, the latter of which is involved in reducing the activities of RNase L. Lineage-a betacoronaviruses also encode an \u201cinternal\u201d protein through a gene completely overlapping with the nucleocapsid gene.", [["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 33, 50], ["murine coronavirus", "ORGANISM", 65, 83], ["MHV", "ORGANISM", 85, 88], ["hemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 132, 154], ["5\u2019-oligoadenylate phosphodiesterase", "GENE_OR_GENE_PRODUCT", 164, 199], ["RNase", "GENE_OR_GENE_PRODUCT", 263, 268], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 282, 299], ["betacoronaviruses", "PROTEIN", 33, 50], ["hemagglutinin esterase", "PROTEIN", 132, 154], ["2\u2019,5\u2019-oligoadenylate phosphodiesterase", "PROTEIN", 161, 199], ["RNase", "PROTEIN", 263, 268], ["\u201cinternal\u201d protein", "PROTEIN", 315, 333], ["nucleocapsid gene", "DNA", 381, 398], ["murine", "SPECIES", 65, 71], ["coronavirus", "SPECIES", 72, 83], ["murine coronavirus", "SPECIES", 65, 83], ["MHV", "SPECIES", 85, 88], ["murine coronavirus (MHV)", "PROBLEM", 65, 89], ["some related viruses", "PROBLEM", 102, 122], ["a hemagglutinin esterase", "TEST", 130, 154], ["5\u2019-oligoadenylate phosphodiesterase", "TREATMENT", 164, 199], ["an \u201cinternal\u201d protein", "TREATMENT", 312, 333], ["viruses", "OBSERVATION", 115, 122], ["nucleocapsid gene", "OBSERVATION", 381, 398]]], ["Betacoronaviruses of lineage c, the most prominent example for which is the newly emerging Middle East Respiratory Syndrome coronavirus (MERS-CoV), feature a similar gene \u201cwithin\u201d the nucleocapsid gene.", [["Middle East Respiratory Syndrome coronavirus", "DISEASE", 91, 135], ["lineage c", "CELL", 21, 30], ["Middle East Respiratory Syndrome coronavirus", "ORGANISM", 91, 135], ["MERS-CoV", "ORGANISM", 137, 145], ["nucleocapsid gene", "DNA", 184, 201], ["Middle East Respiratory Syndrome coronavirus", "SPECIES", 91, 135], ["MERS-CoV", "SPECIES", 137, 145], ["Middle East Respiratory Syndrome coronavirus", "PROBLEM", 91, 135], ["lineage c", "OBSERVATION", 21, 30], ["most prominent", "OBSERVATION_MODIFIER", 36, 50], ["Middle", "ANATOMY_MODIFIER", 91, 97], ["Respiratory Syndrome", "OBSERVATION", 103, 123], ["nucleocapsid gene", "OBSERVATION", 184, 201]]], ["The bat coronavirus HKU9, a member of betacoronavirus lineage d, and some alphacoronaviruses such as Feline Infectious Peritonitis Virus (FIPV) contain open reading frames downstream of the nucleocapsid gene.", [["Feline", "DISEASE", 101, 107], ["Infectious Peritonitis", "DISEASE", 108, 130], ["bat coronavirus", "ORGANISM", 4, 19], ["HKU9", "GENE_OR_GENE_PRODUCT", 20, 24], ["betacoronavirus lineage", "CELL", 38, 61], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 74, 92], ["Feline Infectious Peritonitis Virus", "ORGANISM", 101, 136], ["FIPV", "GENE_OR_GENE_PRODUCT", 138, 142], ["open reading frames", "DNA", 152, 171], ["nucleocapsid gene", "DNA", 190, 207], ["bat coronavirus", "SPECIES", 4, 19], ["Feline Infectious Peritonitis Virus", "SPECIES", 101, 136], ["bat coronavirus", "SPECIES", 4, 19], ["Feline Infectious Peritonitis Virus", "SPECIES", 101, 136], ["FIPV", "SPECIES", 138, 142], ["The bat coronavirus HKU9", "TEST", 0, 24], ["betacoronavirus lineage d", "PROBLEM", 38, 63], ["some alphacoronaviruses", "PROBLEM", 69, 92], ["Feline Infectious Peritonitis Virus (FIPV)", "PROBLEM", 101, 143], ["Infectious", "OBSERVATION_MODIFIER", 108, 118], ["Peritonitis", "OBSERVATION", 119, 130], ["nucleocapsid gene", "OBSERVATION", 190, 207]]], ["Proteins 7a and 7b of FIPV are involved in counteracting the antiviral response exerted by type-I interferons, with support from proteins 3a and 3b.", [["7b", "GENE_OR_GENE_PRODUCT", 16, 18], ["FIPV", "GENE_OR_GENE_PRODUCT", 22, 26], ["type-I interferons", "GENE_OR_GENE_PRODUCT", 91, 109], ["3b", "GENE_OR_GENE_PRODUCT", 145, 147], ["Proteins 7a and 7b", "PROTEIN", 0, 18], ["FIPV", "PROTEIN", 22, 26], ["type-I interferons", "PROTEIN", 91, 109], ["proteins 3a and 3b", "PROTEIN", 129, 147], ["Proteins", "TEST", 0, 8], ["FIPV", "PROBLEM", 22, 26], ["antiviral response", "OBSERVATION", 61, 79]]], ["None of the accessory proteins of other alphacoronaviruses or of the gammacoronavirus Infectious Bronchitis Virus appear to have important in vivo functions, but again, further characterization is required to shed more light on their functions.", [["Infectious Bronchitis Virus", "DISEASE", 86, 113], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 40, 58], ["gammacoronavirus Infectious Bronchitis Virus", "ORGANISM", 69, 113], ["accessory proteins", "PROTEIN", 12, 30], ["Infectious Bronchitis Virus", "SPECIES", 86, 113], ["other alphacoronaviruses", "PROBLEM", 34, 58], ["the gammacoronavirus Infectious Bronchitis Virus", "PROBLEM", 65, 113], ["further characterization", "TEST", 169, 193]]]], "81c1b982a28194aa9787468b4e9c7158043f22b7": [["IntroductionFiloviruses are enveloped, single-stranded negative-sense RNA viruses.", [["IntroductionFiloviruses", "TREATMENT", 0, 23], ["sense RNA viruses", "PROBLEM", 64, 81], ["RNA viruses", "OBSERVATION", 70, 81]]], ["The family Filoviridae comprises three genera, Ebolavirus, Marburgvirus, and Cuevavirus 1 .", [["Cuevavirus 1", "CELL", 77, 89], ["The family Filoviridae", "TREATMENT", 0, 22], ["Ebolavirus", "PROBLEM", 47, 57], ["Marburgvirus", "TREATMENT", 59, 71], ["Cuevavirus", "TREATMENT", 77, 87]]], ["Both ebolaviruses and marburgviruses cause severe human disease, with mortality rates of 24%-90% 2,3 .", [["marburgviruses", "DISEASE", 22, 36], ["human disease", "DISEASE", 50, 63], ["human", "ORGANISM", 50, 55], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["severe human disease", "PROBLEM", 43, 63], ["mortality rates", "TEST", 70, 85], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["human disease", "OBSERVATION", 50, 63]]], ["Cuevavirus is found in bats, and whether it is infectious to humans remains unknown.", [["Cuevavirus", "CHEMICAL", 0, 10], ["bats", "ORGANISM", 23, 27], ["humans", "ORGANISM", 61, 67], ["humans", "SPECIES", 61, 67], ["humans", "SPECIES", 61, 67], ["infectious", "OBSERVATION", 47, 57]]], ["Ebola virus (EBOV, species Zaire ebolavirus) is the most frequently erupting filovirus.", [["Ebola virus", "DISEASE", 0, 11], ["filovirus", "DISEASE", 77, 86], ["Ebola virus", "ORGANISM", 0, 11], ["EBOV", "ORGANISM", 13, 17], ["species Zaire ebolavirus", "ORGANISM", 19, 43], ["filovirus", "ORGANISM", 77, 86], ["Ebola virus", "SPECIES", 0, 11], ["Zaire ebolavirus", "SPECIES", 27, 43], ["Ebola virus", "SPECIES", 0, 11], ["EBOV", "SPECIES", 13, 17], ["Zaire ebolavirus", "SPECIES", 27, 43], ["Ebola virus", "PROBLEM", 0, 11], ["EBOV", "PROBLEM", 13, 17], ["species Zaire ebolavirus", "PROBLEM", 19, 43], ["erupting filovirus", "PROBLEM", 68, 86]]], ["It caused the 2013-2015 EBOV epidemic in West Africa, resulting in more than 28,000 suspected cases and 11,310 confirmed deaths 4 .", [["EBOV", "DISEASE", 24, 28], ["deaths", "DISEASE", 121, 127], ["EBOV", "ORGANISM", 24, 28]]], ["The etiology of Ebola virus disease remains unclear, and new cases appeared in May 2017 5 .", [["Ebola virus disease", "DISEASE", 16, 35], ["Ebola virus", "ORGANISM", 16, 27], ["Ebola virus", "SPECIES", 16, 27], ["Ebola virus", "SPECIES", 16, 27], ["Ebola virus disease", "PROBLEM", 16, 35], ["Ebola virus disease", "OBSERVATION", 16, 35]]], ["Although some vaccines and drugs under study have shown effects [6] [7] [8] , there are still no licensed anti-filovirus agents available.", [["anti-filovirus agents", "SIMPLE_CHEMICAL", 106, 127], ["some vaccines", "TREATMENT", 9, 22], ["drugs", "TREATMENT", 27, 32], ["licensed anti-filovirus agents", "TREATMENT", 97, 127]]], ["Filoviruses are select agents and listed as World Health Organization Risk Group 4 Pathogens, for which live virus research requires BSL-4 facilities 9,10 , limiting the development of anti-filovirus vaccines and drugs.IntroductionHere, we aimed to establish a sequential in vitro and in vivo filovirus entry inhibitor evaluation system that could be performed in BSL-2 facilities.", [["Filoviruses", "TREATMENT", 0, 11], ["4 Pathogens", "PROBLEM", 81, 92], ["anti-filovirus vaccines", "TREATMENT", 185, 208], ["drugs", "TREATMENT", 213, 218], ["a sequential in vitro", "TREATMENT", 259, 280], ["evaluation system", "TEST", 319, 336]]], ["Because of its safety, pseudovirus based on an HIV-core (pNL4-3.Luc.R -E -) is a powerful model for highly pathogenic enveloped viral entry studies in vitro (filovirus, highly pathogenic H5N1 influenza virus, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, and etc.) [11] [12] [13] [14] [15] .", [["H5N1 influenza virus", "DISEASE", 187, 207], ["acute respiratory syndrome coronavirus", "DISEASE", 216, 254], ["Middle East respiratory syndrome coronavirus", "DISEASE", 256, 300], ["pseudovirus", "ORGANISM", 23, 34], ["R -E", "GENE_OR_GENE_PRODUCT", 68, 72], ["highly pathogenic H5N1 influenza virus", "ORGANISM", 169, 207], ["[11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 312, 336], ["pNL4", "DNA", 57, 61], ["3.Luc", "DNA", 62, 67], ["HIV", "SPECIES", 47, 50], ["H5N1 influenza virus", "SPECIES", 187, 207], ["HIV", "SPECIES", 47, 50], ["H5N1 influenza virus", "SPECIES", 187, 207], ["severe acute respiratory syndrome coronavirus", "SPECIES", 209, 254], ["Middle East respiratory syndrome coronavirus", "SPECIES", 256, 300], ["pseudovirus", "PROBLEM", 23, 34], ["an HIV", "TEST", 44, 50], ["pNL4", "TEST", 57, 61], ["highly pathogenic enveloped viral entry studies", "PROBLEM", 100, 147], ["vitro (filovirus", "PROBLEM", 151, 167], ["highly pathogenic H5N1 influenza virus", "PROBLEM", 169, 207], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 209, 254], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 256, 300], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["respiratory syndrome", "OBSERVATION", 222, 242], ["Middle", "ANATOMY_MODIFIER", 256, 262]]], ["The bioluminescence imaging assay is a visualizing tool that has been used for viral studies in animal models [16] [17] [18] .", [["The bioluminescence imaging assay", "TEST", 0, 33], ["viral studies", "TEST", 79, 92]]], ["Although some Ebola virus-like particles used for vaccine studies in vivo have been reported [19] [20] [21] , to the best of our knowledge, there is no study on the comparative in vivo pharmacodynamics of filovirus entry inhibitors on different genera of filoviruses.", [["Ebola virus-like particles", "ORGANISM", 14, 40], ["filovirus", "ORGANISM", 205, 214], ["filoviruses", "CANCER", 255, 266], ["Ebola virus", "SPECIES", 14, 25], ["Ebola virus", "SPECIES", 14, 25], ["some Ebola virus", "PROBLEM", 9, 25], ["vaccine studies", "TEST", 50, 65], ["study", "TEST", 152, 157], ["filovirus entry inhibitors", "TREATMENT", 205, 231], ["filoviruses", "PROBLEM", 255, 266], ["Ebola virus", "OBSERVATION", 14, 25]]], ["In this study, we constructed nine pseudo-filoviruses, covering all filovirus genera, for screening of filovirus entry inhibitors in vitro, and we successfully established three in vivo mouse infection models for filovirus entry inhibitor evaluation using the pseudotyped EBOV, Marburg virus (MARV), and Lloviu virus (LLOV) as representative viruses.", [["infection", "DISEASE", 192, 201], ["filovirus", "ORGANISM", 103, 112], ["mouse", "ORGANISM", 186, 191], ["filovirus", "ORGANISM", 213, 222], ["pseudotyped EBOV", "ORGANISM", 260, 276], ["Marburg virus", "ORGANISM", 278, 291], ["MARV", "ORGANISM", 293, 297], ["Lloviu virus", "ORGANISM", 304, 316], ["LLOV", "CANCER", 318, 322], ["mouse", "SPECIES", 186, 191], ["EBOV", "SPECIES", 272, 276], ["Marburg virus", "SPECIES", 278, 291], ["Lloviu virus", "SPECIES", 304, 316], ["mouse", "SPECIES", 186, 191], ["EBOV", "SPECIES", 272, 276], ["Marburg virus", "SPECIES", 278, 291], ["MARV", "SPECIES", 293, 297], ["Lloviu virus", "SPECIES", 304, 316], ["LLOV", "SPECIES", 318, 322], ["this study", "TEST", 3, 13], ["nine pseudo-filoviruses", "PROBLEM", 30, 53], ["all filovirus genera", "TREATMENT", 64, 84], ["filovirus entry inhibitors", "TREATMENT", 103, 129], ["vivo mouse infection models", "TREATMENT", 181, 208], ["filovirus entry inhibitor evaluation", "TEST", 213, 249], ["the pseudotyped EBOV", "TREATMENT", 256, 276], ["Marburg virus (MARV", "TREATMENT", 278, 297], ["Lloviu virus", "PROBLEM", 304, 316], ["filoviruses", "OBSERVATION", 42, 53]]], ["The robustness of this evaluation system was confirmed by the assessment of two known filovirus entry inhibitors, clomiphene and toremiphene 22 .", [["clomiphene", "CHEMICAL", 114, 124], ["toremiphene", "CHEMICAL", 129, 140], ["clomiphene", "CHEMICAL", 114, 124], ["toremiphene 22", "CHEMICAL", 129, 143], ["clomiphene", "SIMPLE_CHEMICAL", 114, 124], ["toremiphene 22", "SIMPLE_CHEMICAL", 129, 143], ["this evaluation system", "TEST", 18, 40], ["the assessment", "TEST", 58, 72], ["clomiphene", "TREATMENT", 114, 124], ["toremiphene", "TREATMENT", 129, 140]]], ["This sequential in vitro and in vivo filovirus entry inhibitor evaluation system in BSL-2 conditions will provide powerful technical support for the development of broad-spectrum anti-filovirus agents.Cells and plasmidsHuman embryonic kidney 293T cells were obtained from the American Type Culture Collection and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Invitrogen Luc.R \u00c0 E \u00c0 ), which contains a luciferase reporter gene, was obtained from the National Institutes of Health AIDS Research and Reference Reagent Program (Germantown, MD).Pseudo-filovirus preparationPseudo-filoviruses were produced as previously described 11, 13 .", [["Cells", "ANATOMY", 201, 206], ["plasmids", "ANATOMY", 211, 219], ["embryonic kidney 293T cells", "ANATOMY", 225, 252], ["fetal bovine serum", "ANATOMY", 391, 409], ["penicillin", "CHEMICAL", 417, 427], ["streptomycin", "CHEMICAL", 428, 440], ["AIDS", "DISEASE", 563, 567], ["penicillin", "CHEMICAL", 417, 427], ["streptomycin", "CHEMICAL", 428, 440], ["BSL-2", "CELL", 84, 89], ["Cells", "CELL", 201, 206], ["Human", "ORGANISM", 219, 224], ["embryonic kidney 293T cells", "CELL", 225, 252], ["bovine", "ORGANISM", 397, 403], ["serum", "ORGANISM_SUBSTANCE", 404, 409], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 417, 440], ["Invitrogen Luc", "ORGANISM", 442, 456], ["R \u00c0 E \u00c0", "GENE_OR_GENE_PRODUCT", 457, 464], ["luciferase", "GENE_OR_GENE_PRODUCT", 485, 495], ["plasmids", "DNA", 211, 219], ["Human embryonic kidney 293T cells", "CELL_LINE", 219, 252], ["luciferase reporter gene", "DNA", 485, 509], ["Human", "SPECIES", 219, 224], ["bovine", "SPECIES", 397, 403], ["Human", "SPECIES", 219, 224], ["bovine", "SPECIES", 397, 403], ["evaluation system", "TEST", 63, 80], ["powerful technical support", "TREATMENT", 114, 140], ["broad-spectrum anti-filovirus agents", "TREATMENT", 164, 200], ["plasmids", "TREATMENT", 211, 219], ["Human embryonic kidney 293T cells", "PROBLEM", 219, 252], ["Dulbecco's modified Eagle's medium (DMEM)", "TREATMENT", 327, 368], ["10% fetal bovine serum", "TREATMENT", 387, 409], ["penicillin", "TREATMENT", 417, 427], ["streptomycin", "TREATMENT", 428, 440], ["Pseudo", "PROBLEM", 624, 630], ["filoviruses", "PROBLEM", 659, 670], ["kidney", "ANATOMY", 235, 241], ["293T cells", "OBSERVATION", 242, 252], ["filovirus", "OBSERVATION", 631, 640], ["filoviruses", "OBSERVATION", 659, 670]]], ["Briefly, the plasmids encoding filovirus-GP and the HIV vector (pNL4.3.Luc-R \u00c0 E \u00c0 ) were co-transfected at a 1:1 ratio into 293T producer cells in a 100-mm culture dish using jetPRIME transfection reagent according to the manufacturer's protocol (Polyplustransfection).", [["plasmids", "ANATOMY", 13, 21], ["293T producer cells", "ANATOMY", 125, 144], ["filovirus-GP", "ORGANISM", 31, 43], ["HIV", "ORGANISM", 52, 55], ["Luc-R \u00c0 E \u00c0", "GENE_OR_GENE_PRODUCT", 71, 82], ["293T producer cells", "CELL", 125, 144], ["plasmids", "DNA", 13, 21], ["filovirus-GP and the HIV vector", "DNA", 31, 62], ["pNL4.3", "DNA", 64, 70], ["Luc", "PROTEIN", 71, 74], ["R \u00c0 E \u00c0", "DNA", 75, 82], ["293T producer cells", "CELL_LINE", 125, 144], ["HIV", "SPECIES", 52, 55], ["HIV", "SPECIES", 52, 55], ["the plasmids encoding filovirus", "PROBLEM", 9, 40], ["the HIV vector", "TREATMENT", 48, 62], ["Luc", "TEST", 71, 74], ["jetPRIME transfection reagent", "TREATMENT", 176, 205], ["the manufacturer's protocol", "TREATMENT", 219, 246]]], ["Forty-eight hours post-transfection, the HIV/filovirus-GP pseudovirions containing cell culture supernatants were collected and filtered through a 0.45 \u03bcm pore size filter (Millipore).", [["cell", "ANATOMY", 83, 87], ["supernatants", "ANATOMY", 96, 108], ["pore", "ANATOMY", 155, 159], ["HIV", "ORGANISM", 41, 44], ["filovirus", "ORGANISM", 45, 54], ["GP", "ORGANISM", 55, 57], ["pseudovirions", "ORGANISM", 58, 71], ["cell", "CELL", 83, 87], ["HIV", "SPECIES", 41, 44], ["HIV", "SPECIES", 41, 44], ["the HIV/filovirus", "PROBLEM", 37, 54], ["GP pseudovirions", "TREATMENT", 55, 71], ["cell culture supernatants", "TEST", 83, 108], ["a 0.45 \u03bcm pore size filter (Millipore", "TREATMENT", 145, 182], ["size", "OBSERVATION_MODIFIER", 160, 164], ["filter", "OBSERVATION", 165, 171]]], ["Then, for the in vivo study, the pseudoviruses were layered onto a cushion of 20% (w/v) sucrose and centrifuged at 50,000 rpm for 2 h in a Beckman SW55 rotor at 4\u00b0C. The pelleted pseudoviruses were re-suspended in ice-cold NTE buffer (10 mmol/L Tris, 100 mmol/L NaCl, 1 mmol/L EDTA, pH 7.5) and stored at -80\u00b0C until use.", [["pseudoviruses", "ANATOMY", 179, 192], ["sucrose", "CHEMICAL", 88, 95], ["NaCl", "CHEMICAL", 262, 266], ["sucrose", "CHEMICAL", 88, 95], ["Tris", "CHEMICAL", 245, 249], ["NaCl", "CHEMICAL", 262, 266], ["EDTA", "CHEMICAL", 277, 281], ["sucrose", "SIMPLE_CHEMICAL", 88, 95], ["EDTA", "SIMPLE_CHEMICAL", 277, 281], ["the in vivo study", "TEST", 10, 27], ["the pseudoviruses", "TREATMENT", 29, 46], ["a cushion", "TREATMENT", 65, 74], ["sucrose", "TREATMENT", 88, 95], ["The pelleted pseudoviruses", "TREATMENT", 166, 192], ["Tris", "TREATMENT", 245, 249], ["NaCl", "TREATMENT", 262, 266], ["pH", "TEST", 283, 285]]], ["HIV-1 p24 protein in the viral particles was detected by an HIV-1 p24 ELISA kit (Sino Biological Inc.) according to the manufacturer's protocol.Viral infection assay and compound activity assay in vitro293T cells were seeded into 24-well plates at a density of 5\u00d710 4 cells/well.", [["293T cells", "ANATOMY", 202, 212], ["5\u00d710 4 cells", "ANATOMY", 261, 273], ["Viral infection", "DISEASE", 144, 159], ["HIV-1", "ORGANISM", 0, 5], ["p24", "GENE_OR_GENE_PRODUCT", 6, 9], ["Viral", "ORGANISM", 144, 149], ["293T cells", "CELL", 202, 212], ["cells", "CELL", 268, 273], ["HIV-1 p24 protein", "PROTEIN", 0, 17], ["vitro293T cells", "CELL_LINE", 197, 212], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 60, 65], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 60, 65], ["HIV", "TEST", 0, 3], ["p24 protein", "TEST", 6, 17], ["the viral particles", "TEST", 21, 40], ["an HIV", "TEST", 57, 63], ["the manufacturer's protocol", "TREATMENT", 116, 143], ["Viral infection assay", "PROBLEM", 144, 165], ["compound activity assay in vitro293T cells", "PROBLEM", 170, 212], ["viral particles", "OBSERVATION", 25, 40], ["infection", "OBSERVATION", 150, 159], ["activity", "OBSERVATION_MODIFIER", 179, 187]]], ["After 24 h, the cells were infected with pseudovirions.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["the cells", "PROBLEM", 12, 21], ["pseudovirions", "TREATMENT", 41, 54], ["infected", "OBSERVATION", 27, 35]]], ["Forty-eight hours post-infection, the cells were lysed, and luciferase activity was measured using an FB15 luminometer (Berthold Detection Systems) and a luciferase assay kit (Promega).", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["luciferase", "GENE_OR_GENE_PRODUCT", 60, 70], ["luciferase", "GENE_OR_GENE_PRODUCT", 154, 164], ["luciferase", "PROTEIN", 60, 70], ["luciferase", "PROTEIN", 154, 164], ["the cells", "PROBLEM", 34, 43], ["luciferase activity", "TEST", 60, 79], ["an FB15 luminometer (Berthold Detection Systems", "TREATMENT", 99, 146], ["a luciferase assay", "TEST", 152, 170]]], ["To detect the in vitro anti-filovirus activities of clomiphene citrate (CAS #50-41-9, Sigma-Aldrich) and toremiphene citrate (CAS#89778-27-8, Meilun Inc.), the 293 T cells were incubated with various concentrations of the compounds (0.1-10 \u03bcmol/L, three-fold dilution) 15 min prior to infection and then incubated with the pseudoviruses for 48 h.", [["293 T cells", "ANATOMY", 160, 171], ["clomiphene citrate", "CHEMICAL", 52, 70], ["CAS #50-41-9, Sigma-Aldrich", "CHEMICAL", 72, 99], ["toremiphene citrate", "CHEMICAL", 105, 124], ["CAS#89778-27-8", "CHEMICAL", 126, 140], ["infection", "DISEASE", 285, 294], ["clomiphene citrate", "CHEMICAL", 52, 70], ["CAS #50-41-9", "CHEMICAL", 72, 84], ["toremiphene citrate", "CHEMICAL", 105, 124], ["CAS#89778-27-8", "CHEMICAL", 126, 140], ["clomiphene citrate", "SIMPLE_CHEMICAL", 52, 70], ["CAS #50-41-9", "SIMPLE_CHEMICAL", 72, 84], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 86, 99], ["toremiphene citrate", "SIMPLE_CHEMICAL", 105, 124], ["CAS#89778-27-8", "SIMPLE_CHEMICAL", 126, 140], ["293 T cells", "CELL", 160, 171], ["293 T cells", "CELL_LINE", 160, 171], ["clomiphene citrate", "TREATMENT", 52, 70], ["Sigma-Aldrich)", "TREATMENT", 86, 100], ["toremiphene citrate", "TREATMENT", 105, 124], ["the compounds", "TREATMENT", 218, 231], ["three-fold dilution", "TREATMENT", 248, 267], ["infection", "PROBLEM", 285, 294], ["the pseudoviruses", "TREATMENT", 319, 336], ["infection", "OBSERVATION", 285, 294]]], ["The luciferase activity of the DMSO solvent control was used as the 100% infectivity indicator, and the 50% inhibitory concentration (IC 50 ) of the compound was calculated.", [["DMSO", "CHEMICAL", 31, 35], ["DMSO", "CHEMICAL", 31, 35], ["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["DMSO", "SIMPLE_CHEMICAL", 31, 35], ["luciferase", "PROTEIN", 4, 14], ["the DMSO solvent control", "TREATMENT", 27, 51], ["the 50% inhibitory concentration (IC", "TREATMENT", 100, 136]]], ["Each experiment was repeated three times.Animal experimentsSix-to eight-week-old female BALB/c mice (Beijing HFK Bioscience Co., Ltd., Beijing, China) were housed and raised in specific pathogen-free animal facilities of the Institute of Materia Medica (PUMC & CAMS, Beijing, China).", [["BALB/c mice", "ORGANISM", 88, 99], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99]]], ["Animals were randomly grouped.", [["Animals", "ORGANISM", 0, 7]]], ["Animal experimentation was not blinded to the study investigators but was blinded to the personnel who performed the intraperitoneal injection of pseudovirus solution into mice.", [["intraperitoneal", "ANATOMY", 117, 132], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 132], ["pseudovirus", "ORGANISM", 146, 157], ["mice", "ORGANISM", 172, 176], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 172, 176], ["the study", "TEST", 42, 51], ["the intraperitoneal injection of pseudovirus solution", "TREATMENT", 113, 166]]], ["Each mouse was inoculated with 0.2 mL pseudovirus solution.", [["mouse", "ORGANISM", 5, 10], ["pseudovirus", "ORGANISM", 38, 49], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["0.2 mL pseudovirus solution", "TREATMENT", 31, 58]]], ["For the compound activity experiments, the mice were intraperitoneally (i.p.) administered with different concentrations of compounds, which were dissolved in 0.5% Tween-80/saline with an injection dose of 10 mL/kg, at the time points indicated.", [["intraperitoneally", "ANATOMY", 53, 70], ["Tween-80", "CHEMICAL", 164, 172], ["Tween-80", "CHEMICAL", 164, 172], ["mice", "ORGANISM", 43, 47], ["Tween-80", "SIMPLE_CHEMICAL", 164, 172], ["saline", "SIMPLE_CHEMICAL", 173, 179], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["different concentrations of compounds", "TREATMENT", 96, 133], ["saline", "TREATMENT", 173, 179], ["activity", "OBSERVATION_MODIFIER", 17, 25]]], ["Mice in the solvent control group were administered 0.5% Tween-80/saline simultaneously with the drug groups on day -1 and day 0 (-1 h) pre-challenge.", [["Tween-80", "CHEMICAL", 57, 65], ["Tween-80", "CHEMICAL", 57, 65], ["Mice", "ORGANISM", 0, 4], ["Tween-80", "SIMPLE_CHEMICAL", 57, 65], ["saline", "SIMPLE_CHEMICAL", 66, 72], ["Mice", "SPECIES", 0, 4], ["the solvent control group", "TREATMENT", 8, 33], ["saline", "TREATMENT", 66, 72]]], ["For viral challenge, the pseudovirus stocks were diluted in DMEM at the indicated infection dose and administered i.p. at an injection volume of 0.2 mL/mouse.", [["infection", "DISEASE", 82, 91], ["pseudovirus", "ORGANISM", 25, 36], ["mouse", "ORGANISM", 152, 157], ["mouse", "SPECIES", 152, 157], ["pseudovirus", "SPECIES", 25, 36], ["mouse", "SPECIES", 152, 157], ["viral challenge", "TREATMENT", 4, 19], ["the pseudovirus stocks", "TREATMENT", 21, 43], ["DMEM", "TREATMENT", 60, 64], ["infection dose", "TREATMENT", 82, 96], ["an injection volume", "TREATMENT", 122, 141], ["infection", "OBSERVATION", 82, 91]]], ["Animal bioluminescence was monitored at the time points indicated, and the body weights of mice were recorded daily until the bioluminescence imaging test was completed.Bioluminescence imaging assay in vivoBioluminescence imaging in mice was conducted using an IVIS Spectrum CT imaging system (PerkinElmer).", [["body", "ANATOMY", 75, 79], ["body", "ORGANISM_SUBDIVISION", 75, 79], ["mice", "ORGANISM", 91, 95], ["mice", "ORGANISM", 233, 237], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 233, 237], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 233, 237], ["Animal bioluminescence", "TEST", 0, 22], ["the body weights of mice", "TREATMENT", 71, 95], ["the bioluminescence imaging test", "TEST", 122, 154], ["Bioluminescence imaging assay", "TEST", 169, 198], ["vivoBioluminescence imaging", "TEST", 202, 229], ["an IVIS Spectrum CT imaging system", "TEST", 258, 292]]], ["Briefly, each mouse was injected i.p. with 0.2 mL of a 15 mg/mL solution of D-luciferin potassium salt substrate (XenoLight, PerkinElmer) and anesthetized with isoflurane.", [["D-luciferin potassium", "CHEMICAL", 76, 97], ["isoflurane", "CHEMICAL", 160, 170], ["D-luciferin potassium salt", "CHEMICAL", 76, 102], ["isoflurane", "CHEMICAL", 160, 170], ["mouse", "ORGANISM", 14, 19], ["D-luciferin potassium salt substrate", "SIMPLE_CHEMICAL", 76, 112], ["XenoLight", "SIMPLE_CHEMICAL", 114, 123], ["isoflurane", "SIMPLE_CHEMICAL", 160, 170], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["D-luciferin potassium salt substrate (XenoLight, PerkinElmer)", "TREATMENT", 76, 137], ["isoflurane", "TREATMENT", 160, 170]]], ["Two to five minutes after injection of the substrate, the bioluminescence signals were acquired for 60 s, and the mice were anesthetized during the imaging through nose-cone delivery of isoflurane.", [["isoflurane", "CHEMICAL", 186, 196], ["isoflurane", "CHEMICAL", 186, 196], ["mice", "ORGANISM", 114, 118], ["isoflurane", "SIMPLE_CHEMICAL", 186, 196], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 114, 118], ["the substrate", "TREATMENT", 39, 52], ["the bioluminescence signals", "TEST", 54, 81], ["the imaging", "TEST", 144, 155], ["isoflurane", "TREATMENT", 186, 196]]], ["To quantify the number of photons emitted from mice, the whole body of the individual mouse was manually defined as the region of interest (ROI), and the relative bioluminescence, which is shown as the total flux (photons/second), was calculated using Living Image 3.0 software (Caliper Life Sciences).Statistical analysisThe data are expressed as the means 7 SEM (standard error of the mean) or SD (standard deviation).", [["body", "ANATOMY", 63, 67], ["mice", "ORGANISM", 47, 51], ["body", "ORGANISM_SUBDIVISION", 63, 67], ["mouse", "ORGANISM", 86, 91], ["mice", "SPECIES", 47, 51], ["mouse", "SPECIES", 86, 91], ["mice", "SPECIES", 47, 51], ["mouse", "SPECIES", 86, 91], ["Statistical analysis", "TEST", 302, 322], ["SD (standard deviation)", "PROBLEM", 396, 419]]], ["A P value of o0.05 indicated significant, a P value of o0.01 indicated very significant, and a P value of o0.001 indicated extremely significant.Pseudo-filovirus can be used for entry inhibitor evaluation in vitroIn the filovirus family, EBOV, SUDV, BDBV, TAFV, and RESTV are the members which belong to five species of the Ebolavirus genus.", [["filovirus", "ORGANISM", 220, 229], ["EBOV", "ORGANISM", 238, 242], ["SUDV", "GENE_OR_GENE_PRODUCT", 244, 248], ["BDBV", "GENE_OR_GENE_PRODUCT", 250, 254], ["TAFV", "GENE_OR_GENE_PRODUCT", 256, 260], ["RESTV", "GENE_OR_GENE_PRODUCT", 266, 271], ["Ebolavirus genus", "ORGANISM", 324, 340], ["SUDV", "PROTEIN", 244, 248], ["BDBV", "PROTEIN", 250, 254], ["TAFV", "PROTEIN", 256, 260], ["RESTV", "PROTEIN", 266, 271], ["EBOV", "SPECIES", 238, 242], ["SUDV", "SPECIES", 244, 248], ["BDBV", "SPECIES", 250, 254], ["TAFV", "SPECIES", 256, 260], ["RESTV", "SPECIES", 266, 271], ["A P value", "TEST", 0, 9], ["a P value", "TEST", 42, 51], ["a P value", "TEST", 93, 102], ["Pseudo-filovirus", "PROBLEM", 145, 161], ["entry inhibitor evaluation", "TEST", 178, 204], ["filovirus", "OBSERVATION", 152, 161], ["Ebolavirus genus", "OBSERVATION", 324, 340]]], ["RESTV causes asymptomatic infections, and the other four ebolaviruses cause severe and fatal hemorrhagic fever in humans; the Marburgvirus genus contains one species, Marburg marburgvirus, which includes MARV and RAVV; the Cuevavirus genus contains one species, Lloviu cuevavirus, with only one member, LLOV.", [["RESTV", "CHEMICAL", 0, 5], ["infections", "DISEASE", 26, 36], ["ebolaviruses", "DISEASE", 57, 69], ["hemorrhagic fever", "DISEASE", 93, 110], ["humans", "ORGANISM", 114, 120], ["Marburgvirus genus", "ORGANISM", 126, 144], ["Marburg marburgvirus", "ORGANISM", 167, 187], ["MARV", "ORGANISM", 204, 208], ["Cuevavirus genus", "ORGANISM", 223, 239], ["Lloviu cuevavirus", "ORGANISM", 262, 279], ["LLOV", "CANCER", 303, 307], ["LLOV", "PROTEIN", 303, 307], ["humans", "SPECIES", 114, 120], ["Lloviu cuevavirus", "SPECIES", 262, 279], ["humans", "SPECIES", 114, 120], ["Marburg marburgvirus", "SPECIES", 167, 187], ["MARV", "SPECIES", 204, 208], ["RAVV", "SPECIES", 213, 217], ["Lloviu cuevavirus", "SPECIES", 262, 279], ["asymptomatic infections", "PROBLEM", 13, 36], ["severe and fatal hemorrhagic fever in humans", "PROBLEM", 76, 120], ["the Marburgvirus genus", "PROBLEM", 122, 144], ["one species", "PROBLEM", 154, 165], ["Marburg marburgvirus", "PROBLEM", 167, 187], ["MARV", "PROBLEM", 204, 208], ["asymptomatic", "OBSERVATION_MODIFIER", 13, 25], ["infections", "OBSERVATION", 26, 36], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["fatal", "OBSERVATION_MODIFIER", 87, 92], ["hemorrhagic", "OBSERVATION_MODIFIER", 93, 104], ["fever", "OBSERVATION", 105, 110], ["one", "OBSERVATION_MODIFIER", 154, 157], ["species", "OBSERVATION_MODIFIER", 158, 165], ["one species", "OBSERVATION", 249, 260]]], ["For all filoviruses, the glycoprotein (GP) is the only viral component responsible for entry, and the phylogenetic relationship between filovirus-GPs is shown in Fig. 1A .", [["glycoprotein", "GENE_OR_GENE_PRODUCT", 25, 37], ["GP", "GENE_OR_GENE_PRODUCT", 39, 41], ["filovirus", "ORGANISM", 136, 145], ["glycoprotein", "PROTEIN", 25, 37], ["GP", "PROTEIN", 39, 41], ["all filoviruses", "PROBLEM", 4, 19], ["filoviruses", "OBSERVATION", 8, 19]]], ["In this study, we prepared nine HIV-based pseudofiloviruses covering all species of filovirus.", [["filovirus", "DISEASE", 84, 93], ["filovirus", "ORGANISM", 84, 93], ["HIV", "SPECIES", 32, 35], ["this study", "TEST", 3, 13], ["HIV-based pseudofiloviruses", "TREATMENT", 32, 59], ["filovirus", "PROBLEM", 84, 93]]], ["The pseudoviruses were produced by co-transfection of the HIV-core (pNL4-3.Luc.", [["HIV", "ORGANISM", 58, 61], ["HIV-core", "DNA", 58, 66], ["pNL4", "DNA", 68, 72], ["3.Luc", "DNA", 73, 78], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 58, 61], ["The pseudoviruses", "PROBLEM", 0, 17], ["pNL4", "TEST", 68, 72]]], ["R \u2212 E \u2212 ), which contained a firefly luciferase gene, with the filovirus-GP expressing plasmid into 293 T cells.", [["plasmid", "ANATOMY", 87, 94], ["293 T cells", "ANATOMY", 100, 111], ["R \u2212 E", "GENE_OR_GENE_PRODUCT", 0, 5], ["luciferase", "GENE_OR_GENE_PRODUCT", 37, 47], ["293 T cells", "CELL", 100, 111], ["firefly luciferase gene", "DNA", 29, 52], ["filovirus-GP expressing plasmid", "DNA", 63, 94], ["293 T cells", "CELL_LINE", 100, 111], ["a firefly luciferase gene", "PROBLEM", 27, 52], ["the filovirus", "TEST", 59, 72]]], ["The packaged HIV/filovirus-GP virions had viral envelopes encased with filovirus-GP, which could mediate one-round viral entry into host cells, and the luciferase in infected cells could be used as a reporter for infectivity evaluation.", [["cells", "ANATOMY", 137, 142], ["cells", "ANATOMY", 175, 180], ["HIV/filovirus", "ORGANISM", 13, 26], ["-GP virions", "ORGANISM", 26, 37], ["GP", "GENE_OR_GENE_PRODUCT", 81, 83], ["host cells", "CELL", 132, 142], ["luciferase", "GENE_OR_GENE_PRODUCT", 152, 162], ["cells", "CELL", 175, 180], ["host cells", "CELL_TYPE", 132, 142], ["luciferase", "PROTEIN", 152, 162], ["infected cells", "CELL_TYPE", 166, 180], ["HIV", "SPECIES", 13, 16], ["HIV", "SPECIES", 13, 16], ["The packaged HIV/filovirus", "PROBLEM", 0, 26], ["GP virions", "TREATMENT", 27, 37], ["viral envelopes", "PROBLEM", 42, 57], ["filovirus", "PROBLEM", 71, 80], ["the luciferase in infected cells", "PROBLEM", 148, 180], ["infectivity evaluation", "TEST", 213, 235], ["HIV", "OBSERVATION", 13, 16], ["host cells", "OBSERVATION", 132, 142], ["infected cells", "OBSERVATION", 166, 180]]], ["In this system, besides the HIV/filovirus-GP virions, the HIV-alone virions, which had no envelope glycoprotein, and the HIV/VSV-G virions, with the envelope protein of vesicular stomatitis virus glycoprotein (VSV-G), were also prepared as the model controls.", [["virions", "ANATOMY", 68, 75], ["HIV/filovirus", "ORGANISM", 28, 41], ["-GP virions", "ORGANISM", 41, 52], ["HIV", "ORGANISM", 58, 61], ["HIV/VSV-G virions", "ORGANISM", 121, 138], ["vesicular stomatitis virus glycoprotein", "ORGANISM", 169, 208], ["VSV-G", "ORGANISM", 210, 215], ["envelope glycoprotein", "PROTEIN", 90, 111], ["envelope protein", "PROTEIN", 149, 165], ["vesicular stomatitis virus glycoprotein", "PROTEIN", 169, 208], ["VSV", "PROTEIN", 210, 213], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 121, 124], ["vesicular stomatitis virus", "SPECIES", 169, 195], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 121, 124], ["VSV", "SPECIES", 125, 128], ["stomatitis virus", "SPECIES", 179, 195], ["the HIV/filovirus", "PROBLEM", 24, 41], ["the HIV-alone virions", "PROBLEM", 54, 75], ["envelope glycoprotein", "PROBLEM", 90, 111], ["the HIV/VSV", "TEST", 117, 128], ["G virions", "PROBLEM", 129, 138], ["the envelope protein", "TEST", 145, 165], ["vesicular stomatitis virus glycoprotein", "PROBLEM", 169, 208], ["vesicular stomatitis", "OBSERVATION", 169, 189]]], ["The pseudo-filoviruses infecting 293T cells yielded 6 to 8 log signals, and the HIV-alone virions and HIV/VSV-G virions yielded 2 and 8 log signals, respectively (Fig. 1B) .", [["293T cells", "ANATOMY", 33, 43], ["293T cells", "CELL", 33, 43], ["HIV", "ORGANISM", 80, 83], ["HIV/VSV-G virions", "ORGANISM", 102, 119], ["293T cells", "CELL_LINE", 33, 43], ["HIV", "SPECIES", 80, 83], ["HIV", "SPECIES", 102, 105], ["HIV", "SPECIES", 80, 83], ["HIV", "SPECIES", 102, 105], ["VSV", "SPECIES", 106, 109], ["The pseudo", "TEST", 0, 10], ["log signals", "TEST", 59, 70], ["the HIV", "TEST", 76, 83], ["HIV/VSV", "TEST", 102, 109], ["G virions", "TEST", 110, 119], ["filoviruses", "OBSERVATION", 11, 22], ["293T cells", "OBSERVATION", 33, 43]]], ["Clomiphene and toremiphene, two known filovirus entry inhibitors, were evaluated on these pseudoviruses for system validation.", [["Clomiphene", "CHEMICAL", 0, 10], ["toremiphene", "CHEMICAL", 15, 26], ["Clomiphene", "CHEMICAL", 0, 10], ["toremiphene", "CHEMICAL", 15, 26], ["Clomiphene", "SIMPLE_CHEMICAL", 0, 10], ["toremiphene", "SIMPLE_CHEMICAL", 15, 26], ["Clomiphene", "TREATMENT", 0, 10], ["toremiphene", "TREATMENT", 15, 26], ["filovirus entry inhibitors", "TREATMENT", 38, 64], ["system validation", "TEST", 108, 125]]], ["As shown in Table 1 , the IC 50 of clomiphene on filoviruses ranged from 0.28 to 2.26 \u03bcmol/L, and the IC 50 of toremiphene on filoviruses ranged from 0.13 to 3.81 \u03bcmol/L; the specificity of the compounds was confirmed by the HIV/VSV-G model (Fig. 1C and D) .", [["clomiphene", "CHEMICAL", 35, 45], ["toremiphene", "CHEMICAL", 111, 122], ["clomiphene", "CHEMICAL", 35, 45], ["toremiphene", "CHEMICAL", 111, 122], ["clomiphene", "SIMPLE_CHEMICAL", 35, 45], ["toremiphene", "SIMPLE_CHEMICAL", 111, 122], ["HIV/VSV", "SPECIES", 225, 232], ["the IC", "TREATMENT", 22, 28], ["clomiphene", "TREATMENT", 35, 45], ["filoviruses", "TEST", 49, 60], ["toremiphene", "TREATMENT", 111, 122], ["filoviruses", "TEST", 126, 137], ["the HIV/VSV", "TEST", 221, 232]]], ["These results were consistent with the previously reported effects of the compounds on live ebolavirus and marburgvirus 22 .Pseudo-filovirus infection in mice can be assessed by bioluminescence imagingFor the in vivo study, the virus collections were purified and condensed by sucrose cushion centrifugation to remove possible immunogenic interference mixtures, such as the serum-containing cell culture media and other cellular metabolites.", [["serum", "ANATOMY", 374, 379], ["cell", "ANATOMY", 391, 395], ["cellular", "ANATOMY", 420, 428], ["filovirus infection", "DISEASE", 131, 150], ["sucrose", "CHEMICAL", 277, 284], ["sucrose", "CHEMICAL", 277, 284], ["marburgvirus 22", "ORGANISM", 107, 122], ["Pseudo-filovirus", "ORGANISM", 124, 140], ["mice", "ORGANISM", 154, 158], ["serum", "ORGANISM_SUBSTANCE", 374, 379], ["cell", "CELL", 391, 395], ["cellular", "CELL", 420, 428], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 154, 158], ["the compounds", "PROBLEM", 70, 83], ["marburgvirus", "TEST", 107, 119], ["Pseudo-filovirus infection", "PROBLEM", 124, 150], ["bioluminescence imaging", "TEST", 178, 201], ["the in vivo study", "TEST", 205, 222], ["the virus collections", "PROBLEM", 224, 245], ["sucrose cushion centrifugation", "TREATMENT", 277, 307], ["immunogenic interference mixtures", "PROBLEM", 327, 360], ["the serum", "TEST", 370, 379], ["cell culture media", "TEST", 391, 409], ["consistent with", "UNCERTAINTY", 19, 34], ["filovirus infection", "OBSERVATION", 131, 150], ["cellular metabolites", "OBSERVATION", 420, 440]]], ["Then, the amounts of HIV-1 p24 protein of pelleted pseudovirions were quantified by ELISA and used as the measure of viral content.Pseudo-filovirus infection in mice can be assessed by bioluminescence imagingWe first investigated the infection of HIV/EBOV-GP (Mayinga strain, 40 ng p24/mouse) in living mice at the 4th day postinfection (d.p.i.).", [["pseudovirions", "ANATOMY", 51, 64], ["filovirus infection", "DISEASE", 138, 157], ["infection", "DISEASE", 234, 243], ["HIV-1", "ORGANISM", 21, 26], ["p24", "GENE_OR_GENE_PRODUCT", 27, 30], ["Pseudo-filovirus", "ORGANISM", 131, 147], ["mice", "ORGANISM", 161, 165], ["HIV", "ORGANISM", 247, 250], ["EBOV-GP", "ORGANISM", 251, 258], ["Mayinga strain", "ORGANISM", 260, 274], ["p24", "ORGANISM", 282, 285], ["mouse", "ORGANISM", 286, 291], ["mice", "ORGANISM", 303, 307], ["HIV-1 p24 protein", "PROTEIN", 21, 38], ["pelleted pseudovirions", "PROTEIN", 42, 64], ["p24", "PROTEIN", 282, 285], ["HIV-1", "SPECIES", 21, 26], ["mice", "SPECIES", 161, 165], ["HIV", "SPECIES", 247, 250], ["mouse", "SPECIES", 286, 291], ["mice", "SPECIES", 303, 307], ["HIV-1", "SPECIES", 21, 26], ["mice", "SPECIES", 161, 165], ["HIV/EBOV", "SPECIES", 247, 255], ["mouse", "SPECIES", 286, 291], ["mice", "SPECIES", 303, 307], ["HIV", "TEST", 21, 24], ["pelleted pseudovirions", "TREATMENT", 42, 64], ["ELISA", "TEST", 84, 89], ["viral content", "PROBLEM", 117, 130], ["Pseudo-filovirus infection", "PROBLEM", 131, 157], ["bioluminescence imaging", "TEST", 185, 208], ["the infection", "PROBLEM", 230, 243], ["HIV", "PROBLEM", 247, 250], ["EBOV", "PROBLEM", 251, 255], ["Mayinga strain", "TREATMENT", 260, 274], ["viral content", "OBSERVATION", 117, 130], ["filovirus infection", "OBSERVATION", 138, 157], ["infection", "OBSERVATION", 234, 243]]], ["The inoculation route for mice was intraperitoneal injection, the same route as the live ebolavirus mouse-adapted model in BSL-4 facilities.", [["intraperitoneal", "ANATOMY", 35, 50], ["mice", "ORGANISM", 26, 30], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 50], ["mouse", "ORGANISM", 100, 105], ["mice", "SPECIES", 26, 30], ["mouse", "SPECIES", 100, 105], ["mice", "SPECIES", 26, 30], ["mouse", "SPECIES", 100, 105], ["The inoculation route", "TREATMENT", 0, 21], ["intraperitoneal injection", "TREATMENT", 35, 60]]], ["As shown in Fig. 2A , the bioluminescence in mice infected with HIV/EBOV-GP could be observed; as with uninfected control mice, the HIV-alone virion-infected mice showed no bioluminescence.", [["2A", "GENE_OR_GENE_PRODUCT", 17, 19], ["mice", "ORGANISM", 45, 49], ["HIV/EBOV-GP", "ORGANISM", 64, 75], ["mice", "ORGANISM", 122, 126], ["HIV-alone virion", "ORGANISM", 132, 148], ["mice", "ORGANISM", 158, 162], ["mice", "SPECIES", 45, 49], ["HIV", "SPECIES", 64, 67], ["mice", "SPECIES", 122, 126], ["HIV-", "SPECIES", 132, 136], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 45, 49], ["HIV", "SPECIES", 64, 67], ["EBOV", "SPECIES", 68, 72], ["mice", "SPECIES", 122, 126], ["HIV", "SPECIES", 132, 135], ["mice", "SPECIES", 158, 162], ["the bioluminescence", "TEST", 22, 41], ["HIV", "PROBLEM", 64, 67], ["EBOV", "PROBLEM", 68, 72], ["the HIV", "TEST", 128, 135], ["bioluminescence", "PROBLEM", 173, 188], ["Fig", "OBSERVATION", 12, 15], ["no", "UNCERTAINTY", 170, 172]]], ["The photon flux collected from HIV/ EBOV-GP-infected mice showed significant differences (Po0.001) from that collected from the uninfected control mice (Fig. 2B) .", [["HIV/ EBOV-GP", "ORGANISM", 31, 43], ["mice", "ORGANISM", 53, 57], ["mice", "ORGANISM", 147, 151], ["HIV", "SPECIES", 31, 34], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 147, 151], ["HIV", "SPECIES", 31, 34], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 147, 151], ["The photon flux", "TEST", 0, 15], ["HIV/ EBOV", "TEST", 31, 40], ["significant differences", "PROBLEM", 65, 88], ["significant", "OBSERVATION_MODIFIER", 65, 76]]], ["The strongest bioluminescence region in mice was on the upper chest, and the 3-dimensional (3D) bioluminescence imaging indicated that the bioluminescence in HIV/EBOV-GPinfected mice mainly accumulated in the thymus (Fig. 2C) .Pseudo-filovirus infection in mice can be assessed by bioluminescence imagingThe bioluminescence in HIV/MARV-GP-and HIV/LLOV-GP-infected mice was further monitored.", [["upper chest", "ANATOMY", 56, 67], ["thymus", "ANATOMY", 209, 215], ["filovirus infection", "DISEASE", 234, 253], ["mice", "ORGANISM", 40, 44], ["upper chest", "ORGANISM_SUBDIVISION", 56, 67], ["HIV/EBOV", "ORGANISM", 158, 166], ["-GPinfected mice", "ORGANISM", 166, 182], ["thymus", "ORGAN", 209, 215], ["Pseudo-filovirus", "ORGANISM", 227, 243], ["mice", "ORGANISM", 257, 261], ["HIV/MARV", "ORGANISM", 327, 335], ["-GP", "ORGANISM", 335, 338], ["HIV/", "ORGANISM", 343, 347], ["LLOV-GP", "ORGANISM", 347, 354], ["mice", "ORGANISM", 364, 368], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 257, 261], ["HIV", "SPECIES", 327, 330], ["HIV", "SPECIES", 343, 346], ["mice", "SPECIES", 364, 368], ["mice", "SPECIES", 40, 44], ["HIV/EBOV", "SPECIES", 158, 166], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 257, 261], ["HIV", "SPECIES", 327, 330], ["MARV", "SPECIES", 331, 335], ["HIV", "SPECIES", 343, 346], ["mice", "SPECIES", 364, 368], ["bioluminescence imaging", "TEST", 96, 119], ["the bioluminescence", "TEST", 135, 154], ["HIV/EBOV", "TEST", 158, 166], ["GPinfected mice", "PROBLEM", 167, 182], ["Pseudo-filovirus infection", "PROBLEM", 227, 253], ["bioluminescence imaging", "TEST", 281, 304], ["The bioluminescence", "TEST", 304, 323], ["HIV/MARV", "TEST", 327, 335], ["GP", "TEST", 336, 338], ["HIV", "PROBLEM", 343, 346], ["LLOV", "TEST", 347, 351], ["infected mice", "PROBLEM", 355, 368], ["upper", "ANATOMY_MODIFIER", 56, 61], ["chest", "ANATOMY", 62, 67], ["EBOV", "OBSERVATION", 162, 166], ["thymus", "ANATOMY", 209, 215], ["filovirus infection", "OBSERVATION", 234, 253], ["infected", "OBSERVATION", 355, 363]]], ["As shown in Fig. 3 , these two pseudo-filoviruses could also effectively infect mice, and the bioluminescence localization in mice was identical with the HIV/EBOV-GP group.", [["mice", "ORGANISM", 80, 84], ["mice", "ORGANISM", 126, 130], ["HIV/EBOV-GP", "ORGANISM", 154, 165], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 126, 130], ["HIV/EBOV", "SPECIES", 154, 162], ["these two pseudo-filoviruses", "PROBLEM", 21, 49], ["the bioluminescence localization", "TEST", 90, 122], ["Fig", "OBSERVATION", 12, 15], ["filoviruses", "OBSERVATION", 38, 49], ["EBOV", "OBSERVATION", 158, 162]]], ["All pseudo-filovirus-infected mice showed a chronological bioluminescence increase in intensity; after reaching the peak value, the intensity gradually descended.", [["filovirus", "ORGANISM", 11, 20], ["mice", "ORGANISM", 30, 34], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["All pseudo-filovirus", "TEST", 0, 20], ["a chronological bioluminescence increase in intensity", "PROBLEM", 42, 95], ["the peak value", "TEST", 112, 126], ["filovirus", "OBSERVATION", 11, 20], ["bioluminescence", "OBSERVATION_MODIFIER", 58, 73], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["intensity", "OBSERVATION_MODIFIER", 86, 95]]], ["The time point at which the bioluminescence in pseudo-filovirusinfected mice reached the peak differed slightly: for HIV/EBOV-GP and HIV/MARV-GP groups, the peak appeared around 114 h post-infection (h.p.i.), i.e., the 5th d.p.i., while for HIV/LLOV-GP group, the peak appeared around 90 h.p.i., i.e., the 4th d.p.i.", [["mice", "ORGANISM", 72, 76], ["HIV/EBOV-GP", "ORGANISM", 117, 128], ["HIV/MARV-GP", "ORGANISM", 133, 144], ["HIV/LLOV-GP", "ORGANISM", 241, 252], ["mice", "SPECIES", 72, 76], ["HIV", "SPECIES", 117, 120], ["HIV", "SPECIES", 133, 136], ["HIV", "SPECIES", 241, 244], ["mice", "SPECIES", 72, 76], ["HIV", "SPECIES", 117, 120], ["EBOV", "SPECIES", 121, 125], ["HIV", "SPECIES", 133, 136], ["MARV", "SPECIES", 137, 141], ["HIV", "SPECIES", 241, 244], ["the bioluminescence", "TEST", 24, 43], ["pseudo", "TEST", 47, 53], ["HIV", "PROBLEM", 117, 120], ["EBOV", "PROBLEM", 121, 125], ["HIV", "TEST", 133, 136], ["HIV", "PROBLEM", 241, 244]]], ["In addition, the HIV/EBOV-GP-infected mice showed a higher peak intensity of bioluminescence than the HIV/MARV-GP and HIV/LLOV-GP groups at a 160 ng p24/mouse dose.", [["HIV/", "ORGANISM", 17, 21], ["EBOV-GP", "ORGANISM", 21, 28], ["mice", "ORGANISM", 38, 42], ["HIV", "ORGANISM", 102, 105], ["MARV-GP", "ORGANISM", 106, 113], ["HIV", "ORGANISM", 118, 121], ["LLOV-GP", "ORGANISM", 122, 129], ["mouse", "ORGANISM", 153, 158], ["p24", "PROTEIN", 149, 152], ["HIV", "SPECIES", 17, 20], ["mice", "SPECIES", 38, 42], ["HIV", "SPECIES", 102, 105], ["HIV", "SPECIES", 118, 121], ["mouse", "SPECIES", 153, 158], ["HIV", "SPECIES", 17, 20], ["EBOV", "SPECIES", 21, 25], ["mice", "SPECIES", 38, 42], ["HIV", "SPECIES", 102, 105], ["MARV", "SPECIES", 106, 110], ["HIV", "SPECIES", 118, 121], ["mouse", "SPECIES", 153, 158], ["the HIV/EBOV", "TEST", 13, 25], ["a higher peak intensity of bioluminescence", "PROBLEM", 50, 92], ["the HIV", "TEST", 98, 105], ["HIV/LLOV", "PROBLEM", 118, 126], ["higher", "OBSERVATION_MODIFIER", 52, 58], ["peak intensity", "OBSERVATION_MODIFIER", 59, 73]]], ["In order to obtain identical in vivo viral infecting levels among pseudofiloviruses, the viral dose of 40 ng p24/mouse, at which the HIV/ ng p24/mouse), the mice were tested with the IVIS Spectrum CT imaging system.", [["p24", "GENE_OR_GENE_PRODUCT", 109, 112], ["mouse", "ORGANISM", 113, 118], ["HIV", "ORGANISM", 133, 136], ["p24", "GENE_OR_GENE_PRODUCT", 141, 144], ["mouse", "ORGANISM", 145, 150], ["mice", "ORGANISM", 157, 161], ["p24", "PROTEIN", 109, 112], ["p24", "PROTEIN", 141, 144], ["mouse", "SPECIES", 113, 118], ["mouse", "SPECIES", 145, 150], ["mice", "SPECIES", 157, 161], ["mouse", "SPECIES", 113, 118], ["mouse", "SPECIES", 145, 150], ["mice", "SPECIES", 157, 161], ["the viral dose", "TREATMENT", 85, 99], ["the HIV/ ng p24/mouse", "TREATMENT", 129, 150], ["the IVIS Spectrum CT imaging system", "TEST", 179, 214]]], ["All groups, including the uninfected control mice, were i.p. injected with the D-luciferin substrate reagent (p/s/cm 2 / sr, photon flux per second per square centimeter per steradian).", [["D-luciferin", "CHEMICAL", 79, 90], ["D-luciferin", "CHEMICAL", 79, 90], ["mice", "ORGANISM", 45, 49], ["D-luciferin", "SIMPLE_CHEMICAL", 79, 90], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["the D-luciferin substrate reagent", "TREATMENT", 75, 108], ["photon flux", "TREATMENT", 125, 136]]], ["(B) The bioluminescence intensity of the whole body region of interest (ROI) in mice was represented as total photon flux per second.", [["body", "ANATOMY", 47, 51], ["body", "ORGANISM_SUBDIVISION", 47, 51], ["mice", "ORGANISM", 80, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84]]], ["The data are represented as the means 7 SEM (n \u00bc4 per group).", [["The data", "TEST", 0, 8]]], ["The asterisks represent significant differences: ns, no significance; *** Po0.001.", [["significant", "OBSERVATION_MODIFIER", 24, 35]]], ["(C) Representative 3D reconstruction of bioluminescence in HIV/EBOV-GP-infected mice was generated by Diffuse Luminescence Imaging Tomography (DLIT) analysis using the IVIS Spectrum CT imaging system.", [["HIV/", "ORGANISM", 59, 63], ["EBOV-GP", "ORGANISM", 63, 70], ["mice", "ORGANISM", 80, 84], ["HIV", "SPECIES", 59, 62], ["mice", "SPECIES", 80, 84], ["HIV", "SPECIES", 59, 62], ["EBOV", "SPECIES", 63, 67], ["mice", "SPECIES", 80, 84], ["bioluminescence", "TEST", 40, 55], ["HIV/EBOV", "TEST", 59, 67], ["Diffuse Luminescence Imaging Tomography", "TEST", 102, 141], ["the IVIS Spectrum CT imaging system", "TEST", 164, 199]]], ["The 3D imaging was performed at 4 days post-infection.", [["The 3D imaging", "TEST", 0, 14]]], ["The x-y, y-z, and x-z axle planes displayed the coronal, sagittal, and transaxial planes, respectively.DiscussionEbolaviruses and marburgviruses were discovered in 1976 and 1967, respectively, but neither anti-filovirus drugs nor vaccines have been approved until now.", [["coronal", "ANATOMY", 48, 55], ["coronal", "MULTI-TISSUE_STRUCTURE", 48, 55], ["Ebolaviruses", "GENE_OR_GENE_PRODUCT", 113, 125], ["marburgviruses", "GENE_OR_GENE_PRODUCT", 130, 144], ["The x-y, y-z, and x-z axle planes", "TEST", 0, 33], ["marburgviruses", "TEST", 130, 144], ["anti-filovirus drugs", "TREATMENT", 205, 225], ["vaccines", "TREATMENT", 230, 238]]], ["On the other hand, several agents have been reported to be effective against filovirus infection in vitro 7,23 , but few of them have been tested in vivo, which is partially due to the BSL-4 facilities restriction.", [["filovirus infection", "DISEASE", 77, 96], ["filovirus", "ORGANISM", 77, 86], ["filovirus infection", "PROBLEM", 77, 96]]], ["The infection of host cells with HIV-based pseudovirus is a single round infection mediated by GP-receptor recognition 23 , and expression of the luciferase reporter gene in infected cells or organs can be conveniently used to quantify infection.", [["cells", "ANATOMY", 22, 27], ["cells", "ANATOMY", 183, 188], ["organs", "ANATOMY", 192, 198], ["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 73, 82], ["infection", "DISEASE", 236, 245], ["host cells", "CELL", 17, 27], ["HIV-based pseudovirus", "ORGANISM", 33, 54], ["GP-receptor recognition 23", "GENE_OR_GENE_PRODUCT", 95, 121], ["luciferase", "GENE_OR_GENE_PRODUCT", 146, 156], ["cells", "CELL", 183, 188], ["organs", "ORGAN", 192, 198], ["host cells", "CELL_TYPE", 17, 27], ["GP", "PROTEIN", 95, 97], ["luciferase reporter gene", "DNA", 146, 170], ["infected cells", "CELL_TYPE", 174, 188], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 33, 36], ["The infection of host cells", "PROBLEM", 0, 27], ["HIV-based pseudovirus", "PROBLEM", 33, 54], ["a single round infection", "PROBLEM", 58, 82], ["the luciferase reporter gene in infected cells", "PROBLEM", 142, 188], ["infection", "PROBLEM", 236, 245], ["infection", "OBSERVATION", 4, 13], ["host cells", "OBSERVATION", 17, 27], ["round", "OBSERVATION_MODIFIER", 67, 72], ["infection", "OBSERVATION", 73, 82], ["infected cells", "OBSERVATION", 174, 188]]], ["These features make pseudoviruses a highly secure and efficient model for drug evaluation.", [["drug evaluation", "TEST", 74, 89]]], ["Among animal models, the mouse-adapted model is the most widely used for the primary identification of antiviral drugs because of its easy operation and low cost.", [["mouse", "ORGANISM", 25, 30], ["mouse", "SPECIES", 25, 30], ["mouse", "SPECIES", 25, 30], ["antiviral drugs", "TREATMENT", 103, 118], ["its easy operation", "TREATMENT", 130, 148]]], ["Therefore, in this study, we established pseudo-filovirus-based in vivo mouse models that can be performed in BSL-2 facilities for compound activity evaluation.", [["mouse", "ORGANISM", 72, 77], ["mouse", "SPECIES", 72, 77], ["mouse", "SPECIES", 72, 77], ["this study", "TEST", 14, 24], ["pseudo-filovirus", "PROBLEM", 41, 57], ["compound activity evaluation", "TEST", 131, 159]]], ["For the live virus models, one difficulty is the nonlethal characteristic of wild-type ebolaviruses and marburgviruses in immunocompetent adult mice.", [["marburgviruses", "DISEASE", 104, 118], ["ebolaviruses", "GENE_OR_GENE_PRODUCT", 87, 99], ["marburgviruses", "GENE_OR_GENE_PRODUCT", 104, 118], ["mice", "ORGANISM", 144, 148], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 144, 148], ["the live virus models", "PROBLEM", 4, 25]]], ["Multiple rounds of virus passages had to be conducted and assayed in suckling and immunodeficient mice to obtain the lethal mutant mouse-adapted virus strains for adult mice, and this made the constructions of live ebolavirus and marburgvirus mouse models time-consuming 24, 25 .", [["suckling", "ORGANISM_SUBDIVISION", 69, 77], ["immunodeficient mice", "ORGANISM", 82, 102], ["mouse", "ORGANISM", 131, 136], ["-adapted virus strains", "ORGANISM", 136, 158], ["mice", "ORGANISM", 169, 173], ["mouse", "ORGANISM", 243, 248], ["mice", "SPECIES", 98, 102], ["mouse", "SPECIES", 131, 136], ["mice", "SPECIES", 169, 173], ["mouse", "SPECIES", 243, 248], ["mice", "SPECIES", 98, 102], ["mouse", "SPECIES", 131, 136], ["mice", "SPECIES", 169, 173], ["mouse", "SPECIES", 243, 248], ["virus passages", "TREATMENT", 19, 33], ["the lethal mutant mouse", "PROBLEM", 113, 136], ["virus passages", "OBSERVATION", 19, 33]]], ["Moreover, it is also difficult to achieve in vivo live virus infection models for the virus strains of low pathogenicity and the strains that could be identified only by sequencing.", [["infection", "DISEASE", 61, 70], ["vivo live virus infection models", "PROBLEM", 45, 77], ["the virus strains", "PROBLEM", 82, 99], ["low pathogenicity", "PROBLEM", 103, 120], ["the strains", "PROBLEM", 125, 136], ["low pathogenicity", "OBSERVATION_MODIFIER", 103, 120]]], ["Furthermore, the mutated sites of virus proteins of mouse-adapted virus models might cause some drug candidates to be overlooked, especially small compounds targeting just those sites in wild-type viral proteins.", [["mouse", "ORGANISM", 52, 57], ["virus proteins", "PROTEIN", 34, 48], ["wild-type viral proteins", "PROTEIN", 187, 211], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 52, 57], ["virus proteins of mouse", "TREATMENT", 34, 57], ["adapted virus models", "TREATMENT", 58, 78], ["small compounds", "PROBLEM", 141, 156], ["type viral proteins", "PROBLEM", 192, 211], ["small", "OBSERVATION_MODIFIER", 141, 146], ["compounds", "OBSERVATION_MODIFIER", 147, 156]]], ["These flaws could be compensated for by pseudo-filovirus in vivo models, which could directly use the identical clinically-occurring viral GP gene to construct a corresponding in vivo imaging model.", [["viral GP gene", "DNA", 133, 146], ["pseudo-filovirus in vivo models", "PROBLEM", 40, 71], ["filovirus", "OBSERVATION", 47, 56]]], ["This would nicely reflect the features of clinically existing viruses and allow for quick response when new types of viruses appear.ConclusionsWe established a pseudo-filovirus-based sequential in vitro and in vivo filovirus entry inhibitor evaluation system that can be performed in BSL-2 facilities.", [["clinically existing viruses", "PROBLEM", 42, 69], ["viruses", "PROBLEM", 117, 124], ["a pseudo-filovirus", "TREATMENT", 158, 176], ["evaluation system", "TEST", 241, 258], ["viruses", "OBSERVATION", 62, 69], ["viruses", "OBSERVATION", 117, 124]]], ["The system covered all genera of filoviruses, including nine pseudo-filovirus in vitro models and three bioluminescence imaging in vivo mouse models.", [["filoviruses", "ANATOMY", 33, 44], ["filoviruses", "CANCER", 33, 44], ["mouse", "ORGANISM", 136, 141], ["mouse", "SPECIES", 136, 141], ["mouse", "SPECIES", 136, 141], ["filoviruses", "PROBLEM", 33, 44], ["nine pseudo-filovirus in vitro models", "PROBLEM", 56, 93], ["three bioluminescence imaging", "TEST", 98, 127]]], ["The verification of two known filovirus entry inhibitors on these models confirmed the success of the model establishments.", [["these models", "TEST", 60, 72]]], ["The high safety, efficiency, and viability of pseudo-filovirus models shed light on anti-filovirus drug research, and this platform can contribute to the discovery of broad-spectrum filovirus entry inhibitors.", [["filovirus", "ORGANISM", 182, 191], ["pseudo-filovirus models", "PROBLEM", 46, 69], ["anti-filovirus drug research", "TREATMENT", 84, 112], ["broad-spectrum filovirus entry inhibitors", "TREATMENT", 167, 208], ["high", "OBSERVATION_MODIFIER", 4, 8]]]], "2af6283bd82df96685005957e90be8d9270d6dd6": [["IntroductionLung related disease is emerged as one of the most prevalent medical conditions in humans, globally.", [["humans", "ORGANISM", 95, 101], ["humans", "SPECIES", 95, 101], ["humans", "SPECIES", 95, 101], ["IntroductionLung related disease", "PROBLEM", 0, 32], ["disease", "OBSERVATION", 25, 32]]], ["The diseases in the lung can be categorized as, (i) airway diseases, (ii) circulation diseases, and (iii) tissue disease [1] , [2] , [3] .", [["lung", "ANATOMY", 20, 24], ["airway", "ANATOMY", 52, 58], ["tissue", "ANATOMY", 106, 112], ["airway diseases", "DISEASE", 52, 67], ["circulation diseases", "DISEASE", 74, 94], ["lung", "ORGAN", 20, 24], ["airway", "MULTI-TISSUE_STRUCTURE", 52, 58], ["tissue", "TISSUE", 106, 112], ["The diseases in the lung", "PROBLEM", 0, 24], ["airway diseases, (ii) circulation diseases", "PROBLEM", 52, 94], ["(iii) tissue disease", "PROBLEM", 100, 120], ["diseases", "OBSERVATION", 4, 12], ["lung", "ANATOMY", 20, 24], ["airway", "ANATOMY", 52, 58], ["diseases", "OBSERVATION", 59, 67]]], ["The airway diseases cause interruption of the oxygen and other gases air supply through tubes, e.g. of the disease are asthma, cystic fibrosis, Chronic obstructive pulmonary disease (COPD), Tuberculosis (TB), bronchitis, etc. The circulation diseases have an adverse effect on the flow of blood in the lungs due to the clotting inside blood vessels, e.g., pulmonary embolism and pulmonary hypertension come under this category.", [["airway", "ANATOMY", 4, 10], ["cystic", "ANATOMY", 127, 133], ["pulmonary", "ANATOMY", 164, 173], ["blood", "ANATOMY", 289, 294], ["lungs", "ANATOMY", 302, 307], ["blood vessels", "ANATOMY", 335, 348], ["pulmonary", "ANATOMY", 356, 365], ["pulmonary", "ANATOMY", 379, 388], ["airway diseases", "DISEASE", 4, 19], ["oxygen", "CHEMICAL", 46, 52], ["asthma", "DISEASE", 119, 125], ["cystic fibrosis", "DISEASE", 127, 142], ["Chronic obstructive pulmonary disease", "DISEASE", 144, 181], ["COPD", "DISEASE", 183, 187], ["Tuberculosis", "DISEASE", 190, 202], ["TB", "DISEASE", 204, 206], ["bronchitis", "DISEASE", 209, 219], ["circulation diseases", "DISEASE", 230, 250], ["pulmonary embolism", "DISEASE", 356, 374], ["pulmonary hypertension", "DISEASE", 379, 401], ["oxygen", "CHEMICAL", 46, 52], ["airway", "MULTI-TISSUE_STRUCTURE", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["pulmonary", "ORGAN", 164, 173], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["lungs", "ORGAN", 302, 307], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 335, 348], ["pulmonary", "ORGAN", 356, 365], ["pulmonary", "ORGAN", 379, 388], ["The airway diseases", "PROBLEM", 0, 19], ["the oxygen", "TREATMENT", 42, 52], ["other gases air supply through tubes", "TREATMENT", 57, 93], ["the disease", "PROBLEM", 103, 114], ["asthma", "PROBLEM", 119, 125], ["cystic fibrosis", "PROBLEM", 127, 142], ["Chronic obstructive pulmonary disease", "PROBLEM", 144, 181], ["COPD)", "PROBLEM", 183, 188], ["Tuberculosis (TB)", "PROBLEM", 190, 207], ["bronchitis", "PROBLEM", 209, 219], ["The circulation diseases", "PROBLEM", 226, 250], ["an adverse effect", "PROBLEM", 256, 273], ["blood in the lungs", "PROBLEM", 289, 307], ["the clotting inside blood vessels", "PROBLEM", 315, 348], ["pulmonary embolism", "PROBLEM", 356, 374], ["pulmonary hypertension", "PROBLEM", 379, 401], ["airway", "ANATOMY", 4, 10], ["diseases", "OBSERVATION", 11, 19], ["oxygen", "OBSERVATION_MODIFIER", 46, 52], ["tubes", "OBSERVATION", 88, 93], ["disease", "OBSERVATION", 107, 114], ["asthma", "OBSERVATION", 119, 125], ["cystic", "OBSERVATION_MODIFIER", 127, 133], ["fibrosis", "OBSERVATION", 134, 142], ["Chronic", "OBSERVATION_MODIFIER", 144, 151], ["obstructive", "OBSERVATION_MODIFIER", 152, 163], ["pulmonary", "ANATOMY", 164, 173], ["disease", "OBSERVATION", 174, 181], ["COPD", "OBSERVATION", 183, 187], ["Tuberculosis", "OBSERVATION", 190, 202], ["bronchitis", "OBSERVATION", 209, 219], ["circulation", "ANATOMY", 230, 241], ["diseases", "OBSERVATION", 242, 250], ["adverse effect", "OBSERVATION", 259, 273], ["flow", "OBSERVATION", 281, 285], ["lungs", "ANATOMY", 302, 307], ["clotting", "OBSERVATION", 319, 327], ["vessels", "ANATOMY", 341, 348], ["pulmonary", "ANATOMY", 356, 365], ["embolism", "OBSERVATION", 366, 374], ["pulmonary", "ANATOMY", 379, 388], ["hypertension", "OBSERVATION", 389, 401]]], ["Lung tissue diseases are caused due to inflammation of the tissue that affects the lung expansion ability, e.g. sarcoidosis and pulmonary fibrosis.", [["Lung tissue", "ANATOMY", 0, 11], ["tissue", "ANATOMY", 59, 65], ["lung", "ANATOMY", 83, 87], ["pulmonary", "ANATOMY", 128, 137], ["Lung tissue diseases", "DISEASE", 0, 20], ["inflammation", "DISEASE", 39, 51], ["sarcoidosis", "DISEASE", 112, 123], ["pulmonary fibrosis", "DISEASE", 128, 146], ["Lung tissue", "TISSUE", 0, 11], ["tissue", "TISSUE", 59, 65], ["lung", "ORGAN", 83, 87], ["pulmonary", "ORGAN", 128, 137], ["Lung tissue diseases", "PROBLEM", 0, 20], ["inflammation of the tissue", "PROBLEM", 39, 65], ["sarcoidosis", "PROBLEM", 112, 123], ["pulmonary fibrosis", "PROBLEM", 128, 146], ["tissue", "ANATOMY", 5, 11], ["diseases", "OBSERVATION", 12, 20], ["caused due to", "UNCERTAINTY", 25, 38], ["inflammation", "OBSERVATION", 39, 51], ["tissue", "OBSERVATION", 59, 65], ["lung", "ANATOMY", 83, 87], ["expansion", "OBSERVATION_MODIFIER", 88, 97], ["ability", "OBSERVATION_MODIFIER", 98, 105], ["sarcoidosis", "OBSERVATION", 112, 123], ["pulmonary", "ANATOMY", 128, 137], ["fibrosis", "OBSERVATION", 138, 146]]], ["The other diseases that affect lungs are lung cancer, pneumothorax, pneumonia, and Acute Respiratory Distress Syndrome (ARDS) [4] .IntroductionThe Coronavirus Disease (COVID-19) is one of the rapidly communicable infectious diseases, affected a large number of the population globally, irrespective of their gender and race.", [["lungs", "ANATOMY", 31, 36], ["lung cancer", "ANATOMY", 41, 52], ["lung cancer", "DISEASE", 41, 52], ["pneumothorax", "DISEASE", 54, 66], ["pneumonia", "DISEASE", 68, 77], ["Acute Respiratory Distress Syndrome", "DISEASE", 83, 118], ["ARDS", "DISEASE", 120, 124], ["Coronavirus Disease", "DISEASE", 147, 166], ["infectious diseases", "DISEASE", 213, 232], ["lungs", "ORGAN", 31, 36], ["lung cancer", "CANCER", 41, 52], ["The other diseases", "PROBLEM", 0, 18], ["lung cancer", "PROBLEM", 41, 52], ["pneumothorax", "PROBLEM", 54, 66], ["pneumonia", "PROBLEM", 68, 77], ["Acute Respiratory Distress Syndrome", "PROBLEM", 83, 118], ["ARDS)", "PROBLEM", 120, 125], ["The Coronavirus Disease", "PROBLEM", 143, 166], ["the rapidly communicable infectious diseases", "PROBLEM", 188, 232], ["diseases", "OBSERVATION", 10, 18], ["lungs", "ANATOMY", 31, 36], ["lung", "ANATOMY", 41, 45], ["cancer", "OBSERVATION", 46, 52], ["pneumothorax", "OBSERVATION", 54, 66], ["pneumonia", "OBSERVATION", 68, 77], ["Acute", "OBSERVATION_MODIFIER", 83, 88], ["Respiratory Distress Syndrome", "OBSERVATION", 89, 118], ["Coronavirus Disease", "OBSERVATION", 147, 166], ["rapidly", "OBSERVATION_MODIFIER", 192, 199], ["communicable", "OBSERVATION_MODIFIER", 200, 212], ["infectious", "OBSERVATION", 213, 223], ["large", "OBSERVATION_MODIFIER", 245, 250], ["number", "OBSERVATION_MODIFIER", 251, 257], ["population", "OBSERVATION_MODIFIER", 265, 275], ["globally", "OBSERVATION_MODIFIER", 276, 284]]], ["The infection due to COVID-19 severely affects the respiratory tracts and creates a layer of the lesion on the lungs; which affects the normal functioning of the lungs.", [["respiratory tracts", "ANATOMY", 51, 69], ["lesion", "ANATOMY", 97, 103], ["lungs", "ANATOMY", 111, 116], ["lungs", "ANATOMY", 162, 167], ["infection", "DISEASE", 4, 13], ["COVID-19", "CHEMICAL", 21, 29], ["lungs", "ORGAN", 111, 116], ["lungs", "ORGAN", 162, 167], ["The infection", "PROBLEM", 0, 13], ["COVID", "TEST", 21, 26], ["the respiratory tracts", "PROBLEM", 47, 69], ["the lesion on the lungs", "PROBLEM", 93, 116], ["infection", "OBSERVATION", 4, 13], ["respiratory tracts", "OBSERVATION", 51, 69], ["layer", "OBSERVATION_MODIFIER", 84, 89], ["lesion", "OBSERVATION", 97, 103], ["lungs", "ANATOMY", 111, 116], ["normal", "OBSERVATION", 136, 142], ["functioning", "OBSERVATION_MODIFIER", 143, 154], ["lungs", "ANATOMY", 162, 167]]], ["The infection due to COVID-19 is initially discovered in Wuhan, China during December 2019.", [["infection", "DISEASE", 4, 13], ["COVID-19", "CHEMICAL", 21, 29], ["COVID-19", "DNA", 21, 29], ["COVID-19", "SPECIES", 21, 29], ["The infection", "PROBLEM", 0, 13], ["COVID", "TEST", 21, 26], ["infection", "OBSERVATION", 4, 13]]], ["On February 11, 2020, the International Committee on Taxonomy of Viruses (ICTV) announced the new name of the virus as \"severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\" and WHO declared the name \"COVID-19\" [5] , [6] .", [["acute respiratory syndrome coronavirus", "DISEASE", 127, 165], ["COVID-19", "CHEMICAL", 209, 217], ["ICTV", "SPECIES", 74, 78], ["severe acute respiratory syndrome coronavirus", "SPECIES", 120, 165], ["SARS-CoV-2", "SPECIES", 169, 179], ["the virus", "PROBLEM", 106, 115], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 120, 165], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["respiratory syndrome", "OBSERVATION", 133, 153]]], ["The symptoms of COVID-19 ranges from dry cough, tiredness, mild to moderate respiratory illness, loss of taste sensation to fever [7] .", [["respiratory", "ANATOMY", 76, 87], ["COVID", "DISEASE", 16, 21], ["dry cough", "DISEASE", 37, 46], ["tiredness", "DISEASE", 48, 57], ["respiratory illness", "DISEASE", 76, 95], ["loss of taste sensation", "DISEASE", 97, 120], ["fever", "DISEASE", 124, 129], ["taste", "ORGANISM_SUBDIVISION", 105, 110], ["The symptoms", "PROBLEM", 0, 12], ["COVID", "TEST", 16, 21], ["dry cough", "PROBLEM", 37, 46], ["tiredness", "PROBLEM", 48, 57], ["mild to moderate respiratory illness", "PROBLEM", 59, 95], ["loss of taste sensation", "PROBLEM", 97, 120], ["fever", "PROBLEM", 124, 129], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["moderate", "OBSERVATION_MODIFIER", 67, 75], ["respiratory illness", "OBSERVATION", 76, 95]]], ["The disease spreads from a person infected with COVID-19 to another person through the transmission of micron size droplets from the nose and/or mouth, that is expelled when a person with COVID-19 sneezes, coughs and even speaks.", [["nose", "ANATOMY", 133, 137], ["mouth", "ANATOMY", 145, 150], ["coughs", "DISEASE", 206, 212], ["nose", "ORGAN", 133, 137], ["mouth", "ORGAN", 145, 150], ["person", "SPECIES", 27, 33], ["person", "SPECIES", 68, 74], ["person", "SPECIES", 176, 182], ["The disease spreads", "PROBLEM", 0, 19], ["COVID", "TREATMENT", 48, 53], ["micron size droplets", "TREATMENT", 103, 123], ["COVID", "TREATMENT", 188, 193], ["coughs", "PROBLEM", 206, 212], ["disease", "OBSERVATION", 4, 11], ["nose", "ANATOMY", 133, 137], ["mouth", "ANATOMY", 145, 150]]], ["People having medical problems like diabetes, chronic respiratory disease, cardiovascular diseases, and cancer are more likely to develop serious illness.", [["respiratory", "ANATOMY", 54, 65], ["cardiovascular", "ANATOMY", 75, 89], ["cancer", "ANATOMY", 104, 110], ["diabetes", "DISEASE", 36, 44], ["chronic respiratory disease", "DISEASE", 46, 73], ["cardiovascular diseases", "DISEASE", 75, 98], ["cancer", "DISEASE", 104, 110], ["cardiovascular", "ANATOMICAL_SYSTEM", 75, 89], ["cancer", "CANCER", 104, 110], ["People", "SPECIES", 0, 6], ["medical problems", "PROBLEM", 14, 30], ["diabetes", "PROBLEM", 36, 44], ["chronic respiratory disease", "PROBLEM", 46, 73], ["cardiovascular diseases", "PROBLEM", 75, 98], ["cancer", "PROBLEM", 104, 110], ["serious illness", "PROBLEM", 138, 153], ["diabetes", "OBSERVATION", 36, 44], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["respiratory disease", "OBSERVATION", 54, 73], ["cardiovascular", "ANATOMY", 75, 89], ["diseases", "OBSERVATION", 90, 98], ["cancer", "OBSERVATION", 104, 110], ["more likely", "UNCERTAINTY", 115, 126]]], ["It has been shown that old populations with other medical complications are more prone to infections compared to the young age group.", [["infections", "DISEASE", 90, 100], ["old populations", "PROBLEM", 23, 38], ["other medical complications", "PROBLEM", 44, 71], ["infections", "PROBLEM", 90, 100], ["old", "OBSERVATION_MODIFIER", 23, 26], ["populations", "OBSERVATION_MODIFIER", 27, 38]]], ["Till May 13, 2020, total COVID-19 cases reported are USA 14,08,636, Spain 2,69,520, Russia 2,32,243, UK 2,26,463, and Italy 2,21,216 [6] .", [["total COVID", "TEST", 19, 30], ["UK", "TEST", 101, 103]]], ["The death cases due to COVID-19 in these countries are 83,425 in the USA, 26,920 in Spain, 2,116 in Russia, 32,692 in the UK, and Italy 30,911.", [["death", "DISEASE", 4, 9], ["The death cases", "TEST", 0, 15], ["COVID", "TEST", 23, 28]]], ["Although in India total cases reported as on May 13, 2020 , are 74,480, and deaths reported are 2,415.", [["deaths", "DISEASE", 76, 82]]], ["All across the world, researchers are working on numerous areas related to COVID-19 diagnosis and treatment, e.g., medical equipment to detect COVID-19 and vaccines for the treatment.IntroductionThe COVID-19 pandemic testing kits are divided into two categories: a) antigen tests-detect currently infected patients and b) antibody tests-detect the antibodies in the blood of a person previously infected with the virus.", [["blood", "ANATOMY", 366, 371], ["COVID-19", "CHEMICAL", 143, 151], ["patients", "ORGANISM", 306, 314], ["blood", "ORGANISM_SUBSTANCE", 366, 371], ["antibodies", "PROTEIN", 348, 358], ["patients", "SPECIES", 306, 314], ["person", "SPECIES", 377, 383], ["COVID", "TEST", 75, 80], ["treatment", "TREATMENT", 98, 107], ["medical equipment", "TREATMENT", 115, 132], ["COVID", "TEST", 143, 148], ["vaccines", "TREATMENT", 156, 164], ["the treatment", "TREATMENT", 169, 182], ["The COVID", "TREATMENT", 195, 204], ["pandemic testing kits", "TEST", 208, 229], ["a) antigen tests", "TEST", 263, 279], ["b) antibody tests", "TEST", 319, 336], ["the antibodies", "TEST", 344, 358], ["the virus", "PROBLEM", 409, 418]]], ["The majority of antigen tests being produced to detect the COVID-19 disease are termed as PCR tests because they use a polymerase chain reaction (PCR).", [["COVID-19", "SPECIES", 59, 67], ["antigen tests", "TEST", 16, 29], ["the COVID-19 disease", "PROBLEM", 55, 75], ["PCR tests", "TEST", 90, 99], ["a polymerase chain reaction", "PROBLEM", 117, 144], ["PCR", "TEST", 146, 149]]], ["The steps involved in the PCR test are the collection of a clinical specimen with a nasopharyngeal swab, storage of the swab, sending the samples to the laboratories for extraction of RNA, and quantitative reverse transcription PCR [8] .", [["specimen", "ANATOMY", 68, 76], ["nasopharyngeal swab", "ANATOMY", 84, 103], ["swab", "ANATOMY", 120, 124], ["samples", "ANATOMY", 138, 145], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 84, 103], ["the PCR test", "TEST", 22, 34], ["a nasopharyngeal swab", "TEST", 82, 103], ["the swab", "TEST", 116, 124], ["extraction of RNA", "TREATMENT", 170, 187], ["quantitative reverse transcription PCR", "TEST", 193, 231]]], ["The major challenges in the COVID-19 rapid detection are as follows: a) conventional PCR test kits take longer duration for diagnosis of disease, b) longer time in the production of probes, primers, and physical equipment (swab, containers, etc.).", [["the COVID", "TEST", 24, 33], ["conventional PCR test kits", "TEST", 72, 98], ["disease", "PROBLEM", 137, 144], ["disease", "OBSERVATION", 137, 144]]], ["Globally, the governments are not able to reduce the COVID-19 spread in the population due to the following reasons: a) insufficient kit for COVID-19 detection/million population; b) vaccines and drug treatments are not available till date [9] .", [["the COVID", "TEST", 49, 58], ["COVID", "TEST", 141, 146], ["detection/million population", "TREATMENT", 150, 178], ["b) vaccines", "TREATMENT", 180, 191], ["drug treatments", "TREATMENT", 196, 211]]], ["Total tests conducted for COVID-19 in various countries are as follows: 9,935,720 in the USA; 2,467,761 in Spain; 5,805,404 in Russia; 2,007,146 in the UK; 2,673,655 in Italy [6] .", [["Total tests", "TEST", 0, 11], ["COVID", "TEST", 26, 31]]], ["The statistical data of total tests per million population in these countries are USA-30,017, Spain-52,781, Russia-39,781, UK-29,566, and Italy-44,221.", [["total tests", "TEST", 24, 35], ["USA", "TEST", 82, 85], ["Spain", "TEST", 94, 99], ["Russia", "TEST", 108, 114], ["UK", "TEST", 123, 125], ["Italy", "TEST", 138, 143]]], ["Whereas in India total tests conducted are 1,854,250 and total tests per million population are 1,344.", [["India total tests", "TEST", 11, 28], ["total tests", "TEST", 57, 68]]], ["Thus, due to the shortage of COVID-19 testing kits, a smaller number of tests are conducted per million population.IntroductionCOVID-19 pandemic has a very severe impact on the respiratory as well as other systems of the human body.", [["respiratory", "ANATOMY", 177, 188], ["body", "ANATOMY", 227, 231], ["human", "ORGANISM", 221, 226], ["body", "ORGANISM_SUBDIVISION", 227, 231], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 221, 226], ["COVID", "TEST", 29, 34], ["tests", "TEST", 72, 77], ["IntroductionCOVID", "TEST", 115, 132], ["a very severe impact", "PROBLEM", 149, 169], ["very", "OBSERVATION_MODIFIER", 151, 155], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["impact", "OBSERVATION", 163, 169], ["respiratory", "ANATOMY", 177, 188], ["human body", "ANATOMY", 221, 231]]], ["Thus, medical imaging features of chest radiography is found to be useful for rapid COVID-19 detection.", [["chest", "ANATOMY", 34, 39], ["chest", "ORGAN", 34, 39], ["medical imaging", "TEST", 6, 21], ["chest radiography", "TEST", 34, 51], ["rapid COVID", "TEST", 78, 89], ["chest", "ANATOMY", 34, 39]]], ["The imaging features of the chest can be obtained through medical imaging modalities like CT (Computed Tomography) scan and Xrays.", [["chest", "ANATOMY", 28, 33], ["chest", "ORGAN", 28, 33], ["The imaging features of the chest", "TEST", 0, 33], ["medical imaging modalities", "TEST", 58, 84], ["CT (Computed Tomography) scan", "TEST", 90, 119], ["Xrays", "TEST", 124, 129], ["chest", "ANATOMY", 28, 33]]], ["The advantages of CT scan over x-ray include a) 3-D view formation of organs in CT scan, b) convenient examination of disease, and its location.", [["organs", "ANATOMY", 70, 76], ["organs", "ORGAN", 70, 76], ["CT scan over x-ray", "TEST", 18, 36], ["a) 3-D view formation", "TEST", 45, 66], ["CT scan", "TEST", 80, 87], ["convenient examination", "TEST", 92, 114], ["disease", "PROBLEM", 118, 125], ["organs", "ANATOMY", 70, 76], ["disease", "OBSERVATION", 118, 125]]], ["Whereas with X-rays, a 2-D view of an organ is obtained that can help in the examination of dense tissues only.", [["organ", "ANATOMY", 38, 43], ["tissues", "ANATOMY", 98, 105], ["organ", "ORGAN", 38, 43], ["tissues", "TISSUE", 98, 105], ["a 2-D view", "TEST", 21, 31], ["an organ", "TEST", 35, 43], ["the examination", "TEST", 73, 88], ["organ", "ANATOMY", 38, 43], ["dense tissues", "OBSERVATION", 92, 105]]], ["Also, the machinery to acquire these CT scan images is already available in an optimum amount in every country.", [["these CT scan images", "TEST", 31, 51]]], ["Therefore, for COVID-19 detection, a CT scan of the chest is drawing the researchers' attention [10] , [11] .", [["chest", "ANATOMY", 52, 57], ["chest", "ORGAN", 52, 57], ["COVID", "TEST", 15, 20], ["a CT scan of the chest", "TEST", 35, 57], ["chest", "ANATOMY", 52, 57]]], ["Expert radiologist guidance is required for accurate and rapid COVID-19 detection using a CT scan of the chest.", [["chest", "ANATOMY", 105, 110], ["chest", "ORGAN", 105, 110], ["a CT scan of the chest", "TEST", 88, 110], ["chest", "ANATOMY", 105, 110]]], ["Timely and accurate treatment of COVID-19 disease is a challenging task for the healthcare givers.", [["COVID-19 disease", "PROBLEM", 33, 49]]], ["But the limited availability of conventional COVID-19 detection kits is a major issue.", [["conventional COVID", "TEST", 32, 50]]], ["Thus, an automatic diagnosis model is required for COVID-19 detection using imaging modality to reduce the manual involvement in disease detection using a CT scan of chest images.IntroductionThe proposed work aims to automatically detect and localize COVID-19 using a CT scan of the chest.", [["chest", "ANATOMY", 166, 171], ["chest", "ANATOMY", 283, 288], ["chest", "ORGAN", 166, 171], ["chest", "ORGAN", 283, 288], ["COVID-19", "DNA", 251, 259], ["COVID", "TEST", 51, 56], ["imaging modality", "TEST", 76, 92], ["disease detection", "TEST", 129, 146], ["a CT scan of chest images", "TEST", 153, 178], ["COVID", "TEST", 251, 256], ["a CT scan of the chest", "TEST", 266, 288], ["chest", "ANATOMY", 166, 171], ["chest", "ANATOMY", 283, 288]]], ["For this, a novel three-phase COVID-19 detection model is proposed: a) Phase 1-data augmentation using wavelets, b) Phase 2-disease detection, and c) Phase 3-abnormality localization.", [["wavelets", "TEST", 103, 111], ["disease detection", "TEST", 124, 141], ["Phase 3-abnormality localization", "PROBLEM", 150, 182]]], ["However, there are a limited number of CT scans of COVID-19 disease available online for the research community.", [["CT scans", "TEST", 39, 47], ["COVID", "TEST", 51, 56]]], ["To overcome the need for large databases for training purposes and overfitting issues, the pre-processed images are decomposed to three levels using stationary wavelets.", [["training purposes", "TREATMENT", 45, 62], ["overfitting issues", "PROBLEM", 67, 85], ["the pre-processed images", "TEST", 87, 111]]], ["Then shear, rotation, and translational operation are applied to all these images.", [["rotation", "TREATMENT", 12, 20], ["translational operation", "TREATMENT", 26, 49], ["all these images", "TEST", 65, 81], ["shear", "OBSERVATION_MODIFIER", 5, 10]]], ["In phase 2, CT scans are classified into binary classes, i.e., COVID and Non-COVID using transfer learning-based techniques.", [["CT scans", "TEST", 12, 20]]], ["Then, the best training model is obtained based on the evaluation of common performance parameters of transfer learning models.", [["the evaluation", "TEST", 51, 65]]], ["In Phase 3, abnormality in chest CT-scan images of COVID-19 positive cases is localized using the feature map and activation layers of best performing pre-trained transfer learning model.", [["chest", "ANATOMY", 27, 32], ["chest", "ORGAN", 27, 32], ["abnormality in chest CT", "TEST", 12, 35], ["scan images", "TEST", 36, 47], ["COVID", "TEST", 51, 56], ["chest", "ANATOMY", 27, 32]]], ["The contribution of the proposed work can be summarized as i) the proposed methodology with the novel data augmentation on the limited dataset is used to classify the CT scan data into binary classes, i.e., COVID-19 and non-COVID, ii) The performance of four pre-trained transfer learning models are compared to address the issue of COVID-19 detection through CT scan with the limited dataset, iii) Further, the feature maps of the deeper layer (pooling layer) of the best performing transfer learning model are used to investigate the abnormality in COVID-19 positive patients.IntroductionThe paper is summarized as follows: section 2 illustrates the literature review; section 3 discusses the proposed methodology.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 551, 559], ["patients", "ORGANISM", 569, 577], ["patients", "SPECIES", 569, 577], ["the CT scan data", "TEST", 163, 179], ["COVID", "TEST", 207, 212], ["COVID", "TEST", 333, 338], ["CT scan", "TEST", 360, 367], ["the abnormality", "PROBLEM", 532, 547], ["COVID", "TEST", 551, 556], ["deeper", "OBSERVATION_MODIFIER", 432, 438], ["layer", "OBSERVATION_MODIFIER", 439, 444]]], ["Section 5 put forth the experimentation and discussion and section 6 provides the conclusion of the proposed work.Literature reviewThe state-of-the-art put forth in Table 1 claims that AI along-with radiology imaging of COVID-19 positive patients can be helpful for timely and accurate diagnosis of disease [12] .Literature reviewFrom the brief review of research carried on COVID-19 diagnosis, it can be concluded that a limited number of chest radiographic data is available for COVID-19 detection and deep learning is beneficial in COVID-19 detection using chest CT radiography.", [["chest", "ANATOMY", 440, 445], ["COVID-19", "GENE_OR_GENE_PRODUCT", 220, 228], ["patients", "ORGANISM", 238, 246], ["chest", "ORGAN", 440, 445], ["patients", "SPECIES", 238, 246], ["radiology imaging", "TEST", 199, 216], ["COVID", "TEST", 220, 225], ["disease", "PROBLEM", 299, 306], ["chest radiographic data", "TEST", 440, 463], ["COVID", "TEST", 481, 486], ["chest CT radiography", "TEST", 560, 580], ["chest", "ANATOMY", 440, 445], ["chest", "ANATOMY", 560, 565]]], ["The conventional method of COVID-19 detection, i.e., PCR kits and reverse transmission polymerase chain reaction (RT-PCR) are having certain drawbacks like less production of the kits, time consumption in getting the results, pooled sensitivity of RT-PCR is very less. i.e., 89% etc [7] .", [["COVID", "TEST", 27, 32], ["PCR kits", "TEST", 53, 61], ["reverse transmission polymerase chain reaction", "PROBLEM", 66, 112], ["RT-PCR", "TEST", 114, 120], ["RT-PCR", "TEST", 248, 254]]], ["The real-time clinical problem in COVID-19 detection using conventional RT-PCR test kit is false negatives.", [["conventional RT-PCR test kit", "TEST", 59, 87]]], ["Thus, to resolve the issues caused due to PCR kits, researchers are looking into chest radiography as an alternative to COVID-19 detection.Literature reviewResearchers have mainly analyzed chest X-ray Imaging and chest CT scan modality of patients with COVID-19 positive cases.", [["chest", "ANATOMY", 189, 194], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 239, 247], ["the issues", "PROBLEM", 17, 27], ["PCR kits", "TEST", 42, 50], ["chest radiography", "TEST", 81, 98], ["COVID", "TEST", 120, 125], ["chest X-ray", "TEST", 189, 200], ["Imaging", "TEST", 201, 208], ["chest CT scan modality", "TEST", 213, 235], ["COVID", "TEST", 253, 258], ["chest", "ANATOMY", 81, 86], ["chest", "ANATOMY", 189, 194], ["chest", "ANATOMY", 213, 218]]], ["The CT scans of chest display bilateral ground-glass opacity [42] .", [["chest", "ANATOMY", 16, 21], ["chest", "ORGAN", 16, 21], ["The CT scans of chest", "TEST", 0, 21], ["bilateral ground-glass opacity", "PROBLEM", 30, 60], ["chest", "ANATOMY", 16, 21], ["bilateral", "ANATOMY_MODIFIER", 30, 39], ["glass opacity", "OBSERVATION", 47, 60]]], ["Recent studies found that the sensitivity of CT for COVID-19 infection is 98% compared to RT-PCR sensitivity of 71% [46] .", [["infection", "DISEASE", 61, 70], ["COVID-19", "SPECIES", 52, 60], ["Recent studies", "TEST", 0, 14], ["CT", "TEST", 45, 47], ["COVID", "TEST", 52, 57], ["infection", "PROBLEM", 61, 70], ["RT", "TEST", 90, 92], ["PCR sensitivity", "TEST", 93, 108]]], ["However, CT scan is more useful in COVID-19 detection because it can provide a complete 3-D view of organ and thus nature of abnormality can be better diagnosed in comparison to X-ray images [47] , [48] , [49] , [50] .", [["organ", "ANATOMY", 100, 105], ["organ", "ORGAN", 100, 105], ["CT scan", "TEST", 9, 16], ["abnormality", "PROBLEM", 125, 136], ["X-ray images", "TEST", 178, 190], ["organ", "ANATOMY", 100, 105]]], ["But the availability of CT scan chest images of COVID-19 positive cases is limited.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 48, 56], ["CT scan chest images", "TEST", 24, 44], ["COVID", "TEST", 48, 53], ["chest", "ANATOMY", 32, 37]]], ["Thus, transfer learning along-with data augmentation is proved to be a useful method for the detection of abnormality from a small dataset of chest radiography of COVID-19 patients.Literature reviewApart from COVID-19 detection, certain efforts have been made to forecast the COVID-19 disease spread.", [["chest", "ANATOMY", 142, 147], ["chest", "ORGANISM_SUBDIVISION", 142, 147], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["abnormality", "PROBLEM", 106, 117], ["chest radiography", "TEST", 142, 159], ["COVID", "TEST", 163, 168], ["COVID", "TEST", 209, 214], ["disease spread", "PROBLEM", 285, 299], ["small", "OBSERVATION_MODIFIER", 125, 130], ["chest", "ANATOMY", 142, 147]]], ["Composite Monte Carlo (CMC) simulation method alongwith deep learning network and fuzzy rule induction is used to forecast the COVID-19 pandemic spread [51] .", [["Monte Carlo", "CHEMICAL", 10, 21], ["pandemic", "DISEASE", 136, 144], ["Composite Monte Carlo (CMC) simulation method", "TREATMENT", 0, 45], ["deep learning network", "TREATMENT", 56, 77], ["fuzzy rule induction", "TREATMENT", 82, 102]]], ["Further, Polynomial Neural Network with corrective feedback (PNN+cf) is used to forecast COVID-19 pandemic spread with relatively lower prediction error [52] .MethodologyIn the proposed work, the immense need for a large number of COVID-19 positive lung CT scan image dataset is resolved using stationary wavelet-based data augmentation techniques.", [["lung", "ANATOMY", 249, 253], ["lung", "ORGAN", 249, 253], ["COVID-19 positive lung CT scan image dataset", "DNA", 231, 275], ["corrective feedback (PNN+cf)", "TREATMENT", 40, 68], ["COVID", "TEST", 231, 236], ["positive lung CT scan image dataset", "TEST", 240, 275], ["stationary wavelet", "TEST", 294, 312], ["lung", "ANATOMY", 249, 253]]], ["The pre-trained model extracts features from trained augmented images and incorporates multi-scale discriminant features to detect binary class labels (COVID-19 and Non-COVID).", [["trained augmented images", "TEST", 45, 69], ["COVID", "TEST", 152, 157]]], ["The hierarchical representation of the proposed methodology for three-phase COVID-19 detection using lung CT scan slices are shown in Figure 1 .Phase-1 (Data Augmentation)In the present study, there is a need to make CT scan images compatible with the pre-trained transfer learning-based model.", [["lung CT scan slices", "ANATOMY", 101, 120], ["lung", "ORGAN", 101, 105], ["lung CT scan slices", "TEST", 101, 120], ["the present study", "TEST", 174, 191], ["CT scan images", "TEST", 217, 231], ["lung", "ANATOMY", 101, 105]]], ["For this, pre-processing steps: change in input image data type, resizing of the input images, and normalization of input images.", [["the input images", "TEST", 77, 93], ["input images", "TEST", 116, 128]]], ["However, a limited number of CT scan data of COVID-19 positive cases are available.", [["CT scan data", "TEST", 29, 41], ["COVID", "TEST", 45, 50]]], ["To resolve this, the pre-trained transfer learning-based CNN model with data augmentation is performed.Phase-1 (Data Augmentation)The proposed methodology is implemented on a database of CT scan images of lungs of COVID-19 positive patients and normal patients.", [["lungs", "ANATOMY", 205, 210], ["lungs", "ORGAN", 205, 210], ["patients", "ORGANISM", 232, 240], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 252, 260], ["CT scan images", "TEST", 187, 201], ["COVID", "TEST", 214, 219], ["lungs", "ANATOMY", 205, 210]]], ["The database contains 349 CT COVID-19 positive CT images from 216 patients and 397 CT images of Non-COVID patients [35] , [38] , [39] , [40] .", [["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 106, 114], ["The database", "TEST", 0, 12], ["CT COVID", "TEST", 26, 34], ["positive CT images", "TEST", 38, 56], ["CT images", "TEST", 83, 92]]], ["The input CT images are available in different sizes and numerous image formats (JPEG, png).", [["The input CT images", "TEST", 0, 19], ["numerous image formats", "TEST", 57, 79], ["JPEG", "TEST", 81, 85]]], ["Figure 2 presents the sample CT scan images of COVID-19 and normal patients from the database used.Phase-1 (Data Augmentation)The input data of CT scan images used in the proposed work are put forth in Table 2 .", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["the sample CT scan images", "TEST", 18, 43], ["COVID", "TEST", 47, 52], ["CT scan images", "TEST", 144, 158]]], ["Initially, the input images are converted into a JPEG image format and resized to 256x256x3.", [["the input images", "TEST", 11, 27], ["a JPEG image", "TEST", 47, 59]]], ["In the prepossessing stage, CT scan images in the input dataset are of different sizes, thus to maintain the uniformity the input images are resized to 256x256x3.", [["256x256x3", "DNA", 152, 161], ["CT scan images", "TEST", 28, 42], ["sizes", "OBSERVATION_MODIFIER", 81, 86]]], ["These images are compatible with stationary wavelet decomposition up to three levels because the size of all the images in three levels remains the same, i.e., 256x256x3.", [["These images", "TEST", 0, 12], ["stationary wavelet decomposition", "TEST", 33, 65], ["all the images", "TEST", 105, 119], ["compatible with", "UNCERTAINTY", 17, 32], ["size", "OBSERVATION_MODIFIER", 97, 101]]], ["Further, 4 different transfer learning models (ResNets-18, -50,-101, and Squeezenet) used for the binary classification, have different input size requirements.", [["ResNets", "TEST", 47, 54], ["different input size requirements", "PROBLEM", 126, 159], ["size", "OBSERVATION_MODIFIER", 142, 146]]], ["So, during the transfer learning process, images sizes are again adjusted but the uniformity in size of input CT scan used by the pretrained layers is retained due to pre-processing step.", [["input CT scan", "TEST", 104, 117], ["size", "OBSERVATION_MODIFIER", 96, 100]]], ["Then resized CT scan images are normalized within the confined range [0 1] using (1) .Phase-1 (Data Augmentation)Here, 'In' represents the input CT scan images from binary classes (COVID and non-COVID).", [["CT scan images", "TEST", 13, 27], ["the input CT scan images", "TEST", 135, 159]]], ["Let us assume the generalized size of 'In' is having a size p x q x 3, and the normalized image is represented by 'I norm'.", [["generalized", "OBSERVATION_MODIFIER", 18, 29], ["size", "OBSERVATION_MODIFIER", 30, 34]]], ["Thus data augmentation technique is applied to the training [14] , [15] , [16] .", [["data augmentation technique", "TREATMENT", 5, 32]]], ["The Inception Net model achieved an accuracy of 99.96% and AUC of 1 in classifying COVID-19 positive cases from combined pneumonia and normal patients.", [["pneumonia", "DISEASE", 121, 130], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["an accuracy", "TEST", 33, 44], ["AUC", "TEST", 59, 62], ["COVID", "TEST", 83, 88], ["combined pneumonia", "PROBLEM", 112, 130], ["pneumonia", "OBSERVATION", 121, 130], ["normal", "OBSERVATION", 135, 141]]], ["An accuracy of 99.92% and AUC of 0.99 in classifying COVID-19 positive cases from combined pneumonia, tuberculosis, and normal X-ray.Phase-1 (Data Augmentation)2Phase-1 (Data Augmentation)Darknet [17] 127 COVID-19 positive cases [14] .Phase-1 (Data Augmentation)Achieved an accuracy of 98.08% for binary classification of COVID vs. Non-COVID.", [["pneumonia", "DISEASE", 91, 100], ["tuberculosis", "DISEASE", 102, 114], ["COVID", "DISEASE", 322, 327], ["An accuracy", "TEST", 0, 11], ["AUC", "TEST", 26, 29], ["COVID", "TEST", 53, 58], ["combined pneumonia", "PROBLEM", 82, 100], ["tuberculosis", "PROBLEM", 102, 114], ["Phase", "TEST", 133, 138], ["Augmentation", "TEST", 147, 159], ["2Phase", "TEST", 160, 166], ["Augmentation", "TEST", 175, 187], ["Darknet", "TEST", 188, 195], ["COVID", "TEST", 205, 210], ["positive cases", "TEST", 214, 228], ["an accuracy", "TEST", 271, 282], ["COVID", "PROBLEM", 322, 327], ["pneumonia", "OBSERVATION", 91, 100], ["tuberculosis", "OBSERVATION", 102, 114]]], ["For multi-class classification (COVID, pneumonia, and no findings) accuracy of 87.02% is achieved.Phase-1 (Data Augmentation)3 Generative Adversarial Networks (GAN) and transfer learning-based models namely, AlexNet, GoogleNet, ResNet 18 and squeezeNet [18] X-ray 5863 images divided into two classes: normal and pneumonia [19] , [20] .Phase-1 (Data Augmentation)ResNet18 achieved precision, recall, and F1 score of 98.97%.", [["pneumonia", "DISEASE", 39, 48], ["pneumonia", "DISEASE", 313, 322], ["pneumonia", "PROBLEM", 39, 48], ["accuracy", "TEST", 67, 75], ["Phase", "TEST", 98, 103], ["X-ray", "TEST", 258, 263], ["images", "TEST", 269, 275], ["pneumonia", "PROBLEM", 313, 322], ["Phase", "TEST", 336, 341], ["F1 score", "TEST", 404, 412], ["pneumonia", "OBSERVATION", 39, 48], ["normal", "OBSERVATION", 302, 308], ["pneumonia", "OBSERVATION", 313, 322]]], ["4 Deep learning techniques (Resnet50 and VGG16) [21] 102 both positive COVID-19 cases and pneumonia cases [14] , [22] , [23] , [24] .Phase-1 (Data Augmentation)An accuracy of 89.2% and an AUC of 0.95 is obtained.5Convolution Neural Networks (ResNet18, ResNet50, SqueezeNet, and DenseNet-121) [25] COVID-Xray-5k dataset [14] , [26] , and ChexPert dataset [27] .5Obtained sensitivity of 97.5% and specificity of 90%.565Transfer learning-based model [28] Two types of datasets are used: a) 224 images of COVID-19 disease, 700 images of common bacterial pneumonia and 504 images of normal patients, b) 224 images of COVID-19 disease, 714 images of bacterial pneumonia and 504 images of normal patients [ [14] , [29] .5An accuracy, sensitivity, and specificity of 96.78%, 98.66%, and 96.46% respectively is obtained.575Deep learning-based model (composed of three components: a) backbone network, b) classification head, and c) anomaly detection head [30] X-ray 100 chest images of COVID-19 positive cases [18] and 1431 images of pneumonia [31] The sensitivity of 96.00% and specificity of 70.65% is achieved.585ResNet50, InceptionV3 and Inception-ResNetV2 [32] 50 images of each COVID-19 positive cases [18] and normal cases [15] .5An accuracy of 98% obtained with ResNet50, 97% accuracy with InceptionV3, and Inception-ResNetV2 gives 87% accuracy.595Otsu based method [33] 90 slices of coronal-view and 20 slices of axialview of lungs [34] .5COVID-19 pneumonia infection and its rate are detected in CT scan images of both coronal and axial views.10Transfer learning based DenseNet model [35] CT 349 COVID positive CT samples and 463 non-COVID-19 CT samples [31] , [36] Obtained an accuracy of 84.7% and F1 score 85.3% on the binary classification of data into classes: COVID CT scan and Non-COVID CT scan.", [["head", "ANATOMY", 910, 914], ["head", "ANATOMY", 941, 945], ["slices", "ANATOMY", 1373, 1379], ["slices", "ANATOMY", 1403, 1409], ["lungs", "ANATOMY", 1426, 1431], ["coronal", "ANATOMY", 1520, 1527], ["CT samples", "ANATOMY", 1612, 1622], ["samples", "ANATOMY", 1647, 1654], ["pneumonia", "DISEASE", 90, 99], ["pneumonia", "DISEASE", 550, 559], ["pneumonia", "DISEASE", 654, 663], ["pneumonia", "DISEASE", 1025, 1034], ["pneumonia", "DISEASE", 1448, 1457], ["infection", "DISEASE", 1458, 1467], ["patients", "ORGANISM", 585, 593], ["patients", "ORGANISM", 689, 697], ["head", "ORGANISM_SUBDIVISION", 910, 914], ["lungs", "ORGAN", 1426, 1431], ["CT samples", "CANCER", 1612, 1622], ["ResNet18", "PROTEIN", 242, 250], ["ResNet50", "PROTEIN", 252, 260], ["Xray", "PROTEIN", 303, 307], ["ResNetV2", "PROTEIN", 1316, 1324], ["patients", "SPECIES", 585, 593], ["patients", "SPECIES", 689, 697], ["COVID", "TEST", 71, 76], ["pneumonia cases", "PROBLEM", 90, 105], ["An accuracy", "TEST", 160, 171], ["an AUC", "TEST", 185, 191], ["sensitivity", "TEST", 370, 381], ["specificity", "TEST", 395, 406], ["COVID", "TEST", 501, 506], ["19 disease", "PROBLEM", 507, 517], ["common bacterial pneumonia", "PROBLEM", 533, 559], ["images", "TEST", 568, 574], ["images", "TEST", 602, 608], ["COVID", "TEST", 612, 617], ["images", "TEST", 634, 640], ["bacterial pneumonia", "PROBLEM", 644, 663], ["images", "TEST", 672, 678], ["accuracy", "TEST", 717, 725], ["sensitivity", "TEST", 727, 738], ["specificity", "TEST", 744, 755], ["classification head, and c) anomaly detection head", "TEST", 895, 945], ["X-ray", "TEST", 951, 956], ["chest images", "TEST", 961, 973], ["COVID", "TEST", 977, 982], ["pneumonia", "PROBLEM", 1025, 1034], ["The sensitivity", "TEST", 1040, 1055], ["specificity", "TEST", 1070, 1081], ["COVID", "TEST", 1175, 1180], ["positive cases", "TEST", 1184, 1198], ["accuracy", "TEST", 1231, 1239], ["ResNet50", "TEST", 1261, 1269], ["accuracy", "TEST", 1275, 1283], ["InceptionV3", "TEST", 1289, 1300], ["Inception", "TEST", 1306, 1315], ["ResNetV2", "TEST", 1316, 1324], ["coronal-view", "TEST", 1383, 1395], ["lungs", "TEST", 1426, 1431], [".5COVID", "TEST", 1437, 1444], ["pneumonia infection", "PROBLEM", 1448, 1467], ["its rate", "TEST", 1472, 1480], ["CT scan images", "TEST", 1497, 1511], ["CT", "TEST", 1590, 1592], ["CT samples", "TEST", 1612, 1622], ["non-COVID", "TEST", 1631, 1640], ["CT samples", "TEST", 1644, 1654], ["an accuracy", "TEST", 1676, 1687], ["F1 score", "TEST", 1701, 1709], ["COVID CT scan", "TEST", 1767, 1780], ["Non-COVID CT scan", "TEST", 1785, 1802], ["pneumonia", "OBSERVATION", 90, 99], ["pneumonia", "OBSERVATION", 550, 559], ["bacterial", "OBSERVATION_MODIFIER", 644, 653], ["pneumonia", "OBSERVATION", 654, 663], ["head", "ANATOMY", 910, 914], ["head", "ANATOMY", 941, 945], ["chest", "ANATOMY", 961, 966], ["pneumonia", "OBSERVATION", 1025, 1034], ["lungs", "ANATOMY", 1426, 1431], ["pneumonia", "OBSERVATION", 1448, 1457]]], ["349 COVID positive and 397 Non-COVID CT scan [35] , [38] , [39] , [40] .10ResNet50 is the best performing model and achieved 82.91% testing accuracy.122D and 3D deep learning models [41] Datasets of Chinese control and infected patients.", [["Chinese control and infected", "DISEASE", 199, 227], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["COVID", "TEST", 4, 9], ["Non-COVID CT scan", "TEST", 27, 44], ["testing accuracy", "TEST", 132, 148], ["Chinese control", "TREATMENT", 199, 214]]], ["Creation of heat map or a 3D volume display of COVID-19 cases along-with Corona score.", [["heat map", "TEST", 12, 20], ["COVID", "TEST", 47, 52], ["Corona score", "PROBLEM", 73, 85]]], ["The sensitivity of 98.2%, the specificity of 92.2%, and AUC of 0.996, achieved for binary classification of the COVID vs Non-COVID dataset.121312Deep learning-based Multi-Objective Differential Evolution (MODE) and (CNN) [42] The binary classification of a person into COVID-19 affected or not.", [["COVID-19", "DNA", 269, 277], ["person", "SPECIES", 257, 263], ["The sensitivity", "TEST", 0, 15], ["the specificity", "TEST", 26, 41], ["AUC", "TEST", 56, 59]]], ["Wavelets such as Daubechies, Harr, and Coiflets, etc., through certain modifications in parameters, contain useful properties such as compact-support symmetry, regularity, and smoothness.", [["Daubechies", "TEST", 17, 27], ["Coiflets", "TREATMENT", 39, 47]]], ["This makes wavelets compatible with image processing applications.", [["image processing applications", "TREATMENT", 36, 65]]], ["The dimension of output decomposed image depends on dimensions of I norm and level (k).", [["output decomposed image", "TEST", 17, 40], ["output", "OBSERVATION_MODIFIER", 17, 23], ["decomposed", "OBSERVATION", 24, 34]]], ["Suppose, I norm is a 2-D matrix and level k greater than 1, the outputs are 3-D arrays with following stationary wavelet coefficients: In Equation 3, For n less than equal to k and t= 1, 2, 3, the output matrix H(:,:,t,n), V(:,:,t,n) and D(:,:,t,n) contain the coefficients of details of level n (horizontal, vertical, and diagonal) and A(:,:,t,n) is coefficients of approximation of level n [53] , [54] .12In the proposed work, stationary wavelet transform performs 3 levels of the wavelet decomposition.", [["level k", "TEST", 36, 43], ["the outputs", "TEST", 60, 71], ["Equation", "TEST", 138, 146], ["the output matrix H", "TEST", 193, 212], ["t", "TEST", 217, 218], ["the coefficients", "TEST", 257, 273], ["vertical", "TEST", 309, 317], ["the wavelet decomposition", "TREATMENT", 479, 504], ["diagonal", "ANATOMY_MODIFIER", 323, 331]]], ["The 2-D stationary wavelet is orthogonal (Haar; Daubechies: db1, db2,..., db10, etc.), and a biorthogonal wavelet (bior1.1, bior1.3, and bior1.5, etc.).", [["db10", "PROTEIN", 74, 78], ["db1", "TEST", 60, 63], ["db2", "TEST", 65, 68], ["a biorthogonal wavelet", "TEST", 91, 113], ["bior", "TEST", 115, 119], ["bior", "TEST", 124, 128], ["bior", "TEST", 137, 141]]], ["In the proposed work, a 2-D stationary wavelet is decomposed using a db2 orthogonal filter.", [["a 2-D stationary wavelet", "TREATMENT", 22, 46], ["a db2 orthogonal filter", "TREATMENT", 67, 90], ["orthogonal filter", "OBSERVATION", 73, 90]]], ["In 2-D stationary wavelet decomposition, the normalized input image I norm passes through a set of the Low Pass Filters (LPF) and High Pass Filters (HPF).", [["LPF", "PROTEIN", 121, 124], ["D stationary wavelet decomposition", "TREATMENT", 5, 39], ["the Low Pass Filters (LPF", "TREATMENT", 99, 124], ["High Pass Filters", "TREATMENT", 130, 147], ["High", "OBSERVATION_MODIFIER", 130, 134], ["Pass Filters", "OBSERVATION", 135, 147]]], ["In level 1 decomposition using wavelets, I norm is down-sampled by a factor of 2 and output obtained is: level 1 approximate coefficient (A1) of low frequency and detail coefficients (H1, V1, and D1) of high frequency.", [["A1", "PROTEIN", 138, 140], ["H1", "PROTEIN", 184, 186], ["V1", "PROTEIN", 188, 190], ["D1", "PROTEIN", 196, 198], ["high frequency", "PROBLEM", 203, 217], ["low frequency", "OBSERVATION_MODIFIER", 145, 158], ["high frequency", "OBSERVATION_MODIFIER", 203, 217]]], ["In second level decomposition, the output coefficient is level 2 approximate coefficient (A2) and detail coefficients of level 2 (H2, V2, and D2).", [["D2", "PROTEIN", 142, 144], ["the output coefficient", "TEST", 31, 53], ["decomposition", "OBSERVATION_MODIFIER", 16, 29], ["output", "OBSERVATION_MODIFIER", 35, 41], ["coefficient", "OBSERVATION_MODIFIER", 42, 53]]], ["Similarly, output coefficients from level 3 are approximation coefficient A3, and detailed coefficients V3, H3, and D3.", [["output", "OBSERVATION_MODIFIER", 11, 17], ["coefficients", "OBSERVATION_MODIFIER", 18, 30]]], ["The detailed hierarchy of normalized input CT scan images decomposed up to three levels is shown in Figure 3 .", [["CT scan images", "TEST", 43, 57]]], ["The A1, A2, and A3 images obtained from wavelet decomposition up to 3 levels contain the most useful information and the size of the image remains unaltered.", [["A1", "GENE_OR_GENE_PRODUCT", 4, 6], ["A2", "GENE_OR_GENE_PRODUCT", 8, 10], ["A1", "DNA", 4, 6], ["A2", "PROTEIN", 8, 10], ["wavelet decomposition", "TEST", 40, 61], ["size", "OBSERVATION_MODIFIER", 121, 125], ["unaltered", "OBSERVATION", 147, 156]]], ["Thus, to enhance the training data, these wavelet decomposed images further undergone through random rotation, shear, and translation operation under a specific range as shown in Figure 4 .Phase-2 (Transfer Learning Models)The pre-trained transfer learning-based COVID-19 detection model classifies a CT scan of lungs into binary classes: a) COVID-19 and, b) Non-COVID.", [["lungs", "ANATOMY", 312, 317], ["lungs", "ORGAN", 312, 317], ["COVID", "DNA", 263, 268], ["the training data", "TEST", 17, 34], ["these wavelet decomposed images", "TEST", 36, 67], ["random rotation, shear", "TREATMENT", 94, 116], ["translation operation", "TREATMENT", 122, 143], ["a CT scan of lungs", "TEST", 299, 317], ["COVID", "TEST", 342, 347], ["lungs", "ANATOMY", 312, 317]]], ["The size of the training augmented images is adjusted based upon the compatibility with numerous pre-trained CNN models.", [["the training augmented images", "TEST", 12, 41], ["size", "OBSERVATION_MODIFIER", 4, 8]]], ["The size requirement for transfer learning models are: ResNet18 (224x224x3), ResNet50 (224x224x3), ResNet101 (224x224x3) and Squeeze Net (227x227x3).Phase-2 (Transfer Learning Models)The pre-trained models can classify CT scan images based upon class labels assigned to the training dataset, i.e., COVID-19 and Non-COVID.", [["Res", "CHEMICAL", 77, 80], ["CT scan images", "TEST", 219, 233], ["the training dataset", "TEST", 270, 290], ["COVID", "TEST", 298, 303], ["size", "OBSERVATION_MODIFIER", 4, 8]]], ["To classify new images, retrain a pre-trained model by updating fully connected layers according to the input augmented dataset.", [["layers", "TISSUE", 80, 86], ["new images", "TEST", 12, 22]]], ["The training parameters opted for the transfer learning-based CNN model are: a) 'sgdm' optimizer is used, b) mini-batch size is 64, b) the training is performed up to 50 epochs, c) validation frequency is set to value 3, and d) pre-specified initial learning rate for the training is 3e-4.", [["the transfer learning", "TREATMENT", 34, 55], ["a) 'sgdm' optimizer", "TREATMENT", 77, 96]]], ["The performance of different pre-trained networks is examined based on the following parameters: accuracy, precision, Negative Predictive Value (NPV), sensitivity, AUC, F1-score, and specificity.", [["pre-trained networks", "MULTI-TISSUE_STRUCTURE", 29, 49], ["NPV", "TEST", 145, 148], ["sensitivity", "TEST", 151, 162], ["AUC", "TEST", 164, 167]]], ["Further, the deeper layer of the best performing model is used for abnormality detection in CT scan images of COVID-19 positive cases. abnormality detection in CT scan images of COVID-19 positive cases.Phase-3 (Abnormality localization using deeper layer)In phase-3 of the proposed methodology, the activations of layers and different channels of the pre-trained network are examined.", [["pre-trained network", "MULTI-TISSUE_STRUCTURE", 351, 370], ["abnormality detection", "TEST", 67, 88], ["CT scan images", "TEST", 92, 106], ["COVID", "TEST", 110, 115], ["abnormality detection", "TEST", 135, 156], ["CT scan images", "TEST", 160, 174], ["COVID", "TEST", 178, 183], ["Phase", "TEST", 202, 207], ["deeper", "OBSERVATION_MODIFIER", 13, 19], ["layer", "OBSERVATION_MODIFIER", 20, 25]]], ["Each layer of a pre-trained CNN network contains channels (consists of many 2-D arrays).", [["CNN network", "MULTI-TISSUE_STRUCTURE", 28, 39], ["pre-trained CNN network", "PROTEIN", 16, 39], ["a pre-trained CNN network", "TREATMENT", 14, 39], ["many 2-D arrays)", "TREATMENT", 71, 87], ["layer", "OBSERVATION_MODIFIER", 5, 10]]], ["The output activations of the first convolution layer (conv1) and deeper layer are used to localize abnormality in the COVID-19Transfer learning modelThe transfer learning-based CNN models has the following advantages a) limit pre-processing of the dataset is required, b) faster-learning process, c) time complexity can be adjusted by decreasing the numerous parameters, and d) works well on the limited dataset, thus suitable for the medical image classification task.", [["CNN", "DNA", 178, 181], ["The output activations", "TEST", 0, 22], ["the COVID", "TEST", 115, 124], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["In the proposed work, transfer learning is used for binary classification of chest CT scan images into COVID-19 and Non-COVID.", [["COVID-19", "DNA", 103, 111], ["chest CT scan images", "TEST", 77, 97], ["COVID", "TEST", 103, 108], ["chest", "ANATOMY", 77, 82]]], ["The CNN models are trained to classify into 1000 object categories from the image net database [55] , [56] .", [["CNN models", "DNA", 4, 14]]], ["The pretrained transfer learning models are retrained for the binary classification data of a chest CT scan into 2 classes.Transfer learning modelSqueezeNet is used to investigate the performance of the binary classification of chest CT images on smaller deep learning neural networks.", [["neural networks", "ANATOMY", 269, 284], ["Squeeze", "CHEMICAL", 146, 153], ["neural networks", "MULTI-TISSUE_STRUCTURE", 269, 284], ["a chest CT scan", "TEST", 92, 107], ["chest CT images", "TEST", 228, 243], ["chest", "ANATOMY", 94, 99], ["chest", "ANATOMY", 228, 233], ["deep", "ANATOMY_MODIFIER", 255, 259], ["neural networks", "OBSERVATION", 269, 284]]], ["The squeeze net is 68 layers model and requires a 227x227x3 size input image [57] .", [["68 layers", "OBSERVATION_MODIFIER", 19, 28]]], ["Although time complexity is resolved with squeezeNet but performance is not satisfactory on the proposed model.", [["not", "UNCERTAINTY", 72, 75], ["satisfactory", "OBSERVATION", 76, 88]]], ["The pre-trained ResNet18 model used for binary classification of CT scan images is 71 layers deep and requires an input image size of 224x224x3 [58] .", [["pre-trained ResNet18 model", "DNA", 4, 30], ["CT scan images", "TEST", 65, 79], ["an input image size", "TEST", 111, 130], ["layers", "OBSERVATION_MODIFIER", 86, 92], ["deep", "OBSERVATION_MODIFIER", 93, 97]]], ["The \"sgdm\" optimizer is used for the training.", [["The \"sgdm\" optimizer", "TREATMENT", 0, 20], ["the training", "TREATMENT", 33, 45]]], ["The ResNet50 model used in the proposed work is 177 layers deep and required a 224x224x3 size input image.", [["ResNet50 model", "DNA", 4, 18], ["a 224x224x3 size input image", "TREATMENT", 77, 105]]], ["Further, the ResNet101 is 347-layer and thus it is more complex than the other two residual models used.", [["ResNet101", "GENE_OR_GENE_PRODUCT", 13, 22], ["ResNet101", "DNA", 13, 22], ["layer", "OBSERVATION_MODIFIER", 30, 35], ["more complex", "OBSERVATION_MODIFIER", 51, 63]]], ["The network requires an image input size of 224x224x3.", [["an image input size", "TEST", 21, 40], ["size", "OBSERVATION_MODIFIER", 36, 40]]], ["The residual model is chosen because of its ability of easy optimization, converges faster, and enhancement in the accuracy with increased depth [59] .", [["increased depth", "PROBLEM", 129, 144], ["residual model", "OBSERVATION", 4, 18], ["enhancement", "OBSERVATION_MODIFIER", 96, 107], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["depth", "OBSERVATION_MODIFIER", 139, 144]]], ["However, time consumption is increased with an increase in layers of each residual network.", [["increased", "OBSERVATION_MODIFIER", 29, 38], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["layers", "OBSERVATION_MODIFIER", 59, 65]]], ["The ResNet18 model is the best performing model thus its architecture is explained in detail.", [["ResNet18", "DNA", 4, 12]]], ["Figure 5 put forth the descriptive block diagram of ResNet18 architecture.", [["ResNet18", "GENE_OR_GENE_PRODUCT", 52, 60], ["ResNet18", "PROTEIN", 52, 60]]], ["The input images are pre-processed to make it compatible with a pre-trained residual network, i.e., an image of size 256x256x3 converted into 224x224x3.", [["224x224x3", "CELL_LINE", 142, 151], ["The input images", "TEST", 0, 16], ["a pre-trained residual network", "PROBLEM", 62, 92], ["an image of size", "TEST", 100, 116], ["residual network", "OBSERVATION", 76, 92], ["size", "OBSERVATION_MODIFIER", 112, 116]]], ["The convolutional layers (conv1, conv2 x, conv3 x, etc.) apply a filter that scans the whole pre-processed CT scan image.", [["convolutional layers", "ANATOMY", 4, 24], ["convolutional layers", "TISSUE", 4, 24], ["a filter", "TREATMENT", 63, 71], ["the whole pre-processed CT scan image", "TEST", 83, 120], ["convolutional", "OBSERVATION_MODIFIER", 4, 17], ["layers", "OBSERVATION_MODIFIER", 18, 24]]], ["Then the convolution layer creates a feature map to predict the class probabilities for each feature map obtained.", [["each feature map", "TEST", 88, 104]]], ["The role of the first convolution layer, i.e., conv1 is to provide low-level features like color, edges, and gradient operation, etc. The deeper convolution layer provides high-level features like in the proposed work abnormality in CT scan images is localized in the deeper layer.", [["conv1", "DNA", 47, 52], ["gradient operation", "TREATMENT", 109, 127], ["high-level features", "PROBLEM", 172, 191], ["the proposed work abnormality", "PROBLEM", 200, 229], ["CT scan images", "TEST", 233, 247], ["edges", "OBSERVATION_MODIFIER", 98, 103], ["gradient operation", "OBSERVATION", 109, 127], ["deeper", "OBSERVATION_MODIFIER", 138, 144], ["convolution", "OBSERVATION_MODIFIER", 145, 156], ["layer", "OBSERVATION_MODIFIER", 157, 162], ["high-level features", "OBSERVATION_MODIFIER", 172, 191], ["deeper", "ANATOMY_MODIFIER", 268, 274], ["layer", "ANATOMY_MODIFIER", 275, 280]]], ["The spatial size of convolution Size of the input image 224x224x3 10Transfer learning modelNew \"Fc\" Weight-2x 512, Bias-2 x1, Activation-1x1x2 ResNets introduce skip connection to add the output from a previous layer to an upcoming layer, thus learning does not degrade from the first layer to a deeper layer.", [["1x1x2 ResNets", "DNA", 137, 150], ["the input image", "TEST", 40, 55], ["Weight", "TEST", 100, 106], ["Bias", "TEST", 115, 119], ["the output", "PROBLEM", 184, 194], ["spatial", "OBSERVATION_MODIFIER", 4, 11], ["size", "OBSERVATION_MODIFIER", 12, 16], ["convolution", "OBSERVATION_MODIFIER", 20, 31], ["Size", "OBSERVATION_MODIFIER", 32, 36]]], ["Rectified Linear Unit (ReLU) is a type of activation function used in CNN models.", [["Linear", "OBSERVATION_MODIFIER", 10, 16]]], ["The CNN based ResNet models are implemented with skipping of the double layer or triple layer with non-linearities (ReLU) and additional weight matrix are used to learn the skip weights.", [["the double layer or triple layer with non-linearities", "PROBLEM", 61, 114], ["additional weight matrix", "TREATMENT", 126, 150], ["double layer", "OBSERVATION_MODIFIER", 65, 77], ["triple layer", "OBSERVATION_MODIFIER", 81, 93]]], ["This helps to resolve the vanishing gradient issue in deep learning networks.", [["learning networks", "MULTI-TISSUE_STRUCTURE", 59, 76]]], ["As the residual network learns the feature space, it gradually restores the skipped layers as shown in Figure 6 .", [["residual network", "MULTI-TISSUE_STRUCTURE", 7, 23], ["feature space", "OBSERVATION", 35, 48], ["layers", "OBSERVATION_MODIFIER", 84, 90]]], ["The details of the hyperparameter used for the pre-trained ResNet18 model are provided in Table 3 .", [["the hyperparameter", "TREATMENT", 15, 33], ["the pre-trained ResNet18 model", "TREATMENT", 43, 73]]], ["Deep transfer learning-based automated detection of COVID-19 from lung CT scan slicesExperimentation and discussionThe proposed methodology is implemented on MATLAB 2019b software with the NVIDIA GeForce MX130 GPU system.", [["lung CT scan slices", "ANATOMY", 66, 85], ["lung", "ORGAN", 66, 70], ["COVID-19", "DNA", 52, 60], ["COVID", "TEST", 52, 57], ["lung CT scan slices", "TEST", 66, 85], ["lung", "ANATOMY", 66, 70]]], ["The system requirements are the Intel Core i7 processor, 2 GB graphic card, 64-bit operating system at 1.80 GHz, and 8 GB RAM.The pre-trained transfer learning modelIn the proposed research, the pre-trained transfer learning model is trained and validated for binary classification of input CT scan images into COVID-19 and Non-COVID.", [["COVID-19", "DNA", 311, 319], ["GHz", "TEST", 108, 111], ["CT scan images", "TEST", 291, 305], ["COVID", "TEST", 311, 316], ["GB RAM", "ANATOMY", 119, 125]]], ["For the binary classification task, 4 different transfer learning Fig. 9 GIyph plot for the performance evaluation of pre-trained transfer learning models Table 5 Performance parameters of transfer learning models on testing data Figure 7 shows the convergence graph of training and validation accuracy of the ResNet18 model along-with loss function up to 50 epochs (7:3 training and validation data).", [["the performance evaluation", "TEST", 88, 114], ["testing data", "TEST", 217, 229], ["validation accuracy", "TEST", 283, 302], ["loss function", "PROBLEM", 336, 349], ["validation data", "TEST", 384, 399]]], ["The classification performance of the ResNet18 model with and without augmentation is put forth in Table 4 .", [["the ResNet18 model", "TREATMENT", 34, 52], ["augmentation", "TREATMENT", 70, 82]]], ["The performance with novel data augmentation technique is much superior to model accuracy on training done on without augmentation.", [["novel data augmentation technique", "TREATMENT", 21, 54], ["augmentation", "TREATMENT", 118, 130]]], ["Also, the data augmentation technique eliminates the overfitting issues with the transfer learning model trained on a limited COVID-19 positive CT scan dataset.", [["COVID-19 positive CT scan dataset", "DNA", 126, 159], ["the data augmentation technique", "TEST", 6, 37], ["the overfitting issues", "PROBLEM", 49, 71], ["a limited COVID", "TEST", 116, 131], ["positive CT scan dataset", "TEST", 135, 159]]], ["However, the model robustness can be further investigated by implementing the proposed methodology on larger datasets.The pre-trained transfer learning modelClassification performance of the pre-trained transfer learning model on testing data is evaluated based on following parameters: a) sensitivity defines patients with a COVID-19 disease, b) specificity defines correct detection of normal patients based on CT scan images, c) accuracy is the ratio of correct predictions to total predictions of the COVID-19 disease, d) AUC value defines the ability of pre-trained transfer learning model to differentiate between binary classes, i.e., COVID and Non-COVID, and e) F1 score is a measure of the harmonic mean of sensitivity and precision.", [["patients", "ORGANISM", 310, 318], ["patients", "ORGANISM", 395, 403], ["patients", "SPECIES", 310, 318], ["patients", "SPECIES", 395, 403], ["testing data", "TEST", 230, 242], ["a COVID-19 disease", "PROBLEM", 324, 342], ["CT scan images", "TEST", 413, 427], ["the COVID", "TEST", 501, 510], ["AUC value", "TEST", 526, 535]]], ["The ResNet18 pre-trained transfer learning model obtained testing accuracy of 99.4% and major outcomes are: a) COVID and Non-COVID images are classified with 98.6% specificity and 100% sensitivity, (c) AUC of 0.9965 (shown in Figure 8 ).", [["ResNet18", "DNA", 4, 12], ["testing accuracy", "TEST", 58, 74], ["Non-COVID images", "TEST", 121, 137], ["specificity", "TEST", 164, 175], ["sensitivity", "TEST", 185, 196], ["AUC", "TEST", 202, 205]]], ["The performance parameters are summarized in Table 5 (TP-True Positive,Localization of abnormality using feature mapsThe first convolutional layer (conv1) and the deeper layer from the pre-trained transfer learning model 'ResNet18' are used to obtain the features map.", [["The performance parameters", "TEST", 0, 26], ["TP", "TEST", 54, 56], ["abnormality", "PROBLEM", 87, 98], ["feature maps", "TEST", 105, 117], ["layer", "OBSERVATION_MODIFIER", 141, 146], ["deeper", "OBSERVATION_MODIFIER", 163, 169], ["layer", "OBSERVATION_MODIFIER", 170, 175]]], ["The low-level features; namely, texture, color, and edges are generally evaluated using the first convolutional layer (conv 1).", [["low-level features", "OBSERVATION_MODIFIER", 4, 22], ["texture", "OBSERVATION_MODIFIER", 32, 39], ["color", "OBSERVATION_MODIFIER", 41, 46], ["edges", "OBSERVATION_MODIFIER", 52, 57]]], ["The output activation is obtained by passing the testing image (COVID-19 positive CT scan image) through the best performing ResNet18 pre-trained network.", [["ResNet18", "PROTEIN", 125, 133], ["The output activation", "TEST", 0, 21], ["the testing image", "TEST", 45, 62], ["COVID", "TEST", 64, 69], ["positive CT scan image", "TEST", 73, 95], ["output activation", "OBSERVATION", 4, 21]]], ["The details of the abnormality (location, and severity) in medical data can be obtained from a more complex feature of the deeper layers of the CNN model.", [["CNN", "GENE_OR_GENE_PRODUCT", 144, 147], ["the abnormality", "PROBLEM", 15, 30], ["abnormality", "OBSERVATION", 19, 30], ["deeper layers", "OBSERVATION_MODIFIER", 123, 136]]], ["In the proposed pre-trained ResNet18 model the deeper layers used are conv5 x and pooling layer.", [["deeper", "OBSERVATION_MODIFIER", 47, 53], ["layers", "OBSERVATION_MODIFIER", 54, 60], ["layer", "OBSERVATION_MODIFIER", 90, 95]]], ["In these layers, feature maps symbolize the features learned by the pre-trained model on the CT scan datasets used.", [["layers", "TISSUE", 9, 15], ["the CT scan datasets", "TEST", 89, 109], ["layers", "OBSERVATION_MODIFIER", 9, 15], ["maps symbolize", "OBSERVATION", 25, 39]]], ["Further, the features useful for abnormality localization in COVID-19 positive CT scans are obtained through the strongest activation channel.", [["abnormality localization", "TEST", 33, 57], ["COVID", "TEST", 61, 66], ["positive CT scans", "TEST", 70, 87]]], ["Table 6 presents the brief details of the performance comparison of the proposed methodology for COVID-19 detection with the techniques available in the literature using chest radiography.ConclusionThis work proposes a three-phase methodology to classify the considered lung CT scan slices into COVID-19 and non-COVID-19 class.", [["lung CT scan slices", "ANATOMY", 270, 289], ["lung", "ORGAN", 270, 274], ["COVID-19 and non-COVID-19 class", "DNA", 295, 326], ["the techniques", "TEST", 121, 135], ["chest radiography", "TEST", 170, 187], ["lung CT scan slices", "TEST", 270, 289], ["COVID", "TEST", 295, 300], ["non-COVID", "TEST", 308, 317], ["chest", "ANATOMY", 170, 175], ["lung", "ANATOMY", 270, 274]]], ["Initially, the collected images are resized based on the requirement, and the following procedures are implemented sequentially; in phase-1, data augmentation is implemented to decompose the CT scan slices into 3 levels using stationary wavelets.", [["the collected images", "TEST", 11, 31], ["the CT scan slices", "TEST", 187, 205], ["stationary wavelets", "TREATMENT", 226, 245]]], ["Further, other operations, such as random rotation, translation, and shear operations are applied to increase the dataset size.", [["other operations", "TREATMENT", 9, 25], ["random rotation, translation", "TREATMENT", 35, 63], ["shear operations", "TREATMENT", 69, 85], ["size", "OBSERVATION_MODIFIER", 122, 126]]], ["In phase-2, a two-level classification is executed using four different transfer learning-based architectures, such as ResNet18, ResNet50, ResNet101, and SqueezeNet, and their performances are verified.", [["Res", "CHEMICAL", 129, 132], ["SqueezeNet", "CELL_LINE", 154, 164]]], ["The highest classification accuracy for training (99.82%) and validation (97.32%) is achieved with the ResNet18 using the transfer learning model.", [["ResNet18", "DNA", 103, 111], ["training", "TEST", 40, 48], ["validation", "TEST", 62, 72], ["the transfer learning model", "TREATMENT", 118, 145]]], ["The testing data yields an accuracy of 99.4%, the sensitivity of 100%, the specificity of 98.6%, and AUC with the highest value of 0.9965.", [["The testing data", "TEST", 0, 16], ["an accuracy", "TEST", 24, 35], ["the sensitivity", "TEST", 46, 61], ["the specificity", "TEST", 71, 86], ["AUC", "TEST", 101, 104]]], ["In phase-3, the selected best performing model (ResNet18) is selected and implemented for abnormality localization in the chest CT scan slices of COVID-19 positive cases.", [["chest CT scan slices", "ANATOMY", 122, 142], ["ResNet18", "CELL_LINE", 48, 56], ["abnormality localization", "TEST", 90, 114], ["the chest CT scan slices", "TEST", 118, 142], ["COVID", "TEST", 146, 151], ["chest", "ANATOMY", 122, 127]]], ["The developed model will certainly help in the rapid and accurate detection of COVID-19 signature from lungs CT scan slices.", [["lungs", "ANATOMY", 103, 108], ["COVID-19", "CELL", 79, 87], ["lungs", "ORGAN", 103, 108], ["COVID-19 signature", "DNA", 79, 97], ["COVID", "TEST", 79, 84], ["lungs CT scan slices", "TEST", 103, 123], ["lungs", "ANATOMY", 103, 108]]], ["In the future, the performance of the proposed system can be considered to examine the clinically obtained CT scan slices with COVID-19 infection.", [["slices", "ANATOMY", 115, 121], ["infection", "DISEASE", 136, 145], ["CT scan slices", "TEST", 107, 121], ["COVID", "TEST", 127, 132], ["19 infection", "PROBLEM", 133, 145], ["infection", "OBSERVATION", 136, 145]]], ["Further, the proposed methodology needs to be investigated on the larger set of COVID-19 positive CT scan of patients.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["COVID", "TEST", 80, 85], ["positive CT scan", "TEST", 89, 105]]]], "8c1ce184893bc8724fb7b42bc24fbcc1faa8f604": [["INTRODUCTIONCoronaviruses (CoVs, family Coronaviridae, subfamily Coronavirinae) are important human and animal pathogens which, according to the latest release of Virus Taxonomy by the International Committee on Taxonomy of Viruses (ICTV, http://www.ictvonline.org/virusTaxonomy.asp?msl_id=26), currently comprise four distinct genera: Alphacoronavirus (\u03b1CoV), Betacoronavirus (\u03b2CoV), Gammacoronavirus (\u03b3CoV) and Deltacronavirus (\u03b4CoV) .", [["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 65, 78], ["human", "ORGANISM", 94, 99], ["Alphacoronavirus (\u03b1CoV", "ORGANISM", 336, 358], ["Betacoronavirus (\u03b2CoV", "ORGANISM", 361, 382], ["Gammacoronavirus (\u03b3CoV", "ORGANISM", 385, 407], ["Deltacronavirus", "GENE_OR_GENE_PRODUCT", 413, 428], ["\u03b4CoV", "ORGANISM", 430, 434], ["Betacoronavirus", "PROTEIN", 361, 376], ["Gammacoronavirus", "PROTEIN", 385, 401], ["Deltacronavirus", "PROTEIN", 413, 428], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["\u03b1CoV", "SPECIES", 354, 358], ["\u03b2CoV", "SPECIES", 378, 382], ["\u03b3CoV", "SPECIES", 403, 407], ["Deltacronavirus (\u03b4CoV", "SPECIES", 413, 434], ["Alphacoronavirus", "TEST", 336, 352], ["Betacoronavirus", "TEST", 361, 376], ["Gammacoronavirus (\u03b3CoV)", "TREATMENT", 385, 408], ["Deltacronavirus", "TREATMENT", 413, 428]]], ["This large group of viruses has a wide spectrum of hosts, including humans, rodents, carnivores, chiropters and avians, and cause respiratory, enteric, hepatic and neurological diseases (Lai et al, 2007) .", [["avians", "ANATOMY", 112, 118], ["respiratory", "ANATOMY", 130, 141], ["hepatic", "ANATOMY", 152, 159], ["neurological", "ANATOMY", 164, 176], ["chiropters", "DISEASE", 97, 107], ["avians", "DISEASE", 112, 118], ["respiratory, enteric, hepatic and neurological diseases", "DISEASE", 130, 185], ["humans", "ORGANISM", 68, 74], ["hepatic", "MULTI-TISSUE_STRUCTURE", 152, 159], ["humans", "SPECIES", 68, 74], ["humans", "SPECIES", 68, 74], ["respiratory, enteric, hepatic and neurological diseases", "PROBLEM", 130, 185], ["large", "OBSERVATION_MODIFIER", 5, 10], ["viruses", "OBSERVATION", 20, 27], ["wide spectrum", "OBSERVATION_MODIFIER", 34, 47], ["respiratory", "ANATOMY", 130, 141], ["enteric", "ANATOMY", 143, 150], ["hepatic", "ANATOMY", 152, 159], ["neurological diseases", "OBSERVATION", 164, 185]]], ["They include even public threats such as the severe acute respiratory syndrome (SARS) and the current Middle East respiratory syndrome (MERS) (Moratelli et al, 2015) .", [["acute respiratory syndrome", "DISEASE", 52, 78], ["SARS", "DISEASE", 80, 84], ["Middle East respiratory syndrome", "DISEASE", 102, 134], ["MERS", "DISEASE", 136, 140], ["Middle East respiratory syndrome (MERS)", "SPECIES", 102, 141], ["the severe acute respiratory syndrome", "PROBLEM", 41, 78], ["SARS", "PROBLEM", 80, 84], ["the current Middle East respiratory syndrome", "PROBLEM", 90, 134], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome", "OBSERVATION", 58, 78], ["Middle", "ANATOMY_MODIFIER", 102, 108], ["respiratory syndrome", "OBSERVATION", 114, 134]]], ["Bats are host animals of diverse \u03b1CoVs and \u03b2CoVs that may serve as the ancestral origins of mammalian CoVs (Falcon et al, 2011; Woo et al, 2012) .", [["Bats", "CELL", 0, 4], ["\u03b1CoVs", "GENE_OR_GENE_PRODUCT", 33, 38], ["\u03b2CoVs", "GENE_OR_GENE_PRODUCT", 43, 48], ["CoVs", "GENE_OR_GENE_PRODUCT", 102, 106], ["\u03b1CoVs", "PROTEIN", 33, 38], ["\u03b2CoVs", "PROTEIN", 43, 48], ["diverse \u03b1CoVs", "PROBLEM", 25, 38], ["\u03b2CoVs", "PROBLEM", 43, 48], ["mammalian CoVs", "OBSERVATION", 92, 106]]], ["In last decade, increasing numbers of bat CoVs with wide molecular diversities have been reported worldwide, particularly in China (Li et al, 2005; Tang et al, 2006; Woo et al, 2007; Chu et al, 2008; Yuan et al, 2010; He et al, 2014) , some of which likely have the potential ability to cause human diseases (Ge et al, 2013; He et al, 2014; Menachery et al, 2015) .", [["bat", "ORGANISM", 38, 41], ["CoVs", "GENE_OR_GENE_PRODUCT", 42, 46], ["human", "ORGANISM", 293, 298], ["human", "SPECIES", 293, 298], ["human", "SPECIES", 293, 298], ["increasing numbers of bat CoVs", "PROBLEM", 16, 46], ["wide molecular diversities", "PROBLEM", 52, 78], ["human diseases", "PROBLEM", 293, 307], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["numbers", "OBSERVATION_MODIFIER", 27, 34], ["bat CoVs", "OBSERVATION", 38, 46], ["wide", "OBSERVATION_MODIFIER", 52, 56], ["molecular diversities", "OBSERVATION", 57, 78], ["worldwide", "OBSERVATION_MODIFIER", 98, 107]]], ["These findings indicate that further diverse CoVs circulate in bat populations.", [["CoVs", "GENE_OR_GENE_PRODUCT", 45, 49], ["bat populations", "CELL", 63, 78], ["CoVs", "PROTEIN", 45, 49], ["further diverse CoVs circulate in bat populations", "PROBLEM", 29, 78], ["diverse CoVs", "OBSERVATION", 37, 49]]], ["China has a nationwide distribution of about 120 bat species, with many roosting regions remaining uninvestigated for harbored mammal viruses.", [["120 bat species", "PROBLEM", 45, 60], ["many roosting regions", "PROBLEM", 67, 88], ["harbored mammal viruses", "PROBLEM", 118, 141], ["mammal viruses", "OBSERVATION", 127, 141]]], ["Here, we report a continuing investigation on bat-borne CoVs in some unexplored regions in China, the results of which have revealed more novel CoVs that circulate and evolve in bat populations with great molecular diversity and wide geographic distribution.Bat collection and species conformationA total of 951 bats covering 5 families and 21 species were captured between 2005 and 2013, in Jilin, Liaoning, Yunnan, Guangdong provinces and the Tibet Autonomous Region, China.", [["CoVs", "GENE_OR_GENE_PRODUCT", 56, 60], ["CoVs", "GENE_OR_GENE_PRODUCT", 144, 148], ["bat populations", "CELL", 178, 193], ["CoVs", "PROTEIN", 144, 148], ["borne CoVs", "PROBLEM", 50, 60], ["novel CoVs", "PROBLEM", 138, 148], ["Bat collection", "TEST", 258, 272], ["great", "OBSERVATION_MODIFIER", 199, 204], ["molecular diversity", "OBSERVATION", 205, 224], ["wide", "OBSERVATION_MODIFIER", 229, 233], ["geographic", "OBSERVATION_MODIFIER", 234, 244], ["distribution", "OBSERVATION_MODIFIER", 245, 257], ["Tibet Autonomous", "OBSERVATION", 445, 461]]], ["Bat species were morphologically identified by a trained field biologist and further confirmed by PCR of their mitochondrial cytochrome b gene sequence (Wang et al, 2003) .", [["mitochondrial", "ANATOMY", 111, 124], ["Bat", "ORGANISM", 0, 3], ["mitochondrial", "CELLULAR_COMPONENT", 111, 124], ["cytochrome b", "GENE_OR_GENE_PRODUCT", 125, 137], ["mitochondrial cytochrome b gene sequence", "DNA", 111, 151], ["PCR", "TEST", 98, 101]]], ["Respiratory and intestinal tissue specimens were collected separately from each bat and stored at -80 \u00b0C immediately until further processing.RNA extraction and detection by RT-PCRViral RNA of each specimen was extracted by using the RNeasy Mini Kit (Qiagen, Hilden, Germany), and was immediately reverse-transcribed with the Superscript III Kit (Invitrogen, San Diego, CA) using random primers.", [["Respiratory", "ANATOMY", 0, 11], ["intestinal tissue specimens", "ANATOMY", 16, 43], ["specimen", "ANATOMY", 198, 206], ["intestinal tissue specimens", "TISSUE", 16, 43], ["RT-PCRViral RNA", "RNA", 174, 189], ["Superscript III", "PROTEIN", 326, 341], ["Respiratory and intestinal tissue specimens", "TEST", 0, 43], ["RNA extraction", "TEST", 142, 156], ["detection", "TEST", 161, 170], ["RT", "TEST", 174, 176], ["random primers", "TREATMENT", 380, 394], ["intestinal tissue", "ANATOMY", 16, 33]]], ["Pan-CoV nested PCR primers were used to amplify a 440-nt sequence in the RNA-dependent RNA polymerase (RdRP) gene by our published methods (He et al. 2014 ) (see Supplementary Table S1 for primer information).", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 73, 101], ["Pan-CoV nested PCR primers", "DNA", 0, 26], ["440-nt sequence", "DNA", 50, 65], ["RNA-dependent RNA polymerase (RdRP) gene", "DNA", 73, 113], ["Pan-CoV nested PCR primers", "TREATMENT", 0, 26], ["a 440-nt sequence", "TREATMENT", 48, 65]]], ["Expected PCR amplicons were directly sequenced by the Sanger method in an ABI 3730 sequencer (Comate Bio, Changchun, China).RdRP gene amplification and whole genome sequencingThe complete RdRP genes of positive samples were amplified using LA Taq (TaKaRa, Dalian, China).", [["samples", "ANATOMY", 211, 218], ["LA", "CHEMICAL", 240, 242], ["PCR amplicons", "DNA", 9, 22], ["RdRP gene", "DNA", 124, 133], ["RdRP genes", "DNA", 188, 198], ["Expected PCR amplicons", "TREATMENT", 0, 22], ["RdRP gene amplification", "TREATMENT", 124, 147], ["whole genome sequencing", "TREATMENT", 152, 175], ["positive samples", "PROBLEM", 202, 218], ["LA Taq (TaKaRa, Dalian", "TREATMENT", 240, 262]]], ["Primers were designed based on RdRP gene sequences of representative \u03b1CoV and \u03b2CoV strains available in Gen-Bank.", [["\u03b1CoV", "ORGANISM", 69, 73], ["\u03b2CoV", "ORGANISM", 78, 82], ["RdRP gene sequences", "DNA", 31, 50], ["\u03b1CoV", "SPECIES", 69, 73], ["\u03b2CoV", "SPECIES", 78, 82], ["RdRP gene sequences", "TEST", 31, 50], ["CoV strains", "PROBLEM", 79, 90]]], ["Reactions were carried out with a touch-down PCR program: 94 \u00b0C for 3 min, then 10 temperature decrement cycles (94 \u00b0C for 30 s, 58 \u00b0C minus 1 \u00b0C per cycle for 30 s, 72 \u00b0C for 2 min), followed by 35 normal cycles (94 \u00b0C for 30 s, 52 \u00b0C for 30 s, 72 \u00b0C for 3 min), and a last extension of 72 \u00b0C for 10 min.RdRP gene amplification and whole genome sequencingTo obtain the full genomes of the interesting specimens, overlapping amplicons were obtained by the above PCR program following by assembly into contigs.", [["specimens", "ANATOMY", 402, 411], ["specimens", "CANCER", 402, 411], ["RdRP gene", "DNA", 305, 314], ["RdRP gene amplification", "TREATMENT", 305, 328], ["whole genome sequencing", "TREATMENT", 333, 356], ["overlapping amplicons", "PROBLEM", 413, 434]]], ["In ad-dition, deep sequencing and genome walking were also undertaken to recover more genomic sequences.", [["genomic sequences", "DNA", 86, 103], ["deep sequencing", "TEST", 14, 29], ["genome walking", "TEST", 34, 48], ["deep", "ANATOMY_MODIFIER", 14, 18]]], ["The 5\u2032 and 3\u2032 termini were sequenced using a 5\u2032 Full RACE Kit with TAP and a 3\u2032 Full RACE Core Set with PrimeScript RTase (TaKaRa, Dalian, China).", [["TAP", "GENE_OR_GENE_PRODUCT", 67, 70], ["5\u2032 and 3\u2032 termini", "DNA", 4, 21], ["TAP", "PROTEIN", 67, 70], ["PrimeScript RTase", "DNA", 104, 121], ["The 5\u2032 and 3\u2032 termini", "TREATMENT", 0, 21], ["TAP", "TREATMENT", 67, 70]]], ["Primer sequences for full-length genome amplification are shown in Supplementary Table S1 .Genomic and phylogenetic analysesGenomic structures of the CoV complete sequences were predicted by the SeqBuilder program of the DNAStar software package and compared with other representatives from GenBank.", [["CoV", "ORGANISM", 150, 153], ["Primer sequences", "DNA", 0, 16], ["CoV complete sequences", "DNA", 150, 172], ["DNAStar software package", "DNA", 221, 245], ["Primer sequences", "TEST", 0, 16], ["full-length genome amplification", "TREATMENT", 21, 53], ["Genomic and phylogenetic analyses", "TEST", 91, 124], ["the CoV complete sequences", "TEST", 146, 172]]], ["Nonstructural proteins (nsps) in ORF1a and ORF1b (replicase) of the CoVs were predicted using Z-Curve version 2.0, a CoV-specific genefinding system (Gao et al, 2003) .Genomic and phylogenetic analysesAll 400-bp amplicons (the primer truncation of 440-nt sequences) were aligned with their closest phylogenetic neighbors in GenBank using Clustal W version 2.0.", [["Nonstructural proteins", "GENE_OR_GENE_PRODUCT", 0, 22], ["nsps", "GENE_OR_GENE_PRODUCT", 24, 28], ["ORF1a", "GENE_OR_GENE_PRODUCT", 33, 38], ["ORF1b", "GENE_OR_GENE_PRODUCT", 43, 48], ["CoVs", "GENE_OR_GENE_PRODUCT", 68, 72], ["Nonstructural proteins", "PROTEIN", 0, 22], ["nsps", "PROTEIN", 24, 28], ["ORF1a", "PROTEIN", 33, 38], ["ORF1b", "PROTEIN", 43, 48], ["replicase", "PROTEIN", 50, 59], ["CoVs", "PROTEIN", 68, 72], ["400-bp amplicons", "DNA", 205, 221], ["440-nt sequences", "DNA", 248, 264], ["Nonstructural proteins", "TEST", 0, 22], ["nsps", "TEST", 24, 28], ["ORF1a", "TEST", 33, 38], ["Z-Curve version", "TEST", 94, 109], ["Genomic and phylogenetic analyses", "TEST", 168, 201], ["bp amplicons", "TEST", 209, 221], ["the primer truncation", "TEST", 223, 244], ["Clustal W version", "TREATMENT", 338, 355]]], ["The phylogenetic tree was then constructed by the maximum likelihood method of MEGA 6.06 with 1,000 bootstrap replications.", [["bootstrap replications", "TREATMENT", 100, 122], ["phylogenetic tree", "OBSERVATION", 4, 21]]], ["To better understand their evolutionary relationships, the complete RdRP genes were further amplified and used for the analysis.Nucleotide sequence accession numbersThe partial RdRP sequences obtained from all positive samples and the complete genome or full length RdRP sequences of some specimens were submitted to the GenBank under accession numbers KU182954 to KU183005.Detection of CoVsOf 951 bats tested 50 intestinal specimens (5.3%) were CoV positive, but surprisingly all respiratory specimens showed negative amplification.", [["samples", "ANATOMY", 219, 226], ["specimens", "ANATOMY", 289, 298], ["intestinal specimens", "ANATOMY", 413, 433], ["respiratory specimens", "ANATOMY", 481, 502], ["KU183005", "CHEMICAL", 365, 373], ["RdRP", "GENE_OR_GENE_PRODUCT", 68, 72], ["specimens", "CANCER", 289, 298], ["CoVsOf", "GENE_OR_GENE_PRODUCT", 387, 393], ["intestinal specimens", "CANCER", 413, 433], ["CoV", "ORGANISM", 446, 449], ["RdRP genes", "DNA", 68, 78], ["RdRP sequences", "DNA", 177, 191], ["RdRP sequences", "DNA", 266, 280], ["the complete RdRP genes", "TREATMENT", 55, 78], ["the analysis", "TEST", 115, 127], ["The partial RdRP sequences", "TEST", 165, 191], ["full length RdRP sequences", "TEST", 254, 280], ["some specimens", "TEST", 284, 298], ["CoVsOf 951 bats", "TEST", 387, 402], ["intestinal specimens", "TEST", 413, 433], ["CoV positive", "PROBLEM", 446, 458], ["all respiratory specimens", "TEST", 477, 502]]], ["As shown in Table 1 , among 181 bats from 6 species in 3 families in Guangdong province, 16.2% (6/37) Rousettus leschenaultia and 27.5% (14/51) Cynopterus sphinx were CoV positive.", [["Rousettus leschenaultia", "ORGANISM", 102, 125], ["Cynopterus sphinx", "ORGANISM", 144, 161], ["CoV", "ORGANISM", 167, 170], ["Rousettus leschenaultia", "SPECIES", 102, 125], ["Cynopterus sphinx", "SPECIES", 144, 161], ["Rousettus leschenaultia", "SPECIES", 102, 125], ["Cynopterus sphinx", "SPECIES", 144, 161], ["leschenaultia", "TEST", 112, 125]]], ["Among 599 bats from 17 species in 5 families in Yunnan province, 14.0% (14/100) Rousettus leschenaulti, 2.4% (1/41) Megaerops kusnotei, 9.0% (7/78) Rhinolophus sinicus and 5.3% (5/95) Myotis daubentonii were CoV positive.", [["Rousettus leschenaulti", "ORGANISM", 80, 102], ["Megaerops kusnotei", "ORGANISM", 116, 134], ["Rhinolophus sinicus", "ORGANISM", 148, 167], ["Myotis daubentonii", "ORGANISM", 184, 202], ["CoV", "ORGANISM", 208, 211], ["Rousettus leschenaulti", "SPECIES", 80, 102], ["Megaerops kusnotei", "SPECIES", 116, 134], ["Rhinolophus sinicus", "SPECIES", 148, 167], ["Myotis daubentonii", "SPECIES", 184, 202], ["Rousettus leschenaulti", "SPECIES", 80, 102], ["Megaerops kusnotei", "SPECIES", 116, 134], ["Rhinolophus sinicus", "SPECIES", 148, 167], ["Myotis daubentonii", "SPECIES", 184, 202], ["leschenaulti", "TEST", 90, 102], ["Megaerops", "TEST", 116, 125], ["kusnotei", "TEST", 126, 134]]], ["As the first study of this kind in the Tibet Autonomous Region, fifteen Hipposideros cineraceus and five Rhinolophus hipposideros collected in south Tibet were tested and only 6.7% (1/15) Hipposideros cineraceus showed positive amplification.", [["Hipposideros cineraceus", "ORGANISM", 72, 95], ["Rhinolophus hipposideros", "ORGANISM", 105, 129], ["Hipposideros cineraceus", "ORGANISM", 188, 211], ["Hipposideros cineraceus", "SPECIES", 72, 95], ["Rhinolophus hipposideros", "SPECIES", 105, 129], ["Hipposideros cineraceus", "SPECIES", 188, 211], ["Hipposideros cineraceus", "SPECIES", 72, 95], ["Rhinolophus hipposideros", "SPECIES", 105, 129], ["Hipposideros cineraceus", "SPECIES", 188, 211], ["the first study", "TEST", 3, 18], ["fifteen Hipposideros cineraceus", "TREATMENT", 64, 95], ["five Rhinolophus hipposideros", "TEST", 100, 129], ["Hipposideros cineraceus", "TEST", 188, 211], ["positive amplification", "PROBLEM", 219, 241], ["Tibet", "ANATOMY", 39, 44], ["positive amplification", "OBSERVATION", 219, 241]]], ["In northeast China, 2 of 97 (2.1%) bats in Jilin province were positive: one from Murina leucogaster and another from Rhinolophus ferrumequinum.", [["bats", "ORGANISM", 35, 39], ["Murina leucogaster", "ORGANISM", 82, 100], ["Rhinolophus ferrumequinum", "ORGANISM", 118, 143], ["Murina leucogaster", "SPECIES", 82, 100], ["Rhinolophus ferrumequinum", "SPECIES", 118, 143], ["Murina leucogaster", "SPECIES", 82, 100], ["Rhinolophus ferrumequinum", "SPECIES", 118, 143]]], ["In contrast, all 16 Rhinolophus ferrumequinum and 38 Myotis ricketti in Liaoning province showed negative amplification.", [["Rhinolophus ferrumequinum", "ORGANISM", 20, 45], ["Myotis ricketti", "ORGANISM", 53, 68], ["Rhinolophus ferrumequinum", "SPECIES", 20, 45], ["Myotis ricketti", "SPECIES", 53, 68], ["Rhinolophus ferrumequinum", "SPECIES", 20, 45], ["Myotis ricketti", "SPECIES", 53, 68], ["negative amplification", "OBSERVATION", 97, 119]]], ["These results revealed a higher CoV incidence in three fruit bat species of the family Pteropodidae than in the four insectivorous bat families, indicating that fruit bats are more likely to harbor CoVs.Phylogenetic analysisTo describe the genetic relationships among the 50 sequences obtained in this study and previously known CoVs, 400-nt RdRP sequences were obtained from the primer truncation of 440-nt sequences and phylogenetically analyzed.", [["Pteropodidae", "GENE_OR_GENE_PRODUCT", 87, 99], ["bat", "ORGANISM", 131, 134], ["CoVs", "GENE_OR_GENE_PRODUCT", 198, 202], ["CoVs", "GENE_OR_GENE_PRODUCT", 329, 333], ["CoVs", "PROTEIN", 198, 202], ["50 sequences", "DNA", 272, 284], ["CoVs", "DNA", 329, 333], ["400-nt RdRP sequences", "DNA", 335, 356], ["440-nt sequences", "DNA", 401, 417], ["a higher CoV incidence", "PROBLEM", 23, 45], ["Phylogenetic analysis", "TEST", 203, 224], ["this study", "TEST", 297, 307], ["nt RdRP sequences", "TEST", 339, 356], ["the primer truncation", "TEST", 376, 397], ["nt sequences", "TEST", 405, 417], ["higher CoV", "OBSERVATION", 25, 35], ["fruit bat species", "OBSERVATION", 55, 72], ["fruit bats", "OBSERVATION", 161, 171]]], ["Results showed that 8 sequences grouped into 3 clusters within the genus \u03b1CoV ( Figure 1A ).", [["\u03b1CoV", "SPECIES", 73, 77], ["8 sequences", "TEST", 20, 31], ["genus", "ANATOMY", 67, 72]]], ["YDB5C is the first reported bat-borne CoV (Hipposideros cineraceus) in Tibet and clustered closely with MLHJC4, a CoV from Rhinolophus sinicus in Yunnan, both sharing 94% nt identity with previously reported strain HKU2/ GD/430/2006 from Guangdong .", [["YDB5C", "CHEMICAL", 0, 5], ["YDB5C", "GENE_OR_GENE_PRODUCT", 0, 5], ["bat-borne CoV", "ORGANISM", 28, 41], ["Hipposideros cineraceus", "ORGANISM", 43, 66], ["MLHJC4", "GENE_OR_GENE_PRODUCT", 104, 110], ["CoV", "ORGANISM", 114, 117], ["Rhinolophus sinicus", "ORGANISM", 123, 142], ["Hipposideros cineraceus", "SPECIES", 43, 66], ["Rhinolophus sinicus", "SPECIES", 123, 142], ["bat-borne CoV", "SPECIES", 28, 41], ["Hipposideros cineraceus", "SPECIES", 43, 66], ["Rhinolophus sinicus", "SPECIES", 123, 142], ["HKU2/ GD/430/2006", "SPECIES", 215, 232]]], ["The remaining 42 bat CoV sequences were classified as \u03b2CoV and fell into 5 clusters ( Figure 1B ).", [["CoV", "ORGANISM", 21, 24], ["42 bat CoV sequences", "DNA", 14, 34], ["\u03b2CoV", "DNA", 54, 58], ["bat CoV", "SPECIES", 17, 24], ["\u03b2CoV", "SPECIES", 54, 58], ["The remaining 42 bat CoV sequences", "TEST", 0, 34], ["CoV", "TEST", 55, 58]]], ["Twenty identified in Guangdong fell into lineage \u03b24, which showed the geographical relationship and was further divided into two distinct clusters, one with 6 sequences sharing 99% highest nt identity with HKU9-10-1 (Lau et al, 2010) , while another including 14 sequences sharing the closest relationship with BtCoV/ BRT55630/H.lek/CK/Tha/05/2012 detected in Hipposideros lekaguli in Thailand (Wacharapluesadee et al, 2015) .", [["\u03b24", "CELL", 49, 51], ["BtCoV", "GENE_OR_GENE_PRODUCT", 311, 316], ["lek", "GENE_OR_GENE_PRODUCT", 329, 332], ["CK", "GENE_OR_GENE_PRODUCT", 333, 335], ["Hipposideros lekaguli", "ORGANISM", 360, 381], ["lineage \u03b24", "DNA", 41, 51], ["HKU9-10-1", "DNA", 206, 215], ["BtCoV", "DNA", 311, 316], ["BRT55630", "DNA", 318, 326], ["CK", "PROTEIN", 333, 335], ["Tha", "PROTEIN", 336, 339], ["05/2012", "PROTEIN", 340, 347], ["Hipposideros lekaguli", "SPECIES", 360, 381], ["lek/CK/Tha/05/2012", "SPECIES", 329, 347], ["Hipposideros lekaguli", "SPECIES", 360, 381], ["6 sequences", "TEST", 157, 168], ["HKU9", "TEST", 206, 210], ["lek/CK/Tha", "TEST", 329, 339]]], ["The 21 \u03b2CoVs identified in Yunnan province exhibited considerable genetic diversity and were distributed among lineages \u03b22, \u03b23 and \u03b24.", [["\u03b2CoVs", "GENE_OR_GENE_PRODUCT", 7, 12], ["\u03b22", "GENE_OR_GENE_PRODUCT", 120, 122], ["\u03b23", "GENE_OR_GENE_PRODUCT", 124, 126], ["\u03b24", "GENE_OR_GENE_PRODUCT", 131, 133], ["21 \u03b2CoVs", "DNA", 4, 12], ["\u03b22", "DNA", 120, 122], ["\u03b23", "DNA", 124, 126], ["\u03b24", "DNA", 131, 133], ["considerable genetic diversity", "PROBLEM", 53, 83], ["considerable", "OBSERVATION_MODIFIER", 53, 65], ["genetic diversity", "OBSERVATION", 66, 83]]], ["Fifteen fell into \u03b24 and further divided into 2 lineages, fourteen sequences showing closest relationship to previously reported Bt-CoV/BRT55629/H.lek/CK/Tha/05/2012 (Wacharapluesadee et al, 2015) , while another (ML92C) grouped with the Diverse coronaviruses from bats above Guangdong sequences.", [["\u03b24", "GENE_OR_GENE_PRODUCT", 18, 20], ["Bt-CoV", "GENE_OR_GENE_PRODUCT", 129, 135], ["CK", "GENE_OR_GENE_PRODUCT", 151, 153], ["coronaviruses", "ORGANISM", 246, 259], ["\u03b24", "DNA", 18, 20], ["CK", "PROTEIN", 151, 153], ["Guangdong sequences", "DNA", 276, 295], ["Bt-CoV", "SPECIES", 129, 135], ["lek/CK/Tha/05/2012", "SPECIES", 147, 165], ["fourteen sequences", "TEST", 58, 76], ["Bt", "TEST", 129, 131], ["lek/CK/Tha", "TEST", 147, 157], ["the Diverse coronaviruses", "PROBLEM", 234, 259]]], ["Five sequences detected from Myotis daubentonii clustered within lineage \u03b23, sharing > 91% nt identities with previously reported HKU4-4 from Tylonycteris pachypus .", [["lineage \u03b23", "ANATOMY", 65, 75], ["Myotis daubentonii", "ORGANISM", 29, 47], ["lineage \u03b23", "CELL", 65, 75], ["HKU4-4", "GENE_OR_GENE_PRODUCT", 130, 136], ["Tylonycteris pachypus", "ORGANISM", 142, 163], ["lineage \u03b23", "DNA", 65, 75], ["HKU4-4", "DNA", 130, 136], ["Myotis daubentonii", "SPECIES", 29, 47], ["Tylonycteris pachypus", "SPECIES", 142, 163], ["Myotis daubentonii", "SPECIES", 29, 47], ["Tylonycteris pachypus", "SPECIES", 142, 163], ["Five sequences", "TEST", 0, 14], ["HKU4", "TEST", 130, 134], ["Tylonycteris pachypus", "PROBLEM", 142, 163]]], ["This group showed about 80% nt identity with MERS-CoVs recently identified in China and Korea (Kim et al, 2015) .", [["MERS-CoVs", "GENE_OR_GENE_PRODUCT", 45, 54], ["MERS-CoVs", "DNA", 45, 54], ["MERS", "PROBLEM", 45, 49], ["CoVs", "PROBLEM", 50, 54]]], ["The remaining Yunnan bat CoV sequence, MLHJC35, detected in Rhinolophus sinicus, and the only Jilin province sequence, JTMC15, identified in Rhinolophus ferrumequinum were clustered into \u03b22 and showed highest nt identities to SARS-related batborne CoVs (SARSr-BatCoVs).", [["SARS", "DISEASE", 226, 230], ["Yunnan bat CoV", "ORGANISM", 14, 28], ["MLHJC35", "GENE_OR_GENE_PRODUCT", 39, 46], ["Rhinolophus sinicus", "ORGANISM", 60, 79], ["JTMC15", "GENE_OR_GENE_PRODUCT", 119, 125], ["Rhinolophus ferrumequinum", "ORGANISM", 141, 166], ["\u03b22", "GENE_OR_GENE_PRODUCT", 187, 189], ["CoVs", "GENE_OR_GENE_PRODUCT", 248, 252], ["SARSr-BatCoVs", "GENE_OR_GENE_PRODUCT", 254, 267], ["Yunnan bat CoV sequence", "DNA", 14, 37], ["MLHJC35", "DNA", 39, 46], ["Jilin province sequence", "DNA", 94, 117], ["JTMC15", "DNA", 119, 125], ["\u03b22", "DNA", 187, 189], ["batborne CoVs", "DNA", 239, 252], ["SARSr", "DNA", 254, 259], ["BatCoVs", "DNA", 260, 267], ["Yunnan bat CoV", "SPECIES", 14, 28], ["Rhinolophus sinicus", "SPECIES", 60, 79], ["Rhinolophus ferrumequinum", "SPECIES", 141, 166], ["Yunnan bat CoV", "SPECIES", 14, 28], ["Rhinolophus sinicus", "SPECIES", 60, 79], ["Rhinolophus ferrumequinum", "SPECIES", 141, 166], ["The remaining Yunnan bat CoV sequence", "TEST", 0, 37], ["MLHJC35", "TEST", 39, 46], ["JTMC15", "TEST", 119, 125], ["highest nt identities to SARS", "PROBLEM", 201, 230]]], ["MLHJC35 was 97% identical with SARSr-BatCoV Cp/Yunnan2011 previously isolated in Yunnan province (Yang et al, 2011) , while JTMC15 shared 99% identity with SARSr-Bat-CoV Rf1 found in Rhinolophus ferrumequinum, Hubei province (Li et al, 2005) .Phylogenetic analysisTo obtain more precise analysis, representative specimens of the 8 phylogenetic clusters were subjected to full RdRP gene amplification.", [["specimens", "ANATOMY", 312, 321], ["MLHJC35", "GENE_OR_GENE_PRODUCT", 0, 7], ["JTMC15", "GENE_OR_GENE_PRODUCT", 124, 130], ["SARSr-Bat-CoV Rf1", "ORGANISM", 156, 173], ["Rhinolophus ferrumequinum", "ORGANISM", 183, 208], ["specimens", "CANCER", 312, 321], ["MLHJC35", "DNA", 0, 7], ["SARSr-BatCoV Cp", "DNA", 31, 46], ["JTMC15", "DNA", 124, 130], ["SARSr-Bat-CoV Rf1", "DNA", 156, 173], ["RdRP gene", "DNA", 376, 385], ["Rhinolophus ferrumequinum", "SPECIES", 183, 208], ["Bat-CoV", "SPECIES", 162, 169], ["Rhinolophus ferrumequinum", "SPECIES", 183, 208], ["MLHJC35", "TEST", 0, 7], ["SARSr", "TEST", 156, 161], ["CoV Rf1", "PROBLEM", 166, 173], ["precise analysis", "TEST", 279, 295], ["the 8 phylogenetic clusters", "PROBLEM", 325, 352], ["full RdRP gene amplification", "TREATMENT", 371, 399], ["Bat", "ANATOMY", 162, 165]]], ["Complete RdRP sequences were obtained with 13 specimens belonging to 6 clusters comprised of 3 \u03b1CoVs and 10 \u03b2CoVs.", [["specimens", "ANATOMY", 46, 55], ["\u03b1CoVs", "GENE_OR_GENE_PRODUCT", 95, 100], ["\u03b2CoVs", "GENE_OR_GENE_PRODUCT", 108, 113], ["RdRP sequences", "DNA", 9, 23], ["\u03b1CoVs", "DNA", 95, 100], ["\u03b2CoVs", "DNA", 108, 113], ["Complete RdRP sequences", "TEST", 0, 23], ["3 \u03b1CoVs", "TREATMENT", 93, 100]]], ["Phylogenetic analysis based on the full RdRP gene sequences was highly consistent with Figure 1 (Phylogenetic tree of the full RdRP gene sequences is not shown).Full genomic sequences characterizationFull genomic sequencing was successful in 2 of the above 13 specimens: JTMC15 from Rhinolophus ferrumequinum, Jilin province, and JPDB144 from Myotis daubentonii, Yunnan province, with a nearly complete genome sequence obtained of JTAC2 from Murina leucogaster.", [["specimens", "ANATOMY", 260, 269], ["Rhinolophus ferrumequinum", "ORGANISM", 283, 308], ["Myotis daubentonii", "ORGANISM", 343, 361], ["JTAC2", "GENE_OR_GENE_PRODUCT", 431, 436], ["Murina leucogaster", "ORGANISM", 442, 460], ["RdRP gene sequences", "DNA", 40, 59], ["RdRP gene sequences", "DNA", 127, 146], ["JTAC2", "DNA", 431, 436], ["Rhinolophus ferrumequinum", "SPECIES", 283, 308], ["Myotis daubentonii", "SPECIES", 343, 361], ["Murina leucogaster", "SPECIES", 442, 460], ["Rhinolophus ferrumequinum", "SPECIES", 283, 308], ["Myotis daubentonii", "SPECIES", 343, 361], ["Murina leucogaster", "SPECIES", 442, 460], ["Phylogenetic analysis", "TEST", 0, 21], ["the full RdRP gene sequences", "TEST", 31, 59], ["the full RdRP gene sequences", "TEST", 118, 146], ["Full genomic sequences characterization", "TEST", 161, 200], ["JTMC15", "TREATMENT", 271, 277]]], ["The full genomes of JTMC15 and JPDB144 (including complete terminal sequences of 5\u2032 end and 3\u2032poly A) and near-complete genome of JTAC2 were 28,761 nt, 30,321 nt and 25,719 nt in size respectively, with G+C contents of 38.1%, 41.0% and 43.4%.", [["JTMC15", "GENE_OR_GENE_PRODUCT", 20, 26], ["JPDB144", "GENE_OR_GENE_PRODUCT", 31, 38], ["3\u2032poly A", "GENE_OR_GENE_PRODUCT", 92, 100], ["JTAC2", "GENE_OR_GENE_PRODUCT", 130, 135], ["G+C", "SIMPLE_CHEMICAL", 203, 206], ["JTMC15", "DNA", 20, 26], ["JPDB144", "DNA", 31, 38], ["complete terminal sequences", "DNA", 50, 77], ["3\u2032poly A", "DNA", 92, 100], ["near-complete genome", "DNA", 106, 126], ["JTAC2", "DNA", 130, 135], ["28,761 nt", "DNA", 141, 150], ["JTMC15", "TEST", 20, 26], ["JPDB144", "TREATMENT", 31, 38], ["complete terminal sequences", "TEST", 50, 77], ["JTAC2", "TEST", 130, 135], ["nt", "TEST", 148, 150], ["nt", "TEST", 159, 161], ["G+C contents", "TEST", 203, 215], ["size", "OBSERVATION_MODIFIER", 179, 183]]], ["It is proved that two proteinases, papain-like proteinase (PL Pro ) encoded by nsp3 gene and main proteinase (M Pro ) encoded by nsp5 gene in ORF1a of CoVs are able to cleave the complex of ORF1a and ORF1b (replicase) into 16 mature nonstructural proteins (nsps) (Neuman et al, 2008) .", [["papain-like proteinase", "GENE_OR_GENE_PRODUCT", 35, 57], ["PL Pro", "GENE_OR_GENE_PRODUCT", 59, 65], ["nsp3", "GENE_OR_GENE_PRODUCT", 79, 83], ["M Pro", "GENE_OR_GENE_PRODUCT", 110, 115], ["nsp5", "GENE_OR_GENE_PRODUCT", 129, 133], ["ORF1a", "GENE_OR_GENE_PRODUCT", 142, 147], ["CoVs", "GENE_OR_GENE_PRODUCT", 151, 155], ["ORF1a", "GENE_OR_GENE_PRODUCT", 190, 195], ["ORF1b", "GENE_OR_GENE_PRODUCT", 200, 205], ["proteinases", "PROTEIN", 22, 33], ["papain-like proteinase", "PROTEIN", 35, 57], ["PL Pro", "PROTEIN", 59, 65], ["nsp3 gene", "DNA", 79, 88], ["proteinase", "PROTEIN", 98, 108], ["M Pro", "PROTEIN", 110, 115], ["nsp5 gene", "DNA", 129, 138], ["ORF1a", "DNA", 142, 147], ["CoVs", "PROTEIN", 151, 155], ["ORF1a", "PROTEIN", 190, 195], ["ORF1b", "PROTEIN", 200, 205], ["replicase", "PROTEIN", 207, 216], ["16 mature nonstructural proteins", "PROTEIN", 223, 255], ["nsps", "PROTEIN", 257, 261], ["papain", "TREATMENT", 35, 41], ["proteinase (PL Pro )", "TREATMENT", 47, 67], ["CoVs", "PROBLEM", 151, 155], ["ORF1b (replicase", "TREATMENT", 200, 216]]], ["Our analysis of the nsps in ORF1ab revealed that all the three bat CoV genomic sequences contain 16 nsps (nsp1-nsp16) in ORF1ab, but the cleavage sites are different for nsp3 or nsp5 in different CoVs.", [["nsps", "GENE_OR_GENE_PRODUCT", 20, 24], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 28, 34], ["bat CoV", "ORGANISM", 63, 70], ["nsps", "GENE_OR_GENE_PRODUCT", 100, 104], ["nsp1-nsp16", "GENE_OR_GENE_PRODUCT", 106, 116], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 121, 127], ["nsp3", "GENE_OR_GENE_PRODUCT", 170, 174], ["nsp5", "GENE_OR_GENE_PRODUCT", 178, 182], ["CoVs", "GENE_OR_GENE_PRODUCT", 196, 200], ["nsps", "DNA", 20, 24], ["ORF1ab", "DNA", 28, 34], ["bat CoV genomic sequences", "DNA", 63, 88], ["16 nsps", "DNA", 97, 104], ["nsp1", "DNA", 106, 110], ["nsp16", "DNA", 111, 116], ["ORF1ab", "DNA", 121, 127], ["cleavage sites", "DNA", 137, 151], ["nsp3", "PROTEIN", 170, 174], ["nsp5", "DNA", 178, 182], ["CoVs", "DNA", 196, 200], ["bat CoV", "SPECIES", 63, 70], ["Our analysis", "TEST", 0, 12], ["the nsps in ORF1ab", "TEST", 16, 34], ["nsp1", "TEST", 106, 110], ["ORF1ab", "TREATMENT", 121, 127], ["the cleavage sites", "PROBLEM", 133, 151], ["nsp3", "PROBLEM", 170, 174], ["different CoVs", "OBSERVATION", 186, 200]]], ["The length of deduced amino acids of putative nsps, their first-last residue and position in replicase are shown in Supplementary Table S2 .Full genomic sequences characterizationBase on the nearly complete genomic sequence obtained, JTAC2 possesses the same genome structure as PEDVs with 7 genes in the order: 5\u2032-ORF1a, 1b, spike (S), 3a, envelope (E), membrane (M) and nudeocapsid (N)-3\u2032 (Figure 2A ).", [["membrane", "ANATOMY", 355, 363], ["amino acids", "CHEMICAL", 22, 33], ["amino acids", "CHEMICAL", 22, 33], ["amino acids", "AMINO_ACID", 22, 33], ["nsps", "GENE_OR_GENE_PRODUCT", 46, 50], ["JTAC2", "GENE_OR_GENE_PRODUCT", 234, 239], ["membrane", "CELLULAR_COMPONENT", 355, 363], ["nsps", "PROTEIN", 46, 50], ["JTAC2", "DNA", 234, 239], ["PEDVs", "DNA", 279, 284], ["deduced amino acids", "TREATMENT", 14, 33], ["putative nsps", "PROBLEM", 37, 50], ["position in replicase", "TREATMENT", 81, 102], ["ORF1a", "TEST", 315, 320], ["nudeocapsid", "TEST", 372, 383]]], ["JTAC2 showed the nearest relation-ship (87.9% in ORF1a and 92.8% in ORF1b) with Lushi MI bat CoV isolates Neixiang-14 and Neixiang-52, but the latter two have very limited sequences available for further analysis.", [["JTAC2", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF1a", "CANCER", 49, 54], ["Lushi MI bat CoV", "ORGANISM", 80, 96], ["Neixiang-14", "ORGANISM", 106, 117], ["Neixiang-52", "CELL", 122, 133], ["JTAC2", "PROTEIN", 0, 5], ["Lushi MI bat CoV", "SPECIES", 80, 96], ["Neixiang-52", "SPECIES", 122, 133], ["ORF1a", "TEST", 49, 54], ["Lushi MI", "TREATMENT", 80, 88], ["CoV isolates Neixiang", "TEST", 93, 114], ["Neixiang", "TEST", 122, 130], ["further analysis", "TEST", 196, 212]]], ["The recent PEDV-1C isolated from a piglet with diarrhea and vomiting (Sun et al, 2015) was therefore used for sequence comparison and genomic organization analysis, since it has been fully sequenced and shares high identity with JTAC2 ( Figure 1A and Supplementary Table S3 ).", [["piglet", "ANATOMY", 35, 41], ["PEDV-1C", "CHEMICAL", 11, 18], ["diarrhea", "DISEASE", 47, 55], ["vomiting", "DISEASE", 60, 68], ["PEDV-1C", "ORGANISM", 11, 18], ["piglet", "ORGANISM", 35, 41], ["PEDV", "PROTEIN", 11, 15], ["JTAC2", "PROTEIN", 229, 234], ["piglet", "SPECIES", 35, 41], ["The recent PEDV", "PROBLEM", 0, 15], ["diarrhea", "PROBLEM", 47, 55], ["vomiting", "PROBLEM", 60, 68], ["sequence comparison", "TEST", 110, 129], ["genomic organization analysis", "TEST", 134, 163], ["PEDV", "OBSERVATION", 11, 15]]], ["The aa identity comparison shown in Supplementary Table S3 suggests that JTAC2 is a novel \u03b1CoV.Full genomic sequences characterizationJTMC15 is a SARSr-BatCoV having the same genome organization as other SARSr-BatCoVs (e.g., Rf1), but sequence deletions were observed in ORF1a and N, and between genes 7b-8.", [["JTAC2", "GENE_OR_GENE_PRODUCT", 73, 78], ["\u03b1CoV", "GENE_OR_GENE_PRODUCT", 90, 94], ["SARSr-BatCoV", "GENE_OR_GENE_PRODUCT", 146, 158], ["SARSr-BatCoVs", "GENE_OR_GENE_PRODUCT", 204, 217], ["Rf1", "GENE_OR_GENE_PRODUCT", 225, 228], ["ORF1a", "GENE_OR_GENE_PRODUCT", 271, 276], ["7b-8", "GENE_OR_GENE_PRODUCT", 302, 306], ["JTAC2", "PROTEIN", 73, 78], ["\u03b1CoV", "PROTEIN", 90, 94], ["genomic sequences", "DNA", 100, 117], ["characterizationJTMC15", "DNA", 118, 140], ["SARSr-BatCoV", "DNA", 146, 158], ["SARSr", "DNA", 204, 209], ["BatCoVs", "DNA", 210, 217], ["Rf1", "DNA", 225, 228], ["ORF1a", "DNA", 271, 276], ["N", "DNA", 281, 282], ["between genes 7b-8", "DNA", 288, 306], ["\u03b1CoV", "SPECIES", 90, 94], ["Full genomic sequences characterizationJTMC15", "TEST", 95, 140], ["a SARSr", "TEST", 144, 151], ["other SARSr", "TEST", 198, 209], ["sequence deletions", "PROBLEM", 235, 253], ["JTAC2", "OBSERVATION", 73, 78]]], ["A 579-nt deletion in ORF1a of JTMC15 was also observed in SARSr-BatCoV Rs672 from a Rhinolophus sinicus bat (Yuan et al, 2010 ) and a human SARS-CoV ShanghaiQXC2 from the late phase of the 2003 epidemic (GenBank #AY463060).", [["ORF1a", "GENE_OR_GENE_PRODUCT", 21, 26], ["JTMC15", "GENE_OR_GENE_PRODUCT", 30, 36], ["Rhinolophus sinicus bat", "ORGANISM", 84, 107], ["human", "ORGANISM", 134, 139], ["SARS-CoV ShanghaiQXC2", "ORGANISM", 140, 161], ["579-nt deletion", "DNA", 2, 17], ["ORF1a", "DNA", 21, 26], ["JTMC15", "DNA", 30, 36], ["human SARS-CoV ShanghaiQXC2", "DNA", 134, 161], ["Rhinolophus sinicus bat", "SPECIES", 84, 107], ["human", "SPECIES", 134, 139], ["Rhinolophus sinicus bat", "SPECIES", 84, 107], ["human SARS-CoV", "SPECIES", 134, 148], ["A 579-nt deletion", "PROBLEM", 0, 17], ["a human SARS", "TEST", 132, 144]]], ["This 579nt deletion results in a 193-aa deletion of nsp3 in ORF1a, from residues 1059 to 1251 in the nucleic acid-binding (NAB) domain (Serrano et al, 2009) .", [["nsp3", "GENE_OR_GENE_PRODUCT", 52, 56], ["ORF1a", "GENE_OR_GENE_PRODUCT", 60, 65], ["579nt deletion", "DNA", 5, 19], ["193-aa deletion", "DNA", 33, 48], ["nsp3", "DNA", 52, 56], ["ORF1a", "DNA", 60, 65], ["nucleic acid-binding (NAB) domain", "PROTEIN", 101, 134], ["nsp3", "PROBLEM", 52, 56], ["the nucleic acid-binding", "TEST", 97, 121]]], ["A second deletion in the N gene of JTMC15 (1156-1158 nt, one residue Q 368 ) was also found in 3 SARSr-BatCoV strains, Rp/Shaanxi2011 , Rm1 (Li et al, 2005) and 279/2005 (Tang et al, 2006) .", [["JTMC15", "GENE_OR_GENE_PRODUCT", 35, 41], ["SARSr", "GENE_OR_GENE_PRODUCT", 97, 102], ["N gene", "DNA", 25, 31], ["JTMC15", "DNA", 35, 41], ["1156-1158 nt", "DNA", 43, 55], ["A second deletion", "PROBLEM", 0, 17], ["JTMC15", "TEST", 35, 41], ["Rp/Shaanxi2011", "TEST", 119, 133]]], ["Interestingly, four discontinuous deletions were identified in JTMC15 between genes 7b and 8, which is unique in JTMC15, resulting in an ORF shift and elimination of gene 8 ( Figure 2B ).", [["JTMC15 between genes 7b", "GENE_OR_GENE_PRODUCT", 63, 86], ["8", "GENE_OR_GENE_PRODUCT", 91, 92], ["JTMC15", "GENE_OR_GENE_PRODUCT", 113, 119], ["JTMC15 between genes 7b and 8", "DNA", 63, 92], ["JTMC15", "DNA", 113, 119], ["ORF", "DNA", 137, 140], ["gene 8", "DNA", 166, 172], ["four discontinuous deletions", "PROBLEM", 15, 43], ["an ORF shift", "PROBLEM", 134, 146], ["ORF shift", "OBSERVATION", 137, 146]]], ["Similar to known CoVs, extensive S gene variations were also observed in JTMC15, resulting in low aa identities with other SARSr-BatCoV strains (the highest being 86.1% to Rf1) as compared with other gene fragments in the genome.", [["CoVs", "GENE_OR_GENE_PRODUCT", 17, 21], ["JTMC15", "GENE_OR_GENE_PRODUCT", 73, 79], ["SARSr-BatCoV", "GENE_OR_GENE_PRODUCT", 123, 135], ["CoVs", "DNA", 17, 21], ["S gene", "DNA", 33, 39], ["JTMC15", "DNA", 73, 79], ["Rf1", "DNA", 172, 175], ["gene fragments", "DNA", 200, 214], ["known CoVs", "PROBLEM", 11, 21], ["extensive S gene variations", "PROBLEM", 23, 50], ["low aa identities", "PROBLEM", 94, 111], ["BatCoV strains", "PROBLEM", 129, 143], ["CoVs", "OBSERVATION", 17, 21], ["low aa", "OBSERVATION_MODIFIER", 94, 100], ["fragments", "OBSERVATION", 205, 214], ["genome", "ANATOMY", 222, 228]]], ["Receptor-binding motif (RBM) is an extended loop that lies on the surface of the receptor binding domain (RBD) of the spike protein, and is the most important domain for SARSr-BatCoV to recognize its host receptor, angiotensin-converting enzyme 2 (ACE2) (Ren et al, 2008; Baez-Santos et al, 2015) .", [["surface", "ANATOMY", 66, 73], ["angiotensin", "CHEMICAL", 215, 226], ["surface", "CELLULAR_COMPONENT", 66, 73], ["SARSr-BatCoV", "GENE_OR_GENE_PRODUCT", 170, 182], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 215, 246], ["ACE2", "GENE_OR_GENE_PRODUCT", 248, 252], ["Receptor-binding motif", "PROTEIN", 0, 22], ["RBM", "PROTEIN", 24, 27], ["receptor binding domain", "PROTEIN", 81, 104], ["RBD", "PROTEIN", 106, 109], ["spike protein", "PROTEIN", 118, 131], ["SARSr", "PROTEIN", 170, 175], ["BatCoV", "PROTEIN", 176, 182], ["angiotensin-converting enzyme 2", "PROTEIN", 215, 246], ["ACE2", "PROTEIN", 248, 252], ["Receptor-binding motif (RBM", "TREATMENT", 0, 27], ["an extended loop", "PROBLEM", 32, 48], ["the spike protein", "PROBLEM", 114, 131], ["SARSr", "TEST", 170, 175], ["angiotensin", "TEST", 215, 226], ["binding motif", "OBSERVATION", 9, 22], ["extended", "OBSERVATION_MODIFIER", 35, 43], ["loop", "OBSERVATION", 44, 48]]], ["Further alignment of the deduced amino acid sequences of RBM (55 aa) showed a closer relationship of JTMC15 to SARSr-BatCoVs than to human or civet SARS-CoVs (Supplementary Figure S1 ).", [["amino acid", "CHEMICAL", 33, 43], ["SARS", "DISEASE", 148, 152], ["amino acid", "CHEMICAL", 33, 43], ["amino acid", "AMINO_ACID", 33, 43], ["JTMC15", "GENE_OR_GENE_PRODUCT", 101, 107], ["SARSr-BatCoVs", "GENE_OR_GENE_PRODUCT", 111, 124], ["human", "ORGANISM", 133, 138], ["RBM", "PROTEIN", 57, 60], ["JTMC15", "PROTEIN", 101, 107], ["SARSr", "PROTEIN", 111, 116], ["BatCoVs", "PROTEIN", 117, 124], ["human or civet SARS-CoVs", "DNA", 133, 157], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["the deduced amino acid sequences", "TEST", 21, 53]]], ["Taking the above altogether, as shown in Figure 2A and Table 2 , there are 13 genes predicted in JTMC15: 1b, S, 3a, 3b, E, M, 6, 7a, 7b, N, 9a, .", [["3b", "SIMPLE_CHEMICAL", 116, 118], ["E, M, 6, 7a, 7b, N, 9a", "SIMPLE_CHEMICAL", 120, 142], ["JTMC15", "TEST", 97, 103], ["7b", "TEST", 133, 135]]], ["Apart from gene 7b (83.0%) and S (86.1%) all ORFs of JTMC15 had high aa identities to Rf1, ranging from 94.4% (9b gene) to 99.1% (M gene), indicating that JTMC15 is a new variant within the SAR-Sr-BatCoV Rf1 species.Full genomic sequences characterizationFor JPDB144, the genome organization is almost the same as HKU4-4, with 10 genes in the order: 1b, S, 3a, 3b, 3c, 3d, E, M, (Figure 2A) .", [["JTMC15", "GENE_OR_GENE_PRODUCT", 53, 59], ["Rf1", "GENE_OR_GENE_PRODUCT", 86, 89], ["JTMC15", "GENE_OR_GENE_PRODUCT", 155, 161], ["SAR", "GENE_OR_GENE_PRODUCT", 190, 193], ["Sr", "GENE_OR_GENE_PRODUCT", 194, 196], ["HKU4-4", "GENE_OR_GENE_PRODUCT", 314, 320], ["gene 7b", "DNA", 11, 18], ["ORFs", "DNA", 45, 49], ["JTMC15", "DNA", 53, 59], ["Rf1", "DNA", 86, 89], ["JTMC15", "DNA", 155, 161], ["SAR-Sr-BatCoV Rf1 species", "DNA", 190, 215], ["JPDB144", "DNA", 259, 266], ["HKU4-4", "DNA", 314, 320], ["gene 7b", "TEST", 11, 18], ["S", "TEST", 31, 32], ["all ORFs", "TEST", 41, 49], ["JTMC15", "TEST", 53, 59], ["high aa identities", "PROBLEM", 64, 82], ["Rf1", "TEST", 86, 89], ["a new variant", "PROBLEM", 165, 178], ["the SAR", "TEST", 186, 193], ["BatCoV Rf1 species", "PROBLEM", 197, 215], ["Full genomic sequences characterization", "TEST", 216, 255], ["3c", "TEST", 365, 367], ["3d", "TEST", 369, 371], ["E", "TEST", 373, 374], ["new", "OBSERVATION_MODIFIER", 167, 170], ["Rf1 species", "OBSERVATION", 204, 215]]], ["However, two differences were observed in the nsp2 of JPDB144: a 12-nt insertion (residues 1143 to 1146 of 1a) and a 3-nt deletion (residue 1155 of 1a).", [["JPDB144", "CHEMICAL", 54, 61], ["nsp2", "GENE_OR_GENE_PRODUCT", 46, 50], ["JPDB144", "GENE_OR_GENE_PRODUCT", 54, 61], ["nsp2", "DNA", 46, 50], ["JPDB144", "DNA", 54, 61], ["12-nt insertion", "DNA", 65, 80], ["3-nt deletion", "DNA", 117, 130], ["a 12-nt insertion (residues", "TREATMENT", 63, 90], ["a 3-nt deletion (residue", "TREATMENT", 115, 139]]], ["Other JPDB144 ORFs were the same as HKU4-4 in length, sharing aa identities of between 88.8% (3c gene) and 98.8% (E gene); however, an aa sequence comparison of JPDB144 ORFs to those of HKU5 and MERS-CoV strains in the Betacoronavirus lineage 3 showed rather low similarities (Supplementary Table S4 ).", [["JPDB144", "GENE_OR_GENE_PRODUCT", 6, 13], ["HKU4-4", "GENE_OR_GENE_PRODUCT", 36, 42], ["JPDB144", "GENE_OR_GENE_PRODUCT", 161, 168], ["HKU5", "GENE_OR_GENE_PRODUCT", 186, 190], ["MERS-CoV strains", "ORGANISM", 195, 211], ["Betacoronavirus lineage 3", "CELL", 219, 244], ["JPDB144 ORFs", "DNA", 6, 18], ["HKU4-4", "DNA", 36, 42], ["E gene", "DNA", 114, 120], ["JPDB144 ORFs", "DNA", 161, 173], ["Betacoronavirus lineage 3", "CELL_LINE", 219, 244], ["MERS-CoV", "SPECIES", 195, 203], ["Other JPDB144 ORFs", "TEST", 0, 18], ["HKU4", "TEST", 36, 40], ["sharing aa identities", "TEST", 54, 75], ["an aa sequence", "TEST", 132, 146], ["JPDB144 ORFs", "PROBLEM", 161, 173], ["HKU5", "TEST", 186, 190], ["MERS", "TEST", 195, 199], ["CoV strains", "PROBLEM", 200, 211], ["the Betacoronavirus lineage", "TEST", 215, 242], ["rather low similarities", "PROBLEM", 252, 275]]], ["Figure 1 , diverse \u03b1CoVs and \u03b2CoVs have been identified in the present study from different bats sampled at 25 locations in 4 provinces and the Tibet Autonomous Region, demonstrating the wide distribution of CoVs among a range of bat species.", [["\u03b1CoVs", "GENE_OR_GENE_PRODUCT", 19, 24], ["\u03b2CoVs", "GENE_OR_GENE_PRODUCT", 29, 34], ["CoVs", "GENE_OR_GENE_PRODUCT", 208, 212], ["\u03b1CoVs", "DNA", 19, 24], ["\u03b2CoVs", "DNA", 29, 34], ["diverse \u03b1CoVs and \u03b2CoVs", "PROBLEM", 11, 34], ["CoVs", "PROBLEM", 208, 212], ["Tibet", "ANATOMY", 144, 149], ["Autonomous", "ANATOMY_MODIFIER", 150, 160], ["wide", "OBSERVATION_MODIFIER", 187, 191], ["distribution", "OBSERVATION_MODIFIER", 192, 204], ["CoVs", "OBSERVATION", 208, 212]]], ["Of 8 \u03b1CoVs identified, YDB5C is the first bat-borne CoV identified in the Tibet and Himalayan area, detected in 1 of 15 Hipposideros cineraceus bats collected in Yadong county of Tibet, located at the southern edge of the Himalayas bordering on Bhutan and India.", [["\u03b1CoVs", "GENE_OR_GENE_PRODUCT", 5, 10], ["YDB5C", "GENE_OR_GENE_PRODUCT", 23, 28], ["bat-borne CoV", "ORGANISM", 42, 55], ["Hipposideros cineraceus bats", "ORGANISM", 120, 148], ["\u03b1CoVs", "PROTEIN", 5, 10], ["YDB5C", "DNA", 23, 28], ["Hipposideros cineraceus", "SPECIES", 120, 143], ["Hipposideros cineraceus", "SPECIES", 120, 143], ["borne CoV", "PROBLEM", 46, 55], ["8 \u03b1CoVs", "OBSERVATION_MODIFIER", 3, 10], ["Tibet", "ANATOMY", 74, 79], ["Himalayan area", "ANATOMY", 84, 98], ["Tibet", "ANATOMY", 179, 184], ["southern", "ANATOMY_MODIFIER", 201, 209], ["edge", "ANATOMY_MODIFIER", 210, 214], ["Himalayas", "ANATOMY_MODIFIER", 222, 231]]], ["Another newly identified CoV, MLHJC4, was detected in Rhinolophus sinicus in Yunnan province, which phylogenetically clustered closely with YDB5C, both showing 94% nt identity to HKU2/GD/430/2006 identified in Guangdong , indicating that this type of \u03b1CoV has a wide range of bat reservoirs and geo-distribution in south-west China and perhaps neighboring regions.", [["CoV", "GENE_OR_GENE_PRODUCT", 25, 28], ["MLHJC4", "GENE_OR_GENE_PRODUCT", 30, 36], ["Rhinolophus sinicus", "ORGANISM", 54, 73], ["YDB5C", "GENE_OR_GENE_PRODUCT", 140, 145], ["\u03b1CoV", "ORGANISM", 251, 255], ["CoV", "DNA", 25, 28], ["MLHJC4", "DNA", 30, 36], ["YDB5C", "DNA", 140, 145], ["HKU2", "DNA", 179, 183], ["Rhinolophus sinicus", "SPECIES", 54, 73], ["Rhinolophus sinicus", "SPECIES", 54, 73], ["HKU2/GD/430/2006", "SPECIES", 179, 195], ["\u03b1CoV", "SPECIES", 251, 255], ["Another newly identified CoV, MLHJC4", "PROBLEM", 0, 36], ["YDB5C", "TEST", 140, 145], ["HKU2", "TEST", 179, 183], ["\u03b1CoV", "PROBLEM", 251, 255], ["CoV", "OBSERVATION", 25, 28], ["wide", "OBSERVATION_MODIFIER", 262, 266], ["bat reservoirs", "OBSERVATION", 276, 290], ["geo-distribution", "OBSERVATION_MODIFIER", 295, 311]]], ["In addition, six other \u03b1CoV sequences JTAC2, MLHJC2, MLHJC6, MLHJC8, MLHJC22 and MLHJC34, found in this study clustered as two novel CoV groups.", [["\u03b1CoV", "GENE_OR_GENE_PRODUCT", 23, 27], ["JTAC2", "GENE_OR_GENE_PRODUCT", 38, 43], ["MLHJC2", "GENE_OR_GENE_PRODUCT", 45, 51], ["MLHJC6", "GENE_OR_GENE_PRODUCT", 53, 59], ["MLHJC8", "GENE_OR_GENE_PRODUCT", 61, 67], ["MLHJC22", "GENE_OR_GENE_PRODUCT", 69, 76], ["MLHJC34", "GENE_OR_GENE_PRODUCT", 81, 88], ["CoV", "ORGANISM", 133, 136], ["\u03b1CoV sequences", "DNA", 23, 37], ["JTAC2", "DNA", 38, 43], ["MLHJC2", "DNA", 45, 51], ["MLHJC6", "DNA", 53, 59], ["MLHJC8", "DNA", 61, 67], ["MLHJC22", "DNA", 69, 76], ["MLHJC34", "DNA", 81, 88], ["CoV sequences", "TEST", 24, 37], ["JTAC2", "TEST", 38, 43], ["MLHJC2", "TEST", 45, 51], ["MLHJC6", "TEST", 53, 59], ["MLHJC22", "TEST", 69, 76], ["MLHJC34", "TEST", 81, 88], ["this study", "TEST", 99, 109]]], ["Although not novel, the \u03b2CoVs identified here showed abundance in genetic and geographical diversities.", [["\u03b2CoVs", "GENE_OR_GENE_PRODUCT", 24, 29], ["\u03b2CoVs", "DNA", 24, 29], ["the \u03b2CoVs", "TEST", 20, 29], ["abundance in genetic and geographical diversities", "PROBLEM", 53, 102], ["abundance", "OBSERVATION_MODIFIER", 53, 62], ["geographical diversities", "OBSERVATION", 78, 102]]], ["It is interesting to note that SARSr-and MERS-like CoVs were identified, particularly JTMC15 isolated in Jilin province -the first SAR-Sr-Bat CoV to be discovered in Northeast China.As shown inIn consideration of bat species, sampling locations and CoVs diversities, four pathogen/host/environment situations can be proposed.", [["SARSr", "GENE_OR_GENE_PRODUCT", 31, 36], ["MERS", "GENE_OR_GENE_PRODUCT", 41, 45], ["CoVs", "GENE_OR_GENE_PRODUCT", 51, 55], ["Sr-Bat CoV", "ORGANISM", 135, 145], ["CoVs", "GENE_OR_GENE_PRODUCT", 249, 253], ["SARSr", "PROTEIN", 31, 36], ["MERS", "PROTEIN", 41, 45], ["CoVs", "DNA", 51, 55], ["JTMC15", "DNA", 86, 92], ["Bat CoV", "SPECIES", 138, 145], ["SARSr", "TEST", 31, 36], ["MERS", "PROBLEM", 41, 45], ["CoVs", "PROBLEM", 51, 55], ["the first SAR", "TEST", 121, 134], ["bat species", "PROBLEM", 213, 224], ["CoVs diversities", "PROBLEM", 249, 265]]], ["First, a single bat species at one location (even a single cave) harboring different CoV species (e.g., Rhinolophus sinicus collected at the same site in Menglian county, Yunnan province, harboring three CoV species: HKU2-like, SARSr-and new \u03b1CoVs).", [["CoV", "ORGANISM", 85, 88], ["Rhinolophus sinicus", "ORGANISM", 104, 123], ["CoV", "ORGANISM", 204, 207], ["HKU2", "GENE_OR_GENE_PRODUCT", 217, 221], ["SARSr", "GENE_OR_GENE_PRODUCT", 228, 233], ["\u03b1CoVs", "GENE_OR_GENE_PRODUCT", 242, 247], ["HKU2", "PROTEIN", 217, 221], ["SARSr", "PROTEIN", 228, 233], ["\u03b1CoVs", "PROTEIN", 242, 247], ["Rhinolophus sinicus", "SPECIES", 104, 123], ["Rhinolophus sinicus", "SPECIES", 104, 123], ["a single bat species", "PROBLEM", 7, 27], ["harboring different CoV species", "PROBLEM", 65, 96], ["Rhinolophus sinicus", "PROBLEM", 104, 123], ["HKU2", "TEST", 217, 221], ["SARSr", "TEST", 228, 233], ["different CoV species", "OBSERVATION", 75, 96]]], ["Second, a single bat species roosting at different locations harboring the same CoVs (e.g., Rousettus leschenaulti collected in Mengla county (south Yunnan) and Wand- ing county (west Yunnan) harboring the same \u03b2CoVs).", [["CoVs", "GENE_OR_GENE_PRODUCT", 80, 84], ["Rousettus leschenaulti", "ORGANISM", 92, 114], ["\u03b2CoVs", "DNA", 211, 216], ["Rousettus leschenaulti", "SPECIES", 92, 114], ["Rousettus leschenaulti", "SPECIES", 92, 114], ["a single bat species", "PROBLEM", 8, 28], ["same CoVs", "OBSERVATION", 75, 84]]], ["Third, multiple bat species sampled at the same site harboring the same CoVs (e.g., Rousettus leschenaulti and Megaerops kusnotei sampled at the same location in Wanding county harboring the same \u03b2CoVs).", [["CoVs", "GENE_OR_GENE_PRODUCT", 72, 76], ["Rousettus leschenaulti", "ORGANISM", 84, 106], ["Megaerops kusnotei", "ORGANISM", 111, 129], ["\u03b2CoVs", "DNA", 196, 201], ["Rousettus leschenaulti", "SPECIES", 84, 106], ["Megaerops kusnotei", "SPECIES", 111, 129], ["Rousettus leschenaulti", "SPECIES", 84, 106], ["Megaerops kusnotei", "SPECIES", 111, 129], ["multiple bat species", "PROBLEM", 7, 27], ["Rousettus leschenaulti", "TREATMENT", 84, 106], ["Megaerops kusnotei", "TREATMENT", 111, 129], ["multiple", "OBSERVATION_MODIFIER", 7, 15], ["bat species", "OBSERVATION", 16, 27], ["same CoVs", "OBSERVATION", 67, 76]]], ["Different bat species collected at different locations may even harbor the same CoVs: e.g., a Hipposideros cineraceus in Yadong, Tibet and a Rhinolophus sinicus in Menglian, Yunnan harbored HKU2-like viruses, and another Rhinolophus sinicus in Menglian and a Rhinolophus ferrumequinum in Tonghua county, Jilin province, harbored SARSr CoVs.", [["CoVs", "GENE_OR_GENE_PRODUCT", 80, 84], ["Hipposideros cineraceus", "ORGANISM", 94, 117], ["Rhinolophus sinicus", "ORGANISM", 141, 160], ["HKU2-like viruses", "ORGANISM", 190, 207], ["Rhinolophus sinicus", "ORGANISM", 221, 240], ["Rhinolophus ferrumequinum", "ORGANISM", 259, 284], ["Hipposideros cineraceus", "SPECIES", 94, 117], ["Rhinolophus sinicus", "SPECIES", 141, 160], ["Rhinolophus sinicus", "SPECIES", 221, 240], ["Rhinolophus ferrumequinum", "SPECIES", 259, 284], ["Hipposideros cineraceus", "SPECIES", 94, 117], ["Rhinolophus sinicus", "SPECIES", 141, 160], ["Rhinolophus sinicus", "SPECIES", 221, 240], ["Rhinolophus ferrumequinum", "SPECIES", 259, 284], ["Different bat species", "PROBLEM", 0, 21], ["a Hipposideros cineraceus", "PROBLEM", 92, 117], ["like viruses", "PROBLEM", 195, 207], ["another Rhinolophus sinicus in Menglian", "PROBLEM", 213, 252], ["Tibet", "ANATOMY", 129, 134], ["viruses", "OBSERVATION", 200, 207], ["SARSr CoVs", "OBSERVATION", 329, 339]]], ["Altogether, the data provided further evidence for the wide distribution of CoVs among bat populations in China, and for the suggestion that different CoVs employ different bat species as reservoirs.As shown inThe present study has identified genetically diverse bat-borne CoVs, which were detected from intestinal tissue specimens of different bat speices of wide geographic distribution.", [["intestinal tissue specimens", "ANATOMY", 304, 331], ["CoVs", "GENE_OR_GENE_PRODUCT", 76, 80], ["CoVs", "GENE_OR_GENE_PRODUCT", 151, 155], ["bat", "ORGANISM", 263, 266], ["CoVs", "GENE_OR_GENE_PRODUCT", 273, 277], ["intestinal tissue specimens", "TISSUE", 304, 331], ["CoVs", "PROTEIN", 151, 155], ["the data", "TEST", 12, 20], ["CoVs", "PROBLEM", 76, 80], ["different CoVs employ different bat species", "PROBLEM", 141, 184], ["The present study", "TEST", 210, 227], ["genetically diverse bat-borne CoVs", "PROBLEM", 243, 277], ["CoVs", "OBSERVATION", 76, 80], ["genetically", "OBSERVATION_MODIFIER", 243, 254], ["diverse", "OBSERVATION_MODIFIER", 255, 262], ["bat", "OBSERVATION_MODIFIER", 263, 266], ["borne CoVs", "OBSERVATION", 267, 277], ["intestinal tissue", "ANATOMY", 304, 321], ["different", "OBSERVATION_MODIFIER", 335, 344], ["bat speices", "OBSERVATION", 345, 356], ["wide", "OBSERVATION_MODIFIER", 360, 364], ["geographic", "OBSERVATION_MODIFIER", 365, 375], ["distribution", "OBSERVATION_MODIFIER", 376, 388]]], ["But we failed to detect any CoV sequence from the respiratory specimens that probably due to the low virus load in the lung or specific intestinetropism of CoV in bats.", [["respiratory specimens", "ANATOMY", 50, 71], ["lung", "ANATOMY", 119, 123], ["CoV", "ORGANISM", 28, 31], ["lung", "ORGAN", 119, 123], ["CoV", "ORGANISM", 156, 159], ["CoV sequence", "DNA", 28, 40], ["any CoV sequence", "PROBLEM", 24, 40], ["the respiratory specimens", "TEST", 46, 71], ["the low virus load in the lung", "PROBLEM", 93, 123], ["respiratory", "ANATOMY", 50, 61], ["probably due to", "UNCERTAINTY", 77, 92], ["virus", "OBSERVATION", 101, 106], ["lung", "ANATOMY", 119, 123], ["CoV", "OBSERVATION_MODIFIER", 156, 159]]], ["Bats are considered the gene source of Alphacoronavirus and Betacoronavirus (Woo et al, 2012) , especially of pathogenic CoVs that cause public threats.", [["Bats", "CELL", 0, 4], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 39, 55], ["CoVs", "GENE_OR_GENE_PRODUCT", 121, 125], ["Alphacoronavirus", "PROBLEM", 39, 55], ["Betacoronavirus", "PROBLEM", 60, 75], ["pathogenic CoVs", "PROBLEM", 110, 125], ["pathogenic CoVs", "OBSERVATION", 110, 125]]], ["In last decade, increasing number of CoVs have been identified in bats, in which the viral genes were presumably originated and evolved with high mutation and recombination rates .", [["CoVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["CoVs", "PROTEIN", 37, 41], ["viral genes", "DNA", 85, 96], ["CoVs", "PROBLEM", 37, 41], ["high mutation", "PROBLEM", 141, 154], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["number", "OBSERVATION_MODIFIER", 27, 33], ["CoVs", "OBSERVATION", 37, 41], ["viral genes", "OBSERVATION", 85, 96], ["high mutation", "OBSERVATION", 141, 154]]], ["It is ap-parent that large numbers of circulating CoVs remain unidentified, and are evolving worldwide within the bat population.", [["CoVs", "GENE_OR_GENE_PRODUCT", 50, 54], ["circulating CoVs", "PROBLEM", 38, 54], ["large", "OBSERVATION_MODIFIER", 21, 26], ["numbers", "OBSERVATION_MODIFIER", 27, 34], ["circulating CoVs", "OBSERVATION", 38, 54], ["worldwide", "OBSERVATION_MODIFIER", 93, 102]]], ["Investigations in unexplored regions are therefore urgently needed to gain further insights into CoV diversity and evolutionary dynamics.ACKNOWLEDGMENTSThis work was supported by the Science and Technology Basic Work Program from the Ministry of Science and Technology of China (2013FY113600), NSFC-Yunnan Province Joint Fund (U1036601) and Military Medical Health (13CXZ024).COMPLIANCE WITH ETHICS GUIDELINESThe authors declared that they have no conflict of interest.", [["CoV", "ORGANISM", 97, 100], ["evolutionary dynamics", "TEST", 115, 136], ["Joint", "ANATOMY", 315, 320]]], ["The whole study was approved by the Administrative Committee on Animal Welfare of the Institute of Military Veterinary, Academy of Military Medical Sciences, China (Laboratory Animal Care and Use Committee Authorization, permit number JSY-DW-2010-02).", [["The whole study", "TEST", 0, 15]]], ["All institutional and national guidelines for the care and use of laboratory animals were followed.AUTHOR CONTRIBUTIONSCT conceived the study and LX carried it out with BH's guidance.", [["laboratory animals", "TEST", 66, 84], ["the study", "TEST", 132, 141], ["BH's guidance", "TREATMENT", 169, 182]]], ["FZ, WY, TJ, GL, TH, GC, YF, YZ, QF, JF and HZ were responsible for field investigation and bat sampling.", [["TH", "GENE_OR_GENE_PRODUCT", 16, 18], ["HZ", "ORGANISM", 43, 45], ["FZ", "TEST", 0, 2], ["GC", "TEST", 20, 22], ["YZ", "TEST", 28, 30], ["HZ", "TEST", 43, 45], ["field investigation", "TEST", 67, 86], ["bat sampling", "TEST", 91, 103], ["JF", "ANATOMY", 36, 38]]], ["TJ and GL identified bat species morphologically.", [["TJ", "ANATOMY", 0, 2], ["TJ", "CELL", 0, 2], ["TJ", "PROTEIN", 0, 2], ["GL", "PROTEIN", 7, 9], ["bat", "ANATOMY", 21, 24], ["species", "OBSERVATION_MODIFIER", 25, 32], ["morphologically", "OBSERVATION_MODIFIER", 33, 48]]], ["XL took part in samples screening and CoVs detection.", [["samples", "ANATOMY", 16, 23], ["samples", "CANCER", 16, 23], ["CoVs", "SIMPLE_CHEMICAL", 38, 42], ["samples screening", "TEST", 16, 33], ["CoVs detection", "TEST", 38, 52]]], ["LX wrote the paper, CT and BH then revised it.", [["CT", "TEST", 20, 22]]]]}